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Background: Protein biomarkers with associations with the activity and outcomes of diseases are being
identified by modern proteomic technologies. They may be simple, accessible, cheap and safe tests that
can inform diagnosis, prognosis, treatment selection, monitoring of disease activity and therapy and may
substitute for complex, invasive and expensive tests. However, their potential is not yet being realised.
Design and methods: The study consisted of three workstreams to create a framework for research:
workstream 1, methodology – to define current practice and explore methodology innovations for biomarkers
for monitoring disease; workstream 2, clinical translation – to create a framework of research practice,
high-quality samples and related clinical data to evaluate the validity and clinical utility of protein biomarkers;
and workstream 3, the ELF to Uncover Cirrhosis as an Indication for Diagnosis and Action for Treatable Event
(ELUCIDATE) randomised controlled trial (RCT) – an exemplar RCT of an established test, the ADVIA Centaur®
Enhanced Liver Fibrosis (ELF) test (Siemens Healthcare Diagnostics Ltd, Camberley, UK) [consisting of a panel
of three markers – (1) serum hyaluronic acid, (2) amino-terminal propeptide of type III procollagen and
(3) tissue inhibitor of metalloproteinase 1], for liver cirrhosis to determine its impact on diagnostic timing
and the management of cirrhosis and the process of care and improving outcomes.
Results: The methodology workstream evaluated the quality of recommendations for using prostate-specific
antigen to monitor patients, systematically reviewed RCTs of monitoring strategies and reviewed the
monitoring biomarker literature and how monitoring can have an impact on outcomes. Simulation studies
were conducted to evaluate monitoring and improve the merits of health care. The monitoring biomarker
literature is modest and robust conclusions are infrequent. We recommend improvements in research
practice. Patients strongly endorsed the need for robust and conclusive research in this area. The clinical
translation workstream focused on analytical and clinical validity. Cohorts were established for renal cell
carcinoma (RCC) and renal transplantation (RT), with samples and patient data from multiple centres, as a
rapid-access resource to evaluate the validity of biomarkers. Candidate biomarkers for RCC and RT were
identified from the literature and their quality was evaluated and selected biomarkers were prioritised. The
duration of follow-up was a limitation but biomarkers were identified that may be taken forward for clinical
utility. In the third workstream, the ELUCIDATE trial registered 1303 patients and randomised 878 patients
out of a target of 1000. The trial started late and recruited slowly initially but ultimately recruited with good
statistical power to answer the key questions. ELF monitoring altered the patient process of care and may
show benefits from the early introduction of interventions with further follow-up. The ELUCIDATE trial was
an ‘exemplar’ trial that has demonstrated the challenges of evaluating biomarker strategies in ‘end-to-end’
RCTs and will inform future study designs.
Conclusions: The limitations in the programme were principally that, during the collection and curation
of the cohorts of patients with RCC and RT, the pace of discovery of new biomarkers in commercial and
non-commercial research was slower than anticipated and so conclusive evaluations using the cohorts are
few; however, access to the cohorts will be sustained for future new biomarkers. The ELUCIDATE trial was
slow to start and recruit to, with a late surge of recruitment, and so final conclusions about the impact of
the ELF test on long-term outcomes await further follow-up. The findings from the three workstreams
ABSTRACT
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were used to synthesise a strategy and framework for future biomarker evaluations incorporating
innovations in study design, health economics and health informatics.
Trial registration: Current Controlled Trials ISRCTN74815110, UKCRN ID 9954 and UKCRN ID 11930.
Funding: This project was funded by the NIHR Programme Grants for Applied Research programme and
will be published in full in Programme Grants for Applied Research; Vol. 6, No. 3. See the NIHR Journals
Library website for further project information.
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Plain English summary
P rotein biomarkers are substances that can be measured, often in body fluids, to provide informationabout patients and their illness. Measuring biomarkers in blood or urine is simple and safe and may
help diagnose disease and its severity and help choose treatment. New research is discovering more
biomarkers but there is no quick way to decide how useful they are.
Our research was aimed at methods to assess the clinical usefulness of biomarkers as quickly and
efficiently as possible:
l We identified the best research methods for monitoring disease or treatment with biomarkers. We
showed that the literature is modest in scale and of variable quality. We made recommendations
for improvements.
l We created a sample ‘banking’ system for collecting and storing patient samples and relevant clinical
data from large numbers of patients, for renal cell carcinoma and renal transplantation. Biomarkers
were identified and analysed and the system was used to show their value.
l We conducted a trial of the ‘enhanced liver fibrosis’ test in 878 patients. We showed that it alters patient
care but longer follow-up is needed to show if this results in improvements in long-term outcomes.
Our experience is part of the basis of a new framework for evaluating diagnostic tests in four centres
in England.
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Scientific summary
P rotein biomarkers in body fluids that have demonstrable associations with the activity and outcomes of awide range of diseases are now being identified by modern proteomic technologies. They may be simple,
accessible, cheap and safe tests that can inform diagnosis, prognosis, treatment selection, monitoring of
disease activity and therapy. They may substitute for or augment more complex, invasive and expensive tests.
However, their substantial potential to improve patient care and health service provision is not yet being
realised because the pathway linking biomarker research to health services research is still quite poorly
defined. Liver and renal diseases generate huge and growing patient and service burdens and are amenable
to biomarker application.
Our programme consisted of three workstreams that relate to the development pipeline for new biomarkers
in renal and liver diseases and aimed to create a framework for research and innovation in this area:
1. workstream 1, methodology – to define current best practice and explore innovations, particularly in
relation to the use of biomarkers to monitor disease activity
2. workstream 2, clinical translation – to create and evaluate a framework of practice, samples and clinical
data to rapidly identify protein biomarkers with the appropriate analytical and clinical validity and
performance characteristics to justify evaluation of their clinical utility in the health service in liver and
renal diseases
3. workstream 3, ELF to Uncover Cirrhosis as an Indication for Diagnosis and Action for Treatable Event
(ELUCIDATE) randomised controlled trial (RCT) – a RCT on an established biomarker test, the ADVIA
Centaur® Enhanced Liver Fibrosis (ELF) test (Siemens Healthcare Diagnostics Ltd, Camberley, UK), for
liver fibrosis and cirrhosis, for which clinical evidence for its potential value in chronic liver disease
(CLD) is excellent, to determine whether or not its use will sufficiently alter the diagnostic timing and
subsequent management of cirrhosis of the liver in order to change the process of care and reduce
serious complications and improve outcomes for patients and service provision.
We assembled an outstanding internationally recognised multidisciplinary team of methodologists,
clinicians, clinical biochemists, statisticians and marker scientists to deliver these workstreams.
The methodology workstream evaluated published evidence on the quality of recommendations for using
prostate-specific antigen (PSA) to monitor patients with prostate cancer, systematically reviewed the use of
RCTs to evaluate monitoring strategies, reviewed the monitoring biomarker literature and how monitoring
can have an impact on patient outcomes and conducted simulation studies to evaluate monitoring strategies
and how monitoring strategies can meet the requirements to improve the value of health-care services.
These studies confirmed that the literature on the use of biomarkers in monitoring diseases is modest in
scale and robust conclusions are infrequent and we recommend improvements in research practice.
We considered the guidelines that are available for using PSA measurement to monitor patients after they
have received either radical surgery or radical radiotherapy for localised disease. The guideline methods
were assessed using a formal research evaluation framework, which examined the systematic search
methods used in the studies, the selection criteria, the clarity of the formulation of recommendations,
the consideration given in the recommendations to relevant issues around monitoring, the explicit nature
of the use of evidence, the use of external review and the description of updating procedures. Of the
nine main guidelines evaluated using an objective scoring system, the rigour of guideline development
varied, with the best score obtained for the 2008 National Institute for Health and Care Excellence (NICE)
guidelines. Only one guideline modified its recommendation to reflect the fact that a single PSA measurement
may be technically unreliable and it did so by recommending retesting within 2 months. Three guidelines
recommended the use of the same assay on every test occasion. Only four guidelines attempted to justify the
interval between tests that they recommended. Overall, there was evidence of considerable inconsistency in
guideline recommendations for the use of PSA measurement, even when they were published within a few
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years of each other. We concluded that general failings in the guideline development process are likely to
contribute significantly to the variations between published guidelines. Only the NICE and Australian Cancer
Network guidelines cited handbooks on guideline development. It was notable that these guidelines scored
relatively well on the evaluation instrument used in our study.
Randomised controlled trials of monitoring regimens are challenging to design and deliver. Such trials are
complex and involve serial testing. There are complex interactions between repeated test results, clinical
decisions based on these results, the response of clinicians to the results and, of course, the identification
through long follow-up times of important patient outcomes. We conducted a methodological review of
RCTs of monitoring. Although the target sample size was 60 RCTs, after a comprehensive search 120 titles
were selected for further evaluation. Following full-text review, 49 trials published in 58 publications
were selected for inclusion. Cancer, followed by cardiovascular disease and renal disease, were the
most frequently reported topics. Half of the trials evaluated patient-related primary outcomes, one-third
evaluated the impact on mortality and half aimed to report the impact of the monitoring strategy on the
detection of new or recurrent disease. Process of care outcomes were evaluated primarily in relation to the
number of patients treated in the different trial arms or the time taken to arrive at that treatment. Twelve
trials reported statistically significant effects of monitoring on the primary outcome. Only limited attention
was given to the test properties and intervention effectiveness in the populations of interest before the
trials were undertaken. There was a lack of detailed description of the protocols for trial monitoring and
considerable evidence for a lack of compliance to the monitoring strategies. The impact of the monitoring
strategies on clinical behaviours, such as whether to administer treatment or withhold treatment, was not
always consistent with the test results. It appeared that the monitoring test was treated by clinicians as a
guide to possible changes rather than as a definitive indication for a particular change in care. There was
an apparent lack of power to detect significant effects in the studies as a whole.
We reviewed the literature on monitoring strategies used to direct the care of patients with recurrent or
progressive disease. After a formal search and filtering, the literature was categorised and tabulated.
The review identified a limited amount of methodological literature on monitoring strategies. We then
focused on the relationship between the monitoring care pathway and the points in that pathway where
monitoring might be expected to affect patient outcomes. Three identified frameworks for this were
reviewed. Clinical trials of relevance were grouped into three main categories: (1) new monitoring strategies
vs. existing strategies; (2) a monitoring strategy vs. immediate treatment; and (3) a monitoring strategy vs.
no monitoring. Differences in study design from the use of biomarkers for screening and diagnosis were
evaluated. Monitoring strategies considered included (1) detection of significant clinical change earlier
than in conventional practice to deploy treatment early; (2) to reduce the invasiveness and cost of testing;
(3) to reduce the volume and frequency of testing; (4) to reduce overtreatment; and (5) to delay or avoid
treatment. The analysis led to the recommendation that a test validation paradigm be adopted in which a
number of methods are used to determine whether or not the results of a test are going to be meaningful
in practice and generate benefits for patients. RCTs will be needed in some settings but this level of
evidence will not always be essential. Strategic approaches need to be multidisciplinary, involving evaluation
of the performance of the tests in the laboratory, rigorous study design and analysis and close collaboration
with clinicians and biochemists to determine the appropriate technical and clinical options for evaluation
and the probability of changing clinical behaviours with test results.
We describe simulation studies as well as the impact of the simulation studies on the conduct, redesign
and extension of the ELUCIDATE trial. Data sources were not always adequate for comprehensive
simulation until quite late in the progress of the programme and ELUCIDATE trial. The modelling work
allowed the accurate calculation of power based on observed and predicted event rates. This allowed trial
recruitment to be completed, the reporting of process of care outcomes and the initiation of long-term
follow-up strategies from health-care informatics sources.
Introducing new biomarkers into clinical practice to promote the introduction of a more personalised,
precise and stratified approach to patient management requires evaluation of the characteristics of the
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tests and their impact on clinical outcomes and the quality and cost of the care delivered. There is
tremendous pressure to increase the efficiency of health-care systems by introducing cost-effective new
tests. The elimination of unnecessary tests is being explored. We focused especially on the role of
monitoring tests and methods to evaluate their health economics. We compared the use of conventional
clinical utilities with an approach based on cost-effectiveness, described the framework for characterising
personalised medicine technologies and drew on an existing method for optimising diagnostic tests to
meet cost-effectiveness targets and extended this to monitoring tests. This work demonstrated, among
other things, that the cut-off points used for a test when used repeatedly for monitoring may under some
circumstances be different from those used when the test is used for diagnosis.
The findings were formulated to be shared with patients, who strongly endorsed the need for robust and
conclusive research in this area and for improved communication about test results between clinicians
and patients.
The clinical translation workstream focused on the analytical and clinical validity of tests in renal disease.
Prospective cohorts were established for renal cell carcinoma (RCC) and renal transplantation (RT), with
samples and patient data obtained from multiple NHS centres and the samples and patient data from
workstream 3 (liver disease) curated. The recruitment of patients to obtain high-quality samples and clinical
data was challenging but was ultimately completed to target. These resources provide, and will continue to
provide, a rapid-access resource for evaluating the validity of biomarkers that are candidates for evaluation to
see whether or not they can improve NHS services. To identify tests to be evaluated using this resource, all
candidate biomarkers for RCC and RT were identified from the literature, the quality of the studies was
evaluated and selected biomarkers were prioritised. Four selected biomarkers were studied further by rigorous
evaluation of the validity of the tests and evaluation of their performance within the workstream 2 sample/
data cohorts. Systematic evaluation of tests relevant to RCC in the literature suggested that osteopontin
(OPN), vascular endothelial growth factor (VEGF), carbonic anhydrase IX (CAIX) and C-reactive protein (CRP)
should be prioritised and evaluated further. For RT, the most promising serum biomarkers for the early
detection of delayed graft function appeared to be neutrophil gelatinase-associated lipocalin (NGAL), serum
cystatin C and serum aminoacylase-1, previously discovered by our group. The performance of available
assays for the four prioritised biomarkers (VEGF, CAIX, OPN and NGAL) was rigorously evaluated, including
pre-analytical aspects and verification protocols. Therefore, specific biomarker technical evaluations were
performed for all of the biomarkers studied within the programme. The important technical aspects of
evaluating biomarker assays are illustrated in these studies as well as the critical importance of the principle
that all assays must be technically robust before being employed in NHS diagnostics or in clinical trials.
Without assay characterisation and validation as part of the early phase of biomarker translation the field
will continue to move slowly and waste resources. High-quality biobanking and detailed consideration of
pre-analytical factors are essential in this field. The four RCC biomarkers evaluated in the cohorts showed
promise but, after multivariate analysis, at this stage we can demonstrate only that CRP has added value to
the established panels of tests and clinical data (the Leibovich score) used in RCC practice. More importantly,
however, we have demonstrated how to establish a streamlined approach to new biomarker validation.
The duration of follow-up was a limitation of the cohorts but we were able to substantiate several existing
findings and identify biomarkers that may be taken forward for clinical utility studies.
The ELUCIDATE trial workstream involved the design, conduct and analysis of a trial that registered
1303 patients with CLD and randomised 878 patients out of a target of 1000. The trial started late and
recruited slowly initially. However, the trial team identified and opened additional centres, clinicians
recruited patients energetically in most centres and new modelling techniques and data collection
approaches were introduced by the team so that the trial ultimately recruited an adequate number of
patients to provide good statistical power to answer the key clinical questions. Analysis showed that,
within the trial, the use of the ELF monitoring strategy altered the patient process of care and led to the
introduction of tests that will identify patients who should benefit from the early introduction of
interventions to manage serious complications and improve outcomes. The ELUCIDATE trial was an
‘exemplar’ trial that has demonstrated the challenges of evaluating biomarker strategies in ‘end-to-end’
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RCTs, in which patients are randomised between a new monitoring strategy and conventional care and
are then followed up through to ultimate end points including survival. Its lessons will inform future
study design.
There were significant interactions between the three workstreams. Workstream 1 gave the programme
investigators a clear insight into the historical, methodological and study design challenges within this
field and the scope of previous contributions. Innovations in study design, simulation strategies and the
applications of health economic methods to evaluating monitoring tests were developed. These informed
the revision of the study design for the ELUCIDATE trial and provided innovative approaches to power
calculations based on pre-existing published cohorts and the early trial data. Workstream 2 showed clearly
the importance of rigorous assay evaluation. This informed the development of the ELUCIDATE trial and
in particular the work to re-evaluate the performance of the ELF test in the context of intra-laboratory
variation and inter-laboratory variation. The challenges of delivering the ELUCIDATE trial have informed
our recommendations for future methodological approaches. The interactions between workstreams bring
out the advantages of developing the clinical cohorts and conducting the RCT within the context of a
programme, which included a strong multidisciplinary team of methodologists, clinical biochemists, triallists
and clinicians. However, incorporating all three workstreams in a single programme also meant that the
work of the programme as a whole was potentially prone to delays. For instance, delays in the recruitment
of the cohorts and in the set-up of and recruitment into the ELUCIDATE trial limited our ability to feed
back substantial bodies of data, and the outcome evaluation, from the RCT to the methodology
workstream.
The findings from the three workstreams were used to synthesise a strategy and framework for future
biomarker evaluation by the investigators, with a defined pipeline and innovative contributions to study
design, health economics and health informatics, which became the basis of a successful application to
become one of four National Institute for Health Research (NIHR) Diagnostic Evidence Co-operatives
in England.
Trial registration
This trial is registered as Current Controlled Trials ISRCTN74815110, UKCRN ID 9954 and UKCRN ID 11930.
Funding
Funding for this study was provided by the Programme Grants for Applied Research programme of
the NIHR.
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Chapter 1 Introducing new biomarkers for renal
and hepatic diseases into health-care systems
Background
Protein biomarkers in body fluids are now being regularly identified using new techniques and are
associated with the presence and activity of diseases and treatment benefits/toxicities. They are accessible,
measurable in real time and inexpensive to test for. However, their potential benefit to the NHS is
not being realised because of the absence of a defined pathway linking biomarker research to health
services research. This programme aimed to establish a process for the stringent evaluation of promising
biomarkers, encompassing methodological developments, clinical evaluation and a randomised controlled
trial (RCT) to enable assessment of their impact on clinical outcomes, the process of care, resource use and
service configurations.
Our specific objectives were to:
l evaluate and develop methodology for the optimal use of biomarkers for disease monitoring and to
optimise benefits, for patients and the NHS
l establish a sample and clinical data bank together with a robust system for the evaluation of promising
markers to facilitate their rapid assessment prior to large-scale trialling in the NHS
l conduct a RCT of an established panel of biomarkers of potential value in chronic liver disease (CLD) to
diagnose cirrhosis at an early stage when interventions may reduce dangerous complications and to
determine patient and NHS benefits.
Biomarkers have major potential benefits for patients and the NHS, particularly in contributing to
‘personalised’ and/or ‘stratified’ medicine and improved safety. They may supplement or replace invasive
procedures or imaging tests for:
l accurate and early diagnosis
l measurement of the activity and extent of disease
l indication of prognosis
l selection and prediction of optimal treatments
l monitoring for treatment response/toxicity or disease progression.
In addition, biomarker information may inform patient counselling on lifestyle issues (e.g. alcohol avoidance
or diet) and motivate patients towards healthy alternatives. Overall, better biomarkers should lead to
improvements in outcomes and more efficient, cost-effective and evidence-based use of NHS resources.
With ongoing technological developments, particularly in proteomics, the rate of identification of potential
new biomarkers may be expected to increase. Various stages in the ‘biomarker pipeline’ have been defined,
but the translational work needed to progress through these – involving technology transfer, methodological
considerations and aspirations of different stakeholders – presents challenges. The lack of a clear evaluative
infrastructure means that the route from stringent evaluation and/or validation to clinical implementation
and then to evaluation of impact on outcomes and health care is not yet established, representing a major
threat to achieving full patient benefit.1–9 As an indication, the number of new protein markers approved by
the US Food and Drug Administration (FDA) has gradually declined, with only 10 approved in the period
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from 1994 to 2002, only two of which were approved in 1998–2002.10 Encouragingly, the need for national
strategies for the rapid evaluation and introduction of new biomarker tests is now better appreciated, for
example by the National Institutes of Health (NIH) in the USA11 and by the Royal College of Pathologists in
the UK.12
A framework is, therefore, required for the pipeline to justify and guide the introduction of biomarkers,
including specification and establishment of the infrastructure to acquire such evidence, appropriate
assessment of test results, identification of whether or not RCTs are required and the means of deciding
when and how biomarker development and introduction should be accelerated.
Selected diseases
Chronic liver disease and renal diseases provided ideal subjects with which to work up such a framework.
Liver and renal diseases generate huge and increasing burdens on patients and the NHS. The care of
patients would be transformed with improved outcomes, more appropriate use of complex and expensive
therapies and avoidance of expensive and invasive investigations if biomarkers of real health-care value
could be found.
Chronic liver disease
Chronic liver disease is the fifth most common cause of death in the UK and the second most common
cause of death in men aged 35–54 years. It is usually associated with alcoholic liver disease, fatty liver
disease or hepatitis C infection, any of which may lead to fibrosis, cirrhosis and hepatocellular carcinoma
(HCC).13–15 Life-threatening complications include variceal bleeding, recurrent ascites and hepatic
encephalopathy. Once cirrhosis has developed, HCC arises in 1–6% of patients per annum.16,17 Social
issues such as an inability to work constitute a huge health-care and financial burden. Evidence shows
that earlier cirrhosis detection results in better survival and reduced morbidity rates.
Acute renal transplant
Currently, in the UK there are 23,000 patients with functioning transplants (see Chapter 10). Annually,
almost 3080 renal transplants are performed. Transplantation represents the best therapy for improving
survival and quality of life and is the most cost-effective, saving the NHS > £490M per year compared
with dialysis. Acute rejection (AR; 25% of patients) and delayed graft function (DGF; 40% of patients)
significantly reduce short- and long-term graft survival. Early diagnosis of AR/DGF is critical for optimal
treatment. The biomarker serum creatinine is slow to respond and is insensitive. Currently, renal biopsy is
required for a definitive diagnosis, which is invasive and may not be available immediately.18–24 Biomarkers
allowing the earlier diagnosis of DGF and AR and discrimination of subgroups, a strategic priority of the
American Society of Nephrology,25 would allow earlier and more appropriate therapeutic intervention.
Renal cell carcinoma
Accounting for approximately 3% of adult malignancies, the incidence of renal cell carcinoma (RCC) is
increasing, with approximately 330,000 new cases each year worldwide and 10,000 new cases each year
in the UK and > 140,000 deaths worldwide (see Chapter 10).26,27 Locally advanced or metastatic disease
affects > 50% of patients, for which treatments are limited. New drugs have improved response rates and
relapse-free survival (RFS) but they are expensive and markers for the diagnosis, prognosis and selection of
expensive therapy are desperately needed.28–31
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Protein biomarkers
Protein biomarkers in body fluids have substantial potential to improve the quality of health care. There are
active pipelines identifying them in both the commercial and the non-commercial sectors, but robust
methodological approaches and well-organised rapid clinical and health service evaluation is still limited.
In a clinical setting, the value of a protein biomarker depends on test performance and its relation to
health improvements. Methods of reporting, and hence judging, test performance are well developed for
biomarkers and other kinds of measures when these are used in a prognostic role and in a diagnostic
role.32,33 The methodology for evaluating biomarker test performance when used in an individual patient
monitoring role is, however, poorly developed.
After the initial discovery and preliminary evaluation of a protein biomarker, robust evaluation of its clinical
characteristics [sensitivity, specificity, receiver operating characteristic (ROC), etc.] is often performed slowly
and in limited sample numbers. We set out to establish a robust system using samples and clinical data in
adequate numbers to rapidly evaluate markers that may be useful in the NHS and select those that justify
formal evaluation.
Chronic liver disease can frequently progress to cirrhosis and to life-threatening complications. Early diagnosis
of cirrhosis with appropriate management can reduce the incidence of these complications, and a panel of
protein biomarkers that directly evaluate fibrosis has excellent clinical characteristics [ADVIA Centaur® Enhanced
Liver Fibrosis (ELF) test; Siemens Healthcare Diagnostics Ltd, Camberley, UK]. We proposed and have conducted
a RCT to establish whether or not its use can substantially improve patient outcomes and health-care provision.
Previous work on the ELF test shows that it has a proven clinical association with cirrhosis and its complications.
This provides justification for its evaluation to see whether or not it can be used to monitor patients and allow
the diagnosis of cirrhosis at a time when interventions will reduce the morbidity and mortality associated with
these complications.34–37
Monitoring studies
Considerable research has been carried out into the use of biomarkers for prognosis (including prediction
of response to treatment). In contrast, there is a relatively small amount of literature on the use of
biomarkers for monitoring.38,39 Methodological work has not yet been conducted on the design and
interpretation of studies with repeated measurements of biomarkers, and we used value of information
analysis in this context.
Monitoring may be undertaken for various purposes. In chronic diseases, it may assess whether or not
interventions are keeping the disease and symptoms under control; assess the rate of progression of disease
(e.g. the ELF test in our RCT); detect recurrence of disease; or evaluate the efficacy of treatments. Monitoring
may also allow adverse effects to be avoided. A strategy is required for the frequency of testing and rules for
clinical actions (including retesting). Although each test result can be judged on its own, there is the potential
also to learn from the change since the previous test or the rate of change over time or to devise and
calibrate a model of change over time. Rules may be devised using suitable cut-off points, changes between
values or values of fitted model parameters or confidence intervals (CIs) thereof. In addition, it will be
important to understand natural variability because of measurement error, prognostic factor-related trends
(e.g. in age) and the risks of incorrect decisions.
Few biomarkers have been studied in this context. Examples in cancer include cancer antigen 125 (CA-125)
for monitoring patients with ovarian cancer for recurrence and prostate-specific antigen (PSA) for monitoring
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men at risk of prostate cancer and for monitoring prostate cancer for recurrence.40,41 Serum creatinine
measurements are used to monitor patients with chronic kidney disease (CKD) and transplants. An important
question for monitoring by repeated measurement is whether prognosis relates to the actual marker level or
the change over time or more complex models.42
Two different questions need to be considered, relating first to the interpretation of specific marker values
and sequences of such values, and second to the implementation of such information, for example to
determine how frequently measurements should be taken. There is a need for large, high-quality data sets
with repeated measurements to inform the development of decision rules for monitoring.
Choice of the Enhanced Liver Fibrosis test for the ELUCIDATE randomised
controlled trial
Within our range of liver and renal diseases, we identified the ELF test as having ideal characteristics for
our RCT because:
l the ELF test has convincing clinical evaluation data showing an association with cirrhosis (e.g. ROC of
> 0.8) but the clinical and health service benefits from monitoring CLD for cirrhosis are untested
l the burden of CLD and cirrhosis on patients and the NHS is huge and increasing
l early diagnosis of cirrhosis allows effective surveillance and the use of interventions to improve clinical
outcomes and care
l a simple blood test could radically improve and provide cost-effective care for CLD patients
l this model will provide an excellent prototype for health service biomarker research and vital data sets
for our methodologists.
In the vast majority of cases, liver fibrosis is asymptomatic and cirrhosis develops insidiously with non-specific
symptoms, so that opportunities for disease modification or cure are missed. Standard biochemical tests of
liver function are not specific or sensitive. Liver biopsy is hazardous and inaccurate and subject to sampling
error and variation in interpretation.43–45 Imaging has a major role in the detection and assessment of liver
fibrosis. However, all imaging modalities, including ultrasound, elastography and cross-sectional imaging
with X-rays or magnetic resonance, require access to expensive technology and skilled operators.46,47
With cirrhotic diseases of the liver, we are in the relatively fortunate position of having a number of
treatments (such as beta-blocker therapy or surgery for low-volume HCC) that are known to be effective at
reducing complications, if the cirrhotic condition is detected early enough. The ELF test seeks to identify a
‘pool’ of patients with a slowly progressing disorder who can be treated prophylactically and in whom the
incidence of severe complications can be reduced.
Evidence shows that the early detection of varices and treatment with prophylactic use of beta-blockers
to reduce portal hypertension or band ligation reduces morbidity and increases survival, and respected
guidelines recommend surveillance because of its benefits and health economic justification.48–52 Similarly,
the early detection of ascites and treatment has been shown to reduce the morbidity associated with
bacterial peritonitis from 17% to 2%.53 The case for surveillance and early detection of HCC is more
contentious, with some RCTs showing evidence of benefit and others showing none. International
guidelines now advocate surveillance.54–56 Retrospective analyses have identified criteria, essentially
the presence of small tumours, that are associated with better outcomes of HCC resection and liver
transplantation, but many patients are diagnosed after the growth of their tumours has ruled them out
for curative resection or transplantation.57,58
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Studies and systematic reviews have demonstrated that single direct markers are less accurate than panels of
markers for the detection of liver fibrosis.59,60 One such panel of direct markers is the ELF test, the only CE
(Conformité Européene)-marked [European Union (EU) regulatory approval] test for liver fibrosis measuring
constituents of liver matrix [hyaluronic acid (HA) and procollagen III amino-terminal peptide (PIIINP)] and a
molecule critical to the regulation of matrix remodelling [tissue inhibitor of metalloproteinase 1 (TIMP-1)] using
sensitive automated enzyme-linked immunosorbent assays (ELISAs) designed and manufactured specifically
for this purpose.61 The three individual biomarkers were selected as being optimal from among 20 candidates.
The results of the individual assays are combined in an algorithm that was derived and validated in > 1000
cases of liver fibrosis to generate a score that correlates with the severity of liver fibrosis on liver biopsy. ELF
values have been shown to be highly predictive of clinical outcomes, including variceal bleeding, ascites, HCC
and mortality. Subsequent validation studies in hepatitis C, fatty liver disease, human immunodeficiency virus
(HIV)–hepatitis C virus (HCV) co-infection and primary biliary cirrhosis have confirmed the performance of the
test.34–37 Although performance is best in the detection of advanced fibrosis and cirrhosis, the test can also
detect mild and moderate degrees of fibrosis accurately, with area under the curve (AUC) ROCs of 0.83 for
Ishak fibrosis stages of 0–3 compared with 4–6 and 0.86 for Ishak fibrosis stages of 0–4 compared with 5–6.
The ELF test is excellent at detecting advanced fibrosis/cirrhosis in a range of CLDs and is, thus, well suited for
use in screening populations at risk for cirrhosis. The ELF test has been developed by Siemens Healthcare
Diagnostics Ltd (formerly Bayer Healthcare) in conjunction with the University of Southampton and iQur Ltd
(Southampton, UK).
The overall shape of this programme of work is provided in Figure 1.
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FIGURE 1 The programme of work. NEQAS, National External Quality Assessment Service.
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Chapter 2 Introduction to the methodology
workstream (workstream 1)
In this chapter we introduce the methodology workstream on monitoring tests, described in Chapters 3–9.
Monitoring is the repeated application of a test, or set of tests, over time to assist in the management
of a disease or condition. It is a fundamental element of patient care, comprising much of the clinical
workload.62 Often thought of in terms of treatment titration and maintenance, in which the aim is to
keep a marker within predefined limits until treatment can be discontinued or an alternative treatment is
required, monitoring is also used to manage individuals with a disease or condition that is likely to progress
or recur at some time in the future, allowing timely decisions to be made regarding patient management.
Patients are usually asymptomatic or mildly symptomatic but not yet receiving treatment, or they may
experience symptoms of a disease that puts them at risk of developing other conditions. Monitoring often
involves a general clinical assessment and physical examination of patients but is likely to include the
application of specific tests, from tools assessing functional or psychological status, to blood or urine tests,
physiological measurements such as blood pressure, imaging tests or more invasive assessments such
as colonoscopy or biopsy. Although subsequent chapters of this report focus on protein biomarkers in
particular, the methodological considerations that underlie the development and evaluation of monitoring
strategies are relatively universal and can be applied regardless of type of test.
Historically, methodological research around test evaluation has lagged behind methodological research
around interventions. Over the last 10–15 years, however, considerable research effort has focused on
identifying optimal methods for establishing diagnostic test accuracy and, more recently, on the evaluation
of diagnostic tests and strategies in terms of their impact on patient management and outcomes.63,64
Monitoring tests, particularly in terms of treatment titration, are now beginning to receive attention in
the literature.38,65 Our particular interest is in monitoring patients for disease progression or recurrence.
The development and evaluation of tests for monitoring purposes bears many resemblances to the
development and evaluation of diagnostic tests but with a few key differences.62,66,67 First, unlike tests for
diagnosis, tests for monitoring often do not aim to detect present disease but rather some marker of
preclinical or early-stage disease that precedes the development of clinical disease progression or
recurrence. Vitally, this latent stage of disease must be of a reasonable duration to make the repeated
application of a monitoring test worthwhile – too short and recurrence or progression may be missed
regardless of the monitoring schedule adopted, too long and frequent monitoring may not be of clinical
benefit. Second, although diagnostic tests are often applied once, perhaps with a repeat application to
confirm diagnosis, by the very nature of monitoring, monitoring tests are applied repeatedly over an
indefinite period of time and according to some predetermined schedule. With patients’ true disease status
often not established until clinical disease progression occurs, a cross-sectional evaluation of the diagnostic
accuracy of a test can be impossible to establish and more longitudinal measures to capture how well a test
predicts clinical outcome have been suggested.65 The same principle of detecting true disease (recurrence
and progression) while limiting false-positive results applies, with the further consideration that the test
should be able to differentiate long-term change in disease status from short-term measurement variability.
The further in advance of the clinical event of interest the marker is measured, the less predictive it may be
and the greater the potential influence from measurement variability on false-positive and false-negative
results. More complex decision rules to determine the point at which some clinical action should be taken
may also be relevant for monitoring. Although each test result can be judged on its own, as in a diagnostic
context, serial values over time may provide valuable information. Rules may be devised using individual
thresholds, the change in measurement since the previous test, the rate of change in measurement values,
values of fitted model parameters or CIs thereof. Finally, whereas a diagnostic test may be applied to assist
in the ruling in or out of a number of differential diagnoses and any number of therapeutic approaches may
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be indicated, a positive monitoring test often only increases the probability of a particular future clinical
event and, furthermore, a series of further investigations may be initiated before a particular treatment
approach is applied.
Many of these considerations are particularly true of protein biomarkers, for which changes in biomarker
levels may occur before any clinical symptoms or signs become apparent. Measuring biomarkers in blood or
urine is relatively simple and safe for patients, making them an attractive alternative or complement to more
complex, invasive or expensive tests. However, initially promising results at the biomarker identification
stage do not necessarily translate into clinical benefit in practice.
Our aim was to identify and describe general methodological considerations for the development and
evaluation of testing strategies to monitor for disease progression or recurrence, reviewing current best
practice and exploring methodological innovations.
Chapters 3–9 all address aspects of the evaluation of monitoring biomarkers, but they do so from different
starting points, depending on the amount and nature of the relevant literature being used as the starting point
for the work. Each chapter, therefore, begins with a brief introduction, presenting the background elements
most relevant to explaining the work to be reported. This approach has created a degree of repetition, but
does enable the chapters to be read separately without the need for extensive cross-referencing to material
presented elsewhere in the report. The chapters do also show some stylistic differences, reflecting in part the
nature of the work reported, but also the discipline background of their lead authors.
Chapter 3 reviews monitoring strategies recommended in available clinical guidelines, with specific
reference to the use of PSA for the detection of recurrent prostate cancer. PSA was chosen because of the
extensive literature surrounding it and, in the event, there was so much material to consider, and so many
generalisable considerations were emerging, we decided to focus entirely on PSA rather than pursue our
original plan to add a number of ‘mini’ case studies from other clinical areas. The particular focus was on
the degree of consistency between guidelines, the explicit consideration of factors important for specifying
a monitoring strategy and the use of supporting evidence to justify any recommendations.
Ultimately, monitoring strategies are employed to allow timely decisions to be made regarding patient
management, thereby improving patient outcomes, for example through earlier initiation of treatment to
prevent or delay some clinical outcome. The RCT design is considered to be the gold standard approach to
the evaluation of patient benefit from therapeutic interventions; however, testing strategies are complex
interventions with many components, with their evaluation presenting considerable challenges. Chapter 4
reports a methodological review of RCTs of monitoring strategies to consider how successfully the design
has been used to identify patient benefit from monitoring.
The methodological research is reviewed in Chapter 5. Although it is generally acknowledged that
methodological work around monitoring tests has been lacking, there are areas of research that could be
used or adapted for the development and evaluation of monitoring strategies for monitoring for disease
progression or recurrence.
Chapter 6 focuses on the wider impact of monitoring on patients. Ferrante di Ruffano et al.68 have
produced a framework to assist those designing and evaluating trials of diagnostic tests to understand the
ways in which changes to testing strategies can affect patient outcomes. We have adapted this framework
to tests for monitoring, in light of our review of randomised trials. In this chapter we consider the potential
for benefit and harm from monitoring in broad terms, before considering the ways in which patient
outcomes can be mediated by particular aspects of the monitoring care pathway, noting the similarities
and differences between diagnostic and monitoring tests.
Chapter 7 considers how simulation modelling can be used to identify optimal monitoring strategies, prior
to or alongside a randomised trial. Simulation offers a powerful tool to design and evaluate monitoring
INTRODUCTION TO THE METHODOLOGY WORKSTREAM (WORKSTREAM 1)
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rules. However, such models are data intensive, requiring many pieces of information to allow their
construction. For many tests and diseases, limitations in the available data may affect the reliability of the
final model. We explored how information obtained during an ongoing study [the ELF to Uncover Cirrhosis
as an Indication for Diagnosis and Action for Treatable Event (ELUCIDATE) trial] could be incorporated into
a simulation model of the ELF biomarker panel for monitoring patients with known liver fibrosis. The aim
was to optimise monitoring rules to allow earlier detection of liver cirrhosis and to consider whether or not
any resulting adaptations to the design of the ongoing study that were suggested by the model could be
implemented without compromising the validity or clinical value of the trial.
Chapter 8 takes a health economic approach, modelling a method of optimising a monitoring test to meet
a cost-effectiveness target and exploring the feasibility of using value of information analysis to inform
biomarker research and development (R&D).
The final chapter in workstream 1, Chapter 9, brings together our findings and reports on a consultation
with patient and public representatives, considering what we know from current practice in monitoring for
disease progression and recurrence, what we have learned in terms of understanding the monitoring
process and how this should inform the future development and evaluation of monitoring strategies.
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Chapter 3 How is evidence being used to make
recommendations about monitoring?: the example of
prostate-specific antigen
The work described in this chapter has been published in Dinnes et al.69
Introduction
Monitoring involves the scheduled, repeated use of a test or tests in an individual over time to make
decisions about the management of a disease or condition. It is a central activity in the management of
patients, making up a considerable part of the clinical workload and associated cost.62 In contrast, the
volume of published literature on the evaluation and use of tests for monitoring purposes is relatively small.
Mant66 and others62,67 have provided a framework for developing and evaluating a monitoring strategy.
The framework has four main steps: (1) deciding whether or not to monitor, (2) choosing a test,
(3) specifying and assessing the monitoring strategy to be used and (4) an implementation phase.
Underlying this is the key concept that the ‘signal’ from the test, reflecting the status of the underlying
condition, should be greater than the surrounding ‘noise’, or measurement variability, that may affect test
interpretation.66,67 If the ‘noise’ around a test measurement is too high in relation to the signal, one’s
certainty in a given test result will be considerably reduced.
The repeated measurement of PSA in men who have undergone primary treatment of prostate cancer is
an apparently successful example of a rule-based monitoring strategy. The behaviour of PSA following
radical treatment varies, but, in general, recurrence of disease is associated with the presence of PSA
(following radical prostatectomy) or some rise in [following radical radiotherapy (RTX)] PSA level.70 When a
predefined level of PSA is reached, biochemical failure is said to have occurred. The usefulness of PSA as a
monitoring test is based on the assumption that biochemical failure predates clinical failure within some
clinically meaningful time frame. The decision to initiate treatment for recurrence, however, will depend on
multiple factors (M-Factors) rather than on a single PSA value alone.71
We undertook a review of clinical guidelines on monitoring with PSA testing for the detection of recurrent
prostate cancer to determine the extent to which they take into account key factors that should inform
rule-based strategies for monitoring. Our particular focus was on the degree of consistency between
guidelines, the explicit consideration of factors important for specifying a monitoring strategy and the use
of supporting evidence to justify any recommendations.
Methods
Inclusion criteria
Guidelines that considered the use of PSA measurement as a test for monitoring patients treated with
either radical prostatectomy or RTX for localised prostate cancer were eligible. Guidelines that considered
only screening or treatment were excluded. Guideline recommendations regarding PSA measurement
following other potentially curative treatments or as part of active surveillance were not considered.
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Literature searches
MEDLINE was searched from 1999 to July 2009 using the medical subject heading terms (‘Prostatic
Neoplasms’ OR ‘Prostate-Specific Antigen’) AND ‘Practice Guideline’, limited to English-language publications.
The National Library of Guidelines, the Trip database and The Cochrane Library were also accessed and
reference lists of retrieved papers were checked. Titles and abstracts of retrieved records were assessed for
inclusion by two authors independently (JD and JJD), with discrepancies resolved by consensus.
Data extraction
Recommendations or statements relating to the use of PSA testing following treatment with curative intent
were extracted and references to any supporting evidence were noted. Guideline methods were assessed
using the Appraisal of Guidelines for Research and Evaluation (AGREE) framework, which contains 23 key
items organised into six domains.72 We applied only the seven items included in the ‘rigour of development’
domain (Table 1). We replaced the fourth item in this domain with one relevant to using tests for monitoring
as opposed to consideration of benefits and harms of interventions.
A maximum score of 4 points was attached to each of the seven items, giving a maximum score of
28 points. A generous approach to scoring items was used. For example, if a systematic search was
reported to have been carried out but was not reported in detail, the guideline would score 3 out of a
possible 4 points. If a discussion of evidence was provided that appeared to relate to a recommended
monitoring schedule, an explicit link with evidence was judged to have been provided, without closer
examination of the actual evidence cited. We did not make a judgement about the acceptability of any
rationale presented for test frequency or threshold, but indicated whether a rationale was presented or not.
Synthesis
A narrative synthesis was undertaken.
Results
Guidelines (n = 7) or best practice statements (n = 2) from nine organisations were identified.75–83 Four were
North American in origin,77,79,82,83 four were from Europe75,78,80,81 and one was from Australia.76 Eight of the
guidelines75–79,81–83 scored poorly on the framework criteria, with scores between 9 and 16 out of a possible
28 points (Figure 2). The National Institute for Health and Care Excellence (NICE) guideline80 scored
considerably higher, with 22 points. The highest scoring item overall was the use of systematic searches,
which was reported in most guidelines, even if it was often not described in any detail. Methods for
recommendation formulation were described in only three guidelines.78–80 Only one guideline80 fully
considered relevant issues for monitoring tests; this was the only guideline to consistently provide clear links
between its recommendations and the underlying evidence base. It also reported its methods in more detail
than most of the other guidelines in the sample.
Table 2 shows the lack of consistency in guideline recommendations regarding the frequency of follow-up
assessments and thresholds; there does not appear to be any clear pattern in recommendations over time.
Eight75–81,83 of the nine guidelines acknowledged that PSA levels may be affected by technical or biological
variability but in most cases this was presented in the introductory sections of the guidelines, with only one
guideline78 tempering its recommendations with reference to the fact that a single PSA measurement may
be unreliable (recommending retesting within 2 months). Three guidelines79,80,83 acknowledged the potential
impact from technical variation, recommending that the same assay be used at each measurement. Four
guidelines75,78,80,82 made some attempt to justify the interval between tests and three75,79,80 discussed relevant
issues affecting the choice of threshold. A further three76,77,79 stated that it was not possible to provide a
recommendation on the most appropriate biochemical failure definition. Only three77,79,80 of the nine
guidelines commented on the difficulty of using PSA as a monitoring tool because of the uncertainties in its
behaviour following radical treatment, with two79,80 clearly recognising that not all men with biochemical
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TABLE 1 Criteria used to assess the rigour of guideline development with details and examples
Criteria Details Example
1. Systematic search
methods used
Details of the strategy used to search for
evidence should be provided including
search terms used, sources consulted and
dates of the literature covered
Sources may include electronic databases [e.g.
MEDLINE, EMBASE, Cumulative Index to Nursing
and Allied Health Literature (CINAHL)], databases
of systematic reviews [e.g. The Cochrane Library,
Database of Abstracts of Reviews of Effects
(DARE)], handsearching journals, conference
proceedings and other guidelines (e.g. the US
National Guideline Clearinghouse, the German
Guidelines Clearinghouse). Further point for
judgement on the completeness of the search
2. Selection criteria
clearly described
Criteria for including/excluding evidence
identified by the search should be
provided. These criteria should be
explicitly described and reasons for
including and excluding evidence should
be clearly stated
For example, guideline authors may decide to
include only evidence from randomised clinical
trials and to exclude articles not written in English.
Further point for judgement on the application of
the criteria
3. Formulation of
recommendations
clearly described
There should be a description of the
methods used to formulate the
recommendations and how final decisions
were arrived at. Areas of disagreement
and methods of resolving them should be
specified
Methods include, for example, a voting system,
formal consensus techniques (e.g. Delphi, Glaser
techniques)
4. Considers relevant
issues for monitoring
in recommendationsa
The guideline should consider factors
relevant to the monitoring test
Variability in measurements/need for repeat
testing, rationale presented for interval frequency
and PSA threshold and acknowledgement of
the uncertainties in the natural history of PSA
following radical treatment
5. Explicit link with
supporting evidence
There should be an explicit link between
the recommendations and the evidence
on which they are based. Each
recommendation should be linked with a
list of references on which it is based
An explicit link between the recommendations and
the evidence on which they are based should be
included in the guideline. The guideline user should
be able to identify the components of the body of
evidence relevant to each recommendation
6. Pre-publication
external review
A guideline should be reviewed externally
before it is published. A description of the
methodology used to conduct the external
review should be presented, which may
include a list of the reviewers and their
affiliations
Reviewers should not have been involved in
the development group and should include
some experts in the clinical area and some
methodological experts. Patients’ representatives
may also be included
7. Update procedure
described
Guidelines need to reflect current
research. There should be a clear
statement about the procedure for
updating guidelines
For example a timescale has been given or a
standing panel receives regularly updated
literature searches and makes changes as required
a Item 4 relates the original AGREE criterion regarding the ‘health benefits, side effects, and risks of treatment’73 to issues
relevant to monitoring.74
Adapted with permission from Dinnes et al.69 and The AGREE Collaboration73 © Copyright 2010–2014 The AGREE
Research Trust. www.agreetrust.org/
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failure go on to experience clinical failure, such that evidence of the former alone may not be sufficient to
alter treatment.
Many recommendations on frequency or threshold were made with no or few supporting citations (see
Table 1). Only one guideline78 cited a primary study in support of its recommended monitoring intervals and
only four78,80–82 of the nine indicated the level of evidence supporting their recommendations. The levels of
evidence suggested ranged from ‘Guideline Development Group consensus only’ to ‘well-conducted clinical
studies’ (see Table 1), suggesting that different guideline groups had varying views on the quality of the
evidence available.
Despite the general lack of citations in individual guideline documents, a wide range of papers were cited
across the guidelines. In total, 49 papers were cited71,84–131 (Tables 3–5); 31% (15/49) were reviews or
consensus statements and the remainder were primary studies, almost exclusively retrospective in nature.
Of the primary studies, we judged half to have studied the natural history of PSA following treatment and
one-quarter to have evaluated the effect of different biochemical failure definitions on clinical outcomes.
Only two primary studies examining measurement variability were cited.
Most studies were cited by only one or two of the guidelines, but a handful of studies were cited three or
more times (see Table 5). Two consensus statements84,85 were among the most frequently cited studies, as
was a review of biochemical failure definitions.71 The four primary studies had among the largest sample
sizes of all of the cited primary studies: three86–88 evaluated the use of different biochemical failure
definitions and one89 studied the natural history of disease progression in men with raised PSA.
The findings are summarised in Table 6.
Discussion
We found considerable inconsistency in the recommendations in guidelines for the use of PSA as a
monitoring test, even when they were published within a few years of each other. Factors considered to
be important when specifying a monitoring strategy were given limited attention and were not well
supported with reference to primary literature.
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TABLE 2 Guideline statements or recommendations and indication of supporting evidence cited, if any
Recommendation
Guideline
Number of
guidelines
UK PCWG
199975
Aus CN
200276 AUA 200777 aDUA 200778
NCI PDQ
200879 aNICE 200880 AUA 200983 aEAU 200981 aNCCN 200982
1. Frequency of follow-up visits after radical treatment 6/9
Quarterly for 1 or
2 years, then 6
monthly or
annually
✓,b ASTROc – – ✓✓,d 3 primary
studies (level 3)
– – – ✓✓,d none cited
(grade B)
– 3
Every 6 months
(for 2 or 5 years)
then annual
– – ✓,e none
cited
– – ✓✓,b no direct
evidence
(consensus)
– – ✓✓,e 1 primary
study (level 2a)
3
2.1 Threshold for ‘intervention’ following prostatectomy 9/9
Any detectable PSA ✓, none cited – – – ✓, 3 primary
studies
– – – ✓✓, none
cited (level 2a)
3
PSA > 0.2 ng/ml – – – ✓✓, 1 primary
study, 1 review
(level 4)
– ✓, 3 primary
studies, 2
reviews
✓✓, 1 primary
studies, 1
review
✓✓, 4 primary
studies, 2 reviews
(grade B)
– 4
No definite
threshold
recommended
– ✓, 1 primary
study
✓, none cited – – – – – – 2
2.2 Threshold for ‘intervention’ following radiotherapy 9/9
Three consecutive
increases in PSA
(ASTROc)
✓, ASTROc – – ✓✓, ASTROc
(level 4)
– – – – – 2
PSA nadir+ 2 ng/ml
(Phoenixc)
– – – – – – ✓✓, 2 primary
studies,
Phoenixc
✓✓, 2 primary
studies, ASTRO,c
Phoenixc (grade B)
✓✓, Phoenixc
(level 2a)
3
PSA nadir+ 4 ng/ml – – – – – ✓, 3 primary
studies, 1
review, Phoenixc
– – – 1
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TABLE 2 Guideline statements or recommendations and indication of supporting evidence cited, if any (continued )
Recommendation
Guideline
Number of
guidelines
UK PCWG
199975
Aus CN
200276 AUA 200777 aDUA 200778
NCI PDQ
200879 aNICE 200880 AUA 200983 aEAU 200981 aNCCN 200982
No specific
recommendation
– ✓, 2 primary
studies, 1
review
✓, none cited – ✓, 2 primary
studies,
ASTRO,c
Phoenixc
– – – – 3
3. Sources of PSA variability acknowledged and/or remedial action recommendedd 8/9
Technical
variability possible
✓ ✓, 1 primary
study
– ✓, 1 review ✓, 1 primary
study
✓✓ (consensus) ✓, 3 primary
studies
✓, 4 primary
studies
– 7
Biological
variability possible
– ✓ ✓ ✓, 3 primary
studies
– – ✓, 18 primary
studies
✓, 8 primary
studies
– 5
Remedial action
recommended
– – – ✓✓, repeat at
1–2 months
Same assay Same assay Same assay,
3–6 weeks
after biopsy
– 4
4. Acknowledgement of uncertainties in the natural history of PSA and prostate cancer following primary treatment 3/9
– – ✓✓, 1 review – ✓✓, 4 primary
studies
✓✓, 1 primary
study, 1 review
– – –
✓, factors were considered anywhere within the guideline document; ✓✓, factors were considered within the guideline recommendations; –, factors were not acknowledged in the
document; Aus CN, Australian Cancer Network; AUA, American Urological Association; DUA, Dutch Urological Association; EAU, European Association of Urology; NCCN, National
Comprehensive Cancer Network; NCI PDQ, National Cancer Institute – Physician Data Query; UK PCWG, UK Prostate Cancer Working Group.
a Levels of evidence as reported in individual guideline documents: DUA: level 3 – at least one RCT, other comparative study or non-comparative study, level 4 – expert opinion from,
for example, working group members; NICE: consensus – Guideline Development Group consensus; EAU: grade B – well-conducted clinical studies, but without RCTs; NCCN: level 2a –
lower-level evidence and uniform NCCN consensus.
b Initial follow-up schedule to be followed for 2 years.
c Consensus threshold definitions: ASTRO – American Society for Therapeutic Radiology and Oncology 1997 consensus statement;84 Phoenix – 2005 revision of the ASTRO
consensus statement.85
d Initial follow-up schedule to be followed for 1 year.
e Initial follow-up schedule to be followed for 5 years.
Adapted with permission from Dinnes et al.69
Note
An indication of the amount and type of supporting evidence (if any) cited by the guideline is also provided, along with the level of evidence accorded to the recommendation by the
guideline development group in question.
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TABLE 3 Studies used to support guideline recommendations
Study Study design/aim (extracted from abstract) Focus of study
Used to support guideline statements on
Frequency Threshold (RP) Threshold (RT) Variability
Natural
history
ASTRO 199784 Consensus statement providing guidelines for PSA
monitoring following RT
ASTRO consensus
statement
UK PCWG UK PCWG, DUA,
NCI PDQ
Cox 199991 Report of ASTRO consensus panel to develop
evidence-based guidelines for (1) prostate rebiopsy
after radiation and (2) RT with rising PSA levels after
radical prostatectomy in the management of
patients with localised prostatic cancer
ASTRO consensus
statement
NCCN
Roach 200685 Reports second consensus conference to revise the
ASTRO definition of BF
ASTRO consensus
statement
NICE, AUA 2009,
EAU, NCCN, NCI
PDQ
Carroll 200192 Best practice statement (AUA) Best practice statement NICE
Aus 200693 Review of high-intensity focused ultrasound and
cryosurgery as the primary treatment option in
patients with prostate cancer
Review EAU
Bott 200494 Review of management of recurrence following RP Review EAU
Catton 200395 Review/comment paper examining follow-up
strategies
Review NICE
Cookson 200771 AUA review of the variability in published definitions
of biochemical recurrence; recommends a standard
definition in patients treated with RP
Review NICE, AUA 2009 AUA
2007
Edelman 199796 Review of available data on follow-up strategies Review NICE
Lee 200597 Review of PSA kinetics in addition to clinical factors
in the selection of patients for salvage local therapy
Review NCCN
Nelson 200398 Review of RP for prostate cancer Review DUA DUA
Polascik 199999 Review of PSA Review EAU
Selley 1997100 HTA review of prostate cancer management Review Aus CN
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TABLE 3 Studies used to support guideline recommendations (continued )
Study Study design/aim (extracted from abstract) Focus of study
Used to support guideline statements on
Frequency Threshold (RP) Threshold (RT) Variability
Natural
history
Vicini 200590 Review of PSA for monitoring patients after radical
treatment
Review NICE NICE
Yao 2003101 Review/comment paper examining follow-up
strategies
Review NICE
Albertsen
2004102
Retrospective(?) study of 1136 men undergoing
surgery or RT to document patterns of PSA
recurrence and quantify the extent to which
increasing PSA levels predict death
Natural history of
patients post treatment
EAU
Amling 2001103 Retrospective(?) analysis of 2782 men who had
undergone RP to attempt to determine the best PSA
cut-off point for defining BF
Testing definitions of BF EAU
Booker 2004104 Study of telephone follow-up led by a specialist
nurse for patients undergoing RT
Follow-up acceptability NICE
Buyyounouski
2005105
Retrospective(?) review of 688 men who had
undergone RT to compare three definitions of BF in
terms of sensitivity, specificity, etc. for detecting
clinical progression
Testing definitions of BF DUA
Cathala 2003106 Feasibility study of 140 patients undergoing RP to
determine the acceptability of an internet follow-up
service
Follow-up acceptability NICE
Cheung 2005107 Retrospective(?) analysis of 101 men who received
salvage RT for BF after RP to compare outcomes for
patients who received RT alone and for those who
received combined RT and hormonal therapy
Prognosis following
salvage treatment
NCCN
Crook 1997108 Prospective study of 207 patients to correlate the
failure pattern after RT with pretreatment PSA and
post-RT nadir PSA levels
Natural history of
patients post treatment
UK PCWG
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Study Study design/aim (extracted from abstract) Focus of study
Used to support guideline statements on
Frequency Threshold (RP) Threshold (RT) Variability
Natural
history
D’Amico 2004109 Retrospective review of 8669 men who had
undergone radical treatment to determine whether
or not a short post-treatment PSA doubling time is a
suitable surrogate end point for prostate cancer-
specific mortality
Natural history of
patients without
treatment
NICE
Eastham 2003110 Retrospective analysis of an unscreened population
of 972 men over 4 years to determine whether or
not year-to-year fluctuations in PSA levels are due to
natural variation, rendering a single PSA test result
unreliable
Measurement variability EAU
Frazier 1993111 Analysis of 226 patients who underwent radical
perineal prostatectomy to identify whether or
not a raised serum PSA level infers failure of the
procedure
Natural history of
patients post treatment
NCI PDQ NCI PDQ
Horwitz 200587 Determined the sensitivity and specificity of several
BF definitions using pooled data on 4839 patients
treated with external-beam RT alone
Testing definitions of BF AUA 2007, AUA
2009, NICE
Klotz 2005112 Reports PSA doubling time in a series of 299
patients undergoing active surveillance for prostate
cancer
Natural history of
patients post treatment
DUA
Kuban 200686 Primary study of 2693 patients treated with a
radioisotopic implant as solitary treatment for T1–T2
prostatic adenocarcinoma. Multiple PSA failure
definitions were tested for their ability to predict
clinical failure
Testing definitions of BF AUA 2007, AUA
2009, NICE
NCI PDQ
Leibman 1995113 Retrospective review of 628 patients who
underwent RP to determine whether or not prostate
cancer recurrence can occur without an increase in
serum PSA levels
Natural history of
patients post treatment
EAU
Nielsen 2008114 Retrospective review of data from 2570 men who
had undergone RP to examine the effect of applying
the 2005 ASTRO definition of BF (for RT patients) to
surgical series
Testing definitions of BF AUA 2009
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TABLE 3 Studies used to support guideline recommendations (continued )
Study Study design/aim (extracted from abstract) Focus of study
Used to support guideline statements on
Frequency Threshold (RP) Threshold (RT) Variability
Natural
history
Niwakawa
2002115
Study of 221 patients treated with RP to determine
the optimal frequency and method of follow-up to
minimise medical costs
Follow-up – optimal
frequency
DUA
Oefelein 1995116 Retrospective review of data from 394 men who
underwent RP to characterise the incidence of
recurrent carcinoma despite undetectable serum
PSA levels
Natural history of
patients post treatment
EAU
Patel 2005117 Retrospective review of 48 patients who had
undergone salvage RT for biochemical relapse after
RP to determine whether or not PSA velocity is a
suitable selection criterion for salvage radiotherapy
Prognosis following
salvage treatment
NCCN
Pickles 2006118 Analysis of a ‘prospective’ database of 2030
patients who underwent external-beam RT or
brachytherapy to determine the false-call rate for
PSA relapse according to nine different PSA relapse
definitions after a PSA bounce has occurred
Testing definitions of BF NICE
Pound 199989 Retrospective review of a large surgical series
(n= 1997) to examine the natural history of
progression to distant metastases in men with a
raised PSA level following surgery
Natural history of
patients post treatment
DUA,
NCCN
NCI PDQ, DUA,
NICE, EAU
NCI PDQ,
NICE
Ragde 1997119 Study of 126 patients with localised prostate cancer
to determine the efficacy of treatment with iodine-
125 radionuclides (two definitions of PSA failure
used)
Testing definitions of BF Aus CN
Ray 2006120 Retrospective(?) review of 4839 patients treated
definitively with RT to determine the significance of
PSA nadir and time to PSA nadir in predicting
biochemical or clinical DSF
Natural history of
patients post treatment
EAU
Ritter 1992121 Study of the prognostic value of PSA in
pretreatment evaluation and post-treatment
follow-up in 63 patients undergoing RT for localised
prostate cancer
Natural history of
patients post treatment
Aus CN
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Study Study design/aim (extracted from abstract) Focus of study
Used to support guideline statements on
Frequency Threshold (RP) Threshold (RT) Variability
Natural
history
Rose 1996122 To identify patients’ symptoms following completion
of RT for common cancers by a nurse-managed
telephone interview (n= 111)
Follow-up acceptability NICE
Sandler 2000123 Retrospective database study of 1844 patients who
had undergone RT and had a minimum of two
post-RT PSA measurements separated by at least
1 week to determine the significance of BF (i.e. in
terms of survival)
Natural history of
patients post treatment
NCI PDQ NCI PDQ
Sartor 1997124 Primary study of 400 patients treated with RT to
determine whether or not the rate of PSA rise could
differentiate future local vs. metastatic failure
Natural history of
patients post treatment
UK PCWG
Stamey 1989125 Study of pre- and post-treatment serum PSA levels
in 102 men who underwent RP to determine the
usefulness of PSA as a preoperative marker
Natural history of
patients post treatment
NCI PDQ, EAU
Stephan 2006126 Assessed five frequently used commercial assay
combinations in sera from 314 patients with
prostate cancer and 282 men with no evidence of
prostate cancer to identify the interchangeability of
the PSA values
Measurement variability EAU
Stephenson
2004127
Retrospective review of 501 patients who underwent
salvage RT following RP to identify those variables
indicative of a durable response
Prognosis following
salvage treatment
NCCN
Stephenson
200688
Tested 10 definitions of BF on 3125 patients who
underwent RP, to identify the one that best explains
metastatic progression
Testing definitions of BF AUA 2009, EAU,
NICE
Trapasso 1994128 Primary study of 601 patients undergoing radical
retropubic prostatectomy followed by serial PSA
measurement. Evaluated rate of detectable PSA
(> 0.4 ng/ml) as an indicator of cancer progression
Natural history of
patients post treatment
EAU EAU
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TABLE 3 Studies used to support guideline recommendations (continued )
Study Study design/aim (extracted from abstract) Focus of study
Used to support guideline statements on
Frequency Threshold (RP) Threshold (RT) Variability
Natural
history
Trock 2008129 Retrospective analysis of a cohort of 635 men
undergoing RP and who experienced biochemical
and/or local recurrence to determine the effect of
salvage RT and to identify subgroups for whom
salvage treatment is most beneficial
Prognosis following
salvage treatment
NCCN
Ward 2004130 Retrospective cohort study of 211 men with
detectable PSA levels following RP to determine
whether or not PSA doubling time predicts
outcomes following salvage RT
Natural history of
patients post treatment
NCCN
Zagars 1997131 Analysis of 841 men with serial PSA measurements
who underwent external-beam RT without
androgen ablation to determine the kinetics of
serum PSA after RT and to evaluate whether or not
such kinetics provide prognostic information
Natural history of
patients post treatment
UK PCWG
Aus CN, Australian Cancer Network; AUA, American Urological Association; BF, biochemical failure; DFS, disease-free survival; DUA, Dutch Urological Association; EAU, European Association
of Urology; HTA, health technology assessment; NCCN, National Comprehensive Cancer Network; NCI PDQ, National Cancer Institute – Physician Data Query; RP, radical prostatectomy;
RT, radiotherapy; UK PCWG, UK Prostate Cancer Working Group.
Adapted with permission from Dinnes et al.69
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TABLE 4 Types of studies used to support guideline recommendations
Type of study
Number of
studies per
group
Used to support guideline recommendations on
Test
frequency
Threshold
(RP)
Threshold
(RT) Variability
Uncertainty
in natural
history
ASTRO consensus statements 3 ✗ ✗
Best practice statement 1 ✗
Reviews 11 ✗ ✗ ✗ ✗ ✗
Primary studies 34 ✗ ✗ ✗ ✗
Follow-up (acceptability of) 3 ✗
Follow-up (optimal frequency) 1 ✗
Natural history of PSA post
treatment
15 ✗ ✗ ✗ ✗
Natural history of PSA
without treatment
1 ✗
Salvage RTX outcomes 4 ✗
Testing BF definitions 8 ✗ ✗ ✗
Measurement variability 2 ✗
Number of guidelines citing
evidence
4 6 7 2 3
ASTRO, American Society for Therapeutic Radiology and Oncology; BF, biochemical failure; RP, radical prostatectomy;
RT, radiotherapy.
Adapted with permission from Dinnes et al.69
TABLE 5 Most commonly (three or more) cited studies supporting guideline statements
Study Study design/aim (extracted from abstract)
Used to support
statements on
Number of
times cited
Roach
200685
Reports second consensus conference to revise the ASTRO definition of BF Threshold (RTX) 5
Pound
199989
Retrospective review of a large surgical series (n = 1997) to examine the
natural history of progression to distant metastases in men with a raised
PSA level following surgery
Frequency,
threshold (RP),
natural history
5
Kuban
200686
Primary study of patients treated with a radioisotopic implant as solitary
treatment for localised prostate cancer (n= 2693). Multiple PSA failure
definitions were tested for their ability to predict clinical failure
Threshold (RTX),
natural history
4
ASTRO
199784
Consensus statement providing guidelines for PSA testing following
radiation therapy
Frequency,
threshold (RTX)
3
Cookson
200771
AUA review of the variability in published definitions of biochemical
recurrence; recommends a standard definition in patients treated with RP
Threshold (RP),
natural history
3
Horwitz
200587
Determined the sensitivity and specificity of several BF definitions using pooled
data on 4839 patients treated with external-beam radiotherapy alone
Threshold (RTX) 3
Stephenson
200688
Tested 10 definitions of BF on 3125 patients who underwent RP, to identify
the one that best explains metastatic progression
Threshold (RP) 3
ASTRO, American Society for Therapeutic Radiology and Oncology; AUA, American Urological Association; BF, biochemical
failure; RP, radical prostatectomy.
Adapted with permission from Dinnes et al.69
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TABLE 6 Table of identified guidelines and summary of the rigour of development (adapted from AGREE framework72)
Study Brief description
Rating on the evaluation instrument
Comment
Systematic
search
methods
used
Selection
criteria
clearly
described
Formulation of
recommendations
clearly described
Considers
relevant issues
for monitoring in
recommendations
Explicit
link with
supporting
evidence
Pre-
publication
external
review
Update
procedure
described Total
AUA 200777 Localised prostate
cancer management
guideline
2 3 1 1 1 2 3 13 One database used, search poorly reported;
inclusion criteria described but grounds
for later exclusion of papers not clear;
limited description of recommendation
formulation; no basis for interval between
measurements; evidence-based
recommendations for threshold not possible;
natural history uncertainty acknowledged in
recommendations, variability acknowledged
but not in recommendations; no link
between recommendations and evidence;
external review carried out but not
described; update recommended and to
include only RCT evidence
AUA 200983 PSA best practice
statement
1 1 2 1 2 2 1 10 No systematic search; inclusion criteria
not described; some description of
recommendation formulation; no interval
between measurements recommended;
consensus definition of threshold
used; natural history uncertainty not
acknowledged; variability acknowledged
but not in recommendations; some
supporting evidence cited; peer review
carried out but not described in detail;
no mention of update
Aus CN 200276 Localised prostate
cancer management
evidence-based
recommendations
4 1 2 1 2 2 2 14 Comprehensive and systematic search
described; inclusion criteria not described;
no interval between measurements
recommended; states no widely accepted
biochemical range applicable; natural
history uncertainty not acknowledged;
variability acknowledged but not in
recommendations; some supporting
evidence cited; internal review carried out
but not described in detail; update
recommended but procedure not
described
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Study Brief description
Rating on the evaluation instrument
Comment
Systematic
search
methods
used
Selection
criteria
clearly
described
Formulation of
recommendations
clearly described
Considers
relevant issues
for monitoring in
recommendations
Explicit
link with
supporting
evidence
Pre-
publication
external
review
Update
procedure
described Total
DUA 200778 Prostate cancer
management
guideline
3 2 3 2 2 2 2 16 Systematic search carried out but not fully
described; some description of inclusion
criteria; interval between measurements
based on evidence; consensus threshold
used for post RT, no justification for
threshold post RP; natural history uncertainty
not acknowledged; variability acknowledged
but not in recommendations; some link to
supporting evidence; external review partly
described; update recommended but
procedure not described
EAU 200981 Prostate cancer
management
guideline
2 1 1 1 2 2 1 10 Systematic search carried out but only
partly described; no description of inclusion
criteria; formulation of recommendations
not described; no basis for interval between
measurements; consensus thresholds
used; natural history uncertainty not
acknowledged; variability acknowledged
but not in recommendations; some link to
supporting evidence; external review
conducted but not described; no mention
of update
NCI PDQ 200879 Prostate cancer
treatment evidence-
based summary for
health professionals
1 1 3 3 2 1 2 13 No search described; no description of
inclusion criteria; formulation of
recommendations not described; no interval
between measurements recommended;
evidence-based recommendations for
threshold post RT not possible, basis for
post-RP threshold given; natural history
uncertainty acknowledged in
recommendations; the importance of
variability was acknowledged, but no
specific recommendations were made about
the handling of variability and the associated
uncertainty; some links to supporting
evidence; external review not described;
limited description of update procedures
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TABLE 6 Table of identified guidelines and summary of the rigour of development (adapted from AGREE framework72) (continued )
Study Brief description
Rating on the evaluation instrument
Comment
Systematic
search
methods
used
Selection
criteria
clearly
described
Formulation of
recommendations
clearly described
Considers
relevant issues
for monitoring in
recommendations
Explicit
link with
supporting
evidence
Pre-
publication
external
review
Update
procedure
described Total
NCCN 200982 Prostate cancer
management
guideline
1 1 1 2 2 1 1 9 No search described; no description of
inclusion criteria; no description of
formulation of recommendations; some
justification given for interval between
measurements; consensus threshold used
for post RT, no justification for post-RP
threshold; natural history uncertainty and
variability not acknowledged; some links
to supporting evidence; external review
not described; no mention of update
NICE 200880 Prostate cancer
diagnosis and
treatment guideline
4 3 3 4 3 2 3 22 Systematic search carried out and fully
described; inclusion criteria developed
for each question but not reported;
recommendation formulation described
but methods used to deal with
disagreement not reported; attempted to
find evidence to justify interval between
measurements; relevant discussion
regarding choice of thresholds; natural
history uncertainty and variability
acknowledged in recommendations; clear
link to supporting evidence; external
review not described; an update of the
guideline was recommended and some
details of the procedure required are
described
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Study Brief description
Rating on the evaluation instrument
Comment
Systematic
search
methods
used
Selection
criteria
clearly
described
Formulation of
recommendations
clearly described
Considers
relevant issues
for monitoring in
recommendations
Explicit
link with
supporting
evidence
Pre-
publication
external
review
Update
procedure
described Total
Royal College of
Radiologists’
Clinical Oncology
Information
Network, British
Association of
Urological
Surgeons 199975
Prostate cancer
management
guideline
3 1 2 2 2 1 1 12 Systematic search carried out and fully
described; inclusion criteria developed
for each question but not reported;
recommendation formulation described but
methods used to deal with disagreement
not reported; interval between
measurements justified; relevant discussion
regarding choice of threshold post RT
only; natural history uncertainty not
acknowledged, variability acknowledged
but not in recommendations; clear link to
supporting evidence; external review not
described; update recommended but and
procedure described
Aus CN, Australian Cancer Network; AUA, American Urological Association; DUA, Dutch Urological Association; EAU, European Association of Urology; NCCN, National Comprehensive
Cancer Network; NCI PDQ, National Cancer Institute – Physician Data Query; RP, radical prostatectomy; RT, radiotherapy.
Adapted with permission from Dinnes et al.69
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Recommendations on when to test and what action to take following a given test result were very much
considered in isolation from each other. ‘When to test’ appeared to be almost exclusively determined by
standard follow-up schedules rather than having any scientific basis. Although most guidelines acknowledged
the potential presence of measurement variability, they did not attempt to account for its potential effect on
test interpretation. A systematic review of biological variation in PSA levels has found a mean biological
variability of 20%.132 Using reference change value (RCV) methodology it concluded that, to be 95% sure
that a change in total PSA level is not the result of random variation, the change needs to be around 50%
of the previous measurement.132 This review was not cited by any of the eight guidelines subsequently
published.
Recommendations on when to take action were based on consensus statements or retrospective case
series, with little attention paid to variations in the definition of the threshold, the definition of clinical
failure and the frequency and length of follow-up between studies, all of which can affect the accuracy of
any given cut-off point. Sensitivity and specificity are also known to be affected by differences in patient
case mix between studies.133 This was not acknowledged by any of the identified guidelines. However,
a 2005 review of PSA measurement for monitoring prostate cancer90 found it impossible to recommend
any single definition of biochemical failure following either surgery or radiotherapy for the reasons listed
above. This review was cited by only one of the nine guidelines,80 possibly because it was not a full
systematic review. Given the lack of description of inclusion criteria used in the guidelines, it is difficult to
reconcile why an individual study or review was included or not.
Reviews of guidelines in other areas have shown similar findings regarding the presentation of evidence for
recommended monitoring schedules.134,135 Reviews of treatment and diagnostic guidelines have identified a
similar inconsistency in recommendations between guidelines and variation in evidence cited, with some
referring to a substantial body of evidence and others presenting very little evidence.136–140
A number of factors are likely to contribute to these findings. In the first instance, although this area is
beginning to receive more attention, there is a lack of high-quality evidence, and indeed lack of clear
methodological guidance, on what to consider when establishing monitoring strategies.38 It is, therefore,
perhaps not surprising that relevant evidence has not been used to inform guidelines.
Second, the various pieces of information needed to inform a monitoring strategy are not usually available
from a single study. Ideally, one or more monitoring strategies should be evaluated in a RCT or some form
of prospective comparative study. When there is high-quality evidence, greater consensus between
guideline recommendations and stronger guideline recommendations have been found.136 Randomised
trials of monitoring, however, have their own challenges and are consequently relatively rare. Instead,
evidence has to be gathered from various sources. Although the diversity of evidence needed to inform
coherent monitoring strategies makes the identification of relevant pieces of evidence a challenge for
guideline developers and likely adds to the inconsistency in recommendations between guidelines,
guideline developers have a responsibility to highlight recommendations for which there is a lack of
evidence or the evidence is inconsistent.
Efforts to improve the evidence base for monitoring are ongoing. For example, a Bayesian hierarchical
change-point model has been used to simulate multiple post-radiotherapy PSA series from primary data;
the sensitivity and specificity of different definitions of biochemical failure were then compared, allowing
characteristics that might affect accuracy to be controlled for.141 More pertinently, statistical models using
estimates of mean change and variability in a measurement over time to suggest optimal monitoring
intervals are being developed. A review142 of four case studies143–146 found that for each topic the results
suggested overfrequent monitoring. There is clear potential for the extension of this work to monitoring in
other settings.
Finally, general failings in the guideline development process are likely to contribute significantly to the
variations between published guidelines. In a review of hypertension guidelines, Campbell et al.138 found a
HOW IS EVIDENCE BEING USED TO MAKE RECOMMENDATIONS ABOUT MONITORING?
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lack of methodological rigour in the guideline development process. In our sample, NICE80 and the Australian
Cancer Network76 were the only organisations to cite a published handbook on guideline development,147
which may explain their higher ratings on the evaluation instrument; those clearly based on expert consensus
tended to score considerably lower.83 Others suggest that the greater the involvement of clinical experts in
the development process of the guideline, the less the recommendations reflect the research evidence.137 It is
likely that, in the absence of clear methodologies for assessing monitoring strategies, greater involvement of
methodologists on guideline panels would be beneficial.
Strengths and limitations
Our research has some limitations. Our literature search was limited to one major medical database,
supplemented with searches of more specialist resources, and records were limited to English-language
studies only. We believe, however, that we have identified key guidelines that provide a good
representation of the methodologies in use by well-known agencies. Although other guidelines may be
available, they are unlikely to have used alternative methods or to have reported on evidence that the
included guidelines have missed.
Second, our use of the original AGREE instrument may be criticised given that it was published in 2003;
however, at the time that the framework was chosen, the update to the original instrument148 and other
potentially useful frameworks were not yet available.146,149,150 Nevertheless, our approach to assessing
the development and content of the guidelines was systematic and provides a reasonable means of
comparison between guidelines.
We were not able to comment fully on the state of the underlying literature cited in support of the
monitoring schedules as we did not retrieve copies of all of the cited primary studies. Furthermore, our
‘generous’ approach to associating citations to recommendations may have inadvertently led to citations
being incorrectly associated with recommendations. This may have led to some bias in favour of the
guidelines. However, this could be avoided only by carrying out a full review of all of the evidence cited or
by direct contact with the guideline authors to determine which aspect of the recommendations were
supported by the citations given, both of which were outside the scope of this review.
Finally, our use of only one case study may limit the generalisability of our results to other topic areas.
However, we have no reason to believe that the picture would be any better or any worse for other fields
and, indeed, Moschetti et al.135 found similar results for monitoring in cardiovascular disease.
Our systematic approach to assessing the development and content of the guidelines provides a valuable
insight into how strategies for monitoring are developed and reported and we were able to present a
general picture of the types of evidence that have been cited. The true picture may be even worse given
our attempt to attribute citations to recommendations whenever possible.
Conclusions
Our findings highlight the lack of a scientific or systematic approach to the development of monitoring
schedules for the use of PSA testing, as reported in clinical guidelines. This is the result of both
inadequacies in the evidence base and inappropriate use of the available evidence, resulting in
considerable inconsistencies between guidelines.
Guideline developers should be encouraged to adopt systematic approaches to guideline development,
such as those developed in Australia149 and the USA,150 and should take care to explicitly consider each
element of a recommended monitoring schedule (interval, threshold and action to be taken on crossing
that threshold) and the standard of its evidence base.
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Chapter 4 Has the randomised controlled trial
design been successfully used to evaluate strategies
for monitoring disease progression or recurrence?
An assessment of experience to date
Introduction
Clinical consultations between patient and clinician usually involve the use of tests, often starting with a
general clinical assessment and physical examination but also including the application of specific tests,
from tools assessing functional or psychological status, to blood or urine tests, physiological measurements
of, for example, blood pressure, imaging tests or more invasive assessments such as a colonoscopy or
biopsy. Testing can inform a diagnosis or can be used for monitoring whereby a test, or set of tests, is
applied repeatedly over time to assist in the management of a disease or condition. Our particular interest
is in monitoring individuals with (or at risk of) a disease or condition that is likely to progress or recur
at some time in the future. This is distinct from monitoring in a treatment titration context, in which the
aim is to keep a marker within predefined limits until treatment can be discontinued or an alternative
treatment is required. Although monitoring for disease progression or recurrence can serve many purposes,
including providing reassurance to patients or clinicians, it is usually undertaken to allow timely decisions
to be made regarding patient management. Management decisions include the initiation of treatment to
prevent some clinical outcome from occurring (e.g. variceal bleeding subsequent to cirrhosis of the liver
or infertility as a result of Turner syndrome), delay a clinical event [e.g. progression to acquired immune
deficiency syndrome (AIDS) in HIV infection] or otherwise improve outcome (e.g. through earlier treatment
of cancer recurrence); additionally, the goal may be to avoid or delay treatment in those who may not
need it (e.g. surveillance of mild hip dysplasia in infants).
Whatever the goal, monitoring is a central activity for patient and disease management and, just as for
therapeutic interventions and for tests used in a diagnostic context, it is important to identify its impact on
patient outcomes: ‘the primary purpose of using . . . tests should . . . be to prevent premature death and
suffering and restore functional health’.151 Given the advantages of the RCT design for the evaluation of
therapeutic interventions, it is tempting to assume that the same approach must be the gold standard for
the evaluation of all monitoring strategies.
Trials of monitoring regimes present considerable challenges, however. As for diagnostic tests, trials of
monitoring evaluate a particular strategy, with tests applied at specific intervals, defined thresholds for
changing patient management and prescription of effective interventions, all of which should be specified
in advance and ideally supported by previous research. The complexity of such strategies, and in particular
the serial nature of testing, and consequent potential for ‘interactions between tests, repeated tests, test
results and the decisions based on these results’ may necessitate unfeasibly large sample sizes to detect
an effect on important patient outcomes.152 Furthermore, even with careful planning it may be difficult to
capture in a RCT the wider patient impact of testing, whether it is used for diagnostic, screening or
monitoring purposes. Ferrante di Ruffano et al.68 have outlined a range of effects from testing in a
diagnostic context, including emotional, cognitive and behavioural effects, which also have applications
in monitoring.
We conducted a methodological review of RCTs of monitoring to gain some insight into how successfully
the design has been used to identify patient benefit from monitoring.
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Methods
Literature search
Our target sample size was 60 RCTs. The Cochrane Central Register of Controlled Trials (CENTRAL) was
searched to retrieve relevant records (last updated 21 July 2011; details available from authors). The search
was supplemented by screening all RCTs funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and those published in the Trials journal (to December 2011). After
assimilation of studies meeting the inclusion criteria, a search of the US NIH ClinicalTrials.gov database was
carried out (using the keywords monitor#, surveill# or early or immediate treatment) and the results were
purposively sampled to include trials conducted in topic areas that would complement those already
identified. The sampling was not carried out on the basis of trial quality. Attempts were made to identify
publications related to these trials using Google Scholar and by contacting trial principal investigators to
request copies of their protocols or trial reports.
Inclusion criteria
Trials were eligible for inclusion if they considered monitoring of a disease or condition that is likely to
progress or recur at some time in the future. RCTs in which the main purpose of monitoring was treatment
titration or improvement in adherence to a treatment regimen or those evaluating methods of delivering
monitoring were excluded as were trials of tests used for population-based screening or for diagnosis. Trials
had to compare at least one formal monitoring strategy with no formal monitoring, an alternative monitoring
strategy or an immediate treatment option. All clinical topics, test types and outcomes were eligible.
Trials reported only as protocols were included, but those available only in abstract form and non-English-
language papers were excluded. Multiple reports of a single trial were assimilated through cross-referencing.
The search was conducted by and search results were screened by one reviewer (JaD).
Data extraction and analysis
A data extraction form was designed and piloted. Data were extracted on items including the study
population and topic area, monitoring strategies or interventions in the experimental and control arms
(including details of the testing frequency, threshold and intervention), the citation of evidence to support
these features of the monitoring strategies, study design and validity criteria (see Table 1). Details of the
primary outcomes used were also extracted, with outcomes classified as patient, process or composite
outcomes; if not clearly reported the outcome used in the study’s power calculation was extracted or, failing
that, the outcome most closely related to the study aim was extracted. When final analyses were reported,
the result for the primary outcome was extracted and, when possible, this was compared graphically with
that predicted in the sample size calculation. For 30 trials, data were extracted independently by two
authors (JaD and AS or JP); for the remaining 28 trials, data were extracted by one author (JaD) and were
checked by a second (AS or JP). Any disagreements were resolved by consensus.
Studies were considered according to topic area, types of tests and monitoring strategies, the study aim
and change in patient care that was evaluated, study validity and primary outcomes and results.
Results
The CENTRAL search retrieved 4697 potentially eligible records (Figure 3), of which 119 titles were selected
for further evaluation, along with nine trials identified from the Health Technology Assessment database
and the Trials journal. Following full-text review, 49 trials published in 58 publications were selected for
inclusion. Twenty trials identified from the ClinicalTrials.gov database were selected and the trial principal
investigators were contacted. Documents related to 12 of these were successfully retrieved, of which seven
met the inclusion criteria. Reference list screening identified a further two eligible trials. Of the 58 included
trials, five were reported in two publications153,154 and 19 previous or related publications were also
RCT DESIGN FOR MONITORING DISEASE PROGRESSION AND RECURRENCE
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identified (for a total of 74 papers153–225). Figure 4 shows that there was a general upwards trend in the
number of trials published per year.
General description of the included trials
The trials were primarily conducted in the fields of cancer (29%), cardiovascular disease (16%) and renal
disease (16%) (Table 7). A further 9% of trials were conducted in patients with aneurysm – either
abdominal aortic or cranial – and 9% of trials were conducted in transplant recipients, including stem cell
and bone marrow transplant recipients. Most were parallel in design, except for six multiarm trials; the
total number of experimental arms was 68.
Of the 58 trials, 34 were available as full trial reports, 10 as interim analyses and 14 as trial protocols.
Twelve trials were stopped early (21%); interim analyses were available for nine of these trials and a
protocol only was available for the remaining three trials. The most common reason for a trial stopping
was a lower than expected event rate in the control group (33%; 4/12). Three-quarters of the trials
reported sample size calculations (78%; 45/58) and one-quarter were industry sponsored (24%; 14/58).
The median sample size was 272 [interquartile range (IQR) 120–599] and the median follow-up was
21 months (IQR 12–60).
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FIGURE 3 Flow diagram of the trial selection process. HTA, Health Technology Assessment.
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Description of monitoring strategies
A total of 139 tests were applied in the control arms of 55 RCTs, excluding those with no formal
surveillance or those in which all patients were treated (Table 8). After clinical examination, imaging tests
were the most commonly used tests (39%). The 55 ‘new’ tests applied in the experimental arms included
biochemical (35%), imaging (34%) and physiological (16%) tests and implanted devices (9%).
Figure 5 shows that, although the frequency of application of the tests was well reported, the method of
application of the tests was provided for only two-thirds of the experimental arms and fewer than half
of the control arms. The test thresholds, describing when a change is patient management is indicated,
were reported for 79% and 51% of the experimental and control arms, respectively. A simple threshold
approach (i.e. in which the patient crosses a predefined threshold on a single test measurement) was used
to judge an abnormal test result in 35% of control tests and 38% of experimental tests (see Table 8). Few
trials reported using test measurements over time to define an abnormal result, although the percentages
were higher for the experimental tests: the change from the previous measurement was reported for 1%
of control tests and 7% of experimental tests and a more complex algorithm taking account of more than
one test result was reported for 7% and 11% of the control and experimental tests, respectively. There
was also limited reporting of repeated testing to confirm abnormal or indeterminate test results [reported
for < 20% of tests in both arms (see Table 8)].
The recommended change in patient management following a positive monitoring test was the same in
the experimental and control groups for 69% of trials. The change in management prescribed was usually
treatment (45% of both the control and the experimental arms). Some form of confirmatory testing was
indicated in 31% and 41% of the control and experimental arms, respectively (see Table 8), with many
studies also recommending the treatment to be used following a positive confirmatory test. Details of
the actual intervention given and method of application of the intervention were provided for 74% and
28% of the experimental arms, respectively, compared with only 62% and 22% of the control arms,
respectively (see Figure 5).
More evidence was cited to support the various elements of the monitoring strategies for the experimental
arms than for the control arms (Figure 6); however, many of the previous studies were cited in the
introduction or discussion sections of the papers rather than being cited to explicitly support particular test
frequencies, test thresholds or interventions reported in the methods sections.
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FIGURE 4 Number of trials published over time. The seven trials identified from ClinicalTrials.gov were published in
2007 (n= 1), 2009 (n= 1), 2010 (n = 3) and 2011 (n= 2).
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TABLE 7 General description of the included trials (N= 58)
Characteristic
Number
of trials
Percentage
of trials Notes
Patient group
Cancer 17 29
Cardiovascular disease 9 16 All with implanted devices
Renal disease 9 16 All haemodialysis recipients
Aneurysm 5 9 4 abdominal aortic
aneurysm, 1 intracranial
aneurysm
Transplant recipients 5 9 3 stem cell/bone marrow,
2 solid organ
Other (fewer than three trials per group) 13 22
Number of study arms
2 52 90
3 2 3
4 4 7
Publication type
Full trial report 34 59
Interim analysis 11 19 9/11 stopped early
Protocol 13 22 3/13 stopped early
Trial early-stopping reasons (n= 12)
Recruitment difficulties 3 25
Technology issues 3 25
Interim analyses showed (n= 12)
Early superiority 1 8
No evidence of benefit 1 8
Low event rate in control group 4 33
Sample size calculations
Reported 45 78
Full trial reports (n= 34) 25 74
Interim analyses (n= 10) 8 80
Protocol only (n = 14) 12 86
Study funding
Industry sponsored 14 24
Non-industry sponsored 33 57
Not reported 11 19
Total number of participants randomised, median (IQR; range)a 272 (120–599; 64–4439)
Length of follow-up (months), median (IQR; range)a 21 (12–60; 1–240)
IQR, interquartile range.
a Full trial reports only (n= 34).
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TABLE 8 Details of monitoring schemes
Details
Trial arm
Control (N= 139 testsa) Experimental (N= 55 testsb)
n % n %
Type of test
Biochemical 15 11 19 35
Clinical 53 38 0 0
Cytological 0 0 2 4
Histological 1 1 1 2
Imaging 46 33 16 29
Imaging (invasive) 8 6 3 5
Implanted device 4 3 5 9
Physiological 12 9 9 16
Type of threshold used (excluding clinical assessment)
Not reported 41 48 18 33
Simple threshold 30 35 21 38
Change from previous measurement 1 1 4 7
Algorithm 6 7 6 11
More than one threshold 8 9 6 11
Trial arm
Control (N= 86 testsc) Experimental (N= 55 tests)
n % n %
Repeat measure taken to confirm abnormal result (excluding clinical assessments)
All abnormal 8 9 4 7
Indeterminate only 7 8 4 7
Not repeated 0 0 1 2
Not reported 71 83 46 84
Change in patient management following positive monitoring test (N = 58 trials)
Confirmatory testing (non-invasive) 10d 17 10 17
Confirmatory testing (invasive) 8 14 14 24
Treatment 26 45 26e 45
Treatment or further investigation 2 3 1 2
More intensive surveillance + treatment option 1 2 2 3
Not described 11 19 5 9
a Excludes one trial in which the control arm underwent immediate treatment and two trials in which no formal
surveillance was standard practice.
b Out of a total of 68 experimental arms, we excluded 13 arms in which no new test was introduced (test frequency
varied), nine ‘treat all on recruitment’ arms (the remaining three of the treatment trials were included as randomisation
was conditional on crossing a predefined threshold) and one study evaluating no formal surveillance. Of the 45
remaining experimental arms, eight added or replaced more than one test; hence, the total number of tests is 55.
c Excludes 53 ‘clinical assessments’.
d Includes one trial in which the experimental arm involved ‘treat all on recruitment’ but the confirmatory test was
performed first.
e Includes 12 trials in which the experimental arms received immediate treatment.
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What was the aim of the monitoring evaluation and what change in patient care
was implemented?
In 78% (45/58) of the trials, usual care in the control arm was based on some form of clinical assessment
(Table 9), often with a focus on one main test (12/58) or more commonly a battery of other tests (21/58).
Across the 68 experimental arms, the most common change in monitoring was the addition of a new test
to an existing monitoring strategy (n = 29) or as triage to a more invasive test (n = 3). In 12 experimental
arms, there was no change in the tests used, but test frequency was increased (n = 5) or decreased (n = 7).
In 53% of the experimental arms (36/68), the frequency of outpatient visits undertaken by patients was
the same as for the control arm.
For most trials, the change in patient management was intended to improve patient outcomes (75%; 51/68),
either through earlier initiation of treatment or better selection of patients requiring treatment (Figure 7). This
was generally achieved through the addition of a new test to an existing monitoring strategy (55%; 28/51),
although, in 12 (24%) studies, triallists evaluated earlier treatment by enrolling patients who had not yet
reached the standard (implicit or explicit) threshold for treatment and randomising them to either an
immediate treatment option or continued surveillance. In four studies,155–157,226 there was an explicit underlying
evaluation of a monitoring strategy as patients in both groups were monitored with a specific test following
recruitment and randomised only when their test result crossed a predefined threshold for intervention.
For the remainder of the studies, the goal was to maintain the same patient outcomes (25%; 17/68) but
to reduce the amount of testing undertaken, either by reducing the number of tests (n = 9) or reducing
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FIGURE 5 Adequate description of monitoring strategy elements.
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FIGURE 6 Citation of evidence to support features of the monitoring strategies. NA, not applicable; Rx, treated.
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TABLE 9 What change in patient care was evaluated?
Control arms
(n= 58a) Total, n
% of total
(n= 8)
Experimental arms (n= 68a)
Change in testing strategy
Effect on frequency of office
visits
Addition
of test
As triage to
existing
test
Replacement
test
Same test(s)
(change in test
frequency)
Fewer tests (no
monitoring)
Immediate
treatment More Same Less
Not
reported
No formal
monitoring
2 3 4 0 0 0 0 0 4 0 0 0
Monitoring
focused on single
test
11 19 2 2 5 5 0 0 3 6 5 0
Clinical
assessment
12 21 10 0 0 0 0 2 1 8 1 2
Clinical
assessment plus
one main test
12 21 4 0 0 4 0 5 0 4 4 5
Clinical
assessment plus
multiple testsb
21 36 9 1 5 4 1 5 0 18 2 5
Total 58 29 3 10c 13d 1 12e 8 36 12 12
% of experimental
arms (n = 68)
43 4 15 19 1 18 12 53 18 3
a 58 control arms and 68 experimental arms because six trials were multiarm trials.
b Includes one trial in which standard care was treatment on recruitment with subsequent regular follow-up; the experimental arm underwent treatment only if the surveillance tests
continued to show abnormalities at later follow-up points.
c Test frequency was also reduced in three arms.
d Test frequency was increased in five experimental arms, reduced in seven and stayed the same in one (this was a trial of treatment vs. surveillance, but following treatment patients in the
control arm underwent the same surveillance as those in the experimental arm158).
e Includes three trials in which all patients were monitored with a new test following trial recruitment and were randomised only on crossing a given threshold. Participants in the control
arms of these trials continued to undergo standard monitoring following randomisation and were treated according to usual criteria.
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8
the amount of invasive testing carried out (n = 7), or introduce surveillance to avoid treatment (n = 1) (see
Figure 7). This was achieved by replacing an existing test (n = 4), reducing the frequency of testing (n = 8),
adding a new triage test (n = 3) to select patients for a more invasive test or reducing the number of tests
performed at each visit (n = 1). The remaining study was a non-inferiority trial that aimed to demonstrate
that additional testing did not improve the survival of patients with colorectal cancer.211
In terms of study validity, sequence generation and allocation concealment were judged to be adequate in
48% and 45% of the studies, respectively (Figure 8). Blinding of study participants, study personnel and
outcome assessment was rarely implemented; in the majority of the studies, blinding was not described
and a judgement had to be made as to the likelihood of blinding being present or not. Uniform and
unbiased outcome assessment (in which the primary outcome was assessed in the same way in both arms
and was not determined by the monitoring test under evaluation) was carried out in 83% of studies. In
eight trials, however, the presence of the primary outcome was clearly measured by the monitoring test, so
that the outcome was defined differently between arms.
Primary outcomes and results
Approximately half of the trials chose to evaluate patient-related primary outcomes (Table 10), of which
one-third (n = 9/31) aimed to assess the impact of monitoring on mortality and over half aimed to detect
either new (n = 9/31) or recurrent (n = 7/31) disease. Process outcomes evaluated were primarily related to
the numbers of patients treated between arms (n = 8/13) or the time to treatment (n = 4/13).
Around one-third of the full trial reports (12/34) reported statistically significant effects on the primary
outcome (Table 11). The 16 trials reporting power calculations and reporting results as risk differences
generally found smaller effects on the primary outcome than were predicted (Figure 9).
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FIGURE 7 Aim of monitoring evaluation (N= 68 experimental arms). Rx, treated.
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FIGURE 8 Trial validity.
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Discussion
This is the first review that we know of to have examined the use of the randomised trial design to
evaluate monitoring tests. We found that triallists have made valiant attempts to evaluate a wide range of
monitoring strategies in various medical fields and clinical settings and the number of studies published per
year appears to be increasing over time. Many of the strategies examined were relatively complex, involving
the addition or replacement of a test within an existing battery of tests or changing the frequency of one or
more tests, presenting considerable challenges for their evaluation. Only a small proportion of trials reported
statistically significant results for the primary outcome; various possible reasons for this and the impact of
other key features of the trials are worth exploring. From data presented in the Hopewell et al.227 publication
bias paper, between 55% and 75% of published trials reviewed in five studies demonstrated statistically
significant effects.
In the first instance, a striking lack of scientific basis for the monitoring strategies that were evaluated was
presented. Just as reviews of monitoring strategies specified in clinical guidelines have shown,69,134,135 any
existing evidence base for the strategies was poorly cited. Potential issues with the tests, thresholds or
interventions, which could have been avoided with a thorough evaluation of each component of the new
monitoring strategies in the context in which they were to be applied, were identified only in retrospect.228
Key to this is the consideration of relevant evidence related to the test(s) to be used (in terms of both
accuracy and the ability to predate the appearance of clinically relevant disease), the interval between test
applications (which should be influenced by the expected natural history of disease and by the degree
TABLE 10 Description of the primary outcomes used and the main result
Topic n %
Type of primary outcome measures
Patient 31 53
Process 13 22
Composite 10 17
Unclear/not described 4 7
Patient outcomes used
Clinical 4 13
Function 1 3
New disease rate 9 29
Recurrent disease rate 7 23
Mortality 9 29
Psychological morbidity 1 3
Process outcomes used
Diagnostic yield 1 8
Therapeutic yield 8 62
Timing of care 4 31
Was the effect on the primary outcome statistically significant? (n= 34a)
Yes 12 35
No 20 59
Not reported 2 6
a Full trial reports only.
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of measurement variability associated with the test in the given setting) and the change in patient
management that is to be implemented (particularly in terms of establishing the effectiveness of any
intervention in the trial population). Providing evidence (or, at the very minimum, a rationale) for each of
these components is key to the interpretation of trials of monitoring; as others have pointed out, ‘a
mediocre test could improve outcomes when it is coupled with effective management; similarly a quality
test could fail to improve outcomes in the absence of effective management’.151
It appears, however, that insufficient attention was paid to establishing test properties and intervention
effectiveness in the populations of interest before trials were undertaken. For example, although one
TABLE 11 Full trial reports according to statistical significance of the primary outcome
Study features assessed for full trial reports
Results
Chi-squared
test
Non-significant
(N= 22)
Statistically significant
(N= 12)
Mean sample size, n 405 778
Median sample size (range) 274 (64–1340) 225 (79–4439)
Industry funded, n/N (%) 4/22 (18) 4/12 (33) p = 0.912
Median follow-up (months) 35 12
Adequate sequence generation, n/N (%) 18/22 (82) 2/12 (17) p < 0.001
Adequate allocation concealment, n/N (%) 12/22 (55) 4/12 (33) p = 0.24
Outcome assessment blinded, n/N (%) 3/22 (14) 3/12 (25) p = 0.41
No uniform outcome assessment, n/N (%) 3/22 (14) 2/12 (17) p = 0.81
Primary outcome – patient outcome, n/N (%) 16/22 (73) 5/12 (42) p = 0.07
Primary outcome – process outcome, n/N (%) 4/22 (17) 5/12 (41) p = 0.14
Evidence cited (methods) for experimental arm, n/N (%) 11/22 (50) 4/12 (33) p = 0.35
Evidence cited (methods) for control arm, n/N (%) 6/22 (27) 3/12 (25) p = 0.89
Evidence cited (methods) in either arm, n/N (%) 11/22 (50) 5/12 (42) p = 0.64
Any evidence cited for experimental arm, n/N (%) 16/22 (73) 9/12 (75) p = 0.89
Any evidence cited for control arm, n/N (%) 11/22 (50) 4/12 (33) p = 0.35
Any evidence cited in either arm, n/N (%) 17/22 (77) 10/12 (83) p = 0.67
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FIGURE 9 Comparison of observed vs. predicted effects.
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might expect both the rate of disease progression and the degree of measurement variability associated
with a given test to be taken into account when setting test frequency, test intervals were apparently
determined by convenience or by fear of missing a key clinical event.38 There was little acknowledgement
of the potential for false-positive results, limited use of repeated testing to confirm abnormal or
indeterminate test results and examples of ‘personal tailoring’ of decisions based on risk from previous
tests, for example by changing the frequency of testing or altering thresholds for intervention on the basis
of previous test results, were rare. A small number of studies did acknowledge problems with technical
aspects of the tests evaluated, or with the test thresholds evaluated,159–162 with one reporting a change to
the threshold in the trial protocol (to minimise the number of biopsies undertaken in the experimental
arm).162 Others found that, although the new monitoring strategies identified potential disease earlier in
the disease pathway, as was intended, the disease was detected too early to warrant intervention, the
intervention itself may have been ineffective or the lack of observed benefit from monitoring may have
resulted from the effectiveness of treatment in the control group.163–165 It is difficult to assess how
widespread such issues might be without a more in-depth examination of each topic area; however,
it is clear that, before a trial is undertaken, the specifics of the monitoring strategies to be evaluated
should be established using appropriate methods and in a similar population to that eligible for the trial.
The second characteristic of the trials was the lack of detailed description of the protocols for monitoring,
particularly for the control groups. Overall, the methods of application of the tests and interventions, and
of how test results should be used to inform downstream management, were particularly poorly reported.
Given the multiple components of a monitoring strategy and the multitude of ways in which these might
interact to affect outcomes, a clearly defined protocol for testing and subsequent management is essential,
not only so that the ‘intervention’ can be replicated in the future, but also so that the mechanisms by
which outcomes are affected can be better understood and the generalisability of the results beyond the
trial can be judged.151,228 The reasons behind the lack of description are not clear. It may be partly down to
poor reporting but could also be related to a lack of acknowledgement of testing strategies as complex
interventions or an unwillingness to standardise a complex intervention.229
Even for those elements of the intended monitoring strategies that were described, we found some
evidence of lack of compliance, for example trials reporting the use of the experimental test or the use of
extensive additional testing in the control arm; failure to administer treatment despite positive test results;
and the prescribing of treatment despite negative test results.160,163,166–168 This apparent lack of ‘buy in’
by clinicians is difficult to interpret. One explanation might be that a monitoring test is considered more
of a guide to potential changes in management rather than as a definitive indication for a particular
intervention. The often lengthy time frame of monitoring may also increase the likelihood of trial fatigue,
making the intended intervention difficult to implement over long periods. Delaney et al.228 advocate that a
variety of methods might be used to ensure that complex interventions are delivered reliably over a period
of time. Alternative designs might also be considered, particularly when monitoring relies primarily on a
single test. For example, monitoring of all enrolled patients with randomisation to immediate treatment
or a continued surveillance option on crossing a particular threshold leaves less to chance in terms of
downstream management.155–157,169
In terms of study validity, trials of tests should be subject to the same validity standards of randomisation
and allocation concealment as the wider RCT literature; however, in many instances, the same standards
of blinding of patients, and particularly clinicians, will be difficult to achieve (Box 1). In theory, patient or
clinician blinding might be more easily implemented for simpler tests such as blood tests or when tests are
applied by a non-treating clinician such as a radiographer, but in many contexts blinding could be more
difficult and even inappropriate given that it is not just the test per se that is being evaluated but its
interaction with other components of the overall monitoring process. Although we found two examples in
which stringent attempts at blinding patients mitigated the potential benefit from monitoring (both using
implanted devices),170,171 the full impact of not using blinding in a monitoring trial is as yet unclear.
Nevertheless, its impact may be mitigated through the use of objective outcome measures and blinded and
uniform outcome assessment. Blinded outcome assessment should be feasible for most trials, but its use
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was reported for less than one-fifth of our sample and in over half of these trials the blinding related to
outcome adjudicators rather than those collecting the outcome data. Furthermore, we observed a small
number of trials with a ‘fatal flaw’ in terms of the outcome assessment, whereby the presence of the
primary outcome, for example recurrence of cancer, was defined by a different test in each arm, thereby
introducing an additional source of bias. It is fundamentally important that the primary outcome is
uniformly defined in the same way between groups, ideally at the same point in time.
A final characteristic of these monitoring trials was an apparent lack of power to detect significant effects.
This is not a phenomenon limited to trials of tests; previous authors have found sample size calculations to
be based on inaccurate assumptions for the control group, with others suggesting that up to 10–20% of
trials might be inappropriately discontinued because of a perceived insufficient rate of recruitment.232–234
BOX 1 Validity assessment
The adequacy of random sequence generation and allocation concealment was judged according to The
Cochrane Collaboration’s risk of bias assessment tool:230
1. Sequence generation:
l Adequate – random number table, computer random number generator, coin tossing, shuffling of
cards/envelopes, throwing dice, drawing lots, minimisation.
2. Allocation concealment:
l Adequate – central allocation (including telephone, web-based and pharmacy-controlled
randomisation), sequentially numbered, opaque sealed envelopes.
The presence of blinding was judged using the risk of bias assessment tool supplemented with the instructions
for estimating unclearly reported blinding status outlined by Akl et al.:231
3. Blinding [assessed for four groups: (1) patients, (2) treating clinicians (i.e. those making subsequent
management decisions), (3) non-treating clinicians (e.g. those undertaking the monitoring test) and
(4) outcome assessment (both primary and secondary, e.g. outcome adjudicators)]:
l Explicit statement that a group was blinded – definitely yes.
l Explicit statement that a group was not blinded – definitely no.
l Explicit statement that investigators were blinded – definitely yes for clinicians and outcome assessors.
l Explicit description of the trial as ‘open’ or ‘unblinded’ – definitely no.
l If no explicit statement about blinding status – probably no.
l Described as single or double blinded – use best judgement to assign ‘probably yes’ to one or more
groups as appropriate.
The method of assessment/definition of the primary outcome was appraised for both groups:
4. Uniform outcome assessment:
l Present if the primary outcome was defined/measured in the same way in all groups or if attempts were
made to ensure that the primary outcome definition captured relevant events in both groups.
l Absent if differences in measurement of the primary outcome were likely to have led to bias between the
groups (i.e. if the monitoring test result was used to define the primary outcome, e.g. when the presence
of recurrence was defined by an existing test in one arm and by the new test in the experimental arm).
l Unclear – if insufficient information was available to judge.
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However, statistically significant effects are easiest to achieve when two groups are allocated to different
treatments; in trials of testing strategies all ‘test-positive’ patients usually undergo the same treatment,
reducing the potential to demonstrate clear differences in outcome between groups. We have not yet
conducted an in-depth look at the sample size calculations of trials in our sample and cannot yet comment
on the assumptions made around the predicted benefit from monitoring; however, we did find evidence of
lower than expected control group event rates both in trials that were stopped early and other trials, with
some forced to revise their sample size calculations or change their primary outcome from overall survival
(OS) to a surrogate outcome of number of recurrences treated surgically with curative intent.156,170–173
Our research has some limitations. We are unlikely to have retrieved all of the available eligible trials. This is in
part because of our focus on one main database, although this was supplemented with searches of more
specialist resources, and in part because of a lack of standard terminology for trials of monitoring, which
made searching for trials a challenge. However, an exhaustive search is not as important for a methodological
review as for a systematic review of effectiveness. We did not aim to systematically identify all of the available
trials but to retrieve a sample of trials that provide a good representation of those available. Although other
trials may be available, it seems likely that our review has flagged up many of the key issues.
Our review has identified a range of problems with available randomised trials of monitoring, raising real
questions regarding the feasibility and appropriateness of this approach for evaluating monitoring. Trial
investigators have perhaps underestimated the complexity of the interventions that they were trying to
evaluate and the multitude of ways in which the effect of an intended change in a monitoring strategy might
be mediated by other factors. The recommendations in Box 2 provide guidance for future researchers
evaluating monitoring strategies.
BOX 2 Recommendations for future practice
Triallists should:
l provide a scientific basis, or at a minimum a carefully considered rationale, for the monitoring strategy to
be evaluated, including the –
¢ test interval
¢ test threshold
¢ intervention(s) to be used following a positive test result
l ensure that the test(s) operate as expected and that the interventions are effective in the intended
patient population
l provide clear guidance to clinicians taking part in the trial regarding how they are expected to respond to a
positive, indeterminate or negative monitoring test result
l make stringent attempts to avoid known biases, for example using –
¢ proper randomisation
¢ adequate concealment of allocation
¢ blinded outcome assessment
l avoid additional bias from non-uniform outcome assessment between study arms [i.e. the (primary)
outcome must not be determined by the monitoring test under evaluation]
l ensure that the trial follow-up is sufficiently long to allow important events to occur
l be realistic with estimates used in sample size calculations
l follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines for trial reporting235 and clearly
report the care provided in both the experimental and the control arms of trials.
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Chapter 5 A review of the monitoring-related
methodology literature
Introduction
Monitoring strategies used to direct the care of patients with potential recurrent or progressive disease are
rarely evidence based.69 Monitoring strategies specify the frequency of observations, the duration of monitoring,
the decision rule and the threshold for a positive test result, with a positive result prompting a change in patient
management. There is a need for monitoring strategies to be developed based on evidence of how a disease
will progress and the performance of the monitoring test to be used. Too often test frequencies are based on
routine care schedules with decision rules and thresholds chosen in an ad hoc manner.
Methods
Methodological information related to monitoring was first sought from the first edition of the book
Evidence-Based Medical Monitoring,38 edited by Paul Glasziou, Les Irwig and Jeffrey Aronson. Key
textwords related to monitoring methodology were identified and purposive searches of MEDLINE were
undertaken from 2000 to 2010 (searches conducted on 26 March 2010). Reference tracking and citation
tracking using Science Citation Index were used to identify additional relevant literature.
A variety of searches were performed to identify relevant literature using various combinations of the
following text words:
l monitor*
l measure* or biomarker* or marker*
l serial or repeat* or periodic or longitudinal or trajectory*
l recurrence or progression
l rule* or threshold* or trigger
l statistical process control or control chart* or reference change value or critical difference
l screen* with frequenc* or intensit* or interval*
When necessary, the results were filtered to select:
l statistical or epidemiological journal titles (Biostatistics, Biometrics, Statistics in Medicine, Methods of
Information in Medicine, Lifetime Data Analysis, Journal of Clinical Epidemiology, American Journal of
Epidemiology and Annals of Epidemiology)
l RCTs (sensitive search).
Additional searches were undertaken to identify literature related to statistical process control, RCVs and
the methodology of health screening.
The papers selected for review are summarised in Table 12 and in the following sections.
Results: development and evaluation of monitoring strategies
Limited methodological literature was identified that provides guidance on the design of studies to
evaluate monitoring tests. Work has focused more on analytical techniques to assist with the design of
monitoring strategies, primarily through analysis of existing data in order to make recommendations on
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TABLE 12 Summary of reviewed studies
Study
Design Analysis
Citationsa
(n)
Test
frequency
Test
thresholds
Decision
rules
Review of
methods Other
General
data
structure
Linear
mixed-effects
modelling/SNR
Joint
modelling
Cost-
effectiveness
Review of
methods Other
Monitoring
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2003236
✓ ✓ 32
Bell 2008237 ✓ 19
Bell 2009238 ✓ 36
Bell 2009239 ✓ ✓ 13
Bell 2011240 ✓ 8
Bellera 2008241 ✓ 12
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Bellera 2009141 ✓ ✓ ✓ 5
Buclin 2011146 ✓ ✓ ✓ ✓ 6
Cole 2004243 ✓ 28
DeLong 1985244 ✓ 20
Glasziou 2007245 ✓ 195
Glasziou 2008143 ✓ 55
Inoue 2004246 ✓ 23
Keenan 2009144 ✓ 40
Li 2012247 ✓ ✓ 1
Oke 2012248 ✓ ✓ 2
Powers 2011249 ✓ 50
Proust-Lima
2009250
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Proust-Lima
2014251
✓ ✓ 3
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TABLE 12 Summary of reviewed studies (continued )
Study
Design Analysis
Citationsa
(n)
Test
frequency
Test
thresholds
Decision
rules
Review of
methods Other
General
data
structure
Linear
mixed-effects
modelling/SNR
Joint
modelling
Cost-
effectiveness
Review of
methods Other
Sturgeon 2009270 ✓b 28
Sturgeon 2010271 ✓ ✓ 16
Screening
Day 1984272 ✓ 119
Etzioni 1997273 ✓ 9
Frame 1998274 ✓ 27
Lee 1998275 ✓ 31
Lee 2004276 ✓ 13
McIntosh 2002277 ✓ 40
McIntosh 2003278 ✓ 36
Walter 1983279 ✓ 91
Zelen 1993280 ✓ 49
Time-dependent ROC curves
Cai 2006281 ✓ 26
Etzioni 1999282 ✓ 42
Parker 2003283 ✓ 14
Pepe 2008284 ✓ ✓ 24
Slate 2000252 ✓ 44
Subtil 2009285 ✓ 3
Zheng 2004286 ✓ 21
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TABLE 12 Summary of reviewed studies (continued )
Study
Design Analysis
Citationsa
(n)
Test
frequency
Test
thresholds
Decision
rules
Review of
methods Other
General
data
structure
Linear
mixed-effects
modelling/SNR
Joint
modelling
Cost-
effectiveness
Review of
methods Other
Real options approaches
Driffield 2007305 ✓ ✓ 17
Lasserre 2006306 ✓ ✓ 6
Meyer 2012307 ✓ ✓ 1
Palmer 2000308 ✓ ✓ 66
Shechter 2010309 ✓ ✓ 0
Whynes 1995310 ✓ ✓ 2
SNR, signal-to-noise ratio.
a Citations from Scopus search 24 July 2014.
b Review of current practice.
c Reporting guidelines.
d Review of reporting standards.
e Review of literature.
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monitoring frequency or decision rules, or simulation work, with both approaches being specific to the
disease area researched.
Designing studies to evaluate monitoring strategies
A small number of papers from the biomarker development field cover study design issues of relevance to
the monitoring field; however, these largely take the form of commentary papers highlighting study design
issues often not considered in biomarker development, rather than reporting empirical work.
Pepe et al.267 discuss the five stages of biomarker development for cancer: preclinical exploratory studies,
clinical assay development for clinical disease, retrospective longitudinal repository studies, prospective
screening studies and cancer control studies. The initial stage is the primary search for promising biomarkers;
this stage is preclinical and generally involves comparison of diseased and non-diseased tissue for many
potential biomarkers. At this initial stage, biomarkers are assessed on their ability to produce stable results
and to discriminate between disease and non-disease. The next stage sees the development of a clinical
assay that can be carried out non-invasively, with the discriminative ability of the assay being assessed. The
third stage of the process involves comparing the ability of the biomarker to differentiate between samples
taken from patients with disease prior to the diagnosis of disease and samples taken from patients who are
free of disease, with the aim of this stage being to evaluate whether or not the biomarker can detect preto
clinical disease and understand what biomarker values should be used to classify a result as positive. The
fourth stage uses the biomarker to prospectively screen patients, with those having a positive result also
receiving definitive diagnostic tests; this stage of the process allows the stage of disease that the biomarker
is able to detect to be identified, as well as the likely positive and false-positive yield of the test. The final
stage of the process is to test the benefit of screening to the population in terms of reducing mortality. In
this last stage participants should be representative of the population to be screened and a RCT approach
can be taken to understand the difference between groups offered screening with the biomarker and those
not undertaking screening.
Biomarker development studies have been criticised on a number of counts:1 for producing novel findings
that are often unreliable and not replicable and being open to bias, both before and after the laboratory
receives the study samples, primarily because of a lack of standardisation. A number of papers have
discussed issues of bias in both randomised and non-randomised study designs and, to improve the
development and evaluation of biomarkers, have provided recommendations on both study design and
analysis.1,263,264 Baker et al.,263 Baker,264 Ransohoff1 and Ransohoff and Gourlay269 provide further discussion
of other issues related to biomarker development studies.
Lumbreras et al.265 present a tool for evaluating the quality of test accuracy studies of new biomarker
(or ‘-omics’) technologies and Parker et al.266 report an evaluation of the QUADOMICS tool [an adaptation
of the Quality Assessment of Diagnostic Accuracy Assessment Studies (QUADAS) tool311].
In terms of specific study designs, in an overview paper of study design and methods for evaluating biomarkers
for the early detection of cancer, Baker et al.263 cover four different types of prospective study design:
1. a cohort-type design in which asymptomatic patients are tested with a biomarker and followed up to
clinical diagnosis may be an option when there is limited available evidence of benefit of the biomarker
and no ethical grounds to make decisions based on the test result
2. a longitudinal accuracy study in which all asymptomatic patients are tested with a biomarker and all
patients receive a biopsy or definitive testing; however, some concerns have been raised around this
design because of overdiagnosis
3. a randomised trial design in which sensitivity is estimated using the number of positive tests and the
number who develop disease within the time frame
4. a design in which only those asymptomatic patients with a positive biomarker result receive definitive
testing, with discussion of the issue of patients with a negative result not receiving definitive testing.
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Pepe et al.268 further discuss a study design entitled the PRoBE design (prospective-specimen-collection,
retrospective-blinded-evaluation). In this paper they suggest the prospective nested case–control design as
a means of ensuring that biomarker development is rigorous and robust. In the first instance, specimens
should be prospectively collected from a randomly selected cohort reflective of the population in which the
proposed biomarker would be used, and then stored, prior to development of the outcome of interest.
Cases and controls (i.e. those who do/do not experience the clinical event of interest) are then randomly
selected and their specimens are retrieved from storage and tested for the biomarker of interest, blinded to
case/control status. The authors also suggest that the performance that would be required of a new
biomarker be established in a clinical context. The design has clear potential for application in a monitoring
context, with the possibility of obtaining repeat biomarker measurements on a relatively frequent schedule,
so that the best threshold and test interval can be determined from the data.
A further design proposed for the evaluation of a biomarker as a screening test, which is, therefore,
potentially applicable to the monitoring of disease, is the paired design, in which different screening
strategies are introduced at different centres and screening performance is assessed by comparing the
number of interval cases (symptomatic cases detected in the interval after screening) observed.264
Analytical approaches to developing monitoring strategies
The literature in the area of monitoring focuses on modelling approaches (linear mixed modelling, joint
modelling and non-linear modelling). The review of the literature also identified some simulation studies
and some work on the evaluation of monitoring strategies.
Linear mixed-effects models and estimation of signal-to-noise ratio
Glasziou et al.245 question the need for RCTs of monitoring under certain circumstances, pointing to the need
to understand the background variation and evaluate the signal-to-noise ratio when assessing treatment
effects. They suggest that large estimated treatment effects would be required to demonstrate an effect.
General description of models
Stevens et al.142 have reviewed statistical models used for the control phase of monitoring and explain
how models can be fitted to observed monitoring data, providing details of maximum likelihood methods,
moment-based methods and literature-based methods, with parameter estimates obtained from reviewing
the literature. They introduce a generic model for monitoring data, defining Yit as the observed monitoring
values, including assay noise and variability, and Uit as the ‘true’ underlying and unobserved values:
Uit = αi + βi,t and Y it = Uit + ωi,t, (1)
where αi is the true value at time 0, βi,t is the change in the true value over time and ωi,t is random error.
Signal and noise
Modelling methods are used with repeated test data in the hope of distinguishing ‘signal’ from ‘noise’.
The ‘noise’ is normal fluctuation in test results for patients (caused by the measurement variability of the
test) and the ‘signal’ is a change in test results signifying a true change in disease state.
Thompson and Pocock259 present their findings following the analysis of repeated serum cholesterol
measurements in 14,600 men and women. Their work focused on the impact of within-individual
variability on screening and monitoring. Using the cholesterol data, a single observed measurement did not
reflect the true underlying value. They showed how the probability of a measure being classed as ‘high’
varied with the true underlying value and whether the classification was based on a single measure or the
mean value of multiple measures. The use of multiple measures was shown to improve classification. The
authors identified regression to the mean when analysing multiple measures and variability in the measures
for untreated individuals over time, leading them to doubt whether or not repeated measures would be
able to identify the benefit of treatment. The authors state that the use of repeated measures could be
‘very discouraging’ for some patients.
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Buclin et al.146 defined two decision rules that could be used to guide the treatment of patients with HIV
infection with antiretroviral therapy based on cluster of differentiation 4 (CD4) cell measurements using a
review of longitudinal analyses of CD4 cell trajectories. The first decision rule is a ‘snap-shot rule’ – dependent
on a single CD4 measure – and the other is a ‘track-shot rule’ – in which multiple CD4 measurements are
required. The devised rules are then tested using clinical data, with the view of minimising false findings, and
recommendations are made regarding the frequency of testing.
Bell et al.237 developed a framework to identify when monitoring of initial response to treatment would
be beneficial using data from RCTs. The findings showed that monitoring of initial response to treatment
would be useful only when there is variation in the treatment effect between patients and not all treated
patients achieved results at the level targeted.
Other examples of the use of mixed modelling and signal-to-noise ratio estimation to understand when it is
appropriate to monitor response to treatment, thresholds or monitoring frequency include for the monitoring
of cholesterol, bone mineral density, blood pressure, lipids and diabetes mellitus.143,144,237–240,248,249,255,256
Joint modelling of longitudinal and outcome data
Joint latent class models
When fitting a joint latent class model subjects are split into a finite number of latent subgroups. The
trajectory of biomarker measurements and the risk of an event are specific to each latent class, meaning
that the joint latent class model allows for the dependency of biomarker values and the risk of the event.
Biomarker measurements and time to event are conditionally dependent, given the latent class. More
specifically, a multinomial logistic regression model is used to assign subjects to subgroups. A linear mixed
model is then used to model repeated biomarker measurements given the assigned latent class of the
subject and a survival model is used to model the time to event, again given the latent class of the subject.
The model is fitted using maximum likelihood estimation.251
Examples of the use of joint latent class models can be seen in work by Proust-Lima and Taylor250 and Li
and Gatsonis,247 both applied to monitoring with PSA for prostate cancer recurrence.
Proust-Lima and Taylor250 discuss the derivation of a posterior probability of recurrence from a joint latent
class model to identify a ‘dynamic prognostic tool of recurrence’. The posterior probability obtained from
the joint latent class model gives the probability of an event occurring between time s and time s + t (with
the subject being event free at time s). Estimating the probability of an event after a certain time requires
fitting survival models to subjects at each time being estimated with only covariates available at time s.
As biomarker data are often discrete, imputation techniques are used to allow predictions of an event to
be obtained at multiple time points. Proust-Lima and Taylor250 also discuss the validation of predictive tools
and the lack of consensus in this area.
Li and Gatsonis247 use a joint latent class model to develop a strategy that modifies monitoring intervals.
They use a two-stage approach when fitting the joint latent class model in which the model used to
identify latent classes is fitted separately. The Bayesian information criterion is used to select the number
of classes. The two-stage approach has the advantage of being less computationally intensive and the
expectation–maximisation (EM) algorithm can be used to estimate parameters at each point of monitoring.
The uncertainty of latent class assignment is evaluated using multiple imputation, assuming that latent class is
missing completely at random. For prospective studies the two-stage procedure is repeated as new information
is collected (measures, events and study end). Li and Gatsonis247 demonstrate the method using simulated PSA
measurements for 150 patients with prostate cancer with testing to identify recurrence. Predictions from the
model inform a utility function, which is used to identify the appropriate monitoring intervals for each patient.
The expected value of the utility function used is U˜ (t)= aP(event at time t), where a is a negative value if the
event occurs and zero otherwise. The optimal monitoring interval can be identified for individuals or groups of
patients; the authors advocate optimising by latent class as these intervals can then be adapted for new patients.
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Bayesian hierarchical change-point models
Bayesian hierarchical change-point models model the trajectory of test results prior to the onset of disease, the
onset of disease and the trajectory of test results after the onset of disease simultaneously. These models also
allow for the within-individual correlation, as individuals have multiple test measurements, between-subject
variation in trajectories and the random change-point. Bayesian hierarchical change-point models use a
piecewise or segmented linear model in which the parameters of the model are the trajectory of test results
prior to the change point, the test result value at the time of the change point, the time of the change point
and the trajectory of test results after the change point; each of the parameters is a random effect within the
model. Non-informative prior distributions are used for the parameters in the model, with the parameters
describing the distributions of the parameters used in the model being drawn from non-informative
prior distributions.241,252
Slate and Turnbull252 discuss and demonstrate the use of Bayesian hierarchical change-point models using
PSA data from the Nutritional Prevention of Cancer Trial. They state that the advantages of using Bayesian
hierarchical change-point models are the ‘borrowing of strength’ when estimating parameters specific to
individuals whilst also accounting for the correlation of measures and, by obtaining posterior distributions
using Gibbs sampling, the model can give the probability that an individual has reached the change point.
Bellera et al.241 also demonstrate the use of Bayesian hierarchical change-point modelling using PSA data.
They state that the additional advantages of this type of modelling are the ability of the model to provide
precise estimates compared with simpler models, that the parameters used by the model are all of clinical
importance, that estimates of test measurement variability can be estimated as a function of the test result
value and that the model is flexible and can be easily adapted. Bellera et al.241 do, however, comment that
the model can be influenced by the timing of and the number of test measurements for individuals, with
the potential for this to cause bias, as participants with more test results will provide more information
for the model and participants with more test results may be different from those with fewer test results.
Subsequent work by Bellera et al.241 uses an empirical simulation approach with Bayesian hierarchical
change-point modelling to evaluate and compare different rules used in detecting the recurrence of
prostate cancer based on PSA measurements.141 Bayesian hierarchical change-point models were used to
identify whether or not the rules used in practice were able to adequately classify patients with real
progression of PSA measurements and those with stable PSA values.
Inoue et al.246 combined longitudinal PSA measurements from three different studies using a non-linear
Bayesian hierarchical model. At the individual level a non-linear model is used to model PSA over time and
the hierarchical model component then accounts for the variability between studies.
Non-linear mixed models
Non-linear mixed models allow more flexibility in modelling as linearity of the parameters is not necessary,
which may be appropriate for modelling longitudinal test data in some conditions. Multiple measures
for each individual can also be accounted for by non-linear mixed models with the incorporation of
random effects.
Examples of the use of non-linear mixed models can be seen in work by Subtil and Rabilloud254 and
Taylor et al.257
Alternative modelling approaches
Alternative modelling approaches are used by Thiébaut et al.258 and Wolbers et al.261 in the area of CD4
cell monitoring to understand when to initiate treatment for patients with HIV infection.
Machine learning methods
We have also considered machine learning methods. These essentially arise from a set of pattern recognition
processes or algorithms. They are primarily concerned with non-continuous data, such as radiographic
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images or electronic health records, and for machine learning methods to provide high-quality predictions
these pattern recognition processes would usually be applied to large data sets.312,313 The biomarker data are
continuous and a limited number of data are available. The statistical analysis and modelling approach also
enables testing of different trial design strategies, as discussed extensively in Chapter 7. In conclusion, we
believe that machine learning technologies may have a future role in shaping and supporting monitoring
strategies. However, it is too soon to say in what form this role may be expected to develop. Machine
learning methods are still in the developmental stage and may become useful in the field of biomarkers in
the future, as the field develops. Issues remain about such methods not always providing estimates of
uncertainty and being hard to interpret. The logic and mathematics to underpin these processes are still
being developed and are not trivial. The task of modelling these data sets is very complex and requires many
assumptions, which need verifying, as for statistical approaches.312,314 Use of machine learning methods is
currently limited by the lack of availability of simple off-the-shelf application packages.
Monitoring simulation studies
With knowledge of the progression of disease and the variability of the test used to monitor the disease,
data can be simulated allowing the evaluation and comparison of decision rules and testing frequency.
Simulation approaches have been used by Sölétormos et al.253 and Bellera et al.242
Evaluation of monitoring strategies
How the performance of a monitoring strategy is measured will be different from, and more complex than,
the measurement of the performance of testing at a single time point, because of repeated testing and
the potential for patients to change disease state. DeLong et al.244 discuss the sensitivity and specificity of
monitoring tests and Li and Gatsonis247 provide guidance on the evaluation of monitoring strategies.
Pooled analysis of prospective cohort studies
In some disease areas data sets from multiple cohort studies exist and it is possible to combine the data
and analyse the pooled group of patients. When the data in multiple cohort studies are combined, the
data set may be useful to allow analyses that compare groups of patients, correct for case mix and allow
investigators to infer the findings, which might otherwise require a RCT. The cohort approach has been
used to evaluate the appropriate CD4 cell level at which to begin antiretroviral treatment for patients with
HIV infection by the When To Start Consortium260 (using a method introduced by Cole et al.243) and
Ahdieh-Grant et al.236
Results
Screening literature
The aim of screening is to benefit patients by detecting disease prior to the onset of symptoms, as is the
case with monitoring. The detectable preclinical stage of disease is the time when screening may detect
asymptomatic disease; this is also known as the sojourn time. The delay time is the period of the sojourn
time when the screening has not detected disease and the lead time is the period of the sojourn time after
screening has detected disease. The greater the lead time, the greater the potential benefit of screening.
Walter and Day279 discuss the biases that need to be considered when analysing screening data. First, the
population participating in screening may vary from the population not participating in screening, having a
higher or lower risk of having the disease that the screening process aims to detect. This is likely to be less
of an issue for monitoring populations, although it is conceivable that there will be differences between
those who do participate in monitoring and those who either drop out (perceiving themselves to be at
low risk of the event in question) or who demand some form of treatment (perceiving themselves to be at
high risk of the event in question). Other biases that may affect monitoring studies include length-biased
sampling and lead time bias. Length-bias sampling occurs as patients with more aggressive disease will be
in the preclinical phase of disease when screening will detect disease (sojourn time) for a shorter length of
time than those with less aggressive disease. Screening is most likely to detect cases with a longer sojourn
DOI: 10.3310/pgfar06030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Selby et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
time, hence cases of less aggressive disease, which will likely have a better prognosis. Lead time bias is
when survival times for screened cases appear to be greater than survival times for cases identified by
different means when there is actually no difference in survival; the only difference is that cases identified
by screening are detected earlier.
There is a body of work in the area of screening that focuses on estimating the duration of the preclinical
stage of disease,272,273,279 which enabled further work into the optimal frequency of screening.274–276,280
Others have considered how to set the optimal decision rule for a screening strategy using a new test
when the length of the sojourn period is not known.277,278
Biomarker development process
Methods for analysis and study design used in the biomarker development process
The methods for the analysis and design of studies of biomarker development are discussed by Baker
et al.,263 Pepe et al.268 and Sturgeon et al.271 Baker262 discusses a method for evaluating multiple biomarkers
for selection for further study. Baker et al.,263 Baker,264 Ransohoff1 and Ransohoff and Gourlay269 discuss
the issues around biomarker development studies.
Sturgeon et al.270 provide information on the biomarkers that have been developed to identify cancer and
the extent of their use in practice.
Time-dependent receiver operating characteristic curves
When a test provides a binary result (positive or negative) the performance of the test is usually assessed by
calculating sensitivity and specificity. When the result of a test is a continuous value the performance of the
test is evaluated for various cut-off points by calculating the sensitivity and specificity of the test for each
possible result value and plotting sensitivity against 1 – specificity, a ROC plot. The ROC plot and the AUC
produced can then be used to assess the performance of the test and identify optimal thresholds for use of
the test in practice. When allowing for time in ROC analysis, time-dependent ROC methods are used.
Sensitivity and specificity
Pepe et al.284 undertook a review of time-dependent ROC curves. The definition of the sensitivity of a test
is dependent on the time when the test is performed. As it is assumed that diseased cases will present
with positive test values early in the testing process, it is thought that sensitivity will decrease with time.
Pepe et al.284 also discussed cumulative sensitivity, which would provide the sensitivity of a test for an
interval of time, and how this can be derived. The false-positive fraction, or 1 – specificity, is problematic to
define as the disease status of individuals can change over time, making it difficult to classify individuals as
diseased or non-diseased, especially in situations in which all individuals will have an event at some point.
One approach is to choose a time point specific to the context being assessed, with individuals treated as
non-diseased if they are free of the event at the specified time (the static false-positive fraction). Another
approach is to allow the false-positive fraction to vary with the time since the test was performed (the
dynamic false-positive fraction). When using the dynamic false-positive fraction test performance may be
misleading as a positive result will be falsely positive shortly before an individual develops disease. For tests
with continuous results, time-dependent ROC curves compare individuals with and without disease at each
time point. If using the dynamic false-positive fraction, ROC curves are difficult to interpret because of the
non-diseased group changing over time.
Cai et al.281 present equivalent time-dependent definitions of sensitivity and 1 – specificity, but with the
emphasis on the time that an event occurs, defining sensitivity and 1 – specificity as functions of time
relative to the time of disease or time of an event. The authors state that most research in this area
assumes that the test and assessment of disease status are carried out simultaneously, raising the issue of
the predictive accuracy of a test being dependent on the time that it is carried out in comparison to the
onset of disease, assuming an increase in accuracy if the test is carried out closer to the time of an event.
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Cai et al.281 also fit semiparametric models using longitudinal test data to separately estimate sensitivity and
1 – specificity. Zheng and Heagerty286 discuss sensitivity and specificity for time-dependent ROC analysis as
functions of both the time of testing and the time of an event. They also discuss the difference between
estimating incident and estimating prevalent ROC curves, restricting their work to incident ROC curves.
Subtil et al.285 discuss how estimation of incident sensitivity requires a test to be performed a given number
of days prior to the onset of disease and offers a way of taking into account the variation in time between
individuals receiving a test and individuals developing disease. They introduce a Bayesian method to allow
for the interval-censored measurements. The results from using this method compared with the method
without adjustment suggest that the ‘crude’ method underestimates sensitivity.
Parker and DeLong283 provide a method to convert estimates of sensitivity and specificity for monitoring
tests for ROC curve analysis. The estimates of sensitivity and specificity used are those introduced by
DeLong et al.,244 which are derived using partial likelihood estimation under the assumption that diseased
participants can have at most one test result when in the diseased state.
Modelling to produce time-dependent receiving operating characteristic curves
Slate and Turnbull252 review methods used to analyse repeated test data when the test is used to screen or
monitor for the onset of disease in a population. These methods are used to estimate the ROC curve for
each test and the resulting ROC curves are compared. The review discusses the use of time-dependent Cox
proportional hazards modelling, joint modelling of longitudinal test data and time of diagnosis, Weibull
methods to model two time events, random-effects models and integrated Onstein–Uhlnbeck stochastic
processes, multistate models and Markov models and change-point models.
Zheng and Heagerty286 discuss a semiparametric regression approach used to estimate ROC curves and an
approach based on asymptotic distribution theory, which will allow covariates to change the distributional
shape of test results.
Etzioni et al.282 introduce and demonstrate two methods for modelling the effect of lead time on the ROC
curve. The first approach requires modelling of longitudinal test data; then, using parameter estimates
from the model the ROC curve can be estimated at varying time points. The second approach directly
models the ROC curve as a function of covariates, including the time of the test relative to the time of
diagnosis. Etzioni et al.282 discuss how the methods can be adapted to compare two tests. The first method
requires separate fitting of models using data for the two tests followed by comparison of the derived ROC
curves, whereas the approach of modelling the ROC curve directly more easily allows for a comparison of
tests and the difference between tests to be assessed. Other advantages of the direct modelling approach
are fewer distributional assumptions with the method using the ranking of data points, robustness and
flexibility and ease of implementation.
Differentiating measurement change from measurement variability
Variability: reference change values and coefficients of variation
The variability of repeated test measures for an individual can be broken down into three components:
pre-analytical variability, analytical variability and individual variability. Analytical variability is the variation in
results caused by the laboratory test and individual variation is the within-patient variability. Pre-analytical
variability can be minimised by ensuring that the collection and storage of the samples is carried out in
a standard way and so is not regularly considered when calculating the total variability of successive
measurements. Analytical and individual variability are combined using:
SDT =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SD2A + SD
2
I ,
q
(2)
where SD2A represents analytical variation, SD
2
I represents individual variation and SD
2
T represents the total
variation of repeated measures for an individual. The coefficient of variation (CV) is calculated by dividing
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the standard deviation (SD) by the mean and is commonly used in place of SDs as it allows for a RCV to be
calculated to reflect percentage changes rather than absolute changes. Normality is assumed and the RCV
is given by:
ﬃﬃﬃ
2
p
Z
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CV 2A + CV
2
I
q
, (3)
where CVA is the analytical variation, expressed as a CV, CVI is the within-individual variability, expressed as
a CV, and Z refers to the z-statistic (value from the standard normal distribution). Given the values of
analytical and within-individual variation, a difference between two results greater than the RCV suggests
a real change in condition.292 Sölétormos et al.297 used this rule in a computer model for monitoring
progression to metastatic breast cancer with cancer antigen 15-3 (CA-15-3), carcinoembryonic antigen
(CEA) and tissue polypeptide antigen.
The use of RCVs is discussed further by Smellie,296 Petersen,294 Fraser,290 Fraser et al.289 Klee,291 Petersen
et al.295 and Omar et al.293 Biosca et al.287 report a study of biological variability to identify the appropriate
RCV to use in their specific clinical situation and Clerico and Emdin288 highlight differences in analytical
sensitivity across studies carried out in differing populations.
Statistical process control and statistical rules for the interpretation of sequential tests
Statistical process control methods (first developed by Shewhart) are often used in manufacturing and
can be used for medical applications when a process can be measured directly or using a biomarker.292
Statistical process control procedures measure variability across time, with variability divided into common-
cause and special-cause variability (or assignable-cause variability). Special-cause variability is akin to signal
and signifies true change in the disease state of an individual. Common-cause variability, as noise, reflects
random variability in measures.292
X-bar charts are used to display measurements over time for an individual. If a process is stable,
measurements are expected to fluctuate around the mean and the SD of observed measures is expected to
be constant over time. Estimates of the mean (µ) and SD (σ) can be taken from stable processes, with an
unbiased estimate of the SD obtained using a moving range (the difference between consecutive measures)
and dividing the mean of the moving range estimates by a constant (d2 = 1.128). Estimates of the mean and
SD of a stable process can then be used to identify control limits. The control limits can be identified using
many criteria and should be modified depending on the situation; it may be that target values are safety
driven. Moving range charts and exponentially weighted moving average charts (moving averages are
calculated with greater weight given to the most recent observations) are also used in similar ways. The
variability of a process can be quantified using the capability index, the difference between the upper and
lower limit divided by 6σ. The off-target ratio, ST =
(µ−T)
σ
, where T is the target value, measures how far the
process is from the specified target value in terms of SDs. Process control charts use the assumption of
independent normally distributed outcomes and generally require at least 20–25 observations.292
Tennant et al.299 reviewed studies in which patients are monitored using statistical process control methods
and compared the use of statistical control methods with currently used rules and guidelines. Clinical
areas found to use process control methods are peak flow measurements for patients with asthma, blood
pressure measurements for patients with hypertension and serum creatinine measurements for patients
after undergoing a kidney transplant. Thor et al.300 also reviewed studies using statistical process control
methods to monitor patients and highlight the disadvantages of using these methods. They discuss how,
in some studies, methods had been employed for which there was a clear lack of understanding.
The authors also comment on issues around autocorrelated measures, the collection of data and the
application of the methods.
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Gavit et al.298 discuss a slightly different approach to process control using change-point analysis.
Change-point analysis uses cumulative sum charts of the difference between the mean value and the
recorded value. Change points are then analysed as bootstrapping methods are used to generate a CI
for the change point. The change-point method can also be used to identify differences in variability.
An advantage of the change-point method is the ability to analyse non-normal data because of the lack
of distributional assumptions. Gavit et al.298 also claim that the change-point method is able to identify
subtle changes that would not be picked up by control charts.
Health economic approaches
Decision-analytic models
Decision-analytic modelling evaluates the costs, outcomes and cost-effectiveness of interventions. In the
case of repeated testing appropriate techniques need to be used for this evaluation.
Karnon et al.302 review models for measuring the cost-effectiveness of screening regimes, featuring the
Baker301 and Parmigiani303 approaches. Sutton et al.304 introduce comprehensive decision modelling.
Real options approaches
Palmer and Smith308 introduce real options approaches, inspired by methods used in financial markets,
which aim to include the uncertainty around the use of a new technology along with health economic
evaluation. The approach uses the potential to delay introducing a new technology (akin to a change in
management) and the irreversibility of using a new technology. Analyses factor in deferring using a
technology and the better evidence that may be available after deferral using expected value of perfect
information methods.
Real options approaches are further discussed and expanded on by Driffield and Smith,305 Meyer and
Rees307 and Shechter et al.,309 whereas Whynes310 and Lasserre et al.306 discuss a similar method.
Summary and conclusions
This review has revealed that there is limited methodological literature on the design of monitoring
strategies. Work has focused primarily on the analysis of data, allowing subsequent recommendations to
be made for monitoring frequency or decision rules, or simulation work, with both approaches being
specific to the disease area being researched. Methods have been developed in the area of screening,
with the focus being on identifying the optimal frequency of screening, which could be used for designing
monitoring strategies. Some work has been carried out on the design of biomarker development studies,
which could potentially be adapted to allow for the evaluation of a monitoring strategy using previously
collected specimens. It appears that thresholds are often developed by analysis of the variability of the test
being used, identified by the literature describing signal-to-noise ratios, biomarker development studies,
statistical process control and RCVs.
The study by Buclin et al.146 shows an approach in which decision rules were devised by a review of the
literature and, then, using an obtained data set and analysis of signal and noise the rules were refined to
minimise false results. Following this, recommendations on the decision rule and frequency of monitoring
could be made. Takahashi et al.255,256 and Oke et al.248 also used signal and noise methods when analysing
data and subsequently recommendations could be made for future monitoring strategies.
A number of applications of the signal and noise approach were identified, largely in the area of treatment
titration.143,144,146,237–240,245,248,249,255,256,259 The limitations of this approach for monitoring disease progression or
recurrence are that rules and thresholds are devised purely by analysing the variability of test measures and
the minimisation of false findings rather than the detection of disease at the earliest point possible and the
impact on patients.
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The simulation approach proposed by Li and Gatsonis247 uses a joint latent class model that combines
predictions from the model with a utility function to identify optimal monitoring frequencies. The results of
a simulation study reported by Li and Gatsonis247 appear promising; however, the approach has not been
widely adopted, perhaps because of the complex nature of the model. Other simulation approaches may
also have potential under certain circumstances, particularly if measurement error and a link between
biomarker values and true disease state can be included.
The biases that are well documented in the screening literature are also applicable to the area of
monitoring. Length time bias and lead time bias should be considered when analysing monitoring data and
when designing monitoring studies. There is also the issue of post-screening noise, which is again important
to take into consideration when evaluating a monitoring strategy; the time point at which monitored and
non-monitored patients are compared should be selected to minimise the issue of incidence after the final
testing point and should also consider the number of likely events. Harm to patients is vitally important in
screening and monitoring as this harm may occur at several time points and this must be thought of when
designing strategies.
A further consideration in the analysis of monitoring data concerns the number of test measurements and
the timing of test measurements: people with more results will contribute more data to the model but
they may be very different from those with fewer results.241 Measurement error and particularly biological
variability should also be considered. Studies have shown that RCVs from biological variability studies of
healthy participants are not necessarily reflective of the true RCV for a diseased population. As methods to
derive test thresholds used in monitoring rely heavily on the variability of test results it is important that
estimates from biological variability studies are accurate. In addition, the quality of studies undertaken
when developing new biomarkers is not always rigorous; however, there is literature concerning the design
of these studies268 and the evaluation of quality of these studies.265
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Chapter 6 How can monitoring impact on
patient outcomes?
Much of the test evaluation literature centres on establishing key test properties such as test accuracy.However, the ultimate use of any test in clinical practice should be based on the knowledge that
testing does more good than harm to patients. Comparison of patient outcomes resulting from different
interventions is ideally assessed using a RCT design and the same design can be applied to the evaluations
of tests. RCTs are less commonly used for assessing medical tests but are increasing in number both for
diagnostic68 and for monitoring tests (see Chapter 4), such that a thorough understanding of the ways in
which testing can affect patient outcomes is important.
Patient monitoring is undertaken for many purposes, most obviously within the context of ongoing
treatment as the main tool for treatment titration and maintenance, with the goal being to maintain test
results within certain limits of a given marker until such a time as treatment can be discontinued or an
alternative treatment is needed. Our particular interest is in monitoring people who have a known disease
or condition that is likely to progress or recur at some point in the future but that does not yet require
treatment. Patients are usually asymptomatic (e.g. following primary treatment for the first occurrence of a
disease), but may be mildly symptomatic but not yet receiving treatment or may experience symptoms of a
disease that puts them at risk of developing other conditions. The primary goal is usually earlier treatment
or the avoidance or delay of treatment, with the crux of monitoring being to detect the need for a change
in patient management in a timely manner.
Particular challenges to evaluating the impact of monitoring tests on patient outcomes are, first, that the
effect on outcomes will be relatively small, thus requiring large samples of patients to demonstrate
statistically significant effects, and, second, that changing patient outcomes is reliant on patients and
clinicians following potentially complex protocols both for testing and for treatment.
Over the last 10–15 years a number of framework papers related to the development and evaluation of
tests for screening, diagnosis, prognosis and treatment monitoring purposes have been published, many of
which have been comprehensively reviewed by previous authors.315,316 We have selected three frameworks
of particular relevance to the consideration of patient outcomes in monitoring. The first, by Adriaensen
et al.,317 presents a stepwise evaluation process for new screening strategies, which includes a consideration
of the trade-off between the harms and the benefits from a new test. The second, by Ferrante di Ruffano
et al.,68 aims to assist those evaluating diagnostic tests to understand the ways in which changes to testing
strategies can affect patient outcomes. The third, by Lord et al.,318 considers the circumstances in which
randomised evidence of patient impact from a new diagnostic test may be needed. With these in mind, our
aim was to consider the potential impact of monitoring on patient outcomes, illustrated by our review of
randomised trials of monitoring strategies.
Methods
A monitoring care pathway was outlined to identify in simple terms the points at which monitoring might
affect outcomes (Figure 10). The three identified frameworks68,317,318 were reviewed in terms of their
relevance to this monitoring context and 58 trials from a review of RCTs in which monitoring was carried
out in at least one arm of the trial (see Chapter 4) were used for illustration purposes. The trials were
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grouped into three main categories in terms of the change in patient care under evaluation and the
intended impact on patient outcome:
1. A new monitoring strategy compared with an existing monitoring strategy, such that the current
monitoring test might be replaced by a new and more accurate test, a new test might be added to
the strategy or the currently used test might be applied at a different intensity or with an alternative
threshold for intervention. Depending on the associated change in patient care, the new monitoring
strategy may be intended to detect patients at an earlier stage of disease, to more accurately detect
those in need of treatment or to reduce the invasiveness or frequency of testing.
2. A monitoring strategy compared with immediate treatment of all patients at risk of an adverse
outcome, in which monitoring may be used to avoid or delay treatment in those who do not need it.
3. A monitoring strategy compared with no monitoring, in which patients are usually treated on the basis
of clinical presentation only and the likely aim of monitoring is the detection and treatment of disease
at an earlier stage.
In the following sections, we first consider the similarities and differences between monitoring, screening
and diagnosis, before broadly outlining the potential for benefit and harm from monitoring and
considering the ways in which patient outcomes can be mediated by particular aspects of the monitoring
care pathway according to the aim of monitoring and the change in strategy under evaluation.
Test results
2
Ongoing process
Monitoring decision3
Monitoring test
1
Treatment implementation
4
Patient outcome
(a)
Test threshold:
• Simple
• Change from prior
• Algorithm
Monitoring test Test result
Repeat test
Monitoring
decision
–ve
+ve
At prespecified
intervals
(b)
FIGURE 10 Monitoring care pathway: (a) pathway; and (b) detail of ongoing monitoring process. Adapted from
Ferrante di Ruffano et al.69 with permission. +ve, positive; –ve, negative.
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Monitoring compared with screening or diagnosis
The monitoring care pathway outlined in Figure 10 bears close resemblance to that for diagnosis and for
screening.68,317 In a monitoring context, (1) a test is administered according to a predetermined schedule to
detect a target condition or some precursor or marker of that condition, (2) the test result is considered
(often in relation to previous measurements and with the potential for repeat testing to confirm abnormal
or indeterminate results), (3) the test result is considered alongside other evidence (usually including the
results of further investigations) to decide whether or not therapeutic intervention is needed and (4) the
necessary intervention is implemented.
Where the pathway diverges from that for diagnosis is with the added dimension of repeated testing over
time and a merging of the ‘diagnostic’ and ‘management’ decisions outlined in the diagnostic care pathway
of Ferrante di Ruffano et al.68 The serial nature of testing for monitoring purposes can affect patient
outcomes in a number of ways, most obviously by increasing the physical and psychological burden of
testing on patients but also potentially impacting on other outcomes, for example through patient and
physician compliance with testing protocols. Furthermore, although a diagnostic test informs both a
‘diagnostic decision’ (often when more than one differential diagnosis may be available) and a ‘management
decision’ (assisting in the choice of a range of therapeutic options), a monitoring test is often relatively less
definitive, providing more of a guide to the need for changes in patient management. A positive monitoring
test result frequently triggers further investigation to determine whether or not and when a particular
treatment should be implemented, rather than informing the choice of one of a range of therapeutic
options. In this respect, monitoring is more akin to screening, in which a test is applied repeatedly over time
to detect and treat a particular clinical condition, rather than to differentiate between diagnoses, with the
caveat that monitoring populations have a higher risk of the clinical event of interest occurring and that,
although the ultimate goal of a new screening programme is usually a reduction in disease-specific mortality,
monitoring can be implemented for a range of reasons.
Potential benefits and harms from monitoring
Figure 11 uses the concept of a 2 × 2 contingency table to illustrate that assigning potential benefits and
harms from a monitoring test is not as straightforward as might be imagined. For simplicity, the following
is set mainly in the context of a new monitoring strategy to allow earlier detection and treatment.
In general terms, for those patients with a ‘true’ result, benefits accrue both to those who would otherwise
have experienced a poor clinical outcome but for the new test (A) and to those who would have been
detected clinically and successfully treated but the new test allows this to happen at an earlier point in the
disease process (B). Benefit also occurs for those with no disease and for whom a negative monitoring test
result has a reassurance value, increasing a patient’s sense of control over the disease (G). Positive benefits
might also be experienced by all patients, for example with the use of a less invasive test or less frequent
testing (H).
Patients who have a ‘false’ monitoring test result will experience harm from the new testing strategy in a
similar manner to that experienced after false-negative or false-positive diagnostic test results. False-negative
test results can lead to a false feeling of security, delayed detection of disease and potentially a delay in
effective treatment until the disease becomes clinically apparent (D). False-positive test results can lead to
unnecessary further investigation and/or unnecessary treatment (E). For monitoring tests that aim to detect
preclinical or very-early-stage disease, ‘early’ false-positive results (i.e. in patients whose disease would not
have progressed to clinically overt disease within a clinically meaningful time frame) will lead to a longer
period of time in a diseased state and potentially in overdiagnosis and unnecessary treatment (F). Similarly,
‘early’ positive monitoring tests in those with a true-positive test result (C) can cause harm for those patients
who go on to experience a poor clinical outcome and who undergo a longer period of treatment (with
associated side effects and a longer period of time in a ‘diseased’ state).
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FP
TNFN
TP
All
+ Would have experienced clinical
outcome (e.g. death) but cured,
owing to (earlier) detection and effective
treatment (A)
+ Would have been successfully treated
for disease anyway, but quality of life is
improved owing to detection (at an earlier
stage of disease), ± less debilitating
treatment (B)
– Would have experienced clinical
indications of disease at a later time
point, but clinical outcome not improved
and quality of life potentially decreased
by earlier detection and treatment (C)
– Do not have the disease, or any
precursor, and undergo unneccessary
further investigation and treatment (E)
– Have preclinical or early-stage disease
that would not have progressed to
clinically overt disease within a
‘reasonable’ time frame (or could
potentially even have regressed),
resulting in overdiagnosis and
unnecessary treatment and a longer
period of time in a 'diseased' state (F)
+ Do not have the disease or preclinical
indicator of disease and are reassured
by the negative results of a monitoring
test that correctly shows that they do
not have the disease (G)
– Have the disease (or a progressive
precursor of disease) but have a
negative monitoring test resulting in a
false feeling of security, delayed
detection and delay of effective
treatment (D)
TPs FPs
TNsFNs
All
+ Experience benefit from the monitoring
experience, either psychologically or because 
of less frequent or less invasive testing (H)
– Experience direct harm from the monitoring
test(s) or from any confirmatory testing (I)
– Experience psychological impact from
increased anxiety or labelling effects (J)
FIGURE 11 Summary of the potential harms and benefits from a new monitoring strategy. Harms and benefits are similar to those identified from a screening context by
Adriaensen et al.317 FN, false neagative; FP, false positive; TN, true negative; TP, true positive.
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More direct harms can also be incurred by the testing experience, relating to repeated applications of the
monitoring test, to any confirmatory testing and to any intervention that is implemented (I and J). These
can be physical or psychological in nature and may result from either positive or negative test results,
with the serial nature of testing in a monitoring context necessarily multiplying the potential impact. In
particular, the ongoing monitoring process (even with repeated negative results) may raise general levels of
anxiety and distress and can also have a ‘labelling’ effect that can have a negative influence on patients’
perceptions of themselves and their disease.319,320
When is randomised evidence needed?
The RCT is the gold standard approach to assessing impact on patient outcomes but, given the challenges
to implementing this design for the assessment of test impact, its use requires careful consideration.
Lord et al.318 determined the need for randomised evidence for a new diagnostic test based, first, on
whether or not the cases detected by the new test represent a similar spectrum of disease to those
detected by the old test and, second, whether or not treatment has been shown to be, or can be assumed
to be, as effective in the new group of patients, regardless of disease spectrum. Incorporating the time
dimension of monitoring into this framework, for a new monitoring strategy one must determine, first,
whether or not the cases detected by the new strategy represent a similar spectrum of disease, both in
terms of the biological characteristic that is measured by the test and in terms of the time point in the
disease process at which disease recurrence or progression is identified, and, second, whether or not
treatment has been shown to be, or can be assumed to be, as effective in the new group of patients,
regardless of disease spectrum and the timing of detection in relation to the stage of disease.
Notwithstanding the simple appeal of this approach, testing strategies are necessarily complex interventions,
with various components and possible interactions that can combine to affect patient outcomes; even a
‘perfect’ test and highly effective treatment will not necessarily improve patient outcomes. Ferrante di
Ruffano et al.68 developed a framework to consider how testing can affect health outcomes. This has
been adapted for the monitoring context in Table 13, considering factors such as timing, test properties,
treatment effectiveness, potential to change practice and the patient experience.68 Many of these can apply
equally to patients undergoing monitoring; however, some require more or less emphasis or need to be
adapted to the monitoring context.
We considered the extent to which these factors might affect a monitoring evaluation according to the
aim of the new strategy and the way in which it fits with standard care, to demonstrate how this could
inform the need for randomised evidence (Table 14).
Earlier detection and treatment
Evaluations of monitoring strategies that aim to detect and treat disease at an earlier stage or time point
will generally take the form of a new monitoring regime compared with an existing monitoring regime or
the initiation of monitoring when no previous monitoring was undertaken. In this setting, the goal of
earlier detection almost necessarily implies that those patients detected and treated by a new monitoring
strategy will have a different spectrum from those previously treated. Although patient outcomes may be
affected by all of the identified mechanisms, it is the clinical validity of the test(s) used, their ability to
detect long-term change within a clinically meaningful time frame and the effectiveness of the treatment
at the particular stage of disease that are of overarching importance. Longitudinal studies can establish test
properties and identify the spectrum of patients detected by the test(s). If no randomised evidence for
treatment in this group of patients exists or if it is not clear whether or not the existing evidence will apply
in the new group of patients, a new RCT may be needed, as for example in a trial evaluating a lower CD4
threshold for the initiation of antiviral treatment in HIV infection.157 Alternatively, the evidence may be such
that no trial is indicated. A trial of ultrasound to detect small HCCs in patients with cirrhosis of the liver
found that many of the lesions detected were too small to warrant treatment, with some even regressing
rather than progressing.163 This high rate of ‘early false-positive’ results could potentially have been
identified in a longitudinal study without the need for a RCT.
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TABLE 13 Patient outcome framework for monitoring tests
Care pathway component
DefinitionNo. Attribute
Test delivery
1 Test feasibility Completion of the test process, where reasons for non-completion might
include:
l counterindication (clinician refusal to administer test)
l technical failure (ability of test equipment to produce data)
2 Test procedure Patients’ interaction with the test procedure, potentially causing physical
or psychological harms or benefits
3 Test frequency Patients’ response to serial testing, potentially multiplying the impact of
any physical harms and incurring additional psychological impact
Test result
4 Interpretability After successful completion of the test process, the likelihood of high
frequencies of indeterminate or unreadable test results (distinct from the
measurement variability associated with an individual test result, which
will affect the ability of the test to detect true changes in disease status)
5 Clinical validity The ability of a test to predict the presence of, or development of, clinical
or overt disease
6 Timing of test result The ability of the test to predict overt disease within a clinically meaningful
time frame
7 Detection of long-term change The ability of a test to differentiate true changes in patients’ disease status
from short-term variations
Management decision
8 Added clinical value The degree to which the test contributes to a change in management:
l indication for treatment
l indication for further confirmatory testing
l indication for closer monitoring
l indication for less frequent monitoring
[Also incorporates any other information used by a clinician to formulate a
change in management (such as prior or additional test results)]
9 Time frame of management
decision
The time frame within which patients undergo a change in management
10 Clinical confidence The degree of confidence that clinicians have in the validity or applicability
of a test result
Treatment implementation
11 Timing of treatment The time frame within which patients receive treatment
12 Efficacy The ability of the intervention to improve patient outcomes at the
particular stage of disease detected
13 Adherence The extent to which patients participate in the management plan, as
advised by their physician, in order to attain the therapeutic goal
Adapted from Ferrante di Ruffano et al.68 with permission.
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TABLE 14 Analysis of the need for randomised evidence for a new monitoring strategy
Goal of strategy and
comparison
Change in
testing Key effects on patient outcomes Example Is a RCT necessary?
Earlier detection and treatment
New monitoring strategy vs.
existing monitoring strategy
Add or replace
test
Timing
Test properties – limit early false-
positive results
Treatment effectiveness – at earlier
stage of disease?
Added clinical value – what does test
or change in threshold/frequency add
to clinical decision making?
Patient experience – test more/less
invasive?
Addition of PET scans at 3 and 15 months
to standard surveillance for the detection of
recurrent colon or rectal cancer (includes CT
scans at 3 and 15 months)175
Longitudinal studies could identify additional
cases detected by the new test if the
management decision made after standard
surveillance is compared with the
management decision made following the
new test or if it is ethical to blind the results of
additional (interim) investigations and act only
on those carried out according to the original
follow-up schedule
RCTs are needed to determine the effect on
patient outcomes of earlier treatment if
randomised evidence does not already exist
Change an
existing test
threshold
aSurveillance of patients with HIV infection
and treatment at a higher CD4 threshold157
More frequent
testing
Increased frequency of Doppler US for the
detection of HCC in patients with
compensated cirrhosis of the liver163
Monitoring vs. no monitoring New testing
strategy
Timing
Test properties – limit false-positive
results
Treatment effectiveness – at earlier
stage of disease?
Added clinical value
Patient experience – potential adverse
effects from invasive test;
psychological impact
Introduction of new endoscopic surveillance
compared with endoscopy on demand to
allow the earlier detection of oesophageal
carcinoma in patients with Barrett’s
oesophagus176
Akin to screening context; randomised
evidence is needed to determine the benefit of
formalised monitoring
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TABLE 14 Analysis of the need for randomised evidence for a new monitoring strategy (continued )
Goal of strategy and
comparison
Change in
testing Key effects on patient outcomes Example Is a RCT necessary?
Reduce the invasiveness of testing
New monitoring strategy vs.
existing monitoring strategy
Replacement
test
Timing
Test properties – should be similar to
existing strategy
Treatment effectiveness
Added clinical value – effect on
patient confidence?
Patient experience – less invasive,
safer test
Less invasive biopsy approach for patients at
risk of colorectal cancer177
No. Unlikely to be a change in disease
spectrum. The accuracy/predictive ability of the
new biopsy approach is key; the value of the
new test may be inferred from an assessment
of safety and/or cost
Triage test Timing – potential increase in time to
treatment
Test properties – low false-negative
rate needed
Treatment effectiveness – outcomes in
those not treated key
Added clinical value – patient/clinician
confidence in triage test
Patient experience – less invasive,
safer test
Gene expression profiling as triage to
endomyocardial biopsy to detect cardiac
transplant rejection162
Yes. Only a subset of patients will be identified
by the new test. Treatment will be as effective
in the subset of patients but clinical outcomes
will be unknown in those not selected by the
new test
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Goal of strategy and
comparison
Change in
testing Key effects on patient outcomes Example Is a RCT necessary?
Reduce the volume of testing
New (or no) monitoring
strategy vs. existing
monitoring strategy
Fewer tests or
less frequent
testing
Timing – potential increase in time to
treatment
Test properties
Treatment effectiveness – possible
treatment at a later stage
Added clinical value – patient/clinician
confidence in less testing
Patient experience – possible
psychological impact
Reduction in the number of CT scans from
five over 36 months to two in 12 months
for the detection of recurrence of
non-seminoma testicular cancer180
Yes. Beyond 3 months’ follow-up the
spectrum will change to the later stage of
disease, especially for those whose disease has
not recurred by 12 months. Treatment
options/effectiveness are likely to be similar for
those detected in the first 12 months
A longitudinal study could indicate the
number of positive tests that would be missed
by reducing the test frequency but could not
compare clinical outcomes between strategies
Reduce overtreatment
New monitoring strategy vs.
existing monitoring strategy
Add or replace
test
Timing
Test properties – similarly predictive
with fewer false-positive results
Treatment effectiveness – does test
detect same marker?
Added clinical value – clinician
confidence key
Patient experience – impact depends
on nature of new test
DNA-based test vs. antigenemia test to
allow pre-emptive instead of prophylactic
treatment of HCMV infection following
solid organ transplantation181
No. The two tests reflect different aspects of
virus replication but there is apparently no
indication of a differential treatment response
in this example. A RCT is needed only if
treatment on the basis of the new test is
expected to result in a different treatment
response
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TABLE 14 Analysis of the need for randomised evidence for a new monitoring strategy (continued )
Goal of strategy and
comparison
Change in
testing Key effects on patient outcomes Example Is a RCT necessary?
Delay/avoid treatment by introducing a new surveillance strategy
New monitoring strategy vs.
treatment
New testing
strategy
Timing – possible unnecessary delay in
treatment
Test properties – should minimise
false-negative results
Treatment effectiveness – possible
treatment at later stage of disease
Added clinical value – patient/clinician
confidence key
Patient experience – increase in
testing but reduction in treatment
Sonographic surveillance vs. immediate
treatment of mild hip dysplasia in
newborns158
Yes. The spectrum changes to more severe
disease as some cases resolve without
treatment. A RCT may be needed to establish
whether or not later/no treatment leads to
poorer outcomes
CT, computed tomography; DNA, deoxyribonucleic acid; HCMV, human cytomegalovirus; PET, positron emission tomography; US, ultrasound.
a Note for this example, a collaborative analysis of 18 cohort studies from the When To Start Consortium31 supported the higher threshold for antiretroviral therapy initiation.
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Even when clinically valid, timely monitoring tests and effective treatments are available, the potential for a
monitoring strategy to have a positive impact on patients will be influenced both by the degree to which
it can substantively add clinical value over and above that of usual clinical practice and by the degree of
clinical and patient confidence in the new strategy. When an individual monitoring test provides a clear
guide to future management, as in the CD4 example above, the added contribution of the change in
strategy might be relatively easy to discern. However, when a new monitoring test is one component of a
bigger surveillance programme, for example the addition of biochemical tests and/or imaging tests to an
existing surveillance programme, its added value may be more difficult to ascertain. In some circumstances,
the accuracy of the confirmatory test could also mitigate any impact of the monitoring test, especially
if the new test is able to detect very-early-stage disease that is not detectable by the confirmatory
test.182–184,321
Clinician and patient confidence in and compliance with a prescribed monitoring strategy can be vital to
the success of a monitoring evaluation. For example, if clinicians have a high degree of faith in a new test,
its ‘off-protocol’ use in the control arm of a trial may dilute the observed effect. This was observed in
a trial of ultrasound for the detection of HCC, which also attempted to evaluate the added value of
serial alpha-fetoprotein (AFP) measurements; high rates of serum AFP assay use in the two groups not
randomised to AFP (60.5% and 54.8%, respectively) precluded reliable interpretation of the data and led
to a final analysis restricted to ultrasound randomisation only.163
The effect of the patient experience of monitoring on outcome will depend on the nature of the test(s)
involved and of the care that would otherwise have been received, especially if no monitoring was
previously carried out. In the TOMBOLA (Trial Of Management of Borderline and Other Low-grade
Abnormal smears) trial, for example, non-attendance was higher in the cytological surveillance arm: 10.6%
did not attend the first cytological surveillance appointment whereas 6.8% did not attend for immediate
colposcopy.178 Of the 10% who did not attend the first cytological surveillance appointment, 2% did not
attend at all and 8% attended > 6 months after the test was due. Some tests (or subsequent confirmatory
testing) will carry a risk of immediate or long-term physical harm, for example the introduction of routine
endoscopic surveillance with biopsies in patients with Barrett’s oesophagus to allow the earlier detection
of oesophageal carcinoma or the initiation of 6-monthly computed tomography (CT) in patients at risk of
colorectal cancer recurrence, with the potential to affect patient compliance.176 Strategies that afford
patients more control over a disease, however, might increase adherence to treatment regimens, as in a
trial of daily foot skin temperature monitoring by patients with diabetes mellitus in which those who were
compliant with the monitoring strategy for at least 50% of the time were significantly less likely to develop
a foot ulcer.174
Patients will also experience a sometimes complex psychological impact from the monitoring experience.
A qualitative study of patients’ attitudes to and understanding of CA-125 testing for the monitoring of
ovarian cancer recurrence found that both negative and positive test results can reassure patients if the
result appears to legitimise patients’ own subjective experience of the disease, with a positive result
confirming their worst suspicion or a negative result providing reassurance that they are as ‘well’ as they
feel.322 Positive, or rising, test results can mediate a patient’s experience of any clinical symptoms, with
the knowledge that he or she is probably experiencing a relapse potentially making symptoms more
unbearable or causing him or her to reinterpret earlier ‘symptoms’ that had previously been discounted.322
Similar findings in other monitoring situations have also been observed.320
Reduce the invasiveness of testing
Patients’ exposure to invasive tests can be reduced in two ways: (1) by replacing an existing test with a less
invasive one or (2) by introducing a triage test to select the most appropriate patients for invasive testing.
For the former option, assuming that the new test aims to detect disease at a similar stage or time point,
it will be important to establish its properties in relation to the existing test and to ensure that it identifies
a similar spectrum of patients. If so, treatment can be expected to be similarly effective and the impact of
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the test on patient outcomes will result from the less invasive nature of the test, as for example with the
use of a less invasive biopsy approach in patients at risk of colorectal cancer.177
If a new triage test is introduced to prevent harm from the testing process, such as gene expression
profiling as triage for endomyocardial biopsy when monitoring for acute cardiac transplant rejection162 or
the introduction of cytological surveillance to reduce the number of colposcopies undertaken in women
with mild dyskaryosis,178 the need for a randomised trial will be greater. Only a subgroup of patients will
be selected for further investigation and treatment, such that treatment effectiveness could vary and
outcomes in those no longer selected for treatment must also be assessed. In this setting, the properties
of the new test (in particular the rate of false-negative results), the timing of detection and treatment
effectiveness are likely to be of overarching importance. Patient and clinician confidence in the new triage
test will also be needed to ensure that any potential benefits are realised in practice. An element of ‘trust’
that the new, less invasive test will accurately identify those in need of the more invasive test is required on
both parts. Patient preference is not always as intuitive as it might appear, for example gene testing was
favoured over endomyocardial biopsy in the example above,162 whereas patients at risk of bladder cancer
recurrence preferred an immediate result from a more invasive test (cystoscopy) to the result from a less
invasive (urine) test a week later.179
Reduce the volume of testing
Sometimes new monitoring strategies aim to reduce the number or frequency of tests without adversely
having an impact on patient outcome, as is often the goal when monitoring for cancer recurrence.180,184
One example is the proposal to reduce the number of CT scans from five over a 3-year period to two in
the first year of follow-up following primary treatment of non-seminoma testicular cancer.180 Under the
new regime, there could be a change in spectrum to later-stage disease in those detected at the 12-month
follow-up point and detection of those patients whose disease recurs beyond 12 months would rely on
clinical relapse or detection by biochemical markers or chest radiography. In this situation, the number of
cases that would be missed and the stage of disease at detection could be identified using a longitudinal
study design but the clinical outcomes for the different strategies could not be directly compared without a
RCT. If, however, sufficient evidence exists for treatment at the various stages of disease, this could be
linked to data from a longitudinal study using a decision-analytic-type model.318
A trial of less frequent fetal surveillance of small-for-gestational-age fetuses demonstrates the sometimes
complex responses of clinicians and patients to monitoring. Over half of the experimental group in this
trial attended for ultrasound more frequently than scheduled and underwent additional tests of fetal
well-being, suggesting that clinicians were not always comfortable with the planned reduced frequency of
fetal surveillance and making it difficult to assess whether or not the apparent safety of less frequent
monitoring may have been in part because of this additional surveillance.158 At the same time, 17% of
women in the twice-weekly surveillance group attended less frequently than requested, suggesting a
patient perception of over-frequent monitoring.185
Reduce overtreatment
In some monitoring contexts, a new test can be introduced to replace another simply to better select the
right patients, for example a new deoxyribonucleic acid (DNA)-based test to detect human cytomegalovirus
infection following stem cell transplantation compared with the existing antigenemia test.167 This is more
akin to a diagnostic test context in which the goal is to use the most sensitive and/or specific test, as the
time dimension of monitoring is less relevant than the properties of the test concerned. Although the new
test may detect a different biochemical marker, if there is no indication of a differential treatment response
according to the marker used, and randomised evidence exists for the effectiveness of treatment in the
patients identified, then a study to establish the properties of the tests concerned may be sufficient
evidence for the introduction of the new test.
To fully affect patient outcomes, however, clinicians must have confidence to act on the results of the
new test. Only half of patients who tested positive on the DNA-based test in the example above actually
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underwent treatment, whereas, in a trial of a new galactomannan assay in patients at risk of invasive
aspergillosis following stem cell transplantation, two-thirds of those treated in the experimental arm had a
negative monitoring test, perhaps because clinicians had previously relied on clinical assessment as the
basis for treatment decisions.167,168
Delay or avoid treatment when it is not required
The final scenario is one in which monitoring is introduced as an alternative to immediate treatment. In
this circumstance, patient outcome might be affected by later treatment in the surveillance arm, further
delays to necessary treatment because of false-negative test results, the effectiveness of treatment at a
later stage of disease and the need for clinician and patient confidence in the monitoring regime. When
immediate treatment is the standard care option, evidence for treatment at a later stage of disease may
not be available, so the onus is not only on demonstrating that the monitoring test used is clinically valid
and able to detect the point at which treatment is needed, but also on evidencing treatment effectiveness
in the surveillance group. In a small trial in infants with mild hip dysplasia, sonographic surveillance allowed
abduction treatment to be delayed or avoided with no significant difference in radiological outcomes at
1 year compared with immediate abduction treatment; < 50% of those in the surveillance arm underwent
treatment during the course of the trial.158
Conclusion
The impact of a monitoring strategy is driven not only by the properties and timing of testing and the
effectiveness of treatment but also by patients’ responses to the type and frequency of testing and
clinicians trust in, and willingness to comply with, the monitoring protocol. Reitsma et al.323 advocate that
what is more important for clinical decision-making than the level or change in a given marker is the
confidence with which that marker can be used to inform patient management. A move towards a test
validation paradigm is advocated, by which a number of methods (including establishing test properties)
are used to determine whether or not the results of a test are meaningful in practice. In some
circumstances, randomised evidence will be needed to fully assess the impact of a test, but this level of
evidence will not be needed in every circumstance.
For example, the feasibility of testing and interpretability of test results can be estimated in the development
phase of a test, as long as the technical properties of the test are established in clinically relevant populations
rather than in laboratory-based studies alone.316 Patients’ interaction with the testing experience and their
likely adherence to monitoring or to subsequent management can be assessed in qualitative studies.
Feasibility or pilot studies can help identify what a new test adds to current clinical practice, particularly in
terms of clinicians’ interaction with and likely adherence to a new monitoring strategy, and can help identify
potential barriers to implementation, as has been recommended for trials of complex interventions.228
Estimates of key aspects of test performance can be obtained from non-randomised, preferably longitudinal
studies comparing tests against a (delayed) reference standard or clinical outcome.65 The efficacy of treatment
is the only mechanism that requires evaluation in a RCT per se; however, the combined effect of the
individual mechanisms that come into play may be fully assessable only in a RCT.
Any decision to undertake a RCT should be informed at a minimum by good evidence of the natural
history of the disease, the establishment of test properties (in terms of clinical validity and estimation of
long-term change in disease status) and evidence (or lack) of treatment efficacy in those patients who are
identified by the new monitoring strategy.
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Chapter 7 Simulating monitoring data and
evaluating monitoring strategies
Introduction
Tests are used in health care to monitor, and subsequently manage, a variety of chronic conditions.
The focus of this research is the monitoring of progressive or recurrent conditions, in which the aim of
monitoring is to identify early signs of recurrence or progression, prompting a change in management,
typically the initiation of treatment or further testing.
Monitoring strategies are complex interventions combining a test, a schedule, a decision rule and further
diagnostic or therapeutic action. Monitoring strategies stipulate the frequency of testing and the ‘monitoring
rule’ used to identify when a change in patient management is necessary. A monitoring rule indicates the value
or values that would trigger a change in management. Monitoring rules can be simple, such as when a single
value above a threshold will prompt a change in management (a ‘snapshot rule’), or more complex, such as
when a patient requires a series of test results observed at different time points that fit certain criteria (such as a
relative increase from previous measures) to initiate a change in management (a ‘track-shot rule’).146
Although patient monitoring is a fundamental function of health care, resulting in considerable costs to
health-care providers, the area of monitoring is under-researched and there is an increased need for
monitoring strategies to be systematically developed with knowledge of the likely progression of disease and
the performance of the monitoring test to be used.62,324 Dinnes et al.,69 in Chapter 3, reviewed the evidence
base for PSA monitoring to identify the recurrence of prostate cancer. The review identified the lack of a
systematic approach to developing a monitoring strategy, with monitoring intervals based on standard
follow-up schedules and limited evidence of consensus over the thresholds used to initiate treatment.
Stevens et al.142 discussed various statistical models of the transition between the maintenance and the
re-established control phases of monitoring (the process of detecting when a disease is out of control,
leading to a change in management, e.g. treatment or more intensive monitoring) and identified a general
statistical model for the evolution of monitoring data over time, outlining possible sources of variation. This
general statistical model proposes the form of monitoring data based on the observed values of sequential
monitoring tests, the values of measurement error and other sources of variability and the true disease
state, which can be modelled based on epidemiological evidence but never observed.
This general model, along with existing data and evidence gathered from the literature, can be used to
simulate monitoring data and allow for the evaluation of strategies for a given target condition. The potential
effect of monitoring strategies can then be evaluated and ranked, prior to full-scale investigation.325
The example presented here investigates the use of the ELF biomarker in monitoring patients with known
liver fibrosis, alongside the ELUCIDATE trial,326 a prospective multicentre randomised trial. The ELUCIDATE
trial is evaluating the ELF test for the early detection of progression from liver fibrosis to liver cirrhosis
compared with routine care, with the aim of enabling earlier treatment and providing potentially improved
patient outcomes. It is described fully in Chapters 16–24.
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Aims and objectives
The aim of this study was to identify the optimal monitoring strategy, from candidate monitoring
strategies, for patients known to have liver fibrosis receiving repeated testing using the ELF biomarker.
Candidate strategies were selected and evaluated to:
l compare the alternative frequencies of monitoring (6-month or 12-month intervals)
l evaluate the benefit of using targeted retesting compared with no retesting
l compare decision rules [positive results based on crossing a threshold determined by a single value
(snapshot simple threshold rule) and positive results dependent on track-shot rules based on absolute
or relative increases from the first test value, absolute or relative increases from the last test value and
prediction from a linear regression model].
Methods
First, we describe the model used to generate the underlying and unobserved disease progression,
incorporating estimates of disease progression and the variability of these estimates, for a cohort of
simulated individuals. Then, the process of obtaining observed test result values using the true disease
progression values and estimates of test performance is described. Finally, the methods used to evaluate
and compare selected monitoring strategies, using both the observed test values and the true disease
status, are given. An explanation of the notation used in the model is provided in Table 15.
TABLE 15 Model notation
Description Notation
Individual number ii
Number of initially simulated individuals nn
Number of simulated individuals eligible for randomisation NN
Fibrosis stage ss
Time within fibrosis stage x jsx js
Time across fibrosis stages tt
Monitoring time points TT
Fibrosis progression pipi
Mean fibrosis progression µpµp
SD of fibrosis progression σpσp
Starting fibrosis stage SiSi
Probability of starting in each fibrosis stage ρsρs
ELF value at each stage of fibrosis EsEs
Mean ELF value at each fibrosis stage µsµs
SD of ELF value at each fibrosis stage σsσs
Observed mean ELF value at each fibrosis stage µY sµY s
Observed SD of ELF value at each fibrosis stage σY sσY s
ELF value progression between fibrosis stages EisEis
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Simulation of true disease progression
The model simulated true disease progression, generating a random slope and random intercept in terms
of fibrosis stage for each patient. The model then converted the fibrosis stages to ELF values.
Fibrosis progression: random slope
The rate at which patients progress through the fibrosis stages was assumed to be constant throughout
the stages of fibrosis and normally distributed:
pi∼N(µp, σ
2
p), (4)
TABLE 15 Model notation (continued )
Description Notation
Values from the standard normal distribution zizi
Gradient of ELF progression βisβis
Time point when patients progress in fibrosis stage π isπ is
True ELF value by time in fibrosis stage EijsEijs
True ELF value across fibrosis stages EitEit
True ELF value over the period of the trial UitUit
Time at registration τr iτr i
Time at randomisation τt iτt i
Total observation error ωitωit
SD of total observation error σωσω
Observed ELF value Y itY it
Observed ELF value at monitoring points Y iTY iT
Entry ELF criteria Y*r Y
*
r
Frequency of observations θθ
Range for targeted retesting ΔΔ
Time period before entering compensation cirrhosis when a patient is considered diseased δδ
Simple decision rule threshold Y*Y*
Simple decision rule threshold at the point of randomisation Y*0Y
*
0
Absolute increase from start value decision rule threshold Y*DY
*
D
Absolute increase from last value decision rule threshold Y*EY
*
E
Relative increase from start value decision rule threshold Y*FY
*
F
Relative increase from last value decision rule threshold Y*GY
*
G
Linear regression decision rule threshold Y*HY
*
H
Maximum time in cirrhosis before trial entry c1c1
Maximum time in fibrosis before trial entry c2c2
Time between registration and randomisation c3c3
Trial duration c4c4
Time between test and retest measures εε
DOI: 10.3310/pgfar06030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Selby et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
77
where i = 1, . . ,n and n is the number of simulated individuals, µp is the mean fibrosis progression and σp is
the SD of fibrosis progression. Fibrosis progression was restricted to only positive values, by fixing pi at 0.01
if pi ≤ 0, meaning that only increases in fibrosis stage were simulated, with no patients having decreasing
fibrosis stages; however, as the increase is just 0.01 fibrosis units per year, this effectively means that these
patients are in a stable fibrosis state.
Fibrosis stage at entry: random intercept
Patients recruited to a trial would be in varying stages of disease at entry. Using data on the likely
distribution of fibrosis stage for a population with known liver fibrosis, a multinomial distribution was used
to simulate a starting stage for each individual:
Si∼Mn (0, 1, 2, 3, 4)(ρ0, ρ1, ρ2, ρ3, ρ4), (5)
where ρs is the probability of starting in each stage, s is the fibrosis stage and s = 0, . . ,4.
Enhanced Liver Fibrosis score link to fibrosis stage
For each stage of fibrosis, the distribution of true ELF values within fibrosis stage was assumed to follow a
normal distribution:
Es∼N (µs,σ
2
s ), (6)
where s is the fibrosis stage and s = 0, . . ,4, µS is the mean value of ELF at each fibrosis stage and σs is the
SD of the mean ELF value at each fibrosis stage.
Enhanced Liver Fibrosis progression between fibrosis stages
The model used fibrosis stage on a continuous scale rather than on a discrete scale. To generate ELF values
for each patient at all stages of fibrosis, ELF progression between consecutive integer fibrosis stages was
assumed to be linear. It was assumed that patients would have ELF values at the same point of the normal
distribution for each fibrosis stage (patients would remain a given number of SDs from the mean). To
randomly select the point of the normal distribution that patients would follow, a value from the standard
normal distribution was generated for each patient, zi∼N (0,1). The ELF value for each participant at each
stage of fibrosis was Eis = µs + (ziσs) (Figure 12a).
Enhanced Liver Fibrosis progression: random slope
The ELF values at the beginning of each fibrosis stage for each individual (Eis) and the rate at which each
simulated participant progresses through fibrosis (pi) were combined to calculate the increase in ELF per year.
The gradient of ELF progression was βis = (Ei,s+1 − Ei,s)pi, for s = 0, . . ,3. The gradient of ELF progression after
stage 4 was assumed to be the same as the gradient between stages 3 and 4 (βi3 = βi4). The time point
signalling when each individual would progress to the next fibrosis stage was πis = spi. βis is the random slope
in terms of ELF progression.
The underlying and true ELF progression for each stage and all time points from the onset of fibrosis was
then calculated as:
Ei js = Eis + βisx js, (7)
where xjs is time within stage s and:
0≤ x js < π i, s+1−π i, s for s = 0, . . , 3. (8)
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For stage 4, s = 4 and xjs = 0, . . ,∞. The true ELF values for each individual across time could also be
expressed as:
Eit =
Ei j0 for 0≤ t < π i1
Ei j1 for π i1≤ t < π i2
Ei j2 for π i2≤ t < π i3
Ei j3 for π i3≤ t < π i4
Ei j4 for π i4≤ t,
8>>>><
>>>>:
(9)
where t is time across all stages (t = 0, . . ,∞). This allowed the simulation of lifetime progression data for
a cohort of patients (see Figure 12b). ELF values were truncated at 0 if a negative value was simulated.
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FIGURE 12 (a) Fibrosis units linked to ELF value; (b) ELF value progression through time; and (c) starting stage
adjusted ELF value progression through time.
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Enhanced Liver Fibrosis value at entry: random intercept
The time at registration for each participant (τr i ) was a randomly selected time point from the time period
when the individual was in his or her generated fibrosis stage at study entry (Si), that is, a random value
from the interval ½π i, si , πi, si+1 ), where Si is the starting stage for each individual and Si = 0, . . ,3. If the
participant was in stage 4 of fibrosis at entry, Si = 4 and τr i was generated by identifying a random value
from the interval [πi,4,πi,4 + c1], where c1 is the longest given amount of time that a patient can be in stage 4
of liver fibrosis before entering the trial. τr i also has a maximum value of c2, where c2 is the longest
amount of time that a patient can have fibrosis on registration to the trial. If, for a simulated individual,
τr i > π i,4 + c1 or τr i > c2, the data for that individual were not used in the analysis. This was done to prevent
patients being included when they would be confirmed as having cirrhosis or were at a point of fibrosis that
they would not have reached in their lifetime because of their simulated progression rate. The c1 time used
means that participants registering in the trial who are in stage 4 of liver fibrosis have been in stage 4 for a
maximum of c1 years. The c2 time used means that participants have liver fibrosis for a maximum of
c2 years before being registered in the trial.
In the ELUCIDATE trial, a registration ELF test was given to each patient to assess eligibility. The first ELF
test included in the trial data was taken at the point of randomisation. If the start of the trial occurred
c3 time units after registration, then the time at randomisation was τt i = τr i + c3. The random intercept in
terms of ELF is αi = Eit for t = τt i .
Random slope and random intercept model in terms of the Enhanced Liver Fibrosis test
The underlying disease progression for the simulated individuals over the time of the trial was Uit = Eit for
τt i≤ t < τt i + c4, where c4 is the duration of the trial and i denotes simulated patients with an eligible
registration ELF value (i = 1, . . ,N, where N is the number of simulated patients available for randomisation)
(see Figure 12c).
Simulation of observed values
The true underlying ELF measurements were converted to observed ELF measures by the addition of error.
Error
The error at each observation point (ωit) was formed of within-individual variation and analytical variation.
Error was assumed to be normally distributed with a mean of zero:
ωit∼N (0, σ2ω ). (10)
The observed ELF measurement at any given time was:
Y it = Uit + ωit. (11)
Values were adjusted to equal 0 if a negative observed ELF value was simulated.
Entry criteria
To fulfil trial entry criteria the observed ELF measurement at registration had to be greater than the preset
value of Y *r ; thus, the equation:
Y it > Y
*
r for t = τr (12)
had to be satisfied for each simulated participant to be included in the trial data. An example of simulated
observed ELF measures can be seen in Figure 13.
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Data sources
Data sources were used to estimate the fibrosis progression rate, fibrosis stage at trial entry, measurement
error and ELF value link to fibrosis stage. Additional information regarding the data sources used is
provided in Table 16.
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FIGURE 13 Observed ELF values.
TABLE 16 Data used in the simulation model
Estimate
required Data Estimates used in the model
Fibrosis
progression rate
Estimate of median fibrosis progression (Scheuer
fibrosis units per year): 0.133 (95% CI 0.125 to
0.143)327
Estimate calculated from Poynard et al.:327 pi ∼ N
(0.13, 0.172)
Estimate after adjustment (to be used in
sensitivity analyses) – estimate of fibrosis
progression was increased to reflect expert
opinion: pi∼ N (0.27, 0.17
2)
ELF stage at entry
to trial
Cross-sectional data set61 – estimated proportion
of patients in each stage: stage 0, 0.25; stage 1,
0.35; stage 2, 0.13; stage 3, 0.15; stage 4, 0.12
The cross-sectional data set was used: ρ0 = 0.25,
ρ1= 0.35, ρ2 = 0.13, ρ3 = 0.15, ρ4 = 0.12
Measurement
error
Longitudinal data set – estimate of the SD of the
measurement error of 0.81
Siemens – estimate of the SD of the total
measurement error of 0.11
ELUCIDATE trial registration and randomisation
data: estimate of the SD of the total
measurement error of 0.47
Estimate obtained from the ELUCIDATE trial was
used: ωit ∼ N (0, 0.47
2)
ELF value link to
fibrosis stage
Cross-sectional data set61 – estimates of ELF
mean (SD) value at each fibrosis stage: stage 0,
8.82 (0.87); stage 1, 9.18 (0.96); stage 3, 9.55
(1.00); stage 4, 11.32 (1.47)
After adjustment – measurement error is
accounted for to give the true unobserved ELF
values and modified to represent values for each
stage: E0 ∼ N (8.63, 0.732), E1 ∼ N (9.00, 0.842),
E2∼ N (9.36, 0.89
2), E3 ∼ N (9.91, 1.22
2), E4 ∼ N
(10.80, 1.392)
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Fibrosis progression rate
An estimate of the median rate of fibrosis progression based on data for 1157 patients was obtained
from Poynard et al.;327 the estimate of the median was assumed to be equal to the mean and the 95% CI
for the median was used to calculate the SD. When consulting clinical experts it was suggested that the
estimate provided by Poynard et al.327 was identified in a population that was not comparable with that
of the ELUCIDATE trial (participants in the Poynard study were thought to have less severe disease). The
estimate from Poynard et al.327 was used primarily in the simulation model, with an adjusted estimate used
for sensitivity analyses. Estimates of fibrosis progression are given as Scheuer fibrosis units per year, where
Scheuer scores range from 0 to 4 and measure the severity of liver disease, with stage 0 showing no
fibrosis and stage 4 showing liver cirrhosis.328
Fibrosis stage at entry
As the purpose of the study was to simulate and evaluate trial data, not all participants would enter the
trial at the same stage of fibrosis. A cross-sectional data set with ELF results and Scheuer fibrosis scores
following liver biopsy for 921 patients was used to identify the distribution of fibrosis stages in
the cohort.61
Measurement error
To estimate the error associated with each observed ELF test value, three data sources were considered.
First, a longitudinal data set with repeat ELF measurements (baseline and 3 months) for 220 patients was
subjected to analysis of variance (ANOVA) to identify variability at the individual level. The manufacturer of
the test also provided information on the performance of the ELF test.329 Because of discrepancies between
the estimates from the two sources, data were obtained directly from the ELUCIDATE trial. Registration
and randomisation ELF values for 112 eligible participants were again subjected to ANOVA to identify the
variability at the individual level. The estimate obtained from the ELUCIDATE trial data was used in the
simulation model.
Enhanced Liver Fibrosis value link to fibrosis stage
The cross-sectional data set was used to provide an estimate of the observed ELF value for patients at each
level of fibrosis, with a corresponding measure of variability.61 To estimate the true and unobserved SD of
the ELF value at each fibrosis stage, the measurement error that would have been included in these
observed measures, inflating the variability, was accounted for. As σ2s and σ
2
ω are independent in
the simulation:
σY
2
s = σ
2
s + σ
2
ω
so σs =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
σY
2
s −σ2ω
p
, (13)
where σY s is the observed SD at each stage of fibrosis. To estimate the true and unobserved mean ELF
value at each stage of fibrosis, the observed estimates were assumed to give the mean value for the
midpoint of the corresponding fibrosis stage and, thus, were altered to reflect an ELF value for the point
when a patient initially enters each stage of fibrosis:
µs = µY s+
µY s + µY s−1
2
for s = 1, . . 4, (14)
where µY s is the observed mean ELF value at each stage of fibrosis; when:
s = 0,µs = µ0 = µY 0 +
µY1 + µY 0
2
σs
2
(15)
is the between-individual variability at each fibrosis stage.
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Implementation of a monitoring strategy
The effect of implementing different monitoring strategies was predicted using simulated observed values
of ELF. The specified monitoring strategy (decision rule, use of retesting and frequency of testing) changed
the simulated observed values that would be measured and the how the value or values for each individual
would be interpreted.
Monitoring data required
The observed values that would have been measured under each monitoring strategy were extracted;
the exact values required were dependent on both the frequency and the duration of monitoring. The
duration of monitoring was specified by the duration of the trial, c4. If the frequency of monitoring was
every θ time units after randomisation, the observed values used to guide the management of participants
would be Yit for t = τt i + θT , where T = 0, 1, . . .,
c4
θ
and c4
θ
is the number of observation points additional to
randomisation. The subscript used for time is now simplified to indicate monitoring time points; this will be
T, where T = t−πti
θ
.
To incorporate a targeted retest component an additional test would be carried out ε time units after the
scheduled tests for patients with an observed value at that time point within a specified range (Δ) of the value
used to trigger a positive test. When a patient required retesting, the mean of the original test and the retest
result was calculated and this value was subjected to the decision rules to identify positive participants:
Y r iT =
Y iT + Y iT+ε
2
. (16)
Patients with a value above the upper limit of the range were classed as positive on the initial test without
further testing and patients below the limit of the retesting range were classed as negative using just the
initial test.
Monitoring strategies
Monitoring strategies are defined by the decision rule for identifying a positive result and the data that the
decision rule is applied to, which is dependent on the frequency of monitoring and the use of retesting.
Simple decision rule (strategy A)
The simplest decision rule was based on a single-value threshold (snapshot rule). The threshold value, Y*,
was specified and any single observed value over this threshold indicated a positive result for that
participant at that time point. A result was considered positive when YiT > Y*.
Retesting (strategy B)
Patients with an initial test value within Δ of the threshold value, Y*, were subjected to retesting. Patients
required retesting when Y* − Δ > YiT < Y* + Δ and these patients were considered positive when Y r iT > Y
*.
When patients did not require retesting, YiT ≤ Y* − Δ or YiT ≥ Y* + Δ, patients were considered positive
when YiT > Y*. The retesting component could be used with any of the alternative decision rules explained
(strategies D–H).
Frequency of monitoring (strategy C)
The frequency of monitoring was every θ time units after the initial test at randomisation. By decreasing
or increasing the value of θ the timing of the monitoring tests became more or less frequent, respectively.
When varying the frequency of monitoring, the time points and, hence, the observations evaluated
changed. When changing the frequency of monitoring, the value of θ determines the data evaluated, as:
T =
t−τt i
θ
, (17)
and patients are considered positive when YiT > Y*. Varying the frequency of monitoring could be used in
conjunction with any of the alternative decision rules explained (strategies D–H).
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Alternative decision rules
Decision rules incorporating previous test results as well as the current result (track-shot rules) to identify
positive patients were also considered. Absolute and relative increases from the randomisation ELF value or
from the last recorded ELF value were investigated. A rule using predictions from a linear regression model
fitted using all available observed data points was also considered.
Decisions rules based on absolute and relative increases and the linear regression method required at
least two observations to declare a participant as positive. A simple threshold rule was used to identify
participants at the point of randomisation using Yi0 > Y
*
0. Y
*
D, Y
*
E, Y
*
F, Y
*
G and Y
*
H are specified thresholds for
the corresponding decision rule method.
Absolute increase from start value (strategy D) A result was considered positive when the absolute
difference between the test value and the first recorded value for the patient was greater than
the threshold:
Y*D,Y iT −Y i0 > Y
*
D. (18)
Absolute increase from last observed value (strategy E) A result was considered positive when the
absolute difference between the test value and the last observed test value for that patient was greater
than the threshold:
Y*E ,Y iT −Y iT −1 > Y
*
E . (19)
Relative increase from start value (strategy F) A result was considered positive when the relative
difference between the test value and the first recorded test value for the patient was greater than
the threshold:
Y*F ,
Y iT
Y i0
> Y*F . (20)
Relative increase from last observed value (strategy G) A result was considered positive when the
relative difference between the test value and the last observed test value for that patient was greater than
the threshold:
Y*G,
Y iT
Y iT −1
> Y*G. (21)
Linear regression (strategy H) The linear regression decision rule involved the fitting of a linear
regression model for each participant at each time point, using all available measures for that participant
at the time point; the prediction from the model was then used to identify the patient as test positive or
test negative. A result was considered positive when the prediction from the linear regression model was
greater than Y *H.
Evaluation of a monitoring strategy
To evaluate each strategy, the decision made from implementing that monitoring strategy using the
simulated observed values and the corresponding true underlying values was assessed. With knowledge of
the true underlying disease state of each participant, the performance of a variety of monitoring strategies
was evaluated.
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Comparison of observed results with the underlying disease state
Participants had a positive or negative test result based on the simulated observed data and the decision rule
employed. The test result was then found to be either true or false depending on the underlying disease
state. The purpose of the ELF test was to identify when patients enter compensated cirrhosis, stage 4. From
the simulation of underlying true ELF values, the time point when each individual enters stage 4 was πi,4. As it
may be beneficial to identify patients prior to time πi,4, participants were classed as ‘diseased’ δ units of time
prior to πi,4 and onwards. If at a testing point a participant was diseased (≥ πi,4 − δ), a positive result would
be a true positive and a negative result would be a false negative. If at a testing point the patient was not
diseased (< πi,4 − δ), a negative result would be a true negative and a positive result would be a false positive.
As a positive result (truly or falsely) caused a change in management and cessation of monitoring, patients
who achieved a positive result did not have a test result at subsequent monitoring times. Figure 14 illustrates
how a strategy with a simple threshold decision rule can be evaluated.
Measuring the performance of a monitoring strategy
The performance of a monitoring strategy was assessed at each monitoring point by calculating the
number of patients at each monitoring test visit and specifically the number of true-positive, false-positive,
true-negative and false-negative test results. The number of tests carried out across the duration of the
strategy was used to represent resource use. The positive predictive value (PPV) was used to investigate
how likely it was for an individual with a positive result to be diseased. To measure patient harm the delay
from onset of disease to the point of diagnosis was calculated; this was the time between the onset of
compensated cirrhosis (πi,4) and a patient having a positive test result.
When comparing strategies the number of tests per person for the duration of monitoring, the PPV
(for all tests over the duration of monitoring) and the percentage of patients with a delayed diagnosis
(delay from onset of disease to diagnosis of > 12 months) were used to measure performance. To allow
for comparisons to be made between strategies in which only two of the three measures of performance
ranged, thresholds used by monitoring strategies were varied to obtain a PPV of 25%. A PPV of 25% was
chosen as this would be an acceptable PPV in practice.
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FIGURE 14 Results of implementing a monitoring strategy.
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Evaluation of strategies
The strategy evaluated first was the simple threshold strategy, with observations every 6 months and no
retest component (reference strategy). Alternative strategies were evaluated in which individual components
of the reference strategy were varied: the frequency of monitoring (θ), the decision rule and whether or not
a retest value was used. The same simulated data were used when evaluating strategies A–H.
Sensitivity analyses were carried out to estimate the effect of inaccurate information regarding test
performance and progression of liver disease. Estimates used in the simulation of data were altered (halved and
doubled) and the reference strategy was evaluated with all aspects of the strategy kept constant (including the
threshold value). Results for the reference strategy with the threshold varied to give a PPV of 25% using data
with altered estimates were also obtained. Further sensitivity analyses were undertaken in which the fibrosis
progression rate was adjusted based on expert opinion; these were analyses of strategies A–H as for the main
analysis (with PPV held at 25%) and the reference strategy using varied estimates to generate monitoring data.
To assess the accuracy of the model, the mean randomisation ELF values and SDs were calculated and
compared for the ELUCIDATE and simulated data sets. ANOVA was used to assess between-individual and
within-individual variability in the ELF values recorded for patients in the trial and the simulated results.
Multilevel models were fitted using the simulated observed values and the observed values from the
ELUCIDATE trial (for participants with two or more ELF measures post registration) and the results from these
models were compared. In the ELUCIDATE trial ELF measurements were not taken in the majority of cases
after participants had an ELF value of ≥ 9.5. To allow for this, the ELUCIDATE and simulated data sets were
modified so that each patient with an ELF value of ≥ 9.5 did not undergo any subsequent measurements.
Simulations were based on a cohort of 20,000 patients to give adequate precision. With 20,000 test
results, if one of the performance measures gave an estimate of 15%, the corresponding 95% CI would
range from 14.5% to 15.5%; for an estimate of 1.5% the 95% CI would range from 1.3% to 1.7%.
Results
The estimates from various data sources and details of the data used in the simulation model can be found
in Table 16. In addition, the estimates regarding the trial used in the simulation are shown in Table 17.
When evaluating strategies patients were considered truly positive if they received a positive result 3 months
prior to entering compensated cirrhosis (δ = 0.25). When using targeted retesting, patients with initial
values within ±1 of the threshold value have a retest (Δ = 1).
The same simulated data were used when evaluating strategies A–H. For the simulated cohort of 20,000
patients, 5314 (26.6%) would develop cirrhosis if there were no intervention during the period of the trial.
Reference monitoring strategy (strategy A)
Table 18 shows the performance of the reference monitoring strategy at each testing time point. For the
reference monitoring strategy (simple threshold, observations 6-monthly and no retest component), the
threshold required to maintain the PPV at 25% was an ELF value of 10.715. The sensitivity and PPV
calculated for the strategy were highest at the initial observation point and the percentage of tests with a
positive result was also larger, because of cases being identified from a prevalent population at the initial
testing point. The percentage of false-negative results generally increased as the strategy continued over
time. Over the duration of the monitoring strategy 7.64 tests per person (152,724 tests in total) were
performed and 6.10% of all patients experienced a delay to diagnosis.
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Comparing strategies with changes to individual components with the
reference strategy
Table 19 and Figure 15 show the performance of various monitoring strategies. The results of each
strategy by observation point are provided in Tables 20–26.
Inferior strategies
The retest strategy (strategy B) and the strategies with decision rules based on absolute and relative
increases from the first and last recorded value (strategies D–G) were inferior to the reference strategy,
requiring more tests and causing more patients who had progressed to liver cirrhosis to experience a delay
to diagnosis.
Compared with the reference strategy, the main effect of the retest strategy was to increase the number
of tests performed (increase of 3.30 tests per person), with also a small increase in the percentage of
patients with a delay to diagnosis (absolute increase of 0.40 percentage points), whereas the strategies
with decision rules based on absolute and relative increases from the initial value showed only small
increases in the number of tests required (increases of 0.14 and 0.18 tests per person, respectively) but
larger increases in the percentage of patients with a delay to diagnosis (absolute increases of 1.58 and
2.05 percentage points, respectively). The absolute and relative increase from last recorded value decision
rules both increased the number of tests required (by 0.98 and 1.18 per person, respectively) and
increased the percentage of patients with a delay to diagnosis (to 10.42% and 11.09%, respectively).
‘Trade-off’ strategies
The reduced monitoring frequency strategy (strategy C) showed a ‘trade-off’ between delay to diagnosis
and the number of tests required compared with the reference strategy. The number of tests required
decreased by 3.30 tests per person and the percentage of patients with a delay to diagnosis increased by
0.15 percentage points (absolute increase) compared with the reference strategy.
Superior strategies
The reference strategy was found to be inferior to the linear regression strategy. The linear regression
strategy used fewer tests (decrease of 0.12 tests per person) and resulted in a lower percentage of
patients with a delay to diagnosis (absolute decrease of 0.47 percentage points) compared with the
reference strategy.
TABLE 17 Trial estimates used in simulation modelling
Description Estimate used in simulation modelling
Maximum time in cirrhosis before trial entry To avoid simulating patients who are in advanced cirrhosis, the maximum
amount of time that a patient has been cirrhotic was set to 2 years: c1 = 2
Maximum time in fibrosis before entry to the
trial
To avoid patients being simulated at a point of disease that they would
not have reached given their fibrosis progression rate the maximum
amount of time that a patient has had fibrosis for at the time of entering
the trial was set at 20 years: c2 = 20
Time between registration and randomisation The time between the registration ELF test and the randomisation ELF test
was estimated to be 3 months: c3= 0.25
Trial duration The duration of the trial used in all simulations was 5 years: c4= 5
Time between test and retest measures The time between a patient having a test and a patient having a retest
(if the original test were in the target range) was estimated to be 1 week:
ε= 0.02
DOI: 10.3310/pgfar06030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Selby et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87
TABLE 18 Results by observation point for the reference strategy (strategy A)
Observation time
(months) Tests, N
Results, n (%)
Diseased,a
n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1162 (5.8) 2236 (11.2) 771 (3.9) 15,831 (79.2) 3398 (17.0) 1933 (9.7) 34.2 60.1
6 16,602 207 (1.2) 920 (5.5) 733 (4.4) 14,742 (88.8) 1127 (6.8) 940 (5.7) 18.4 22.0
12 15,475 147 (0.9) 661 (4.3) 740 (4.8) 13,927 (90.0) 808 (5.2) 887 (5.7) 18.2 16.6
18 14,667 102 (0.7) 558 (3.8) 783 (5.3) 13,224 (90.2) 660 (4.5) 885 (6.0) 15.5 11.5
24 14,007 113 (0.8) 495 (3.5) 786 (5.6) 12,613 (90.0) 608 (4.3) 899 (6.4) 18.6 12.6
30 13,399 104 (0.8) 446 (3.3) 813 (6.1) 12,036 (89.8) 550 (4.1) 917 (6.8) 18.9 11.3
36 12,849 127 (1.0) 458 (3.6) 805 (6.3) 11,459 (89.2) 585 (4.6) 932 (7.3) 21.7 13.6
42 12,264 121 (1.0) 429 (3.5) 828 (6.8) 10,886 (88.8) 550 (4.5) 949 (7.7) 22.0 12.8
48 11,714 129 (1.1) 449 (3.8) 817 (7.0) 10,319 (88.1) 578 (4.9) 946 (8.1) 22.3 13.6
54 11,136 135 (1.2) 390 (3.5) 806 (7.2) 9805 (88.0) 525 (4.7) 941 (8.5) 25.7 14.3
60 10,611 125 (1.2) 369 (3.5) 814 (7.7) 9303 (87.7) 494 (4.7) 939 (8.8) 25.3 13.3
All 152,724 2472 (1.6) 7411 (4.9) 8696 (5.7) 134,145 (87.8) 9883 (6.5) 11,168 (7.3) 25.0 22.1
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 19 Results of strategies A–H
Strategy
Monitoring strategy components
PPV, %
Tests
a
Delay to diagnosis
b
Test performance
Decision rule
Threshold
value
Observation
interval
(months) Retest
Initial
threshold N
N per
person
c
Median
IQR N
% of
all
d
% of
stage 4
e
TP per
personf
FP per
person
g
Positive, n (%)
Sensitivity,
%
A Simple threshold 10.715 6 False – 25 152,724 7.64 11 (3, 11) 1220 6.10 22.96 0.12 0.37 9883 (6.47) 22.13
B Simple threshold 10.58 6 True – 25 218,974h 10.95 12 (6, 15) 1300 6.50 24.46 0.12 0.35 9406 (6.11) 21.15
C Simple threshold 10.55 12 False – 25 86,787 4.34 6 (2, 6) 1249 6.25 23.5 0.13 0.38 10,053 (11.58) 35.34
D Absolute increase from
initial value
1.295 6 False 10.715 25 155,648 7.78 11 (4, 11) 1536 7.68 28.9 0.13 0.40 10,598 (6.81) 19.85
E Absolute increase from
last value
1.46 6 False 10.715 25 172,363 8.62 11 (7, 11) 2085 10.42 39.24 0.08 0.24 6305 (3.66) 8.45
F Relative increase from
initial value
1.144 6 False 10.715 25 156,460 7.82 11 (4, 11) 1630 8.15 30.67 0.13 0.38 10,266 (6.56) 18.12
G Relative increase from
last value
1.1795 6 False 10.715 25 176,385 8.82 11 (9, 11) 2217 11.09 41.72 0.07 0.20 5338 (3.03) 6.68
H Linear regression 10.495 6 False 10.715 25 150,478 7.52 11 (2, 11) 1126 5.63 21.19 0.12 0.35 9342 (6.21) 21.58
FP, false positive; TP, true positive.
a Tests over the duration of monitoring.
b Patients with a delayed diagnosis (delay from onset of disease to diagnosis of > 12 months).
c Number of tests per person over the duration of monitoring.
d % of all patients with a delay to diagnosis.
e % of patients who would reach cirrhosis within the trial period with a delay to diagnosis.
f The number of TP results per person over the duration of monitoring.
g The number of FP results per person over the duration of monitoring.
h 218, 974 tests were carried out to generate 153,971 results because of retests being used.
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Sensitivity analyses
Comparing results from the reference strategy when varying estimates of test
performance and disease progression
Table 27 demonstrates the effect on the reference strategy of increasing (doubling) or decreasing (halving)
various parameter estimates. The results at each monitoring time point using these alternative estimates
are provided in Tables 28–39.
Improved estimates of test performance (decreased measurement error and decreased between-individual
variability) both improved the PPV (absolute increases of 4.6 and 8.7 percentage points, respectively) and
increased the number of tests required (increases of 0.73 and 0.91 tests per person, respectively), with
the decreased measurement error also increasing the percentage of patients with a delay to diagnosis
(absolute increase of 1.30 percentage points). Both increased and decreased between-individual variability
reduced the percentage of patients with a delay to diagnosis (absolute decrease of 0.72 and 2.12
percentage points, respectively). An increased rate of fibrosis progression led to both an increased PPV
(absolute increase of 4.2 percentage points) and an increase in the percentage of patients with a delay to
diagnosis (absolute increase of 1.52 percentage points) but decreased the number of tests required
(decrease of 0.64 tests per person).
The largest difference in PPV was achieved by increasing the between-individual variability (absolute
decrease of 8.8 percentage points); the largest difference in number of tests required was achieved by
increasing the measurement error (decrease of 1.84 tests per person); and the largest difference in the
percentage of patients with a delay to diagnosis was achieved by decreasing between-individual variability
(absolute decrease of 2.12 percentage points).
Adjusted fibrosis progression rate
The results of evaluating strategies based on data with the adjusted estimate of fibrosis progression are
provided in Tables 40–60 and Figure 16. Results for strategies compared with the reference strategy
appeared similar to results when using the unadjusted estimate.
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FIGURE 15 Results of various monitoring strategies.
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TABLE 20 Results by observation point using the retest monitoring strategy (strategy B)
Observation time (months) Tests,a N/n
Results, n (%)
Diseased,b n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 28,357/20,000 1233 (6.2) 2447 (12.2) 700 (3.5) 15,620 (78.1) 3680 (18.4) 1933 (9.7) 33.5 63.8
6 22,924/16,320 144 (0.9) 796 (4.9) 711 (4.4) 14,669 (89.9) 940 (5.8) 855 (5.2) 15.3 16.8
12 21,549/15,380 125 (0.8) 568 (3.7) 734 (4.8) 13,953 (90.7) 693 (4.5) 859 (5.6) 18.0 14.6
18 20,617/14,687 97 (0.7) 494 (3.4) 775 (5.3) 13,321 (90.7) 591 (4.0) 872 (5.9) 16.4 11.1
24 19,913/14,096 117 (0.8) 438 (3.1) 776 (5.5) 12,765 (90.6) 555 (3.9) 893 (6.3) 21.1 13.1
30 19,167/13,541 103 (0.8) 408 (3.0) 803 (5.9) 12,227 (90.3) 511 (3.8) 906 (6.7) 20.2 11.4
36 18,555/13,030 105 (0.8) 413 (3.2) 816 (6.3) 11,696 (89.8) 518 (4.0) 921 (7.1) 20.3 11.4
42 17,927/12,512 105 (0.8) 422 (3.4) 849 (6.8) 11,136 (89.0) 527 (4.2) 954 (7.6) 19.9 11.0
48 17,272/11,985 108 (0.9) 408 (3.4) 858 (7.2) 10,611 (88.5) 516 (4.3) 966 (8.1) 20.9 11.2
54 16,674/11,469 126 (1.1) 392 (3.4) 855 (7.5) 10,096 (88.0) 518 (4.5) 981 (8.6) 24.3 12.8
60 16,019/10,951 88 (0.8) 269 (2.5) 887 (8.1) 9707 (88.6) 357 (3.3) 975 (8.9) 24.6 9.0
All 218,974/153,971 2351 (1.5) 7055 (4.6) 8764 (5.7) 13,5801 (88.2) 9406 (6.1) 11,115 (7.2) 25.0 21.2
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed/number of people who tests were performed on (number of results generated).
b Tests performed when the patient was diseased.
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TABLE 21 Results by observation point using the reduced frequency of monitoring strategy (strategy C)
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1247 (6.2) 2735 (13.7) 686 (3.4) 15,332 (76.7) 3982 (19.9) 1933 (9.7) 31.3 64.5
12 16,018 277 (1.7) 1253 (7.8) 739 (4.6) 13,749 (85.8) 1530 (9.6) 1016 (6.3) 18.1 27.3
24 14,488 243 (1.7) 983 (6.8) 775 (5.3) 12,487 (86.2) 1226 (8.5) 1018 (7.0) 19.8 23.9
36 13,262 247 (1.9) 952 (7.2) 782 (5.9) 11,281 (85.1) 1199 (9.0) 1029 (7.8) 20.6 24.0
48 12,063 246 (2.0) 861 (7.1) 806 (6.7) 10,150 (84.1) 1107 (9.2) 1052 (8.7) 22.2 23.4
60 10,956 252 (2.3) 757 (6.9) 809 (7.4) 9138 (83.4) 1009 (9.2) 1061 (9.7) 25.0 23.8
All 86,787 2512 (2.9) 7541 (8.7) 4597 (5.3) 72,137 (83.1) 10,053 (11.6) 7109 (8.2) 25.0 35.3
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 22 Results by observation point using the absolute increase from start value monitoring strategy (strategy D)
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1162 (5.8) 2236 (11.2) 771 (3.9) 15,831 (79.2) 3398 (17.0) 1933 (9.7) 34.2 60.1
6 16,602 50 (0.3) 564 (3.4) 890 (5.4) 15,098 (90.9) 614 (3.7) 940 (5.7) 8.1 5.3
12 15,988 66 (0.4) 517 (3.2) 1014 (6.3) 14,391 (90.0) 583 (3.6) 1080 (6.8) 11.3 6.1
18 15,405 95 (0.6) 550 (3.6) 1085 (7.0) 13,675 (88.8) 645 (4.2) 1180 (7.7) 14.7 8.1
24 14,760 116 (0.8) 582 (3.9) 1132 (7.7) 12,930 (87.6) 698 (4.7) 1248 (8.5) 16.6 9.3
30 14,062 169 (1.2) 559 (4.0) 1123 (8.0) 12,211 (86.8) 728 (5.2) 1292 (9.2) 23.2 13.1
36 13,334 187 (1.4) 603 (4.5) 1066 (8.0) 11,478 (86.1) 790 (5.9) 1253 (9.4) 23.7 14.9
42 12,544 174 (1.4) 586 (4.7) 1048 (8.4) 10,736 (85.6) 760 (6.1) 1222 (9.7) 22.9 14.2
48 11,784 212 (1.8) 583 (4.9) 955 (8.1) 10,034 (85.1) 795 (6.7) 1167 (9.9) 26.7 18.2
54 10,989 218 (2.0) 591 (5.4) 865 (7.9) 9315 (84.8) 809 (7.4) 1083 (9.9) 26.9 20.1
60 10,180 204 (2.0) 574 (5.6) 765 (7.5) 8637 (84.8) 778 (7.6) 969 (9.5) 26.2 21.1
All 155,648 2653 (1.7) 7945 (5.1) 10,714 (6.9) 134,336 (86.3) 10,598 (6.8) 13,367 (8.6) 25.0 19.8
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 23 Results by observation point using the absolute increase from last value monitoring strategy (strategy E)
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1162 (5.8) 2236 (11.2) 771 (3.9) 15,831 (79.2) 3398 (17.0) 1933 (9.7) 34.2 60.1
6 16,602 28 (0.2) 342 (2.1) 912 (5.5) 15,320 (92.3) 370 (2.2) 940 (5.7) 7.6 3.0
12 16,232 22 (0.1) 281 (1.7) 1086 (6.7) 14,843 (91.4) 303 (1.9) 1108 (6.8) 7.3 2.0
18 15,929 32 (0.2) 256 (1.6) 1230 (7.7) 14,411 (90.5) 288 (1.8) 1262 (7.9) 11.1 2.5
24 15,641 31 (0.2) 256 (1.6) 1378 (8.8) 13,976 (89.4) 287 (1.8) 1409 (9.0) 10.8 2.2
30 15,354 34 (0.2) 240 (1.6) 1538 (10.0) 13,542 (88.2) 274 (1.8) 1572 (10.2) 12.4 2.2
36 15,080 39 (0.3) 248 (1.6) 1682 (11.2) 13,111 (86.9) 287 (1.9) 1721 (11.4) 13.6 2.3
42 14,793 52 (0.4) 228 (1.5) 1860 (12.6) 12,653 (85.5) 280 (1.9) 1912 (12.9) 18.6 2.7
48 14,513 56 (0.4) 223 (1.5) 2014 (13.9) 12,220 (84.2) 279 (1.9) 2070 (14.3) 20.1 2.7
54 14,234 45 (0.3) 204 (1.4) 2212 (15.5) 11,773 (82.7) 249 (1.7) 2257 (15.9) 18.1 2.0
60 13,985 78 (0.6) 212 (1.5) 2423 (17.3) 11,272 (80.6) 290 (2.1) 2501 (17.9) 26.9 3.1
All 172,363 1579 (0.9) 4726 (2.7) 17,106 (9.9) 148,952 (86.4) 6305 (3.7) 18,685 (10.8) 25.0 8.5
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 24 Results by observation point using the relative increase from start value monitoring strategy (strategy F)
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1162 (5.8) 2236 (11.2) 771 (3.9) 15,831 (79.2) 3398 (17.0) 1933 (9.7) 34.2 60.1
6 16,602 44 (0.3) 641 (3.9) 896 (5.4) 15,021 (90.5) 685 (4.1) 940 (5.7) 6.4 4.7
12 15,917 48 (0.3) 539 (3.4) 1041 (6.5) 14,289 (89.8) 587 (3.7) 1089 (6.8) 8.2 4.4
18 15,330 84 (0.5) 525 (3.4) 1125 (7.3) 13,596 (88.7) 609 (4.0) 1209 (7.9) 13.8 6.9
24 14,721 100 (0.7) 558 (3.8) 1193 (8.1) 12,870 (87.4) 658 (4.5) 1293 (8.8) 15.2 7.7
30 14,063 143 (1.0) 524 (3.7) 1217 (8.7) 12,179 (86.6) 667 (4.7) 1360 (9.7) 21.4 10.5
36 13,396 169 (1.3) 519 (3.9) 1184 (8.8) 11,524 (86.0) 688 (5.1) 1353 (10.1) 24.6 12.5
42 12,708 179 (1.4) 528 (4.2) 1164 (9.2) 10,837 (85.3) 707 (5.6) 1343 (10.6) 25.3 13.3
48 12,001 195 (1.6) 568 (4.7) 1099 (9.2) 10,139 (84.5) 763 (6.4) 1294 (10.8) 25.6 15.1
54 11,238 226 (2.0) 528 (4.7) 1009 (9.0) 9475 (84.3) 754 (6.7) 1235 (11.0) 30.0 18.3
60 10,484 220 (2.1) 530 (5.1) 918 (8.8) 8816 (84.1) 750 (7.2) 1138 (10.9) 29.3 19.3
All 156,460 2570 (1.6) 7696 (4.9) 11,617 (7.4) 134,577 (86.0) 10,266 (6.6) 14187 (9.1) 25.0 18.1
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 25 Results by observation point using the relative increase from last value monitoring strategy (strategy G)
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1162 (5.8) 2236 (11.2) 771 (3.9) 15,831 (79.2) 3398 (17.0) 1933 (9.7) 34.2 60.1
6 16,602 16 (0.1) 263 (1.6) 924 (5.6) 15,399 (92.8) 279 (1.7) 940 (5.7) 5.7 1.7
12 16,323 9 (0.1) 206 (1.3) 1117 (6.8) 14,991 (91.8) 215 (1.3) 1126 (6.9) 4.2 0.8
18 16,108 18 (0.1) 199 (1.2) 1280 (7.9) 14,611 (90.7) 217 (1.3) 1298 (8.1) 8.3 1.4
24 15,891 13 (0.1) 184 (1.2) 1455 (9.2) 14,239 (89.6) 197 (1.2) 1468 (9.2) 6.6 0.9
30 15,694 16 (0.1) 170 (1.1) 1642 (10.5) 13,866 (88.4) 186 (1.2) 1658 (10.6) 8.6 1.0
36 15,508 13 (0.1) 172 (1.1) 1829 (11.8) 13,494 (87.0) 185 (1.2) 1842 (11.9) 7.0 0.7
42 15,323 22 (0.1) 161 (1.1) 2054 (13.4) 13,086 (85.4) 183 (1.2) 2076 (13.5) 12.0 1.1
48 15,140 25 (0.2) 140 (0.9) 2264 (15.0) 12,711 (84.0) 165 (1.1) 2289 (15.1) 15.2 1.1
54 14,975 20 (0.1) 134 (0.9) 2511 (16.8) 12,310 (82.2) 154 (1.0) 2531 (16.9) 13.0 0.8
60 14,821 21 (0.1) 138 (0.9) 2809 (19.0) 11,853 (80.0) 159 (1.1) 2830 (19.1) 13.2 0.7
All 176,385 1335 (0.8) 4003 (2.3) 18,656 (10.6) 152,391 (86.4) 5338 (3.0) 19,991 (11.3) 25.0 6.7
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 26 Results by observation point using the linear regression monitoring strategy (strategy H)
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1162 (5.8) 2236 (11.2) 771 (3.9) 15,831 (79.2) 3398 (17.0) 1933 (9.7) 34.2 60.1
6 16,602 280 (1.7) 1488 (9.0) 660 (4.0) 14,174 (85.4) 1768 (10.6) 940 (5.7) 15.8 29.8
12 14,834 146 (1.0) 741 (5.0) 650 (4.4) 13,297 (89.6) 887 (6.0) 796 (5.4) 16.5 18.3
18 13,947 92 (0.7) 492 (3.5) 685 (4.9) 12,678 (90.9) 584 (4.2) 777 (5.6) 15.8 11.8
24 13,363 87 (0.7) 385 (2.9) 706 (5.3) 12,185 (91.2) 472 (3.5) 793 (5.9) 18.4 11.0
30 12,891 93 (0.7) 307 (2.4) 742 (5.8) 11,749 (91.1) 400 (3.1) 835 (6.5) 23.2 11.1
36 12,491 85 (0.7) 284 (2.3) 772 (6.2) 11,350 (90.9) 369 (3.0) 857 (6.9) 23.0 9.9
42 12,122 68 (0.6) 268 (2.2) 838 (6.9) 10,948 (90.3) 336 (2.8) 906 (7.5) 20.2 7.5
48 11,786 100 (0.8) 273 (2.3) 859 (7.3) 10,554 (89.5) 373 (3.2) 959 (8.1) 26.8 10.4
54 11,413 107 (0.9) 277 (2.4) 880 (7.7) 10,149 (88.9) 384 (3.4) 987 (8.6) 27.9 10.8
60 11,029 111 (1.0) 260 (2.4) 906 (8.2) 9752 (88.4) 371 (3.4) 1017 (9.2) 29.9 10.9
All 150,478 2331 (1.5) 7011 (4.7) 8469 (5.6) 132,667 (88.2) 9342 (6.2) 10,800 (7.2) 25.0 21.6
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 27 Results of the reference strategy when changing estimates required for data simulation
Change in data simulation Threshold value PPV, % Tests per person, na Delayb (%) Develop cirrhosis,c n (%)
None 10.715 25.0 7.64 6.10 5314 (26.6)
Decreasedd measurement error 10.715 29.6 (+4.6) 8.37 (+0.73) 7.40 (+1.30) 5248 (26.2) [–66 (0.33)]
10.450 25.0 7.70 (+0.06) 5.73 (–0.37)
Increasede measurement error 10.715 17.6 (–7.4) 5.84 (–1.80) 3.85 (–2.25) 5421 (27.1) [+107 (0.54)]
11.365 25.0 7.65 (+0.01) 7.05 (+0.95)
Decreased between-individual variability 10.715 33.6 (+8.6) 8.55 (+0.91) 3.98 (–2.12) 5139 (25.7) [–175 (0.88)]
10.463 25.0 7.84 (+0.20) 2.28 (–3.82)
Increasede between-individual variability 10.715 16.5 (–8.8) 5.80 (–1.84) 5.38 (–0.72) 5272 (26.4) [–42 (0.21)]
11.905 25.0 8.26 (+0.62) 9.95 (+3.85)
Decreasedd fibrosis progression rate 10.715 22.7 (–2.3) 7.90 (+0.26) 4.95 (–1.15) 4440 (22.2) [–874 (4.37)]
10.860 25.0 8.29 (+0.65) 5.68 (–0.42)
Increasede fibrosis progression rate 10.715 29.2 (+4.2) 7.00 (–0.64) 7.62 (+1.52) 7689 (38.4) [+2375 (11.88)]
10.460 25.0 6.21 (–1.43) 5.63 (–0.47)
a Number of tests per person over the duration of monitoring.
b % of all patients with a delayed diagnosis (delay from onset of disease to diagnosis of > 12 months).
c Patients who would go on to develop cirrhosis in the monitoring duration if no intervention were received.
d Decrease is halving the estimate used in the original simulation.
e Increase is doubling the estimate used in the original simulation.
Note
Values in italics represent the difference from the reference strategy for the original simulation data.
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TABLE 28 Results by observation point using the reference strategy with decreased measurement error
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1153 (5.8) 1931 (9.7) 750 (3.8) 16,166 (80.8) 3084 (15.4) 1903 (9.5) 37.4 60.6
6 16,916 113 (0.7) 478 (2.8) 810 (4.8) 15,515 (91.7) 591 (3.5) 923 (5.5) 19.1 12.2
12 16,325 92 (0.6) 371 (2.3) 881 (5.4) 14,981 (91.8) 463 (2.8) 973 (6.0) 19.9 9.5
18 15,862 109 (0.7) 341 (2.1) 934 (5.9) 14,478 (91.3) 450 (2.8) 1043 (6.6) 24.2 10.5
24 15,412 103 (0.7) 331 (2.1) 967 (6.3) 14,011 (90.9) 434 (2.8) 1070 (6.9) 23.7 9.6
30 14,978 93 (0.6) 356 (2.4) 1025 (6.8) 13,504 (90.2) 449 (3.0) 1118 (7.5) 20.7 8.3
36 14,529 129 (0.9) 353 (2.4) 1032 (7.1) 13,015 (89.6) 482 (3.3) 1161 (8.0) 26.8 11.1
42 14,047 128 (0.9) 356 (2.5) 1061 (7.6) 12,502 (89.0) 484 (3.4) 1189 (8.5) 26.4 10.8
48 13,563 112 (0.8) 341 (2.5) 1086 (8.0) 12,024 (88.7) 453 (3.3) 1198 (8.8) 24.7 9.3
54 13,110 137 (1.0) 334 (2.5) 1105 (8.4) 11,534 (88.0) 471 (3.6) 1242 (9.5) 29.1 11.0
60 12,639 164 (1.3) 370 (2.9) 1095 (8.7) 11,010 (87.1) 534 (4.2) 1259 (10.0) 30.7 13.0
All 167,381 2333 (1.4) 5562 (3.3) 10,746 (6.4) 148,740 (88.9) 7895 (4.7) 13,079 (7.8) 29.6 17.8
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 29 Results by observation point using the reference strategy with decreased measurement error and a PPV of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1289 (6.4) 2755 (13.8) 614 (3.1) 15,342 (76.7) 4044 (20.2) 1903 (9.5) 31.9 67.7
6 15,956 114 (0.7) 665 (4.2) 645 (4.0) 14,532 (91.1) 779 (4.9) 759 (4.8) 14.6 15.0
12 15,177 93 (0.6) 441 (2.9) 686 (4.5) 13,957 (92.0) 534 (3.5) 779 (5.1) 17.4 11.9
18 14,643 97 (0.7) 431 (2.9) 726 (5.0) 13,389 (91.4) 528 (3.6) 823 (5.6) 18.4 11.8
24 14,115 83 (0.6) 438 (3.1) 761 (5.4) 12,833 (90.9) 521 (3.7) 844 (6.0) 15.9 9.8
30 13,594 111 (0.8) 410 (3.0) 772 (5.7) 12,301 (90.5) 521 (3.8) 883 (6.5) 21.3 12.6
36 13,073 100 (0.8) 399 (3.1) 785 (6.0) 11,789 (90.2) 499 (3.8) 885 (6.8) 20.0 11.3
42 12,574 108 (0.9) 361 (2.9) 815 (6.5) 11,290 (89.8) 469 (3.7) 923 (7.3) 23.0 11.7
48 12,105 108 (0.9) 379 (3.1) 818 (6.8) 10,800 (89.2) 487 (4.0) 926 (7.6) 22.2 11.7
54 11,618 133 (1.1) 383 (3.3) 817 (7.0) 10,285 (88.5) 516 (4.4) 950 (8.2) 25.8 14.0
60 11,102 118 (1.1) 393 (3.5) 815 (7.3) 9776 (88.1) 511 (4.6) 933 (8.4) 23.1 12.6
All 153,957 2354 (1.5) 7055 (4.6) 8254 (5.4) 136,294 (88.5) 9409 (6.1) 10,608 (6.9) 25.0 22.2
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 30 Results by observation point using the reference strategy with increased measurement error
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1169 (5.8) 3257 (16.3) 812 (4.1) 14,762 (73.8) 4426 (22.1) 1981 (9.9) 26.4 59.0
6 15,574 369 (2.4) 1897 (12.2) 621 (4.0) 12,687 (81.5) 2266 (14.5) 990 (6.4) 16.3 37.3
12 13,308 213 (1.6) 1360 (10.2) 540 (4.1) 11,195 (84.1) 1573 (11.8) 753 (5.7) 13.5 28.3
18 11,735 141 (1.2) 1130 (9.6) 495 (4.2) 9969 (85.0) 1271 (10.8) 636 (5.4) 11.1 22.2
24 10,464 123 (1.2) 881 (8.4) 455 (4.3) 9005 (86.1) 1004 (9.6) 578 (5.5) 12.3 21.3
30 9460 99 (1.0) 753 (8.0) 430 (4.5) 8178 (86.4) 852 (9.0) 529 (5.6) 11.6 18.7
36 8608 93 (1.1) 682 (7.9) 408 (4.7) 7425 (86.3) 775 (9.0) 501 (5.8) 12.0 18.6
42 7833 88 (1.1) 534 (6.8) 404 (5.2) 6807 (86.9) 622 (7.9) 492 (6.3) 14.1 17.9
48 7211 86 (1.2) 514 (7.1) 391 (5.4) 6220 (86.3) 600 (8.3) 477 (6.6) 14.3 18.0
54 6611 78 (1.2) 454 (6.9) 388 (5.9) 5691 (86.1) 532 (8.0) 466 (7.0) 14.7 16.7
60 6079 77 (1.3) 409 (6.7) 375 (6.2) 5218 (85.8) 486 (8.0) 452 (7.4) 15.8 17.0
All 116,883 2536 (2.2) 11,871 (10.2) 5319 (4.6) 97,157 (83.1) 14,407 (12.3) 7855 (6.7) 17.6 32.3
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 31 Results by observation point using the reference strategy with increased measurement error and a PPV of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 848 (4.2) 1562 (7.8) 1133 (5.7) 16,457 (82.3) 2410 (12.0) 1981 (9.9) 35.2 42.8
6 17,590 368 (2.1) 1081 (6.1) 1001 (5.7) 15,140 (86.1) 1449 (8.2) 1369 (7.8) 25.4 26.9
12 16,141 274 (1.7) 827 (5.1) 942 (5.8) 14,098 (87.3) 1101 (6.8) 1216 (7.5) 24.9 22.5
18 15,040 189 (1.3) 726 (4.8) 913 (6.1) 13,212 (87.8) 915 (6.1) 1102 (7.3) 20.7 17.2
24 14,125 160 (1.1) 583 (4.1) 889 (6.3) 12,493 (88.4) 743 (5.3) 1049 (7.4) 21.5 15.3
30 13,382 139 (1.0) 580 (4.3) 881 (6.6) 11,782 (88.0) 719 (5.4) 1020 (7.6) 19.3 13.6
36 12,663 130 (1.0) 596 (4.7) 861 (6.8) 11,076 (87.5) 726 (5.7) 991 (7.8) 17.9 13.1
42 11,937 121 (1.0) 473 (4.0) 883 (7.4) 10,460 (87.6) 594 (5.0) 1004 (8.4) 20.4 12.1
48 11,343 129 (1.1) 497 (4.4) 877 (7.7) 9840 (86.7) 626 (5.5) 1006 (8.9) 20.6 12.8
54 10,717 119 (1.1) 441 (4.1) 883 (8.2) 9274 (86.5) 560 (5.2) 1002 (9.3) 21.2 11.9
60 10,157 125 (1.2) 433 (4.3) 882 (8.7) 8717 (85.8) 558 (5.5) 1007 (9.9) 22.4 12.4
All 153,095 2602 (1.7) 7799 (5.1) 10,145 (6.6) 132,549 (86.6) 10,401 (6.8) 12,747 (8.3) 25.0 20.4
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 32 Results by observation point using the reference strategy with decreased between-individual variability
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1171 (5.9) 963 (4.8) 639 (3.2) 17,227 (86.1) 2134 (10.7) 1810 (9.0) 54.9 64.7
6 17,866 290 (1.6) 548 (3.1) 514 (2.9) 16,514 (92.4) 838 (4.7) 804 (4.5) 34.6 36.1
12 17,028 185 (1.1) 421 (2.5) 500 (2.9) 15,922 (93.5) 606 (3.6) 685 (4.0) 30.5 27
18 16,422 181 (1.1) 406 (2.5) 464 (2.8) 15,371 (93.6) 587 (3.6) 645 (3.9) 30.8 28.1
24 15,835 128 (0.8) 391 (2.5) 447 (2.8) 14,869 (93.9) 519 (3.3) 575 (3.6) 24.7 22.3
30 15,316 117 (0.8) 373 (2.4) 449 (2.9) 14,377 (93.9) 490 (3.2) 566 (3.7) 23.9 20.7
36 14,826 127 (0.9) 445 (3.0) 434 (2.9) 13,820 (93.2) 572 (3.9) 561 (3.8) 22.2 22.6
42 14,254 117 (0.8) 424 (3.0) 436 (3.1) 13,277 (93.1) 541 (3.8) 553 (3.9) 21.6 21.2
48 13,713 127 (0.9) 471 (3.4) 431 (3.1) 12,684 (92.5) 598 (4.4) 558 (4.1) 21.2 22.8
54 13,115 136 (1.0) 424 (3.2) 435 (3.3) 12,120 (92.4) 560 (4.3) 571 (4.4) 24.3 23.8
60 12,555 124 (1.0) 474 (3.8) 442 (3.5) 11,515 (91.7) 598 (4.8) 566 (4.5) 20.7 21.9
All 170,930 2703 (1.6) 5340 (3.1) 5191 (3.0) 157,696 (92.3) 8043 (4.7) 7894 (4.6) 33.6 34.2
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 33 Results by observation point using the reference strategy with decreased between-individual variability and a PPV of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1333 (6.7) 1517 (7.6) 477 (2.4) 16,673 (83.4) 2850 (14.2) 1810 (9.0) 46.8 73.6
6 17,150 259 (1.5) 826 (4.8) 333 (1.9) 15,732 (91.7) 1085 (6.3) 592 (3.5) 23.9 43.8
12 16,065 156 (1.0) 655 (4.1) 298 (1.9) 14,956 (93.1) 811 (5.0) 454 (2.8) 19.2 34.4
18 15,254 131 (0.9) 558 (3.7) 271 (1.8) 14,294 (93.7) 689 (4.5) 402 (2.6) 19.0 32.6
24 14,565 86 (0.6) 562 (3.9) 253 (1.7) 13,664 (93.8) 648 (4.4) 339 (2.3) 13.3 25.4
30 13,917 79 (0.6) 552 (4.0) 256 (1.8) 13,030 (93.6) 631 (4.5) 335 (2.4) 12.5 23.6
36 13,286 96 (0.7) 576 (4.3) 241 (1.8) 12,373 (93.1) 672 (5.1) 337 (2.5) 14.3 28.5
42 12,614 72 (0.6) 529 (4.2) 238 (1.9) 11,775 (93.3) 601 (4.8) 310 (2.5) 12.0 23.2
48 12,013 85 (0.7) 575 (4.8) 250 (2.1) 11,103 (92.4) 660 (5.5) 335 (2.8) 12.9 25.4
54 11,353 107 (0.9) 565 (5.0) 236 (2.1) 10,445 (92.0) 672 (5.9) 343 (3.0) 15.9 31.2
60 10,681 84 (0.8) 535 (5.0) 236 (2.2) 9826 (92.0) 619 (5.8) 320 (3.0) 13.6 26.2
All 156,898 2488 (1.6) 7450 (4.7) 3089 (2.0) 143,871 (91.7) 9938 (6.3) 5577 (3.6) 25.0 44.6
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
S
IM
U
LA
TIN
G
M
O
N
ITO
R
IN
G
D
A
TA
A
N
D
E
V
A
LU
A
TIN
G
M
O
N
ITO
R
IN
G
S
TR
A
TE
G
IE
S
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
1
0
4
TABLE 34 Results by observation point using the reference strategy with increased between-individual variability
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1279 (6.4) 5806 (29.0) 656 (3.3) 12,259 (61.3) 7085 (35.4) 1935 (9.7) 18.1 66.1
6 12,915 104 (0.8) 1193 (9.2) 685 (5.3) 10,933 (84.7) 1297 (10.0) 789 (6.1) 8.0 13.2
12 11,618 78 (0.7) 768 (6.6) 707 (6.1) 10,065 (86.6) 846 (7.3) 785 (6.8) 9.2 9.9
18 10,772 81 (0.8) 589 (5.5) 734 (6.8) 9368 (87.0) 670 (6.2) 815 (7.6) 12.1 9.9
24 10,102 85 (0.8) 468 (4.6) 757 (7.5) 8792 (87.0) 553 (5.5) 842 (8.3) 15.4 10.1
30 9549 84 (0.9) 392 (4.1) 745 (7.8) 8328 (87.2) 476 (5.0) 829 (8.7) 17.6 10.1
36 9073 78 (0.9) 368 (4.1) 758 (8.4) 7869 (86.7) 446 (4.9) 836 (9.2) 17.5 9.3
42 8627 85 (1.0) 356 (4.1) 774 (9.0) 7412 (85.9) 441 (5.1) 859 (10.0) 19.3 9.9
48 8186 90 (1.1) 302 (3.7) 768 (9.4) 7026 (85.8) 392 (4.8) 858 (10.5) 23.0 10.5
54 7794 99 (1.3) 285 (3.7) 779 (10.0) 6631 (85.1) 384 (4.9) 878 (11.3) 25.8 11.3
60 7410 79 (1.1) 305 (4.1) 794 (10.7) 6232 (84.1) 384 (5.2) 873 (11.8) 20.6 9.0
All 116,046 2142 (1.8) 10,832 (9.3) 8157 (7.0) 94,915 (81.8) 12,974 (11.2) 10,299 (8.9) 16.5 20.8
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 35 Results by observation point using the reference strategy with increased between-individual variability and a PPV of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 890 (4.4) 2368 (11.8) 1045 (5.2) 15,697 (78.5) 3258 (16.3) 1935 (9.7) 27.3 46.0
6 16,742 117 (0.7) 610 (3.6) 1127 (6.7) 14,888 (88.9) 727 (4.3) 1244 (7.4) 16.1 9.4
12 16,015 98 (0.6) 413 (2.6) 1208 (7.5) 14,296 (89.3) 511 (3.2) 1306 (8.2) 19.2 7.5
18 15,504 102 (0.7) 339 (2.2) 1286 (8.3) 13,777 (88.9) 441 (2.8) 1388 (9.0) 23.1 7.3
24 15,063 81 (0.5) 332 (2.2) 1399 (9.3) 13,251 (88.0) 413 (2.7) 1480 (9.8) 19.6 5.5
30 14,650 78 (0.5) 308 (2.1) 1490 (10.2) 12,774 (87.2) 386 (2.6) 1568 (10.7) 20.2 5.0
36 14,264 114 (0.8) 295 (2.1) 1535 (10.8) 12,320 (86.4) 409 (2.9) 1649 (11.6) 27.9 6.9
42 13,855 103 (0.7) 276 (2.0) 1606 (11.6) 11,870 (85.7) 379 (2.7) 1709 (12.3) 27.2 6.0
48 13,476 122 (0.9) 318 (2.4) 1641 (12.2) 11,395 (84.6) 440 (3.3) 1763 (13.1) 27.7 6.9
54 13,036 103 (0.8) 271 (2.1) 1742 (13.4) 10,920 (83.8) 374 (2.9) 1845 (14.2) 27.5 5.6
60 12,662 130 (1.0) 286 (2.3) 1817 (14.4) 10,429 (82.4) 416 (3.3) 1947 (15.4) 31.2 6.7
All 165,267 1938 (1.2) 5816 (3.5) 15,896 (9.6) 141,617 (85.7) 7754 (4.7) 17,834 (10.8) 25.0 10.9
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 36 Results by observation point using the reference strategy with a decreased fibrosis progression rate
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1038 (5.2) 2122 (10.6) 698 (3.5) 16,142 (80.7) 3160 (15.8) 1736 (8.7) 32.8 59.8
6 16,840 172 (1.0) 848 (5.0) 631 (3.7) 15,189 (90.2) 1020 (6.1) 803 (4.8) 16.9 21.4
12 15,820 110 (0.7) 603 (3.8) 617 (3.9) 14,490 (91.6) 713 (4.5) 727 (4.6) 15.4 15.1
18 15,107 97 (0.6) 580 (3.8) 624 (4.1) 13,806 (91.4) 677 (4.5) 721 (4.8) 14.3 13.5
24 14,430 86 (0.6) 448 (3.1) 648 (4.5) 13,248 (91.8) 534 (3.7) 734 (5.1) 16.1 11.7
30 13,896 84 (0.6) 402 (2.9) 655 (4.7) 12,755 (91.8) 486 (3.5) 739 (5.3) 17.3 11.4
36 13,410 82 (0.6) 459 (3.4) 677 (5.0) 12,192 (90.9) 541 (4.0) 759 (5.7) 15.2 10.8
42 12,869 102 (0.8) 413 (3.2) 667 (5.2) 11,687 (90.8) 515 (4.0) 769 (6.0) 19.8 13.3
48 12,354 108 (0.9) 416 (3.4) 646 (5.2) 11,184 (90.5) 524 (4.2) 754 (6.1) 20.6 14.3
54 11,830 84 (0.7) 371 (3.1) 663 (5.6) 10,712 (90.5) 455 (3.8) 747 (6.3) 18.5 11.2
60 11,375 96 (0.8) 351 (3.1) 678 (6.0) 10,250 (90.1) 447 (3.9) 774 (6.8) 21.5 12.4
All 157,931 2059 (1.3) 7013 (4.4) 7204 (4.6) 141,655 (89.7) 9072 (5.7) 9263 (5.9) 22.7 22.2
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 37 Results by observation point using the reference strategy with a decreased fibrosis progression rate and a PPV of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 960 (4.8) 1707 (8.5) 776 (3.9) 16,557 (82.8) 2667 (13.3) 1736 (8.7) 36.0 55.3
6 17,333 184 (1.1) 730 (4.2) 707 (4.1) 15,712 (90.6) 914 (5.3) 891 (5.1) 20.1 20.7
12 16,419 125 (0.8) 516 (3.1) 692 (4.2) 15,086 (91.9) 641 (3.9) 817 (5.0) 19.5 15.3
18 15,778 101 (0.6) 466 (3.0) 706 (4.5) 14,505 (91.9) 567 (3.6) 807 (5.1) 17.8 12.5
24 15,211 96 (0.6) 395 (2.6) 735 (4.8) 13,985 (91.9) 491 (3.2) 831 (5.5) 19.6 11.6
30 14,720 77 (0.5) 393 (2.7) 760 (5.2) 13,490 (91.6) 470 (3.2) 837 (5.7) 16.4 9.2
36 14,250 83 (0.6) 427 (3.0) 792 (5.6) 12,948 (90.9) 510 (3.6) 875 (6.1) 16.3 9.5
42 13,740 101 (0.7) 374 (2.7) 793 (5.8) 12,472 (90.8) 475 (3.5) 894 (6.5) 21.3 11.3
48 13,265 110 (0.8) 381 (2.9) 783 (5.9) 11,991 (90.4) 491 (3.7) 893 (6.7) 22.4 12.3
54 12,774 100 (0.8) 379 (3.0) 795 (6.2) 11,500 (90.0) 479 (3.7) 895 (7.0) 20.9 11.2
60 12,295 105 (0.9) 342 (2.8) 813 (6.6) 11,035 (89.8) 447 (3.6) 918 (7.5) 23.5 11.4
All 165,785 2042 (1.2) 6110 (3.7) 8352 (5.0) 149,281 (90.0) 8152 (4.9) 10,394 (6.3) 25.0 19.6
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
S
IM
U
LA
TIN
G
M
O
N
ITO
R
IN
G
D
A
TA
A
N
D
E
V
A
LU
A
TIN
G
M
O
N
ITO
R
IN
G
S
TR
A
TE
G
IE
S
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
1
0
8
TABLE 38 Results by observation point using the reference strategy with an increased fibrosis progression rate
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1535 (7.7) 2428 (12.1) 947 (4.7) 15,090 (75.4) 3963 (19.8) 2482 (12.4) 38.7 61.8
6 16,037 269 (1.7) 990 (6.2) 909 (5.7) 13,869 (86.5) 1259 (7.9) 1178 (7.3) 21.4 22.8
12 14,778 200 (1.4) 772 (5.2) 930 (6.3) 12,876 (87.1) 972 (6.6) 1130 (7.6) 20.6 17.7
18 13,806 186 (1.3) 649 (4.7) 945 (6.8) 12,026 (87.1) 835 (6.0) 1131 (8.2) 22.3 16.4
24 12,971 163 (1.3) 607 (4.7) 938 (7.2) 11,263 (86.8) 770 (5.9) 1101 (8.5) 21.2 14.8
30 12,201 165 (1.4) 557 (4.6) 975 (8.0) 10,504 (86.1) 722 (5.9) 1140 (9.3) 22.9 14.5
36 11,479 196 (1.7) 596 (5.2) 969 (8.4) 9718 (84.7) 792 (6.9) 1165 (10.1) 24.7 16.8
42 10,687 171 (1.6) 506 (4.7) 974 (9.1) 9036 (84.6) 677 (6.3) 1145 (10.7) 25.3 14.9
48 10,010 204 (2.0) 512 (5.1) 979 (9.8) 8315 (83.1) 716 (7.2) 1183 (11.8) 28.5 17.2
54 9294 197 (2.1) 440 (4.7) 1009 (10.9) 7648 (82.3) 637 (6.9) 1206 (13.0) 30.9 16.3
60 8657 205 (2.4) 413 (4.8) 1009 (11.7) 7030 (81.2) 618 (7.1) 1214 (14.0) 33.2 16.9
All 139,920 3491 (2.5) 8470 (6.1) 10,584 (7.6) 117,375 (83.9) 11,961 (8.5) 14,075 (10.1) 29.2 24.8
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 39 Results by observation point using the reference strategy with an increased fibrosis progression rate and a PPV of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1704 (8.5) 3332 (16.7) 778 (3.9) 14,186 (70.9) 5036 (25.2) 2482 (12.4) 33.8 68.7
6 14,964 271 (1.8) 1308 (8.7) 709 (4.7) 12,676 (84.7) 1579 (10.6) 980 (6.5) 17.2 27.7
12 13,385 183 (1.4) 979 (7.3) 699 (5.2) 11,524 (86.1) 1162 (8.7) 882 (6.6) 15.7 20.7
18 12,223 174 (1.4) 743 (6.1) 705 (5.8) 10,601 (86.7) 917 (7.5) 879 (7.2) 19.0 19.8
24 11,306 147 (1.3) 691 (6.1) 680 (6.0) 9788 (86.6) 838 (7.4) 827 (7.3) 17.5 17.8
30 10,468 139 (1.3) 566 (5.4) 693 (6.6) 9070 (86.6) 705 (6.7) 832 (7.9) 19.7 16.7
36 9763 139 (1.4) 591 (6.1) 699 (7.2) 8334 (85.4) 730 (7.5) 838 (8.6) 19.0 16.6
42 9033 146 (1.6) 553 (6.1) 684 (7.6) 7650 (84.7) 699 (7.7) 830 (9.2) 20.9 17.6
48 8334 159 (1.9) 472 (5.7) 689 (8.3) 7014 (84.2) 631 (7.6) 848 (10.2) 25.2 18.8
54 7703 162 (2.1) 465 (6.0) 706 (9.2) 6370 (82.7) 627 (8.1) 868 (11.3) 25.8 18.7
60 7076 163 (2.3) 450 (6.4) 712 (10.1) 5751 (81.3) 613 (8.7) 875 (12.4) 26.6 18.6
All 124,255 3387 (2.7) 10150 (8.2) 7754 (6.2) 102,964 (82.9) 13,537 (10.9) 11,141 (9.0) 25.0 30.4
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 40 Results of strategies A–H using the adjusted fibrosis progression estimate data
Strategy
Monitoring strategy components
PPV, %
Tests
a
Delay to diagnosis
b
Test performance
Decision rule
Threshold
value
Observation
interval
(months) Retest
Initial
threshold
value N
N per
person
c
Median
IQR N % of all
d
% of
stage 4
e
TP per
person
f
FP per
person
g
Positive, n (%)
Sensitivity,
%
A Simple threshold 10.46 6 False – 25 124,255 6.21 6 (1, 11) 1126 5.63 14.64 0.17 0.51 13,537 (10.89) 30.40
B Simple threshold 10.325 6 True – 25 192,590h 9.63 11 (2, 15) 1194 5.97 15.53 0.16 0.49 13,048 (10.43) 29.88
C Simple threshold 10.265 12 False – 25 72,001 3.60 4 (1, 6) 1128 5.64 14.67 0.17 0.52 13,814 (19.19) 47.02
D Absolute increase
from initial value
1.138 6 False 10.46 25 125,699 6.28 7 (1, 11) 1415 7.07 18.40 0.18 0.54 14,509 (11.54) 28.57
E Absolute increase
from last value
1.245 6 False 10.46 25 142,849 7.14 10 (1, 11) 2220 11.10 28.87 0.13 0.40 10,587 (7.41) 13.40
F Relative increase from
initial value
1.122 6 False 10.46 25 124,237 6.21 6 (1, 11) 1450 7.25 18.86 0.18 0.55 14,565 (11.72) 27.98
G Relative increase from
last value
1.154 6 False 10.46 25 151,266 7.56 11 (1, 11) 2547 12.73 33.13 0.11 0.33 8673 (5.73) 9.60
H Linear regression 10.235 6 False 10.46 25 121,214 6.06 5 (1, 11) 1039 5.20 13.51 0.16 0.48 12,930 (10.67) 30.01
FP, false positive; TP, true positive.
a Number of tests over the duration of monitoring.
b Patients with a delayed diagnosis (delay from onset of disease to diagnosis of > 12 months).
c Number of tests per person over the duration of monitoring.
d % of all patients with a delay to diagnosis.
e % of patients who would go on to develop cirrhosis within the trial period with a delay to diagnosis.
f The number of true-positive results per person over the duration of monitoring.
g The number of false-positive results per person over the duration of monitoring.
h 192,590 tests were carried out to generate 125,091 results because of retests being used.
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TABLE 41 Results by observation point for the reference strategy (strategy A) using the adjusted fibrosis progression estimate data
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1704 (8.5) 3332 (16.7) 778 (3.9) 14,186 (70.9) 5036 (25.2) 2482 (12.4) 33.8 68.7
6 14,964 271 (1.8) 1308 (8.7) 709 (4.7) 12,676 (84.7) 1579 (10.6) 980 (6.5) 17.2 27.7
12 13,385 183 (1.4) 979 (7.3) 699 (5.2) 11,524 (86.1) 1162 (8.7) 882 (6.6) 15.7 20.7
18 12,223 174 (1.4) 743 (6.1) 705 (5.8) 10,601 (86.7) 917 (7.5) 879 (7.2) 19.0 19.8
24 11,306 147 (1.3) 691 (6.1) 680 (6.0) 9788 (86.6) 838 (7.4) 827 (7.3) 17.5 17.8
30 10,468 139 (1.3) 566 (5.4) 693 (6.6) 9070 (86.6) 705 (6.7) 832 (7.9) 19.7 16.7
36 9763 139 (1.4) 591 (6.1) 699 (7.2) 8334 (85.4) 730 (7.5) 838 (8.6) 19.0 16.6
42 9033 146 (1.6) 553 (6.1) 684 (7.6) 7650 (84.7) 699 (7.7) 830 (9.2) 20.9 17.6
48 8334 159 (1.9) 472 (5.7) 689 (8.3) 7014 (84.2) 631 (7.6) 848 (10.2) 25.2 18.8
54 7703 162 (2.1) 465 (6.0) 706 (9.2) 6370 (82.7) 627 (8.1) 868 (11.3) 25.8 18.7
60 7076 163 (2.3) 450 (6.4) 712 (10.1) 5751 (81.3) 613 (8.7) 875 (12.4) 26.6 18.6
All 124,255 3387 (2.7) 10,150 (8.2) 7754 (6.2) 102,964 (82.9) 13,537 (10.9) 11,141 (9.0) 25.0 30.4
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 42 Results by observation point for the retest monitoring strategy (strategy B) using the adjusted fibrosis progression estimate data
Observation time (months) Tests,a N/n
Results, n (%)
Diseased,b n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 30,364/20,000 1805 (9.0) 3694 (18.5) 677 (3.4) 13,824 (69.1) 5499 (27.5) 2482 (12.4) 32.8 72.7
6 22,078/14,501 196 (1.4) 1108 (7.6) 656 (4.5) 12,541 (86.5) 1304 (9.0) 852 (5.9) 15.0 23.0
12 20,017/13,197 141 (1.1) 827 (6.3) 682 (5.2) 11,547 (87.5) 968 (7.3) 823 (6.2) 14.6 17.1
18 18,707/12,229 139 (1.1) 691 (5.7) 709 (5.8) 10,690 (87.4) 830 (6.8) 848 (6.9) 16.7 16.4
24 17,432/11,399 146 (1.3) 585 (5.1) 682 (6.0) 9986 (87.6) 731 (6.4) 828 (7.3) 20.0 17.6
30 16,494/10,668 132 (1.2) 564 (5.3) 706 (6.6) 9266 (86.9) 696 (6.5) 838 (7.9) 19.0 15.8
36 15,442/9972 153 (1.5) 562 (5.6) 698 (7.0) 8559 (85.8) 715 (7.2) 851 (8.5) 21.4 18.0
42 14,378/9257 145 (1.6) 537 (5.8) 686 (7.4) 7889 (85.2) 682 (7.4) 831 (9.0) 21.3 17.4
48 13,460/8575 161 (1.9) 466 (5.4) 683 (8.0) 7265 (84.7) 627 (7.3) 844 (9.8) 25.7 19.1
54 12,558/7948 141 (1.8) 462 (5.8) 703 (8.8) 6642 (83.6) 603 (7.6) 844 (10.6) 23.4 16.7
60 11,660/7345 100 (1.4) 293 (4.0) 766 (10.4) 6186 (84.2) 393 (5.4) 866 (11.8) 25.4 11.5
All 192,590/125,091 3259 (2.6) 9789 (7.8) 7648 (6.1) 104,395 (83.5) 13,048 (10.4) 10,907 (8.7) 25.0 29.9
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed/number of people who tests were performed on (number of results generated).
b Tests performed when the patient was diseased.
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TABLE 43 Results by observation point for the reduced frequency of monitoring strategy (strategy C) using adjusted fibrosis progression estimate data
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1818 (9.1) 4227 (21.1) 664 (3.3) 13,291 (66.5) 6045 (30.2) 2482 (12.4) 30.1 73.2
12 13,955 383 (2.7) 1789 (12.8) 650 (4.7) 11,133 (79.8) 2172 (15.6) 1033 (7.4) 17.6 37.1
24 11,783 314 (2.7) 1327 (11.3) 634 (5.4) 9508 (80.7) 1641 (13.9) 948 (8.0) 19.1 33.1
36 10,142 292 (2.9) 1133 (11.2) 654 (6.4) 8063 (79.5) 1425 (14.1) 946 (9.3) 20.5 30.9
48 8717 318 (3.6) 995 (11.4) 641 (7.4) 6763 (77.6) 1313 (15.1) 959 (11.0) 24.2 33.2
60 7404 331 (4.5) 887 (12.0) 651 (8.8) 5535 (74.8) 1218 (16.5) 982 (13.3) 27.2 33.7
All 72,001 3456 (4.8) 10,358 (14.4) 3894 (5.4) 54,293 (75.4) 13,814 (19.2) 7350 (10.2) 25.0 47.0
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 44 Results by observation point for the absolute increase from start value monitoring strategy (strategy D) using the adjusted fibrosis progression estimate data
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1704 (8.5) 3332 (16.7) 778 (3.9) 14,186 (70.9) 5036 (25.2) 2482 (12.4) 33.8 68.7
6 14,964 90 (0.6) 867 (5.8) 890 (5.9) 13,117 (87.7) 957 (6.4) 980 (6.5) 9.4 9.2
12 14,007 132 (0.9) 816 (5.8) 968 (6.9) 12,091 (86.3) 948 (6.8) 1100 (7.9) 13.9 12.0
18 13,059 172 (1.3) 852 (6.5) 1008 (7.7) 11,027 (84.4) 1024 (7.8) 1180 (9.0) 16.8 14.6
24 12,035 185 (1.5) 754 (6.3) 991 (8.2) 10,105 (84.0) 939 (7.8) 1176 (9.8) 19.7 15.7
30 11,096 222 (2.0) 780 (7.0) 966 (8.7) 9128 (82.3) 1002 (9.0) 1188 (10.7) 22.2 18.7
36 10,094 233 (2.3) 785 (7.8) 882 (8.7) 8194 (81.2) 1018 (10.1) 1115 (11.0) 22.9 20.9
42 9076 231 (2.5) 794 (8.7) 789 (8.7) 7262 (80.0) 1025 (11.3) 1020 (11.2) 22.5 22.6
48 8051 249 (3.1) 732 (9.1) 688 (8.5) 6382 (79.3) 981 (12.2) 937 (11.6) 25.4 26.6
54 7070 224 (3.2) 599 (8.5) 594 (8.4) 5653 (80.0) 823 (11.6) 818 (11.6) 27.2 27.4
60 6247 190 (3.0) 566 (9.1) 527 (8.4) 4964 (79.5) 756 (12.1) 717 (11.5) 25.1 26.5
All 125,699 3632 (2.9) 10,877 (8.7) 9081 (7.2) 102,109 (81.2) 14,509 (11.5) 12,713 (10.1) 25.0 28.6
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 45 Results by observation point for the absolute increase from last value monitoring strategy (strategy E) using the adjusted fibrosis progression estimate data
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1704 (8.5) 3332 (16.7) 778 (3.9) 14,186 (70.9) 5036 (25.2) 2482 (12.4) 33.8 68.7
6 14,964 63 (0.4) 629 (4.2) 917 (6.1) 13,355 (89.2) 692 (4.6) 980 (6.5) 9.1 6.4
12 14,272 61 (0.4) 600 (4.2) 1078 (7.6) 12,533 (87.8) 661 (4.6) 1139 (8.0) 9.2 5.4
18 13,611 69 (0.5) 534 (3.9) 1231 (9.0) 11,777 (86.5) 603 (4.4) 1300 (9.6) 11.4 5.3
24 13,008 76 (0.6) 451 (3.5) 1360 (10.5) 11,121 (85.5) 527 (4.1) 1436 (11.0) 14.4 5.3
30 12,481 89 (0.7) 445 (3.6) 1520 (12.2) 10,427 (83.5) 534 (4.3) 1609 (12.9) 16.7 5.5
36 11,947 83 (0.7) 425 (3.6) 1687 (14.1) 9752 (81.6) 508 (4.3) 1770 (14.8) 16.3 4.7
42 11,439 101 (0.9) 431 (3.8) 1852 (16.2) 9055 (79.2) 532 (4.7) 1953 (17.1) 19.0 5.2
48 10,907 135 (1.2) 428 (3.9) 2034 (18.6) 8310 (76.2) 563 (5.2) 2169 (19.9) 24.0 6.2
54 10,344 123 (1.2) 345 (3.3) 2256 (21.8) 7620 (73.7) 468 (4.5) 2379 (23.0) 26.3 5.2
60 9876 147 (1.5) 316 (3.2) 2423 (24.5) 6990 (70.8) 463 (4.7) 2570 (26.0) 31.7 5.7
All 142,849 2651 (1.9) 7936 (5.6) 17,136 (12.0) 115,126 (80.6) 10,587 (7.4) 19,787 (13.9) 25.0 13.4
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 46 Results by observation point for the relative increase from start value monitoring strategy (strategy F) using the adjusted fibrosis progression estimate data
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1704 (8.5) 3332 (16.7) 778 (3.9) 14,186 (70.9) 5036 (25.2) 2482 (12.4) 33.8 68.7
6 14,964 87 (0.6) 1020 (6.8) 893 (6.0) 12,964 (86.6) 1107 (7.4) 980 (6.5) 7.9 8.9
12 13,857 133 (1.0) 877 (6.3) 975 (7.0) 11,872 (85.7) 1010 (7.3) 1108 (8.0) 13.2 12.0
18 12,847 159 (1.2) 862 (6.7) 1028 (8.0) 10,798 (84.1) 1021 (7.9) 1187 (9.2) 15.6 13.4
24 11,826 182 (1.5) 784 (6.6) 1019 (8.6) 9841 (83.2) 966 (8.2) 1201 (10.2) 18.8 15.2
30 10,860 227 (2.1) 737 (6.8) 994 (9.2) 8902 (82.0) 964 (8.9) 1221 (11.2) 23.5 18.6
36 9896 243 (2.5) 759 (7.7) 911 (9.2) 7983 (80.7) 1002 (10.1) 1154 (11.7) 24.3 21.1
42 8894 215 (2.4) 731 (8.2) 843 (9.5) 7105 (79.9) 946 (10.6) 1058 (11.9) 22.7 20.3
48 7948 255 (3.2) 701 (8.8) 737 (9.3) 6255 (78.7) 956 (12.0) 992 (12.5) 26.7 25.7
54 6992 241 (3.4) 598 (8.6) 637 (9.1) 5516 (78.9) 839 (12.0) 878 (12.6) 28.7 27.4
60 6153 196 (3.2) 522 (8.5) 558 (9.1) 4877 (79.3) 718 (11.7) 754 (12.3) 27.3 26.0
All 124,237 3642 (2.9) 10,923 (8.8) 9373 (7.5) 100,299 (80.7) 14,565 (11.7) 13,015 (10.5) 25.0 28.0
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 47 Results by observation point for the relative increase from last value monitoring strategy (strategy G) using the adjusted fibrosis progression estimate data
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1704 (8.5) 3332 (16.7) 778 (3.9) 14,186 (70.9) 5036 (25.2) 2482 (12.4) 33.8 68.7
6 14,964 33 (0.2) 455 (3.0) 947 (6.3) 13,529 (90.4) 488 (3.3) 980 (6.5) 6.8 3.4
12 14,476 41 (0.3) 429 (3.0) 1135 (7.8) 12,871 (88.9) 470 (3.2) 1176 (8.1) 8.7 3.5
18 14,006 40 (0.3) 379 (2.7) 1321 (9.4) 12,266 (87.6) 419 (3.0) 1361 (9.7) 9.5 2.9
24 13,587 44 (0.3) 327 (2.4) 1508 (11.1) 11,708 (86.2) 371 (2.7) 1552 (11.4) 11.9 2.8
30 13,216 45 (0.3) 311 (2.4) 1741 (13.2) 11,119 (84.1) 356 (2.7) 1786 (13.5) 12.6 2.5
36 12,860 44 (0.3) 290 (2.3) 1978 (15.4) 10,548 (82.0) 334 (2.6) 2022 (15.7) 13.2 2.2
42 12,526 47 (0.4) 282 (2.3) 2254 (18.0) 9943 (79.4) 329 (2.6) 2301 (18.4) 14.3 2.0
48 12,197 63 (0.5) 283 (2.3) 2565 (21.0) 9286 (76.1) 346 (2.8) 2628 (21.5) 18.2 2.4
54 11,851 56 (0.5) 212 (1.8) 2923 (24.7) 8660 (73.1) 268 (2.3) 2979 (25.1) 20.9 1.9
60 11,583 52 (0.4) 204 (1.8) 3267 (28.2) 8060 (69.6) 256 (2.2) 3319 (28.7) 20.3 1.6
All 151,266 2169 (1.4) 6504 (4.3) 20,417 (13.5) 122,176 (80.8) 8673 (5.7) 22,586 (14.9) 25.0 9.6
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 48 Results by observation point for the linear regression monitoring strategy (strategy H) using the adjusted fibrosis progression estimate data
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1704 (8.5) 3332 (16.7) 778 (3.9) 14,186 (70.9) 5036 (25.2) 2482 (12.4) 33.8 68.7
6 14,964 367 (2.5) 2070 (13.8) 613 (4.1) 11,914 (79.6) 2437 (16.3) 980 (6.5) 15.1 37.4
12 12,527 156 (1.2) 1032 (8.2) 607 (4.8) 10,732 (85.7) 1188 (9.5) 763 (6.1) 13.1 20.4
18 11,339 135 (1.2) 703 (6.2) 619 (5.5) 9882 (87.2) 838 (7.4) 754 (6.6) 16.1 17.9
24 10,501 126 (1.2) 513 (4.9) 597 (5.7) 9265 (88.2) 639 (6.1) 723 (6.9) 19.7 17.4
30 9862 99 (1.0) 397 (4.0) 649 (6.6) 8717 (88.4) 496 (5.0) 748 (7.6) 20.0 13.2
36 9366 97 (1.0) 413 (4.4) 684 (7.3) 8172 (87.3) 510 (5.4) 781 (8.3) 19.0 12.4
42 8856 125 (1.4) 362 (4.1) 702 (7.9) 7667 (86.6) 487 (5.5) 827 (9.3) 25.7 15.1
48 8369 130 (1.6) 297 (3.5) 737 (8.8) 7205 (86.1) 427 (5.1) 867 (10.4) 30.4 15.0
54 7942 151 (1.9) 303 (3.8) 764 (9.6) 6724 (84.7) 454 (5.7) 915 (11.5) 33.3 16.5
60 7488 147 (2.0) 271 (3.6) 801 (10.7) 6269 (83.7) 418 (5.6) 948 (12.7) 35.2 15.5
All 121,214 3237 (2.7) 9693 (8.0) 7551 (6.2) 100,733 (83.1) 12,930 (10.7) 10,788 (8.9) 25.0 30.0
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 49 Results of the reference strategy when changing estimates required for data simulation
Change in data simulation Threshold value PPV, % Number of tests per persona Delay,b % Develop cirrhosis,c n (%)
None 10.460 25.0 6.21 5.63 7689 (38.45)
Decreasedd measurement error 10.460 29.7 (+4.7) 7.04 (+0.83) 7.18 (+1.55) 7664 (38.32) [–25 (0.13)]
10.205 25.0 6.22 (+0.01) 5.16 (–0.47)
Increasede measurement error 10.460 19.9 (–5.1) 4.64 (–1.57) 3.86 (–1.77) 7808 (39.04) [+119 (0.60)]
10.97 25.0 6.01 (–0.21) 6.60 (+0.97)
Decreased between-individual variability 10.460 28.5 (+3.5) 7.10 (+0.89) 2.97 (–2.66) 7531 (37.66) [–158 (0.79)]
10.35 25.0 6.66 (+0.45) 2.23 (–3.40)
Increasede between-individual variability 10.460 19.7 (–5.3) 4.78 (–1.43) 5.63 (+0.00) 7659 (37.85) [–120 (0.60)]
11.32 25.0 6.68 (+0.47) 10.08 (+4.45)
Decreasedd fibrosis progression rate 10.460 20.7 (–4.3) 6.85 (+0.64) 4.72 (–0.91) 5314 (26.57) [–2375 (11.88)]
10.725 25.0 7.64 (+1.43) 6.10 (+0.47)
Increasede fibrosis progression rate 10.460 36.3 (+11.3) 5.13 (–1.08) 9.29 (+3.66) 13967 (69.84) [+6278 (31.39)]
9.765 25.0 3.14 (–3.07) 2.81 (–2.82)
a Number of tests per person over the duration of monitoring.
b % of all patients with a delayed diagnosis (delay from onset of disease to diagnosis of > 12 months).
c Patients who would go on to develop cirrhosis in the monitoring duration if no intervention were received.
d Decrease is halving the estimate used in the original simulation.
e Increase is doubling the estimate used in the original simulation.
Note
Values in italics represent the difference from the reference strategy for the original adjusted fibrosis progression estimate simulation data. change in simulation data.
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TABLE 50 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with a decreased measurement error
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1705 (8.5) 2899 (14.5) 752 (3.8) 14,644 (73.2) 4604 (23.0) 2457 (12.3) 37.0 69.4
6 15,396 152 (1.0) 773 (5.0) 802 (5.2) 13,669 (88.8) 925 (6.0) 954 (6.2) 16.4 15.9
12 14,471 157 (1.1) 563 (3.9) 845 (5.8) 12,906 (89.2) 720 (5.0) 1002 (6.9) 21.8 15.7
18 13,751 150 (1.1) 543 (3.9) 899 (6.5) 12,159 (88.4) 693 (5.0) 1049 (7.6) 21.6 14.3
24 13,058 161 (1.2) 521 (4.0) 895 (6.9) 11,481 (87.9) 682 (5.2) 1056 (8.1) 23.6 15.2
30 12,376 168 (1.4) 490 (4.0) 928 (7.5) 10,790 (87.2) 658 (5.3) 1096 (8.9) 25.5 15.3
36 11,718 165 (1.4) 519 (4.4) 941 (8.0) 10,093 (86.1) 684 (5.8) 1106 (9.4) 24.1 14.9
42 11,034 166 (1.5) 502 (4.5) 959 (8.7) 9407 (85.3) 668 (6.1) 1125 (10.2) 24.9 14.8
48 10,366 218 (2.1) 490 (4.7) 958 (9.2) 8700 (83.9) 708 (6.8) 1176 (11.3) 30.8 18.5
54 9658 191 (2.0) 462 (4.8) 978 (10.1) 8027 (83.1) 653 (6.8) 1169 (12.1) 29.2 16.3
60 9005 230 (2.6) 427 (4.7) 963 (10.7) 7385 (82.0) 657 (7.3) 1193 (13.2) 35.0 19.3
All 140,833 3463 (2.5) 8189 (5.8) 9920 (7.0) 119,261 (84.7) 11,652 (8.3) 13,383 (9.5) 29.7 25.9
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 51 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with a decreased measurement error and PPV
of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1869 (9.3) 4113 (20.6) 588 (2.9) 13,430 (67.2) 5982 (29.9) 2457 (12.3) 31.2 76.1
6 14,018 142 (1.0) 926 (6.6) 607 (4.3) 12,343 (88.1) 1068 (7.6) 749 (5.3) 13.3 19.0
12 12,950 135 (1.0) 675 (5.2) 632 (4.9) 11,508 (88.9) 810 (6.3) 767 (5.9) 16.7 17.6
18 12,140 133 (1.1) 661 (5.4) 657 (5.4) 10,689 (88.0) 794 (6.5) 790 (6.5) 16.8 16.8
24 11,346 119 (1.0) 555 (4.9) 655 (5.8) 10,017 (88.3) 674 (5.9) 774 (6.8) 17.7 15.4
30 10,672 139 (1.3) 598 (5.6) 664 (6.2) 9271 (86.9) 737 (6.9) 803 (7.5) 18.9 17.3
36 9935 138 (1.4) 525 (5.3) 660 (6.6) 8612 (86.7) 663 (6.7) 798 (8.0) 20.8 17.3
42 9272 121 (1.3) 537 (5.8) 673 (7.3) 7941 (85.6) 658 (7.1) 794 (8.6) 18.4 15.2
48 8614 170 (2.0) 451 (5.2) 647 (7.5) 7346 (85.3) 621 (7.2) 817 (9.5) 27.4 20.8
54 7993 165 (2.1) 464 (5.8) 653 (8.2) 6711 (84.0) 629 (7.9) 818 (10.2) 26.2 20.2
60 7364 190 (2.6) 439 (6.0) 624 (8.5) 6111 (83.0) 629 (8.5) 814 (11.1) 30.2 23.3
All 124,304 3321 (2.7) 9944 (8.0) 7060 (5.7) 103,979 (83.6) 13,265 (10.7) 10,381 (8.4) 25.0 32.0
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 52 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with an increased measurement error
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1790 (8.9) 4412 (22.1) 773 (3.9) 13,025 (65.1) 6202 (31.0) 2563 (12.8) 28.9 69.8
6 13,798 385 (2.8) 2254 (16.3) 608 (4.4) 10,551 (76.5) 2639 (19.1) 993 (7.2) 14.6 38.8
12 11,159 243 (2.2) 1572 (14.1) 532 (4.8) 8812 (79.0) 1815 (16.3) 775 (6.9) 13.4 31.4
18 9344 169 (1.8) 1255 (13.4) 484 (5.2) 7436 (79.6) 1424 (15.2) 653 (7.0) 11.9 25.9
24 7920 123 (1.6) 892 (11.3) 452 (5.7) 6453 (81.5) 1015 (12.8) 575 (7.3) 12.1 21.4
30 6905 130 (1.9) 738 (10.7) 432 (6.3) 5605 (81.2) 868 (12.6) 562 (8.1) 15.0 23.1
36 6037 105 (1.7) 636 (10.5) 406 (6.7) 4890 (81.0) 741 (12.3) 511 (8.5) 14.2 20.5
42 5296 95 (1.8) 528 (10.0) 380 (7.2) 4293 (81.1) 623 (11.8) 475 (9.0) 15.2 20.0
48 4673 99 (2.1) 464 (9.9) 372 (8.0) 3738 (80.0) 563 (12.0) 471 (10.1) 17.6 21.0
54 4110 89 (2.2) 378 (9.2) 374 (9.1) 3269 (79.5) 467 (11.4) 463 (11.3) 19.1 19.2
60 3643 101 (2.8) 312 (8.6) 363 (10.0) 2867 (78.7) 413 (11.3) 464 (12.7) 24.5 21.8
All 92,885 3329 (3.6) 13,441 (14.5) 5176 (5.6) 70,939 (76.4) 16,770 (18.1) 8505 (9.2) 19.9 39.1
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 53 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with an increased measurement error and a
PPV of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1468 (7.3) 2728 (13.6) 1095 (5.5) 14,709 (73.5) 4196 (21.0) 2563 (12.8) 35.0 57.3
6 15,804 464 (2.9) 1604 (10.1) 916 (5.8) 12,820 (81.1) 2068 (13.1) 1380 (8.7) 22.4 33.6
12 13,736 278 (2.0) 1252 (9.1) 871 (6.3) 11,335 (82.5) 1530 (11.1) 1149 (8.4) 18.2 24.2
18 12,206 222 (1.8) 1015 (8.3) 826 (6.8) 10,143 (83.1) 1237 (10.1) 1048 (8.6) 17.9 21.2
24 10,969 206 (1.9) 811 (7.4) 768 (7.0) 9184 (83.7) 1017 (9.3) 974 (8.9) 20.3 21.1
30 9952 177 (1.8) 750 (7.5) 760 (7.6) 8265 (83.0) 927 (9.3) 937 (9.4) 19.1 18.9
36 9025 168 (1.9) 651 (7.2) 735 (8.1) 7471 (82.8) 819 (9.1) 903 (10.0) 20.5 18.6
42 8206 145 (1.8) 582 (7.1) 723 (8.8) 6756 (82.3) 727 (8.9) 868 (10.6) 19.9 16.7
48 7479 173 (2.3) 543 (7.3) 709 (9.5) 6054 (80.9) 716 (9.6) 882 (11.8) 24.2 19.6
54 6763 159 (2.4) 460 (6.8) 721 (10.7) 5423 (80.2) 619 (9.2) 880 (13.0) 25.7 18.1
60 6144 139 (2.3) 388 (6.3) 731 (11.9) 4886 (79.5) 527 (8.6) 870 (14.2) 26.4 16.0
All 120,284 3599 (3.0) 10,784 (9.0) 8855 (7.4) 97,046 (80.7) 14,383 (12.0) 12,454 (10.4) 25.0 28.9
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 54 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with a decreased between-individual variability
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1809 (9.0) 1745 (8.7) 546 (2.7) 15,900 (79.5) 3554 (17.8) 2355 (11.8) 50.9 76.8
6 16,446 349 (2.1) 925 (5.6) 397 (2.4) 14,775 (89.8) 1274 (7.7) 746 (4.5) 27.4 46.8
12 15,172 189 (1.2) 771 (5.1) 368 (2.4) 13,844 (91.2) 960 (6.3) 557 (3.7) 19.7 33.9
18 14,212 143 (1.0) 731 (5.1) 367 (2.6) 12,971 (91.3) 874 (6.1) 510 (3.6) 16.4 28.0
24 13,338 139 (1.0) 668 (5.0) 335 (2.5) 12,196 (91.4) 807 (6.1) 474 (3.6) 17.2 29.3
30 12,531 141 (1.1) 660 (5.3) 334 (2.7) 11,396 (90.9) 801 (6.4) 475 (3.8) 17.6 29.7
36 11,730 140 (1.2) 695 (5.9) 334 (2.8) 10,561 (90.0) 835 (7.1) 474 (4.0) 16.8 29.5
42 10,895 153 (1.4) 665 (6.1) 304 (2.8) 9773 (89.7) 818 (7.5) 457 (4.2) 18.7 33.5
48 10,077 132 (1.3) 698 (6.9) 332 (3.3) 8915 (88.5) 830 (8.2) 464 (4.6) 15.9 28.4
54 9247 153 (1.7) 649 (7.0) 326 (3.5) 8119 (87.8) 802 (8.7) 479 (5.2) 19.1 31.9
60 8445 143 (1.7) 560 (6.6) 341 (4.0) 7401 (87.6) 703 (8.3) 484 (5.7) 20.3 29.5
All 142,093 3491 (2.5) 8767 (6.2) 3984 (2.8) 125,851 (88.6) 12,258 (8.6) 7475 (5.3) 28.5 46.7
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 55 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with a decreased between-individual
variability and PPV of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1917 (9.6) 2120 (10.6) 438 (2.2) 15,525 (77.6) 4037 (20.2) 2355 (11.8) 47.5 81.4
6 15,963 297 (1.9) 1119 (7.0) 321 (2.0) 14,226 (89.1) 1416 (8.9) 618 (3.9) 21.0 48.1
12 14,547 161 (1.1) 951 (6.5) 290 (2.0) 13,145 (90.4) 1112 (7.6) 451 (3.1) 14.5 35.7
18 13,435 127 (0.9) 849 (6.3) 287 (2.1) 12,172 (90.6) 976 (7.3) 414 (3.1) 13.0 30.7
24 12,459 121 (1.0) 757 (6.1) 247 (2.0) 11,334 (91.0) 878 (7.0) 368 (3.0) 13.8 32.9
30 11,581 122 (1.1) 722 (6.2) 235 (2.0) 10,502 (90.7) 844 (7.3) 357 (3.1) 14.5 34.2
36 10,737 119 (1.1) 757 (7.1) 222 (2.1) 9639 (89.8) 876 (8.2) 341 (3.2) 13.6 34.9
42 9861 109 (1.1) 721 (7.3) 211 (2.1) 8820 (89.4) 830 (8.4) 320 (3.2) 13.1 34.1
48 9031 95 (1.1) 696 (7.7) 239 (2.6) 8001 (88.6) 791 (8.8) 334 (3.7) 12.0 28.4
54 8240 126 (1.5) 672 (8.2) 222 (2.7) 7220 (87.6) 798 (9.7) 348 (4.2) 15.8 36.2
60 7442 129 (1.7) 605 (8.1) 221 (3.0) 6487 (87.2) 734 (9.9) 350 (4.7) 17.6 36.9
All 133,296 3323 (2.5) 9969 (7.5) 2933 (2.2) 117,071 (87.8) 13,292 (10.0) 6256 (4.7) 25.0 53.1
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 56 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with an increased between-individual variability
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1779 (8.9) 6916 (34.6) 679 (3.4) 10,626 (53.1) 8695 (43.5) 2458 (12.3) 20.5 72.4
6 11,305 171 (1.5) 1299 (11.5) 683 (6.0) 9152 (81.0) 1470 (13.0) 854 (7.6) 11.6 20.0
12 9835 109 (1.1) 808 (8.2) 741 (7.5) 8177 (83.1) 917 (9.3) 850 (8.6) 11.9 12.8
18 8918 119 (1.3) 631 (7.1) 746 (8.4) 7422 (83.2) 750 (8.4) 865 (9.7) 15.9 13.8
24 8168 99 (1.2) 544 (6.7) 757 (9.3) 6768 (82.9) 643 (7.9) 856 (10.5) 15.4 11.6
30 7525 111 (1.5) 446 (5.9) 765 (10.2) 6203 (82.4) 557 (7.4) 876 (11.6) 19.9 12.7
36 6968 124 (1.8) 390 (5.6) 752 (10.8) 5702 (81.8) 514 (7.4) 876 (12.6) 24.1 14.2
42 6454 129 (2.0) 412 (6.4) 747 (11.6) 5166 (80.0) 541 (8.4) 876 (13.6) 23.8 14.7
48 5913 143 (2.4) 346 (5.9) 718 (12.1) 4706 (79.6) 489 (8.3) 861 (14.6) 29.2 16.6
54 5424 122 (2.2) 305 (5.6) 727 (13.4) 4270 (78.7) 427 (7.9) 849 (15.7) 28.6 14.4
60 4997 130 (2.6) 286 (5.7) 717 (14.3) 3864 (77.3) 416 (8.3) 847 (17.0) 31.2 15.3
All 95,507 3036 (3.2) 12,383 (13.0) 8032 (8.4) 72,056 (75.4) 15,419 (16.1) 11,068 (11.6) 19.7 27.4
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 57 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with an increased between-individual
variability and a PPV of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1406 (7.0) 3876 (19.4) 1052 (5.3) 13,666 (68.3) 5282 (26.4) 2458 (12.3) 26.6 57.2
6 14,718 190 (1.3) 1002 (6.8) 1109 (7.5) 12,417 (84.4) 1192 (8.1) 1299 (8.8) 15.9 14.6
12 13,526 141 (1.0) 667 (4.9) 1215 (9.0) 11,503 (85.0) 808 (6.0) 1356 (10.0) 17.5 10.4
18 12,718 125 (1.0) 523 (4.1) 1272 (10.0) 10,798 (84.9) 648 (5.1) 1397 (11.0) 19.3 8.9
24 12,070 117 (1.0) 461 (3.8) 1349 (11.2) 10,143 (84.0) 578 (4.8) 1466 (12.1) 20.2 8.0
30 11,492 132 (1.1) 423 (3.7) 1418 (12.3) 9519 (82.8) 555 (4.8) 1550 (13.5) 23.8 8.5
36 10,937 159 (1.5) 441 (4.0) 1437 (13.1) 8900 (81.4) 600 (5.5) 1596 (14.6) 26.5 10.0
42 10,337 130 (1.3) 392 (3.8) 1509 (14.6) 8306 (80.4) 522 (5.0) 1639 (15.9) 24.9 7.9
48 9815 161 (1.6) 363 (3.7) 1587 (16.2) 7704 (78.5) 524 (5.3) 1748 (17.8) 30.7 9.2
54 9291 196 (2.1) 342 (3.7) 1627 (17.5) 7126 (76.7) 538 (5.8) 1823 (19.6) 36.4 10.8
60 8753 183 (2.1) 317 (3.6) 1651 (18.9) 6602 (75.4) 500 (5.7) 1834 (21.0) 36.6 10.0
All 133,657 2940 (2.2) 8807 (6.6) 15,226 (11.4) 106,684 (79.8) 11,747 (8.8) 18,166 (13.6) 25.0 16.2
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 58 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with a decreased fibrosis progression rate
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 1290 (6.4) 3094 (15.5) 643 (3.2) 14,973 (74.9) 4384 (21.9) 1933 (9.7) 29.4 66.7
6 15,616 174 (1.1) 1204 (7.7) 606 (3.9) 13,632 (87.3) 1378 (8.8) 780 (5.0) 12.6 22.3
12 14,238 128 (0.9) 833 (5.9) 601 (4.2) 12,676 (89.0) 961 (6.7) 729 (5.1) 13.3 17.6
18 13,277 116 (0.9) 693 (5.2) 602 (4.5) 11,866 (89.4) 809 (6.1) 718 (5.4) 14.3 16.2
24 12,468 99 (0.8) 608 (4.9) 597 (4.8) 11,164 (89.5) 707 (5.7) 696 (5.6) 14.0 14.2
30 11,761 108 (0.9) 532 (4.5) 594 (5.1) 10,527 (89.5) 640 (5.4) 702 (6.0) 16.9 15.4
36 11,121 98 (0.9) 540 (4.9) 596 (5.4) 9887 (88.9) 638 (5.7) 694 (6.2) 15.4 14.1
42 10,483 110 (1.0) 463 (4.4) 593 (5.7) 9317 (88.9) 573 (5.5) 703 (6.7) 19.2 15.6
48 9910 106 (1.1) 460 (4.6) 572 (5.8) 8772 (88.5) 566 (5.7) 678 (6.8) 18.7 15.6
54 9344 90 (1.0) 415 (4.4) 583 (6.2) 8256 (88.4) 505 (5.4) 673 (7.2) 17.8 13.4
60 8839 90 (1.0) 401 (4.5) 587 (6.6) 7761 (87.8) 491 (5.6) 677 (7.7) 18.3 13.3
All 137,057 2409 (1.8) 9243 (6.7) 6574 (4.8) 118,831 (86.7) 11,652 (8.5) 8983 (6.6) 20.7 26.8
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 59 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with an increased fibrosis progression rate
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 2473 (12.4) 3320 (16.6) 1123 (5.6) 13,084 (65.4) 5793 (29.0) 3596 (18.0) 42.7 68.8
6 14,207 447 (3.1) 1394 (9.8) 1097 (7.7) 11,269 (79.3) 1841 (13.0) 1544 (10.9) 24.3 29.0
12 12,366 344 (2.8) 1097 (8.9) 1096 (8.9) 9829 (79.5) 1441 (11.7) 1440 (11.6) 23.9 23.9
18 10,925 311 (2.8) 933 (8.5) 1088 (10.0) 8593 (78.7) 1244 (11.4) 1399 (12.8) 25.0 22.2
24 9681 335 (3.5) 859 (8.9) 1035 (10.7) 7452 (77.0) 1194 (12.3) 1370 (14.2) 28.1 24.5
30 8487 347 (4.1) 766 (9.0) 990 (11.7) 6384 (75.2) 1113 (13.1) 1337 (15.8) 31.2 26.0
36 7374 350 (4.7) 746 (10.1) 1019 (13.8) 5259 (71.3) 1096 (14.9) 1369 (18.6) 31.9 25.6
42 6278 386 (6.1) 579 (9.2) 1036 (16.5) 4277 (68.1) 965 (15.4) 1422 (22.7) 40.0 27.1
48 5313 395 (7.4) 509 (9.6) 1016 (19.1) 3393 (63.9) 904 (17.0) 1411 (26.6) 43.7 28.0
54 4409 421 (9.5) 389 (8.8) 949 (21.5) 2650 (60.1) 810 (18.4) 1370 (31.1) 52.0 30.7
60 3599 391 (10.9) 277 (7.7) 843 (23.4) 2088 (58.0) 668 (18.6) 1234 (34.3) 58.5 31.7
All 102,639 6200 (6.0) 10,869 (10.6) 11,292 (11.0) 74,278 (72.4) 17,069 (16.6) 17,492 (17.0) 36.3 35.4
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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TABLE 60 Adjusted fibrosis progression sensitivity analyses: results by observation point using the reference strategy (strategy A) with an increased fibrosis progression rate
and PPV of 25%
Observation time (months) Tests, N
Results, n (%)
Diseased,a n (%) PPV, % Sensitivity, %TP FP FN TN Positive
0 20,000 3037 (15.2) 6915 (34.6) 559 (2.8) 9489 (47.4) 9952 (49.8) 3596 (18.0) 30.5 84.5
6 10,048 328 (3.3) 2124 (21.1) 454 (4.5) 7142 (71.1) 2452 (24.4) 782 (7.8) 13.4 41.9
12 7596 216 (2.8) 1330 (17.5) 403 (5.3) 5647 (74.3) 1546 (20.4) 619 (8.1) 14.0 34.9
18 6050 207 (3.4) 990 (16.4) 339 (5.6) 4514 (74.6) 1197 (19.8) 546 (9.0) 17.3 37.9
24 4853 153 (3.2) 789 (16.3) 295 (6.1) 3616 (74.5) 942 (19.4) 448 (9.2) 16.2 34.2
30 3911 139 (3.6) 635 (16.2) 277 (7.1) 2860 (73.1) 774 (19.8) 416 (10.6) 18.0 33.4
36 3137 135 (4.3) 493 (15.7) 284 (9.1) 2225 (70.9) 628 (20.0) 419 (13.4) 21.5 32.2
42 2509 158 (6.3) 358 (14.3) 262 (10.4) 1731 (69.0) 516 (20.6) 420 (16.7) 30.6 37.6
48 1993 151 (7.6) 290 (14.6) 247 (12.4) 1305 (65.5) 441 (22.1) 398 (20.0) 34.2 37.9
54 1552 126 (8.1) 219 (14.1) 234 (15.1) 973 (62.7) 345 (22.2) 360 (23.2) 36.5 35.0
60 1207 111 (9.2) 155 (12.8) 213 (17.6) 728 (60.3) 266 (22.0) 324 (26.8) 41.7 34.3
All 62,856 4761 (7.6) 14,298 (22.7) 3567 (5.7) 40,230 (64.0) 19,059 (30.3) 8328 (13.2) 25.0 57.2
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Tests performed when the patient was diseased.
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Comparison with ELUCIDATE trial data
The ELUCIDATE data contained 705 observations taken from 420 participants randomised to the ELF
monitoring arm of the trial. After removing measurements following an ELF value of ≥ 9.5 for each
individual (akin to the trial setting), the simulated data set contained 66,320 observations for 20,000
participants and the simulated data set with an adjusted fibrosis progression rate included 59,000
observations for 20,000 participants. Analysis of the ELF value at the point of randomisation for each of
the data sets showed similar results: the mean (SD) value for the ELUCIDATE data was 9.57 (1.21), for the
simulated data was 9.71 (1.15) and for the simulated data with an adjusted fibrosis progression rate was
9.83 (1.20), with the mean value being slightly lower for the ELUCIDATE data than for the two simulated
data sets. The between-individual SD was higher for the ELUCIDATE data than for the simulated data sets
(0.93 for the ELUCIDATE data vs. 0.76 for the simulated data and 0.82 for the simulated data with an
adjusted fibrosis progression rate). The within-individual SD was similar for the ELUCIDATE data and both
simulated data sets (0.53 for the ELUCIDATE data and 0.51 and 0.52 for the simulated and simulated with
adjusted fibrosis progression data sets, respectively). The results of the analysis of the randomisation ELF
value and ANOVA for ELF measurements at all recorded time points are provided in Table 61.
The ELUCIDATE data modelled consisted of 429 observations from 153 participants, with each participant
having a minimum of two and a maximum of six ELF observations and an average number of observations
per person of 2.8. The number of observation points used from the simulation model was, therefore, capped
to give a similar mean number of observations per person to the value seen in the ELUCIDATE data. Allowing
more observations per person would introduce bias as patients with more slowly progressing disease will
have more ELF measurements prior to having a test result of ≥ 9.5. This bias relates to comments made by
Bellera et al.241 when analysing monitoring data. The model fitted to simulated data used 26,429 observation
points for 9608 simulated participants and the model fitted to simulated data with an adjusted fibrosis
progression rate used 23,972 observations for 8779 simulated participants. For the simulated data sets, the
mean number of observations was 2.8 for the original data set with an unadjusted fibrosis progression rate
and 2.7 for the data set with an adjusted fibrosis progression rate. The results of the modelling of the
ELUCIDATE data, simulated data and simulated date with an adjusted fibrosis progression rate are provided
in Table 62.
Modelling of the ELUCIDATE data showed the increase in ELF value per year to be 0.31 (95% CI 0.22 to
0.39; p < 0.001). Modelling of the simulated data and the simulated data with an adjusted fibrosis
progression rate showed the increase in ELF value per year to be comparable at 0.24 (95% CI 0.23 to
0.26; p < 0.001) and 0.28 (95% CI 0.27 to 0.30; p < 0.001), respectively.
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FIGURE 16 Results of strategies A–H using the adjusted fibrosis progression estimate data.
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Discussion
Reference strategy
At the initial testing point a monitoring strategy will be identifying cases from a prevalent population in
which a large proportion of patients will have high ELF values. At subsequent time points those with a
positive result will not be tested and the tested population will contain cirrhotic patients who either have
been falsely negative at the previous testing point or have developed cirrhosis since the last testing point
(incident cases), hence the difference in results between the initial monitoring time point and the other
time points. The percentage of false-negative results generally increased with each time point as patients
with a low ELF trajectory have reached compensated cirrhosis but as they have a low ELF value for their
disease stage they are required to progress further to have a positive test result using the simple threshold
decision rule. The increasing percentage of false-negative results as the testing points advanced suggests
that the simple threshold should be reduced at later time points to account for the patients who have
false-negative results using the original threshold.
TABLE 61 Results of the analysis of the randomisation ELF value and ANOVA for ELF measurements at all
time points
Variable
Data
ELUCIDATE Simulated
Simulated with adjusted
fibrosis progression
Randomisation point ELF value, mean (SD) 9.57 (1.21) 9.71 (1.15) 9.83 (1.20)
ANOVA
Between-individual SD 0.93 0.76 0.82
Within-individual SD 0.53 0.51 0.52
TABLE 62 Results of the multilevel model of repeated ELF measurements from the ELUCIDATE trial and
monitoring simulation
Variable Estimate 95% CI p-value
ELUCIDATE trial ELF value
Years 0.31 0.22 to 0.39 < 0.001
Constant 8.73 8.63 to 8.82 < 0.001
Between-individual SD 0.43 0.36 to 0.51
Within-individual SD 0.48 0.44 to 0.52
Simulated ELF value
Years 0.24 0.23 to 0.26 < 0.001
Constant 8.84 8.83 to 8.85 < 0.001
Between-individual SD 0.42 0.41 to 0.43
Within-individual SD 0.47 0.46 to 0.47
Simulated ELF value with adjusted fibrosis progression
Years 0.28 0.27 to 0.30 < 0.001
Constant 8.86 8.84 to 8.87 < 0.001
Between-individual SD 0.42 0.41 to 0.43
Within-individual SD 0.46 0.46 to 0.47
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Comparing strategies with changes to individual components with the
reference strategy
Inferior strategies
It was anticipated that the strategy with retesting would result in an increase in the number of tests per
person required compared with the reference strategy, but the percentage of patients with a delay to
diagnosis also increased. For the patients in the target retest range their test result was determined by
combining both the initial and the retest results and their corresponding measurement errors with the
mean of the initial and retest result being used to classify a result as positive or negative. Because of the
measurement error of both the initial and the retest results some patients would have been positive on
their initial test (as with the reference strategy) but, using the mean of the initial test and retest, they have
a negative result. The slight increase in time to diagnosis when using a retest strategy will also have a small
effect on the percentage of participants with a delay to diagnosis.
The strategies using the absolute and relative increase from the last recorded value decision rules were
notably worse than the strategies using the absolute and relative changes from the initial recorded value.
When using a decision rule based on detecting a magnitude of change between one value and another,
the two values used to calculate the change will both have measurement error. Comparisons with the
initial value will consider increases in ELF across the entire monitoring period rather than increases since
the previous monitoring point only. Differences from the initial value rather than the last value were better
for detecting true change over measurement error (signal from noise).
The simple threshold strategy outperformed the strategies comparing current with previous values. This is
in part because of the index of individuality, the ratio between within-individual and between-individual
variation. If a test has a high index of individuality value, whereby an individual can have results spanning
a wide range of the possible results for a group of people, comparison with constant thresholds will be
more meaningful than for tests with low index of individuality values, whereby an individual will have test
results spanning only part of the possible range of results and comparison with previous results will be
more beneficial.290
‘Trade-off’ strategies
The reduced test frequency strategy showed a large decrease in the number of tests per person used for
a small increase in the percentage of people with a delay to diagnosis. It may be that for a substantial
decrease in the number of tests required, and, therefore, the resource used, the slight potential for
increased harm to patients (through later diagnosis) is acceptable.
Superior strategies
The linear regression strategy was the only strategy tested that showed a reduction in both the number
of tests required and the percentage of patients with a delay to diagnosis. By fitting a regression model
using all previous observations for an individual and obtaining a prediction from this, the linear regression
method utilised all available data and some allowance was made for the fluctuation in results because of
measurement error. The linear regression strategy, however, resulted in only small benefits compared with
the reference strategy. This modest improvement in monitoring strategy performance may not merit the
extra complexity involved when using the linear regression method.
Estimates of test performance and disease progression (sensitivity analyses)
The results obtained when varying estimates in the simulation model and evaluating the reference strategy
highlight the importance of including accurate data. The increases and decreases in estimates of test
performance (measurement error and between-individual variability) and fibrosis progression rate affected
the three measures of performance in different ways.
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Measurement error and between-individual variability
The measurement error of a test affects the number of false-positive test results, with larger measurement
error resulting in more false-positive results and smaller measurement error resulting in fewer false-positive
results. Between-individual variability will affect the underlying ELF values possible at each fibrosis stage.
As long as the ELF value is related to fibrosis stage, if the between-individual variability is smaller it will be
easier to correctly identify the fibrosis stage from the ELF value, resulting in fewer false-positive results and
more true-positive results.
With fewer false-positive and more true-positive results, the PPV will increase and the number of tests
required will increase as the reduction in number of false-positive results means that the number of patients
correctly staying in the monitoring programme will increase. With reduced measurement error the observed
values reflect more closely the underlying disease state of each patient; if the threshold does not adequately
account for this, patients will need to progress for longer to have a test value over the threshold, indicating
a positive result. When the between-individual variability is reduced, because of the increase in the number
of true-positive results the percentage of patients with a delay to diagnosis will decrease.
Fibrosis progression rate
The fibrosis progression rate will affect the number of diseased patients. With an increased fibrosis
progression rate more patients will have compensated cirrhosis, which will lead to an increase in the PPV.
With an increased fibrosis progression rate patients have a positive result earlier in the strategy and the
strategy will require fewer tests to be performed. If patients have an increased fibrosis progression rate
more patients will have been in cirrhosis for > 12 months, meaning that more patients can be undetected
for > 12 months.
Limitations
Data sources
The estimates from data sources used to inform the simulation model will have a large impact on the
results of the simulation model. The suitability of the data was assessed by consultation with clinical
colleagues and, when necessary, estimates were adjusted in sensitivity analyses. However, as the model
was dependent on the information used, the quality and suitability of the data used will always be a
limitation. Just one cross-sectional study provided information on both the link between ELF values and
fibrosis stage and the distribution of fibrosis stages at entry to the trial. When looking to identify an
estimate of measurement error several sources were identified, with the estimates from each found to be
vastly different. The data linking ELF values to fibrosis stage defined fibrosis stage by biopsy. Even though
biopsy is the reference standard for staging fibrosis, biopsy is known not to be accurate in some cases.
The ELUCIDATE trial data used to assess the simulation model were not completely appropriate as the data
set contained repeated observations from only 153 participants, with many participants having only two
observations; more observations per person would allow the model to better estimate the error terms
and the changes over time. ELF measurements being taken only until the point of a measurement being
classed as positive also hinders the ability of the data to estimate the true progression of ELF over time,
as those with higher ELF values (and possibly more developed cirrhosis) cease to have their values recorded
and so progression beyond this cannot be assessed. Patients with lower ELF measurements (< 9.5)
continued to be monitored, meaning that they had more measurements taken and, therefore, contributed
more data to the model; however, they were potentially very different from those who had fewer
measurements taken, who were likely to be in a worse health state.
Assumptions
A major limitation of the simulation model is the vast number of assumptions required. Some of the
estimates used to generate the monitoring data, such as fibrosis progression rate and measurement error,
can be varied in magnitude and the results assessed to identify the impact of using data of insufficient
quality or suitability in the model. However, many assumptions, made out of necessity, in the development
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of the model could not be varied and assessed so easily and the consequences explored. The model
assumed that fibrosis progression is constant and requires patients to have positive fibrosis progression;
the minimum fibrosis progression was set at 0.01 fibrosis units per year for the purposes of the simulation
(which would indicate a stable disease state). The model assumed linear increases in ELF values between
fibrosis stages, normally distributed ELF values within fibrosis stage and a constant fibrosis progression rate.
The error associated with each observation was assumed to be normally distributed and a simple error
term was used, with no distinction made between within-individual and analytical variation. The error used
in the simulation may also be simplistic as the error term was randomly chosen from a distribution that
not only is constant across individuals and time but also was not linked to the magnitude of the ELF value.
As no alternative data or substantiated opinion were available to enable modelling of these factors in any
other way, these assumptions were necessary for the development of the model. Longitudinal data sets
with ELF values and biopsy results recorded in addition to data from a biological variability study of ELF
would be required to test these assumptions.
Trial considerations
Several criteria were required to allow the simulation model to generate data for a trial (described in Table 17).
Although these criteria were included to avoid anomalies and were based on clinical advice, there are no data
to support them.
Further work
A greater variety of strategies could be evaluated with multiple components assessed simultaneously. More
complex decision rules and frequencies could be explored, for example a simple threshold decision rule in
which the threshold remains the same across patients but varies by time point within a monitoring strategy
or changing the frequency of testing to be non-constant.
It may be possible for the simulation model to be adapted to account for usual care (and variation in usual
care). If usual care could be modelled, it may be possible to compare the use of monitoring strategies
(in addition to usual care) with usual care alone and with further simulation work estimate differences in
patient outcomes between the approaches.
The model can be used to show lifetime progression for a time-matched cohort of patients with fibrosis
(if the data are simulated with all patients starting at the onset of liver fibrosis). These data may be beneficial
to the assessment of how a strategy would perform in practice rather than specifically in the trial setting,
as they would provide information on how newly diagnosed patients would benefit from monitoring.
Conclusions
Simulation can be used to obtain monitoring data for candidate monitoring strategies and to enable an
appropriate strategy to be selected for full-scale evaluation.
In the case of using ELF measurements to monitor liver fibrosis, only the linear regression monitoring strategy
showed better performance than the simple threshold strategy and, given the additional complexity and
small benefit of using the linear regression strategy, the simple threshold strategy may be most appropriate.
Reducing the frequency of testing may be an alternative to the simple threshold strategy if the compromise
between number of tests and delay to diagnosis is acceptable.
To generate monitoring data there has to be available evidence on the natural history of the disease and
the performance of the monitoring test (measurement error and test accuracy); this evidence can be
obtained from existing data sets, by reviewing the literature or from potentially expert opinion. If the data
informing the simulation model are inaccurate, the results obtained from the evaluation of strategies
will not reflect the truth. Inaccurate estimates will affect the results in a complex way. The results of the
SIMULATING MONITORING DATA AND EVALUATING MONITORING STRATEGIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
136
sensitivity analyses highlighted the importance, for this test and disease area, of having accurate estimates
of test performance and progression.
When comparing data from the ELUCIDATE trial with the simulated data it was clear that, because of
the design of the ELUCIDATE trial, the analysis would have to limit the bias of recorded ELF results.
Comparison of the ELUCIDATE data and the simulated data provided similar results. Bias in monitoring
data, particularly concerning the number of recorded results, should be considered when carrying out
the analyses.
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Chapter 8 Methodological considerations in the
optimisation of monitoring biomarkers to meet
value-based market access hurdles
Components of the work described in this chapter have been published in Longo et al.330
Background
Biomarkers are a central component of the proposed revolution in health care. Sometimes called personal,
precision or stratified medicine, the defining characteristic of personalised medicine is the use of molecular
(including genetic) and imaging information on individual patients, that is, biomarkers, to guide decisions
on their clinical management.
The potential clinical applications of personalised medicine include:
l screening for the risk of developing disease
l diagnosing the presence of disease
l providing prognosis of an individual patient’s disease progression
l identifying whether or not patients are likely to respond to particular treatments (pharmacogenomics)
l identifying whether or not patients are at an elevated risk of adverse events from particular treatments
(pharmacogenomics/toxicogenomics).
The biomedical knowledge that underlies personalised medicine also has significant potential in the discovery
and translation of new therapies; however, consideration of these is outside the scope of this project.
Personalised medicine technologies are being developed at a time when developed health-care systems
are under increasing pressure to increase efficiency, that is, to consider the value of new technologies in
terms of what they produce in relation to how much they cost, and to review current clinical practices
with a view to eliminate those activities that are of low or no value. The former process is implemented
through health technology assessment processes, such as those undertaken by NICE in the UK, the Haute
Autorité de Santé (HAS) in France, the Pharmaceutical Benefits Advisory Committee in Australia and
the Canadian Agency for Drugs and Technologies in Health in Canada. In line with other new health
technologies, personalised medicine innovations tend to come at a substantial financial cost. Commercially
available tests such as Oncotype Dx® (Genomic Health, Inc., Redwood City, CA, USA) are magnitudes more
expensive than conventional laboratory tests and co-dependent therapies, such as crizotinib (Xalkori, Pfizer
Inc., New York, NY, USA), are even more expensive. These price tags mean that they are inevitably subject
to formal health technology assessment prior to market access.
The review of current clinical practices with a view to eliminate those activities that are of low or no value
is being driven internationally by the Choosing Wisely campaign.331 The elimination of unnecessary tests
is at the forefront of the campaign. As a result, there is an inevitable tension between the widespread
adoption of additional tests that are required for personalised medicine and the societal and professional
pressure to make less use of tests. In this context, biomarker tests will be adopted only if they can be
demonstrated to be a high-value use of limited health-care resources. This relatively new pressure to assess
the value of new tests before they are adopted aligns testing with the processes of health technology
assessment that have been used for drugs and some devices for many years. The focus of this theme of
the programme grant has been the development of methods for assessing the value of personalised
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medicine technologies, with a particular focus on monitoring tests, that is, tests that are applied repeatedly
to the same patient over a period of time to inform sequential clinical care decisions.
The remainder of this chapter is structured as follows. In Cost-effectiveness in personalised medicine
technologies we consider the difference between a conventional clinical utility for the individual patient
approach to test optimisation and an approach based on the cost-effectiveness of the test from a
population health perspective. A framework for characterising personalised medicine technologies
describes a framework for characterising personalised medicine technologies. Extending the method of
Phelps and Mushlin for monitoring tests describes an existing method for optimising diagnostic tests
to meet cost-effectiveness targets and its extension for monitoring tests. Some observations on the
estimation of the value of information for monitoring tests describes the formal extension of this
framework for a monitoring test with ‘n’ administrations and provides an illustrative example in which
there are six sequential administrations of the test. The conclusions section then sets out some conceptual
issues related to the calculation of the value of information of additional research for a monitoring test.
Cost-effectiveness in personalised medicine technologies
As described in the previous section, biomarker tests are at the centre of the personalised medicine
revolution. Although some tests are dichotomous, that is, they test the presence or absence of a particular
biomedical characteristic, many tests measure a continuous biomedical parameter, for example blood
glucose or forced expiratory volume. The interpretation of the test result converts the continuous variable
into a categorical variable by defining a certain test result as the transition point between normal and
abnormal. This transition point is referred to as the test cut-off point. Conventionally, the choice of cut-off
point is selected on the basis of clinical utility. Clinical utility considers the risk–benefit ratio of a test from
the perspective of the individual patient. Conditional on the treatment associated with a positive test result
having no or only a low risk of an adverse event, maximising clinical utility leads to preferring a highly
sensitive diagnostic test cut-off point over a highly specific diagnostic test cut-off point.
Figure 17 shows how shifting the cut-off point for a diagnostic test changes the proportions of patients
who receive false-positive and false-negative test results. The upper half of the figures show the test score
distribution for individuals who actually have the condition of interest. The lower half of the diagram
shows the test score distribution for individuals who do not have the condition of interest. Between points
A and B, for any given test result it is possible that an individual may have or be free of the condition of
interest. The initial cut-off point is shown by the solid blue vertical line and the dark green portions show
True-positive cases
True-negative cases
A B
False
positive
False
negative
Test cut-off point
FIGURE 17 Relationship between cut-off point and test performance.
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the proportions of the test results that are incorrect. Individuals who have the condition but who receive a
test score below the cut-off point are defined as false negatives and individuals free of the condition who
receive a test score above the cut-off point are defined as false positives.
Figure 18 shows how the proportions of individuals who receive false-positive and false-negative test results
change as the cut-off point is moved. As the test cut-off point moves to the left (lower), the proportion of
false-negative results reduces but the proportion of false-positive results increases. By contrast, if the cut-off
point moves to the right (higher), the proportion of individuals who receive a false-negative result increases
whereas the proportion of individuals who receive a false-positive result decreases.
As described earlier, because clinical utility is evaluated from the individual patient perspective, the value
attached to a false-positive results tends to be considerably less than the value attached to a false-negative
result. A false-negative result deprives the individual of the opportunity to receive appropriate treatment in
a timely manner. By contrast, a false-positive result exposes the individual to a treatment that they will
not benefit from but that is not expected to do them harm. However, when consideration of the value of
the test is expanded to include the resources consumed by the test and any treatments administered
subsequent to the test result, as is the case for the health technology appraisal of tests, the perspective
True-positive cases
True-negative cases
(a)
A
BFalse positive
False negative
Test cut-off point
True-positive cases
(b)
True-negative cases
False positive
False negative BA
Test cut-off point
FIGURE 18 Relationship between cut-off point and test performance. (a) Test cut-off point moves to the left
(lower); and (b) test cut-off point moves to the right (higher).
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forestablishingvaluemovesfromthe individualpatienttothatofthepopulationthatthehealth-care
system isresponsiblefor.
Fromapopulationhealthperspective, inahealthsystemthatoperateswithabudgetthat isfixed,or
quasi-fixed inrealterms,thecostofatechnology isthehealthforgonebyothers.Weusethe‘bookshelf’
modeldevelopedbyCulyer,McCabeandEdlin332o334 to illustratehowthecost-effectivenessthreshold
representsthehealthforgoneasaresultofthepremiumcostofnewtherapies.
Thecost-effectiveness‘bookshelf’ isagraphicalrepresentationofthehealthsystem inwhicheachavailable
healthtechnology isrepresentedasaunique‘book’onthebookshelf.Abroaddefinitionof‘technology’
isadoptedforthispurpose,which includesanyhealth-care interventionorservicethatconsumesresources
andprovidesvaluetothehealthsystem.
Thewidthofeachbookrepresentseachtechnology’sbudget impact iffunded(i.e.the incrementalcost
ofprovidingthetechnologytoallpatients intherelevant indication),whereastheheightofeachbook
representseachtechnology’s incrementalcost-effectivenessratio(ICER).Forthepurposeofthisstudy,the
preferredunitof‘effectiveness’forahealthtechnologywasassumedtobethequality-adjusted life-year
(QALY),suchthattheheightofeachbookrepresentsthe incrementalcostperadditionalQALYprovided
bythetechnology.Thebooksarestackednexttoeachotheralongthebookshelf(thex-axisofFigure19)
andsortedsothatthemostdesirabletechnologies(representedbytheshortestbooks)areatthefar left
ofthebookshelfandthe leastdesirabletechnologies(thetallestbooks)areatthefarright.Withafixed
healthbudgetnotalltechnologiescanbefunded. Inchoosingwhichtechnologiestofund,thedecision-
makermaximisesthevalueproducedbythehealthsystembyfundingthetechnologyatthefar leftofthe
bookshelffirst(technologyA in inFigure19).Thedecision-makercarriesonfundingeachtechnologyto
itsright inturn(B,C,D,etc.)untilthebudget isspent.The leastdesirabletechnologytobefunded(G)
isreferredtoasthe‘marginal’technology.
Asthehealthsystemhasafixedbudget,fundinganynewtechnologywill inevitablydisplaceoneormore
existing,fundedtechnologies.Forthepurposesofthisexplanation,weassumethatthehealthsystem’s
objective isto improvepopulationhealthwiththeavailablebudget.Hence,anewtechnologywillbe
fundedonly if itprovidesmoreQALYsthanareforgonethroughthedisplacementofcurrentlyfunded
$ per QALY for
each technology
Budget
Total health
expenditure
A B C D E F G H I J K L
FIGURE 19 The cost-effectiveness bookshelf. Republished with permission of SAGE Publications, Inc., from
Determinants of change in the cost-effectiveness threshold, Paulden et al.333 vol. 37, iss. 2, 2018; permission
conveyed through Copyright Clearance Center, Inc.
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technologies. For a new technology to do this it must produce more QALYs per pound spent than the least
valuable technology that is currently paid for. In our bookcase example, a new technology must have a
cost per QALY (ICER) that is equal to or better than that of technology G, the marginal technology, if it is
to produce more QALYs than it displaces. Hence, the health system budget provides an implicit value of
health – the ICER of the marginal technology. This is the value that technologies, including personalised
medicine, must target if they are to be attractive to decision-makers.
Now consider the relationship between the test cut-off point and cost-effectiveness. In Figure 17 we
showed the four categories of test results: true positives and negatives and false positives and negatives.
Table 63 provides illustrative costs and QALYs associated with each of the categories. The rows CP1 and
CP2 provide the distribution of tested individuals between the four possible outcomes for the two different
cut-off points, CP1 and CP2. In the sixth column we report the expected costs and QALYs for the test
using CP1 and CP2. We can see that the expected cost of the test is £5000 using CP2 and £4400 using
CP1. However, the expected QALYs from the test using CP2 are also higher – 0.74 compared with 0.64.
From a population health perspective, is it worth moving from CP1 to CP2? We know that, for this to
be the better-value choice, the incremental cost per QALY produced by this substitution must be lower
than the cost per QALY of the marginal technology. In our example, the cost per QALY of the marginal
technology is £50,000 (top right-hand cell in Table 63) and the incremental cost per QALY of CP2
compared with CP1 is calculated as follows:
ICER =
£5000− £4400
0:74− 0:64
= £6000 per QALY. (22)
As £6000 is considerably lower than £50,000, we would expect the implementation of the test using CP2
rather than CP1 to create more health than is displaced by the additional cost.
When using the cost-effectiveness decision criterion, the increase in population health is maximised by
including new technologies up to the point at which the ICER for the new technology is exactly equal to
the ICER of the marginal technology. Hence, in the cost-effectiveness framework it is possible to go further
than merely identifying whether or not a specific test cut-off point is good value. The framework can be
used to identify the most cost-effective cut-off point for a test. We describe how this is done in more detail
in Extending the method of Phelps and Mushlin for monitoring tests.
TABLE 63 Impact of changing cut-off points on cost and outcomes
Variable
True
positive
True
negative
False
positive
False
negative
Expected
value
Net monetary
benefit (£)
Value of
health (£)
QALYs 0.9 1 0.7 –0.5 50,000
Costs (£) 5000 500 8000 8000
Distribution CP1 0.45 0.3 0.05 0.2 27,600
Expected QALYs 0.405 0.3 0.035 –0.1 0.64
Expected costs (£) 2250 150 400 1600 4400
Distribution CP2 0.5 0.2 0.2 0.1 32,000
Expected QALYs 0.45 0.2 0.14 –0.05 0.74
Expected costs (£) 2500 100 1600 800 5000
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A framework for characterising personalised medicine technologies
The umbrella of personalised medicine covers a wide range of technologies and combinations of
technologies. Identifying the appropriate methods for the economic evaluation of a specific personalised
medicine technology will be significantly helped by a systematic approach to characterising the components
of the technology. In this section we describe a model for characterising personalised medicine technologies
in terms of their constituent technologies, for the purposes of economic evaluation.
As described in the introduction, the foundation characteristic of personalised medicine is a test of
the molecular, including genetic, characteristics of an individual or, or in the case of cancers, a disease.
For screening and diagnostic tests, this may be the sole component of the technology. However, for
prognostic tests and for test–treatment combinations, the technology will require combination of the
molecular information and clinical expression (phenotypic) data. Prognostic technologies inherently link the
molecular information to phenotypic information and, thus, are a combination of two testing technologies. The
magnitude of an individual patient’s health benefit from treatment is dependent on the phenotypic expression
of the disease. The relationship between the molecular characterisation of disease and phenotypic expression is
uncertain in even the monogenetic disorders such as Gaucher’s disease, in which homozygous twins have been
shown to have radically different times to symptomic presentation. In addition to the molecular and phenotypic
test components, some personalised medicine technologies may have an additional pharmacogenomic test
technology, to establish whether or not an individual will respond to the specific therapy, with HER2 (human
epidermal growth factor receptor 2) testing for Herceptin® (trastuzumab; Roche Products Ltd, Welwyn Garden
City, UK) therapy in breast cancer possibly being the most well-known example. The final potential component
of a personalised medicine technology is the treatment itself. Some technologies, such as Kalydeco® [ivacaftor;
Vertex Pharmaceuticals (UK) Ltd, London, UK], the gene-specific treatment for cystic fibrosis, are themselves
personalised medicine technologies, whereas others are more conventional treatments. However, their
economic evaluation will require consideration of at least the phenotypic expression test as well as possibly the
molecular data.
Figure 20 provides a graphical representation of this framework.
The framework allows us to highlight the potential for correlations between the different components
of a specific personalised medicine technology. For example, the effectiveness of treatment is likely to be
systematically related to phenotypic expression. This relationship may be positive or negative depending on
the nature of the treatment. For example, a treatment that stops further progression but does not resolve
accumulated disability will have a less valuable effect the greater the phenotypic expression; in contrast,
a treatment that resolves accumulated disability will have a more valuable effect in patients with greater
disability.
Changes in the phenotypic expression of the population targeted for treatment will change the case mix of
the patients to whom a pharmacogenomic test is administered, with potential implications for the test
performance characteristics of the pharmacogenomic test and, by extension, the expected effectiveness of
the therapy in ‘responders’ identified by that test. For cost-effectiveness analyses, understanding relationships
that impact on the expected magnitude of benefit are clearly central.
In the next section we describe how to identify the optimum cut-off point for a diagnostic test and
consider how this framework can be extended for a monitoring test.
Extending the method of Phelps and Mushlin for monitoring tests
Phelps and Mushlin335 use cost-effectiveness analysis to assess diagnostic technologies. In their work, they
describe how to identify the optimal test cut-off point for a diagnostic test that meets a prespecified
cost-effectiveness threshold. They consider a population in which each person has some probability of
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illness (f) and model the simple case in which a physician uses a dichotomous test to identify patients as
being either sick or healthy depending on the test diagnosis. It is, however, recognised that the population
in whom these diagnostic technologies are applied is heterogeneous and that the probability of each
individual being sick may vary.
The benefits and harms often associated with the use of diagnostic technologies depend on the true state of
health of the patients in whom these technologies are applied. However, it is unlikely for an individual’s true
health state to be observed and, thus, the actual patient benefits and costs will depend on how well the
diagnostic technologies identify these states of health. Ideally, tests will be optimised to identify individuals
but, as resources in every health system are finite, the goal is that the use of diagnostic devices will optimise
population health and this requires adding up the benefits and costs over the population eligible to use the test.
In developing the theoretical framework for assessing diagnostic devises, Phelps and Mushlin335 use the
following notation:
l f = probability that patient is sick
l p = sensitivity
l 1 – q = specificity
l UST(CST) = utility (cost) of sick person, treated
l USN(CSN) = utility (cost) of sick person, not treated
l UHT(CHT) = utility (cost) of healthy person, treated
l UHN(CHN) = utility (cost) of healthy person, not treated.
Using the above information and a predetermined cost-effectiveness threshold (g), they determine the net
benefit for a diagnostic technology and maximise this net benefit in an optimisation setting with respect to
the test performance characteristics, specifically p and q. Phelps and Mushlin335 define an expression for
the net benefit as:
NB = f Ust + (1−p) × Usn½  + (1 − f )½(1− q) × Uhn + q × Uht
− gff × p × C st + (1− p) × C sn½  + (1 − f )½(1− q)Chn + qChtg.
(23)
The combination of p and q that maximises the net benefit can be obtained by varying the diagnostic test
cut-off point used to establish the diagnosis (we can find combinations of p and q in which the net benefit
remains the same by taking the differential of Equation 23 and allowing p and q to vary jointly, but holding
the total change in net benefit to zero). For a given cost-effectiveness threshold, the optimal choice of p and
q that maximises the expected net benefit is given by:
dp
dq
=
(1− f ) × (ΔUH − g × ΔCH)
f × (ΔUS − g × ΔC s)
= βd. (24)
The slope βd corresponds to a cut-off point kd on the ROC curve for our diagnostic test technology of
interest. Using the costs and outcomes of treatments of false positives and false negatives obtained from
the literature, in addition to the ROC curve for our diagnostic test, a cost-effective test cut-off point can be
identified for a given threshold.
As part of this NIHR programme grant we have extended the work of Phelps and Mushlin335 The framework
developed by Phelps and Mushlin335 for a diagnostic test has been used to evaluate the same test, CA-125,
as a monitoring test. Specifically, Phelps and Mushlin335 consider a two-period monitoring test in which
clinicians readminister the same test to patients who are diagnosed as either positive or negative by the first
test (for the reason that these patients display a clear predisposition for the condition of interest). Using the
CA-125 test for monitoring for relapse in ovarian cancer, we show how the repeated use of the initial cut-off
point can lead to a substantially increased false-negative rate compared with the monitoring cut-off point –
over 4% higher in this example – with the associated harms for individual and population health.
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In this monitoring scenario presented by Longo et al.,330 each of the different subgroups of patients that
are retested have a systematically different prevalence (probability of being sick) in the period in which
they are tested compared with the initial population.330 The prevalence in the subgroups in the second
period depends on both the ability of the previous test to correctly classify patients as sick or healthy
and the probability of developing the disease in the time between the two tests. We argue that, if the
prevalences within the subgroups of the population that are being tested in the current period are unique
and different, then, likewise, the optimal combination of test performance characteristics that maximise
the net benefit among these subgroups will also be unique and differ from p and q of the initial test. As a
result, a unique cost-effective test cut-off point can be identified for each subpopulation on a ROC curve
that corresponds to their test performance characteristics. We illustrate this by first updating the prevalence
in Equation 23 to obtain the unique slopes in each subpopulation and then identifying the unique cut-off
points for each subpopulation, as shown below:
(1− f+ve subgroup) × (ΔUH − g × ΔCH)
f+ve subgroup × (ΔUs − g × ΔC s)
= βpositive sub−population (25)
dp
dq
=
(1 − f−ve subgroup) × (ΔUH − g × ΔCH)
f−ve subgroup × (ΔUs − g × ΔC s)
= βnegative sub−population. (26)
It is possible to build on this work to develop a framework that identifies the prevalence and the
corresponding optimal cost-effective test cut-off points for subgroups in the monitoring period for a set of
‘n’ administrations of the test. For simplicity, and ease of computational burden, we use a discrete set of
cut-off points between prespecified test score limits of 0 and 1. We obtain the optimal pathway for our
n-period monitoring using a backward induction approach in a dynamic programming setting.
We consider a monitoring regime in which individuals with or at risk of a disease of interest, presumably a
chronic disease, are followed for i periods. Those who are diagnosed as positive receive treatment whereas
those diagnosed as negative do not receive treatment and we continue to monitor both the positive and
negative subpopulations to the ith period. In each period, a physician decides on a test cut-off point [Tci,j,
where i refers to the monitoring period and j refers to a specific subpopulation within a period (thus, in
period n = 1, j = (1); in period i = 2, j = (1,2); in period i = 3, j = (1,2,3,4)] that will be used to test each
subpopulation. Assuming that Tci,j is measured on a continuous scale and lies anywhere between 0 and 1,
then individuals with test scores above Tci,j are diagnosed as positive and vice versa.
We considered a three-period monitoring regime. In this monitoring regime, a physician decides on Tc1,1 in
period 1 and the initial population is tested with this cut-off point. Individuals whose test score falls above
Tc1,1 are considered as our positive subpopulation and those with test scores below this are considered as
the negative subpopulation. In period i = 2, the physician decides on two test cut off points (Tc2,1 and Tc2,2)
that will be used to test the subgroups. The positive subgroup in period i = 2 is tested with a cut-off point
Tc2,1 whereas the negative subgroup is tested with a cut-off point Tc2,2. Based on the test diagnosis of each
individual in each of the two subpopulations, they are further stratified into four subgroups in period i = 3,
as shown in Figure 21, and the physician has to decide on the test cut-off point for each of these four
subgroups. Thus, for every ith period, a physician is faced with 2i – 1 subpopulations and decides the test
cut-off point that must be applied to each. In Figure 21, every positive subpopulation includes all of the
true positives and false positives whereas every negative subpopulation includes all of the true negatives
and false negatives. The utilities and costs associated with individuals in each of these test outcomes is
different [the utilities (costs) associated with true positives, false positives, true negatives and false
negatives are UTP(CTP), UFP(CFP), UTN(CTN) and UFN(CFN), respectively].
The prevalence of a condition varies under sequential testing and this compels a difference in test cut-off
points.330,336 In the period i = 1, the prevalence in the initial population can in most cases be obtained from
clinical experts, the registry or epidemiological literature.337 Longo et al.330 show that patients presenting for
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monitoring tests have a different prevalence compared with the general population presenting for the
initial test. They estimate the prevalence for the positive and negative subgroups in period i = 2 to be
r1 + (1 – r1) × ρ and (1 – s1) + s1 × ρ, respectively, where r1 and s1 represent the PPV and negative predictive
value (NPV), respectively, and ρ is the probability that a patient is sick when presenting for a test in period
i = 2, given that they were not sick when presenting for a test in period i = 1. Thus, the prevalence of a
condition in the current period is a function of the test performance characteristics in the previous period and
the rate of disease progression.
Developing on the framework we described in Longo et al.,330 consider the case in which individuals are
monitored for more than two periods. We define the following notations:
l i = the monitoring period
l j = set of subpopulations in period i
l fi,j = prevalence for the jth subpopulation in the ith period.
Thus, from Figure 21, we can see that at period i = 2, j = (1, 2) and fi,j = (f2,1, f2,2) and at period i = 3,
j = (1, 2, 3, 4) and fi,j = (f3,1, f3,2, f3,3, f3,4).
We also define k such that:
k = j+1/2∀ j that is odd
k = j/2∀ j that is even.
(27)
Given the above notation, the prevalence for a subpopulation j in period i can be generalised as:
f i, j =
pi − 1,k × f i −1,k + ½(1−qi − 1,k) × (1− f i −1,k) × ρ
pi − 1,k × f i −1,k + (1− qi − 1,k) × (1− f i − 1,k)
∀ j that is odd
and
f i , j =
(1−pi − 1,k) × f i − 1,k + ½(1− qi − 1,k) × (1− f i −1,k) × ρ
(1− pi −1,k) × f i −1,k + (1− qi −1,k) × (1− f i − 1,k)
∀ j that is even.
(28)
If i = 1 then we have the case of a diagnostic test. For i ≥ 2, we have a monitoring scenario. It must also be
noted that f1,1 is exogenous and can be obtained from the epidemiological literature.
First period Second period Third period +
+
–
+
–
–
+
–
–
+
–
+
–
+
1
2
4
3
2
1
FIGURE 21 Decision tree for a three-period monitoring test.
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For a two-period monitoring test, Longo et al.330 show how to calculate the disease prevalence for each
decision node of the second period using the PPV, the NPV and the disease progression rate from the first
period. In our model we generalise on the results published by Longo et al.330 and derive the formulas for
calculating the respective prevalence at each decision node when the monitoring test is administered
repeatedly in n periods. Then, we maximise the expected net benefits resulting from the repeated
administration of the test by finding the optimal test cut-off scores in each period.
Our illustrative model uses the dynamic programming method to calculate the optimal test cut-off scores
for a monitoring test with six periods. In this model the sensitivity and specificity are calculated at each
decision node, which can be achieved by estimating the distributions of the test scores for the sick and
healthy patients at the respective nodes. Next, we show an optimisation example for a monitoring test
administered in six periods (n = 6). Let the model parameters be denoted as follows:
l f = probability that patient is sick
l UST(CST) = utility (cost) of sick person, treated
l USN(CSN) = utility (cost) of sick person, not treated
l UHT(CHT) = utility (cost) of healthy person, treated
l UHN(CHN) = utility (cost) of healthy person, not treated
l g = inverse of the cost-effectiveness threshold
l ρ = rate of disease progression.
The parameters take the values reported in Table 64.
Furthermore, let TS , 0 ≤ TS ≤ 1, denote the test scores of sick patients and TH , 0 ≤ TH ≤ 1, denote the test
scores of healthy patients. We use beta distributions for TS and TH because the beta distribution is restricted
to values in [0, 1] and can be used to model distributions that are symmetric or skewed. Let TS ≈β(2,5) and
TH ≈ β(5,2) for all decision nodes in all periods. However, the model is developed such that the distributions
for TS and TH can be defined distinctly for each decision node.
To solve the optimisation problem and find the optimal cut-off points for each decision node in each
period, we have discretised TS and TH with the granularity 0.1. Thus, TS and TH ε {0,0.1,. . .,1]. Using the
backward induction method of dynamic programming results in the optimal cut-off points depicted in
Table 65.
Some observations on the estimation of the value of information for
monitoring tests
The methods that we have described in the previous section develop Phelps and Mushlin’s335 work to take
account of how the case mix of patients changes after each test administration. However, we assumed
that the ROC curve is the same for each test administration. However, it is known that changing the case
TABLE 64 Parameter values for the illustrative monitoring model
Parameter True positive (ST) False negative (SN) False positive (HT) True negative (HN)
QALYs 0.9 –2 0.5 1
Costs (US$) 500 800 400 0
g 1/50,000= 0.00002 f1 0.01
ρ 0.01
HN, healthy person, not treated; HT, healthy person, treated; SN, sick person, not treated; ST, sick person, treated.
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TABLE 65 Optimising cut-off points
Period
1 2 3 4 5 6
Decision
for first
period
First period
outcomes
Decisions for
second period
Second period
outcomes
Decisions for
third period
Third period
outcomes
Decisions for
fourth period
Fourth period
outcomes
Decisions for
fifth period
Fifth period
outcomes
Decisions for
sixth period
0.3 + 0.5 + 0.6 + 0.6 + 0.7 + 0.7
– 0.6
– 0.6 + 0.6
– 0.5
– 0.5 + 0.6 + 0.6
– 0.5
– 0.5 + 0.5
– 0.5
– 0.4 + 0.5 + 0.6 + 0.6
– 0.5
– 0.5 + 0.6
– 0.5
– 0.4 + 0.5 + 0.6
– 0.5
– 0.4 + 0.5
– 0.4
– 0.3 + 0.5 + 0.6 + 0.6 + 0.7
– 0.6
– 0.5 + 0.6
– 0.5
O
P
TIM
IS
A
TIO
N
O
F
M
O
N
ITO
R
IN
G
B
IO
M
A
R
K
E
R
S
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
1
5
0
P
e
ri
o
d
1
2
3
4
5
6
D
e
ci
si
o
n
fo
r
fi
rs
t
p
e
ri
o
d
F
ir
st
p
e
ri
o
d
o
u
tc
o
m
e
s
D
e
ci
si
o
n
s
fo
r
se
co
n
d
p
e
ri
o
d
S
e
co
n
d
p
e
ri
o
d
o
u
tc
o
m
e
s
D
e
ci
si
o
n
s
fo
r
th
ir
d
p
e
ri
o
d
T
h
ir
d
p
e
ri
o
d
o
u
tc
o
m
e
s
D
e
ci
si
o
n
s
fo
r
fo
u
rt
h
p
e
ri
o
d
F
o
u
rt
h
p
e
ri
o
d
o
u
tc
o
m
e
s
D
e
ci
si
o
n
s
fo
r
fi
ft
h
p
e
ri
o
d
F
if
th
p
e
ri
o
d
o
u
tc
o
m
e
s
D
e
ci
si
o
n
s
fo
r
si
x
th
p
e
ri
o
d
–
0
.5
+
0
.5
+
0
.6
–
0
.5
–
0
.4
+
0
.5
–
0
.4
–
0
.3
+
0
.5
+
0
.6
+
0
.6
–
0
.5
–
0
.5
+
0
.5
–
0
.4
–
0
+
1
+
0
.6
–
0
.5
–
0
.3
+
0
.5
–
0
.3
DOI: 10.3310/pgfar06030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Selby et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
151
mix of the population to which a test is applied will change the sensitivity and specificity and, thus, the
ROC curve for the test at second administration will be significantly different from the ROC curve for the
test at the previous administration and for the individuals who tested positive compared with those who
tested negative in the previous administration. Figures 22 and 23 illustrate how the data driving the
sensitivity and the specificity for the second administration of a test would differ from the data driving the
sensitivity and specificity for the first administration (strictly these figures are correct under the assumption
that there is no disease progression).
Perfect information for a diagnostic test can be characterised as being able to illustrate the distribution of
test scores for each true health state that the test is designed to measure. With this information for each
test score it would be possible to define the probability that an individual who received a particular score
was a true/false positive or true/false negative. Perfect information for a monitoring test requires the same
information plus knowing with certainty how many individuals will have progressed from a true-negative
state to a true-positive state in the time interval between the tests. This would allow the calculation of
sensitivity and specificity, assuming that the test score distribution for the new true-positive individuals is
the same as for the true-positive individuals at the time of the first administration of the test and, hence,
allowing the construction of separate ROC curves for the two groups defined by the initial test.
True-positive cases
False-positive cases
Test cut-off point
FIGURE 22 Data for ROC curve at second administration for test-positive individuals. Reprinted from Clinica
Chimica Acta, vol. 427, Horvath AR, Lord SJ, StJohn A, Sandberg S, Cobbaert CM, Lorenz S, et al. From biomarkers
to medical tests: the changing landscape of test evaluation, pp. 49–57, 2014,338 with permission from Elsevier.
False-negative cases
True-negative cases
Test cut-off point
FIGURE 23 Data for ROC curve at second administration for test-negative individuals.
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It follows that there are three distinct sources of uncertainty in a monitoring test:
1. test score distribution for true-positive individuals
2. test score distribution for true-negative individuals
3. progression rate from true negative to true positive.
The choice of the value of health used in the analysis plays a more complex role in the estimation of the
value of information for a monitoring technology than for an effectiveness parameter. This is because
it is the choice of the value of health that determines the cut-off point for the initial and subsequent
administrations of the test. In determining the initial cut-off point it determines the ROC curves for the
subsequent test administrations. This points to a much more complex relationship between the value of
health and the value of information than is observed for therapies.
Uncertainty about the true health state is unlikely to be evenly distributed across the range of test scores.
Extreme test scores (either high or low) are systematically less likely to be false positives/false negatives
than test scores in the mid-range. The implication of this is that the location of the initial cut-off point will
have a direct effect on the contribution of the test score distributions for true positives and true negatives
to the total value of information about the test performance. Furthermore, the choice of initial cut-off
point will have an impact on the degree to which disease progression can lead to a change of status after
the monitoring test and, hence, the value of additional research around this parameter.
Because of the pivotal role of the choice of the value of health in determining the initial cut-off point and,
hence, the value of further research, value of information analyses will be health system specific to an even
greater degree than is the case for research on the effectiveness and safety of therapeutic interventions.
For monitoring test technologies that are developed for multiple markets, it may be more efficient to
undertake substantial global pre-market studies that characterise all three parameters (test score distribution
for true-positive and true-negative cases and the rate of progression) in some detail as this may be more
efficient than multiple studies that target portions of the evidence base for each parameter.
Conclusions
The work described in this chapter and published in Longo et al.330 provides a new insight into the use of
biomarkers for monitoring tests when the principal evidence of benefit is the cost-effectiveness of the
health-care services that will be managed in the context of the biomarker test results. In future work,
rigorous study designs and careful attention to the choice of cut-off will be essential.
1. By applying Phelps and Mushlin’s335 framework to monitoring tests, we have shown that the test cut-off
point that is cost-effective in monitoring may be quite different from the one that is cost-effective in the
first administration of the test.
2. We show that the extent of this difference, and, hence, its importance to clinicians, patients and
decision-makers, depends on the underlying prevalence of the condition, the test performance
characteristics of the test at its first administration, the rate of disease progression and the interval
between test administrations, as well as the target cost-effectiveness threshold.
3. Decision-makers are likely to be interested in the impact of changing the cost-effectiveness threshold on
the optimal case definition cut-off value; hence, we present the cost-effectiveness threshold curve, which is
able to identify the optimal case definition cut-off value corresponding to each cost-effectiveness threshold.
4. The framework developed by Phelps and Mushlin,335 and extensions such as the ones that we have
described here, offer a formal decision-analytic approach to identify the cut-off points that optimise the
contribution of these technologies to population health in a given health-care system.
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Chapter 9 An overview and patient perspective on
biomarker-guided research
Introduction
Does a marker-guided strategy lead to better outcomes for patients? Despite a wealth of literature on the
development and validation of biomarkers, relatively few studies have directly addressed this question. The
best evidence to answer this kind of question comes from a pragmatic RCT looking at comparative clinical
effectiveness and cost-effectiveness. Few such trials have been conducted and there have been some
major disappointments. In oncology, one of the most active areas for biomarker research, McShane et al.32
concluded in 2005 that ‘the number of markers that have emerged as clinically useful is pitifully small’, an
uncomfortable conclusion that has been echoed several times over the subsequent decade.339–342 It seems,
therefore, that, despite a very active biomarker discovery process, researchers cannot yet claim that the
‘biomarker pipeline’ is working successfully in patient benefit terms.
In this chapter we pull together the salient conclusions of the work in Chapters 2–8, to provide an
overview from the perspective of both researchers and health-care professionals. However, in light of this,
we were keen to explore the patient perspective on our overview of the ‘state of the art’ in this field. The
main findings of the methodology workstream were distilled and presented to a group of patients and
family members and their opinions sought. This chapter also describes that exercise.
The technical language used in methodological writing tends to make the key arguments inaccessible to a
non-technical readership, so we decided to proceed in two main stages. In stage 1, the key points were
identified in discussion between this chapter’s lead author (JH) and two health researchers (MT and JanB),
chosen as they were experienced in patient and public involvement (PPI) but were not familiar with the
methodological literature on biomarkers or test evaluation. This initial step entailed extracting key messages
from nearly 100 pages of methodological writing. Jenny Hewison prepared a description of the main
findings, which itself ran to several pages; Maureen Twiddy and Janine Bestall read the original chapters as
well as JH’s summary and then, over three meetings, key concepts were agreed and provisional plans were
drawn up for how the material might be presented to patient and public representatives. In stage 2, the
points were first discussed with one of the programme’s highly experienced PPI representatives (JoanB) and
amendments made, before the agreed material was presented (by MT and JanB) to a group of patients
and family members from the Liver North patient support group.
Further details of the stage 2 work are provided towards the end of this chapter. The following section
presents the results of the stage 1 work. For completeness, it incorporates a few points that chapter
authors added after the PPI consultation exercise was completed; however, none of the additions was
substantive enough to change the key messages.
The starting point of workstream 1 was that a marker is a type of test, so that, when we took a close
look at the way that marker-guided strategies have been evaluated, we could draw on what is known
about evaluating tests. This is a well-trodden path: most of the basic principles of test evaluation have
been known for a long time. However, as the chapters in this section have shown, these basic principles
are not consistently applied to the evaluation of a biomarker-guided patient management strategy. The
impact of such oversight can be substantial, a reality that seems not to be widely appreciated. It may be
that researchers are unclear about the mechanisms at work, and few patients or members of the public
are likely to have ‘lifted the lid’ and questioned how the performance of a test may be judged. To ensure
that the planned PPI consultation was meaningful, therefore, it was necessary to ensure, first, that the
researchers had a good understanding of the workstream 1 outputs, in order for them to be able to
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explain in non-technical terms the background to the workstream 1 work, the results of the studies
themselves and also some of the implications. The stage 1 document was the means to that end and is
quite lengthy as a result. Methodologist readers may wish to skip the following section (and rejoin the
chapter on p. 164), as it will present them with no surprises and indeed they may find much of the
material self-evident.
Stage 1: understanding outputs from the methodology workstream and
agreeing key areas for discussion with patient and public representatives
This section begins by rehearsing a few terminological basics to ensure that there is enough common
ground for the discussion to follow.
The terminology being used is ACCE (analytical validity; clinical validity; clinical utility; and ethical, legal and
social considerations), which divides the research pipeline into labelled components: analytical validity is
followed by clinical validity, then clinical utility and, finally, ethical, legal and social considerations.340,343,344
Analytical validity,’A’, is about the quality of the measure used for the biomarker and how best to handle
the inevitability of measurement error. Analytical validity is in itself a complex construct, with three main
components: pre-analytical variability (the effect on samples of different storage conditions, transportation
times, etc.), analytical variability (differences between reagents, analysers, software, laboratory quality
assurance procedures, etc.) and biological variability (within-patient differences, reflecting samples collected
at different times of the day, times since the last meal, etc.). Assorted standardisation and calibration
procedures can reduce the variability from these sources, but never eliminate it, so estimating residual
measurement error is an important part of the ‘A’ phase of test development.
Clinical validity, here ‘C1’, is about the relationship between the measure and the clinical condition,
summarised using a variety of parameters. Measurement variability in the marker will necessarily set a limit
to the strength of any such relationship and, hence, to the achievable performance of a marker-based test.
l The case-definition threshold (the cut-off point on a continuous measure) is used to divide the tested
population into test positives and test negatives. Choosing a cut-off point always necessitates trading
off detection rates and false alarms. The balancing act may be data driven, for example using ROC
analysis to identify the cut-off point that minimises misclassifications, or there may be a policy-driven
focus on one parameter, for example the test must detect at least 60% of cases.
l The performance of the test at the chosen cut-off point can be reported using the familiar sensitivity
(how well the test performs in relation to cases) and specificity (how well the test performs in relation
to non-cases). ‘Test accuracy’ as conventionally calculated uses the same principles and essentially
reports the proportion of the total sample (cases and non-cases) correctly classified.
l If the sensitivity and specificity figures observed in one study are replicated in one or more very similar
studies, clinical validity (C1) is considered to have been established, justifying the use of terms such as
‘a validated test’.
Clinical utility, the second ‘C’ in ACCE, refers to information on comparative clinical effectiveness and
cost-effectiveness, information that is usually obtained in a pragmatic RCT.
The way that the ACC components of the pipeline work has major implications for the last component,
ethical, legal and social considerations, so consideration of ‘E’ is deferred until later in this chapter.
Other authorities have labelled up the stages of biomarker development in different ways, but the basic
notion of ‘a pipeline’ is widely accepted. Why then have so few clinically useful biomarkers emerged when
researchers have followed this pathway?
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Some of the answers to this question are familiar from the wider literature on evaluating tests. Evaluation of
marker-guided care often requires a test-and-treat strategy, with an associated increase in sample size, etc.
At its most basic level, ‘benefit’ from early identification and treatment depends not only on the effectiveness
of treatment – the usual consideration when designing a RCT – but also on the number of people who could
benefit if found, together with the ability of the test to find them. Standard treatment trials can take as read
the number of people who could benefit if found and the ability of the test to find them, as these are
incorporated into eligibility criteria and recruitment projections. ‘Test and treat’ trials on the other hand need
to include in their planning estimates – or assumptions – the number of people who could benefit if found
and the ability of the test to find them, including in their power calculations. If treatment as usual includes
existing tests or clinical decision rules, then it follows that studies of comparative effectiveness will need to be
larger still.
The working of the biomarker pipeline is returned to towards the end of the next section, following a brief
rehearsal of the complications entailed when a test is used for monitoring purposes. Most of the above
insights have come from methodological work on the evaluation of tests used for diagnostic purposes and
guidelines for researchers in this area have been available for some time. Our present interest, however,
lies elsewhere, namely in tests used for monitoring purposes, the evaluation of which has received, by
comparison, little methodological attention.
Monitoring tests
Consistent with the wider test literature, the use of biomarkers for monitoring purposes has been very
little studied, despite the widespread use of biomarkers in patient care. This section, therefore, begins by
revisiting some of the basic considerations entailed in a test-and-treat clinical utility evaluation, as described
in the previous section for a diagnostic test.
It is important in designing any clinical utility study to know the number of people who could benefit if
found. In the diagnostic context, the relevant figure is the prevalence of the condition in the sample at the
time of testing (‘time 1’). In the monitoring context, it follows that information is also needed on changes
in prevalence between test occasions.
And what about the ability of the test to find the people who could benefit from treatment? In a
diagnostic context, if the prevalence of the condition and the sensitivity of the test are both known, then
the number of cases detected can be calculated. Real cases, correctly detected, are called ‘true positives’
in test parlance. But not all of the people with positive test results will be true positives. Some will be ‘false
positives’ and their numbers can be calculated from the proportion of non-cases in the sample, together
with the specificity of the test. If no confirmatory testing is carried out, false positives will not be identified
as such and will not be returned to the monitoring sample. In these circumstances, all those testing
positive, that is, false positives as well as true positives, will be managed in the same way, but it would be
reasonable to assume that only the latter might be able to benefit. If the new management regime is
associated with the potential for any kind of harm (further tests of an invasive nature, treatment side
effects) then it must be remembered that false positives as well as true positives will be subject to these.
Any cases missed by the diagnostic test (the ‘false negatives’) will remain in the monitoring sample. Over
time, these will be supplemented by new ‘cases’, arising as a result of disease progression. To estimate the
number of cases in the sample on a subsequent monitoring occasion (‘time 2’), it is necessary to know
three things: the false-negative rate at time 1, the progression rate of the disease and the elapsed time.
Consequently, it cannot be assumed that prevalence at time 2 will be the same as that at time 1 – it could
be higher or it could be lower. The performance of the monitoring test will reflect these new circumstances
and the pattern will repeat itself over subsequent monitoring occasions.
The well-established route along the biomarker research pipeline does not readily generate all of the
information indicated above or make use of it in the design of clinical utility studies, such as a trial to
evaluate a monitoring strategy. Does this matter? If some figures are not available and plausible values
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have to be assumed, how much hangs on the assumed values being ‘about right’? And at what point in
the pipeline should health economic considerations be addressed? Enhanced monitoring or the initiation
of treatment for people unlikely to benefit will waste resources and can overburden health-care systems,
so simply widening the definition of who is eligible for enhanced care is seldom the best approach, even if
the enhanced regime is acceptable and relatively benign.
Workstream 1 aimed to address the above questions and help to bridge the gap between clinical validity
and clinical utility studies. Our topic was the design of pragmatic trials aimed at evaluating the clinical
utility of a marker used for monitoring purposes and our focus was the role of key test and patient
parameters in the design of such studies. We approached the task in a number of different ways, and
from a number of different academic perspectives, but some very similar messages emerged.
A case study
Chapter 3 asked if key test and patient parameters had informed published guidelines on the use of PSA for
monitoring prostate cancer recurrence. Little evidence of such a systematic approach was found. When to
test, for example, ‘appeared to be almost exclusively determined by standard follow-up schedules rather than
being based on any scientific evidence’. Although the potential for variation in measurements was usually
accepted by guideline developers, they showed little interest in the potential effect of such variation on the
interpretation of test results. Relevant evidence was not always available, but, even when it was available,
it was not always used. A systematic review of biological variation in levels of PSA found a mean variability of
20%. Based on this figure, it was calculated that, ‘to be 95% sure that a change in total PSA level is not the
result of random variation, the change needs to be around 50% of the previous measurement’.
This review was not, however, cited by any of the seven guidelines subsequently published. Recommendations
on when to take action were based on consensus statements or retrospective case series rather than on
calculations of optimal values for cut-offs and monitoring frequency in the target population.
Trial evidence
Chapter 4 asked if the RCT design had been successfully used to evaluate strategies for monitoring disease
progression or recurrence. Fifty-eight relevant trials were found, with the intervention usually taking the
form of adding an assessment to an existing schedule of care. The reviewers observed that, ‘although one
might expect both the rate of disease progression and the degree of measurement variability associated
with a given test to be taken into account when setting test frequency, test intervals were apparently
determined by convenience or by fear of missing a key clinical event’. The test strategy that delivers a high
detection rate (i.e. few missed key events) will inevitably also deliver false alarms, but in the published trials
‘[t]here was little acknowledgement of the potential for false-positive results’. The reviewers also noted
that many of the trials seemed to be underpowered. About one-fifth of the 58 trials were stopped early,
often because of a lower than expected event rate in the control groups. For these and no doubt other
reasons, ‘[o]nly a small proportion of trials reported statistically significant results for the primary outcome’.
The methodology literature
Chapter 5 found that the design and evaluation of strategies to monitor disease progression have received
relatively little methodological attention. There is, however, relevant work on the statistical analysis of
monitoring data and on the development and evaluation of screening strategies, with the starting point
for most approaches being quite a detailed understanding of how test results fluctuate in the absence of
disease progression or other ‘signals’ of interest.
How big does a change in marker scores need to be to justify clinical interest? In clinical validity studies,
if patient groups known to differ in clinically important terms show a marker score difference of a particular
magnitude, then consensus can emerge that that constitutes a ‘clinically important difference’. In analytical
validity studies, marker scores alone may reveal patterns of interest. RCVs are a way of quantifying score
fluctuations likely to occur in the absence of a real change in a patient’s underlying condition. Assuming that
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the statistics of the normal curve apply, then a difference between two results greater than the RCV is taken
to indicate that a real change has occurred.
Some work has been carried out on using score variability to develop decision rules, but in the absence
of a demonstrable link to patients’ clinical condition the contribution of ‘signal-to-noise’ approaches to
choosing a monitoring strategy will remain limited. Overall, there is little evidence that methodological
work has informed the functioning of the biomarker research pipeline.
Patient outcomes and monitoring
Chapter 6 explored two ways in which monitoring strategies may improve patient outcomes. If test results
do not influence patient management, then a testing strategy is unlikely to improve patient outcomes.
The purpose of introducing a new test needs first to be made explicit, however: is it to replace an existing
test on the grounds of improved accuracy, or reduced invasiveness, for example? Or is earlier diagnosis the
aim? Or identification of an ‘at-risk’ group who are to receive further investigation? The causal pathways
through which benefit is achieved are not necessarily simple in any of these circumstances, however, so
understanding how the relevant pathways operate and, if necessary, modifying the testing strategy in order
to optimise them, may be necessary if maximum patient benefit is to be obtained. Three key approaches to
structuring the problem in relation to tests for screening and for diagnosis were identified in the literature
and applied to tests used for monitoring, drawing on 58 previously identified trials (see Chapter 9, Trial
evidence) for illustrative purposes.
The focus of the first approach was the trade-off between benefits and harms under new testing regimes
compared with standard care, when tests are introduced for different purposes. This approach highlighted the
extent to which the impact of a monitoring strategy depends not only on the effectiveness of treatment, but
also on the properties and timing of testing and, hence, the extent to which the size and the management
of different subgroups of patients differ in practice between the new and the standard regimes. Prior to
conducting a RCT, these figures should be identified from pilot or feasibility studies.
In the second approach, a new testing strategy was considered to be a complex intervention and its
components were picked apart in those terms. Clinicians’ and patients’ trust in the monitoring protocol,
and their willingness to comply with it, were identified as important considerations that should not simply
be assumed, but should be assessed prior to a trial and, in some circumstances, should be the subject of
research in their own right.
Lastly, the circumstances in which a RCT for the evaluation of patient benefit was both necessary and
timely were scrutinised. Conclusions overlapped with those drawn in the two previous paragraphs: a RCT
may indeed be required to evaluate the net impact of a new monitoring strategy, because the latter is
likely to be exerting its effect via a network of individual mechanisms. However, that RCT will be most
informative if it is based on good estimates of important population, test and treatment parameters.
The first modelling study
The aim of the first modelling study (see Chapter 7) was to see if modelling could help identify a ‘best bet’
monitoring strategy for potential evaluation in a subsequent trial. The approach was to look at different
rules for defining a test-positive result and, on the assumption that true diagnostic status (‘caseness’) would
later be known, compare the different rules in terms of important indicators such as delay to diagnosis. The
statistical model that enabled informative comparisons to be made was found in sensitivity analyses to be
heavily reliant on detailed information about disease progression and test performance. In Chapter 7, the
latter was characterised in terms of two components: (1) measurement error and (2) between-individual
variability. The nature and role of measurement error and – in the biomarker field – its relationship to
analytical validity (‘A’) have been described earlier. Terminology is unfortunately not standardised in this
area, so here it also needs to be noted that between-individual variability is one way of characterising clinical
validity (‘C1’), as it refers to the variation in marker scores observed among individuals belonging –
according to a reference standard – to the same diagnostic category (e.g. cirrhosis or a particular fibrosis
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stage). Such variation within a diagnostic category is likely to be associated with overlap in the score ranges
observed in different categories, which in turn brings the potential for misclassification of individuals when
that is based on marker score – the conventional measure of ‘test accuracy’ characterises the performance
of a test essentially in terms of the overall amount of such misclassification.
Putting the disease progression and test performance parameters together, it can be seen that we are on
familiar territory, because together they determine the number of ‘cases’ in the study sample at a point in
time and also the biomarker test’s ability to identify them.
Regarding the test performance parameters, available information on ELF, generated through the traditional
research route, proved to be insufficient for comparison purposes. On disease progression, longitudinal
descriptive data were needed and even cross-sectional prevalence information would not have sufficed.
Using the simulated data to compare monitoring strategies for liver fibrosis, it was found that a simple
threshold case rule performed very well. A more complex rule using linear regression to summarise
changes in score over time did perform marginally better, but would have been potentially more difficult to
apply in practice. It was emphasised that these comparisons did depend on the assumptions made. For
example, tests that show only limited within-individual variation in their scores lend themselves to rules
that incorporate changes over time, whereas comparison with a simple threshold is more meaningful for
tests generating less stable scores.
The second modelling study
Because of its dependence on the ELUCIDATE trial, the details of this study are provided in the workstream 3
section of this report (see Chapter 21). However, most of the results were available in time for the workstream 1
patient consultation exercise, so key points are reported here. In this simulation study, the measure of success
of the monitoring strategy was not time to diagnosis, but time to severe complications. Reference standard
diagnostic information is not available in many monitoring contexts, so cannot be used to check the clinical
validity of the test or be the determinant of patient management. This was the case in the ELUCIDATE trial and,
furthermore, any ‘diagnostic’ information that became available would be defined differently in the two arms of
the trial: clinically in the control arm and using the ELF test in the intervention arm. Consequently, test accuracy
considerations were not part of this simulation. In addition, the clinical utility of any test-and-treat strategy is
dependent not only on successful diagnosis but also on successful treatment, so simulating the success of the
monitoring strategy as evaluated in the trial required the modelling of patient outcomes. The 2015 Health
Technology Assessment report on non-invasive liver biomarkers noted the value of this approach, on the
grounds that it would provide a hard end point without the need for liver biopsy.345
The key modelled relationship – as in the previously published ELF data – was between ELF values and the
rate of development of severe complications. Measurement error and the test performance of the ELF
test would have contributed to that initial relationship, so were understood to take a similar role here
and, hence, were not specifically addressed in the simulation, although the success of that approach does
depend on the these parameters remaining similar in the two settings. In planning the trial, a cut-off point
of 12.5 on the ELF test was initially adopted as the marker-defined ‘diagnostic’ threshold, but, as a clearer
picture emerged of the ELF value distribution in the trial population, a decision was taken to adopt the
lower value of 9.5 to define an ‘at-risk’ subgroup, eligible for enhanced care.
In this study, trial participants’ time to severe complications was modelled, using early information from
the trial itself. In the ELF arm, the initial distribution of ELF values, together with the observed cumulative
incidence of above-threshold scores), was used to model the relationship between a starting ELF value
and the likelihood of passing the threshold of 9.5 after a given period of time. In the control arm, the
relationship between starting ELF values and the observed cumulative incidence of clinically diagnosed
cirrhosis was modelled, as well as the relationship between clinical diagnosis and concurrent ELF values.
Previously published data on the relationship between ELF ranges and time to severe complications were
then used to model the occurrence of the latter in the two arms of the trial. An assumed treatment effect
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was then applied to all ‘diagnosed’ patients and the two simulated arms were compared over different
durations of follow up. This simulated trial enabled the achieved power of the actual trial to be calculated
and provided an illustration of how the approach could be used for designing future trials.
Measurement error and test accuracy were both indirectly incorporated into this simulation model through
the association reported in the literature between ELF values and the subsequent rate of development of
cirrhosis. Subject to certain assumptions, therefore, it could be said that the traditional research route had
provided enough of the evidence needed to plan a trial. It was, however, clear that it would have been
preferable to have information on key change parameters available, including those relating to sample
composition, prior to designing a trial, ideally in this case from a cohort study incorporating sequential ELF
values. The conclusion about the need for better longitudinal data in order to model the likely numbers of
‘test positives’ more accurately is similar to one drawn in the first simulation study.
The third modelling study
In Chapter 8, a third modelling study had a different focus again. It was conducted from a health
economic perspective and specifically addressed how to optimise the benefit to patients when using an
imperfect test for monitoring. The starting point for such an exercise is that the anticipated effects on all
four outcome groups of testing (true and false positives, true and false negatives) need to be included in
the calculation of benefit. It follows that the number in each of the groups also needs to be known and
that these numbers will depend not only on the numbers of actual cases but also on the definition of a
test-positive result in terms of a threshold score.
In the context of diagnostic testing, the academic literature already contained a method for choosing
a cut-off point in such a way that it would maximise overall patient benefit, taking into account the
consequences for patients and budgets of incorrect as well as correct diagnoses. The third modelling study
applied these methods to the different needs of monitoring tests and in so doing highlighted once again
the importance of understanding how sample composition is likely to change over time.
Health economists can make reasonable estimates of the benefits and the harms, as well as the costs,
consequent on each of the four possible outcomes of testing, namely that the patient has the tested-for
condition and is correctly identified, the patient has the tested-for condition and it is missed, the patient is
well and is correctly identified as such or the patient is mistakenly diagnosed as having the condition.
The overall benefit to the patient population of different testing strategies is calculated by multiplying
these ‘per-patient’ figures by the numbers of patients in the four outcome categories. These numbers
will change according to the cut-off point used for the test, but also, and crucially, they depend on the
proportion of patients in the tested sample who actually have the condition. It follows that the optimum
cut-off point is sample dependent, because the lower the prevalence of the condition in the sample, the
higher will be the proportion of ‘false alarms’ among the patients identified by the test as having the
condition. How then might the composition of a monitored patient cohort change over time? And what
would be the implications for the optimum cut-off point for the monitoring test?
First, the optimum ‘diagnostic’ threshold was calculated, using the best available information on test
accuracy and the consequences for the four resulting categories: true and false positives and true and false
negatives. Considering first the patients not identified as having relapsed (the ‘diagnostic test negatives’)
at that time point, it could be anticipated that, at any subsequent surveillance point, this sample would
contain a mixture of patients who had stayed well, new cases of cancer and cancer cases missed (‘false
negatives’) at the earlier administration of the test. Estimating the numbers of new cases required
information on the rate of disease progression as well as the time elapsed since the previous testing,
whereas estimating the numbers of previously missed cases drew on knowledge of the accuracy of the
diagnostic test, in particular the likelihood that a test-negative result would prove to be correct (a test
parameter known as the NPV). Under plausible estimates of these values, the sample at the second testing
occasion might have a higher or lower disease prevalence than the sample at the time of ‘diagnostic’
testing. A new optimal ‘monitoring’ threshold could then be calculated, reflecting the new prevalence value.
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If the next step for the ‘diagnostic test-positive’ subgroup (i.e. patients identified as having relapsed
according to the initial test) was to be continued monitoring, equivalent calculations could be performed,
but would produce a different optimum cut-off point. It was noted that, in principle, the approach could
be applied to monitoring across multiple occasions.
The potential of a value of information approach was explored towards the end Chapter 8. For a
diagnostic test, ‘perfect information’ consists of the distribution of test scores in ‘cases’ and ‘non cases’.
This information can be used to calculate the probability that a patient with a given test score has been
correctly classified, noting that uncertainty about the patient’s true health state will be systematically
greater for mid-range test scores than for extreme ones. Putting this argument in slightly different terms,
misclassification rates are likely to be greater for mid-range test scores than for very low or very high test
scores. As mid-range scores are also going to be more affected by the choice of cut-off point (choosing a
lower cut-off point, for example, will increase the number of mid-range scorers testing positive), it follows
that the distribution of uncertainty between the test positives and the test negatives will vary according to
the cut-off point adopted.
In the monitoring context, true disease progression data are required, but additional testing complexities
also need to be considered. First, the distribution of test scores in the new cases may differ from that
observed in the cases present on the first testing occasion. Second, the likelihood that a previously
test-negative individual will have become a test-positive individual will depend not only on their true change
in health status, but also on how likely it is that their test score will have crossed the relevant cut-off point
boundary, which in turn depends on where that boundary is set. Adoption of a low cut-off point on the first,
‘diagnostic’ occasion will lead to a reduced likelihood that such a stringently defined subgroup will have
changed its real status the next time around, that is, it reduces the value of information in the monitoring of
originally defined test negatives. Finally, as the modelling reported earlier in Chapter 8 showed, the optimum
cut-off point will always reflect the chosen value of health, suggesting a very complex relationship between
the value of information and the value of health in the monitoring context.
Implications for the design of clinical utility studies
The literature reviews and the case study identified similar issues. The ways in which factors such as disease
progression rate, measurement error, choice of cut-off point and monitoring interval can affect clinical
utility – and, hence, trials to evaluate clinical utility – were then clearly illustrated by the modelling studies.
All three of the modelling exercises concluded that information on changes in the tested sample over time
would greatly improve the usefulness of the models. Disease progression is clearly a major element of
such changes and the need to characterise it could perhaps be regarded as self-evident: if the aim of a
monitoring intervention is to change the progress of a disease over time, then comparison data on the
progress of the disease in the absence of the intervention are clearly a prerequisite for evaluation purposes.
Disease progression data are not, however, provided by the conventional research pipeline, which may
partly explain why their importance has been persistently overlooked.
A trial of a marker-guided monitoring strategy will entail specifying that strategy in terms of thresholds,
monitoring intervals, etc. How, though, should those elements be chosen? And is it always necessary to
know who were the true ‘cases’ and who were not? Modelling study 2, and the trial in workstream 3 of
this programme, were based on identifying an ‘at-risk’ group rather than diagnosing ‘cases’ as such.
Patients were defined as being at risk in terms of ELF value ranges previously observed to be associated
with subsequent differences in patient outcomes. By applying an assumed treatment effect, a trial could
be modelled and its size calculated, based in the usual way on the amount of benefit that it was judged
important to detect. If the results of such an adequately powered trial suggested that it was clinically
effective and cost-effective to monitor with the threshold and the interval used, then it would be tempting
to conclude that the research pipeline was working. But how were the threshold and intervals chosen and
were they the best ones? Maybe the threshold adopted to define an at-risk group was too low, tipping the
balance too much towards detection of every possible case at the expense of increasing the numbers of
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false alarms? Maybe such frequent testing was unnecessary and longer intervals would have been perfectly
adequate? And what if no evidence of clinical effectiveness or cost-effectiveness was found? Where might
the explanation lie? And what would then be the way forward: more trials with different combinations of
thresholds and intervals?
Modelling studies 1 and 3 suggest that a different approach might produce better value from the trial’s
(clinical utility) budget. However, in addition to the disease progression information previously mentioned,
this approach depends on eventual knowledge of true ‘caseness’ and so would require more and better
test performance information (analytical validity and clinical validity) than the pipeline currently supplies.
If available, the information could be used to estimate the effects of different monitoring strategies on
patients much more precisely than is possible at present, enabling ‘best bets’ to be identified for subsequent
evaluation in trials. Better estimates of measurement error, for example, would contribute to increased test
accuracy, to reducing misclassifications and, hence, to increasing benefit (through fewer false negatives)
without disproportionate cost or harm (from treating the false positives who do not benefit).
It may be that part of the problem in the functioning of the biomarkers research pipeline is the prominence
given at the clinical validation stage to just two indicators of test performance: sensitivity (how well the test
performs in relation to cases) and specificity (how well the test performs in relation to non-cases). Both
metrics can be derived from the case–control studies that play a prominent role in test development and
initial validation, and it is perhaps insufficiently appreciated that people using tests in practice – and also
people evaluating test use in practice – are in a fundamentally different position. As in the ELUCIDATE
trial, if it is the test result that is intended to be used by the people making patient management decisions,
then test performance metrics will be needed that take that starting point into account. The test evaluation
literature identifies two such metrics, capturing, first, how many test positives turn out to be cases (the PPV)
and, second, how many test negatives turn out to be non-cases (the NPV). To illustrate how misleading
reliance on sensitivity and specificity can be in this context – and remembering that even a very specific
test will incorrectly identify a small proportion of non-cases as cases (i.e. it has a false-positive rate) – in a
low-prevalence sample (i.e. one mainly consisting of non-cases), the basic arithmetic of applying a small
percentage to a large number will result in many test-positive results being generated by non-cases and a
consequent lowering of the proportion of the test positives coming from cases. In a higher-prevalence
sample, arithmetic dictates that this proportion (the PPV) will be higher.
Applying the same logic to test negatives, in a low-prevalence sample, that is, one containing a small
number of cases, a reasonably sensitive test will miss very few of these and, hence, add only a very small
number of test-negative results to the large number generated by the non-cases. It follows that the
proportion of test negatives who are indeed non-cases – the NPV – will decrease as prevalence increases,
but also that this parameter will change very little across a range of low prevalence values. It also follows
that, in a low-prevalence sample, a lot of the people receiving treatment will not be able to benefit
because, even using a very accurate test with high specificity, although they tested positive, they were
in fact false positives. Lowering the cut-off point used to define ‘caseness’ will increase the number of
people testing positive, but without good prevalence data it is not possible to estimate what proportion of
the test positives have the potential to respond to treatment.
As explained, both PPV and NPV change with the composition of the tested population, that is, they reflect
prevalence, and that is why they cannot be calculated from case–control studies alone. With the correct
input parameters, modelling of all of these effects would enable a much more realistic picture to be built up
of the magnitude of benefit that could potentially accrue from a specific monitoring regime being applied to
a specific patient population, although it might also raise challenging questions about the rationale for the
monitoring intervals and the thresholds currently in use. From a research perspective, there would be clear
advantages in applying such a model to the design of a clinical utility trial.
Therefore, should funders insist on better longitudinal data – on disease progression in the population that
will be the subject of the trial and on how marker scores change over time? And what about the analytical
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validity of the marker as measured outside a research laboratory and test accuracy results, including PPV
and NPV, from a relevant population? Should these be required before funding a monitoring trial? At the
conclusion of the value of information section in Chapter 8, it was argued that the most efficient way
forward for monitoring technologies might be the improved characterisation of test score distributions in
cases and non-cases and of progression rates. The same could perhaps be said to those funding research
on the evaluation of monitoring technologies: extra time and effort spent on providing better-quality
information of this kind would almost certainly lead to a better-designed trial, and the overall research
duration and budget might not be very different.
Stage 2: obtaining patient and public perspectives
Establishing a shared understanding
Following a number of meetings between the three researchers to agree understandings and discuss
possible content, the key areas to be taken forward for discussion with PPI representatives were
identified as:
l assumptions about test development from the laboratory bench to the clinic
l variations in test scores within and between individuals (signal to noise)
l test accuracy (relationship to clinical condition)
l detection of cases and non-cases (sensitivity and specificity)
l prevalence of disease and using prevalence in interpreting tests
l rate of disease progression and its impact on treatment strategies
l development of treatment strategies to improve patient care
l development of guidelines and communication about tests between professionals and patients.
Initial presentation to patient and public involvement representatives
An initial meeting with a PPI representative (one representative was unable to attend) was held in Leeds on
31 July 2015. The key concepts of test measurement, accuracy, performance and interpretation were
highlighted in the context of the NIHR liver biomarkers programme. It was agreed that these issues were
important and interesting for patients and the public to discuss. Preparation for a future workshop with a
larger group of people was discussed.
LIVErNORTH workshop
Twelve people (nine women and three men) took part in the PPI workshop. A range of conditions was
represented, including:
l liver transplant (n = 3)
l primary biliary cirrhosis (n = 3)
l carers (n = 3)
l non-alcoholic fatty liver disease (n = 1)
l overdose with a potentially hepatoxic drug (n = 3)
l primary sclerosing cholangitis (n = 3).
It became clear from questions asked and from the discussion following the presentation that patients
were interested in methodological issues around biomarker evaluation. The group members understood
the concepts and asked sophisticated questions about the biomarker test development process. The key
discussion areas were as noted in Establishing a shared understanding.
Participants assumed that all parts of the biomarker pipeline from laboratory bench to clinic were equally
researched and considered. Any new biomarker test that was evaluated in a trial or implemented into a
service should be ‘fit for purpose’. Participants stated, ‘Don’t set up a test, then move on and think we’ve
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cracked it’. All aspects of test development and evaluation were thought to be equally important and
should carry a similar weight in the research pipeline.
Participants stated that it should be made clear what the level of accuracy of a test is in practice and also
the numbers of false positives and false negatives that the test produces. The signal-to-noise issue was
thought to be important and participants indicated that in their opinion only tests that reached a certain
level of performance should be taken forward for further evaluation.
The variation in test scores within and between patients was acknowledged, with several participants
offering examples of how their test results had an impact on their care. At least one carer had noted
fluctuations in test scores over time and he used these to monitor the patterns in the health of his partner,
concluding that they meant very little on their own. He readily understood the notion of a false-positive
test result and, when he thought about how particular test results could make a big difference to his
partner’s care, he was alarmed to think that the likelihood of such an outcome might not be well
understood by clinicians. Participants agreed that fluctuations in scores or changes in scores were poorly
explained by doctors if at all. The fact that snapshot ‘how you are today’ test results were used to guide
patient care and to instigate treatment changes was thought to be poor practice in the context of chronic
conditions. All agreed that tests should be part of a wider clinical assessment. With the advent of new
technology and the ability to monitor and log routine data it was thought that understanding patterns of
change within and between a cohort of patients with liver disease over a series of different points in time
was really very important. Participants could clearly extrapolate this example to other conditions as well.
Participants found it hard to believe that disease progression rates – of central importance to their
experience as patients – were not routinely available and routinely used for research purposes. They were
almost as taken aback by the lack of interest shown by researchers as well as clinicians in the practical
implications of test inaccuracy and were ‘astonished’ that the routine monitoring of patients was not
captured and made use of to support the assessment of new biomarker tests. Participants could pick up on
the notions of false positives and false negatives without any difficulty and, because the implications for an
individual (clinical but also psychological) of either sort of misclassification were very apparent, they expected
high standards to prevail at every stage of the biomarker pipeline.
Participants stated that it was important that all of the information required to interpret a test result, such
as variation in scores (signal to noise), accuracy, prevalence, performance in practice and evidence-based
treatment strategies, should be communicated to patients. Any information that was put into guidelines
should be developed with the involvement of patient and public representatives and someone with a plain
English remit. Any guidelines developed should be undertaken at a national level and should be reviewed
within a relevant time frame to account for regular updates. A lay summary should be available for patients
if they would like to know more information.
Participants stated that the way in which test results are communicated to patients needs careful
consideration and the involvement of patients and the public to make messages clear. The role of the doctor
in promoting good communication about any monitoring test and about the ‘possibility’ of there being
other interpretations and outcomes of test results should be part of their education programme. Participants
wanted to know about how accurate a test was and the chance of false positives and negatives. How such
results might have an impact on patients in an acute or emergency situation and a routine situation was
considered. Supported decision-making was advocated for both situations. Further awareness of these
issues involving patients and the public should be implemented, with careful thought being given to how
information is presented and the types of examples that are used. Participants clearly stated that decision-
making should be facilitated in partnership with health professionals.
Patient perspectives and the ‘E’ in ACCE
The ‘E’ in ACCE – the ethical, legal and social considerations attendant on biomarker testing – have not
been addressed in this account so far. Emphasis in the literature to date has been on the potential
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implications of test results, for example genetic tests for late-onset conditions, rather than on the quality
and efficiency of the research pipeline. But are there downsides for patients of the present, ‘let’s try it and
see’ approach to biomarker development? The PPI work reported here suggests, first, that quality and
efficiency matter to patients in relation to the research pipeline, as well as in direct care, and, second, that
the widely recognised right of patients to make their own trade-off between length and quality of life
when making treatment decisions may also need to be more consistently and transparently applied to
decisions about tests. The health economic approach provides very useful tools of thought here in its
explicit calculation of harms (physical and psychological) and benefits forgone, as well as the costs,
of over- and under-investigation and treatment.
Patients quite rightly expect trials to be well designed, but it could be argued that, with regard to some of
the aspects discussed here, they are not well served by the existing evidence pipeline. Research funding
mechanisms are currently ‘tuned’ towards traditional A and C1 work in laboratories, and towards clinical
trials, but descriptive longitudinal work is not currently attractive to funders, possibly because its contribution
to bridging the evidence gap is insufficiently appreciated. Secondary use of data collected for other purposes
may offer one practicable way forward.
Patient perspectives are returned to in Chapter 24.
The workstream 1 methodology studies were reported using the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) 2009 checklist.346
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Chapter 10 Biomarker pipelines: ensuring
clinical translation using renal cancer and kidney
transplantation as exemplars
This chapter highlights the main aims of the clinical translation workstream, provides the background tothis aspect of the programme and the clinical context and outlines the various elements of the work
undertaken, which is further described in detail in the following chapters.
Main aims of the clinical translation workstream (workstream 2)
Within the context of the overall aim of the programme to develop strategies to enable the rapid
evaluation and translation of promising protein biomarkers into the NHS for patient benefit with a main
focus on renal and liver diseases, workstream 2 focuses on the clinical biochemistry aspects, with the main
aim being to establish and maintain a multicentre sample and clinical data bank in CLD, renal cancer
and renal transplantation (RT), together with the development of a robust system for the evaluation of
promising emerging biomarkers and related assays, to facilitate rapid biomarker assessment prior to
large-scale trialling in practice within the NHS.
Within this, specific objectives were to:
l undertake systematic reviews of biomarker status in renal cancer particularly relating to prognosis and
in RT relating to acute complications and long-term outcome with a focus on DGF
l prioritise selected biomarkers for further evaluation at the multicentre level and develop and employ
validation strategies for technical validation of relevant biomarker assays, including determination of
significant pre-analytical issues
l design and undertake studies examining the clinical utility of the selected biomarkers within the
chosen disease areas and identify those biomarkers that justify evaluation in a clinical trial, leading to
applications for funding
l create a clinical sample and data resource to underpin studies within this programme but also to
facilitate future rapid and cost-effective biomarker evaluation, with the infrastructure and strategies
developed providing a blueprint for future similar studies in other disease areas.
Critical elements in the biomarker discovery and translation process
General concepts
With the massive investments in large-scale ‘-omics’ studies accompanying increased technological and
bioinformatics capabilities, our understanding of the molecular changes and mechanisms underlying many
diseases has increased dramatically. It is now understood that within a single disease phenotype or diagnosis
there exists underlying molecular heterogeneity, giving rise to previously unrecognised disease subgroups.
With this, there is a drive to use such information to tailor the treatment of each patient on an individual
basis, recognising the heterogeneity within a disease, variously described as ‘personalised’, ‘precision’ or
‘stratified’ medicine.347–351 Consequently, the development of ‘targeted therapies’ has revolutionised
treatment in many diseases, particularly many cancers.352 This vision is of course predicated on the use of
biomarkers to optimise all aspects of the patient pathway, from early and accurate diagnosis, to determining
the extent and activity of the disease and prognosis, predicting response to therapy allowing optimal
treatment selection and monitoring for treatment response/toxicity or disease progression. Using biomarkers
in this way has major potential benefits for patients and the NHS in terms of improving outcomes and
providing more cost-effective care, for example supplementing or replacing invasive or expensive procedures
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or imaging tests, improving patient safety and quality of life and avoiding unnecessary or suboptimal
treatment or toxicities. Interestingly, however, and using therapy-related biomarkers as an example,
although it extends to other biomarkers types equally, there are currently only 26 FDA-approved ‘official’
companion diagnostics, 10 of which relate to HER2 testing for trastuzumab (Herceptin), although there are
considerably more laboratory-developed tests (LDTs).352,353 The need to refine existing methods used in
economic evaluations of companion diagnostics to include additional characteristics of the test performance
itself given the increasing complexities has also been highlighted.354
Genomic analysis of tissue or cells is now routinely used not just in inherited diseases but increasingly
also in many cancers to allow the selection of specific targeted therapies. However, many routinely
measured biomarkers are proteins present in body fluids and as such remain the province of clinical
biochemistry laboratories. Protein biomarkers have the advantages of being comparatively cheap and easy
to measure, being relatively non-invasive and providing dynamic information. At the time of application
for this programme in 2008, the depth of knowledge being generated, as described above, and the extent
of its impact in terms of effectively revolutionising several aspects of patient care in some diseases areas
were not apparent, although expectations were high. Likewise, with the plethora of potential novel
protein biomarkers arising from the surge of discovery efforts in clinical proteomic studies, expectations
surrounding the introduction of new biomarkers to clinical practice were high. However, even in 2008 this
was accompanied by an increasing awareness that the translation of novel biomarkers into clinical practice
was not being realised. A pivotal reason for this was the absence of a clearly defined pathway linking
biomarker research to health services research, and this was compounded by the technical inadequacies of
some of the studies negating any likely translation of the findings. The stages in the ‘biomarker pipeline’
have been variously defined, as illustrated in Figure 24.
The dynamic nature of test evaluation in this pathway from biomarker to medical test is more apparent
when summarised as a cyclical process (Figure 25), as recently described by the Test Evaluation Working
Group of the European Federation of Clinical Chemistry Laboratory Medicine.338
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FIGURE 24 Linear depiction of the phases in the biomarker pathway. WS2, workstream 2.
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Certainly, in 2008, the necessary evaluative framework involving multiple stakeholders, including academia,
industry, health-care providers and regulatory authorities, and with wide-ranging considerations, including
technology transfer, cost-effectiveness, methodological workflows and regulatory hurdles, was not clear or
effective. Without a comprehensive evaluation framework, the route from stringent evaluation to clinical
implementation (including evaluation of the impact on outcomes) and the realisation of the substantial
potential of biomarkers to contribute to improving patient care and health service provision was recognised
to be at risk, with various issues highlighted from multiple perspectives, including those of academia and
industry.1–9,342,355,356 Encouragingly, though, the need for national strategies to overcome this was also
increasingly being appreciated at this time, for example by the NIH in the USA11 and by the Royal College
of Pathologists in the UK.12 This programme of research was essentially established to explore and address
some of these issues, with health economic and trial methodology covered in workstream 1 and workstream 3,
respectively, and with workstream 2 directed at exploring aspects of infrastructure related to sample banking
and assay validation and focusing on renal cancer and RT as exemplars for biomarker testing.
So has the situation changed in the intervening period and decreased the value of this programme? The
answer to this is a resounding no if the situation is reflected in the number of biomarker tests approved
or cleared for marketing by the FDA. In a recent report generated by the consultancy company Amplion
and using specific biomarker definitions, of necessity focused on FDA approval as this is the only agency to
make comprehensive information publicly available, the number of 510(k) clearances of biomarker-based
tests each year fell from just over 120 in 2004 to approximately one-third of this number in 2014.353
Premarket approval was granted in zero to fewer than five cases each year in the same time period.
Importantly, from 2003 to 2014, the average number of novel biomarker targets that went to market
in FDA-reviewed tests was only three and the average time from discovery to clearance/approval was
15 years, although this was highly variable.353 However, it should be recognised that this may be a large
underestimate overall as there are a considerable number of LDTs available that are currently in use
although not centrally registered.352,353 This situation is likely to change in the near future with proposed
Broader
impact
Clinical
performance
Clinical
pathway
Clinical
effectiveness
Cost-
effectiveness
Analytical
performance
FIGURE 25 Cyclical framework for the evaluation of in vitro medical tests. This framework illustrates that the
key components of the test evaluation process are driven by the purpose and role of using a test in the clinical
pathway. Reciprocally, the key test evaluation elements may influence or modify existing clinical pathways. The
outer circle linking the various elements of the test evaluation cycle highlights the interplay between the various
components and how, for example, analytical performance may impact clinical performance and, vice versa, how
clinical performance or effectiveness of a test may call for improved analytical performance and sets new analytical
goals for improving the clinical effectiveness and cost-effectiveness of the test–treatment pathway. Reprinted
from Clin Chim Acta, vol. 427, Horvath AR, Lord SJ, St John A, Sandberg S, Cobbaert CM, Lorenz S, et al., From
biomarkers to medical tests: the changing landscape of test evaluation, pp. 49–57,338 copyright 2014, with
permission from Elsevier.
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compulsory registration with the FDA. Additionally, many tests gaining European approval through CE
marking are not FDA approved, such as the ELF test, which is a central feature of workstream 3.
The perceived obstacles and pitfalls in taking a biomarker (or biomarker panel) along the pathway from
laboratory to clinic essentially remain the same in more recent studies as those highlighted in earlier
studies.338,357–361 Focusing on the laboratory and clinical biochemistry perspectives, some key aspects are
discussed further in the following section and form the subject of specific workstream 2 activities.
Specific laboratory-based/clinical biochemistry aspects
Although this programme covers the later parts of the biomarker pipeline, it is still appropriate to briefly
consider some of the issues that are particularly challenging in biomarker discovery and those that
contribute to the high level of biomarker attrition at the early stages. Particular technical challenges for
novel biomarker discovery in clinical fluids such as serum or plasma include the vast dynamic range of
protein concentrations, spanning a concentration of approximately 40–60 g/l for albumin to a concentration
of < 1 ng/l for cytokines, a range exceeding the analytical capability of proteomic technologies and
necessitating extensive fractionation/enrichment strategies, particularly with just 22 proteins constituting
99% of the entire plasma protein content.10 For urine, low protein concentration and high salt content
present challenges, although as approximately 70% of urinary proteins are thought to be kidney derived
it is an attractive alternative source of enriched biomarkers, particularly for renal diseases.362 However,
normalisation of results is an issue; creatinine is most commonly used although this is not ideal as it is
affected by many factors such as muscle mass and renal function. The results from many studies have
not been confirmed, with a major contributory factor being the poor initial study design. This includes
insufficient statistical power, inherent study bias because of a lack of attention to/awareness of potential
confounding factors and the impact of pre-analytical factors on sample quality, although such issue are
being addressed, with promising results emerging.358–361,363–366 To improve study design and reporting,
several guidelines have now been published in relation to diagnostic markers, such as the REporting
recommendations for tumour MARKer prognostic studies (REMARK)367 and the STAndards for Reporting
Diagnostic accuracy (STARD).368
Other factors preventing further progression include the lack of the necessary tools or resources, such as
the availability of suitable numbers of stringently collected clinical samples with the appropriate associated
clinical data, including long-term follow-up data, which can take years to accumulate. Biobanking is not
co-ordinated internationally, nor is there a complete central database holding such information about
available resources, although there are very good examples of integrated activities within certain disease
areas or countries, for example the Organisation of European Cancer Institutes (OECI) Pathobiology Working
Group,369 with its maintenance of the OECI-TuBaFrost exchange platform, the String of Pearls Initiative in
the Netherlands for CKD370 and specific large-scale more general and less disease-focused national initiatives
in the USA, Japan, Iceland, South Korea and China, for example.371 Similarly, examples of publications
describing specific biobanks and including indicators of the quality of the samples are relatively few, with
some notable exceptions, such as that from the Mayo Clinic in Arizona describing the RCC samples held
within the Multidisciplinary Genitourinary Diseases Biospecimen Bank,372 and, hence, awareness of potential
samples for validation purposes is limited. Encouragingly, given the importance of such resources, the impact
of sample processing protocols, pre-analytical factors and quality on biomarker research is increasingly
appreciated and the need for standardised approaches to processing, quality assessment and recording of
critical variables through initiatives such as SPIDIA (standardisation and improvement of generic pre-analytical
tools and procedures for in vitro diagnostics), BRISQ (Biospecimen Reporting for Improved Study Quality) and
SPREC (Sample PREanalytical Code) are promoted.363,373–375 Other aspects such as governance, ethical issues,
patient involvement, ensuring long-term social, operational and financial sustainability and the importance of
considering and collecting indicators of impact, all critical issues for funders as well as researchers, are also
assuming a higher level of prominence.371,376–380 Importantly, concerns over the issue of the underuse of
samples have been raised in a survey of 456 biobanks in the USA and this adds weight to the importance
of ensuring the visibility and accessibility of such resources to maximise their value and avoid the duplication
of efforts.381,382
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Gradually, these issues these are being addressed. Another bottleneck is the lack of appropriately validated
assays. Awareness of potential pitfalls in the level of validation of assays is increasing, including commercial
assays, and the need for consolidation/harmonisation and the appropriate use of guidelines for validation
is being highlighted.383–393 Additionally, a disjoin in many cases between the ‘discovery’ researchers and
laboratories and the test implementer laboratories, that is, the clinical biochemistry community with its
wealth of experience in using assays and knowledge of the level of performance needed in a routinely
available clinical test, has also contributed to the mismatch between expectations and delivery. Undoubtedly,
the decline in academic activities of clinical biochemists in the UK, driven by the pressures to deliver an
ever-increasing hospital workload and with little time to devote to biomarker-related research, has not
helped the situation.271,394 Thoughtful reviews by clinical biochemists and colleagues on biomarker
progression also add the perspective of the final implementation in hospital laboratories, not just in terms
of the need for evidence-based use but also in terms of the practical considerations important for routine
adoption and the reimbursement considerations.271,342,355
For the regulatory bodies there is a recognition of the need to be flexible and also to accelerate the approval
processes, particularly with the increasing emergence of multiplex marker panels, but also in terms of
retaining safety whilst not slowing drug development in the case of companion diagnostics.353,395,396 Efforts by
governments and funding bodies to increase the progress made in precision or stratified medicine generally and
biomarkers specifically are evident from initiatives such as the development of the infrastructure required to help
generate evidence on the clinical effectiveness and cost-effectiveness of a given in vitro test [e.g. MedTech and
In vitro Diagnostics Co-operatives (MICs)397 and the Innovate UK Medicines Discovery Catapult398]. In the USA
and spanning the whole of the biomarker pipeline, the recently established National Biomarker Development
Alliance is a trans-sector initiative addressing the issues of a ‘dysfunctional and disjointed status of biomarker
R&D [research and development]’ and aiming to develop widely accepted standards, best practices and
guidelines through an ‘end-to-end systems approach’.399,400
Establishing the pipeline in renal cancer and kidney transplantation
Renal cancer
Clinical context
Over one-third of a million cases of renal cancer are diagnosed annually worldwide, with > 143,000
deaths.401 In the UK, it is the eighth most common cancer, with ≈ 10,000 new cases annually, and the
incidence is increasing. For example, in the period between 1975–77 and 2009–11, rates have more than
doubled, increasing by 132% overall and by 168% in women.402 Occurring with a male-to-female ratio of
3 : 2, risk factors include smoking, obesity and hypertension. Most renal cancers (≈90%) are RCCs, cancers
arising from the renal parenchyma, with the most common histological subtype (70–80%) being the
conventional (clear-cell) RCC (ccRCC). Other main histological subtypes include papillary (10–15%),
chromophobe (5–10%) and collecting duct (< 1%) tumours and benign oncocytomas (2%–5%), arising
from various kidney cell types. Novel subtypes of RCC are continually being defined, largely on the basis of
morphology, although genetic characterisation is providing further insights, with > 24 subtypes of renal
cancer now included in the most recent Vancouver classification.403–405 Subtypes have broadly differing
clinical behaviour and underlying genetic changes although these are also heterogeneous and complex
within a subtype. Major increases in our understanding of the underlying molecular genetic and epigenetic
changes and the heterogeneity within the subtypes is leading to changes in the clinical management of
patients, with the most marked impact currently being in the development of targeted therapies.406,407
The majority of patients have few or no symptoms and a recent international prospective study involving
4288 patients with renal masses found that diagnosis was incidental in 67% of patients.408 Approximately
two-thirds of patients with RCC present with disease localised to the kidney and surgery or ablative
therapies are the standard treatment. Although largely curative, 30–40% of patients will subsequently
relapse. Renal cancer is inherently resistant to chemotherapy and radiotherapy and, for patients with
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metastatic disease or those at high risk and warranting adjuvant therapy, the increased biological
knowledge has led to the rational design of therapies targeting specific pathways. In the majority (> 80%)
of sporadic cases of the ccRCC subtype, the von Hippel–Lindau (VHL) tumour suppressor gene has been
implicated.409–412 A major role of the VHL protein relates to its role as a ubiquitin ligase, targeting proteins
such as members of the transcription factor hypoxia-inducible factor (HIF) family for ubiquitination and
subsequent proteasomal degradation. Loss of VHL protein function leads to accumulation of HIF with
consequent transcriptional activation and upregulation of genes including that coding for vascular
endothelial growth factor (VEGF). In the past 10 years, seven agents targeting VHL-related pathways
either through kinase inhibition or antibody-based targeting, namely sorafenib (Nexavar®, Bayer,
Leverteusen Germany), sunitinib (Sutent®, Pfizer New York, NY, USA), pazopanib (Votrient®, Novartis,
Basel, Switzerland), axitinib (Inlyta®, Pfizer), everolimus (Afinitor®, Novartis), temsirolimus (Torisel®, Pfizer),
bevacizumab (Avastin®, Genentech, San Francisco, CA, USA), cabozantinib (Cabometyx®, Exelixis Inc, San
Francisco, CA, USA) and lenvatinib (Lenvima®, Eisai Co, Tokyo, Japan) (in combination with everolimus)
have been approved for treatment of metastatic ccRCC.406,413 Several other genes have also now been
implicated along with epigenetic changes, which may lead to further insights into clinical behaviour and
therapeutic exploitation.404,414 Recent developments in immunotherapy with immune checkpoint inhibitors
based on antibodies to cytotoxic T lymphocyte-associated protein 4, programmed cell death protein 1 and
programmed death ligand 1 are also showing promise in RCC.415 As studies start to define the underlying
molecular changes in the non-clear-cell subtypes, it is likely that novel therapeutic targets may be
found.416–420 However, it is clear that no dominant driver gene equivalent to the VHL gene exists, although
the mesenchymal–epithelial transition (MET) factor gene represents a promising possibility in papillary
tumours.MET gene mutations are evident in only 12% of sporadic cases but copy number gain has been
found in 81% and 46% of type I and type II papillary RCCs, respectively, and MET protein is overexpressed
in up to 90% of cases.419,421–423 A range of tyrosine kinase inhibitors with activity against MET, including
crizotinib (Xalkori®, Pfizer), savolitinib (AstraZeneca, Cambridge, UK), capmatinib (Incyte Corporation,
Wilmington, DE, USA) and volitinib (AstraZeneca), are currently undergoing clinical trial or clinical trials
are planned.
Currently, no circulating biomarkers are routinely used in RCC although clear clinical needs have been
identified and such developments are a priority research area.424,425 Clearly, circulating biomarkers have
the advantage of being accessible and of being measured relatively non-invasively and are able to provide
information longitudinally, even prior to surgical or other treatment. Biomarkers could potentially have
an impact on the patient pathway by enabling earlier diagnosis, determining prognosis for stratification
of follow-up, detecting relapse and selecting patients for specific therapies by predicting response.
A particular challenge, in terms of both diagnosis and prognosis, relates to the management of small
renal masses (≤ 4 cm), up to 25% of which are benign, and the risks of surgery or ablative procedures,
particularly in elderly patients with comorbidities, have to be balanced against the risk and time frame of
progression of the tumour.426,427
At the time of submission of the application for this programme grant there were few emerging diagnostic
biomarkers or predictive biomarkers in RCC, although several prognostic biomarkers seemed to have
apparent potential utility and, hence, the focus was on prognostic biomarkers. We have recently reviewed
existing potential tissue and fluid biomarkers and there are now also some promising initial studies in the
areas of diagnosis and prediction of response to therapy.428 For example, urinary concentrations of the two
proteins aquaporin-1 (AQP-1) and perilipin-2/adipophilin have been shown in several studies by the same
group to be significantly elevated in patients with RCC compared with healthy, benign renal and surgical
control subjects, declining post nephrectomy.429–431 These findings have been extended to 720 patients
undergoing CT scans for a variety of indications using a newly developed ELISA for AQP-1, in which a ROC
AUC of 0.99 was achieved, although elevated concentrations were also seen in other malignancies.432
Clearly, these and some other markers show promise, but lack of the necessary level of evidence in terms of
numbers and sizes of studies, independent validation and availability of robust assays precludes a focus on
exploring these further within this programme at present. However, it is anticipated that such biomarkers
may be the subject of future studies utilising the sample banks assembled within this programme.
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Determining prognosis in renal cell carcinoma
The ability to stratify patients according to risk is highly desirable. Detection of relapse in patients with
localised disease is based on repeated imaging, in some cases with biopsy. This is expensive and has the
associated risks of cumulative radiation exposure and the potential morbidity associated with the biopsy
procedure. Although postoperative surveillance protocols have been developed, detection of relapse is
often not optimal and the ability to rationally guide the surveillance regimens on an individual basis and
also to identify high-risk patients for adjuvant therapy has obvious benefits.433 A critical determinant of a
patient’s prognosis is the stage of the cancer and currently this is determined using the TNM (tumour,
node, metastasis) system based on the extent of the primary tumour (T), whether or not local nodes are
affected (N) and whether or not metastatic disease is present (M).434,435 Other recognised independent
clinicopathological prognostic factors include tumour grade and the presence of necrosis and various
prognostic models or algorithms have been developed incorporating these and other factors.436 The
problems with these include the subjective nature of some elements such as tumour grade and the
grouping of patients into a limited number of risk groups, meaning that estimates of risk can be wide
for individual patients.437 This is exemplified in the widely used system for patients with localised disease
developed at the Mayo Clinic [Stage, Size, Grade and Necrosis score (SSIGN)], which integrates
pathological T stage, N stage, tumour size, nuclear grade and tumour necrosis.438 This divides patients into
low-, intermediate- and high-risk groups with estimated 5-year metastases-free survival rates of 97.1%,
73.8% and 31.2%, respectively. However, the challenge is being able to further stratify these patients,
particularly those placed into the intermediate-risk category.
For patients with metastatic disease, the most widely used clinical prognostic model is that proposed by
the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), which similarly groups
patients into risk categories depending on the number of poor prognostic features present (Karnofsky
performance status of < 80%, < 1 year from diagnosis to treatment, anaemia, hypercalcaemia, neutrophilia
and thrombocytosis).439 For the favourable-, intermediate- and poor-risk groups, median OS of 43.2, 22.5 and
7.8 months, respectively, has been reported.440
Preoperative nomograms that do not include histopathological features but that are based around
parameters such as age, sex, symptoms and CT-determined tumour size, T stage and metastasis have also
been developed, with the advantage of potentially being used to determine optimal treatment strategies
both surgically and in terms of neoadjuvant therapies.441 Tumour expression of selected proteins such
as B7 homolog 1 (B7-H1) protein, survivin and Ki-67 has been shown to have independent prognostic
significance for cancer-specific survival (CSS), either alone or within an algorithm ‘BioScore’,442 and to add
prognostic value to established clinicopathological models, including the Mayo Clinic SSIGN score.438 Other
similar examples with prognostic utility include Ki-67, p53, endothelial vascular endothelial growth factor
receptor-1 (VEGFR-1), epithelial VEGFR-1 and epithelial vascular endothelial growth factor D combined
with performance status and T stage and, in metastatic RCC, carbonic anhydrase IX (CAIX), phosphatase
and tensin homologue, vimentin and p53 combined with T stage and performance status.443,444 Recent
genomic and transcriptomic studies are adding to this, for example a 34-gene classifier, ClearCode34,445
assigns patients to good-risk (ccA) and poor-risk (ccB) groups and a 16-gene signature categorises patients
into low-, intermediate- and high-risk groups.446
In terms of circulating biomarkers, several routinely measured haematological and clinical biochemistry
factors, including the neutrophil–lymphocyte ratio (NLR), thrombocytosis, haemoglobin and serum sodium,
calcium and C-reactive protein (CRP) levels, have been found to be prognostic, as have several more
directly tumour-related proteins, including VEGF and CAIX – attractive possibilities in terms of their ease of
measurement, even preoperatively (reviewed in Chapter 12). Several of these have sufficient evidence to
justify their exploration in a large-scale programme of this type and in particular to determine whether or
not, as a multiplex panel or in combination with additional clinicopathological parameters or models, they
could provide superior performance to that of existing models.
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Kidney transplantation
Clinical context
Chronic kidney disease affects approximately 8–16% of the adult population, with this figure increasing
dramatically, at least in part linked to global epidemics in diabetes mellitus, hypertension and obesity.447–449 It is
estimated that 2–4% of people with CKD will eventually develop end-stage kidney disease (ESKD) and require
renal replacement therapy (RRT; dialysis or transplantation), with 2.6 million people receiving RRT in 2010 and
a similar number being unable to access it and dying prematurely.447 Kidney transplantation represents the
gold standard treatment for patients with ESKD, providing improved quality of life and survival compared
with commencing dialysis.450–452 A functioning kidney transplant is able to re-establish many of the important
functions that the kidneys perform beyond what dialysis can deliver. For example, the kidneys have important
endocrine functions in terms of the regulation of blood pressure and producing erythropoietin (EPO)
(stimulates red blood cell production) and activated vitamin D3 in addition to controlling electrolyte, acid/base
and fluid balance. It has also been recognised that kidney transplantation is of economic benefit to society
compared with treatment with dialysis.453,454 In the first year the cost of kidney transplantation is equal to
that of haemodialysis; however, in subsequent years the cost is halved. The average cost of maintaining a
patient with ESKD on dialysis is £30,800 per year. The cost of a kidney transplant is £17,000 per patient per
transplant, leading to a cost benefit in the second and subsequent years of £25,800 per annum. At the end of
March 2009, > 23,000 people in the UK had a functioning kidney transplant, saving the NHS over £512M for
that year in costs for dialysis that would have been needed if these patients did not have a functioning kidney
transplant.453 At a time of financial pressure in all health-care systems, this is an important aspect to consider.
There are a number of different sources of kidneys for transplantation. The current classification can be
broadly divided into deceased donor and living donor kidney transplantation, depending on the source
of the donor organ.455,456 Deceased donation is further classified as donation after brain death (DBD) and
donation after circulatory death (DCD). Kidneys donated after a circulatory death experience a longer period
of warm ischaemia (reduced blood flow) prior to surgical retrieval than kidneys donated after brain death.
The length of time between the surgical removal of the donated kidney and its implantation into the
recipient is a major factor in determining whether there is immediate kidney function or delayed kidney
function, referred to as DGF. Therefore, deceased donation is associated with a higher rate of DGF than
living donation and DCD kidney transplantation has a higher rate of DGF than DBD kidney transplantation.
Living donor kidney transplants are characterised as being genetically related between parents and children
or between siblings (living related) or genetically non-related between husband and wife, partners and
friends (living unrelated). More recently, there has been an increase in the number of altruistic donors
who wish to donate a kidney to anyone in society who is on the kidney transplant waiting list.
The need for kidney transplantation is far greater than the availability of organs. In 2012 there were
2998 kidney transplants performed in the UK; however, there are > 6000 people on the UK kidney
transplant waiting list.457 The reality is that people will die unnecessarily whilst on the waiting list for a
kidney transplant. Because of the ongoing shortage of kidney transplants the average waiting time for a
deceased donor kidney transplant is 2–3 years. There have been a number of initiatives to increase the
number of organ donors. These initiatives have included the recently introduced opt-out system in Wales,
where the assumption is that people are willing to donate unless they opt out, and accepting kidneys from
expanded-criteria donors (ECD).456 ECDs are defined as those aged > 60 years or aged ≥ 50 years with two
of the following: a terminal serum creatinine level of ≥ 1.5 mg/dl (132 µmol/l), a cerebral vascular accident
as the cause of death or a donor history of hypertension. Patients receiving ECD kidney transplants are
consequently at a higher risk of developing DGF. Pooled living kidney donation has been introduced to
allow pairs of kidney donors and potential recipients who could not donate to one another because of
immunological barriers to be matched with other pairs in the UK to whom they could donate.455 Further
advances in medicine have allowed kidney transplantation to occur across blood group and human
leucocyte antigen (HLA) incompatibility.458,459 The government has recognised the importance of kidney
transplantation and has increased the number of nurses specialised in organ donation to help identify
more potential donors.
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Unfortunately, kidney transplants have a finite lifespan. A number of factors determine how long a
transplanted kidney lasts.455,456 These include donor age and the nature of the donation, for example living
donation compared with deceased donation, immunological matching with respect to blood group and
HLA compatibility, baseline function of the donated kidney, immediate graft function compared with DGF,
the primary kidney disease and the health of the recipient. Overall, the average kidney transplant survival
times are about 95% in the first year, 85–90% at 5 years and 75% by 10 years.460 Living donor kidney
transplants have better long-term outcomes than those from deceased donors. This is in part because of
the controlled nature of the donor assessment and in part because of the reduced ischaemic time and
subsequent DGF.
Following kidney transplantation a number of complications can occur. The early complications are those
common to any surgical procedure, including postoperative chest or wound infection.461 Early postoperative
complications that are specific to kidney transplantation include renal vein thrombosis, DGF, AR and
calcineurin inhibitor toxicity. All of these complications result in a failure of the transplanted kidney to
function effectively. Renal vein thrombosis is detected on renal tract ultrasound scanning and is rarely
reversible, with devastating consequences. A kidney transplant biopsy is required to distinguish between
DGF, AR and calcineurin inhibitor toxicity. This procedure is not without risk and is resource intensive.
Non-invasive diagnostic techniques are needed to allow rapid diagnosis and appropriate treatment.
Delayed graft function
Overall, DGF has a higher risk of mortality, transplant loss, need for dialysis, kidney biopsy and increased
hospital stay.462,463 Management strategies promoting renal function post transplant have major implications
for patient benefit and resource savings.464 DGF is secondary to the ischaemia–reperfusion injury (IRI) that
follows retrieval of the kidney from the donor, with attendant loss of perfusion, and implantation into the
recipient, with restoration of perfusion. During this, the kidney is stored on ice and transported to the
designated kidney transplant unit. This period of time is referred to as the cold ischaemic time (CIT).
Generally speaking, the longer the CIT the more likely the kidney will experience IRI, which is manifest
clinically as DGF.
The multiple definitions of DGF have hindered the ability to characterise its incidence and outcomes.
As many as 18 definitions have been used in the literature.465 The most common definition proposed
has been the receipt of dialysis within 7 days following transplantation.462 However, this is still a crude
definition and holds back the opportunity to stratify different degrees of IRI and outcomes. Within this
programme, any analysis has used the following definitions and the creatinine reduction ratio [CRR =
(day 0 serum creatinine – day 7 serum creatinine)/day 0 serum creatinine]: immediate graft function, in
which there is a significant and sustained fall in serum creatinine within the first 48 hours (CRR ≥ 0.7),
slow graft function, in which serum creatinine fails to fall significantly in the first 48 hours but the patient
does not receive dialysis in the first week (CRR < 0.7) and DGF, in which the patient receives dialysis in the
first week except for isolated hyperkalaemia.
Delayed graft function ranges from 5% to 50% following deceased donor transplantation and depends on
many factors.466,467 Not surprisingly, DGF is significantly lower in live donations, at 4–10%.468 As previously
described, the variations in the reported incidence will depend on the definition of DGF that has been
used.469 The United Network for Organ Sharing database470 recorded a rate of DGF in US patients of
21.3% in early 2011. A number of donor and recipient factors have been identified as contributing to the
development of DGF. There has been an attempt to develop risk calculators for DGF.471,472 These factors
can be categorised as recipient-related factors, including sex, ethnicity, previous transplantation, presence
of diabetes mellitus, HLA mismatch, peak panel reactive antibodies, previous blood transfusions, body
mass index (BMI), duration of dialysis before transplantation, or donor-related factors, including donor age,
CIT, warm ischaemic time (WIT), DBD compared with DCD, presence of hypertension, baseline serum
creatinine level, cause of death and weight.462,471–475
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Delayed graft function is extremely important as an independent risk factor for both early and late kidney
transplant loss and higher mortality.22,476,477 DGF lasting for > 6 days strongly decreases long-term transplant
survival.24 It has been proposed that the kidney donor type may be more important than current DGF
definitions in understanding the impact of DGF on longer-term outcomes. This is corroborated by the fact
that the prediction of poor outcomes associated with DGF is largely independent of many of the definitions
in use and provides further support for the stratified approach to defining DGF that is proposed.469 It has
been shown that the severity and duration of native acute kidney injury (AKI) secondary principally to IRI
predicts the risk of CKD.478 There are obvious parallels between DGF and AKI but with the caveats that there
are other factors at play, such as immunological responses and immunosuppressant medications.462
Delayed graft function is associated with other adverse outcomes such as AR.23 AR is more likely to occur
during an episode of DGF because of increased exposure of donor epitopes and has a significant impact on
kidney transplant survival.479 It is, therefore, important to identify the underlying cause of the DGF following
kidney transplantation. It is usual to perform a kidney transplant biopsy to confirm the histological diagnosis
of tubular injury from IRI and exclude the possibility of AR. The clinical management of DGF requires close
attention to detail, with appropriate management of patients’ medication, acid/base, electrolyte and volume
status. There can be a risk of volume overloading of patients, particularly if they are oliguric. The dose of
specific immunosuppressants, for example calcineurin inhibitors, is usually lowered in the setting of IRI
because of their vasoconstrictive effects, whereas in the case of AR the dose of immunosuppressants
is increased.
In summary, the early identification of DGF and the specific underlying pathology has significant potential
to improve immediate patient management, allowing fluid volume status optimisation and timely
appropriate dialysis and the avoidance of unnecessary investigation and treatment.480 With the increased
use of donor kidneys from deceased donors and ECDs to meet the demand for transplants there is a
concurrent need for new biomarkers to improve the assessment of the quality of donated kidneys prior to
transplantation and enable more objective decisions to be made about viability. The opportunity to stratify
patients and identify those with significant IRI may allow the individualisation of immunosuppressive
regimens (e.g. the avoidance of or use of lowered doses of calcineurin inhibitors) at an earlier time point,
which may in turn result in improved longer-term outcomes. Similarly, improved monitoring of kidney
function or prediction pre or post transplant, earlier diagnosis of early postoperative complications such as
DGF or AR or longer-term prognostic information would allow earlier intervention, avoidance of biopsies
and tailoring of longer-term immunosuppression. Efforts to identify novel biomarkers of DGF to improve
the use of serum creatinine are increasing and potential new biomarkers are reviewed in Chapter 12.
Overview of the work undertaken in the clinical translation workstream
to develop and use these pipelines
An overview of the activities and key deliverables of workstream 2 is shown in Figure 26.
Sample banks and clinical data
Essentially to overcome the inherent inertia in the later stages of the biomarker pipeline, where often readily
available sample sizes are inadequate to provide sufficient statistical power, sample collection has been
inconsistent, clinical data may be incomplete and follow-up time is not mature enough to produce enough
events, a key element of workstream 2 was the assembly of fluid samples together with associated clinical
data, including long-term follow-up data, from cohorts of patients with CLD, renal cancer or ESKD undergoing
RT, the last two being major areas of interest in Leeds. This will provide a valuable underpinning resource for
this programme and future collaborative biomarker studies aimed at evaluating whether or not specific
putative novel biomarkers are likely to benefit patients and health services. This has been achieved through the
RCT in workstream 3 for liver diseases using cross-sectional sample collection and through involving centres
across the local research networks in longitudinal and cross-sectional sampling for RT and renal cancer (10 and
11 centres, respectively) and is described in detail in Chapter 11. In total, this has involved 1967 patients and
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149 healthy volunteers and 5976 sample time points, with many of these sample time points also including
multiple sample types being banked such as serum, plasma and urine and each sample being stored in
multiple aliquots to maximise future use. Standard operating procedures (SOPs) were used for the collection
and processing of samples and data were collected using specific case report forms (CRFs), managed by the
Leeds Clinical Trials Research unit (CTRU), with samples shipped to Leeds and ultimately stored within a
licensed research tissue bank (RTB) to maximise future use and benefits. The theoretical advantages to this
and the level of stringency are, thus, similar to those of a clinical trial (Figure 27).
These prospective samples provide the ability to evaluate biomarkers in the following contexts:
l CLD – identification of patients at risk of the subsequent development of cirrhosis and major liver events
such as HCC
l renal transplantation – prediction/earlier diagnosis of patients with acute post-transplant complications
such as DGF or AR and prognostic stratification for long-term outcomes
l renal cancer – prognostic stratification and longitudinal monitoring with other possibilities including
diagnosis and prediction of response to therapy
l healthy control subjects – enabling determination of reference ranges and effects of factors including
sex, age, ethnicity and diet.
Biomarker prioritisation, assay validation and evaluation of clinical utility
Focusing on the renal diseases, the identification of potential biomarkers to evaluate currently was based on
our ongoing discovery activities relating to novel biomarkers, a systematic review of the relevant literature,
which is the focus of Chapter 12, and approaches from other groups. A certain level of evidence must have
existed already (e.g. significant independent association with prognosis), with selected biomarkers already
having been the subject of initial validation studies and agreed by a subpanel of applicants to be of suitable
scientific quality. When promising biomarkers exist but with a lower level of evidence or requiring further
technical assay validation, further evidence has been sought in some cases using our own local Leeds
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FIGURE 26 An overview of workstream 2. Key activities and deliverables are shown together with the inter-relationships
with workstream 1 and workstream 3. NEQAS, National External Quality Assessment Service.
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multidisciplinary RTB. This phased approach ensures independent validation (or failure to validate) whilst
conserving the NIHR programme-related samples for final multicentre validation studies and ultimately
biomarkers emerging from this would be the subject of future clinical trials similar to that described in
workstream 3. This strategy is illustrated in Figure 28.
Within the time frame of this programme, assays for several potential biomarkers prioritised following
systematic review have been systematically evaluated and validated, including in some cases analysis of
specific pre-analytical aspects, as described in Chapter 13. Following this the prognostic use of serum and
plasma VEGF, plasma osteopontin (OPN) and CAIX and serum CRP, alone or in combination, together
with extensive clinicopathological variables, have been explored in RCC and this is reported in Chapter 14.
In RT, suitable promising biomarkers have been similarly prioritised and, once the outcome data are mature
enough in the next 2–3 years, appropriate studies will be taken forward.
An integrated approach to sample banking and data collection
Leeds NIHR
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   electronic form
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FIGURE 27 Schematic of the integrated approach adopted within the programme to sample banking and clinical
data collection. GCLP, Good Clinical Laboratory Practice; HTA, Health Technology Assessment.
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FIGURE 28 The phased approach to biomarker validation with evidence-based progression and utilisation of
sample banks depending on the stage of the biomarker. HTA, Health Technology Assessment; LTHT, Leeds
Teaching Hospitals NHS Trust; RfPB, NIHR Research for Patient Benefit programme.
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Additional deliverables
The deliverables relating to the activities described above are summarised in Chapter 15, additionally
highlighting others including industry partnerships, academic collaborations, generation of intellectual property,
the additional utilisation of the RTB and plans for long-term sustainability of the resources generated.
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Chapter 11 Establishment of multicentre
prospective observational cohorts with sample banks
for biomarker validation
This chapter describes the development of three multicentre prospective observational cohorts, withhigh-quality biospecimens, in RCC, RT and liver disease. These cohorts have been established to enable
the rapid clinical validation of new biomarkers, as exemplified in Chapter 14. In addition to providing a
summary of the final cohorts, this chapter details and discusses the issues pertaining to study design,
management and governance, providing some generalisable learning for future researchers establishing
similar resources.
Disease areas
Patients were recruited to provide samples and data for future biomarker research from the major
diseases under study: RCC and RT, as described in the Chapter 10, and liver disease, through linkage to
workstream 3 and the clinical trial. A cohort of healthy control subjects was also recruited to determine
reference ranges and potential biological or technical confounding factors such as age, sex and length of
storage. Over the duration of the programme the three studies recruited 2216 participants in total and
5976 samples. These included:
l 847 liver disease patients (847 serum samples)
l 514 patients on the transplant waiting list, including 312 who were subsequently transplanted
(3806 samples, with each sample including multiple aliquots of serum, plasma and urine)
l 706 RCC patients (1132 samples, with each sample including multiple aliquots of serum, plasma,
buffy coat and urine)
l 149 healthy volunteers (191 samples, with each sample including multiple aliquots of serum, plasma
and urine).
Renal cell carcinoma
Objectives and end points
The primary objective for establishing this cohort was to provide prospectively collected high-quality clinical
samples and data from multiple centres to validate the prognostic and longitudinal monitoring biomarkers
of RCC. The end points for such studies would be to determine the association between these markers
and outcome [disease-free survival (DFS), CSS and OS] and their ability to detect relapse, when measured
longitudinally.
Eligibility criteria
Renal cell carcinoma inclusion criteria
l Newly diagnosed suspected RCC (all stages).
l All histological types of RCC.
l No prior treatment for renal cancer.
l Ability and willingness to provide written informed consent.
l Ability and willingness to co-operate with study procedures, including blood and urine sampling.
l Age ≥ 18 years.
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Renal cell carcinoma exclusion criteria
l Diagnosed familial RCC, for example VHL syndrome.
l Renal cancer acquired following/during renal dialysis.
l High risk of or known HIV/AIDS, hepatitis B virus (HBV) infection or HCV infection or similar
infectious diseases.
Healthy volunteer inclusion criteria
l Able to provide consent.
l Willingness to co-operate with study procedures.
l Age ≥ 18 years.
Health volunteer exclusion criteria
l History of any cancer.
l High risk of or known HIV/AIDS, HBV infection or HCV infection or similar infectious diseases.
l History of diagnosed renal disease.
l Current/recent (within the last 3 months) urinary tract infection (UTI).
Study design
A multicentre prospective observational cohort design for retrospective blinded biomarker validation was
adopted.268 Blood and urine samples were requested from eligible patients diagnosed with suspected RCC
attending 11 participating centres (Table 66), according to the study site operating procedure (SSOP),
as summarised below:
l cross-sectional study (target of n = 500 prior to surgery or other treatment) –
¢ a single baseline blood sample (12–18 ml for serum, plasma and buffy coat)
¢ mid-stream urine sample
l longitudinal monitoring study (target of n = 200 prior to nephrectomy) –
¢ two separate baseline blood samples (for serum, plasma and buffy coat)
¢ two separate baseline urine samples
¢ additional blood and urine samples at 3–6, 12, 18 and 24 months post nephrectomy, ceasing at
relapse if earlier, with a sample taken at that time.
For each patient undergoing nephrectomy, a representative formalin-fixed paraffin-embedded (FFPE) block
of tumour tissue was also collected. This was not included in the programme grant application and was
funded from elsewhere but provided added value to the sample collection through enabling multiple
centres to participate in tissue-based studies in the future, given that the clinical data were already being
collected. In the Leeds Teaching Hospitals NHS Trust, frozen tissue was also stored as this was being
undertaken routinely already as part of local research.
Cross-sectional blood and urine samples were also collected from healthy volunteers across the different
centres (target of n = 200; relatives, hospital staff, etc.) to allow the determination of biomarker reference
ranges and the effects of factors including sex, age, ethnicity and diet.
The study schema is outlined in Table 67.
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Statistical considerations
The design and analysis/reporting of many prognostic marker studies has been criticised482–484 and we
conformed to REMARK guidelines.367 There are many imponderables involved in calculating the sample
size for biomarker studies. Patient recruitment in terms of numbers has been powered based on a
consideration of our experience of ongoing marker analysis, for example cathepsin D, for which a 15%
difference was seen between groups at 2 years,485 and CRP, for which the difference was 40–50%.486
Based on relapse rates ranging from 12.5% to 27.5% of the population diagnosed with ccRCC
undergoing nephrectomy or ablation, we have modelled numbers providing from 80% power to 90%
power to correctly separate prognostic groups. A marker with 15% separation between the groups would
require 216–380 patients in total to provide a power of 90% assuming that event frequencies range from
12.5% to 27.5% at 2 years, whereas a marker with 40% separation would require a total of 72 patients
to provide the same power. Given the projected figure of 400 ccRCC patients in total, these targets are
easily met. Cox multivariate proportional hazards model analysis will be used to identify multiple marker
combinations, with significance levels adjusted for the number of variables included. About four times as
many patients are required to detect interaction affects for a pair of dichotomous variables as for an
individual variable, so only combinations of markers with relatively large effects are likely to be identified
definitively. Simulations and sensitivity analyses will be performed to validate and confirm significance
levels for such analyses.
For the longitudinal monitoring, the methodology for evaluating biomarker test performance is more
poorly developed. Experience suggests that, with up to five marker values throughout the follow-up period
for 200 patients, we would have adequate numbers to show the predictive capacity of relevant markers in
this setting and to develop mathematical models, as appropriate, to enhance our understanding of the
disease process in these patients.487
Renal transplant
Objectives and end points
The primary objective for establishing this cohort was to validate biomarkers for use in the monitoring
and diagnosis of early/acute kidney transplant complications. The secondary objective was to validate
biomarkers for use in predicting patient outcomes and loss of transplant function. The end points of such
studies would be to determine the association between the concentration of these biomarkers and the
diagnosis or prediction of disease/outcome.
TABLE 66 Centres recruiting patients with RCC
Site code Hospital
N0000015 Charing Cross Hospital – Imperial College Healthcare NHS Trust (London)
N0000039 Nottingham City Hospital
N0000050 St James’s University Hospital (Leeds)
N0000069 Freeman Hospital (Newcastle)
N0000131 Lister Hospital – East and North Hertfordshire NHS Trust
N0000132 Northwick Park Hospital (London)
N0000153 Churchill Hospital (Oxford)
N0000221 Stepping Hill Hospital (Stockport)
N0000352 University Hospital of Wales (Cardiff)
N0000361 Western General Hospital (Edinburgh)
N0000537 Gartnavel General Hospital (Glasgow)
DOI: 10.3310/pgfar06030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Selby et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
183
TABLE 67 Renal cell carcinoma study schema
Activity
Time point
Screening
Pre treatment
(baseline) Nephrectomy 3–6 months 12 months 18 months 24 months 36 months 48 months 60 months Relapse
Consent ✗
Eligibility ✗
Cross-sectional cohort (n= 500)
Blood samplea ✗
Urine sample ✗
Longitudinal cohort (n= 200)
Blood samplea,b ✗ (2) ✗ ✗ ✗ ✗ ✗c
Urine sampleb ✗ (2) ✗ ✗ ✗ ✗ ✗c
Tissue sample ✗
Demographics ✗
Risk factors ✗
Symptoms ✗ ✗ ✗ ✗ ✗ ✗
Radiology data ✗ ✗ ✗ ✗ ✗ ✗
Pathology data ✗d ✗e
Sites of disease at
baseline and
relapse
✗ ✗ ✗ ✗ ✗ ✗
Treatment details ✗ ✗ ✗ ✗ ✗ ✗
ECOG PS ✗
Comorbidities ✗
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Eligibility criteria
Inclusion criteria
l All sites: active patients on the renal transplant waiting list.
l Ability and willingness to provide written informed consent.
l Ability and willingness to co-operate with study procedures, including blood and urine sampling.
l Age ≥ 18 years.
Exclusion criteria
l High risk of or known HIV/AIDS, HBV infection or HCV infection or similar infectious diseases.
l Patients in the custody of Her Majesty’s Prison Service.
Study design
A multicentre prospective observational cohort design for retrospective blinded biomarker validation was
adopted.268 Blood and urine samples were requested from eligible patients attending participating centres
who were on the waiting list for RT. The 10 centres participating in this study, shown in Table 68, were to
recruit up to 850 renal transplant patients from the waiting list, aiming for a target of 300 deceased donor
and 40 live transplantations within the recruitment period of the study. The study was focused on patients
receiving deceased donor kidney transplants because of the increased risk of DGF and chronic transplant
dysfunction longer term and, therefore, on providing sufficient samples and events for the assessment
of biomarkers.
Blood and urine samples were to be obtained following consent, whilst on the waiting list. When possible,
a second baseline sample was to be collected immediately pre transplant. Samples were then collected
daily during the first week of the hospital stay (approximately five samples) and then at the following
intervals post discharge: weekly for 1 month and then at 2, 3 and 6 months. The study schema is outlined
in Table 69.
Statistical considerations
The frequency of sampling used in this study was designed to enable the clinical validation of biomarkers
of potential use for distinguishing between DGF and AR, detecting DGF or rejection earlier and potentially
predicting chronic kidney transplant dysfunction and patient outcomes. At the time of the application
TABLE 68 Renal transplant study centres
Site code Hospital
N0000046 Royal Liverpool University Hospital
N0000050 St James’s University Hospital (Leeds)
N0000065 York Hospital
N0000069 Freeman Hospital (Newcastle)
N0000078 Hull Royal Infirmary
N0000110 Queen Alexandra Hospital (Portsmouth)
N0000118 Derriford Hospital (Plymouth)
N0000230 Southmead Hospital (Bristol)
N0000232 Northern General Hospital (Sheffield)
N0000299 St Luke’s Hospital (Bradford)
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it was possible to provide only approximate estimates of sample sizes for this proposal. First, several
different patterns could be examined in the data that may predict DGF, AR and later clinical or subclinical
dysfunction, for instance a sudden rise in marker levels, marker levels elevated over time, a slow steady
rise or a sharp rise followed by a sudden drop. Second, normal variability in putative markers is uncertain
and will have to be determined for each individual biomarker. With 20 samples per patient, a slow steady
rise, which is likely to be the most difficult pattern to distinguish, can be estimated fairly accurately.
Preliminary simulations suggest that, in this case, assuming a linear increase in marker levels, with a ± 10%
‘measurement’ error (as a result of patient, pre-analytical and analytical factors), we could clearly detect a
10% increase over 6 months. Rates of increase can then be used as predictors of DGF, AR and later
rejection/dysfunction. We have experience with alternative models, which can be accommodated with
similar magnitudes of variability. Assuming that we have accurate parameters from such models, they can
be used to predict DGF, AR or later clinical or subclinical rejection. Such predictions need to be highly
discriminatory to make them clinically useful, for instance to be able to differentiate between patients with
a 10% chance of DGF ± AR and patients with a 40% chance of DGF ± AR. This requires sample sizes of
approximately 100 patients (with 90% power and a 5% false-positive rate), assuming that the model
parameters are clearly estimated with a small standard error. We also have experience with other
projects involving serial measurements, in which sample sizes of the order of 200 patients, and multiple
measurements over time, were sufficient to enable us to distinguish clinically meaningful effects (see, for
example, Migdal et al.488).
Recognising the variation arising from multiple underlying aetiologies and that associated with different
biomarkers (neither sources being readily quantifiable), we set out to recruit 340 patients over 6 months,
with between 10 and 20 samples, to ensure that any such variation was accounted for.
Liver disease
Samples from patients with liver disease were obtained as part of the main ELUCIDATE trial (see
Chapters 16–23). From the initial 878 randomised patients, 847 consented to take part in the translational
research aspect of the trial and provided a single blood sample in a plain serum clot activator tube at
baseline. The serum was then processed according to the ELUCIDATE SSOP, stored locally at –80°C and
shipped on dry ice to the RTB in Leeds for storage. Patients were followed up and data collected as
specified within the ELUCIDATE protocol. A detailed summary of this cohort is presented in Table 79.
TABLE 69 Renal transplant study schema
Activity
Time point
Screening
Pre
transplant
Daily during
week 1 of
hospital stay
At discharge
from hospital
Weekly for
next month
2, 3 and
6 months post
discharge
Annually
for up to
5 years
Consent ✗
Eligibility ✗
Research samplesa
Blood sampleb ✗ ✗ ✗ ✗ ✗ ✗
Urine sample ✗ ✗ ✗ ✗ ✗ ✗
Clinical data ✗ ✗ ✗ ✗ ✗
Follow-up data ✗ ✗ ✗
a Samples for research to be taken at the same time as clinical samples.
b Blood denotes serum and plasma samples.
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Study management
Investigator authorisation
Patients were recruited once all appropriate authorisations for the centres were granted and the
appropriate regulatory paperwork had been collected. This included but was not limited to:
l investigator contact details, including contact details for research nurses
l an up-to-date, signed and dated curriculum vitae for each individual on the signature and
responsibilities log, including dates of Good Clinical Practice (GCP) training
l written confirmation of local trust R&D approval for the study
l a copy of the site-specific information (SSI) form, signed by the principal investigator
l a signed principal investigator declaration
l authorised signature logs.
Recruitment
Patients were recruited from UK centres, with slight overlap between our selected disease areas. For example,
two of the 11 centres recruiting patients for the RCC study were also among the 10 centres recruiting patients
for the RT study. Research centres were required to have completed a feasibility assessment, obtained local
NHS management approvals and undertaken a site initiation meeting with the study/trial management team
prior to the start of recruitment. The Leeds CTRU was responsible for the monitoring of patient recruitment
and consent and also for the co-ordination and storage of clinical data and logging of sample collection
information, whereas details of the actual samples received were maintained within our local laboratory
information management system SENTRY.
Patient consent
Patients at each site were approached by clinicians or research nurses, trained in taking informed consent,
and provided with study-specific patient information sheets regarding the study and consent forms. In
all cases the information in the patient information sheet was explained fully to patients and they were
given the opportunity to ask any questions. In the renal transplant study, some centres sent patients a
letter along with the patient information sheet prior to them coming to the clinic, informing them of
the research study and giving them time to consider their participation. The right of a patient to refuse
consent without giving a reason was respected. Whenever possible, informed consent was obtained during
a hospital visit before samples were obtained. However, because of the patterns of referral of many of
these patients this was not possible in many instances. In such cases, a full explanation of the study was
provided and patients were given as much time as they needed to make a decision. Healthy participants
were also recruited at each centre by approaching visitors and hospital staff.
Broad consent was sought to store and use patient data and samples for this project and also for
subsequent unspecified studies, given the intended storage within a RTB, if residual tissues and fluids
remained, with examples of the types of subsequent studies provided in the patient information sheet.
Patients were specifically asked to opt in or out, using a multilevel consenting procedure for more sensitive
aspects of the research, including whole-genome sequencing studies; permission to contact their general
practitioner regarding clinically relevant findings; permission to contact relatives regarding clinically relevant
findings; and studies conducted by other groups and commercial partners.
No specific additional risks were involved for patients participating in this study as whenever possible blood
samples were obtained at the time of routine venepuncture and no surgical procedures or treatment other
than those planned as part of their standard treatment were received as part of the study.
Should a patient have required a translation of the study documentation, it was the responsibility of the
individual investigator to translate the patient information leaflet and the consent form, using locally
approved translators. The consent form then had to be appropriately signed and dated by the patient,
the investigator and the translator.
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Original copies of the consent form were retained in the investigator site file; a copy of the consent form
was given to the patient, a second copy was filed in the patient’s health-care records (as per local practice)
and a third copy was returned to the Leeds CTRU.
All patients were free to withdraw from the study at any time at their own request, without prejudice;
they could also be withdrawn from the study at any time at the discretion of the investigator. Unused
samples and data would, after the notice of withdrawal, be disposed of securely and respectfully. Part
discontinuation or withdrawal involved using a subject’s samples already obtained up to the point of
withdrawal. Full discontinuation or withdrawal involved having the subject’s samples destroyed. This
required breaking the study code so that anonymised samples could be identified. In the event that
analysis had already been performed on the sample(s), requests to destroy molecular data could not be
honoured because the associated data could be required for audit purposes by a regulatory authority.
Additionally, the sample may have been pooled with other samples such that it would not be possible to
isolate a particular sample from the pool, and the pool could continue to be analysed until it was used up.
A standard letter for withdrawing consent was included at recruitment alongside the patient information
sheet.
Patient registration
Once a patient was confirmed as being eligible for the study and had given written informed consent, the
investigator or designee completed the supplied registration CRF and contacted the Leeds CTRU’s 24-hour
registration telephone line. The CTRU recorded basic patient details (date of birth, initials and confirmation
of consent) and then allocated a unique trial number to the patient; this trial number was then recorded in
the patient’s medical notes as well as on all study CRFs. Confirmation of the patient’s registration was then
faxed/e-mailed back to the participating site and the original registration and eligibility form was sent to
the CTRU by post.
Data collection and storage
Data collection was managed by the Leeds CTRU. Relevant clinical and demographic data were collected
by research nurses and clinicians on standardised CRFs, appropriate to the participant group. These were
then copied and the originals submitted to the CTRU and held securely in paper and electronic form.
Participating sites were expected to maintain a file of essential study documentation and to keep copies of
all completed forms for at least the duration of the study. All information collected during the course of
the study was kept strictly confidential and the CTRU ensured compliance with all aspects of the Data
Protection Act 1998.481 On completion of the study, data will eventually be transferred to the Medical
Research Council Informatics Centre in Leeds and will be held securely in compliance with all aspects of
the Data Protection Act 1998 for a minimum of 10 years. Site files will be archived by the participating
NHS trusts for 10 years and arrangements for confidential destruction will then be made.
Sample collection and storage
Blood and urine samples were processed promptly at each centre by either research nurses or staff of
the clinical chemistry laboratories, according to SOPs (see Appendix 1); samples were frozen in multiple
aliquots at –80°C until shipped. Details about the time of sampling and processing were recorded. Tissue
samples (FFPE blocks and frozen tissue at Leeds Teaching Hospitals Trust only) were processed by staff in
the pathology department at each centre as part of routine tissue processing procedures.
All samples (tissue and biological fluids) were shipped by courier at regular intervals and stored at a Human
Tissue Authority (HTA)-licensed establishment (St James’s University Hospital/Chapel Allerton Hospital/
University of Leeds – licence number 12279) in compliance with the licensing provisions of the Human
Tissue Act 2004.489 Each set of fluid samples was mirror banked between two secure monitored/logged
–80°C freezers linked to a central alarm system to alert to temperature fluctuations. Frozen tissue (from
Leeds only) was stored securely in the bank’s liquid nitrogen dewars. FFPE tissue blocks were stored in a
secure filing system within the banking facility. In all cases samples were pseudonymised and assigned
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unique storage numbers. Their locations have been logged on a secure laboratory information
management system (SENTRY) in Leeds.
Monitoring and quality assurance
All returned consent forms and CRFs were checked for compliance with the study protocol, inconsistent
data and missing data and timings. Study staff were in regular contact with study centre personnel to
check on progress and deal with any queries that they may have had. In the event of unclear data, the
Leeds CTRU issued a manual query form, giving details of which information was missing or unclear.
Responses to queries were made on the query forms, which were copied and returned. In addition,
data cleaning and checking were undertaken by researchers prior to embarking on research studies.
A study steering committee met every 6 months during the recruitment phase and annually (meeting or
telecom) during the follow-up phase and was responsible for the overall supervision of the study.
Study management results and discussion of issues
Consent
Within this programme a multilevel approach to consent was adopted, in which patients were given a
choice about whether or not they wished to participate in certain more sensitive aspects of the research.
This was considered to be the most appropriate method of respecting the wishes of patients whilst
ensuring that their samples and data could be used in a wide a range of research projects.
Refusal to consent to the optional elements was low (< 10%), with the exception of 18% of patients in
the RCC cohort who did not wish to consent to their relatives being contacted regarding any health
findings if they themselves could not be contacted. This concern among patients reflects similar ongoing
discussions in the ethical field concerning the implications of genetic testing for families and how to
balance the obligation for health-care professionals to disclose someone’s disease status or not with an
individual’s right to know a relative’s disease status.490
The number of consenting issues was quite high, with issues in 79 out of 706 (11.19%) RCC forms and
41 out of 514 (7.98%) renal transplant forms. The vast majority of these issues concerned the optional
consent elements not being appropriately deleted. The cost and time associated with chasing, correcting
and administering the optional consent elements were considered by the trials unit to be more than for a
typical study.
Taken together, these findings provide some evidence to support the case for a broad, as opposed to a
multilevel, consent process, as the number of patients who would not have participated would have been
low. These conclusions are supported by a recent workshop funded by the US NIH.491 This reported that
broad consent is acceptable and pragmatic as long as participants are provided with sufficient information
to make a reasonably informed decision and that sufficient processes are in place to provide independent
oversight and approval of future research. They argue that broad consent can protect the rights of donors
whilst minimising the cost and administrative burden on researchers.
When multilevel consent is required careful attention should be paid to the design of the consent form.
With hindsight, the delete options used in these forms were not clear enough, although they were what
were mandated locally at that time. This was also very much an emerging area with regard to the use of
RTBs and larger-scale genomic analysis becoming more widely used.
Sample processing
Technical pre-analytical factors, including specimen collection, processing, transport and storage, are a
major source of measurement uncertainty in biomarker discovery, clinical trials and clinical laboratory
medicine.373,492,493 To minimise the effects of pre-analytical technical factors on samples, a multicentre
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localised approach was established, as opposed to a centralised processing strategy (e.g. UK Biobank).
Localised strategies have several benefits over centralised strategies, including short processing and
cryostorage times, leading to better preservation of biomarkers, and batch shipments, reducing the overall
cost of transportation. However, localised strategies require appropriate facilities, equipment and staff at
each centre, increasing the burden of training and quality control (QC).
To ensure consistency across all centres, standardised sample packs (Figures 29 and 30) were prepared
centrally and shipped out to centres, all sites underwent an initiation and research staff were trained in
sample processing and handling procedures. SSOPs were carefully prepared for all sample collections,
taking into account our previous experience in Leeds in processing samples and developing protocols
for biomarker discovery studies and published guidance when appropriate.494–496 However, for some
parameters, best practice guidelines were not deemed to be pragmatic for ‘real-world’ sample collection
in the NHS and also some analytes are not optimally processed under such conditions. However, the most
important aspect is consistency and recording conditions so that this can be accounted for in terms of
suitability for specific analytes. Table 70 outlines some of the key pre-analytical parameters and highlights
differences between examples of published standards and guidance and the SOPs. The International
Agency for Research on Cancer (IARC) guidance496 has been developed specifically for biobanking whereas
the Clinical and Laboratory Standards Institute (CLSI) procedures494,495 have been developed for use in the
context of routine clinical chemistry analysis.
Compliance data were collected on key parameters, in particular sample processing times; a summary of
these data is presented in Table 71, along with the percentages of samples meeting SSOP specifications.
Compliance within the RCC cohort was high, with > 94% of samples being centrifuged within 2 hours
and > 89% being frozen within 2 hours. Compliance within the renal transplant cohort was lower,
especially for blood samples, with only 47% of samples being processed in < 2 hours. The primary reason
FIGURE 29 Enhanced liver fibrosis sample and liver biobank sample kit. From top left clockwise: Safebox® (Royal
Mail) for shipping the ELF sample; ELF test sample shipping form; 10 × 0.5-ml liver biobank tubes (Sarstedt Ltd,
Leicester, UK); biobank blood tube label (CILS International, Worthing, UK); pastettes (Scientific Laboratory
Supplies Ltd, Nottingham, UK); 7-ml Bijou (Scientific Laboratory Supplies Ltd); sample form; ELF test blood tube
label (CILS International); and ELF test sample tube (Thermo Fisher Scientific, Loughborough, UK).
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for this became apparent during study set-up at several centres, where most inpatient routine blood
samples are collected in the very early morning (at approximately 06:00), but where most of the local
sample processing staff did not begin work until 08:00. Therefore, a pragmatic decision was made to
process these blood samples in the shortest time frame possible. Compliance with SSOPs for urine samples
was better as these were generally collected fresh by the research nurses.
An inspection of some biomarker results highlighted that a single centre was using inappropriate blood
tubes for the collection of serum samples and this is described in detail in Chapter 14. In this instance, the
confusion stemmed from the tube manufacturer (Greiner Bio-One, Stonehouse, UK) making both a red top
serum tube and a red top ethylenediaminetetraacetic acid (EDTA) plasma tube. In both the SOPs and the
on-site training, careful attention was paid to ensure that sites selected the appropriate tube type for the
collection of serum and plasma. At the time of CRF development it was thought to be overly burdensome
to request sites to record the catalogue and lot numbers of each blood collection tube used; instead,
FIGURE 30 Renal transplant and RCC sample kit. From top left clockwise: sample tube kit (FluidX Ltd, Nether
Alderley, UK); pastettes (Scientific Laboratory Supplies Ltd, Nottingham, UK); sample form; sample tube caps
(FluidX Ltd); 150-ml urine collection pot; 50-ml centrifuge tube; 20-ml barcoded universal tube; and 7-ml Bijou (× 2)
(all Scientific Laboratory Supplies Ltd).
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TABLE 70 Sample processing SOPs compared with examples of published standards and guidelines
Matrix Pre-analytical factor SOP IARC496 CLSI (H18-A4)494 CLSI (GP16-A3)495
Urine Transport temperature Room
temperature
Ambient Room temperature
(if < 2 hours)
Urine Time to processing < 2 hours Minimum < 2 hours
Urine Centrifugation speed 2000 g Not specified Not specified
Urine Centrifugation time 10 minutes Not specified Not specified
Urine Storage temperature < –70°C –80°C Not specified
Serum Tube type Plain clot
activator
Without
anticoagulant
Clot activator
Serum Tube volume 8–10ml Not specified Not specified
Serum Transport temperature Room
temperature
Room temperature Room temperature
Serum Collection procedure Invert 5× Not specified Invert 5–10×
Serum Clotting time > 45 minutes > 30 minutes 5–30 minutes
Serum Venepuncture to
storage
< 2 hours < 1 hour < 2 hours
Serum Centrifugation speed 2000 g 1500 g Not specified
Serum Centrifugation time 10 minutes 10 minutes Not specified
Serum Centrifugation
temperature
Room
temperature
Room temperature 20–22°C
Serum Storage temperature < –70°C –80°C or liquid
nitrogen
< –20°C
Plasma Tube type EDTA EDTA Not specified
Plasma Transport temperature Room
temperature
Room temperature 20–22°C
Plasma Collection procedure Invert 5× Not specified Invert 5–10×
Plasma Venepuncture to
processing
< 45 minutes As soon as possible Immediately
Plasma Venepuncture to
storage
< 2 hours < 1 hour < 2 hours
Plasma Centrifugation speed 2000 g 815 g, then 2500 g Not specified
Plasma Centrifugation time 10 minutes 10 minutes, then
10 minutes
Not specified
Plasma Centrifugation
temperature
Room
temperature
4°C 20–22°C
Plasma Storage temperature < –70°C –80°C or liquid
nitrogen
< –20°C
Buffy
coat
Storage temperature < –70°C –70°C or liquid
nitrogen
Not specified
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TABLE 71 Sample processing times and percentage compliance with SSOPs
Cohort
Sample
Blood Urine
Median time to
centrifugation
(hours:minutes)
Samples
centrifuged
within 45–120
minutes (%)
Missing
data (%)
Median
time to
freezing
(hours:
minutes)
Samples
frozen
within
2 hours (%)
Missing
data (%)
Median time to
centrifugation
(hours:minutes)
Samples
centrifuged
within 45–120
minutes (%)
Missing
data (%)
Median
time to
freezing
(hours:
minutes)
Samples
frozen
within
2 hours (%)
Missing
data (%)
RCC 01:11 98 2 01:20 96 16 01:03 94 14 01:20 89 23
Renal
transplant
01:24 78 8 01:30 47 8 01:10 82 21 01:22 79 19
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researchers selected the manufacturer from a tick list. The lack of standardised colour coding of blood
collection tubes has been previously highlighted as a patient safety issue and the European Federation
of Clinical Chemistry and Laboratory Medicine (EFLM) has called for harmonisation.497 Our experiences
support this view that the current heterogeneity in tube colours presents a significant pre-analytical risk for
multicentre biomarker studies and trials and, until blood collection tubes are harmonised, researchers must
remain vigilant. Unfortunately, it is difficult to standardise blood collection tubes by manufacturer within
multicentre research studies, as the tubes must be compatible with the local venepuncture system. Patient
preference and the terms of ethics approval usually dictate that research blood samples are collected
within the same cycle of venepuncture, using the same venepuncture apparatus as for routine samples.
Clinical data
Compliance to the study protocol and schedule were generally high across both the RCC and the renal
transplant cohorts, as demonstrated in Tables 72 and 73, respectively, by the > 90% and > 85% overall
CRF compliance for the respective studies. However, in both cohorts, sampling fatigue and/or loss to
follow-up was observed. This was more apparent in the RCC cohort than in the transplant cohort, with
only 48% of RCC patients in the longitudinal cohort providing their final sample (at 2 years) compared
with 74% of transplant patients (at 6 months). This is potentially because of both differences in the length
of follow-up and whether or not follow-up occurs at the same hospital as recruitment and the higher
frequency of hospital visits required by transplant patients. However, as follow-up is still ongoing,
compliance may change over time.
Recruitment to time and target
The recruitment rates to the RCC and renal transplant cohorts are shown in Figures 31 and 32, respectively.
The accrual graphs clearly show that recruitment was slower than expected across both studies, with the
RCC cohort aiming to have been completed by December 2012 and the renal transplant cohort by
September 2013. As well as the slower than expected monthly recruitment rate, this was in part because
of the length of time taken to set up individual centres (see Tables 77 and 78). However, 5 of 11 RCC
centres and 8 of 10 renal transplant centres managed to achieve or exceed their target number of patients
TABLE 72 Renal cell carcinoma CRF compliance
CRF
CRFs
Received (n) Due (n) Return rate (%)
F01 Eligibility form 705 706 99.9
F02 Baseline assessment 705 706 99.9
F03 Surgery details 697 706 98.7
F04 Sample form (initial) 699 706 99.0
F04 Sample form (3–6 months) 139 169 82.3
F04 Sample form (12 months) 107 148 72.3
F04 Sample form (18 months) 73 148 49.3
F04 Sample form (24 months) 70 147 47.6
F06 Follow-up 1 year 624 629 99.2
F06 Follow-up 2 years 359 468 76.7
F06 Follow-up 3 years 142 200 71.0
F06 Follow-up 4 years 15 47 31.9
F06 Follow-up 5 years 0 0 NA
Overall compliance 4335 4780 90.7
NA, not applicable.
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by the end of the study period, as shown in Figures 33 and 34, respectively. Over-recruitment was
encouraged and two RCC and six transplant centres over-recruited by > 50% of their original target figure.
However, we observed that there were limited incentives within the system to encourage over-recruitment
and upwards revision of target recruitment figures. One centre in particular excelled at recruiting patients
and hit its recruitment target within 6 months of opening, but declined to increase its target.
Study governance aspects
Ethical considerations
The studies were all performed in accordance with the recommendations for biomedical research involving
human subjects adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964, and subsequent
amendments.498 Permission was sought from each NHS organisation and national/local principles of
research governance were adhered to. The possibility of samples being used in collaboration/partnerships
with commercial companies was made explicitly clear in the patient information sheet and consent form.
TABLE 73 Renal transplant CRF compliance
CRF
CRFs
Received (n) Due (n) Return rate (%)
F01 Baseline assessment 419 433 96.8
F01 RT eligibility and registration 512 512 100.0
F06 RT sample form (pre transplant) 442 512 86.3
F03 RT postoperative investigations 291 297 98.0
F06 RT sample form (hospital stay) 227 298 76.2
F04 RT duration of postoperative stay 290 296 98.0
F05 RT follow-up week 1 272 292 93.2
F06 RT sample form week 1 252 292 86.3
F05 RT follow-up week 2 272 289 94.1
F06 RT sample form week 2 244 289 84.4
F05 RT follow-up week 3 266 289 92.0
F06 RT sample form week 3 244 289 84.4
F05 RT follow-up week 4 268 288 93.1
F06 RT sample form week 4 240 288 83.3
F05 RT follow-up month 2 251 284 88.4
F06 RT sample form month 2 223 284 78.5
F05 RT follow-up month 3 232 280 82.9
F06 RT sample form month 3 199 280 71.1
F05 RT follow-up month 6 219 266 82.3
F06 RT sample form month 6 197 266 74.1
F05 RT follow-up year 1 159 203 78.3
F05 RT follow-up year 2 71 97 73.2
F05 RT follow-up year 3 13 15 86.7
Overall compliance 5803 6639 87.4
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FIGURE 32 Renal transplant: monthly and cumulative recruitment from the waiting list and transplantation.
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All procedures and processes were compliant with the Human Tissue Act 2004489 and the management of
tissues and fluids stored centrally in Leeds was the responsibility of the RTB Management Committee.
Establishment of a research tissue bank
To establish the renal transplant and RCC cohorts, two separate approaches to gaining ethics approval
were available at the time of set-up:
1. project-specific ethics approval
2. RTB ‘generic ethics approval’.
Traditionally, researchers would apply to a research ethics committee (REC) for project-specific ethics
approval, which would enable them to use the material collected in the study for the duration and purpose
of the study. However, if these materials had value beyond the duration of the initial ethics approval,
researchers would need to do one of the following before the end of the study period:
l apply for a renewal of project-specific approval
l obtain a HTA licence and set up a RTB
l transfer samples to a RTB.
Therefore, rather than applying for multiple project-specific approvals and setting up a RTB at the end,
we opted to set up a RTB from the outset and to seek generic ethics approval for the collection and use of
patient data and samples in the current and future projects.
Ethics approval was sought to establish the Leeds NIHR Biomarker Research Tissue Bank (reference
number 10/H1306/6) and a Management Committee was appointed to oversee the collection, storage
and release of material for research (chaired by Professor Banks and Professor Selby and including the
local HTA-designated individual, quality assurance manager, RTB manager, nurse representative, patient
representative, clinical representatives and others). This committee monitors and reviews the bank and
related activities and considers applications for access and proposed use of the samples by other research
groups once the samples have been used to meet the remit of this programme. Priority is given to
collaborative applications and groups need to provide a clear and well-defined research plan according to
the criteria laid out in the application process. Additionally, research groups have to complete a Material
Transfer Agreement (MTA) and demonstrate provision of the correct storage of material, logging of
material and records of storage as required. Groups who are granted permission to access samples from
the bank are expected to meet the costs of having the samples shipped under appropriate conditions to
their establishment. Samples will be provided only if appropriate consent has been given by the patient,
that is, a sample would not be released for a project involving genetic analyses if the patient has not given
consent for the sample to be used in such studies. The bank is promoted to researchers and patients
through the Leeds Multidisciplinary Research Tissue Bank website.499
The Human Tissue Act 2004489 requires that the storage of relevant material is licensed by the HTA.
The relevant material is essentially cellular material for all:
. . . research in connection with disorders, or the functioning, of the human body.
Human Tissue Act 2004.489 © Crown Copyright. Contains public sector information
licensed under the Open Government Licence v3.0
NHS RECs can give generic ethics approval for a RTB to collect, store and release tissues for use in
research, providing the bank is on a HTA-licensed premises. This is advantageous in terms of maximising
the use of samples for future research, ensuring consistent and high-level governance procedures and
minimising administrative burden.
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Local and national NHS approvals
The RCC and renal transplant studies both utilised the generic ethics approval of the RTB (reference
number 10/H1306/6) from the start for recruiting patients and collecting samples. The liver disease serum
samples were collected under the project-specific approval of the ELUCIDATE trial (reference number
10/H1313/2) but broad patient consent was sought for use of the samples in future biomarker research.
The liver samples and data were then subsumed under the governance of the RTB following the
completion of recruitment and sample collection.
Governance results and discussion of issues
Research RTBs are purported to have several advantages over project-specific approvals, notably the ability
to collect, store and use samples for a wide range of applications without seeking specific ethics approval
for individual projects and the fact that there is no requirement for local R&D approvals for tissue collection
centres (Table 74).
However, the reality was more complicated, presenting numerous challenges, as detailed in the
following sections.
National Institute for Health Research Clinical Research Network Portfolio adoption
Adoption onto the NIHR Clinical Research Network (CRN) Portfolio is a fundamental enabler to run
successful multicentre studies in the NHS. Portfolio adoption enables access to NHS service support,
without which most recruiting centres would not have participated.
However, the guidelines for Portfolio eligibility500 specifically exclude the ‘banking of biological samples or
data except where this activity is integral to a self-contained research project designed to test a clear
hypothesis’. This meant that the RTB itself was deemed to be ineligible and, therefore, individual studies
(RCC and RT) were submitted to the CRN Portfolio, using the ethics approval of the RTB.
NHS permissions
Although the individual projects were eventually adopted onto the Portfolio, the creation of projects meant
that local NHS approval was required for every centre participating in the studies. One of the advantages
of RTBs is that tissue collection centres do not need local approval. Furthermore, the unfamiliarity of local
teams with RTBs and the complexity of the project approval process was a source of much confusion and
delay at almost every NHS centre (see Tables 77 and 78).
Human Tissue Act 2004-relevant material
Tissue samples or buffy coats or any cellular material collected under a project-specific REC approval are
not bound by the governance of the HTA for the duration of the project. However, such samples (‘relevant
material’) collected within a RTB infrastructure are governed by the HTA. On the whole, HTA governance
did not impact greatly on our procedures, as it is well aligned with best practice and GCP. However, one
TABLE 74 Pros and cons of RTBs vs. project-specific approval
Areas Project-specific approval RTBs
Portfolio adoption Yes No
Human Tissue Act 2004 applies No Yes
Usage of samples Within scope of original project-specific
approval
Within scope of original RTB approval –
but requires approval of RTB committee
Local NHS R&D approval Required Not required
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aspect mandated by the HTA, that is, storage incidental to transportation, was a significant cause for
concern and incurred significant expense. The HTA defines storage as incidental to transportation if:
. . . tissue is held for a matter of hours or days (but never weeks) pending transfer to a licensed
establishment.
Human Tissue Act 2004.489 © Crown Copyright. Contains public sector information
licensed under the Open Government Licence v3.0
For example, as buffy coat samples (serum, plasma and urine are exempt providing acellular) were to be
stored on site and shipped in batches to save money (£150 for one sample vs. £400 for 100 samples),
the time spent on local sites would have exceeded the time that the HTA considers to be acceptable for
storage incidental to transportation. For centres that had licensed premises this meant that all HTA-relevant
materials needed to be transferred from the local clinic to the licensed premises within 7 days, incurring
additional risk, time and cost. For centres that did not have licensed premises, this meant shipping all
samples back to Leeds within 7 days of collection, significantly increasing the shipping costs and the
amount of administration.
NHS service support costs
Prior to the introduction of the AcoRD (Attributing the costs of health & social care Research & Development)
guidelines in 2012,501 there was ambiguity as to what would be classified as a research cost and what would
be classified as a NHS service support cost. Also, the reimbursement costs for biomarker studies as opposed
to clinical trials of investigational medicinal products (cTIMPs) were at a much lower level and did not vary
depending on whether a single sample and little information was collected or multiple samples and multiple
CRFs were collected. In 2009 when this programme grant was funded, many of the clinical research costs
incurred by sites, including CRF completion, for example, were assumed to be covered by the NHS service
support costs and were, therefore, not funded separately by the NIHR. For the sample and CRF-intensive renal
transplant cohort, this meant that there was insufficient reimbursement to incentivise centres to participate.
The CRN Renal Speciality Group advised that the research group should ask for fewer CRFs to be completed,
making the study more attractive to potential centres. The impact of this amendment can be observed in the
boost to recruitment following March 2013, shown in Figure 32. However, sampling fatigue was an ongoing
issue (see Tables 72 and 73), suggesting that further incentives may help to improve compliance.
Local and national NHS approvals
The process of gaining ethics approval for the RCC and renal transplant studies, through the establishment of a
RTB, took 5 months from REC submission (15 January 2010) to REC approval being granted (15 June 2010).
This was in part because of the committee requesting further information and some revision of documentation
on 8 February 2010 (response 3 March 2010) and again on 1 April 2010 (response 15 April 2010). All three
studies gained adoption onto the National Institute for Health Research Clinical Research Network (NIHR CRN)
Portfolio through the Coordinated System for gaining NHS Permission, ensuring access to local service support.
The timescales for gaining national approval for each study are shown in Table 75. In April 2010 the NIHR
introduced the CRN High Level Objectives,502 which aimed to increase the proportion of studies in the CRN
TABLE 75 Time scales for gaining national approval
Cohort
Time period
CRN Portfolio
approval (months)
NHS R&D approval
(months)
Time from R&D
approval to first
patient (months)
Time from first
to last patient
recruited (months)
RCC 6 January 2011–
24 February 2011 (1.6)
2 February 2011–
1 April 2011 (1.9)
1 April 2011–
14 July 2011 (3.4)
14 July 2011–
30 June 2014 (36)
Renal transplant 19 April 2011–
12 March 2012 (10.8)
16 December 2011–
5 March 2012 (2.6)
5 March 2012–
26 April 2012 (1.7)
26 April 2012–
30 April 15a (37)
a Date of last transplant was 24 September 2015.
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Portfolio that deliver to their planned recruitment time and targets, reduce the time taken to achieve NHS
permission and reduce the time taken to recruit the first participants. This includes a 40-day target for gaining
NHS permission and a 30-day target for recruitment of the first patient following permission. These targets
were not achieved for either the RCC cohort or the renal transplant cohort. In total, for the RCC and renal
transplant cohorts it took 6 and 12 months, respectively, from CRN Portfolio submission to recruitment of the
first patient.
Adoption onto the CRN Portfolio was a challenge, with both the RTB status and also queries concerning
peer review causing delays. Delays in study-wide national sign-off were mainly the result of these being
some of the first RTB studies to come through the Comprehensive Local Research Network (CLRN), which
was, at the time, unfamiliar with the process. The concept of having ethics approval for the Leeds NIHR
Biomarker Research Tissue Bank but not for the specific studies caused confusion, as did having protocols
for the specific studies that sat alongside the RTB protocol. At a local permission level, NHS trust R&D
offices were also unfamiliar with the RTB ethics approval status, asking questions around the need for
study-specific ethics approval. It is worth noting that, towards the end of the programme, some centres
sent letters confirming that local R&D approval was not required because of the RTB status. RTB status also
introduced another source of delay, as MTAs had to be signed off by the trust’s designated individual for
research, as they are responsible under the Human Tissue Act 2004489 for any relevant materials. These
individuals were often unknown to R&D departments or were not in post, were difficult to contact or
simply refused to sign the agreements. Transfer of patient data at several centres was also a cause of
delay, despite using the standard procedures of an accredited CTRU.
Participating NHS hospitals were identified initially by the Chief Investigators, but later through word of
mouth and the invaluable support of CRN Cancer, Liver and Renal Specialty Groups. Tables 76 and 77
show the time taken by individual centres to submit their SSI form (research application), gain local R&D
approval, open the centre following R&D approval and recruit the first patient for the RCC and renal
transplant cohort, respectively. The main source of local delay for the RCC study was the R&D approval
process, taking an average of 3.8 months (range 0.0–7.0 months), whereas the main source of local
delay for the renal transplant study was the submission of the SSI form, taking an average of 4.2 months
TABLE 76 Renal cell carcinoma study time scales for gaining local centre approvala
Hospital
Time from (months)
Total time
(months)
Transfer of SSI
form to submission
Submission of
SSI form to R&D
approval
R&D approval to open
for recruitment
Open for
recruitment to
recruitment of
first patient
1 4.3 0.0 1.3 2.3 6.8
2 3.6 1.2 2.3 5.0 12.1
3 5.8 4.9 1.8 0.7 13.2
4 0.6 3.3 2.0 1.7 7.6
5 0.0 5.8 0.9 5.4 12.2
6 7.0 3.9 1.6 1.8 14.3
7 0.7 2.5 1.3 0.2 4.8
8 1.7 7.0 3.4 0.5 12.5
9 1.7 7.0 3.4 0.5 12.5
9 0.0 2.3 2.3 0.5 5.1
10 0.3 3.5 0.3 0.1 4.1
Median 1.2 3.7 1.9 0.6 12.2
a Sites have been anonymised for this purpose and, therefore, hospital numbers are arbitrary.
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(range 0.6–7.8 months). This difference in timing of R&D approval may be a reflection of the introduction
of the NIHR Performance in Initiating and Delivering Clinical Research exercise in the autumn of 2011.503
This initiative set a 70-day benchmark for local NHS providers to recruit their first patient, following receipt
of a valid research application. The two studies span this transition period, with the majority of RCC
centres (73%) starting in 2011 and the majority of renal transplant centres (90%) starting in 2012/13.
None of the RCC centres achieved the 70-day benchmark (mean 218 days, range 76–369 days), whereas
40% of renal transplant centres did (mean 115 days, range 26–287 days). By combining the two cohorts
together a downwards trend in R&D approval times over time is observed (Figure 35). This supports the
CRN’s own analysis, which reports that in 2014–15 83% of studies are now receiving NHS permission
within 40 days at all sites.504 It was queried during the study period whether or not this reduction in time
to achieve local NHS permissions might in part be the result of ‘gaming’, where centres would withhold
submitting their SSI form until the end of the process to improve their metrics. This hypothesis is supported
to some extent with the increase in median SSI submission times between the cohorts (1.2 months for
RCC vs 5.1 months for RT) and the trend towards increased SSI submission times as a percentage of local
review and approval times (Figure 36). However, Figure 37 does suggest that there might be a trend
towards shorter overall set-up times over time, suggesting that improvements in set-up time may be being
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FIGURE 35 Time taken for R&D approvals plotted over time.
TABLE 77 Renal transplant study time scales for gaining local centre approvala
Hospital
Time from (months)
Total time
(months)
Transfer of
SSI form to
submission
Submission of SSI form
to R&D approval
R&D approval
to open for
recruitment
Open for
recruitment to
recruitment of first
patient
1 0.6 0.7 3.4 0.3 4.9
2 7.8 2.4 0.0 1.7 11.9
3 2.8 0.1 1.1 0.6 4.5
4 0.6 3.7 2.0 3.7 10.0
5 0.7 5.4 1.4 0.7 8.2
6 5.8 0.8 2.6 0.6 9.9
7 5.3 0.9 0.4 0.4 6.9
8 7.0 0.1 0.5 1.0 8.6
9 6.7 1.4 0.7 0.4 9.2
10 4.9 0.0 0.2 0.6 5.7
Median 5.1 0.8 0.9 0.6 8.4
a Sites have been anonymised for this purpose and, therefore, hospital numbers are arbitrary.
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achieved and that this initiative may be having the desired impact on pushing the pace of UK clinical
research. It should be noted, however, that, although of interest, these observations are inconclusive and
could be affected by a multitude of other factors, such as different centre make-up in the comparisons
of the cohorts and differences in the complexity of study set-up for the cohorts. Further evaluation at a
national level should be conducted, taking into account the time from transfer of SSI forms to submission,
the data for which are logged within the Integrated Research Application System.
Summary of the final resource
Liver disease cohort summary statistics
The original recruitment target for the ELUCIDATE trial was 1000 participants. In total, 878 participants
were eventually recruited, of whom 847 contributed a sample to the RTB. The summary statistics of the
final liver biorepository cohort are shown in Table 78.
Renal cell carcinoma and healthy control cohort summary statistics
The recruitment target for the RCC study was 700 patients with suspected RCC (500 cross-sectional cohort
and 200 longitudinal cohort) and 200 healthy control subjects. In total, 706 RCC patients and 149 healthy
control subjects were eventually recruited. The summary statistics of all patients suspected of having RCC
are shown in Table 79 and for the ccRCC subgroup are shown in Table 80. The summary statistics of the
healthy control subjects are shown in Table 81.
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TABLE 78 Characteristics of the liver disease patients
Characteristic Liver disease patients (n= 847)
Age (years), median (range) 55 (23–75)
Sex, n (%)
Male 476 (56)
Female 371 (44)
Weight (kg), median (range) 81.3 (38–166)
Height (cm), median (range) 169 (131–203)
Cause of fibrosis, n (%)
Non-alcoholic fatty liver disease 225 (27)
Viral liver disease 338 (40)
Alcoholic liver disease 59 (7)
Other/unknown 225 (27)
ELF value, median (range)
Registration 9.36 (8.4–17.35)
Randomisation 9.37 (7.13–17.84)
TABLE 79 Characteristics of all patients recruited with suspected RCC
Characteristic All patients (n= 706)
Sex, n (%)
Male 447 (63)
Female 259 (37)
Age (years), median (range) 64 (29–92)
Body mass index (kg/m2), median (range) 27.9 (15.6–74.4)
Symptoms, n (%)
Local 199 (28)
Systemic 103 (15)
Both 151 (21)
None 253 (36)
Procedure, n (%)
Radical nephrectomy 465 (66)
Partial nephrectomy 162 (23)
Radiofrequency ablation 20 (3)
Cryoablation 17 (2)
Biopsy only 12 (2)
None 29 (4)
Missing 1 (< 1)
continued
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TABLE 79 Characteristics of all patients recruited with suspected RCC (continued )
Characteristic All patients (n= 706)
Histological type, n (%)
Clear cell 481 (68)
Papillary 59 (8)
Chromophobe 46 (7)
Oncocytoma 27 (4)
Translocation carcinoma 2 (< 1)
Unclassified 12 (2)
Other 39 (6)
Unknown 39 (6)
Missing 1 (< 1)
TNM stage, n (%)
I 336 (48)
II 71 (10)
III 143 (20)
IV 56 (8)
Not applicablea 93 (13)
Missing 7 (1)
Interval between study blood sample and procedure (days), median (range) 13 (0–737)
a Not applicable to patients found to have benign tumours or other benign conditions.
TABLE 80 Characteristics of the RCC patient cohort with a clear-cell subtype
Characteristic Clear-cell subtype patients (n= 481)
Sex, n (%)
Male 321 (67)
Female 160 (33)
Age (years), median (range) 64 (29–92)
Body mass index (kg/m2), median (range) 28.3 (16–74.4)
Procedure, n (%)
Radical nephrectomy 345 (72)
Partial nephrectomy 103 (21)
Radiofrequency ablation 17 (4)
Cryoablation 9 (2)
Biopsy only 7 (1)
Tumour size (mm), median (range) 55 (11–180)
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TABLE 80 Characteristics of the RCC patient cohort with a clear-cell subtype (continued )
Characteristic Clear-cell subtype patients (n= 481)
Pathological T stage, n (%)
1 239 (50)
2 50 (10)
3 154 (32)
4 5 (1)
Not applicablea 33 (7)
Fuhrman grade, n (%)
1 13 (3)
2 156 (32)
3 231 (48)
4 77 (16)
Missing 4 (< 1)
Necrosis, n (%)
Present 146 (30)
Absent 302 (63)
Missing 33 (7)
Microvascular invasion, n (%)
Present 82 (17)
Absent 365 (76)
Missing 34 (7)
Sarcomatoid change, n (%)
Present 29 (6)
Absent 418 (87)
Missing 34 (7)
Leibovich risk group, n (%)
Low 155 (32)
Intermediate 168 (35)
High 80 (17)
Not applicableb 78 (16)
TNM stage, n (%)
I 257 (53)
II 45 (9)
III 123 (26)
IV 50 (10)
Missing 6 (1)
a Not applicable to patients undergoing ablation or biopsy only.
b Not applicable to patients with stage IV disease or undergoing ablation or biopsy only.
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TABLE 81 Characteristics of the healthy control subjects
Characteristic Healthy control subjects (n= 149)
Sex, n (%)
Male 50 (33.6)
Female 99 (66.4)
Age (years), median (range) 45 (21–88)
Weight (kg), median (range) 71 (41–153)
Height (cm), median (range) 168 (148–203)
Body mass index (kg/m2), median (range) 25 (16–52)
Illnesses, n (%)
None 113 (74.8)
Hypertension 22 (14.6)
Diabetes mellitus 6 (4.0)
Other 10 (6.9)
Ethnicity, n (%)
White 121 (81.2)
Black Caribbean 3 (2.0)
Asian Indian 6 (4.0)
Black African 7 (4.7)
Chinese 1 (0.7)
Asian Pakistani 1 (0.7)
Other Asian 4 (2.7)
Asian Bangladeshi 1 (0.7)
Mixed 2 (1.3)
Other 3 (2.0)
Menopausal status (females), n (%)
Pre 66 (66.7)
Post 25 (25.3)
Peri 8 (8.1)
Smoking status, n (%)
Yes 16 (10.7)
No 105 (70.5)
Ex-smoker 25 (16.8)
Passive smoker 3 (2.0)
Alcohol consumption, n (%)
Light 136 (91.3)
Teetotal 11 (7.4)
Unknown 2 (1.3)
Diet, n (%)
All 136 (91.3)
Vegetarian 9 (6.0)
Vegan 1 (0.7)
Other 3 (2.0)
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Renal transplant cohort summary statistics
The planed recruitment target for the renal transplant cohort was 340 transplanted patients, with a mix of
around 300 deceased donor transplants and 40 live donor transplants. The total number of transplanted
patients recruited was 312, of whom 214 received deceased donor transplants and 86 received live donor
transplants. Within the cohort, acute complications were observed in at least 66 patients (AR, n = 10; DGF,
n = 56). In terms of the causes of end-stage renal disease (ESRD), glomerulonephritis and inherited renal
disease are over-represented in the cohort relative to their frequency in the renal disease population at large,
which often happens in renal studies unless specifically focusing on other causes such as hypertension or
diabetes mellitus. The frequency of DGF is slightly lower than expected, although several patients with
missing data are known to have had dialysis in the first week after transplant and may be confirmed as
having DGF later. This is also partly a reflection of the population recruited, with the live donor proportion
being higher than in the transplant population overall. Efforts are ongoing to obtain the missing data
values and the richness of this cohort will continue to improve over time with further data chasing and up
to 5 years’ long-term follow-up planned. The summary statistics for the cohort are shown in Table 82.
TABLE 82 Characteristics of the renal transplant patients
Characteristics Renal transplant patients (n= 312)
Age at transplantation (years), median (range) (missing, n= 5) 52 (19–80)
Transplants per centre, n (%)
Liverpool 21 (6.7)
Leeds 150 (48.1)
York 18 (5.8)
Newcastle 29 (9.3)
Hull 10 (3.2)
Portsmouth 40 (12.8)
Plymouth 2 (0.6)
Bristol 17 (5.4)
Sheffield 10 (3.2)
Bradford 15 (4.8)
Sex, n (%)
Male 191 (61.2)
Female 110 (35.3)
Missing 11 (3.5)
Ethnicity, n (%)
White 271 (86.9)
Asian 17 (5.4)
Black/African/Caribbean 6 (1.9)
Other 5 (1.6)
Missing 13 (4.2)
continued
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Learning and recommendations for future bioresources
Within this NIHR programme grant, three different patient cohorts have been established, consisting of
5976 sets of samples from 2116 patients across 50 NHS centres.
The parallel development of these three projects, in particular the diverse expertise of the teams and
individual experiences gleaned from each, not only cross-fertilised each of the projects, but also provided
some good learning points worthy of disseminating to future researchers wishing to embark on similar
endeavours:
l The successful delivery of these cohorts confirms that the UK has an outstanding national network of
enthusiastic patients, clinical investigators and NHS centres willing to participate in research studies.
It also verifies the widely shared view that the NIHR CRN’s systems for setting up national research
studies work and, although clearly too slow initially, are improving with regard to both the reduction
of complexity and increased pace. Although notable improvements have been made, the NIHR must
continue to streamline, simplify and speed up the study approval and set-up process. Researchers are
advised, when possible, to keep study elements as simple as possible, as unusual or complex factors
may cause delays. At a local level, study/trial co-ordinators should push for SSI forms to be submitted to
R&D offices quickly, to start the clock towards sign-off.
TABLE 82 Characteristics of the renal transplant patients (continued )
Characteristics Renal transplant patients (n= 312)
Cause of ESRD, n (%)
Pyelonephritis/reflux nephropathy 28 (9.0)
Diabetes mellitus 15 (4.8)
Glomerulonephritis 85 (27.2)
Hypertension/vascular 36 (11.5)
Obstructive 3 (1.0)
Inherited 70 (22.4)
Other/unknown 61 (19.6)
Missing 14 (4.5)
Transplant types, n (%)
DBD 126 (40.3)
DCD 88 (28.2)
Live donor 86 (27.6)
Missing 12 (3.8)
Ischaemic time, median (range) (n= 293; 17 missing CIT and n= 278; 34 missing WIT)
Cold (hours:minutes) 12:17 (00:25–23:53)
Warm (hours:minutes) 00:40 (00:03–02:23)
Acute complications, n (%)
DGF 56 (17.9)
Missing 17 (5.4)
AR 10 (3.2)
Missing 14 (4.5)
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l Another noteworthy highlight of the NIHR CRN is the unprecedented access that it provides to the
smaller or less well-known research sites. The CRN specialty groups played a key role in identifying
potential research centres, many of which went on to be outstanding recruiters to all three of our
cohorts. Not only is this excellent for research, it also provides NHS patients outside the main centres
of academic excellence with the opportunity to participate in and benefit from cutting-edge research.
As many regional services, including transplant and cancer, operate around a hub and spoke model,
researchers need to consider where patients will be identified, consented, treated and followed up.
Multiple centres may be involved in a single patient’s journey and, therefore, good co-ordination of
and communication with sites is essential. Losing patients at follow-up through discharge back to their
initial referring hospital is certainly posing a challenge for the RCC cohort at present at some sites,
for example.
l The RTB ethics approval process may have several benefits over project-specific approvals for certain
types of research, for example collecting surplus surgical tissue. However, for prospective multicentre
observational cohorts, such as those within this programme, a project-specific approval process followed
by transfer to a RTB may with hindsight prove to be easier and quicker to deliver. Project-specific approval
would have negated the delays encountered during NIHR CRN Portfolio approval and the issues around
the Human Tissue Act 2004, in particular the huge burden and cost associated with storage incidental to
transportation. Within this initial phase of a multicentre research programme such as this, there appear
to few benefits to using the RTB process, but certainly for long-term sustainability, governance and
maximising the use of samples the RTB infrastructure will be invaluable.
l At the start of this programme, the zeitgeist surrounding patient consent to biomarker research and
biobanks was very much in favour of giving patients choice and the opportunity to opt in or out of
different aspects. Although this is still a long-term goal, our experience and that of others suggests that
the vast majority of patients do not take up most of these options and are happy to provide broad
consent.490 However, the administrative burden and error rate associated with managing such multilevel
consent processes is high. Electronic patient management and consenting systems will probably reduce
this burden and are under development. However, until such systems are the norm and deployable
across multiple centres (a major challenge), researchers are advised only to consider a multilevel consent
process when the use of broad consent will hinder recruitment. A consideration here, though, is to what
extent this is possible as, in this case, this aspect was raised by the ethics committee at the time as being
necessary. However, practice is evolving and experience of such aspects is greater and undoubtedly
patients’ views will be important in this area. If multilevel consent must be used, it is important to consult
with and thoroughly test the process with patients and health-care professionals.
l Within the RCC cohort, 18% of patients did not consent to their relatives being contacted regarding
any health findings, if they themselves could not be contacted. The precise reasons for this were not
clear and warrant further analysis, but one might speculate that they did not wish their relatives to be
informed of an identified genetic susceptibility to an illness. In the case of a serious and actionable
genetic finding, a health-care professional may believe that he or she has a duty of care to the patient’s
relative(s), which may justify breaching the confidentiality of the donor patient.490 More research with
patients is required in this area to refine patient information leaflets and consent forms, to ensure that
patients adequately understand how their medical information may or may not be used with regard to
their family’s care.
l Pre-analytical factors are a major source of uncertainty in biomarker research, as verified in Chapter 13.
We implemented standardised processes, local training, contingency planning and rigorous QC for
these factors within the cohorts. However, future researchers may benefit from going further and
monitoring/auditing sites for their sample-processing competency and compliance. Researchers should
pay specific attention to blood collection tubes as the lack of standardisation of tube-top colours
makes them especially vulnerable to errors. Investigators should also budget for sample processing
errors within a percentage of the final sample number, for power calculations, etc., depending on the
complexity of the study.
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l In comparison with single-centre sample banking, there are many additional costs associated with
multicentre sample banking. Of particular note are the costs of the manufacturer and distribution of
standardised sample kits, the provision of local freezer storage and temperature-controlled return
shipping. The expense of providing high-quality sample banks and associated clinical data is little
appreciated and often the financial support offered by funders is low compared with what is needed,
a fact that goes against the drive to improve sample quality for research purposes.
l Compliance with CRFs could have been improved within these cohorts. There is no doubt that the use
of handwritten paper-based CRFs sent by post is complex and costly for all involved. The time delay for
data entry into the database also made real-time monitoring and management of the study difficult.
The use of electronic data capture and the increasing use of routinely collected data from electronic
patient records, in particular pathology results, should be further developed and encouraged. Testing
and early auditing of CRFs with research nurses is also advisable.
l We observed a noticeable decline in the number of samples and follow-up forms being completed
after the initial consent visit or discharge. Researchers could consider incentives or penalties to improve
compliance with study protocols. Undoubtedly, this may in part reflect the lack of ‘policing’ in a
biomarker study such as this compared with a cTIMP, in which regular inspections of site files and
compliance with the regulatory requirements of the Medicines and Healthcare products Regulatory
Agency is the norm. In addition, the consequences are quite different.
Concluding remarks
These cohorts form an invaluable resource that will underpin research studies validating biomarkers of
renal cancer, renal transplant and liver disease for many years to come. A review of the learning outcomes
above suggests that, although there is still much to do, many of the problems and challenges encountered
within this programme have been or are already being addressed.
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Chapter 12 Review and prioritisation of circulating
biomarkers in renal cancer and renal transplantation
This chapter describes systematic reviews in two areas to enable serum and plasma protein biomarkerprioritisation for subsequent studies, namely (1) biomarkers of prognosis in localised ccRCC and
(2) biomarkers for the early detection and diagnosis of DGF following RT and long-term prognosis. The
clinical context and rationale for these areas as being the initial focus have been presented in Chapter 10.
Renal cancer
Literature search strategy
During the early part of the programme, a review of the literature was undertaken to identify a small
number of biomarkers with high potential. This was carried out to focus some of the initial technical
studies and in some cases generate further supporting evidence to warrant eventual investigation using
the multicentre bank of samples accrued during the programme (described in Chapter 13). Prior to the
final selection of the biomarkers to evaluate in the first major study involving the assessment of prognosis
in patients with localised ccRCC, a systematic review of the literature was carried out. The search for
publications was carried out using PubMed. Search terms used were as broad as possible to maximise
coverage (Figure 38), with subsequent manual filtering as indicated below to select the relevant references.
Reasons for inclusion or exclusion at the various stages are shown in Figure 38. This strategy was selected
Search Query Items (n)
#1 “renal cancer” OR “kidney cancer” OR “renal cell
carcinoma” OR RCC Filters: English
35,710
#2 Filters: English 30,683
#3 outcome OR prognosis OR prognostic OR predictive
OR recurrence OR relapse
2,296,771
#4 blood OR serum OR plasma OR circulating 4,313,261
#5 #2 AND #3 AND #4 2162
Abstracts reviewed
(n = 2162)
Papers obtained and
checked
(n = 166)
Discounted
(n = 1992)
Non-biomarker studies, reviews, 
case studies, therapeutic 
predictive (therapy) studies, 
non-protein (e.g. circulating
cells, miRNA or DNA), cohorts not 
applicable, (e.g. metastatic or 
dialysis-related RCC)
Papers reviewed
(n = 113)
Discounted
(n = 53)
Predictive (therapy), tissue only, 
single studies
FIGURE 38 The systematic literature review process adopted for circulating serum or plasma biomarkers of
prognosis in ccRCC. The search for publications relating to circulating prognostic biomarkers in ccRCC was carried
out on 23 June 2015 in PubMed. DNA, deoxyribonucleic acid; miRNA, microribonucleic acid.
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following an iterative testing process, checking to see if selected known diverse references were detected,
and for this reason the term ‘biomarker’ was not included as it was too restrictive in some cases. Exclusion
during the search itself using the term ‘metastatic’ was not used either as it was recognised that many
studies involved patients with both localised and metastatic disease and it was important to include these
studies, with later manual filtering removing those studies solely involving patients with metastatic disease.
The term ‘predictive’ was included as, although this should primarily refer to the response to treatment,
it is still often used interchangeably with prognostic. Biomarkers with only single published studies were
excluded as there was insufficient evidence to justify evaluation in a multicentre cohort at this stage, but
some may be evaluated in the future using local samples and eventually the NIHR cohorts, as described in
Chapter 10. To provide further background information or context for specific clinical or biological areas in
which the biomarkers are discussed in this chapter, additional specific references were also searched for as
needed but were not included in the final reference counts in Figure 38.
Review of serum and plasma biomarkers of prognosis in clear-cell renal cell carcinoma
A number of analytes routinely available for measurement in hospital laboratories have demonstrated an
association with outcome in patients presenting with localised RCC, although as yet they are not generally
used clinically for that specific purpose. If sufficient evidence could be provided for any of these, either
alone or as part of a panel, they have the advantages of being relatively easy and cheap to measure, with
widely available and standardised assays in many cases. Although focusing on proteins, we have also
included some other analytes in this category such as electrolytes. It is also important to bear in mind that,
although not within the scope of this review, several routinely measured haematological variables have
also shown promise. Given their routine measurement preoperatively, these variables, particularly the NLR,
would certainly merit inclusion in any analyses.505–511 In the following section, we review those protein
biomarkers that are still currently measured only in the research laboratory environment.
Routinely measured analytes
Many such analytes, not unexpectedly, are associated with prognosis in cancers generally, particularly
in the metastatic disease setting, and this is also true for metastatic RCC with regard to serum lactate
dehydrogenase, calcium and haemoglobin, which, for example, are included within the Memorial Sloan
Kettering Cancer Center nomogram.512 However, even for localised disease, several such factors appear to
have prognostic value, although they are not included as variables in many studies, presumably because of
the perceived likely lack of specificity, and many studies are potentially confounded by the inclusion of all
subtypes. For example, we first reported preoperative sodium as being independently prognostic for DFS
and OS both in patients with localised RCC or when all stages were included (n = 212). This was true
whether it was treated as a continuous variable or it was dichotomised to above and below the median
value [139 mmol/l; hazard ratio (HR) 0.44, 95% CI 0.22 to 0.88; p = 0.014), with patients with values equal
to or below the median value having significantly poorer survival.513 No studies have yet explored this further
although the association of hyponatraemia with worse survival has since been confirmed in patients with
metastatic disease being treated with interleukin (IL)-2/interferon-based therapy or targeted therapies, but
whether or not this is prognostic or predictive is not yet clear.514–516 Interestingly, in a study investigating
the outcomes of patient with tumour thrombus in either the renal vein or the inferior vena cava, sodium
was not listed among the large number of preoperative laboratory variables analysed but high serum
potassium was significantly associated with poor survival on multivariate analysis.517
Hypercalcaemia has been reported to increase with increasing cancer stage, even in the absence of bone
metastases;518 in a large study of 1707 patients with localised ccRCC, hypercalcaemia was found in 9%
of patients and was significantly independently prognostic for CSS (risk ratio 1.64; p = 0.002), together
with anaemia and ESR.519 This was later confirmed in another large study, which also demonstrated the
significant association of tissue parathyroid hormone-like hormone [PTHLH; also known as parathyroid
hormone-related protein] messenger RNA levels with OS in ccRCC. PTHLH has been linked to the
hypercalcaemia seen as part of the paraneoplastic syndrome in cancers such as RCC, for example.520 An
earlier study had shown a significant correlation between serum calcium and PTHLH, with calcium but not
PTHLH being significantly associated with cancer stage, although the authors did highlight possible issues
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with long-term storage of samples and PTHLH measurement and the use of serum rather than plasma.521
A further study demonstrated that a high serum PTHLH level was a significant adverse indicator in terms of
survival at the univariate but not the multivariate level, although numbers were small (n = 51), with only
seven patients having hypercalcaemia.522
In a very early study, serum alkaline phosphatase (ALP), which exists in several isoforms, with major
sources being liver and bone, was reported to be a better indicator of outcome than a bone scan (with
routinely used assays not measuring specific forms of ALP).523 In a study involving 365 patients with RCC,
the incidence of paraneoplastic elevation of ALP was reported to be 21.1%, with no stage-related
differences and a significant association with poorer survival.524 A further similar-sized study examining a
range of common laboratory variables found a significant association of ALP with progression-free survival
(PFS) and, when results for the non-metastatic subgroup were examined, serum ALP was an independent
prognostic factor for CSS.525 However, the previously described study involving 1707 patients with localised
ccRCC found an elevated ALP level in 8% of patients but no significant association with CSS.519 Addressing
very specific clinical groups within RCC populations, two studies evaluated outcome in patients with either
local recurrence or extension into the inferior vena cava.526,527 In the former, serum ALP at the time of
recurrence was prognostic for poor outcome in terms of CSS but only at the univariate level, although
numbers were small (n = 54); in the latter, preoperative ALP was prognostic in multivariate analysis in
the whole group (n = 166) and in univariate analysis only if restricted to patients with non-metastatic
disease.526,527
Recently, gamma-glutamyltransferase has also been implicated as having independent prognostic
significance in a large study involving 921 patients with RCC (all stages and subtypes),528 although, in a
study involving 700 patients with non-metastatic disease only, gamma-glutamyltransferase was significant
only in univariate analysis.529
Obesity is a recognised risk factor for RCC and body mass index is associated with poor prognosis, with
two recent studies independently showing significant associations between low preoperative serum total
cholesterol levels and worse prognosis.530,531 Both studies involved patients with metastatic and localised
disease, with one including only the ccRCC subtype (n = 364)530 and the other including all subtypes
(n = 867).531 In both studies, serum total cholesterol level was a significant independent predictor of CSS
and this was also the case in one study when only the subgroup of patients with localised disease was
examined.531 Interestingly, three studies examining nutritional status, employing varying indices but all of
which included serum albumin level together with varying factors such as cholesterol level or lymphocyte
count, found nutritional deficiency to be a significant independent prognostic factor for recurrence or for
CSS and OS when restricted to patients with local or locoregional disease.532–534
A small number of studies have examined ‘conventional’ tumour markers used in other cancer types. Serum
beta-2-microglobulin was related to both stage and grade of RCC (n = 145) and was significantly inversely
related to survival, although only at the univariate level.535 Analysis of CEA, cancer antigen 50, cancer
antigen 19-9, CA-125 and CA-15-3 found elevated serum levels for all except CEA in a cohort of 154 RCC
patients, with correlations of the last two with stage and grade and independent prognostic value of
CA-125.536 In a more recent study, almost two decades later, CA-15-3, CA-125 and β2-microglobulin
were all associated with stage and grade of RCC and CSS but only CA-15-3 was significant in multivariate
analysis and also for PFS.537 Whether or not the marked differences between the two studies regarding the
relative merits of CA-125 and CA-15-3 reflect changes in assays, differences in the patient populations or
differences in outcome (it is not clear in the earlier study if CSS or OS was examined) is not clear. Two
studies by the same group have also examined the free beta-subunit of human chorionic gonadotropin
(HCG) in 177 and 256 patients with RCC, respectively, with some patients possibly being included in both
studies; the free beta-subunit of HCG was found to be an independent prognostic variable for CSS.538,539
Evaluation of neuron-specific enolase has shown positive correlations with stage and grade of RCC in four
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papers,540–543 two of which were published by the same group,542,543 with a commercially available assay used
in the later study. A significant independent prognostic association with survival was reported.
Abnormalities in coagulation occur widely in cancer patients. Initial findings of significantly higher plasma
fibrinogen concentrations in RCC patients with metastatic disease544 have subsequently been confirmed
and extended by two larger studies.545.546 In one study (n = 286), including all subtypes and stages of RCC,
an independent association was found for fibrinogen with both DFS and OS.545 In a larger study involving
994 patients with localised RCC of all subtypes, there was an association of plasma fibrinogen (measured
prospectively the day before surgery) with tumour stage and grade, with independent prognostic
significance for metastasis-free survival (MFS), CSS and OS, with HRs varying from 2.15 to 2.48 (p < 0.001
for all).546 A further smaller study (n = 128) also found a significant association of plasma fibrinogen with
CSS but additionally reported that D-dimer levels were negatively associated with OS.547 Clearly, this
represent an attractive possibility given the ready availability of standardised assays in clinical laboratories
and these results could be relatively easily confirmed in further prospective studies on a multicentre basis.
C-reactive protein
C-reactive protein is an acute-phase protein that is elevated in many inflammatory diseases and often
raised in patients with cancer. With the main source generally being the liver and expression regulated by
cytokines such as IL-6 and tumour necrosis factor-alpha, it has been shown that IL-6 is produced by renal
cancer cells and functions as an autocrine growth factor.548 The level of circulating IL-6 is increased in
patients with RCC, particularly in those patients with metastatic disease, and several studies have shown
a significant correlation with serum CRP.549–552 High serum IL-6 has been shown to be associated with
poorer survival in univariate analyses but either this was not confirmed in multivariate analysis or further
multivariate analysis was not conducted.550,553 It is now known that CRP is also produced by renal tumour
cells and, indeed, intra-tumoural CRP staining has been shown to be significantly associated with OS.554,555
However, the extent to which this contributes to the circulating CRP pool is unclear as no significant
normalisation of CRP or IL-6 was seen at approximately 3 months post surgery for RCC, although an
earlier study had reported significant concentrations by 6 months post surgery.552,556
Although one of the earliest studies 20 years ago analysing several acute-phase proteins including CRP
found all to be significant at the univariate level but only orosomucoid (α1-acid glycoprotein) at the
multivariate level, a large number of studies have now shown CRP to be a significant independent
prognostic biomarker in RCC and a recent meta-analysis showed that this is the case across the urological
cancers.557 Many of the studies have investigated the value of preoperative serum CRP against the standard
clinicopathological prognostic factors and demonstrated independent prognostic significance for DFS/RFS
and/or CSS in patients with localised disease, although one study involving only patients with disease
extending into the vena cava showed a significant association of CRP with CSS only at the univariate
level.553,558–563 The largest such study included 1161 patients (including 146 with M1 disease) across all
subtypes and confirmed CRP as a significant independent prognostic factor for CSS and OS.564 Interestingly,
although preoperative serum CRP was demonstrated in one study to be a significant independent prognostic
factor for RFS in patients with localised disease (n = 263), non-normalisation of CRP postoperatively rather
than preoperative CRP was significantly associated with OS on multivariate analysis. The 5-year survival
figures were 96.9% and 30% in patients whose CRP normalised or failed to normalise, respectively.565
Several recent studies have also explored the complementarity or additive value of existing clinicopathological
prognostic factors or scoring systems. In a study involving 83 patients with localised disease, CRP and also
the UCLA Integrated Staging System (UISS) and SSIGN scores were all shown to be independent prognostic
predictors of RFS.566 This was confirmed in a similar subsequent study (n = 130) for SSIGN score and CRP
but not the UISS, with only CRP and platelets being independent prognostic predictors of 1-year OS.567 In a
later study by this group, CRP was shown to remain significantly prognostic when lifestyle factors such as
smoking and obesity were included in the model.568 In a study of 313 patients (21% with metastatic disease),
preoperative CRP treated as three categorical variables (≤ 4.0 mg/l, 4.1–23.0 mg/l and > 23.0 mg/l) was
independently prognostic for CSS (p = 0.003). Importantly, CRP added to the UISS prognostic model
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improved its accuracy by 3.8% at 5 years (p < 0.001).569 The TNM-C score, which is based on CRP and the
TNM staging system alone, was developed based on 249 RCC patients with advanced and localised disease,
with CRP dichotomised as < or ≥ 5 mg/l and combined with the TNM staging system to generate four risk
groups, with CSS stratified from 99% to 18% 5-year survival across the groups.570 External validation
was achieved in a further 290 patients, with a C-index of 0.865,570 and subsequently in an additional
518 patients with ccRCC, with a C-index of 0.85.571 More recently, in a cohort of patients with localised
ccRCC (n = 403), preoperative CRP was independently significantly associated with DFS and increased the
prognostic accuracy of the SSIGN score.572 However, the ability to increase the prognostic accuracy in this
way will depend very much on the initial performance of the scoring system and its components; the
addition of CRP to a model including TNM stage, grade and Karnofsky index did not improve the model’s
performance, which already had a high predictive value of 88.1%.573
A study from our own group investigated whether or not CRP measurement prior to nephrectomy adds to
a published model that is solely based on preoperative factors, in this case age, sex, symptoms, tumour
size, clinical T stage and metastatic status.441 Based on 286 patients (84% clear-cell subtype) and with CRP
dichotomized as ≤ or > 15 mg/l, 5-year survival rates of 72% (95% CI 65% to 78%) and 33% (95% CI
23% to 44%), respectively, were shown, with CRP an independent prognostic factor for OS (p < 0.006)
and CSS (p < 0.001) and adding significantly to the preoperative score.511
Clearly, serum CRP has significant prognostic potential and has the major advantage of being easily measured
in hospital laboratories using existing assays, although it is worth noting that, in the more recent studies, the
availability of different generations of higher-sensitivity CRP assays will have allowed quantification over a
wider range. Challenges moving forward will include the possible effects of comorbidities on CRP levels and
the optimal cut-off points, with, for example, the studies above using a variety of cut-off points including 2.5,
3, 4, 5, 7.5, 10 and 15mg/l. Alternatively, the possibility of treating CRP as a continuous variable should be
explored. Only three studies have adopted this,564,567,572 with two of these studies concluding that treating
CRP as a categorical variable was best.567,572
Serum amyloid A
Significantly elevated concentrations of the acute-phase protein serum amyloid A (SAA) have been reported
in patients with RCC, particularly in patients with metastatic disease, with patients with localised disease
having values that are largely similar to those of healthy control patients.574–577 Three studies have now
shown that SAA has significant independent prognostic value for CSS, although these studies included only
moderately sized cohorts (n = 72–119), but of all stages.574,575,578 The two largest and most recent studies
(including the one that we undertook involving only ccRCC patients) provided remarkably similar results
(HR 2.46, 95% CI 1.17 to 5.15; p = 0.017578 vs. HR 2.51, 95% CI 1.09 to 5.78; p = 0.030575). However,
when we also included CRP in our model, SAA was no longer independently significant.578
Ferritin
Serum ferritin is another acute-phase protein whose level is reported to be increased in patients with RCC,
with the level increasing with stage and significantly correlated with tumour volume and with some
evidence supporting the tumour as being a possible source of some of the circulating ferritin.579–581
In a further analysis of serum ferritin in 158 RCC patients of all stages, grouping on the basis of both
preoperative and postoperative ferritin combined (n = 103) relative to normal healthy control values
(i.e. high or normal), and stage, was significantly independently associated with survival.581,582 Preoperative
serum ferritin alone was significant only at the univariate level582 and this was further confirmed in a
smaller study (n = 52),581 with renal vein ferritin being higher than peripheral vein ferritin and both being
significantly associated with survival, but not in multivariate analysis. Interestingly, in some studies, patients
were excluded if they were anaemic, had been transfused recently or had comorbidities that included liver
disease because of possible effects on ferritin and this may preclude its usefulness.
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Erythropoietin
An initial study with 57 patients with RCC found increased plasma EPO levels in 63% of cases but no
correlation with stage or grade.583 However, subsequent studies (n = 165 and n = 195) reported associations
of serum EPO with grade and stage and survival, although this was not significant on multivariate
analysis.584,585 In a more recent study examining both serum EPO (n = 138) and tissue EPO receptor (n = 56)
expression, the association of EPO with stage and grade was confirmed and also the association between
higher EPO levels and lower survival, but examination of patients with localised disease only (n = 110) found
no association of EPO with DFS.583 However, grouping the 47 patients analysed by both serum EPO and
tissue EPO receptor expression identified a group with high levels of both and with worse CSS, although the
numbers included were small.583
Vascular endothelial growth factor
With the role played by VEGF in angiogenesis and its regulation by VHL protein ,and early studies reporting
elevated circulating concentrations of VEGF in patients with RCC, particularly those with metastatic disease,
exploring its potential as a prognostic marker was logical.586–589 However, mixed results were obtained in
survival analyses, with analysis of serum VEGF preoperatively in all subtypes of RCC (n = 146)590 or just
ccRCC (n = 45)591 finding no significant association with outcome, a slightly larger study (n = 161) finding a
significant association but only at the univariate level592 and the most recent study, of a similar size and with
a similar patient mix (n = 124), finding that, on multivariate analysis, VEGF was an independent marker
associated with CSS and RFS.593 There was some indication that concentrations differed between subtypes in
two of these studies but this is unlikely to have accounted for the differences in findings here.592,593 Analysis
of serum VEGF in 83 patients with non-metastatic ccRCC found serum VEGF to be a significant independent
predictor of recurrence (p = 0.013).594 RFS was significantly lower in the cases who stained positively for
VEGF or who had higher serum concentrations, although there was no significant association between VEGF
staining and serum VEGF. Interestingly, serum VEGF has been shown to increase markedly in most patients
(n = 66, including 48 with distant metastases) following nephrectomy and in this study preoperative VEGF or
the pre- to postoperative changes in serum VEGF were not significantly related to outcome.595
Studies have also analysed plasma VEGF concentrations and a significant correlation has been reported
between plasma concentrations and cytoplasmic VEGF staining. However, although tissue VEGF
concentration correlated with outcome, no such relationship was seen for circulating VEGF concentration.596
Using carefully prepared citrated plasma samples to minimise release of VEGF from platelets, plasma VEGF
concentration prior to surgery has been shown to be significantly associated with CSS (n = 74 patients,
including 67 ccRCC patients and 22 stage IV patients), but this is lost on multivariate analysis.597 Focusing on
just the clear-cell subtype but including all stages (n = 102), plasma VEGF was associated with T stage and
grade but not nodal or metastatic disease. However, both tissue and plasma VEGF concentrations were
significantly associated with PFS and CSS.598 A later study analysing plasma samples in ccRCC patients only
(n = 68) reported higher VEGF concentrations in patients with nodal or metastatic spread but found no
significant association with OS.599
Clearly, although VEGF appears to have prognostic potential in several studies, there are inconsistencies in
the findings, probably reflecting the heterogeneity of the studies in terms of RCC subtypes, whether or not
studies were restricted to patients with localised disease only and, possibly, even more critically, whether
serum or plasma was used and how samples were processed. It is now recognised that platelet release of
VEGF is a main contributor to VEGF measured in serum, but equally this may also contribute to circulating
VEGF concentrations measured in plasma, depending on the sample handling conditions.600–603 Platelet
number and serum VEGF concentrations have been reported to be highly significantly correlated in
patients with advanced cancer and, hence, the prognostic value of serum VEGF may actually be related to
the prognostic value of platelet number or thrombocytosis.604,605 These and other pre-analytical aspects of
VEGF measurement are considered further in Chapter 14.
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Carbonic anhydrase IX
Interest in CAIX in RCC stemmed initially from the observation of the selective binding of a monoclonal
antibody (G250) to RCC tissue but not normal proximal epithelium.606 The antigen was later identified as
CAIX, a hypoxia-inducible protein involved in the regulation of intra- and extracellular pH and upregulated as
a consequence of VHL inactivation in RCC.607 Studies examining the prognostic value of CAIX expression in
tissue samples have largely found high expression to be related to better outcomes, although inconsistencies
between studies have been found and it is still not clear whether or not CAIX has independent prognostic
value, as we reviewed in 2016.428 However, with the recognition that CAIX exists as a shed form in the blood
and urine, several studies have explored soluble CAIX as a prognostic marker in RCC, with most using the
same assay as the one that we have used in this programme, making interstudy comparison more feasible,
as summarised by Závada et al.608 In patients with ccRCC (n = 91; n = 79 with localised disease), mean
serum CAIX concentrations were significantly higher in patients with metastatic disease (p = 0.004),
with concentrations correlating with tumour grade, size and stage.609 In univariate analysis, serum CAIX
concentration was significantly associated with early relapse in patients with localised disease.609 In a larger
study involving 361 RCC patients with all subtypes, serum CAIX concentration was related to stage and
grade but failed to reach significance as a prognostic marker for CSS when dichotomised around the median
in the cohort of patients with ccRCC (n = 287) and was not a significant prognostic factor on multivariable
analysis.610 Our subsequent study analysed serum CAIX, CRP and plasma OPN prior to nephrectomy in
216 patients with ccRCC (24% with M1 disease) and found CAIX to be significantly associated with CSS,
DFS and OS on univariate analysis but independently prognostic for OS only on multivariate analysis.486
The combination of the three markers outperformed stage.
Matrix metalloproteinase-7
Matrix metalloproteinase-7 (MMP-7) (matrilysin) is a member of a family of zinc-containing enzymes
involved in proteolytic degradation of many extracellular matrix components and, hence, involved in many
of the pathological processes in cancer, particularly invasion and angiogenesis. Expression of MMP-7 in RCC
tissue has been shown to be increased relative to normal kidney tissue and independently prognostic for
CSS or OS.611,612 Following a two-dimensional polyacrylamide gel electrophoresis study of a RCC cell line
with screening of separated proteins using RCC patient sera to detect immunogenic reactivity, pro-MMP-7
was detected and subsequently reported as being elevated in serum from RCC patients.613 Using an
assay measuring pro-MMP-7, MMP-7 and TIMP-1 complexed forms (according to the manufacturer’s
information), plasma concentrations were found to be significantly elevated in RCC patients (n = 97,
including 45 patients with metastatic disease) compared with healthy control patients. This was particularly
the case for patients with distant metastases and, on multivariate analysis, MMP-7 was found to be
independently prognostic for CSS (HR 2.70, 95% CI 1.39 to 5.24; p = 0.003).614 Pilot data from our group
also support plasma MMP-7 as being associated with tumour size and stage (unpublished data, 2017).
Osteopontin
Osteopontin, also called secreted phosphoprotein 1, is a member of the small integrin-binding ligand
N-linked glycoprotein family (SIBLING). One of the most abundant non-collagenous extracellular matrix
proteins in bone, it is now known to have a widespread tissue distribution and plays a role in many processes
including cell adhesion, remodelling, angiogenesis and inflammation.379 Increased tissue expression has been
reported for many cancer types, including renal cancer.379,615 The first study to demonstrate an independent
prognostic role for OPN in RCC involved 80 patients of all stages and subtypes. Plasma OPN was significantly
elevated in patients with metastatic disease and was the only factor, together with the presence of
metastases, out of several examined to retain independent prognostic significance for CSS in a multivariate
model.616 In a larger study involving 269 patients with renal cancer of all subtypes, analysis of OPN in plasma
and serum samples (n = 75 and 116, respectively, with the ccRCC subtype) found higher concentrations in
plasma (median 2.3-fold higher concentration than in serum) and independent prognostic significance for
CSS in ccRCC, with higher concentrations linked to poorer survival, particularly for plasma, although almost
50% of patients included had metastatic disease.617 The lower OPN concentrations in serum compared with
plasma have been found in other studies and may be accounted for, at least in part, by the known cleavage
by thrombin during clotting; this is discussed further in Chapter 13.618 Surprisingly, neither stage nor grade
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were independently prognostic in this study. Subsequently, our study focusing on ccRCC only (n = 216)
found preoperative plasma OPN to be significantly prognostic for OS, CSS and DFS but only at the univariate
level and not the multivariate level.486 This may have been because CRP was included in our model, which
was strongly prognostic and correlated with OPN, and also because only 24% of participants had metastatic
disease. Interestingly, a group of patients with low-stage RCC who had higher OPN concentrations were
identified as being at high risk of death, mainly from non-cancer-related causes.486 Importantly, and although
not relevant to the initial study proposed here on localised RCC, OPN was one of the markers identified as
being a strong prognostic marker for patients with metastatic RCC in the placebo arms of Phase 2 and 3
trials of pazopanib (Votrient; Novartis Pharmaceuticals UK Ltd, Camberley, UK), outperforming routine
clinical indicators.619
Immunosuppressive acidic protein
Serum immunosuppressive acidic protein (IAP) was first described in 1986 as being elevated in patients
with high-stage RCC compared with low-stage disease,620 which was initially confirmed in a slightly larger
study of 66 patients and 133 previously untreated RCC patients, in which IAP had an area under the ROC
curve of 0.894 for metastatic disease.621,622 IAP was also found to be associated with higher grade in
181 RCC patients, with higher IAP concentrations indicating a more than fourfold risk of higher grade.623
In terms of survival, an initial study (n = 143) showed higher IAP concentrations to be associated with
poorer survival at 3 years, although this was not analysed at the multivariate level;624 a subsequent smaller
study involving 92 patients of mixed stages confirmed the association with survival, although this was
not significant on multivariate analysis.625 In the most recent study from 2006, IAP doubling time when
measured longitudinally after nephrectomy in patients with localised disease who subsequently relapsed
(n = 125) was independently prognostic for survival (p = 0.0026).626 Using the cut-off point of a doubling
time of > or < 200 days, 3-year survival was 58.9% and 12.5%, respectively.626 A limitation of several of
these studies, which has probably accounted for the restriction to Japanese studies and the long time
period over which the studies span, is the availability of the assay, with all but the last study (which used a
nephelometric assay) having used radial immunodiffusion to measure IAP. In addition, it is not clear for
most studies which histological subtypes of RCC were included.
Tumour M2 pyruvate kinase and thymidine kinase
Serum concentrations of the glycolytic dimeric M2 isoenzyme form of tumour M2 pyruvate kinase
(TuM2-PK) were initially reported simultaneously in two studies from 1999 to be increased in some
patients with RCC compared with patents with benign diseases or healthy control patients, correlating
with tumour stage and grade in both studies and with grade in one study.627,628 These results have been
extended, with more recent larger studies largely confirming these findings.629,630 In patients with RCC
of varying subtypes (n = 116), preoperative TuM2-PK concentration was also found to be a significant
independent prognostic marker for disease recurrence (HR 7.3, 95% CI 1.1 to 47.8; p = 0.037), with a
crude 5-year RFS of 55% for patients with elevated concentrations compared with 94% for patients with
normal concentrations (p < 0.001).629 This study also examined the prognostic potential of thymidine
kinase 1, which had previously been reported to be associated with grade, stage and size in in a small
study involving 27 patients,631 and found similar results as for TuM2PK in terms of independent prediction
of disease recurrence, with a crude 5-year RFS of 21% and 90% (p = 0.002) for patients with elevated or
normal concentrations of TK1, respectively.629
Soluble interleukin-2 receptor
Serum concentrations of soluble interleukin-2 receptor (sIL-2R) have been shown to be significantly
increased in RCC patients, with significant associations with clinical stage; higher sIL-2R concentrations
were associated with poorer CSS, although this was not examined at a multivariate level and only
52 patients were included, with subtypes being unclear.632 However, a more recent study involving only
patients with ccRCC (n = 70) has confirmed these findings.633 Significant correlations with stage were
demonstrated; in particular, there were higher concentrations in patients with stage IV disease (p < 0.001)
and the group with a higher sIL-2R concentration was associated with shorter CSS (p < 0.05).633 Larger
studies including multivariable analysis are now needed.
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Basic fibroblast growth factor
Following early demonstrations of elevated serum basic fibroblast growth factor (bFGF) concentrations in
approximately 50% of patients with RCC and a trend towards higher concentrations with increasing stage
and grade,634,635 significant correlations with stage and grade were reported in a larger study involving 206
patients.636 However, although higher bFGF concentrations were associated with poorer survival, they were
not significantly associated with outcome on multivariate analysis.636 In the most recent study performed in
2005 (n = 74), no significant association between serum bFGF and stage was apparent, although higher
concentrations of bFGF were found in patients with metastatic disease.540
Conclusions and prioritisation
Clearly, several circulating markers reflecting diverse aspects of RCC biology appear promising but need
further systematic evaluation, including whether a multiplex panel would be most effective and the optimal
combination of markers and whether or not these markers could add value to or outperform existing
clinicopathological scoring systems. On the basis of the evidence presented in the previous sections, OPN,
VEGF (serum and plasma), CAIX and CRP were prioritised to take forward in the initial prognostic study.
Although fibrinogen appeared to be very promising, this marker was not feasible as it would need to be
measured prospectively on freshly collected, rather than frozen, citrated plasma. MMP-7 also appeared to
be promising but further work needs to be carried out to determine the effects of inhibitors such as TIMP-1
on the assays, the detectability of pro-MMP-7 and the relative suitability of plasma or serum for the assays.
Lack of commercially available assays preclude investigating IAP and further studies are needed with larger
numbers of patients to investigate TK1 and TuM2-PK. Several other markers do not seem to have been
pursued for many years despite earlier promising findings and this may relate to a lack of assays currently.
Several markers also appear to have promise although currently only at the single-study level, covering a
wide range of tumour biology. These include insulin-like growth factor-1,637 soluble B7 family ligand
(B7-H3),633 tumour-associated trypsin inhibitor638 and vitamin D.639 In the future it is possible that these may
be explored using the RTB assembled within this programme, once further supportive evidence is available.
Renal transplantation
We have restricted this review to circulating plasma or serum biomarkers. Although, intuitively, urine
would appear to be the most obvious choice of biological fluid for the detection of biomarkers, in the early
postoperative period following kidney transplantation several considerations reduce the clinical validity of
urinary biomarkers. First, some patients, particularly those who receive a pre-emptive (prior to starting RRT)
kidney transplant, maintain residual urine output from their native kidneys, which will confound the
measured values of biomarkers. Second, patients who develop DGF and who do not have any residual
urine output will have minimal urine output. Third, from an analytical and scientific perspective, there
are a number of issues concerning the normalisation of urinary measurements of biomarkers.
Literature search strategy
Publications were searched using PubMed. Search terms used were as broad as possible to maximise
coverage (Figure 39), with subsequent manual filtering as indicated to select the relevant references.
Reasons for inclusion or exclusion at the various stages are as indicated. This strategy was selected
following an iterative testing process, checking to see if selected known diverse references were detected,
and for this reason the term ‘biomarker’ was not included as it was too restrictive in some cases. To
provide further background information or context for specific clinical or biological areas in which the
biomarkers were discussed, additional specific references were then searched for as needed.
Review of serum and plasma biomarkers of delayed graft function following renal
transplantation: diagnosis and prognostic utility for long-term outcome
Although the focus of this programme was on protein biomarkers, given the relative paucity of biomarkers
with a significant level of supporting evidence currently emerging in this area of RT, at the end of this
section we also mention some promising non-protein studies.
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Creatinine
Although not a protein biomarker, creatinine is of course widely available and routinely measured. Creatinine
is a product of the metabolism of creatine, which is released from muscle. Creatine is non-enzymatically
dehydrated to creatinine in the liver. Creatinine is freely filtered in the glomerulus and does not undergo
significant metabolism or reabsorption in the kidney.640 As such, it is the usual clinical standard for monitoring
kidney function post transplantation, together with urinary output. Consequently, it is the benchmark against
which other biomarkers are compared, which in itself is problematic as it is actually quite a poor biomarker in
several ways.641 For example, increases or decreases in its concentration lag behind true changes in kidney
function, including by a number of days, and it is influenced by a wide variety of factors such as age, sex,
muscle mass, level of nutrition (including protein intake) and liver function.642 In addition, around 10% of
creatinine is cleared by tubular secretion, which can be disrupted by particular medications, for example
trimethoprim and cimetidine. Post transplantation, the use of serum creatinine suffers from all of these
limitations.643 Glomerular filtration rate (GFR) estimates based on serum creatinine, including the commonly
used Modification of Diet in Renal Disease equations644 and the Cockcroft and Gault equation,645 are not
useful unless a steady state is present, which of course is not the case post renal transplant. At lower GFRs,
secretion of creatinine increases as a proportion of creatinine clearance, causing these equations to
overestimate the GFR.
Search Items (n)
#1 31,905
#2 90,010
#3 94,358
#4 2839
#5 2551
#6 4,364,777
#7 1271
#8 1205
#9 47
#10 1158
Abstracts reviewed
(n = 1158)
Papers obtained and
checked
(n = 106)
Discounted
(n = 1052)
Urine, tissue and case studies, 
non-protein (e.g. circulating 
cells, miRNA or DNA) studies, 
non-biomarker studies
Papers included in
the review
(n = 30)
Discounted
(n = 76)
Tissue, paediatric and 
non-biomarker studies
Query
“renal transplant” OR “kidney transplant”
“renal transplantation” OR “kidney transplantation”
#1 OR #2
“delayed graft function” OR “DGF”
#3 AND #4
blood OR serum OR plasma OR circulating
#5 AND #6
Filters: English
Filters: English; Review
#8 NOT #9
FIGURE 39 The systematic literature review process adopted for circulating biomarkers of DGF in RT. The search for
publications relating to circulating biomarkers of DGF in RT to allow a focus on serum and plasma biomarkers was
carried out on 11 October 2015 in PubMed. DNA, deoxyribonucleic acid; miRNA, microribonucleic acid.
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Cystatin C
Cystatin C is a 13.4-kDa cysteine protease inhibitor produced by all nucleated cells. It is an endogenous
marker of GFR as it is freely filtered by the glomerulus and is not reabsorbed into the circulation or
secreted.646 In an early study of serum cystatin C, 41 consecutive deceased donor kidney transplant patients
had concentrations measured before and 1, 3, 6 and 10 days post surgery.647 The study demonstrated that
in patients with DGF the serum cystatin C concentration did not fall. It is unclear from the paper how many
patients developed DGF or what the shape of the ROC curve was.647 In another study, serum cystatin C and
other biomarkers [serum neutrophil gelatinase-associated lipocalin (NGAL) and IL-18] were measured for the
first 3 days in 78 recipients of deceased donor kidney transplants, of whom 26 had DGF.648 Serum cystatin C
values were effective at distinguishing DGF from immediate graft function, with an AUC of 0.83 on day 1
postoperatively.
Fonseca et al.649 investigated the potential of urinary NGAL to predict DGF and 1-year kidney transplant
function in comparison with cystatin C. This prospective study measured serum cystatin C at days 0, 1, 2, 4
and 7 post transplant in 20 consecutive patients, of whom 18 developed DGF. Day 1 cystatin C concentration
predicted DGF, with an AUC of 0.95. Cystatin C was further investigated as a comparative biomarker in a
prospective study of malondialdehyde (MDA) as a predictor of DGF.650 Plasma concentrations were measured
preoperatively (day 0) and postoperatively (days 1, 2, 4 and 7) in 40 consecutive recipients of kidney
transplants, of whom 18 developed DGF. Day 1 serum cystatin C concentrations accurately predicted DGF,
with an AUC of 0.91. The same research group utilised a multiple biomarker approach to detect DGF, which
included urinary NGAL, serum leptin, serum MDA and serum cystatin C.651 This was a prospective cohort study
of 40 consecutive patients, including deceased donor and living donor transplants, of whom 18 developed
DGF. Serum cystatin C had an AUC of 0.914 at 8–12 hours post surgery. The most informative combination
was a triple biomarker approach that included serum creatinine, MDA and serum cystatin C; this combination
had an AUC of 0.96. A further analysis of the data demonstrated that there was a trend for cystatin C values
on day 1 post transplant to correlate with kidney transplant function at 3 months when divided into upper,
middle and lower tertiles. Serum cystatin C demonstrates very good utility as an early predictive biomarker of
DGF following kidney transplantation.
Neutrophil gelatinase-associated lipocalin
In a study of 41 consecutive deceased donor kidney transplant patients, serum NGAL was measured before
and 1, 3, 6 and 10 days post surgery.647 The study demonstrated that, in patients with DGF, the serum
NGAL concentration did not fall. It is unclear from the paper how many patients developed DGF or what
the ROC curve was. However, the authors concluded that serum NGAL needed to be investigated further
as a potential marker of DGF.647 A prospective observational study measured plasma NGAL in 41 patients
receiving a deceased donor (n = 39) or living donor (n = 2) kidney transplant.652 DGF developed in
15 patients, all of whom had received a deceased donor kidney. The plasma NGAL ROC curve at 12 hours
for predicting DGF demonstrated an AUC of 0.97. In another study, serum NGAL and other biomarkers
(serum cystatin C and IL-18) were measured for the first 3 days in 78 recipients of deceased donor kidney
transplants, of whom 26 had DGF.648 Serum NGAL values were ineffective at predicting DGF. In contrast,
in a further study, serum NGAL concentration at 24 hours post transplantation was shown to be an
accurate predictor of DGF, which affected 6 of the 33 transplant patients, with an AUC of 0.82.653
Of these 33 patients, 20 received a deceased donor kidney and 13 received a living donor kidney.
A retrospective study measured serum NGAL (and serum IL-18) in 59 recipients preoperatively and at days 1,
5 and 14 postoperatively.654 The day 1 serum NGAL concentration had an AUC of 0.86 in the 14 patients
who developed DGF. A further retrospective study analysed serum NGAL in 67 patients, of whom 27 received
kidneys donated after a circulatory death.655 The function in the DCD kidneys never recovered, which may
account for the AUC of 0.99 for predicting DGF on the first day postoperatively. Hollmen et al.656 measured
serum NGAL in 176 consecutive deceased donor kidney transplant recipients utilising two different methods.
Sixty-six patients developed DGF and serum NGAL was significantly higher in this group, with an AUC of
0.853 when measured on day 1. Serum NGAL also predicted DGF lasting > 14 days, with an AUC of 0.825.
In a further study of 97 patients (17 living donor transplant recipients and 80 deceased donor transplant
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recipients), of whom 20 developed DGF, there was no correlation between donor plasma NGAL
concentration (and urinary NGAL concentration) and post-transplant DGF.657 In this study, plasma NGAL
predicted DGF, with an AUC of 0.73 at 6 hours, 0.80 at 12 hours and 0.85 at 24 hours post transplant.
A different approach was taken in two studies that investigated the serum concentrations of NGAL in the
kidney donors prior to surgery. Hollmen et al.658 collected serum and urine samples from 99 consecutive
deceased kidney donors prior to the operation and their 176 recipients. Serum NGAL concentrations failed
to predict DGF. Muller et al.659 performed a prospective, multicentre observational study that included
146 brain-dead donors, leading to 243 transplants, with 56 transplant recipients developing DGF. The
concentrations of serum NGAL in the donors failed to predict DGF or normal transplant function in recipients.
There is now a significant body of evidence suggesting that serum NGAL (less so for plasma NGAL) has
good potential for use as an early biomarker for predicting DGF when measured in the recipient but not in
the donor.
Aminoacylase-1
Serum aminoacylase-1 (ACY-1) was identified as a potential outcome biomarker following mass
spectrometry analysis of serum samples before and on day 2 post transplant from five patients with DGF
and five with immediate transplant function.660 Following development of an ELISA for ACY-1, analysis of
the results from an initial validation cohort (n = 55 patients) showed a moderate predictive value for ACY-1
on day 1 or 2 post transplant, complementing cystatin C. A further validation cohort of 194 patients
(54 patients with DGF) confirmed this association, with a day 1 AUC of 0.74 for ACY-1, 0.9 for cystatin C
and 0.93 for the combination of ACY-1 and cystatin C.660 Importantly, however, analysis of long-term
follow-up data for 54 patients with DGF showed a highly significant association between day 1 or day 3
serum ACY-1 concentration and dialysis-free survival, mainly associated with kidney DBD and offering the
potential for use in stratification of follow-up.
Other promising biomarkers
A number of additional biomarkers have been evaluated but either only at the single-study level or in small
patient numbers. The most promising of these, all of which would require further validation before being
considered for multicentre evaluation, are described briefly in the following sections.
Complement
Ischaemia–reperfusion injury in the kidney results in the activation of the complement cascade. A terminal
panel of complement molecules (C3a, C5a and C5b-9/membrane attack complex) was analysed following
kidney transplant reperfusion.661 Seventy-five kidney transplant recipients were divided into early graft
function, slow graft function and DGF groups. Blood samples were collected from the renal vein during
reperfusion. Analysis revealed that C5b-9/membrane attack complex concentrations were two to three
times higher in DGF patients than in patients with early and slow graft function (p < 0.005). In addition,
C5b-9/membrane attack complex concentrations had a relatively high clinical sensitivity and specificity
(70–87.5%) for the prediction of early and 1-year kidney transplant function. ROC curves were not
calculated, which limits the interpretation of this study
C-terminal agrin fragment
The C-terminal agrin fragment (CAF) is a cleavage product of agrin, the major proteoglycan (PG) of the
glomerular basement membrane. It has been proposed that elevated CAF values may be related to
reduced glomerular filtration and clearance. Serum CAF and creatinine concentrations were measured
in 96 healthy individuals and in 110 patients undergoing kidney transplantation, before and after
transplantation.662 Serum CAF concentrations at day 1 and day 3 were significantly associated with DGF
(40 patients), with an AUC of 0.81. This small study demonstrates moderate clinical utility for CAF in the
early prediction of DGF.
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Fms-like tyrosine kinase
Ischaemia–reperfusion induces tubular epithelial and endothelial cell damage in the kidney transplant,
which contribute to the development of DGF. Chapal et al.663 prospectively assessed the kinetics of the
soluble VEGF receptor, soluble Fms-like tyrosine kinase-1 (sFlt-1), in 136 consecutive kidney transplant
patients. Patients with DGF had higher sFlt-1 concentrations at all time points during the first 7 days
following kidney transplantation. Multivariate analysis demonstrated that a peak plasma sFlt-1
concentration of ≥ 250 pg/ml was associated with a 2.5-fold increase in the risk of DGF (p = 0.04).
ROC curves were not calculated, which limits the interpretation of this study.
Immunoglobulin A antibodies to beta-2-glycoprotein 1
The prevalence of immunoglobulin A (IgA) anti-beta-2-glycoprotein 1 antibodies (IgA-aβ2GP1-ab) in
patients on dialysis is elevated (> 30%) and these antibodies correlate with mortality and cardiovascular
morbidity. Isolated IgA-aβ2GP1-ab are associated with thrombosis. A single-centre prospective study
evaluated the effect of IgA-aβ2GP1-ab in 269 patients following kidney transplantation.664 The presence of
IgA-aβ2GP1-ab in pre-transplant serum was examined retrospectively. Eighty-nine patients were positive
for IgA-aβ2GP1-ab. Multivariate analysis showed that the presence of IgA-aβ2GP1-ab was an independent
risk factor for early graft loss (p = 0.04) and DGF (p = 0.04). ROC curves were not calculated, which limits
the interpretation of this study.
Pregnancy-associated plasma protein A
Pregnancy-associated plasma protein A (PAPP-A) has been shown to be a marker of acute coronary
syndrome and cardiovascular pathology. Blood samples were taken from 178 patients prior to receiving their
first deceased donor kidney transplant.665 Sixty-one patients subsequently developed DGF. Pre-transplant
PAPP-A values were significantly elevated in the group of patients with DGF. Multivariate analysis showed
that PAPP-A was an independent risk factor for DGF although ROC curves were not examined.
Interleukin-16
Alachkar et al.666 analysed serum and urine samples from 61 patients 48 hours following kidney
transplantation for a panel of 23 cytokines including IL-16, which has been implicated in IRI. Six patients
developed DGF. The AUC was 0.74 for serum IL-16 in this small study and, therefore, does not provide any
compelling evidence to support the use of IL-16 as an early predictor of DGF.
Interleukin-18
Interleukin-18 is a cytokine that mediates inflammation and ischaemic tissue injury in many organs
including the proximal tubules in the kidney.667 Hall et al.648 compared alternative serum biomarkers
with creatinine for predicting DGF. IL-18 and other biomarkers (serum cystatin C and serum NGAL) were
measured prospectively for the first 3 days in 78 recipients of deceased donor kidney transplants, of whom
26 had DGF. Serum IL-18 measurements were unable to distinguish DGF from slow graft function or
immediate graft function. A retrospective study measured serum IL-18 (and serum NGAL) in 59 recipients
preoperatively and at days 1, 5 and 14 postoperatively.654 Day 1 serum IL-18 had an AUC of 0.63 in the
14 patients who developed DGF and, therefore, had limited value. Serum IL-18 does not appear to be
useful for predicting DGF.
Leptin
Leptin is removed from circulation primarily by the kidney and could be considered a surrogate marker
for kidney function. A prospective study was performed to measure the concentrations of leptin in
40 consecutive patients at days 0, 1, 2, 4 and 7 following kidney transplantation.668 Median leptin
concentrations were significantly higher in patients developing DGF (n = 18) at all times points. The leptin
reduction rate between pre transplant and 1 day postoperatively moderately predicted DGF, with an
AUC of 0.73. The day 1 serum leptin concentration predicted DGF, with an AUC of 0.76. Separating the
analysis by sex improved the performance of leptin in predicting DGF, with an AUC of 0.86 for male sex.
A further prospective cohort study of 40 consecutive kidney transplant patients utilised a multiple
biomarker approach including serum leptin.651 Both deceased donors and living donors were included in
DOI: 10.3310/pgfar06030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Selby et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
227
the study, with 18 transplant recipients developing DGF. Serum leptin had an AUC of 0.76 at 8–12 hours
post surgery. Serum leptin appears to be only moderately useful for predicting DGF.
Resistin
Brain death triggers a complex cascade of molecular and cellular events resulting in the release of
inflammatory mediators. The level of resistin increases during several inflammatory diseases and after
intracerebral bleeding or head trauma. It promotes endothelial activation and may initiate an inflammatory
response. The potential role of plasma resistin values in the brain-dead kidney donors in predicting DGF in
recipients was analysed in 63 kidney transplant patients.669 Twenty-six recipients of kidneys from living
donors were used as control subjects. Donor resistin values in the recipients of kidneys from brain-dead
donors correlated with DGF, with an AUC of 0.765. Donor resistin values appear to be of only moderate
clinical utility in predicting DGF.
Galbeta1,4GlcNAcalpha2,6-sialyltransferase
Galbeta1,4GlcNAcalpha2,6-sialyltransferase (ST6GalI) is an acute-phase reactant whose release from cells
can be induced by proinflammatory cytokines. It has been hypothesised that patients with CKD may have
circulating concentrations of ST6GalI, which might increase the risk of DGF. Serum concentrations of
ST6GalI were measured in 70 patients immediately before receiving a kidney transplant.670 The mean
serum level of ST6GalI was significantly higher in the patients than in 19 control subjects. Twenty patients
developed DGF and had significantly higher concentrations of ST6GalI pre transplant than 50 patients who
had immediate graft function. In a multivariate analysis the ST6GalI level was found to be an independent
risk factor for the development of DGF. ROC curves were not calculated, which limits the interpretation of
this study.
Stem cell factor
Alachkar et al.666 investigated whether or not a panel of serum and urinary cytokines could act as early
biomarkers for predicting DGF and slow graft function. Serum and urine samples from 61 patients were
collected 48 hours following kidney transplantation and analysed using a multiplex ELISA technique to
measure concentrations of 23 cytokines. One of the cytokines included stem cell factor (SCF), which has
been implicated in early inflammation and tissue fibrosis. Six patients developed DGF and eight developed
slow graft function. The AUC was 0.88 for serum SCF; however, sampling was performed at 48 hours
following kidney transplant, which would reduce its clinical utility as an early predictive biomarker of DGF.
Hydroxyeicosatetraenoic acids
Eicosanoids are the active metabolites of arachidonic acid and have been implicated in the pathogenesis of
IRI in the kidney. 20-Hydroxyeicosatetraenoic acid (HETE) is one such active metabolite and is generated by
cytochrome P450 enzymes. To assess the potential roles of eicosanoids the concentrations of lipoxygenase-
derived 5-, 12- and 15-HETE concentrations were measured in 69 kidney transplant recipients.671 The kidney
transplant recipients were divided into early graft function, slow graft function and DGF groups. Blood
was taken directly before and immediately following kidney transplant reperfusion. Application of newly
proposed cut-off limits for 5-HETE, 12-HETE and 15-HETE resulted in 72.5–81.5% sensitivity and 50–54%
specificity for slow graft function/DGF prediction. A mixed-model analysis revealed that recipients classified
according to results of the 5-HETE and 15-HETE cut-off points were able to predict 1-year kidney transplant
function. A further study measured 20-HETE concentrations during the first 5 minutes of kidney transplant
reperfusion and analysed whether or not the concentrations were associated with post-transplant kidney
function.672 Sixty-nine kidney transplant recipients were divided, according to their outcome, into early
graft function, slow graft function and DGF groups. The sensitivity, specificity, PPV and NPV of 20-HETE in
discriminating early and slow graft function from DGF were 69%, 54%, 74% and 48%, respectively. Both
of the studies included a relatively small group of patients and did not calculate the ROC curves, which
limits the interpretation of these studies.
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Malondialdehyde
Ischaemia–reperfusion injury results in cellular death mediated by a number of different pathways. Oxidative
stress is one such pathway, which leads to the generation of reactive oxygen species. MDA is a marker of
oxidative stress and has been investigated as a potential biomarker of DGF and transplant function at
1 year in a prospective study of 40 consecutive kidney transplant patients.650 Plasma concentrations of MDA
were measured preoperatively (day 0) and postoperatively (days 1, 2, 4 and 7). At all time points after
transplantation, mean MDA concentrations were significantly higher in patients developing DGF (n = 18).
Day 1 MDA concentrations accurately predicted DGF, with an AUC of 0.90; the performance of MDA
was higher than that of serum creatinine (AUC of 0.73) and similar to that of cystatin C (AUC of 0.91).
Multivariable analysis revealed that MDA concentrations on day 7 represented an independent predictor of
1-year graft function. Another prospective cohort study of 40 consecutive patients including deceased
donors and living donors utilised a multiple biomarker approach to detect DGF, including urinary NGAL,
serum leptin, serum MDA and serum cystatin C.651 Serum MDA had an AUC of 0.90 at 8–12 hours post
surgery. The most informative combination was a triple biomarker approach that included serum creatinine,
MDA and serum cystatin C, with an AUC of 0.96. MDA used either alone or in combination with other
biomarkers demonstrates good potential as an early biomarker of DGF.
Neutrophil–lymphocyte ratio
The NLR is an indicator of inflammatory status and has been used to assess outcome in critically ill surgical
patients. A retrospective study was performed to investigate the effect of preoperative elevated NLR on
the kidney transplant recipient with regard to the risk of DGF.673 The preoperative white blood cell (WBC)
count of 398 kidney transplant recipients was analysed. In total, 249 patients received kidneys from donors
after brain death (DBD), 61 received kidneys from donors after circulatory death and 88 received kidneys
from living donors. A NLR of > 3.5 was considered to be elevated. A total of 103 patients developed DGF,
of whom 67 had a NLR of > 3.5. Multivariate analysis demonstrated that a NLR of > 3.5 had a HR of 10.673
(95% CI 6.151 to 18.518). ROC curves were not calculated, which limits the interpretation of this study.
Regulatory T-cells
Regulatory T-cells have been shown to be protective in models of AKI and their suppressive function is
predictive of AKI following kidney transplantation. The role of regulatory T-cells as a biomarker of DGF has
been explored in a prospective observational cohort study.674 Fifty-three deceased donor kidney transplant
recipients were divided into those who developed AKI (n = 37), including DGF and slow graft function,
and those with immediate graft function (n = 16). Pre-transplantation peripheral blood CD4CD25FoxP3
regulatory T-cell frequency was quantified by flow cytometry. Regulatory T-cell suppressive function was
measured by suppression of autologous effector T-cell proliferation by regulatory T-cells in co-culture.
In univariate and multivariate analyses accounting for the effects of CIT and donor age, regulatory T-cell
suppressive function accurately predicted AKI (DGF and slow graft function), with an AUC of 0.82. The
same group also performed a prospective observational cohort study utilising flow cytometry to measure
pre-transplant recipient circulating CD4+CD25+CD127lo/– and CD4+CD127lo/– tumour necrosis factor
receptor 2 (TNFR2)+ regulatory T-cells in 76 deceased donor kidney transplant recipients, of whom
18 patients developed DGF.675 The ROC curves demonstrated an AUC of 0.75 and 0.77, respectively, for
the percentage and absolute number of CD4+CD127lo/–TNFR2+ regulatory T-cells in predicting DGF.
Neither of these studies demonstrate good clinical utility of regulatory T-cells in predicting DGF. The first
study had a good AUC but combined DGF with slow graft function.
Summary
The data presented in the systematic review demonstrate that a number of small studies have investigated a
range of potential serum/plasma biomarkers to enable the early detection of DGF, but relatively few have
looked at longer-term outcomes. The studies have been heterogeneous in terms of the populations studied
and definitions of DGF, although most have applied the definition of DGF of receipt of haemodialysis in the
first week following kidney transplantation. The most promising serum biomarkers for the early detection
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of DGF appear to be NGAL and serum cystatin C, with ACY-1 validated but only in a single centre to date.
The use of cystatin C is becoming more widespread throughout the health-care system and with a growing
familiarity it may well be utilised in the future as an earlier biomarker of DGF. In the case of NGAL, there
remain issues of standardisation with respect to which cut-off values to recommend.
A number of emerging biomarkers have been studied in AKI outside kidney transplantation, with the
most recent candidates being TIMP-2 and insulin-like growth factor-binding protein 7 (IGFBP7). It is only
natural to assume that studies of these biomarkers will follow in the setting of kidney transplantation and
predicting outcomes. The most recent study investigating urinary TIMP-2 and IGFBP7 was unfortunately
rather unimpressive.676 The most promising urinary biomarker to date is NGAL and a number of studies have
demonstrated its potential utility. However, as discussed earlier, there are significant issues surrounding the
use of urinary biomarkers post kidney transplant.
There is a distinct lack of studies in the literature that have investigated the clinical use of biomarkers in
predicting longer-term outcomes. It has been proposed by many experts that panels of multiple biomarkers
may be able to improve the predictive value but, again, such studies are lacking. The most obvious panel
to utilise would include serum cystatin C and serum NGAL, which have both demonstrated very good
utility in predicting DGF in the early phase following kidney transplantation; ACY-1 should also be explored
further, particularly in view of its promising prognostic performance. There is now an excellent opportunity
to validate existing biomarkers and investigate novel biomarkers in a cohort of kidney transplant patients
with a well-described phenotype.
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Chapter 13 Exploring technical aspects of
biomarker assays: verification, validation and
pre-analytical variables
Evaluation of the validity and performance of assays is fundamental to their introduction to clinicalpractice. This chapter describes some of the aspects and concepts of, and guidelines for, the technical
evaluation of assay performance together with pre-analytical considerations, before describing the
practices developed and results generated in a series of such studies undertaken within this programme,
in preparation for the analysis of biomarkers in specific research studies.
Appraisal of assay performance
General concepts
Ensuring that assays are appropriately validated is critical in terms of ensuring that measurements of
biomarkers are accurate and reproducible, both across time and between laboratories. It is important
within this to ensure that assays are ‘fit for purpose’ and deliver the level of performance needed for the
study phase or clinical situation, avoiding a dogmatic approach to guidelines that may not be completely
relevant at some stages.385,391,393 The level of validation may vary depending on whether the assay is for
research use only or requires CE marking or FDA approval and is for use in a hospital laboratory or
pharmaceutical laboratory, for example. However, many immunoassays are relatively easy to purchase
and use and many studies are undertaken by researchers with the assumption that, because they are
commercially available, they will be ‘fit for purpose’. It is increasingly recognised that this is not the case
and examples affecting specific analytes include studies using an ELISA (USCN Life Science, Wuhan, China)
for CUB and zona pellucida-like domains protein 1 (CUZD1), which actually measured CA-125,677 and an
ELISA for soluble hemojuvelin from the same company that did not detect the specified target but some
unknown protein.678 A key issue that has been highlighted is the plethora of biotech companies that have
sprung up, marketing a very wide range of immunoassays and antibodies, with several companies often
using the same reagents, although this is not always clear, with very little apparent validation.386 The extent
of this problem was really made apparent with the testing of > 5000 commercially available antibodies
using immunohistochemistry and Western blotting, in which almost 50% failed, although importantly not
all had been certified by the manufacturers for these specific applications and only a generic protocol was
used for all, with a limited range of sample types examined.679 This type of problem is not restricted to
antibodies, with other laboratory biological reagents also posing problems and with limited access to
information to resolve such issues because of commercial sensitivities.680 Although not having the same
impact as for clinically used biomarkers, such issues when encountered in research laboratories are very
costly in terms of inappropriate conclusions regarding clinical utility and utility and the money spent and
samples and time used. Suggestions of how to minimise the impact of antibody-based problems have
been made, covering the various stakeholders.383,386 Clinical laboratories are not immune to such problems
either, with pitfalls and a lack of consistent results identified for gastrin,681 growth hormone and insulin-like
growth factor,682 cardiac troponin388 and even serum creatinine683 measurements, for example, depending
on the assays used.
Guidelines
Numerous guidelines exist to provide a framework and set consistent standards for assay validation. The
CLSI produces some of the most widely used and accepted standards and guidelines for clinical laboratory
measurements, some of which are mandatory for certain regulatory bodies or accreditation.684 These
range from methods and performance standards for specific procedures to safety, laboratory and quality
management system standards and include more than 25 Evaluation Protocols (EPs) for assay evaluation.
These vary depending on the particular stage or aspect of the assay being examined. For example, EP05 is
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an extensive validation protocol covering the initial establishment de novo of the precision of an assay
(i.e. agreement, although it is actually imprecision that is measured), for example when first developing or
significantly changing an assay, whereas EP15 is a shorter verification protocol aimed at confirming stated
imprecision results such as those provided by the manufacturer with a commercially available assay.685 Both
within-run (repeatability) and between-run assessment of precision needs to be determined, with the latter
covering both within-laboratory precision and overall reproducibility, in which assessment involves the
changed conditions across multiple laboratories. A list of the available CLSI EPs (as of December 2015)
showing the breadth of coverage is shown in Table 83.
In addition, insights and educational resources are also provided through bodies such as the EFLM,
exemplified by a recent paper concerning the assessment of quality of analytical methods and the various
parameters to investigate.712 Internationally recognised standards also exist, such as ISO 15189 for medical
laboratories, providing particular requirements for quality and competence, and accreditation of laboratories
will be based on meeting such standards and guidelines as stipulated.
Pre-analytical errors and variation
In addition to appropriate analytical validation of the assay for any specific biomarker, considering and
minimising the impact of pre-analytical variables is arguably just as important to ensure clinically valid
results. In the hospital clinical chemistry laboratory, where the total testing process can be broken down
into pre-, intra- and post-analytical phases, it is generally considered that the majority of errors, possibly up
to 75%, occur in the pre-analytical phase.713–716 There are many anecdotal examples of errors, including
falsely elevated urinary amylase concentrations as a result of contamination with salivary amylase from the
nurses collecting the samples and haemolysed blood samples resulting from contamination with rainwater,
but essentially all aspects of the pre-analytical phase can be affected, either by errors or by variability in
the processes adopted.717 Potential errors include requesting the incorrect test and failure to comply with
any defined requirements, for example carrying out an assay at a particular time of day or after fasting,
through to obtaining a specimen from the correct patient in an inappropriate tube, labelling a tube
incorrectly or failing to process a sample according to agreed protocols, ready for analysis. Although
historically the focus has often been on the analytical phase, this is now regarded as the ‘tip of the
iceberg’ and more efforts in the future will be directed towards addressing quality aspects of the
pre-analytical phase.718–720 Within the EFLM, a Working Group for Preanalytical Phase has been established
to promote these efforts; it published its findings on non-compliance with CLSI guidelines for phlebotomy
in 2015.718,721 Similarly, the Laboratory Errors and Patient Safety working group of the International
Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has included 35 quality indicators relating
to the pre-analytical phase in its model of quality management for the total testing process.720 In the UK,
a Preanalytical Working Group within the Association for Clinical Biochemistry and Laboratory Medicine
(ACB) has also begun to address the pre-analytical phase, with a recent UK-wide survey indicating wide
variation in the recording of pre-analytical issues (e.g. recording of haemolysis, icterus and lipaemia in 80%
of laboratories but sample mislabeling recorded in only 56.9% of laboratories). This provides evidence to
support quality assurance schemes going forwards. A UK National External Quality Assessment Service
(UK NEQAS) pilot scheme has been set up.716 In the research community, the International Society for
Biological and Environmental Repositories (ISBER) has a Biospecimen Science Working Group looking at
aspects of defining and coding critical pre-analytical factors in biobanking (SPREC) and possible QC
procedures and the BRISQ recommendations describe critical elements of the pre-analytical phase that
should be included in publications to aid transparency.375,722–724 The importance of the development of
appropriate information and communication technology tools has also been raised.725
Whenever possible in the hospital environment, automated procedures are used or are being introduced to
reduce the chance of error.713 To reduce variability, standards or guidelines have been produced by the
CLSI covering all procedures, from venepuncture to patient and sample identification, tube specification
and sample processing.494,726–728 Using blood as an example, technical sources of such variability include
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TABLE 83 List of available CLSI EPs (December 2015)
Code Title of CLSI EP
EP05-A3 Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline – Third Edition686
EP06-A Evaluation of the Linearity of Quantitative Measurement Procedures: a Statistical Approach;
Approved Guideline687
EP07-A2 Interference Testing in Clinical Chemistry; Approved Guideline – Second Edition688
EP09-A3 Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved
Guideline – Third Edition689
EP10-A3-AMD Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved
Guideline – Third Edition690
EP12-A2 User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline – Second Edition691
EP14-A3 Evaluation of Commutability of Processed Samples; Approved Guideline – Third Edition692
EP15-A3 User Verification of Precision and Estimation of Bias; Approved Guideline – Third Edition693
EP17-A2 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved
Guideline – Second Edition694
EP18-A2 Risk Management Techniques to Identify and Control Laboratory Error Sources; Approved Guideline –
Second Edition695
EP18-A2/EP23-A WS Sources of Failure Template695,696
EP19-Ed2 A Framework for Using CLSI Documents to Evaluate Clinical Laboratory Measurement Procedures,
Second Edition697
EP21-A Estimation of Total Analytical Error for Clinical Laboratory Methods; Approved Guideline698
EP23-A™ Laboratory Quality Control Based on Risk Management; Approved Guideline699
EP23-A WB Laboratory Quality Control Based on Risk Management; Workbook700
EP23-A WS A Sample Form for Laboratory Quality Control Based on Risk Management; Worksheet701
EP24-A2 Assessment of the Diagnostic Accuracy of Laboratory Tests Using Receiver Operating Characteristic
Curves; Approved Guideline – Second Edition702
EP25-A Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline703
EP26-A User Evaluation of Between-Reagent Lot Variation; Approved Guideline704
EP27-A How to Construct and Interpret an Error Grid for Quantitative Diagnostic Assays; Approved Guideline705
EP28-A3c Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved
Guideline – Third Edition706
EP29-A Expression of Measurement Uncertainty in Laboratory Medicine; Approved Guideline707
EP30-A Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine;
Approved Guideline708
EP31-A-IR Verification of Comparability of Patient Results Within One Health Care System; Approved Guideline
(Interim Revision)709
EP32-R Metrological Traceability and Its Implementation; a Report710
EP36-Ed1 Harmonization of Symbology and Equations, First Edition711
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factors such as type of blood collection tube and components used (even the presence of gel activators can
markedly affect results), inadequate fill compromising sample-to-anticoagulant ratio, haemolysis, elapsed
time between venepuncture and centrifugation, centrifugation speed and temperature, elapsed time
between centrifugation and analysis and, for samples not analysed immediately, the duration and
temperature of storage.729 Storage duration and temperature are particularly important when banking
samples for biomarker research studies. Recent reviews discuss this in greater detail, both from the
perspective of biomarker discovery/validation studies in the research environment, where often the impact is
poorly understood, with many proteins detected in proteomic studies having been little studied, and from
the perspective of hospital laboratories, where it is often better understood for the specific panel of tests in
routine use.363,373,713,715,718,723,729,730 When the potential impacts cannot be controlled for, it is essential that
they are at least appreciated and factored into study protocols and analysis to avoid potential confounding
of the results. Such effects need to be considered in terms of understanding the pre-analytical uncertainty
of measurements and any potential changes, for example the impact of venepuncture or tube type on
measurement of a panel of 15 routinely measured serum analytes has been investigated;492 in addition,
comparison of five tube types for serum preparation found clinically significant differences depending on
tube type for several analytes, including creatinine, amylase and phosphate.731 The consequences of
pre-analytical errors or variation in research studies are generally not appreciated but include loss of time and
wasted resources and further indirect effects through repetition and follow-on studies based on inaccurate
results, all leading to massive financial consequences. More broadly, the irreproducibility in preclinical
research in the life sciences generally has been estimated to cost > $28M per year in the USA alone.732 In the
clinical environment, failure to standardise pre-analytical conditions can have a critical impact on patient
safety, for example in terms of a wrong or delayed diagnosis or inappropriate treatment, and of course
there are also financial implications.715 Within the development of a health economic model assessing the
impact of pre-analytical errors, various clinical case study scenarios were used and the average cost of a
pre-analytical error was remarkably similar in North America and Europe, at just over $200, accounting
for up to 1.2% of hospital operating costs.715
Biological variability must also be taken into account when considering the pre-analytical phase.
Factors such as an age, sex, diet, time of day, comorbidities, effects of drugs, smoking status or alcohol
consumption, body mass and, for females, menstrual cycle stage, pregnancy status and menopausal status
can all potentially have an impact on biological markers. In addition, the acceptability criteria of an assay
for use in a particular clinical context may vary depending on physiological or pathological variability. For
example, a higher level of assay imprecision may be acceptable if a large effect size is being sought and
given a sufficient sample size. Recently, and analogous to the STARD criteria,368 a checklist has been
produced by the EFLM that specifies the key data that need to be reported to allow studies of biological
variation to be interpreted and used effectively.733 A databank of intra-subject and inter-subject variation
for > 300 routinely measured analytes has been compiled from the literature and is available online,734,735
together with two guest essays describing how such data are important in clinical chemistry in defining
quality specifications and desirable performance characteristics such as total error, imprecision and
bias.734,736–738 Although the concept of this database is recognised as being very valuable, recently
issues have been highlighted that limit this value. These include the dubious quality of some of the studies
from which the data were derived, the age of some of the studies, resulting in the use of methodology
that is now outdated, the use of different units of measurement in different studies of the same analyte,
the reliance in some cases on data from only a single study and the limitation of many studies to healthy
individuals.739 The importance of biological variability lies in its requirement for the calculation of the RCV,
which enables the interpretation of the significance of a difference in successive results. It also provides
information on whether or not reference intervals can be used to interpret an individual’s marker results,
for example creatinine has a small within-subject variability and a large between-subject variability
and so any changes should be interpreted in light of that individual’s reference interval. An important
consideration to also bear in mind is how a clinician interprets assay results and to what extent the assay
performance impacts on that.740 There is often confusion about the terminology used and the ‘unfinished
symphony’ of the evolution, meaning and relative merits of various reference values, such as decision
limits, RCVs and reference intervals, has been discussed.741
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Development of verification protocols for commercially available
immunoassays
Key technical validation (verification) elements and criteria
Key technical validation elements and criteria were developed within this programme based on a consideration
of the various guidelines discussed in the previous section and the level of implementation of the assays, that
is, in a Good Clinical Laboratory Practice-level research laboratory rather than in the diagnostic environment.
Key elements to be considered and criteria of acceptability when validating existing immunoassays, often
referred to as verification in that context compared with when establishing a new assay, were decided on,
although the need for flexibility was also recognised. This is illustrated in the examples provided of studies
undertaken within the programme, in which a range of problems were encountered, requiring some unique
investigations that would not be needed generically. A similar flexible approach allowing adjustments or
modifications as needed has been described for a range of pharmacodynamic assays, from their development
within the National Cancer Institute to their deployment in multiple centres.742 Similarly, the assumption is that
samples have been handled under ideal standardised conditions and are, therefore, suitable for assessment
of clinical validity utility, with relaxation of this being possible only once pre-analytical aspects have been
investigated. If this is not the case, evaluation of some pre-analytical aspects may have to occur earlier in
the process.
Essentially, the assay protocol specified by the manufacturer was followed, with any required adjustments
recorded, for example alterations in timings or settings of any specific step. The aspects described below
were investigated as standard, with some being dictated by the performance requirements of the assay,
based on its intended clinical application and available information at the time, for example type of sample
matrix intended for use and range of analyte concentrations.
Once the specific matrix had been decided on, a familiarisation and range-finding run was undertaken to
determine if the initial assay protocol was satisfactory and to determine the selection of samples for use
in the validation studies, such as those with high or low analyte concentrations. Appropriate samples
from the assembled bank of samples (‘surplus diagnostic samples’) with a known high concentration of
endogenous interferents were also needed, together with recombinant/purified proteins (analyte and
proteins with known homology). The following aspects were then assessed for each matrix.
Standard assessments
1. Analytical range:
¢ Limit of detection (LoD) – approximately 20 repetitions of zero standard over multiple plates (mean
blank + 3 SDs).
¢ Lower limit of quantification (LLoQ) – serial dilutions of low standard to the approximate LoD,
analysed over multiple plates (n ≥ 3), to generate a precision profile; LLoQ is the lowest
concentration from the profile, which can be measured with < 20% imprecision and inaccuracy.
¢ Evaluation of the hook effect – the analyte is spiked into the sample at 100–1000 times the
concentration of the highest standard and the reported value should be greater than that of the
highest standard. The spiked sample is diluted back into the assay range and recovery is checked.
¢ It is worth noting that a significant element of confusion is the variable use of terminology and
methodology employed by users and manufacturers to determine the performance of assays,
particularly at the lower concentrations. Values variably quoted include those for functional
sensitivity, the limit of quantification (LoQ) or LLoQ, the LoD, the limit of blank (LoB), the
minimal detectable concentration and sensitivity, making comparisons and interpretation
difficult. In particular, LoD and LLoQ or LoQ are often used interchangeably and it is critical that
a distinction is made between these values and that they are both assessed. This has been
illustrated for LoB, LoQ and LoD.743
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2. Imprecision:
¢ Intra-assay –
¢ Inter-assay –
¢ Assessed with a minimum of two QC samples (pooled or independent) with a high and a low
analyte concentration using five or more independent determinations for each, over each of
5 days, that is, 25 determinations in total minimum. The intra-assay CV should be ≤ 10% and
the inter-assay CV should be ≤ 15% (20% at LLoQ).
3. Accuracy:
¢ Recovery – a spike of recombinant/purified analyte is added to three or more independent pools or
base material of an appropriate matrix at three different concentrations; acceptable recovery
is 80–120%.
¢ Evaluation of suitable reference materials, if available (five or more determinations over three
concentrations; < 20% imprecision and inaccuracy).
¢ Comparison with a reference method if available.
4. Analytical specificity:
¢ Cross-reactivity – identified proteins with homology to the analyte are spiked (recombinant/purified
forms) into independent samples (n ≥ 2) at two concentrations spanning the pathophysiological
cross-reactant range (if known).
¢ Parallelism/dilution linearity (normal working dilution and three or more serial dilutions of a
minimum of three samples). Assessed by back-calculating the diluted concentration of the four
dilutions to the actual concentration, with an acceptability limit of ≤ 15%.
¢ Common interferents – (e.g. rheumatoid factor, lipids, bilirubin, complement, haemolysate) –
¢ The recombinant analyte is spiked into surplus diagnostic samples (n ≥ 3) with known moderate
and high interferent concentrations and recovery is calculated, for example 150 and 300 µmol/l
of total bilirubin or 10 and 25 mmol/l of triglycerides. Alternatively, stock interferents can be
purchased and spiked into samples with known amounts of analytes. Final concentrations would
be 50 or 150 µg/ml of bilirubin (conjugated and unconjugated, respectively) or 30 mg/ml of
triglycerides. For testing the effects of haemolysis, samples containing known concentrations of
analyte can be spiked with haemolysate to produce 5 mg/ml of haemoglobin for serum and
plasma samples or 2.25 µg/ml (which equates to +++ on a urine dipstick as determined
experimentally) for urine samples.
¢ Dilutional linearity is also assessed for at least one spiked test sample.
¢ If recovery is outside 80–120% or significantly different from that of previous samples,
a dose–response series can be undertaken by spiking five or more concentrations of
purified/recombinant/synthetic interferent into samples to further assess the effects (n ≥ 3).
5. Evaluation of curve-fitting model (five or more determinations over multiple runs):
¢ Imprecision (< 10%; 20% at LLoQ).
¢ Inaccuracy (< 10%; 20% at LLoQ) (> 80% of non-zero standards, including highest and lowest,
must pass).
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Additional assessments
These may be necessary depending on the phase of the study:
1. inter-laboratory imprecision (reproducibility)
2. reference ranges
3. analyte stability –
¢ freeze–thaw
¢ short-term bench stability
¢ long-term storage stability (length and temperature)
4. pre-analytical variables –
¢ biological, for example within-subject variability, stress, exercise, diet and alcohol, smoking status,
drugs, pregnancy status, age, sex, comorbidities, race, sample timing
¢ technical, for example phlebotomy technique, blood collection systems, blood collection tubes,
sample preparation procedures, transportation conditions.
Specific biomarker technical (assay and pre-analytical) studies
undertaken within the programme
The assays selected for validation/verification were for biomarkers that we had prioritised for potential
analysis in either the RCC prognostic study undertaken within the time frame of this programme or in future
planned studies in RT in the case of NGAL. Selection was based on published studies at that time and this
has been reconfirmed through more recent studies, as reviewed in the previous chapter. Samples used for
these initial studies were obtained with fully informed consent as part of the Leeds multidisciplinary RTB
and had been collected and processed according to stringent in-house SOPs. For example, the Vacuette®
system was used (Greiner Bio-One, Frickenhausen, Germany), with Z/serum clot-activator tubes (coated with
micronised silica particles) and EDTA plasma tubes (K2EDTA). Samples were processed within 45–60 minutes
of venepuncture, with centrifugation at 2000 g at 20°C for 10 minutes. Serum and plasma were aliquoted
and stored at –80°C until used. The exceptions to this were samples obtained for interference studies
with high concentrations of factors such as bilirubin and lipid, which were obtained from Leeds Teaching
Hospitals Blood Sciences Laboratory as anonymised surplus diagnostic samples under project-specific ethics
approval (reference number 10/H1313/12) and without patient consent. The specific technical studies that
we undertook and the results, many of which have been published as indicated, are described in the
following sections.
Osteopontin
Introduction
Osteopontin is a member of the SIBLING family, which includes bone sialoprotein. An extracellular matrix
glycoprotein, OPN is produced by many cell types and is predominantly secreted, although intracellular
and other forms of OPN with varying post-translational modifications have been reported.744–746 With roles
in cell adhesion through binding to integrins and CD44 splice variants, OPN can differentially affect
adhesion and migration through cleavage by thrombin, with subsequent separation of the integrin- and
CD44-binding domains. Together with effects on proliferation, apoptosis and differentiation, OPN has
been implicated in many processes including tissue remodelling, inflammation and tumourigenesis and is
associated with tumour aggressiveness in several cancer types.744–746 This includes renal cancer in which
tissue expression of OPN and plasma OPN are associated with several prognostic clinical variables and are
prognostic themselves, although only plasma OPN has independent prognostic significance.615,616 Given the
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promising nature of those findings we selected OPN to evaluate further prognostically and consequently
we undertook an evaluation of an OPN ELISA prior to analysis of samples from a cohort of RCC patients
within our Leeds multidisciplinary RTB. The results from that study confirming the prognostic utility of OPN
have now been published486 and this study has been reviewed together with other relevant studies in the
previous chapter and has led to OPN being one of the prioritised biomarkers for evaluation in this NIHR
programme, as described in the following chapter.
Methodology
The OPN ELISA kit used was the Quantikine ELISA for human OPN from R&D Systems (Abingdon, UK).
All samples were assayed in duplicate and according to the manufacturer’s protocol. Assessment of
assay performance was based on our in-house protocol described earlier, including inter- and intra-assay
imprecision, parallelism and recovery (using recombinant OPN from Abcam, Cambridge, UK) and
interference. The main assessment was carried out using EDTA plasma samples as, during the clotting
process, OPN is proteolytically cleaved by thrombin, which is widely thought to lead to the lower OPN
concentrations found in serum.618 EDTA plasma samples from patients with RCC were used for the main
studies, with matched serum and EDTA plasma being used for the plasma–serum comparison that we
undertook to confirm the plasma–serum differences previously reported. In addition, as one of the future
local uses of this assay was for analysis of samples from patients in the Leeds melanoma cohort, whose
samples were shipped by post, we included a small study examining stability over up to 4 days post
venepuncture, as at that time there were no published data on the stability of OPN. For this purpose,
blood samples were collected into EDTA tubes from five melanoma patients and four healthy volunteers
with informed consent. For each individual, two 4-ml tubes of blood were collected, with one being
processed immediately after venepuncture and one being processed after 4 days at room temperature.
In each case, plasma was then removed, aliquoted and stored at −80°C until analysis.
Results
Serum compared with EDTA plasma
Results from a matched comparison of serum and EDTA plasma from six RCC patients clearly showed the
marked differences between serum and plasma OPN concentrations (Table 84). Most serum values ranged
between 40% and 65% of those obtained for plasma, with one exception for which a value of 93.1%
was seen. These differences are presumed to be the result of the thrombin cleavage previously described
and accordingly we used EDTA plasma for the assay evaluation studies.
Imprecision
Overall, intra-assay imprecision was 2.9%, with values of 3.1%, 2.8% and 2.8% for low, medium and
high QC samples, respectively, with each being assayed five times in duplicate in a single assay run.
Inter-assay imprecision was also < 10%.
Parallelism
Samples (n = 5 RCC samples) were titrated in parallel, with serial dilutions from 1 in 12.5 to 1 in 100,
and parallelism CVs ranged from 6.8% to 12.9%, which is within our limits of acceptability (< 15%).
TABLE 84 Comparison of plasma and serum OPN concentrations in matched samples
Sample
Patient
1 2 3 4 5 6
Plasma OPN (ng/ml) 45.11 71.79 36.73 286.65 269.8 99.7
Serum OPN (ng/ml) 21.45 31.30 18.75 137.03 251.2 63.5
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Recovery, interference and hook effect
As shown in Table 85, with the exception of one sample with a low spike for which the replicate CV was
> 10% and for which the result was, therefore, not available, recovery was acceptable for all EDTA plasma
samples (n = 6; n = 3 melanoma and n = 3 RCC samples), with low spikes of +217.5 ng/ml and high spikes
of +389.5 ng/ml.
No evidence of a hook effect was seen and bilirubin, haemolysis, triglycerides and rheumatoid factor
showed no appreciable signs of interference in terms of measured OPN concentration or dilution linearity.
Lower limit of quantification
This was assessed as being < 78 pg/ml, equating to 1.95 ng/ml in a sample diluted 25-fold. Further
evaluation of the LLoQ using lower OPN concentrations to determine an exact value was not carried out as
all samples measured were well above this value.
Sample stability
As shown in Figure 40, there was no significant difference in OPN concentrations in EDTA plasma between
blood samples (four healthy control subjects and five patients with melanoma) processed immediately and
blood samples processed 4 days later (Wilcoxon matched-pairs signed-rank test, p = 0.07), with the
majority of samples differing by < 3% between the two time points.
TABLE 85 The recovery of OPN spiked into EDTA plasma samplesa
Sample Clinical group
% recovery
Low spike High spike
1 Melanoma 102.3 93.1
2 Melanoma – 96.0
3 Melanoma 104.9 109.6
4 RCC 86.5 87.1
5 RCC 82.6 92.9
6 RCC 120.0 116.7
a Spiking was carried out at two concentrations using recombinant OPN.
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FIGURE 40 The effects of immediate vs. delayed processing on plasma OPN concentrations (n = 9). In the delayed
samples, the time elapsed between venepuncture and centrifugation of the EDTA blood samples was 4 days.
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Discussion
The assay performed satisfactorily in all aspects evaluated, briefly referred to in subsequent published
studies486,747 and confirming and extending the manufacturer’s documentation. The main issues to consider
going forwards relate to the forms of OPN measured in the various assays. Although we confirmed
in a small number of samples the marked serum–plasma differences in OPN concentration, which is
commented on in several studies and in the manufacturer’s kit insert as being the result of thrombin
cleavage of OPN, this is actually not clearly evidenced as definitely being the underlying mechanism when
the various studies are reviewed in more detail, as here. At the time that we undertook this evaluation we
clearly had not looked into this in as much detail as would have been ideal and had taken at face value
papers stating that this was based on earlier solid evidence.
Certainly, OPN is cleaved by thrombin experimentally and analysis of the amino acid sequence shows such
a cleavage site to be present.618 For the R&D Systems kit used here there are no data on the epitopes
recognised by the antibodies and so it is impossible to say for certain that this assay detects only the intact
form of OPN, although the lower concentrations of OPN in serum may support this. Similar findings using
this assay (or related R&D Systems reagents and protocol in the first study cited below) have been reported
before by other groups, for example with samples from healthy controls657 or RCC patients557 with
3.8- to 4.8-fold higher or 2.34-fold higher median OPN concentrations, respectively, in EDTA plasma
compared with serum. Using Western blotting to explore the differences in the serum and plasma forms
recognised by one of the antibodies was not conclusive, although it appeared that the monoclonal coating
antibody used recognised multiple forms of OPN, including the cleaved form.748 However, this would not be
quantified if the detection antibody was unable to recognise that fragment, which is not clear; in addition,
the fragments may bind to the coating antibody and compete with the intact form and, hence, affect
measurements indirectly. An alternative commercially available assay kit from Immuno-Biological Laboratories
(Gunma, Japan) documents the antibody specificity, with the kit insert describing the coating antibody as
recognising an epitope in the N-terminal region and the detection antibody binding to an epitope at the
C-terminal side of the thrombin cleavage site. This kit should, therefore, not detect the cleaved form of OPN
but it is very possible that the N-terminal fragment of cleaved OPN would bind to the coating antibody and
competitively inhibit the binding of intact OPN, with unknown quantitative effects, as discussed above,
certainly precluding the use of serum, as indicated by the manufacturer. For plasma this may not be an
issue, assuming that there is no circulating endogenous thrombin-cleaved OPN. A definitive assay for intact
OPN only that did not suffer from any competitive effects of the thrombin-cleaved form would have to
incorporate a coating antibody that recognises an epitope that spans the region of the thrombin cleavage
site and includes amino acids either side and which is accessible within the three-dimensional conformational
structure of OPN under assay conditions. Antibodies to various domains in the OPN protein have been used
in combination to design several ELISAs with different specificities for the different isoforms and truncated
forms (although not as per the above suggestion) and to characterise OPN in cell supernatant and urine
samples, demonstrating that, in the latter, few if any cleaved forms of OPN are present.749 One or possibly
two of these antibodies have been used in the Immuno-Biological Laboratories ELISA.749
Interestingly, OPN has also been reported to bind complement factor H and detection of OPN in serum
samples using an in-house competitive ELISA was possible only once such complexes had been disrupted
through heating in a chaotropic buffer with a reducing agent.750,751 Clearly, the effects of such complex
formation on OPN concentrations measured will be dependent on the antibodies used in the assay,
in the same way as for detection of intact compared with cleaved OPN. Whether or not this could also
contribute to the differences between serum and plasma OPN concentrations is not clear but clearly
spiking studies using complement factor H would be worth pursuing in future studies. In addition to the
presence/absence of calcium-regulating thrombin activity affecting OPN cleavage, OPN also binds calcium
and it is not inconceivable that the presence/absence of calcium in serum and plasma, respectively, could
influence the detection of OPN, depending on calcium-dependent epitopes recognised by antibodies, as
described later in this chapter for NGAL. If calcium is part of the underlying mechanism in this way, a
possible explanation may lie in the fact that OPN undergoes calcium-dependent polymerisation mediated
by transglutaminase 2, which may affect the accessibility of antibodies to binding sites and has been
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proposed to potentially contribute to differences in serum and EDTA plasma OPN concentrations.748
Alternatively, direct sequestration by the clot during formation of serum may account for the findings.748
In terms of stability, multiple freeze–thawing of plasma was not found in other studies to affect OPN
concentrations measured using a new multiplex assay or the R&D Systems assay, at least in the latter case
until the fifth freeze–thaw cycle.752,753 However, a study using the Immuno-Biological Laboratories ELISA
reported effects of freeze–thawing for both serum and to a lesser extent plasma, and even decreased OPN
concentrations after storage at –80 °C for 1–4 weeks, although no details were provided as to the extent
of these differences and whether or not these exceeded the variability of the assay.754 Different storage
conditions for plasma and serum prior to freezing have been reported to have little impact on OPN
concentrations.748 Whereas delaying centrifugation of whole blood prior to serum or plasma removal,
for up to 1 hour at room temperature or 6 hours at 4°C, did not affect plasma OPN concentrations,
similar to our results over a much longer time period, decreased OPN concentrations were detected in
serum measured after 15 or 60 minutes at room temperature, which is presumably occurs during the
clotting process.754
It is difficult to understand whether serum or plasma measurements of OPN provide the optimal
information clinically, particularly given the differences in fluid types used across studies and also with
direct comparison of different assays yielding very different results, whether because of the forms of OPN
present or measured or because of standardisation differences.755 Both serum and plasma OPN have been
shown to be prognostic in advanced non-small-cell lung cancer, for example, but in mesothelioma, with a
matched sample comparison, plasma was superior to serum.754,756–758 In a study of RCC published since
our study,486 both serum and plasma samples were used for OPN measurement, depending on what was
available for each patient, with independent prognostic value shown for both, although this included
multiple RCC subtypes.617 Interestingly, significantly higher OPN concentrations were found in men than in
women, in both plasma and serum, although it is not clear whether or not this was corrected for clinical
factors such as the stage and grade mix in the two groups, for example. This is under investigation in our
RCC cohort, but we did not find any significant sex-specific differences in normal healthy control subjects
and a study determining the reference range for OPN in 300 healthy individuals also found no significant
effects of age or sex and a low biological within-subject variation of 8.2%.753 This study also found similar
precision results for the R&D Systems assay to those in our study.
Clearly, although OPN has shown value in many studies across various disease areas and findings have
been shown to be reproducible in terms of clinical validity, further characterisation of the available
immunoassays with regard to the possible effects proposed here would be of value and could be relatively
easily achieved using spiking experiments, for example with complement factor H, cleaved OPN or serum
with EDTA. This may address some of the variability across studies and provide a clear way forward as to
the optimal way of determining OPN concentrations and importantly provide clarity as to which form(s)
is the most relevant clinically in the different disease areas, allowing the potential of OPN as a biomarker to
be more fully and robustly realised.
Carbonic anhydrase IX
Introduction
Carbonic anhydrase IX is a 46-kDa membrane protein that has been shown to exist in several forms as a
result of alternative splicing, proteolytic cleavage, glycosylation and phosphorylation.759–762 Playing an
important role in regulating intracellular pH, allowing cell survival in hypoxic conditions, for example,
increased expression in renal cancer was initially recognised through positive reactivity of a monoclonal
antibody (clone G250), with the antigen later being identified as CAIX/MN protein.606,607,763,764 It is now
known that this upregulation is also present in other cancers and is mediated through hypoxia-inducible
factor-1α (HIF-1α), which in RCC is increased as a downstream consequence of the VHL gene alterations,
as described in Chapter 10.765 The use of CAIX has been investigated both in diagnostic imaging and as a
therapeutic target in antibody, vaccine or small molecule inhibitor-based strategies.766,767 At the time that
we commenced our studies relating to CAIX, several studies had shown tissue expression of CAIX to be
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prognostic, and soluble CAIX in serum or plasma from patients with RCC and also other cancers appeared to
have both prognostic and predictive potential, although there was inconsistency across studies.428,608–610,768–773
Given these findings and the biological relevance related to the VHL gene, we selected CAIX as a potential
prognostic biomarker to explore further, initially in the Leeds multidisciplinary RTB cohort, which has now
been published,486 and now with further studies using the NIHR cohort, as described in the previous chapter.
We describe here the analytical verification of two commercially available immunoassays for CAIX and the
issues encountered, which have important consequences for some published studies and highlight the
importance of adequate validation in the first place and later verification. Our findings have been published
in detail774 and are summarised here.
Methodology
A total of 17 sets of matched serum and EDTA plasma samples from patients with RCC of varying age,
sex, stage and grade were used for the various parts of the verification study. The assays used were both
commercially available sandwich ELISAs: the human MN/CAIX ELISA kit from Oncogene Science Diagnostics
(Cambridge, MA, USA)/Siemens Healthcare Diagnostics and the Quantikine human CAIX/CA9 ELISA kit
from R&D Systems (Minneapolis, MN, USA). The initial work was carried out using the Siemens assay only
but, once it became apparent that there were some problems with this assay, the R&D Systems assay was
also examined to help resolve the nature of the problems seen and also as a possible alternative to use in
future studies. Samples were assayed in duplicate and the manufacturers’ protocols were followed in each
case. The LoD of the Siemens and R&D Systems assays, as quoted by the manufacturers, are 2.5 and
2.28 pg/ml, respectively. Assay verification was based on our in-house protocol described earlier, including
elements such as imprecision, parallelism, specificity and recovery. Following demonstration of specific issues
with the Siemens assay, additional ad hoc investigations were undertaken, including direct comparisons of
serum and plasma and the effects of metal ions, to determine the nature of the problems.774
Results
Standardisation
Differences in standardisation were apparent, with analysis of recombinant CAIX (rCAIX) showing a ratio
of Siemens-to-R&D assay values of 2.8. Reciprocal analysis of standards between the assays showed
average ratios of 2.51 and 3.13, supporting this, with the slight differences presumably caused by the
differing matrices of the standards between the two assays. However, analysis of 15 plasma samples
showed Siemens-to-R&D ratios that varied from 1.95 to 17.3, with values for 15 matched serum samples
varying from 0 to 7.1, indicating that, with clinical samples, additional factors were affecting the results.
Imprecision
Intra-and inter-assay imprecision for both assays was < 10% at concentrations of CAIX spanning the
standard curve, although CVs of 14.5% and 18.6%, respectively, were found for the lowest concentration
controls analysed using the Siemens assay. For any sample duplicate, the CV was generally < 5% of the
mean and this was the same for both assays.
Parallelism
Issues were found with the Siemens assay, with one of five samples passing compared with five out of five
samples using the R&D assay, as shown in Figure 41.
Recovery and specificity
As shown in Table 86, recovery was acceptable for all EDTA plasma samples tested on both the Siemens
assay and the R&D Systems assay. Serum was not tested in the Siemens assay because of emerging
problems with this assay. For the R&D Systems assay, one of five serum samples showed poor recovery of
both high and low spikes. Cross-reactivity with carbonic anhydrase II and carbonic anhydrase XII was
minimal or non-existent for both assays.
Measurement of carbonic anhydrase IX and effects of metal ions
No significant difference was seen between results obtained for matched EDTA plasma and serum samples in
the R&D Systems assay (Figure 42), with a significant correlation (p < 0.001; R2 = 0.998) and a slope of 0.905.
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FIGURE 41 Results from the assessment of parallelism of the CAIX assays. (a) Siemens assay; and (b) R&D Systems
assay. Open symbols = serum and closed symbols = plasma. Back-calculated concentrations are plotted against
serial doubling dilutions of the samples, with arrows indicating the normal working dilution used in each assay.
Reproduced from Wind et al.774 with permission.
TABLE 86 Recovery of rCAIX spiked into EDTA plasma and serum samples
Assay Sample
Sample
EDTA plasma Serum
Initial CAIX
concentration
(pg/ml)
% recovery Initial CAIX
concentration
(pg/ml)
% recovery
Low spike High spike Low spike High spike
Siemens 1 516.5 102.2 88.4
2 830.9 93.3 81.0
3 485.1 94.1 88.2
R&D Systems 4 483.3 81.7 80.2 502.4 59.4 66.7
5 92.4 82.3 86.3 92.7 86.7 84.9
6 26.9 81.7 83.0 27.4 81.5 91.2
7 47.6 82.0 91.5 53.2 89.9 93.5
8 84.0 97.8 90.7 88.0 94.0 86.6
Reproduced from Wind et al.774 with permission.
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FIGURE 42 The relationship between concentrations of CAIX in EDTA plasma or serum. Results are shown for
15 matched sample pairs assessed using (a) the Siemens assay and (b) the R&D Systems assay. The dotted line
shows the line of equivalence with a slope of 1. (c) shows the effects on the CAIX concentrations as measured
using the Siemens assay of adding 20mmol/l of CaCl2 to EDTA plasma or adding 1.8mg/ml of EDTA to serum.
(d) The reversibility of the effect is shown by the sequential addition of CaCl2 and EDTA to EDTA plasma or rCAIX.
Reproduced from Wind et al.774 with permission. (continued )
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Using the R&D Systems assay, EDTA plasma concentrations ranged from 17.7 pg/ml to 482.9 pg/ml and
serum concentrations ranged from 18.2 pg/ml to 436.6 pg/ml. However, with the Siemens assay, significantly
higher CAIX concentrations were found in the EDTA plasma samples than in the serum samples (p < 0.001)
and, although significantly correlated, (p < 0.001; R2 = 0.961), the slope of the line was only 0.538, with
several outlying samples. EDTA plasma concentrations ranged from 34.5 pg/ml to 1476.4 pg/ml whereas in
the matched serum samples concentrations ranged from < 2.5 pg/ml to 770.6 pg/ml.
These differences between serum and plasma in the Siemens assay were originally assumed to be the
result of clotting events causing a generic reduction in measurable CAIX in serum rather than this being
assay specific as at that time we had not used the R&D Systems assays as a comparator. Addition of excess
calcium to EDTA plasma to promote clot formation and effectively generating serum did reduce the CAIX
concentrations measured, almost to those resulting from analysis of serum directly, as shown in Figure 42,
supporting this possibility. However, this was reversible, with a marked elevation of CAIX detected when
EDTA was added to the serum. Importantly, this was also seen with rCAIX. These results, together with
the fact that the R&D Systems assay showed no difference between serum and plasma, clearly indicated
that clotting per se was not responsible for the effects seen in the Siemens assay but that metal ions
may be the cause. Magnesium and calcium were interchangeable in terms of causing this effect and no
effects were seen with calcium or EDTA addition in the R&D Systems assay, indicating that this was an
assay-specific effect.
Introducing the Siemens capture antibody into the R&D Systems assay did not change the R&D Systems
pattern of results in terms of serum and plasma having similar measured CAIX concentrations. However,
using the R&D Systems capture antibody in combination with the Siemens detection antibody resulted in
marked differences in the values generated for serum and plasma (Figure 43), indicating that the Siemens
detection antibody (M75 clone) is responsible for the effects seen.775 The most likely explanation is that this
antibody recognises a metal ion-dependent epitope.
Discussion
No studies have been published that have undertaken verification of the available assays for soluble CAIX,
despite there now being considerable interest in its potential clinical utility. Early studies, predominantly
focused on RCC, have reported elevated serum or plasma concentrations, decreasing in some cases post
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FIGURE 42 The relationship between concentrations of CAIX in EDTA plasma or serum. Results are shown for
15 matched sample pairs assessed using (a) the Siemens assay and (b) the R&D Systems assay. The dotted line
shows the line of equivalence with a slope of 1. (c) shows the effects on the CAIX concentrations as measured
using the Siemens assay of adding 20mmol/l of CaCl2 to EDTA plasma or adding 1.8 mg/ml of EDTA to serum.
(d) The reversibility of the effect is shown by the sequential addition of CaCl2 and EDTA to EDTA plasma or rCAIX.
Reproduced from Wind et al.774 with permission.
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surgery, and variable associations with tumour size, stage and prognosis.608–610,768,770 There has also been
interest in other cancers and, even since we undertook this validation study, particularly promising results
have been obtained for CAIX within a diagnostic urinary biomarker panel for bladder cancer and further
studies in RCC have been published, as reviewed in the previous chapter.774,776–778 Clearly, our results show
the need to undertake such studies so that results can be generated robustly and that the Siemens assay
has not undergone adequate validation prior to becoming commercially available. In contrast, the R&D
Systems assay performed well although confirmation of the manufacturer’s sensitivity data is needed as
well as the potential effects of other pre-analytical factors.
The explanation of the metal ion effect that we have described on the binding of CAIX to antibodies
within the Siemens assay is not completely clear. Cleavage of the extracellular region of CAIX generates at
least two soluble forms (50 and 54 kDa).608,762 This region contains the carbonic anhydrase (CA) catalytic
domain, which has three metal-binding regions important for the catalytic activity, and the V10 capture
antibody recognises a conformational epitope in this domain.762,779,780 However, our evidence supports
the phenomenon seen in our studies as arising through the M75 detection antibody, which recognises a
linear epitope on the PG-like domain, also present in the extracellular region.781 This could be explained
by the finding that the catalytic activity of CAIX is also regulated by binding of multiple divalent cations to
this negatively charged PG domain. It is conceivable, therefore, that the M75 antibody binds a metal
ion-dependent epitope, with metal ions then either directly inhibiting binding of M75 to CAIX competitively
or inhibiting binding by induction of a conformational change.759 Although this markedly affects the serum
results in particular, effects on plasma measurements when a chelating agent is present may also be
affected to variable extents, depending on the variability in the final concentrations of EDTA, for example.
This issue was not apparent from the data given in the Siemens assay kit insert, but the kit insert did show
a possible trend towards lower concentrations in serum, although slight, and only samples from healthy
volunteers were used, with lower CAIX concentrations. Many published studies have used the R&D Systems
assay but several studies in renal, ovarian, lung and bladder cancer have been undertaken with the Siemens
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FIGURE 43 The effect of crossing over antibodies between assays to determine which antibody–antigen interaction
accounts for the metal ion-dependent effects seen in the measurement of CAIX. Results are shown for four matched
pairs of EDTA plasma and serum samples assayed using the R&D Systems assay, the Siemens assay or each of these
but with the capture antibodies swapped between the assays. Absorbances were measured at 450 nm in both
cases but background subtraction at 540 nm was carried out in the case of the R&D Systems assay. Reproduced from
Wind et al.774 with permission.
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assay or assays involving the M75 antibody and the results may, therefore, be questionable.608,769–773 As the
M75 antibody clone is also used in many immunohistochemical studies, it is possible that results obtained
may depend on the buffers used and the presence/absence of metal ions. This effect of metal ions on
epitope availability and analyte measurements is relatively rare, with possible examples, although not
necessarily occurring through the same mechanism, including the calcium dependence of calretinin782 and
S100A12783 measurements. Our results clearly demonstrate the need for careful independent verification of
commercially available immunoassays, even from large diagnostics companies. As far as we are aware, the
Siemens assay used in this study is still available, although from a different source, Nuclea Biotechnologies
Inc. (Cambridge, MA, USA), as around the time of this study Wilex Inc. acquired the assets of Oncogene
Science from Siemens Healthcare Diagnostics and in 2013 Nuclea Biotechnologies acquired Wilex. It is not
readily apparent that the assay available currently has been modified in any way from the one that we used
and it certainly uses the M75 antibody. Nuclea Biotechnologies has a major interest in CAIX and has recently
announced that its CAIX automated immunohistochemisty (IHC) kit has been granted FDA class I in vitro
diagnostic (IVD) status, which will be of potential utility in several cancer types, although particularly in
determining the aggressiveness of head and neck squamous cell carcinomas. The question of whether it is
the responsibility of the manufacturer or end user to ensure that assays are validated and verified more
robustly was rasied in an editorial focusing on our study784 and it may be that the answer lies in more open
partnerships between the manufacturers and researchers at early stages of biomarker research studies.
Neutrophil gelatinase-associated lipocalin
Introduction
One of the most promising emerging kidney-related biomarkers is NGAL, in particular in AKI, which is
now recognised as a major health problem.785,786 Originally isolated from neutrophils in 1993, NGAL was
proposed as a novel urinary biomarker of ischaemic kidney injury produced predominantly by proximal
tubule cells 10 years later, although subsequently an NGAL reporter mouse model has supported a distal
tubule cellular origin.787–789 Now known to be expressed by several tissues, the predominant form released
by renal tubules is a 25-kDa monomer whereas the main neutrophil-derived form is a 45-kDa homodimer.790
In addition, NGAL exists as a 125-kDa covalently complexed heterodimer with matrix metalloproteinase-9
(MMP-9) and other forms have been found.787,791–793 Key functions are in protecting against MMP-9-
mediated degradation, a role in bacteriostasis through mediating shuttling of iron through binding
siderophores, and multiple effects on cell proliferation, differentiation and apoptosis.790 Our interest in
NGAL was stimulated by the rapidly growing level of interest surrounding NGAL in renal diseases, with
urinary, plasma and serum concentrations of NGAL having been shown to be superior to creatinine
diagnostically or prognostically in AKI in several studies when reviewed at that time and urinary NGAL
outperforming kidney injury molecule-1, cystatin C, IL-18 and liver-type fatty acid-binding protein in a large
prospective study in the emergency department setting.794–797 Of particular interest was emerging evidence
of an association with DGF following RT.798,799
However, it was also apparent even then that, to provide definitive answers to its potential clinical utility,
bigger prospective studies needed to be pursued and the impact of factors such as background levels of
CKD on NGAL determined. In addition, there was a lot of uncertainty regarding the assays used and
form of NGAL being measured, with only a small number of limited studies having been undertaken.800–803
To contribute to the evidence, we undertook a study to independently examine five of the commercially
available assays for NGAL, two CE-marked IVDs and three research use-only ELISAs, using urine samples,
as most assays had been validated only for that matrix. This study has been published804 and the findings
are described in brief in the following sections.
Methodology
Mid-stream urine samples from patients with AKI, RCC, renal stones, recurrent UTI or diabetic albuminuria
or healthy control subjects (to ensure a variety of matrix backgrounds and NGAL concentrations; n = 78
in total) were banked for this study after processing according to local SOPs. The CE-marked assays
evaluated were the NGAL Test™ from BioPorto Diagnostics A/S (Hellerup, Denmark), a particle-enhanced
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turbidimetric immunoassay that we used on the Siemens ADVIA® 1800 platform, and the ARCHITECT®
Urine NGAL assay from Abbott Laboratories (Chicago, IL, USA), a two-step chemiluminescent microparticle
assay that we used on the ARCHITECT i2000SR analyser. The research use-only assays evaluated were
all of the sandwich ELISA format for human NGAL and were the NGAL ELISA (HK330) from Hycult
Biotech (Uden, the Netherlands), the NGAL ELISA Kit 036 from BioPorto Diagnostics and the Quantikine
Lipocalin-2/NGAL (DLCN20) immunoassay from R&D Systems. All assays were performed according to the
manufacturers’ instructions. Assay verification was based on our in-house protocol described earlier, with
assessment of imprecision, parallelism, recovery, selectivity, limit of quantitation, haemoglobin interference
and high-dose hook effect, as described in detail in Kift et al.804 Measurements were performed in
singlicate on the ARCHITECT and ADVIA platforms and in duplicate for all ELISAs, and CVs of < 10%
within replicates were considered acceptable.
Results
Our detailed findings are summarised below and in Table 87. As we found a much higher LLoQ with the
BioPorto/ADVIA assay than expected from the manufacturer’s specification, we were unable to investigate
recovery and effects of the NGAL/MMP-9 complex and haemoglobin with this assay as the endogenous
NGAL concentrations were below the LLoQ determined in practice and so the baseline values could not
be used.
TABLE 87 Summary of the performance data for the five NGAL assays evaluated using urine samplesa
Test
Assay
BioPorto/ADVIA Abbott R&D Systems BioPorto ELISA Hycult
Assay standards (ng/ml), range 150–5000 10–1500 0.156–10 0.01–1 0.4–100
Dilution factor, range NA NA 1/25–1/800 1/500–1/4000 1/20
Imprecision % CV, range (median)
Intra-assay (n= 5 for each of
four QC samples)
0.7–3.0 (2.0) 0.8–10.8 (1.4) 3.2–4.4 (3.6) 0.6–5.1 (3.4) 5.8–34.4 (8.8)
Inter-assay (n= 10 for each
of four QC samples)
1.9–7.9 (3.7) 4.8–9.9 (7.6) 3.2–10.1 (7.1) 6.4–15.8 (12.6) 26.1–33.3 (30.2)
% parallelism, range (median; n) 1.9b (1.9; 1) 2.2–5.8
(3.0; 3)
1.9–7.9
(3.6; 3)
3.2–49.8
(44.6; 3)
17.8–30.2
(21.5; 3)
% recovery, range (median; n) Not determinedb 88.6–99.1
(95.6; 8)
93.5–106.7
(98.9; 9)
100.6–113.4
(104.1; 8)
73.6–95.2
(88.1; 8)
Specificity
+ MMP-9 Not determinedb No effect No effect No effect Inconclusive
+ complex Not determinedb No effect No effect No effect Inconclusive
LoQ (ng/ml) (including sample
dilution factor)
150 5 0.078 (2.0) 0.01 (5.0) 1 (20)
Haemoglobin interference
0.75, 1.125, 2.25 µg/ml
(+/++/+++)
Not determinedb No interference No interference No interference Interference
5.0 mg/ml Not determinedb Interference Interference Interference Interference
Hook analysis Hook effect No effect No effect No effect Inconclusive
NA, not applicable.
a This table represents an adaptation of Table 1 from Kift et al.,804 where full details of all results and spike concentrations
can also be found in Supplementary Table S1.
b Not determined or determined in limited samples because of endogenous NGAL concentrations being below the LLoQ,
as determined by this study.
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Imprecision
Intra-assay imprecision was generally acceptable across all platforms, with one exception of a CV of 34.4%
with the low NGAL QC urine sample in the Hycult assay. Problems with the Hycult assay only were also
seen for inter-assay imprecision, which was unacceptable, and this assay also showed poor agreement
between replicates.
Parallelism
As shown in Figure 44, parallelism was demonstrated for the Abbott and R&D Systems assays but not for the
Hycult assay and for two-thirds of the samples in the BioPorto ELISA. An issue with one sample was also seen
on the BioPorto/ADVIA assay, although the issues relating to the LLoQ meant that this was inconclusive.
Lower limit of quantification
The LLoQ values for the Abbott assay and R&D Systems, BioPorto and Hycult ELISAs were 5, 2, 5 and
20 ng/ml, respectively, including any dilution factors. The LLoQ was 150 ng/ml for the BioPorto/ADVIA
assay, which was much higher than expected given the manufacturer’s figure of 25 ng/ml for the lower
end of the measuring range.
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FIGURE 44 Results from the assessment of parallelism for each of the five assays, comparing dilution-adjusted
NGAL concentrations (log scale) against serial double dilutions of each of three samples represented by different
colours: (a) BioPorto/ADVIA; (b) Abbott; (c) R&D; (d) BioPorto ELISA; and (e) Hycult. The initial dilution factor used
is indicated next to each sample dilution. Fine dashed lines illustrate ±15% of the mean for each sample. ‘<LLoQ’
highlights sample dilutions that fall below the LLoQ determined by this study. Reproduced from Kift et al.804 with
permission. (continued )
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FIGURE 44 Results from the assessment of parallelism for each of the five assays, comparing dilution-adjusted
NGAL concentrations (log scale) against serial double dilutions of each of three samples represented by different
colours: (a) BioPorto/ADVIA; (b) Abbott; (c) R&D; (d) BioPorto ELISA; and (e) Hycult. The initial dilution factor used
is indicated next to each sample dilution. Fine dashed lines illustrate ±15% of the mean for each sample. ‘<LLoQ’
highlights sample dilutions that fall below the LLoQ determined by this study. Reproduced from Kift et al.804
with permission.
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Recovery
A stock solution of recombinant NGAL (rNGAL; 1 mg/ml, with ≈80–90% monomeric form) gave quite
different results across the assays, with near-quantitative results for the BioPorto ELISA but 31% recovery
for the Hycult assay and 67–75% recovery for all other assays. This may reflect differences between the
assays in specificity for the different NGAL forms or in standardisation. To overcome this, the recovery of
spiked rNGAL material in urine samples was related to the assay-specific assigned concentrations for the
rNGAL stock, essentially allowing the determination of relative recoveries and allowing assays to be
compared. Acceptable recoveries were found with the Abbott assay and R&D Systems, BioPorto and
Hycult ELISAs (with the exception of a recovery of 73.6% for one sample in the Hycult ELISA).
Selectivity
None of the assays detected the rNGAL/MMP-9 complex and neither rMMP-9 (recombinant matrix
metalloproteinase 9) nor the complex affected the urinary NGAL results, except for the Hycult assay, where
variable effects were seen.
Haemoglobin interference
The Hycult assay was affected by haemoglobin at all concentrations tested but all other assays were
affected only at the highest concentration of haemoglobin of 5 mg/ml.
Hook effect
A hook effect was absent from the Abbott assay and the R&D Systems and BioPorto ELISAs. However,
using the BioPorto/ADVIA assay, a typical high-dose hook effect was seen, although only at NGAL
concentrations of > ≈70,000 ng/ml. With the Hycult assay an atypical effect was seen in which the assay
appeared to plateau at NGAL concentrations of 20–25 ng/ml, although the range of the standard was up
to 100 ng/ml (Figure 45).
Inter-assay neutrophil gelatinase-associated lipocalin comparison
Using the BioPorto/ADVIA and Hycult assays, > 50% of the urine samples were below our determined
LLoQ values and so could not be included in comparison results involving those assays. From the modified
Bland–Altman plots (Figure 46), it can be seen that there was generally good agreement between the Abbott
and R&D Systems assays, with only two samples falling outside 95% of overall bias and a mean bias of 14%.
A Passing–Bablok analysis for comparison of these two assays only demonstrated that data lay on the line of
equality. Good agreement between the BioPorto ELISA and the Abbott and the BioPorto/ADVIA assays was
also seen, with a mean bias of 13% and 23%, respectively (the latter case included only 22 samples). The
results from the two BioPorto assays tended to be higher than those obtained with the other assays. The
Hycult assay showed a marked negative bias, with 29 of the 32 samples above the LLoQ showing NGAL
concentrations of < 50% of those measured on the Abbott assay, with some values even being < 20%.
With the Hycult assay, no urine samples demonstrated NGAL concentrations of > 20 ng/ml (400 ng/ml
corrected for dilution), which mirrors the plateau effect of this assay shown in the hook effect studies.
Discussion
Our independent verification findings support the Abbott and R&D Systems assays as having been
validated adequately by the manufacturers and producing comparable results. A single published study
evaluating the Abbott assay and sample stability had previously reported excellent reproducibility and
precision, despite not examining other aspects such as recovery, linearity and selectivity, and found
functional sensitivity (based on imprecision of < 20% alone in this case) to be < 2 ng/ml,800 which is similar
to our determination of a LLoQ of < 5 ng/ml. Acceptable variability of the Abbott assay was also reported
in a further small study.803 Excellent performance characteristics had been previously reported for the
BioPorto ELISA in an extensive verification study with both urine and plasma, although issues were
reported for inter-batch variability and there was some evidence of non-parallelism.802 The latter was not as
pronounced as that seen in our study and this may reflect study-specific differences such as the urinary
matrices (paediatric vs. adult), dilution factors or NGAL forms present. The fundamental reasons for the
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saturation of the Hycult assay, essentially rendering it unusable, are not clear but, again, this may reflect a
combination of differences in standardisation and forms of NGAL recognised and potentially interfering.
Although broadly comparable to other assays, we found that the BioPorto assays were biased towards
higher concentrations, although not as marked as the 65% bias previously reported in a comparison of the
BioPorto assay on the Beckman Coulter platform with the Abbott assay.801 Marked biases were also seen in
a study comparing two Bioporto assays with the Abbott assay.805 Whether such results arise because of
differences in standardisation, assay design or NGAL forms measured (including possibly glycoforms) is not
clear but we saw this with both recombinant and endogenous NGAL and, even with assays with good
agreement, differences were apparent in some samples. Clearly, the forms of NGAL detected will depend
on the antibodies used in the various assays but our results demonstrate that the NGAL/MMP-9 complex
was not detected by and did not interfere with measurement of NGAL in the Abbott, BioPorto and R&D
Systems assays.791,793,806–808 The relative specificities of the assays for the monomeric and dimeric forms of
NGAL were not determined, although a study reporting a significant association of monomeric forms with
tubulointerstitial fibrosis in CKD found a significant correlation between urinary NGAL results obtained
using the Abbott assay and the monomeric form detected by Western blotting. However, it appears that a
systematic analysis of the absolute specificity for this form had not been undertaken.792 Assays able to
robustly differentiate between the NGAL forms would be useful in terms of determining potential
contributory sources and providing further clinical insight and this is currently being addressed by several
companies. For example, predominantly homodimeric NGAL is found in urine from patients with UTI
compared with monomeric NGAL in patients with AKI and mainly elevations in homodimeric NGAL in
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FIGURE 45 Results from the hook effect analysis. (a) Point-to-point line illustrates the high-dose hook effect seen
in the BioPorto (in vitro diagnostic) assay, with the dotted line showing the upper limit of the assay range; and
(b) Hycult assay data illustrating the plateauing/saturation effect, with the dotted line showing the upper limit of
the assay range. Reproduced from Kift et al.804 with permission.
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FIGURE 46 Modified Bland–Altman plots for various comparisons of the NGAL assays: (a) Abott vs. R&D Systems;
(b) Abott vs. BioPorto/ADVIA; (c) Abott vs. BioPorto ELISA; (d) R&D Systems vs. BioPorto/ADVIA; (e) R&D Systems
vs. BioPorto ELISA; (f) BioPorto/ADVIA vs. BioPorto ELISA; (g) Hycult vs. Abbott; (h) Hycult vs. R&D Systems; (i) Hycult
vs. BioPorto/ADVIA; and (j) Hycult vs. BioPorto ELISA. Samples that fell below the LLoQ have been omitted from the
relevant plots. In (g)–(j) the y-axis has been expanded to incorporate the differences seen. The solid green line indicates
no bias, with the dotted lines indicating the mean bias and the limits of agreement (mean difference ±1.96 SDs of the
differences). In each case the difference referred to on the y-axis is the second assay in the plot title subtracted from
the first named assay. Reproduced from Kift et al.804 with permission. (continued)
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FIGURE 46 Modified Bland–Altman plots for various comparisons of the NGAL assays: (a) Abott vs. R&D Systems;
(b) Abott vs. BioPorto/ADVIA; (c) Abott vs. BioPorto ELISA; (d) R&D Systems vs. BioPorto/ADVIA; (e) R&D Systems
vs. BioPorto ELISA; (f) BioPorto/ADVIA vs. BioPorto ELISA; (g) Hycult vs. Abbott; (h) Hycult vs. R&D Systems; (i) Hycult
vs. BioPorto/ADVIA; and (j) Hycult vs. BioPorto ELISA. Samples that fell below the LLoQ have been omitted from the
relevant plots. In (g)–(j) the y-axis has been expanded to incorporate the differences seen. The solid green line indicates
no bias, with the dotted lines indicating the mean bias and the limits of agreement (mean difference ±1.96 SDs of the
differences). In each case the difference referred to on the y-axis is the second assay in the plot title subtracted from
the first named assay. Reproduced from Kift et al.804 with permission. (continued )
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FIGURE 46 Modified Bland–Altman plots for various comparisons of the NGAL assays: (a) Abott vs. R&D Systems;
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no bias, with the dotted lines indicating the mean bias and the limits of agreement (mean difference ±1.96 SDs of the
differences). In each case the difference referred to on the y-axis is the second assay in the plot title subtracted from
the first named assay. Reproduced from Kift et al.804 with permission. (continued)
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urine in patients following cardiac surgery in the absence of AKI, suggesting a predominant activated
neutrophil source.793,806 Indeed, in a cohort of 5599 individuals from the general population recruited into
the Copenhagen Heart Study, plasma NGAL measured using an in-house assay was significantly associated
with several inflammatory indices, particularly neutrophil count and CRP, in addition to showing an
inverse association with estimated glomerular filtration rate (eGFR), and was independently associated
with outcome irrespective of eGFR.809 Interestingly, similarly elevated plasma NGAL concentrations were
found in anephric and anuric patients on dialysis compared with healthy individuals, providing support for
the elevated NGAL levels in CKD being predominantly extra-renal, although the balance of increased
production against decreased clearance in accounting for the elevated concentrations is not known.810
The most surprising finding was the marked disparity between the manufacturer’s reported measuring
range for the CE-marked BioPorto/ADVIA assay and our LLoQ findings, which essentially placed the LLoQ
at the suggested optimal cut-off value for NGAL in diagnosing AKI, a situation that is far from ideal given
the inherent greater variability in that area.795 This may well be platform specific as previous studies had
reported the performance of this assay to be acceptable on the Beckman Coulter AU 5822 platform,
although LLoQ, hook effect and recovery were not investigated,801 and also on the Roche Cobas 6000
and Hitachi 917 platforms, although consistently higher results were obtained for EDTA plasma on the
former.811 Following our study, BioPorto issued a new version of the application note for the ADVIA
platform, with a revised measuring range and LLoQ included among the changes.
The significance of the interference of very high concentrations of haemoglobin in all assays (although a
previous study had not found this for the Abbot assay800) is not clear and the extent to which such high
concentrations are found clinically in urine needs to be investigated. Certainly, haemolysis of whole blood
is known to affect plasma NGAL measurements, although this could potentially reflect the presence of
neutrophil-derived NGAL or interference by haemoglobin directly.802 The importance of such technical and
biological pre-analytical effects is beginning to be recognised for NGAL, with an association of leukocyturia
with higher NGAL concentrations, much higher concentrations of NGAL being present in serum compared
with matched EDTA plasma samples, most likely because of release of NGAL from neutrophils, which is of
particular importance when historical studies are compared, and age- and sex-related effects on urinary
NGAL being reported.812–816 Stability during processing and storage does not seem to be an issue under the
conditions examined.817,818
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FIGURE 46 Modified Bland–Altman plots for various comparisons of the NGAL assays: (a) Abott vs. R&D Systems;
(b) Abott vs. BioPorto/ADVIA; (c) Abott vs. BioPorto ELISA; (d) R&D Systems vs. BioPorto/ADVIA; (e) R&D Systems
vs. BioPorto ELISA; (f) BioPorto/ADVIA vs. BioPorto ELISA; (g) Hycult vs. Abbott; (h) Hycult vs. R&D Systems; (i) Hycult
vs. BioPorto/ADVIA; and (j) Hycult vs. BioPorto ELISA. Samples that fell below the LLoQ have been omitted from the
relevant plots. In (g)–(j) the y-axis has been expanded to incorporate the differences seen. The solid green line indicates
no bias, with the dotted lines indicating the mean bias and the limits of agreement (mean difference ±1.96 SDs of the
differences). In each case the difference referred to on the y-axis is the second assay in the plot title subtracted from
the first named assay. Reproduced from Kift et al.804 with permission.
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The aspects of NGAL measurement highlighted in this chapter are crucial to an interpretation of studies
examining the clinical validity and utility of NGAL measurements. However, the extent to which studies or
reviews examining the clinical potential of NGAL785 consider such aspects is highly variable, with, for
example, a review of the broader clinical applications of NGAL only briefly mentioning such aspects, an
earlier meta-analysis of studies examining the potential of NGAL in AKI diagnosis including a consideration
of the assays used786 and a recent review focusing on NGAL in predicting AKI providing a much more
comprehensive overview, including a tabulated summary of the assays used in each study.795 The last
review, although supporting the promise of NGAL, also flagged up the issue that many of the studies had
an inadequate study design and failed to follow guidelines such as the STARD criteria,368 issues to address
if NGAL is to fulfil its potential. Indeed, although agreeing that NGAL is a promising biomarker, the idea
that it is the ‘troponin of the kidney’ has recently been used as an example of one of the ‘false myths and
legends’ in laboratory diagnostics,790 and further analytical and biological insights including understanding
of the impact of comorbidities and specific assays for kidney-derived NGAL are needed to allow rational
evaluation and optimal use.796,819
Vascular endothelial growth factor: relative value of serum or plasma and quality
control aspects
Introduction
Vascular endothelial growth factor-A (VEGF-A), often referred to as VEGF, although there are several family
members, is a major angiogenic cytokine. Existing as several isoforms generated by alternative splicing,
there has been considerable interest in VEGF, particularly in cancer, given its pivotal role in regulating
angiogenesis.820,821 With increased understanding of the underlying mechanisms involving hypoxia and
HIF-1α in upregulating VEGF, numerous therapies have been developed targeting this pathway and are in
use across many cancer types.587 This has particularly been the case in ccRCC, given the widespread
inactivation of the VHL gene and consequent stabilisation of HIFs and increased expression of VEGF and
the ineffectiveness of conventional chemotherapy.822 Accompanying this has been a raft of studies
exploring the possible use of VEGF as a biomarker, in particular for either prognostic use or for predicting
response to VEGF-related therapies. In renal cancer, several studies have reported predictive uses for VEGF
or its receptors, although studies are small and heterogeneous and require further confirmation.823 As
reviewed in the previous chapter, VEGF has also shown promise in RCC prognostically, although this is
complicated by studies using either serum or plasma, in which concentrations vary markedly. When we
and others first reported such serum–plasma differences in VEGF, this was proposed to be the result of
platelets containing and releasing VEGF, which was subsequently confirmed in several studies.600,601,824
Based on the evidence reviewed in Chapter 12, VEGF was included as one of the prioritised biomarkers for
the RCC prognostic study undertaken as part of this programme and we included both plasma and serum
VEGF to determine which, if any, provides clinically useful information, particularly given the impact of
processing, as reviewed extensively below. The results of the prognostic study are described in Chapter 14
but we describe here some of the technical aspects of the measurements.
Methodology
As described in the following chapter, VEGF concentrations were determined for the RCC patients in the
prognostic cohort. Matched serum and EDTA plasma samples were analysed for each patient as available,
with a total of 430 patients having both sample types with detectable VEGF in both. Samples were
analysed using the Human VEGF Quantikine kit from R&D Systems, which is a sandwich ELISA specifically
measuring VEGF-A. This assay is one of the most widely used commercially available assays for VEGF and
we previously carried out validation studies of this assay, both when evaluating the importance of blood
sample handling and also when describing the existence of a novel soluble VEGF receptor variant in
amniotic fluid.630,825 All aspects evaluated, including parallel dilution, within- and between-run precision
and recovery, were acceptable and similar findings were reported in subsequent studies using this
assay.826,827 It was apparent that the assay measured the free form of VEGF and not VEGF complexed with
the receptors and, although specific for VEGF-A, both VEGF121 and VEGF165 isoforms are detected.825
,827,828
The manufacturer’s protocol was followed, with all samples being analysed in duplicate and low, medium
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and high recombinant VEGF controls also being analysed. On inspection of the data, some results
appeared anomalous in terms of almost no difference in values between serum and plasma. To investigate
this further, additional data analysis was carried out and, following this, some of the samples were
subjected to additional measurements of calcium and potassium, undertaken using routine assays in the
Leeds Teaching Hospitals Clinical Chemistry Laboratories, to confirm the presence of potassium EDTA in
the purported plasma aliquots and its absence in the serum aliquots. In addition, to assess stability during a
freeze–thaw cycle, matched aliquots of serum and plasma from 20 patients with RCC were thawed at
room temperature and after approximately 1 hour were refrozen. These 40 aliquots were then analysed
together with 40 matched aliquots that had been stored frozen without any additional freeze–thaw step.
Results
As expected given platelet-derived VEGF being released during clotting, serum VEGF concentrations were
higher than VEGF concentrations in matched plasma samples in most cases. The range for plasma VEGF was
5.2–1480.9 pg/ml (median 67.8 pg/ml), with corresponding values for serum VEGF being 9.9–4283.3 pg/ml
(median 348.4 pg/ml), with one patient providing the sample with the unusually low values for both serum and
plasma VEGF (i.e. 9.9 and 5.2 pg/ml, respectively), which were almost at the limits of the assay (manufacturer’s
LoD 9 pg/ml and 10.9–12.7 pg/ml); these will be reanalysed and the functional sensitivity of the assay
determined in our hands.826 What was striking, however, was a number of samples in which there was
very little difference between plasma and serum VEGF and a number of samples in which the plasma
concentrations of VEGF were higher than the serum concentrations. This is depicted in Figure 47.
When the results were examined further, there were several apparent patterns. For four patients (not
shown in Figure 47) it appeared that the plasma and serum aliquots may have been switched, either at the
time of processing at the four specific sites involved or during analysis, as there were marked differences
between them but in the opposite direction to that expected (e.g. 1480.9 pg/ml vs. 312.2 pg/ml for plasma
and serum VEGF, respectively). For a further group of 48 patients (from around 80% upwards), plasma
and serum samples were much more similar and in many cases differed by < 30 pg/ml (the range of the
standard curve in this assay covers from 15.6 to 1000 pg/ml). This, together with (1) the relatively low
values for serum VEGF concentration in this group (27.5–579 pg/ml, median 98.6 pg/ml) compared with
the group as a whole, (2) the lack of a significant difference between serum VEGF concentrations in this
group of 48 patients (27.5–579 pg/ml, median 98.6 pg/ml) and their matched plasma VEGF concentrations
(25.0–621 pg/ml, median 92.4 pg/ml; p = 0.169), (3) the lack of recorded deviations from the protocol in
terms of processing causing possible spurious results and (4) the fact that 44 of these 48 patients had
been recruited at one specific site led to the hypothesis that most if not all of these patients had actually
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FIGURE 47 Frequency distribution of plasma VEGF concentrations as a percentage of the serum VEGF
concentration for 426 patients with RCC. Results are shown for 426 patients rather than 430 as four of the most
extreme values (210–474%) were omitted to be able to show the spread of the majority of samples optimally.
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had no clotted sample collected for serum at recruitment, but two sets of anticoagulated blood for
plasma collected. This is further supported by Figure 48. By taking the average of the two measurements
(i.e. ‘serum’ and plasma) for each patient and subtracting it from the ‘serum’ result (in this case the ‘serum’
but the same result would be obtained for plasma), and expressing this difference as a percentage of the
average, this could be examined in relation to the known variability of the assay. In Figure 48, essentially
all of these 48 samples make up the columns from 10% down to –20%, as indicated by the arrows, the
majority of which are, therefore, within the variability of the assay (9.1–9.5% inter-run CVs in our study)
and are, therefore, likely to have been determined from two aliquots of the same sample type, that is,
plasma in this case. The most extreme columns from –40% to –70% represent the four samples for which
the most likely explanation is direct switching of serum and plasma at some point.
Biochemical analysis of some of the samples identified as having potential problems showed an absence
of calcium in the ‘serum’ samples and high levels of potassium, consistent with the samples actually
being EDTA plasma. Subsequent biochemical analysis of 235 serum samples from RCC patients for the
prognostic study (run to provide some missing routinely measured analytes) found such results for calcium
and potassium in 40 samples, all of which were from this recruitment site. Enquires at the site where the
44 patients had been recruited from established that staff had been unaware of any issues and had used
Greiner tubes with purple and red tops for EDTA plasma and serum, respectively. However, on close
inspection of the tubes used at that site, it was apparent that the tube with a purple top was a K2EDTA
tube as expected but that the tube with a red top used was actually a K3EDTA tube rather than a red top Z
serum clot activator tube; these two tubes differed purely by a purple band around the top of the patient
label compared with a red band and the small print on the label showing K3EDTA, as shown in Figure 49.
Although we have definitive evidence for samples being collected in the wrong tubes for only 40 patients,
a total of 46 patients recruited at this site had been included in the VEGF sample analysis for the prognostic
study. In addition to the 44 samples known or suspected to be EDTA plasma rather than serum, one sample
appeared to have actually been collected in the correct tube types, with values of 1118.0 and 42.5 pg/ml
for serum and plasma VEGF, respectively (this was actually the first patient recruited at the site), and one
sample was the sample with almost undetectable VEGF in both serum and plasma. At this stage, until all
46 samples are checked by analysing calcium and potassium levels, all ‘serum’ VEGF results from patients
recruited at this site have been removed from the prognostic analysis described in the following chapter,
as a precaution. The four samples from other sites that were part of the group of 48 samples in which
plasma and serum concentrations were similar have been retained in the analysis at present as, in all cases,
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FIGURE 48 Frequency distribution of the difference between the serum VEGF and the average of the matched
serum and plasma VEGF results for each of 430 RCC patients expressed as a percentage of that average. When
serum and plasma results are the same, the value on the x-axis would be zero. The green arrows indicate the bins
containing the 48 samples where both samples may be plasma.
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the serum VEGF concentration was higher than the plasma VEGF concentration, with plasma representing
76–93% of serum, and, therefore, there may not be an issue. Measurement of potassium and calcium
concentrations for the sample with VEGF concentrations of 64.3 and 68.9 pg/ml for plasma and serum,
respectively, confirmed the correctness of the plasma and serum attribution. The other three samples will
also be checked.
For the 380 patients with no apparent issues with the plasma and serum VEGF measurements and
matched results available, serum VEGF ranged from 61.6 to 4283.3 pg/ml (median 377.2 pg/ml) and was
significantly different (p < 0.0001) from the plasma VEGF concentrations, with values of 9.2–419.5 pg/ml
(median 67.5 pg/ml). As shown in Figure 50, the serum VEGF concentration was significantly correlated
with the plasma VEGF concentration (Spearman’s r = 0.594; p < 0.0001) and markedly so with the serum
minus plasma VEGF concentration (Spearman’s r = 0.977; p < 0.0001), which may not be completely
unexpected given that, in 50% of the patients, the plasma VEGF component was ≤ 20% of the total,
that is, the serum VEGF.
For 282 of these patients, platelet counts were available either on the same day as the day that the
biomarker blood sample was collected or within 2 days of this. Platelet counts were highly significantly
correlated with VEGF concentrations, particularly serum or serum minus plasma VEGF concentrations,
with correlation coefficients of 0.57 and 0.56, respectively. Assuming that the serum minus plasma VEGF is
derived from platelets, the calculated VEGF content per platelet is highly variable, ranging from 0.02 to
5.77 pg/106 platelets, with a median value of 1.14 pg/106 platelets. Of note, this was not corrected for
the haematocrit, which we have previously advocated,630 as these data were not available at this time.
FIGURE 49 Greiner blood collection tubes showing the differences and overlap in colour closures and labelling
(top) and the printed indication of additives (bottom). Tubes are (1) K3EDTA for crossmatch, (2) K2EDTA,
(3) K3EDTA, (4) K3EDTA and (5) Z serum clot activator. Tubes 3 and 5 were the intended tubes to be used for
EDTA plasma and serum collection, respectively, but one centre inadvertently used tube 4 instead of tube 5 for
‘serum’ collection.
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FIGURE 50 Relationship between serum VEGF and plasma or serum minus plasma VEGF concentrations (n= 380).
(a) Serum VEGF vs. plasma VEGF; (b) serum VEGF vs. plasma VEGF omitting eight samples with serum VEGF
> 1500 pg/ml to allow expansion of the x-axis; (c) serum VEGF vs. serum – plasma VEGF; (d) serum VEGF
vs. serum – plasma VEGF omitting eight samples with serum VEGF > 1500 pg/ml to allow expansion of the x-axis.
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For the stability study, there was a significant difference between the frozen and freeze–thawed plasma
samples, using the Wilcoxon matched-pairs signed-rank test (range 15–270 pg/ml compared with
11.0–231.0 pg/ml, respectively; median 77.0 pg/ml for both; p = 0.004), but not between the serum
samples (p = 0.065) or the serum minus plasma samples (p = 0.447), as shown in Figure 51. However,
although this was statistically significant, many plasma samples had concentrations of VEGF at the bottom
end of the standard curve, where variability was higher, and only in six cases did the decrease in the
freeze–thawed samples exceed 10%. In 6 out of 20 cases for plasma and 7 out of 20 cases for serum the
results were either the same or higher in the freeze–thaw samples. This requires further investigation in a
larger number of samples and with more samples with higher VEGF concentrations.
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FIGURE 50 Relationship between serum VEGF and plasma or serum minus plasma VEGF concentrations (n= 380).
(a) Serum VEGF vs. plasma VEGF; (b) serum VEGF vs. plasma VEGF omitting eight samples with serum VEGF
> 1500 pg/ml to allow expansion of the x-axis; (c) serum VEGF vs. serum – plasma VEGF; (d) serum VEGF
vs. serum – plasma VEGF omitting eight samples with serum VEGF > 1500 pg/ml to allow expansion of the x-axis.
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FIGURE 51 Comparison of VEGF concentrations in matched plasma and serum samples stored frozen and thawed
immediately prior to analysis with concentrations in paired aliquots that had been subjected to an additional
freeze–thaw cycle. Samples from 20 patients with RCC were used, with storage at –80°C. Aliquots were thawed at
room temperature. F/T, freeze–thaw.
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Discussion
Pre-analytical considerations are of pivotal importance in clinical chemistry laboratories and represent an
area of growing awareness and concern, as reviewed earlier in this chapter. With many biomarker studies
being undertaken in research laboratories, such aspects are often overlooked and not considered either in
the study design phase or during evaluation of the biomarkers, and this will increasingly contribute to the
lack of consistency between published reports and will potentially be a major barrier to progress. A major
finding here was the inadvertent use of the wrong blood tubes at one site, which resulted in no serum
being banked but two samples of EDTA plasma being collected. This was detected both through VEGF
measurements not fitting the usual pattern of serum compared with plasma concentrations and by the low
concentration/absence of calcium and elevated potassium levels in those samples. A further three samples
may also have been inadvertently switched and this will be investigated further. Although many analytes
can be measured equally in plasma or serum, the findings here with VEGF illustrate the importance of
using the correct tube type and specimen type if reliable biomarker results are to be achieved. If VEGF
analysis of both serum and plasma samples had not been undertaken and if none of the clinical chemistry
analysis had been necessary, this error may not have been apparent and the resultant data analysis could
have led to additional inconsistent results appearing in the literature. This occurred despite site inductions
being carried out to ensure that the correct tubes were used and, indeed, it appears as though the first
sample taken at this site may have actually be taken using the correct tubes. Whether or not measurement
of simple analytes such as potassium or calcium or fibrinogen should be undertaken routinely in samples
associated with research biomarker studies in clinical trials, for example, should be considered. This could
confirm sample types as being plasma or serum but unfortunately would still not control for deviations
from sample processing protocols in terms of processing time delays or storage conditions, for example.
CLSI standards and guidelines exist for many pre-analytical areas, including the identification of patients
and samples, venepuncture and sample processing.494,727,728 There is also a guideline covering all aspects of
blood tubes, including construction material, additives and labels; although earlier versions also included
aspects relating to the colour of the tube closures, this has been omitted from the current version.726
Clearly, having similar colour tube caps for different tube types, and indicating the nature of the tube
additives only in small print on the label and by using a small, different coloured band, can easily lead to
errors. Given the heterogeneity in tube types, calls for harmonisation have been made by the EFLM and,
although difficult given the multiple manufacturers, it is hoped that this will be achieved in the future.497
The occurrence of thrombocytosis in many cancers has been recognised for over a hundred years and its
association with shorter survival has been reviewed.829 However, whether this is an epiphenomenon
reflecting systemic elevation of cytokines, such as IL-6 or other tumour-derived thrombopoietic factors,
or has a direct involvement in cancer progression, for example through physical interactions with tumour
cells or the production of platelet-derived cytokines or growth factors, is still not clear. However, over the
last few years it has become increasingly apparent that the sequestration of VEGF by platelets is a major
determinant of the results seen in many studies examining VEGF as a potential biomarker. We found
serum VEGF to be significantly correlated with platelet number, in line with many other studies, for
example the studies by Verheul et al.601 and Salgado et al.604 In a meta-analysis it has been estimated that
the total platelet concentration of VEGF far exceeds the circulating concentration in plasma in cancer
patients by almost 30-fold, with leucocyte-associated VEGF accounting for a much smaller amount and
tumour tissue being one of the main sources.821 Interestingly, however, skeletal muscle was calculated
as having the largest reservoir of VEGF. In an animal study investigating this further, similar findings
were reported with regard to the importance of platelets in terms of their accumulation of VEGF, but
VEGF-impregnated pellets implanted subcutaneously or microscopic xenografts also resulted in increased
platelet VEGF concentrations but not plasma VEGF concentrations, supporting a role for platelets in actively
sequestering such angiogenic factors, with implications for underlying biology and therapies.830
The literature on VEGF as a biomarker is very mixed, with differences in whether serum or plasma has
been used and which type of plasma has been used, the blood collection methods used and the sample
processing/storage methods used; therefore, it is not surprising that there is a lack of consistency generally
about the utility of VEGF as a biomarker.821,831 Importantly, however, the majority of studies have used the
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same ELISA kit as in our studies, allowing studies to be more usefully compared. The consideration of
which anticoagulant to use if circulating endogenous levels of VEGF are to be determined accurately is
important. Our initial studies comparing serum and plasma were based on only four healthy volunteers;
in terms of measuring endogenous circulating VEGF, we found citrate plasma to be optimal for measuring
the lowest VEGF concentrations, presumably because of low levels of platelet activation,600 and this has
been confirmed subsequently.826 In most cases, little or no difference was seen comparing citrate plasma
with EDTA plasma if samples were processed within 30 minutes or with a similar delay, with the samples
kept on ice.600,601,827 However, we reported that EDTA anticoagulated blood appeared to be less stable over
time, with delayed processing up to 4 hours leading to markedly increased plasma VEGF concentrations in
two out of four cases for EDTA plasma and to a lesser extent in one out of four cases for citrate plasma.
This may represent the worst-case scenario, with blood being taken into a syringe before distribution into
anticoagulant-containing tubes, because of the volumes needed, and, hence, possibly leading to more
platelet activation than would have occurred if blood had been collected directly into anticoagulant-
containing tubes.600 In our biobanked RCC blood samples, overall, 97% were centrifuged within 2 hours
of venepuncture, with a median time until centrifugation of 1 hour 11 minutes. Average increases in VEGF
concentrations of 28–34% have been reported for EDTA blood left at room temperature for 1 hour before
processing and of 64–80% for EDTA blood left at room temperature for 2 hours, although no changes
were seen if samples were left at 4°C for prolonged periods.826,827 Centrifugation speeds have also been
highlighted as being important, presumably in terms of generating platelet-poor plasma, together with
avoiding sampling the plasma immediately above the buffy coat, which we also adopt in our SOPs.826,827
However, it is now apparent that, even with citrate, platelet activation occurs and VEGF is released.
Studies adopting a very stringent protocol to avoid any platelet activation in vitro, monitored by concurrent
measurement of platelet factor 4 (PF4), have found that plasma from blood collected into tubes containing
either CTAD (sodium citrate, theophylline, adenosine and dipyridamole) or Edinburgh mixture (EDTA,
prostaglandin E1 and theophylline), with rapid processing at 4°C, contained much lower VEGF concentrations.
There was even more platelet activation if the citrated tubes were maintained at room temperature
rather than at 4°C.831 This study also reported that serum VEGF did not plateau until at least 2 hours after
venepuncture, although plain glass tubes were used rather than clot activator tubes as in our study and we
have shown that clotting in terms of peptide fragmentation is essentially complete within 60 minutes of
venepuncture.831,832 A study comparing samples collected without tourniquet in PECT tubes containing a
mixture similar to that of the Edinburgh mixture at 4 C with citrated plasma collected with tourniquet and at
room temperature, comparing healthy controls and patients with metastatic RCC or other cancers, found
significantly higher VEGF levels in citrated plasma than in PECT plasma.833 In addition, using citrated plasma,
the VEGF concentration was higher in both the RCC group (and similar to the EDTA values in our study) and
the non-RCC group than in the control group whereas using PECT plasma only the RCC group had a higher
VEGF concentration.833 PF4 concentrations were higher in all citrate samples than in the PECT samples,
supporting the fact that, even in citrate samples, some platelet activation is occurring in vitro.833 Interestingly,
we have selected processing at ambient temperature within our biobanking protocols over many years to
avoid the detrimental effects of cold temperatures on platelets, which are normally stored unrefrigerated,
and yet clearly activation and degranulation appear to be inhibited at colder temperatures.834
Comparing VEGF concentrations in serum from four patients with rheumatoid arthritis analysed prior to
freezing with results following subsequent freeze–thaw cycles found a dramatic difference (average 67%
reduction in the freeze–thaw sample, with almost total degradation seen in two samples) after just one
freeze–thaw cycle and a continued decline with subsequent freeze–thaw cycles.835 In absolute terms this
meant a change from a mean of 352 pg/ml (SD 166 pg/ml) to 134 pg/ml (SD 184 pg/ml) after one cycle
and 49 pg/ml (SD 18 pg/ml) after six cycles. Although we did not assay samples fresh (i.e. prior to freezing),
our data examining samples after freezing or one further cycle of freeze–thaw still show very high serum
values in all serum samples and, therefore, are unlikely to support their results, but this needs exploring
further. One notable difference was the thawing of samples at 37°C in the study by Kisand et al.835
Although EDTA plasma VEGF concentrations have been reported to decrease in samples (10 healthy
controls and 10 patients with rheumatoid arthritis) that have been thawed more than once compared
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with once only (mean difference 20%), with no further decline until after 10 thaws, serum VEGF
concentrations declined only after 10 thaws (mean difference 18%).826 We did not find such changes and
another study has reported no changes in EDTA plasma VEGF concentrations until after seven and nine
freeze–thaw cycles.827 Further study using a multiplex chip also found no effect on VEGF concentrations of
freeze–thawing up to at least 10 times compared with immediate analysis using serum or heparinised
plasma.836 Similarly inconsistent results have been reported for storage, with stability for up to at least
2 years at –80°C reported for VEGF in EDTA plasma or serum826 compared with findings of significant
degradation after periods of > 3 months at –75°C for VEGF in serum;835 however, the study by Kisand
et al.835 used accelerated stability tests at elevated temperatures and, given the possible effect of higher
temperatures on VEGF during thawing, this needs to be revisited.
Systematic studies of biological variability of VEGF are few but consistent. In the first reported study
comparing serum and plasma (citrated) we reported no effects of age, sex or menopausal status on plasma
or serum VEGF630 and this has been confirmed since in a large (n = 306) reference range study using EDTA
plasma and serum.826 Some evidence of diurnal variation was reported and examination of intra-individual
variability showed median CVs of 39–56% examined at several points in a month and repeated at
6 months and 1 year later and with exercise having a marked although short-term effect.826 Similar,
relatively large intra-individual variability has been reported in a further study using only EDTA plasma,
with CVs of 69% and 57% for short- and long-term biological variation, respectively, compared with 51%
for inter-individual variation.827 Such biological variation may contribute to the lack of differences seen in
studies using plasma between different groups of patients with breast diseases, which we reported;630 this
has also been reported for patients with colorectal cancer and benign adenoma and disease-free groups.827
Interestingly, platelet-associated VEGF has been reported to show only low levels of intra-individual
variability over time, with CVs of only 17% and inter-subject CVs of 44%, although, interestingly, in this
study the intra-subject variability of citrated platelet-poor plasma processed at ambient temperature was
only 19%, although inter-subject variability was markedly higher at 148%.837
Clearly, the clinical utility of VEGF as a biomarker is far from established and, given the critical effects of
the anticoagulant used on ‘circulating endogenous VEGF’, it appears likely that studies employing EDTA
or even citrated plasma are not truly representative of that VEGF component and may include variable
contributions from platelet-derived VEGF fraction, which is largely covered by serum VEGF measurements.
Similar to the findings here in RCC and with the caveat that background endogenous circulating VEGF
came from measurement of EDTA plasma, there was a wide variation in the calculated platelet content of
VEGF in breast cancer patients and healthy control subjects, with no significant difference between them,
although, in a study examining patients with a range of advanced cancers, platelet VEGF was significantly
increased compared with the VEGF level in healthy control subjects.630,838 There was no relationship
between either plasma or serum VEGF and clinicopathological parameters, although plasma VEGF
discriminated more between control subjects and the various breast disease groups.630 Although several
groups did have elevated VEGF levels compared with normal control subjects, we did not find a clear trend
in breast cancer for plasma or serum VEGF for local disease, remission or metastatic disease, but this was
likely to be the result of a possible effect of tamoxifen on VEGF, both circulating and platelet derived.630
The question of whether or not under standard consistent processing conditions EDTA or citrated plasma
can act as a surrogate of cancer behaviour through essentially integrating platelet VEGF content with the
activatability of platelets or whether or not serum provides a more stable indication of any cancer-
associated properties remains to be determined and, under the conditions recorded in our biobanking
activity, this should be possible to determine in RCC at least and is illustrated in the following chapter.
Interestingly, many of the published findings above regarding plasma VEGF and anticoagulant appear to
have had little impact on the measurement of VEGF in clinical research studies, with variable procedures
still being adopted, and it is important that this is highlighted in a large study. This may be in part because
of the publication of many studies in clinical biochemistry-type journals; a greater impact may result if
studies are published in cancer journals, for example, as many of the studies are led by people working in
cancer research. This issue of continued publication of studies ignoring such facts has also been seen for
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other proteins, for example MMP-9; despite the importance of serum compared with plasma being
highlighted and the effect on the interpretation of results, studies continue to measure MMP-9
inappropriately and neglect pre-analytical considerations.839 We intend to publish the VEGF results from
our studies as a separate paper also highlighting such aspects and additionally exploring further some of
the discrepancies such as the stability of VEGF to freeze–thawing.
Overall conclusions
This chapter has shown several examples of the importance of verifying the performance of commercially
available assays prior to use in biomarker studies and assessing the potential impact of pre-analytical factors.
This illustrates how inconsistent results across studies can easily arise and, with studies employing certified
assays on clinical chemistry platforms and research grade immunoassays being used at various stages in the
biomarker pipeline, it is often difficult to interpret data across studies. Without assay characterisation and
validation in an early phase of the biomarker translational pathway, progress in biomarker translation and
adoption will continue to be slow and result in wasted resources. The value of the biobank can clearly be
seen in this chapter and in the initial prognostic study in RCC described in the following chapter. Collection
of samples in multicentre studies has to be pragmatic and take into account resource availability and
considerations of cost and logistics when deciding on the possible sample types and frequencies of
collection and of course consider future developments, maximising the value as long-term resource.373,493 Of
most importance is consistency of the processes adopted and recording of relevant information both at the
biobank level and in publications, as proposed in the BRISQ recommendations.375,724 Deviations can then be
factored in, but the more complex the protocols the less likely that most centres will comply. Thought needs
to be given to possible quality assurance checks on compliance with the sample types, processing timing
steps and storage and this is being pursued by several groups, for example ISBER, although as yet there is no
universal panel that can be used to provide the information needed.723 However there will be no uniform
protocol for all biomarkers and all fluid types as pre-analytical factors impact on different proteins in
different ways. If a specific biomarker is the focus of studies then protocols can be evidence based and
comply with any known necessary pre-analytical specifications to ensure that measurements are valid, in
just the same way that the assays have to achieve the required technical performance criteria. By adopting
high-standard evidence-based protocols with accurate record keeping and quality systems, it is likely that
biobanks such as the one here will be of value for many years and many questions can be answered and the
suitability of any specific biomarker can be determined based on the processes adopted and knowledge of
pre-analytical impacts as studies evolve.
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Chapter 14 Circulating prognostic biomarkers in
renal cancer: clinical validation study of promising
candidates
Introduction
As outlined in Chapter 10, there remains an urgent clinical need for the identification and validation of
biomarkers that provide prognostic information for patients with localised RCC. It is recognised that
following surgery to remove the primary tumour, around one-third of patients will relapse with distant
metastatic disease. Accurately differentiating these patients from those who are likely to be cured by
surgery alone allows for more rational use of finite NHS resources, in terms of intensity of follow-up, and
stratifies patients for entry into ongoing trials of adjuvant therapy. Such treatments are likely to be both
costly to the NHS and potentially toxic for patients, further highlighting the need to identify and target
high-risk groups.
For a prognostic biomarker (or panel of markers) to be adopted into clinical practice, it must be shown to
be superior, or add value, to currently employed prognostic scoring systems, which for RCC are based on
standard clinicopathological criteria alone.438 Such nomograms fail to adequately reflect individual tumour
biology and the identification of molecular markers in RCC to improve risk stratification and the delivery
of more personalised medicine is recognised as a research priority by both the European Association of
Urology840 and the European Society for Medical Oncology.841
The current study represents the culmination of the RCC-related work, to date, within workstream 2.
It focuses on the clinical validation of candidate circulating biomarkers detectable in serum and/or plasma,
collected pre nephrectomy/ablation, that have been reported in the literature by ourselves and/or others
to carry prognostic value in patients with localised ccRCC, using the assembled multicentre prospective
observational cohort and RTB described in Chapter 11. Markers were shortlisted based on the level of
existing published evidence of their prognostic potential, in addition to the availability of suitable and
robust assays. On this basis, the following proteins were selected for validation: (1) VEGF-A, referred to as
VEGF, (2) OPN, (3) CAIX and (4) CRP. A number of routine laboratory variables were also included in the
analysis, again based on existing supporting literature.513,519,569,570,842,843
The aim of this study was to validate the prognostic utility of the selected markers individually or combined
as a panel or index in a large multicentre cohort of UK patients with localised ccRCC. Furthermore, the
ability of the markers to add value to the widely employed postoperative Leibovich score438 was examined,
in particular among those patients deemed to be at high or intermediate risk of relapse by the score alone.
Methods
Patient population
Patients were identified retrospectively from the whole RCC cohort (described in full in Chapter 11).
Inclusion criteria for the study were broad and included patients with (1) ccRCC, (2) radical/partial
nephrectomy or tumour ablation, (3) localised disease (stages I–III), (4) preoperative serum/plasma sample
availability and (5) preoperative clinical biochemistry/haematology measurement availability. All patients
who fulfilled these criteria were included, except for patients with VHL disease (an exclusion criterion for
the overall study) and coexistent other active cancers. For comparative descriptive purposes only, a subset
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of patients presenting with metastatic disease, who may or may not have undergone nephrectomy but
who otherwise met the inclusion/exclusion criteria, were also included.
Vascular endothelial growth factor, osteopontin and carbonic anhydrase IX measurement
A full description of assay validation is provided in Chapter 13. Similarly, full details of sample collection,
processing and storage are described in Chapter 11. Briefly, OPN and CAIX concentrations were quantified
in EDTA plasma using commercially available ELISA Quantikine kits. Both serum and EDTA plasma VEGF
were analysed, using the Human VEGF Quantikine kit, a sandwich ELISA specifically measuring VEGF-A. The
difference between serum and plasma VEGF concentrations was also examined for its value as a prognostic
variable, calculated as serum minus plasma VEGF concentration. All samples were measured blinded,
in duplicate, and manufacturers’ QC samples were included on each plate. Assay runs not passing QC
standards, that is, QC samples not meeting the specifications supplied by the manufacturer, were rerun
(this applied to two plates only). Similarly, samples for which replicate CVs exceeded 10% were reanalysed.
Other serum analytes, including CRP, were measured by the NHS clinical biochemistry laboratory at each
participating centre, with assays having a CRP concentration of < 10 mg/l being reanalysed using the
high-sensitivity CRP assay in the Leeds Teaching Hospitals Blood Sciences Laboratory.
Clinicopathological variables
Clinical factors examined included sex, age at diagnostic procedure, smoking history, alcohol consumption,
BMI, symptoms (local/systemic/absent) and Eastern Cooperative Oncology Group performance status
(ECOG PS). Pathological factors recorded were tumour size, TNM stage, Fuhrman grade, Leibovich score
and presence or absence (if not commented, assumed to be absent) of histological necrosis, sarcomatoid
change and microvascular invasion (MVI). Routine laboratory variables included haemoglobin, WBC count,
neutrophil count, lymphocyte count, platelet count and serum measurements of sodium, potassium, urea,
alanine transaminase (ALT), calcium, albumin and CRP. The derived parameter, NLR, was also examined on
the basis of previous findings.507,510,511
Statistical methods
Baseline concentrations of each marker were explored in terms of differences within demographic and
clinical factors among all patients (stages I–IV) using the Spearman rank correlation coefficient and
p-value if a single continuous variable or median (range) and p-value from the Wilcoxon–Mann–Whitney
test or Kruskal–Wallis test if comparing two or more subgroups. Correlations between the markers were
investigated using a correlogram, based on simple linear regression and the Spearman rank correlation
coefficient.
Survival analyses were conducted exclusively in patients with stage I–III disease (i.e. non-metastatic). MFS
formed the principal time-to-event end point, calculated as the period from the date of the procedure to
the date of distant metastases, the definition also used in developing the Leibovich score.438 Any patients
without disease recurrence were censored at the date that they were last known to be recurrence free
(for patients who died without recurrence this was the date of death). Secondary end points were OS and
CSS, defined as the period from the date of the procedure to the date of (1) death from any cause (OS) or
(2) death from RCC (CSS). Patients still alive at the time of analysis were censored at the date last known
alive (or at the date of non-cancer-related death when considering CSS).
Cox proportional hazards models were used to determine the prognostic potential of the markers;
survival functions were estimated using the Kaplan–Meier method and compared using the log-rank test.
Markers were initially examined as continuous variables and then as dichotomised variables. The latter was
accomplished by considering all possible cut-off points within the range of each marker and selecting the
one that maximised Harrell’s concordance index (C-index). For each Cox proportional hazards model
constructed, the proportional hazards assumption was tested by assessing Schoenfeld residuals.844
The ability of the shortlisted markers to add prognostic utility to the Leibovich score was explored,
particularly with respect to those patients in the intermediate- and high-risk scoring groups (score 3–5 and
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score ≥ 6, respectively). This was performed by sequentially including each marker into a Cox proportional
hazards model with the Leibovich score as an existing predictor variable and MFS as the response variable.
Statistical analysis was carried out in the R Environment for Statistical Computing (R Core Team, Vienna,
Austria) and reported according to REMARK criteria.845 In making inferences, significance levels were
adjusted for multiple testing, when appropriate. Tests for significance were two-sided and p-values of
< 0.05 were considered significant.
Sample size
Sample size calculations were based on upper and lower extremes of relapse rates at 2 years for patients
with localised ccRCC of 27.5% and 12.5%. Using the higher end of the relapse rate, we assumed a
separation at 2 years of 15% between survival curves to be required for each marker (given a dichotomised
split around a given point) to justify its inclusion in a multiplex marker model. This equates to a HR of
approximately 0.5. Table 88 shows the sample sizes required to identify a HR of 0.5 with 80–95% power
given a significance level (α) of 5% in a 5-year study at the higher and lower relapse rates and at an
intermediate rate of 20%. Samples sizes are shown for unadjusted and adjusted (using Bonferroni correction)
significance levels.
Results
In total, 706 patients were recruited into the full study between July 2011 and June 2014 across 11 UK
centres. Among the 629 patients with a confirmed RCC, 481 (76.5%) had ccRCC, 59 (9.4%) papillary
RCC, 46 (7.3%) chromophobe RCC and 27 (4.3%) oncocytoma; 12 (1.9%) were unclassified and the
remaining four cases were made up of two translocation tumours, one cystic mixed chromophobe RCC
and ccRCC and one mucinous tubular and spindle cell RCC.
Among patients with localised (stage I–III) ccRCC, the majority (n = 406; 94.2%) met the inclusion criteria
for the current study. In addition, a subset of 30 out of the 50 patients with ccRCC presenting with stage
IV disease was examined in parallel, selected to represent recruiting centres and distribution of metastatic
site. These patients were included purely for descriptive purposes of the selected biomarkers, rather than
for an assessment of their prognostic ability within this group. At the time of analysis, the median length
of follow-up from diagnosis among patients still alive was 28.9 months (range 0.6–48.3 months). Among
those presenting with localised RCC, 33 patients had relapsed with distant metastatic disease and 21
patients had died, of which six deaths were directly attributed to cancer. The small number of CSS events
(n = 6) precluded the inclusion of this end point in the current analysis.
TABLE 88 Sample sizes required to obtain 80–95% power when identifying a HR of 0.5 with a 5% significance level
assuming relapse rates of 27.5%, 20% and 12.5%
Power
Relapse rate
27.5% 20% 12.5%
α
1
α
2
α
3
α
1
α
2
α
3
α
1
α
2
α
3
0.80 168 248 282 216 320 362 320 476 538
0.85 192 276 312 244 356 400 364 528 596
0.90 224 316 356 288 404 456 428 600 678
0.95 276 380 422 356 484 540 528 722 804
α1, unadjusted; α2, adjusted for five markers; α3, adjusted for 10 markers.
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Patient and tumour characteristics
Patient characteristics for the 406 patients included in the current study are shown in Table 89. The
male-to-female ratio was 1.9 : 1, confirming the known male preponderance of this tumour type. Based on
BMI, approximately three-quarters of patients were classified as either obese (36%) or overweight (40%).
The majority of patients had an ECOG PS of 0/1 (97%). One-third of patients were asymptomatic at the
time of presentation. Among those patients reporting symptoms, 30% reported local symptoms (such as
haematuria or flank pain), 14% reported systemic symptoms (such as weight loss or fatigue) and 22%
reported both local and systemic symptoms.
TABLE 89 Characteristics of the patients with localised (stage I–III) ccRCC
Characteristic Patients with localised ccRCC (n= 406)
Sex, n (%)
Male 267 (66)
Female 139 (34)
Age (years), median (range) 63 (29–92)
BMI (kg/m2)
< 18.5 (underweight) 4 (1)
18.5–24.9 (healthy) 91 (22)
25–29.9 (overweight) 147 (36)
> 30 (obese) 161 (40)
Missing 3 (1)
ECOG PS, n (%)
0 319 (79)
1 74 (18)
2 11 (3)
3 1 (< 1)
4 1 (< 1)
Symptoms, n (%)
Local 120 (30)
Systemic 57 (14)
Both 88 (22)
None 141 (34)
Pathological T stage, n (%)
1a 122 (30)
1b 100 (25)
2a 38 (9)
2b 9 (2)
3a 106 (26)
3b 9 (2)
3c 1 (< 1)
Not applicablea 21 (5)
Tumour size (mm), median (range) 52 (11–180)
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TABLE 89 Characteristics of the patients with localised (stage I–III) ccRCC (continued )
Characteristic Patients with localised ccRCC (n= 406)
Fuhrman grade, n (%)
1 11 (3)
2 142 (35)
3 203 (50)
4 49 (12)
Missing 1 (< 1)
Necrosis, n (%)
Present 102 (25)
Absent 283 (70)
Not applicablea 21 (5)
Microvascular invasion, n (%)
Present 65 (16)
Absent 320 (79)
Not applicablea 21 (5)
Sarcomatoid change, n (%)
Present 18 (5)
Absent 367 (90)
Not applicablea 21 (5)
Leibovich risk group, n (%)
Low 147 (36)
Intermediate 163 (40)
High 71 (18)
Not applicableb 25 (6)
TNM stage, n (%)
I 240 (59)
II 44 (11)
III 116 (29)
Missing 6 (1)
Procedure, n (%)
Radical nephrectomy 286 (70)
Partial nephrectomy 99 (24)
Radiofrequency ablation 13 (3)
Cryoablation 8 (2)
Relapsed, n (%)
Yes 33 (8)
No 352 (87)
Missing 21 (5)
a Not available in patients undergoing tumour ablation.
b Includes four patients initially thought to be stage IV and, therefore, no risk score was assigned.
DOI: 10.3310/pgfar06030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Selby et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
271
At the time of diagnosis, over half of tumours (55%) were pathological stage T1, of which 30% were
pT1a, and 28% were locally advanced (pT3). Among the 381 patients with localised ccRCC who
underwent a radical or partial nephrectomy with an evaluable Leibovich score, 39%, 43% and 18% were
classified as low, intermediate and high risk, respectively.
Biomarker associations/correlations
Correlation of the markers with each other was examined. The correlation was strongest between plasma
and serum VEGF values (r = 0.59, p < 0.001). In general, the markers were significantly correlated, with the
exception that CAIX showed no correlation with either serum or plasma VEGF values (r = –0.02, p = 0.655,
and r = 0.08, p = 0.112, respectively).
All four markers showed associations with several clinicopathological parameters. Increased preoperative
plasma VEGF concentrations were consistently associated with poor prognostic tumour factors, such as
increased pathological tumour size (r = 0.14, p = 0.005), stage IV disease (p < 0.001), grade 4 tumours
(p = 0.025), high-risk Leibovich score (p = 0.031), the presence of sarcomatoid change (p < 0.001) and
MVI (p = 0.046).
Among patients with localised disease, a trend towards increased plasma VEGF in relapsers compared with
non-relapsers was observed (84.8 vs. 66.5 pg/ml; p = 0.054). Serum VEGF concentrations showed fewer
significant associations, limited to Leibovich score (p = 0.008), presence of necrosis (p = 0.041) and overall
TNM stage (p = 0.018). Serum minus plasma VEGF showed an association with Leibovich score and
presence of necrosis only. Box and whisker plots are shown for the markers according to TNM stage
(Figure 52) and Leibovich score (Figure 53).
Similarly, higher baseline circulating concentrations of OPN, CRP and CAIX were consistently associated with
poor prognostic features, including higher stage and grade, increased tumour size, presence of necrosis,
MVI and sarcomatoid change. An association with Leibovich score was again observed (see Figure 53). Both
CRP (p = 0.002) and OPN (p = 0.001) were elevated in relapsers compared with non-relapsers. In terms of
clinical associations, higher circulating levels of all three biomarkers were associated with poorer ECOG PS.
Circulating concentrations of both CRP and CAIX showed a significant association with BMI, with patients
with a BMI of < 18.5 kg/m2 (underweight) having higher median serum/plasma levels of each biomarker.
However, only six patients made up this group, two of whom had metastatic disease.
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FIGURE 52 Box and whisker plots for preoperative circulating (a) CRP (mg/l), (b) OPN (ng/ml), (c) CAIX (pg/ml),
(d) serum VEGF (pg/ml), (e) plasma VEGF (pg/ml) and (f) serum minus plasma VEGF (pg/ml) according to TNM stage
(I–IV). Boxes correspond to the first and third quartiles (the 25th and 75th percentiles) with median concentration
also shown. Whiskers extend to 1.5 × IQR, with data points beyond classed as outliers.846 (continued )
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FIGURE 52 Box and whisker plots for preoperative circulating (a) CRP (mg/l), (b) OPN (ng/ml), (c) CAIX (pg/ml),
(d) serum VEGF (pg/ml), (e) plasma VEGF (pg/ml) and (f) serum minus plasma VEGF (pg/ml) according to TNM stage
(I–IV). Boxes correspond to the first and third quartiles (the 25th and 75th percentiles) with median concentration
also shown. Whiskers extend to 1.5 × IQR, with data points beyond classed as outliers.846 (continued )
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Univariate analysis of biomarkers and time-to-event end points
Metastasis-free survival
The following were statistically significantly associated with MFS (p < 0.05): sex, WBC count, neutrophil
count, NLR, platelet count, potassium, albumin, CRP, OPN, serum VEGF, plasma VEGF, serum minus
plasma VEGF, pathological tumour size, pathological T stage, Fuhrman grade, necrosis, MVI, sarcomatoid
change, Leibovich score, CT tumour size, CT T stage and overall TNM stage (Table 90). Figure 54 shows
Kaplan–Meier survival curves for Fuhrman grade and TNM stage as two of the most clinically relevant
variables found to be significant in univariate analysis, in addition to the Leibovich score as a main focus of
the study. Chi-squared and associated p-values from the log-rank test to compare survival curves are also
shown and are significant in all three cases. In addition, there was weak evidence of an association with
MFS for serum sodium concentration (HR 0.89, 95% CI 0.79 to 1.01; p = 0.064).
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FIGURE 52 Box and whisker plots for preoperative circulating (a) CRP (mg/l), (b) OPN (ng/ml), (c) CAIX (pg/ml),
(d) serum VEGF (pg/ml), (e) plasma VEGF (pg/ml) and (f) serum minus plasma VEGF (pg/ml) according to TNM stage
(I–IV). Boxes correspond to the first and third quartiles (the 25th and 75th percentiles) with median concentration
also shown. Whiskers extend to 1.5 × IQR, with data points beyond classed as outliers.846
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FIGURE 53 Box and whisker plots for preoperative circulating (a) CRP (mg/l), (b) OPN (ng/ml), (c) CAIX (pg/ml),
(d) serum VEGF (pg/ml), (e) plasma VEGF (pg/ml) and (f) serum minus plasma VEGF (pg/ml) according to Leibovich
risk classification (low, intermediate or high). Boxes correspond to the first and third quartiles (the 25th and 75th
percentiles) with median concentration also shown. Whiskers extend to 1.5 × IQR, with data points beyond classed
as outliers.846 (continued )
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FIGURE 53 Box and whisker plots for preoperative circulating (a) CRP (mg/l), (b) OPN (ng/ml), (c) CAIX (pg/ml),
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FIGURE 53 Box and whisker plots for preoperative circulating (a) CRP (mg/l), (b) OPN (ng/ml), (c) CAIX (pg/ml),
(d) serum VEGF (pg/ml), (e) plasma VEGF (pg/ml) and (f) serum minus plasma VEGF (pg/ml) according to Leibovich
risk classification (low, intermediate or high). Boxes correspond to the first and third quartiles (the 25th and 75th
percentiles) with median concentration also shown. Whiskers extend to 1.5 × IQR, with data points beyond classed
as outliers.846
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TABLE 90 Significant (p < 0.05) univariate Cox proportional hazards results for MFS and/or OS (markers considered
as continuous variables)
Characteristic
Survival
MFS OS
HR (95% CI) p-value HR (95% CI) p-value
Sex
Male – – – –
Female 0.31 (0.11 to 0.90) 0.031 0.46 (0.15 to 1.36) 0.160
WBC count 1.18 (1.02 to 1.37) 0.026 1.15 (0.99 to 1.35) 0.069
Neutrophil count 1.23 (1.05 to 1.44) 0.009 1.15 (0.96 to 1.39) 0.136
NLR 1.13 (1.01 to 1.26) 0.038 0.97 (0.78 to 1.21) 0.770
Platelet count 1.00 (1.00 to 1.01) 0.002 1.00 (1.00 to 1.01) 0.073
Sodium 0.89 (0.79 to 1.01) 0.064 0.8 (0.71 to 0.91) 0.001
Potassium 2.41 (1.11 to 5.24) 0.026 2.70 (1.13 to 6.48) 0.026
Albumin 0.94 (0.90 to 0.98) 0.006 0.93 (0.89 to 0.97) 0.001
CRP 1.01 (1.00 to 1.01) < 0.001 1.00 (1.00 to 1.01) 0.342
OPN 1.01 (1.00 to 1.01) < 0.001 1.00 (1.00 to 1.01) 0.120
CAIX 1.00 (0.99 to 1.00) 0.729 1.00 (1.00 to 1.01) 0.001
Serum VEGF 1.00 (1.00 to 1.00) 0.012 1.00 (1.00 to 1.00) 0.573
Plasma VEGF 1.00 (1.00 to 1.01) 0.032 1.00 (1.00 to 1.01) 0.144
Serum minus plasma VEGF 1.00 (1.00 to 1.00) 0.028 1.00 (1.00 to 1.00) 0.672
Tumour size 1.01 (1.01 to 1.02) 0.002 1.01 (0.99 to 1.02) 0.271
Pathological T stage
T1 – – – –
T2 3.15 (0.89 to 11.16) 0.076 1.01 (0.21 to 4.74) 0.995
T3/T4 6.22 (2.47 to 15.68) < 0.001 2.23 (0.88 to 5.65) 0.092
Grade
1/2 – – – –
3 2.62 (0.85 to 8.04) 0.092 4.68 (1.05 to 20.91) 0.043
4 11.39 (3.59 to 36.12) < 0.001 12.25 (2.54 to 59.04) 0.002
Necrosis
No – – – –
Yes 5.29 (2.44 to 11.51) < 0.001 2.19 (0.91 to 5.29) 0.081
Microvascular invasion
No – – – –
Yes 2.31 (1.02 to 5.24) 0.046 1.93 (0.70 to 5.32) 0.204
Sarcomatoid change
No – – – –
Yes 7.08 (2.67 to 18.77) < 0.001 6.64 (2.21 to 19.97) 0.001
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TABLE 90 Significant (p< 0.05) univariate Cox proportional hazards results for MFS and/or OS (markers considered
as continuous variables) (continued )
Characteristic
Survival
MFS OS
HR (95% CI) p-value HR (95% CI) p-value
Leibovich risk
Low – – – –
Intermediate 1.29 (0.36 to 4.59) 0.691 0.69 (0.21 to 2.26) 0.541
High 11.18 (3.78 to 33.04) < 0.001 2.91 (1.03 to 8.19) 0.043
CT size 1.18 (1.06 to 1.31) 0.003 1.06 (0.92 to 1.21) 0.431
CT stage
T1 – – – –
T2 2.62 (1.01 to 6.80) 0.047 1.54 (0.57 to 4.17) 0.393
T3/T4 4.02 (1.55 to 10.41) 0.004 1.44 (0.46 to 4.52) 0.536
TNM stage
I – – – –
II 3.61 (1.02 to 12.82) 0.047 1.02 (0.22 to 4.74) 0.977
III 6.83 (2.71 to 17.22) < 0.001 2.22 (0.90 to 5.47) 0.083
0
Number at risk
0
20
40
60
80
100
12 24
(a)
36 48
χ2 = 21.89
p = < 0.001
228
40
107
195
30
77
98
23
48
35
10
21 1
Months
M
FS
 (
%
)
I
II
III
TMN stage
FIGURE 54 Kaplan–Meier survival curves showing MFS by (a) TNM stage, (b) Fuhrman grade and (c) Leibovich risk
score. (continued )
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Optimally discriminative cut-off points in terms of maximised C-index were derived as follows: CRP, cut-off
point 14.1 mg/l; OPN, cut-off point 120.8 ng/ml; CAIX, cut-off point 60.4 pg/ml; platelet count, cut-off
point 333 × 109/l; and serum sodium, cut-off point 141 mmol/l). They were all significantly associated with
MFS (p < 0.05) (Table 91). Corresponding Kaplan–Meier survival curves are shown in Figure 55.
Overall survival
When considered as continuous variables, the following were statistically significantly associated with
OS (p < 0.05): haemoglobin, serum sodium, serum potassium, serum albumin, CAIX, Fuhrman grade,
sarcomatoid change and Leibovich score. When the markers serum sodium and platelet count were
considered as dichotomised variables, the following were statistically significant: CAIX (cut-off point
112.1 pg/ml), plasma VEGF (cut-off point 132 pg/ml), platelet count (cut-off point 300 × 109/l) and serum
sodium (cut-off point 137 mmol/l) (see Table 91).
Multivariable analysis of metastasis-free survival
The prognostic ability of the markers to substratify intermediate- and/or high-risk patients by the Leibovich
score was examined by sequentially adding markers found to be significant at the univariate level, in
addition to platelet count and serum sodium as predictor variables, into a Cox proportional hazards model,
with the Leibovich score and MFS as the response variables. In the multivariable setting, for each of the
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FIGURE 54 Kaplan–Meier survival curves showing MFS by (a) TNM stage, (b) Fuhrman grade and (c) Leibovich risk score.
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TABLE 91 Univariate Cox proportional hazards analysis of MFS and OS by optimal cut-off points
Biomarker
Survival
MFS OS
Optimised
cut-off point N
Number of
events HR (95% CI) p-value
Optimised
cut-off point N
Number of
events HR (95% CI) p-value
CRP (mg/l) ≤ 14.1 294 11 1.00 – ≤ 3.9 174 5 1.00 –
> 14.1 72 17 6.62 (3.10 to 14.16) < 0.001 > 3.9 199 15 2.65 (0.96 to 7.29) 0.059
OPN (ng/ml) ≤ 120.8 257 11 1.00 – ≤ 95.4 199 6 1.00 –
> 120.8 86 15 4.28 (1.96 to 9.31) < 0.001 > 95.4 149 11 2.67 (0.99 to 7.22) 0.053
CAIX (pg/ml) ≤ 60.4 176 8 1.00 – ≤ 112.1 289 10 1.00 –
> 60.4 199 20 2.37 (1.04 to 5.38) 0.040 > 112.1 93 11 3.51 (1.48 to 8.28) 0.004
Serum VEGF (µg/ml) ≤ 268.7 106 4 1.00 – ≤ 356.5 169 7 1.00 –
> 268.7 223 20 2.56 (0.87 to 7.50) 0.087 > 356.5 167 11 1.72 (0.67 to 4.44) 0.262
Plasma VEGF (µg/ml) ≤ 60.0 147 7 1.00 – ≤ 132.1 322 14 1.00 –
> 60.0 226 21 2.12 (0.90 to 5.01) 0.086 > 132.1 58 7 3.08 (1.24 to 7.66) 0.015
Serum minus plasma VEGF (µg/ml) ≤ 344.9 194 10 1.00 – ≤ 222.4 122 5 1.00 –
> 344.9 135 14 2.12 (0.94 to 4.78) 0.069 > 222.4 214 13 1.68 (0.6 to 4.74) 0.326
Platelet count (× 109/l) ≤ 333 315 17 1.00 – ≤ 300 280 10 1.00 –
> 333 61 10 3.16 (1.44 to 6.93) 0.004 > 300 103 11 2.84 (1.2 to 6.71) 0.017
Serum sodium (mmol/l) ≤ 141 276 27 1.00 – ≤ 137 71 9 1.00 –
> 141 102 1 0.09 (0.01 to 0.66) 0.018 > 137 314 12 0.23 (0.1 to 0.56) 0.001
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FIGURE 55 Kaplan–Meier survival curves showing MFS for dichotomised markers, serum sodium and platelet count
(only markers found to be significant in univariate analysis are shown). (a) CRP; (b) OPN; (c) CAIX; (d) serum
sodium; and (e) platelet count. (continued )
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FIGURE 55 Kaplan–Meier survival curves showing MFS for dichotomised markers, serum sodium and platelet count
(only markers found to be significant in univariate analysis are shown). (a) CRP; (b) OPN; (c) CAIX; (d) serum
sodium; and (e) platelet count. (continued )
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markers considered, the intermediate and high Leibovich score patients had a greater risk of relapse than
the low Leibovich score patients, although only the high-risk group was significantly different (Table 92).
When markers were considered as continuous variables none was significant (results omitted). When
dichotomised, the only biomarker significant in the multivariable models was CRP (HR 3.22, 95% CI 1.39
to 7.49; p = 0.007). Corresponding Kaplan–Meier survival curves are shown in Figure 56.
Discussion
The multicentre RCC biobank established within this programme represents a unique resource for
biomarker validation in the UK. In this initial study, we have sought to validate a number of proposed
circulating prognostic biomarkers within a large cohort of patients with localised ccRCC.
The characteristics of the current study population are in keeping with previous series. For example, in a
Leeds cohort of 140 patients presenting with localised ccRCC between 1998 and 2005, 58%, 7% and
35% had a pT1, pT2 and pT3 tumour, respectively, compared with 58%, 12% and 40% in the current
series. The prognostic nomogram proposed by Leibovich et al.438 in 2003 was developed in a US study of
1671 patients with localised ccRCC. The tool classified patients into three risk groups, with 41%, 37% and
22% classified as having a low, intermediate and high risk for distant relapse, respectively. In the current
UK cohort, equivalent figures were 39%, 43% and 18%, suggesting that this distribution has changed
little over the past decade.
In the current study, almost one-third of patients were diagnosed with a small renal mass, defined as a
mass of < 4 cm in maximal dimension. The incidental detection of patients with small renal masses
has been rising in recent years because of the more widespread use of cross-sectional imaging.847
Management of these small, typically low-risk tumours poses a significant challenge to clinicians, with
the need to balance the risks of treatment against the chances of the tumour progressing within the
lifetime of the patient. Biomarkers to allow stratification of these tumours by risk of progression remains
a major unmet clinical need, which the current cohort of samples is well placed to help address in the
future as the data mature.848
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FIGURE 55 Kaplan–Meier survival curves showing MFS for dichotomised markers, serum sodium and platelet count
(only markers found to be significant in univariate analysis are shown). (a) CRP; (b) OPN; (c) CAIX; (d) serum
sodium; and (e) platelet count.
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TABLE 92 Multivariable Cox proportional hazards analysis of MFS
Variable HR (95% CI) p-value
CRP (mg/l)
≤ 14.1 1.00 –
> 14.1 3.22 (1.39 to 7.49) 0.007
Leibovich risk
Low 1.00 –
Intermediate 1.21 (0.34 to 4.29) 0.770
High 6.44 (2.03 to 20.41) 0.002
OPN (ng/ml)
≤ 120.8 1.00 –
> 120.8 1.7 (0.73 to 3.97) 0.223
Leibovich risk
Low 1.00 –
Intermediate 1.35 (0.32 to 5.69) 0.680
High 11.29 (3.09 to 41.21) < 0.001
CAIX (pg/ml)
≤ 60.4 1.00 –
> 60.4 1.73 (0.74 to 4.05) 0.205
Leibovich risk
Low 1.00 –
Intermediate 1.11 (0.31 to 4.02) 0.873
High 9.31 (3.04 to 28.48) < 0.001
Serum sodium (mmol/l)
≤ 141 1.00 –
> 141 0.15 (0.02 to 1.14) 0.067
Leibovich risk
Low 1.00 –
Intermediate 1.34 (0.38 to 4.75) 0.651
High 9.17 (3.09 to 27.18) < 0.001
Platelet count (× 109/l)
≤ 333 1.00 –
> 333 1.60 (0.70 to 3.65) 0.265
Leibovich risk
Low 1.00 –
Intermediate 1.71 (0.43 to 6.83) 0.449
High 13.12 (3.78 to 45.52) < 0.001
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FIGURE 56 Kaplan–Meier survival curves showing MFS for dichotomised markers, serum sodium and platelet count
(only markers found to be significant in univariate analysis are shown) with the Leibovich score included as a
further predictor variable. (a) CRP; (b) OPN; (c) CAIX; (d) serum sodium; and (e) platelet count. Optimised marker
cut points were as follows: CRP = 14.1mg/l; OPN = 120.8 ng/ml; CAIX = 60.4 pg/ml; serum sodium= 141mmol/l; and
platelet count = 333 × 109/l. (continued )
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FIGURE 56 Kaplan–Meier survival curves showing MFS for dichotomised markers, serum sodium and platelet count
(only markers found to be significant in univariate analysis are shown) with the Leibovich score included as a
further predictor variable. (a) CRP; (b) OPN; (c) CAIX; (d) serum sodium; and (e) platelet count. Optimised marker
cut points were as follows: CRP = 14.1mg/l; OPN = 120.8 ng/ml; CAIX = 60.4 pg/ml; serum sodium= 141mmol/l; and
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Factors such as increasing tumour stage and grade, as well as the presence of necrosis and sarcomatoid
change, are accepted poor prognosis factors in RCC and were associated with worse MFS in the current
study. Reporting of MVI is variable and, in particular, is thought to be dependent on the meticulousness of
the reviewing pathologist.849 MVI is currently not recommended for inclusion in the TNM staging of RCC.849
In a small study of 48 patients with T1/T2 RCCs (90% ccRCC), MVI was reported in 17% of patients and
was an independent prognostic factor for DFS.850 MVI was found in 29% of centrally reviewed cases in
another study of 255 patients with pT1–pT3bN0M0 tumours (93% ccRCC) and was shown to have
independent prognostic ability in terms of CSS and OS.851 Furthermore, in a more recent study of 1754
patients with localised ccRCC, addition of MVI status was shown to improve the predictive accuracy of the
Leibovich score by 1.4%.852 Conversely, however, in a study of 2078 patients with ccRCC, although MVI
(seen in 19.8%) was significantly associated with a worse CSS among localised disease patients on
univariate analysis, this association was lost on multivariable testing.853 In the current study, MVI was
reported as present in 16% of cases, in keeping with previous series without central slide review, and
showed a significant association with MFS (p = 0.046) on univariate analysis. The independent predictive
ability of MVI was not examined in the current study because of the current small number of events
limiting the power to detect differences in outcome, but will be investigated once the data have matured.
The current study confirms our previous finding from a smaller (n = 216), single-centre cohort of patients
that higher circulating concentrations of OPN, CRP and CAIX are significantly associated with known poor
prognostic factors such as higher stage and grade486 and, in addition, extends these findings to include
associations with other features such as presence of tumour necrosis, sarcomatoid change and MVI
at a univariate level. Both preoperative CRP and OPN, but not CAIX, were associated with MFS when
considered as continuous variables. Conversely, only CAIX was associated with OS on univariate analysis.
We previously reported an association of all three markers with DFS, CSS and OS. MFS was not examined
in the previous study although each of these end points is an expected surrogate of survival. The
differences here are likely to be because of the small number of events observed in the short period of
follow-up.
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FIGURE 56 Kaplan–Meier survival curves showing MFS for dichotomised markers, serum sodium and platelet count
(only markers found to be significant in univariate analysis are shown) with the Leibovich score included as a
further predictor variable. (a) CRP; (b) OPN; (c) CAIX; (d) serum sodium; and (e) platelet count. Optimised marker
cut points were as follows: CRP = 14.1mg/l; OPN = 120.8 ng/ml; CAIX = 60.4 pg/ml; serum sodium= 141mmol/l; and
platelet count = 333 × 109/l.
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Only CRP was found to be independently prognostic when considered in a multivariable model including
the Leibovich risk classification (p = 0.007). Strikingly, the data suggest that patients in the intermediate-
risk group can be substratified, with patients with a preoperative CRP of ≤ 14.1 mg/l associated with an
excellent outcome, equivalent to a low-risk Leibovich group. Such patients could, therefore, be spared
intensive follow-up and the necessity of considering adjuvant therapies. It must be acknowledged,
however, that the relatively small number of events at the time of analysis limited the number of variables
that could be included in multivariable modelling, meaning that the current analysis should be regarded as
exploratory. Categorisation of continuous variables is more clinically applicable although does come at a
cost, as information is lost, reducing statistical power.854 How best to dichotomise the data is also debated,
with studies variably using the median value or, as in the current study, determining an optimal cut-off
point that gives the minimum p-value. Such data-driven approaches have been criticised as they can lead
to overfitting and optimistic model performance.855 Again, this is acknowledged by the authors and, in
subsequent analyses, we will use additional methods for categorisation, such as our previously described
simulation-based method.856 Validation of our previously described optimal cut-off point for CRP (15 mg/l),
as well as cut-off points defined by others (5 mg/l, 7.5 mg/l), will also be undertaken, although such
cross-study comparisons must be performed with care.486,511,570,572 Issues such as differences in the
particular assay used and, when comparing older studies, the more recent availability of high-sensitivity
CRP assays may confound results. Ultimately, whatever method and choice of cut-off point is used, these
issues highlight the necessity to carefully validate initial results using adequately powered, independent
data sets.
We were the first group to report preoperative serum sodium as being independently prognostic for
DFS among patients with localised ccRCC both when considered as a continuous variable (n = 103)
(HR 0.78, 95% CI 0.66 to 0.92; p = 0.003) and when dichotomised to above and below the median value
(139 mmol/l) (n = 137) (HR 0.39, 95% CI 0.18 to 0.84; p = 0.012).513 These findings have since been
replicated in patients with metastatic RCC but, to our knowledge, have not been re-examined in patients
with localised disease.514–516 Here, we show that serum sodium considered as a continuous variable
associates with MFS at the univariate level, although this does not reach significance at the p < 0.05 level
(p = 0.064). As a dichotomised variable, using an optimal cut-off point, patients with a preoperative serum
sodium of > 141 mmol/l had a HR for relapse of 0.09 (95% CI 0.01 to 0.66; p = 0.018), again suggesting
that a higher serum sodium level is associated with a better outcome. The mechanism underlying this
association remains unclear, but has even led some to suggest that correction of relative hyponatraemia
may be worth exploring as a therapeutic strategy in RCC.857
As outlined in Chapter 12 of this report, a number of studies have examined the prognostic utility of
circulating VEGF concentrations in patients with RCC.590,593,594,596,598,773 These studies have variably employed
either serum or plasma, with no consistency in reported findings. The current study is unique in that we
chose to examine both serum and plasma VEGF in parallel and, to our knowledge, is the largest to date to
examine VEGF concentrations using either matrix among patients with localised ccRCC. Both serum and
plasma VEGF concentrations were significantly elevated among patients with M1 compared with M0
disease, but were not different among stage I–III patients. However, among localised disease patients
grouped by Leibovich score, preoperative VEGF concentrations were elevated among patients with
high-risk compared with intermediate- or low-risk tumours, when measured in serum or plasma or when
considering serum minus plasma concentrations. On univariate analysis, both serum and plasma VEGF
associated with MFS when considered as a continuous variable, but not when dichotomised, although
plasma VEGF was significant for OS (cut-off point 132 pg/ml). At present, therefore, it is difficult to
conclude that either fluid is superior to the other in terms of clinical relevance to RCC outcomes and this
requires further future analysis, which is planned.
It is recognised that both the choice and definition of time-to-event end points in clinical trials varies,
making between-trial comparisons imprecise.858 It is equally a potential issue when trying to compare
biomarker studies. At the time of writing this report, in an effort to standardise reporting in RCC trials,
a recent consensus view was published by the DATECAN (Definition for the Assessment of Time-to-event
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Endpoints in CANcer trials) renal cancer group.858 Among patients with localised disease, MFS, DFS and
locoregional-free recurrence were recommended as intermediate end points. MFS was defined as ‘death
from kidney cancer or appearance of metastases, whichever comes first’. In the current study, we defined
MFS as time to appearance of metastases only, not including deaths, as this was the definition of MFS on
which the Leibovich score was developed. Although clearly OS and CSS represent constants, the otherwise
lack of consistency among prognostic studies in choice and definition of intermediate end point is an
important issue that biomarker reporting guidelines such as the REMARK guidelines367 should consider
addressing.
A limitation of the current study is the relatively short median follow-up of approximately 2 years, meaning
that relatively few events had occurred at the time of analysis. As most relapses occur within 18–24 months
of nephrectomy, the currently reported biomarker associations may become more significant with greater
length of follow-up and number of events. Future analyses are, therefore, planned and will be extended,
for example by examining markers as continuous variables transformed using fractional polynomial methods
and by looking at combinations of biomarkers and algorithms. The Leibovich score will be examined not
just by risk group, but also by score (i.e. 0–11) and as individual elements, that is, T stage, N stage, tumour
size, grade and necrosis. Furthermore, as certain elements, such as grade, are subjective and prone to
interobserver variability, and the presence of necrosis is open to sampling error, the value of the selected
markers to the score, excluding these elements, will be examined.859,860
In conclusion, the multicentre RCC biobank established within this programme consists of a large cohort of
patients with ccRCC with a typical distribution of clinicopathological characteristics and expected survival
associations with known prognostic factors such as stage and grade. As such, it represents an excellent
resource for validation studies of prioritised biomarkers. Despite the current relatively small number of
survival events, this initial study has been able to demonstrate promising associations of the selected
biomarkers with outcomes. Exploratory multivariable analysis suggests that, when dichotomised by optimal
cut-off point, preoperative CRP may add value to the Leibovich score. The results justify further exploration
in future analyses, which are planned and will be undertaken once median follow-up has been extended.
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Chapter 15 Conclusions of the clinical
translation workstream
The clinical translation workstream (workstream 2) was designed to evaluate approaches to streamlineand speed up the central components of the biomarker pipeline. The pipeline runs from discovery to
the implementation of the appropriate biomarker testing within the health-care system, generating
benefits for patients and improvements in health-care quality and cost-effectiveness. The central
components include consideration of analytical validity and clinical validity. Robust evaluation of these
two aspects of the pipeline are essential before clinical utility and consequent benefits for patients and
health-care services can be evaluated.
We identified modest amounts of literature in renal cancer and RT, with moderate numbers of candidate
biomarkers, often identified only in single papers in mixed patient groups. Studies sometimes fail to
distinguish the roles of candidate markers in, for example, prognosis or treatment selection. However, in
both cases progress in evaluating the performance of the biomarkers and then taking them to clinical
practice has been slow and few new biomarkers have been introduced in recent decades. Small study size
and study heterogeneity are important factors in this. In liver disease, we were able to study the ELF test
for which a substantial body of evidence for clinical utility existed. This presented us with the opportunity
to take the ELF test into a formal randomised trial, the ELUCIDATE trial, described in subsequent chapters.
The investigators believed at the outset of this workstream that they would find that many of the
candidate biomarkers lacked sufficient evidence for analytical and clinical validity to justify their evaluation
in large prospective studies of clinical utility. They hypothesised that this would be the case because the
acquisition of appropriate clinical samples, annotated with high-quality clinical data, is a slow process and
studies are frequently carried out using samples of uncertain quality and inadequate numbers of samples
and with insufficient attention to methodological considerations.
The acquisition of high-quality sample banks with appropriate clinical data was deemed to be one part of
the solution to speed up the biomarker evaluation pipeline. The simple hypothesis was that a standing
bank of samples, carefully curated and clinically annotated in adequate numbers, would provide a resource
that would allow candidate biomarkers to be robustly evaluated to allow decisions to be made whether or
not they should go through for full evaluation of clinical utility and their place in clinical practice.
The discipline of clinical biochemistry was strongly represented in the investigating team and these
investigators contributed to the definition of the appropriate sample handling and curation requirements.
The synergy between research scientists and clinical biochemists contributed to the rigour of test
development and evaluation. The methodology teams from workstream 1 and workstream 3 advised on
study design, cohort size and evaluation. The expertise of the CTRU, which was designing, delivering and
analysing the ELUCIDATE trial in workstream 3, was used to establish a robust, prospective, high-quality
clinical data annotation process.
The clinical translation workstream has delivered cohorts of patients with high-quality samples and clinical
annotation. The performance of some candidate biomarkers has been evaluated in the immediate term and
has provided a legacy for future studies. This resides in the sample banks and clinical data, which are a
resource that will enable rapid validation of further biomarkers in these disease areas. However, we associate
greater generic value with the outputs and learning points for the general aspects of the biomarker pipeline.
Several publications have already been generated from the programme, ranging from biomarker reviews
through to exploration of technical issues of specific immunoassays and clearly much of the material
described in the previous chapters will also result in further publications. These will include further technical
pre-analytical papers and a commentary on the various aspects of the set-up process, which will be of
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considerable relevance when planning this type of activity going forwards, and, in addition, many biomarker
studies are anticipated.
We would like to emphasise the generic learning points from the work described in Chapters 10–14.
Chapters 10 and 11 describe the preparation and delivery of the multicentre sample banks in renal
diseases. They demonstrate that with rigorous attention to detail it is possible in the NHS to generate
high-quality sample banks and high-quality clinical annotations for biomarker evaluations. The research
and innovation capacity of the NHS was harnessed across multiple centres to generate the samples, clinical
data and infrastructure to rapidly evaluate candidate biomarkers in renal cancer and in patients after RT.
The challenges faced were substantial and are often generalisable. Details of delays in study set-up and
the challenges of quality assuring samples and clinical data are well illustrated by the data in Chapters 11
and 13. This work will serve as a useful exemplar for the strategic approach that we have advocated for
biomarker evaluation. We have provided the NHS, the NIHR and the academic community and partners
with access to materials that allow the prompt and robust evaluation of analytical and clinical validity.
The challenges involved in multicentre studies, the characteristics of successful centres and the energy and
commitment that are necessary to deliver this approach are clear.
In Chapter 12 the investigation team worked to review and prioritise the circulating biomarkers in renal
cancer and RT that were identifiable from the literature. This chapter demonstrates that such candidate
biomarkers exist in reasonable numbers but that the pace of innovation and new discovery, which is
leading to biomarkers of robust analytical and clinical validity, is still slow. All of the investigation team
were disappointed that, during the period of this study, exciting new biomarkers or biomarker panels,
particularly protein biomarkers in body fluids, did not emerge. The review shows that many studies in the
literature are small and inconclusive but the overview analysis clearly identified candidates that could be
evaluated further. This led to the evaluation in Chapter 13 of appropriate assays with suitable analytical
validity. Chapters 13 and 14 describe the delivery of tests of good analytical validity and clinical validity for
the prioritised and selected biomarkers against the sample bank. Candidates for further tests of clinical
utility were also demonstrated.
We cautiously conclude that this approach has merit and can provide an example of how this field can be
streamlined. However, we have highlighted the considerable organisational and logistic challenges that
must be overcome to effectively deliver development of the pipeline.
Critical to continued improvement in the biomarker pipeline will be the multidisciplinary nature of the
approaches that must be taken. For the investigation within this programme we were fortunate to have
enthusiastic inputs from research scientists, clinical biochemists, methodologists, clinicians and triallists.
We believe that there is little prospect of success in individual studies or in continued improvement,
streamlining and speeding up of the biomarker pipeline in the absence of consistent multidisciplinary
inputs of this kind.
The organisational and logistical challenges have been highlighted. During the duration of this study we
noted a steady improvement in set-up times following the hard work carried out by NIHR infrastructure
organisations, including the NIHR CRN. To continue to deliver progress, partnerships between the NHS,
universities and funders are essential. Each brings unique components of the expertise needed to deliver
the improved biomarker pipeline that is sought by all.
Patients played a substantial part in the design, delivery and conduct of this work. Our PPI workstream
and PPI commentaries were important at all stages. The engagement of patients in the methodology
workstreams and of course their engagement as partners in the delivery of the cohorts and the provision of
samples were essential components of the progress that has been identified in this workstream. We have
continued to work very closely with UK industry and have developed strong working relationships, most
notably with Randox Laboratories (Randox Laboratories Crumlin, County Antrim, Northern Ireland, UK) in a
successful first-phase SBRI Healthcare bid.
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The clinical translation workstream provided the basis for the application, including many of the
investigators on the NIHR programme, to become a NIHR Diagnostic Evidence Co-operative (DEC), which
was successful and began work in 2013. We will describe the DEC, the learning from the programme that
underpinned its development and its operations and the extension of its scope beyond the programme to
include our colleagues in musculoskeletal disease and in other aspects of oncology in Chapter 24.
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Chapter 16 Introduction to the ELUCIDATE trial
(including scientific background and explanation
of rationale)
Workstream 3 aimed to conduct a RCT of an established panel of biomarkers (ELF) of potential valuein CLD, to diagnose cirrhosis at an early stage when beneficial interventions to reduce dangerous
complications are possible, which may lead to patient and NHS benefits. The rationale for selecting the
ELF test is discussed in Chapter 1. Briefly, in the vast majority of cases, liver fibrosis is asymptomatic and
cirrhosis develops insidiously with non-specific symptoms, so that opportunities for disease modification or
cure are missed. Standard biochemical tests of liver function are not specific or sensitive. Liver biopsy is
hazardous, inaccurate and subject to sampling error and variation in interpretation.43–45 Imaging plays a
major role in the detection and assessment of liver fibrosis. However, all imaging modalities including
ultrasound, elastography, cross-sectional imaging with radiography or magnetic resonance imaging (MRI)
require access to expensive technology and skilled operators.46,47
Irrespective of the cause of CLD, progressive liver fibrosis culminates in architectural disruption of the
liver by new collagen deposition termed cirrhosis. Once cirrhosis is established the most common and
life-threatening complications of the cirrhotic state include portal hypertension and hepatocellular cancer.
Treatment of the underlying cause of CLD may prevent or delay the onset of cirrhosis. However, once
cirrhosis is established, whatever the cause, RCTs have demonstrated that a number of treatments (such
as beta-blocker therapy for the treatment of varices and surgery for low-volume HCC) are effective at
reducing the incidence of complications of cirrhosis. However, their effectiveness depends on cirrhosis
being detected early enough to allow them to be delivered before disease is too advanced. Frequently,
patients present for the first time when these life-threatening complications result in avoidable morbidity,
mortality and cost. In workstream 3, we sought to identify a ‘pool’ of patients with progressive fibrosis,
transitioning to cirrhosis, who could be treated early enough in the course of their disease to reduce the
incidence of the serious complications of cirrhosis.
Evidence shows that early detection of varices and treatment with prophylactic use of beta-blockers
to reduce portal hypertension, or band ligation, reduces morbidity and increases survival. Respected
guidelines recommend surveillance for varices because of its benefits and health economic justification.48–52
Similarly, early detection of ascites and treatment have been shown to reduce the morbidity associated
with bacterial peritonitis from 17% to 2%.53 The case for surveillance and early detection of HCC is
more contentious, with some RCTs showing evidence of benefit and others showing none. International
guidelines now advocate surveillance for HCC.54–56 Retrospective analyses have identified criteria, essentially
small tumours, that are associated with better outcomes for HCC resection and liver transplantation, but
many patients are diagnosed after the growth of their tumours has ruled them out for curative resection
or transplantation.57,58
Blood tests for fibrosis and cirrhosis are highly attractive, having the potential to be automated, highly accurate
and reproducible and repeatable at relatively shorter intervals than liver biopsy. Serum markers of liver fibrosis
can be divided into those that are ‘indirect’, which measure liver biochemistry and haematological indices, and
those that are ‘direct’, which measure constituents of liver matrix and enzymes involved in fibrogenesis and
fibrolysis.861,862 Indirect measures, although useful for some clinical purposes, are subject to the influence of
inflammation, drug effects and other comorbidities. Direct markers of fibrosis have biological plausibility but
theoretically may be affected by other fibrotic disorders; however, this has not been a major problem in
clinical evaluation.
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Studies and systematic reviews have demonstrated that single direct markers are less accurate than panels
of markers in the detection of liver fibrosis.59,60 One such panel of direct markers is the ELF test, the only
CE-marked (EU regulatory approval) test for liver fibrosis, which measures constituents of liver matrix
(HA and PIIINP) and a molecule critical to the regulation of matrix remodelling (TIMP-1), using sensitive
automated ELISA assays designed and manufactured specifically for this purpose.61 The three individual
biomarkers were selected as optimal from among 11 ‘direct’ and 35 ‘indirect’ candidates. The results of
the individual assays are combined in an algorithm derived and validated in > 1000 cases of liver fibrosis
to generate a score that correlates with the severity of liver fibrosis on liver biopsy and subsequently
fibroelastography. ELF values have been shown to be highly predictive of clinical outcomes, including
variceal bleeding, ascites, HCC and mortality. Subsequent validation studies in hepatitis C, hepatitis B,
fatty liver disease, HIV–HCV co-infection, primary sclerosing cholangitis and primary biliary cirrhosis have
confirmed the performance of the test.34–37 Although performance is best in the detection of advanced
fibrosis and cirrhosis, the test can also detect mild and moderate degrees of fibrosis accurately, with AUC
ROCs of 0.83 for Ishak fibrosis stage 0–3 compared with 4–6 and 0.86 for Ishak fibrosis stage 0–4
compared with 5–6.
The ELF test was developed by Siemens Medical Solutions (formerly Bayer Healthcare) in conjunction with
the University of Southampton and iQur Ltd. We performed independent evaluations of the analytical
validity of the ELF test.
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Chapter 17 Verification of the analytical
performance of the ADVIA Centaur Enhanced Liver
Fibrosis test
The Siemens ELF test is an in vitro diagnostic assay that uses an algorithm combining quantitativemeasurements of serum HA, PIIINP and TIMP-1 to produce a single ELF value that reflects the degree of
liver damage in patients with or at risk of cirrhosis. The ELF test is the subject of the clinical trial described
in Chapters 18–22 and is available on the Siemens ADVIA Centaur automated analyser.
This chapter describes an independent verification of the ELF test’s analytical performance characteristics.
It details two independent studies conducted within accredited NHS laboratories: an intra-laboratory
study evaluating repeatability, intermediate imprecision and bias against control materials; and an
inter-laboratory study evaluating reproducibility. In addition to verifying the manufacturer’s performance
claims for precision and bias, recommendations are also made for further evaluation prior to routine
clinical implementation. To the authors’ knowledge there have not been any published independent
validation/verification studies of the analytical performance of the ELF test.
Introduction to analytical performance evaluation, precision and bias
In vitro diagnostic tests form the basis of ≈70% of clinical decision-making in the NHS.863 The accuracy of,
and associated uncertainty surrounding, diagnostic testing consequently has a major impact on the overall
quality of clinical decisions and the subsequent effectiveness of this and other health-care systems.
Numerous pre-analytical, analytical and biological factors can contribute to uncertainty in diagnostic
testing strategies (Figure 57). These uncertainties accumulate through the measurement system and may
eventually affect patient outcomes.291,864 The same factors can also introduce bias into clinical trials and
contribute to lack of reproducibility in biomarker research studies.865
Performance evaluation, in the form of method validation, is a legal requirement for both commercial and
laboratory-developed diagnostic tests. Such evaluation is recognised as a critical step in mitigating risk as
part of the development of new laboratory methods.866 For commercial IVDs, such as the ELF test, it is the
manufacturers’ responsibility to validate the analytical performance of the method and provide objective
Pre-analytical: technical
Pre-analytical: biological
Patient state
Patient preparation
Time of sampling
Site of sampling
Collection
Handling/transport
Processing
Storage
Specificity
Bias
Analytical: trueness
Analytical: imprecision
Repeatability
Intermediate imprecision (M1 – 4)
Reproducibility
Biological: within individual
Diurnal
Day – day
Week – week
Months or years
UM
FIGURE 57 Feather diagram depicting biological, pre-analytical and analytical factors that may contribute to
measurement uncertainty (UM).
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evidence that the tests meet the evidence requirements for their intended use, prior to seeking market
approval This includes consideration of analytical sensitivity, specificity, accuracy, repeatability
and reproducibility.866
Before introducing any IVD into routine clinical practice, clinical laboratories should also, to fulfil national
accreditation requirements, independently verify the analytical performance of the test. This is to confirm
that the method is performing as claimed by the manufacturer in a routine setting and is necessary to
safeguard patient safety as part of clinical governance.
The performance evaluations described here include verification of the ELF test’s analytical precision and
bias (reflecting ‘trueness’), which together describe the accuracy of a measurement procedure, as
illustrated in Figure 58.867
Precision and imprecision
Precision is defined as ‘the closeness of agreement between indications or measured quantity values
obtained by replicate measurements on the same or similar objects under specified conditions’.869 It is
usually expressed in terms of SD and/or CV using the following equations:870
σ = √V (29)
%CV = (σ/x) × 100, (30)
where σ is the SD, x is the sample mean and V is the sample variance.
Precision reflects the random errors inherent in all measurement procedures and includes variability arising
from M-Factors, including:
l time – the time between measurements
l calibration – how often the equipment is calibrated
l operator – the number of staff carrying out the assay
l equipment – whether or not the same equipment and batches of reagents are used.
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FIGURE 58 Schematic illustration of the relationships between precision, bias, trueness accuracy and uncertainty.
Modified from Bailey and Barwick, LGC Ltd, 2007.868
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Estimates of precision are strongly dependent on the conditions in which precision is assessed. Precision is
generally evaluated with respect to repeatability, intermediate precision and reproducibility.867,871,872 To
assess repeatability, repeated measurements are made while keeping the factors above constant, so that
they do not contribute to the imprecision. Reproducibility is assessed by comparing results for the same
samples as measured in different laboratories, so that technical and additional factors (e.g. environmental,
staff training) will also contribute to variation in results. Hence, repeatability and reproducibility represent
the minimum and maximum extremes of investigation conditions for precision. It is often helpful to
describe precision under conditions somewhere in between repeatability and reproducibility. Such
conditions are referred to as intermediate precision conditions and are described in relation to the number
of M-Factors that differ (M = 1, 2, 3 or 4).872
Trueness and bias
Trueness is defined as ‘the closeness of agreement between the average of an infinite number of replicate
measured quantity values and a reference quantity value’.869 As trueness cannot be expressed numerically,
it is usually expressed in terms of measurement bias. Measurement bias is defined as ‘an estimate of
systematic measurement error’.869 It is evaluated by comparing the difference between the mean of
replicate measures made using a test method (x) and the assigned value of a reference material or method
(x0) or the consensus mean result (x0) for a group of laboratories (e.g. those participating in an external
quality assessment programme) using the following equations:
Bias = x – x0 (31)
%Bias = (x−x0/x0) × 100. (32)
Analytical performance goals incorporating biological variation
To validate a method one must provide objective evidence that it fulfils the evidence requirements for a
specific intended use and is ‘fit for purpose’.869 However, defining these requirements remains a challenge,
even after several decades of intensive efforts by members of the laboratory medicine community.873
In 1999 a landmark conference in Stockholm agreed a hierarchical structure for setting analytical
performance goals (APG).874 A 2014 conference in Milan revised and refined these,875 suggesting three
approaches based on:
1. the effect of analytical performance on clinical outcome (either directly or indirectly)
2. components of biological variation of the measurand or
3. ‘state of the art’.
Analytical performance goals that incorporate biological variation can be calculated as follows:734
l analytical imprecision (CVA) should be < 0.5 × CVI
l analytical bias (BA) should be < 0.25 × (CVI + CVG),
where CVI is the within-individual variability, CVG is the between-individual variability and CVT is the total
measurement variability [CVT =√(CVI2 + CVA2)].
Single-site evaluation of the Enhanced Liver Fibrosis test
As part of the regulatory submission for the ADVIA Centaur ELF test, Siemens undertook an evaluation of
the imprecision of the ELF value. They performed a full validation of within-run (repeatability), between-run
and total intra-laboratory (intermediate) imprecision according to the CLSI protocol EP05-A2 Evaluation of
Precision Performance of Quantitative Measurement Methods.876 Samples were assayed in triplicate, twice
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daily for 20 days (n = 120 replicates per sample). The intermediate imprecision validation was performed
using one ADVIA Centaur XP and one ADVIA Centaur CP system, using one reagent lot and one calibrator
lot; these data are presented in Table 93.
Study aims
The primary aim of this study was to verify the claimed repeatability and intermediate imprecision of the
ELF values (see Table 93) within a routine NHS clinical laboratory environment. Secondary objectives
included verification of ELF value bias using control materials with assigned values and assessment of the
bias, repeatability and intermediate imprecision of the individual assay components (HA, PIIINP and
TIMP-1).
Study design
The imprecision and bias studies were designed according to the ACB guideline Measurement Verification
in the Clinical Laboratory,877 which is based on the CLSI guideline EP15-A2 (User Verification of
Performance and Trueness).878 Five replicates were measured over 5 days using three clinically relevant
concentrations (high, medium and low) of both patient pooled samples and control materials.
Study methods
Sample collection
Serum samples were collected (REC approval 10/H1306/88), processed and stored at –80°C according to
our internal SOPs (SOP03S Serum Plasma Urine Processing v1.01004). The samples were then transferred
on dry ice to Leeds Pathology Research and Development Department, Leeds General Infirmary, and stored
at –80°C until required.
Sample preparation
Approximately 10 anonymised serum samples (Leeds General Infirmary, REC approval 10/H1306/88) were
selected from patients with systemic sclerosis and combined to yield serum pools at three concentrations
spanning the ELF test assay range (low, medium and high). Samples were selected to exclude any with
physical or biochemical evidence of haemolysis, lipaemia and icterus, which could interfere with the assay.
Each pool was mixed in a universal tube for approximately 5 minutes on a roller mixer at room temperature.
Pools were subsequently subaliquoted in 250-µl volumes in cryotubes and immediately frozen at –80°C.
TABLE 93 Manufacturer’s claimed ELF values for within-run (repeatability), between-run and total intra-laboratory
(intermediate) imprecision
ADVIA Centaur
system
Mean ELF
value
SD CV
Within-
run
Between-
run
Total intra-
laboratory
Within
run
Between-
run
Total intra-
laboratory
XP 6.98 0.07 0.04 0.11 1.00 0.57 1.58
XP 7.12 0.04 0.03 0.08 0.56 0.42 1.12
XP 8.95 0.03 0.04 0.09 0.34 0.45 1.01
XP 11.05 0.03 0.04 0.08 0.27 0.36 0.72
XP 14.51 0.04 0.03 0.08 0.28 0.21 0.55
CP 7.09 0.04 0.07 0.11 0.56 0.99 1.55
CP 7.33 0.06 0.03 0.08 0.82 0.41 1.09
CP 9.08 0.05 0.04 0.08 0.55 0.44 0.88
CP 11.15 0.05 0.04 0.08 0.45 0.36 0.72
CP 14.59 0.06 0.04 0.09 0.41 0.27 0.62
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Measurement of pooled serum samples and reference controls
Study sample analysis was conducted during May and June 2015 in the Leeds Teaching Hospitals Blood
Sciences Laboratory on one ADVIA Centaur XP system (serial number 8680). The analytical conditions
(e.g. reagent and calibrator lot) remained unchanged between series. The same member of laboratory staff
prepared and processed the samples. This reflects the analytical conditions of the intermediate imprecision
studies reported by Siemens (see Table 93) (i.e. one reagent lot and one calibrator lot), in accordance with
CLSI guideline EP05-A2.876
Frozen serum samples were defrosted at room temperature, vortexed and centrifuged prior to analysis, as
per local quality assurance procedures within the blood sciences laboratory. Three levels of each type of
pooled serum sample and reference control material (Siemens) were analysed for each component assay
and manually combined to produce the ELF value using the Centaur XP ELF algorithm:
ELF value = 2:278 + 0:851 ln(HA) + 0:751 ln(PIIINP) + 0:394 ln(TIMP–1). (33)
Data analysis and verification
The ELF value and component analyte measurements were determined according to the ACB method
verification protocol.877 Imprecision data analysis was obtained using nested ANOVA to determine
repeatability and intermediate imprecision using the ACB Spreadsheet A,879 which is based on the CLSI
guideline EP15-A2.878 Spreadsheet A was cross-validated with Analyse-it software (Method Validation
Edition; Leeds, UK) and produced comparable results. A false-rejection rate of 5% was used.
The ELF value and component analyte imprecision was compared with published performance claims.
Test performance was also reviewed in line with FDA bioanalytical guidelines880 and the tumour marker
quality requirements guidelines of the National Academy of Clinical Biochemistry (NACB).881 These
specify intermediate imprecision performance goals of ≤ 15% CV for immunoassays and ≤ 5% CV for
high-precision instruments, respectively, and goals for bias of ≤ 15% of the nominal value, except at the
LLoQ, where it should not deviate by > 20%.880,881 APGs for imprecision and bias were determined using
estimates of total measurement variability (CVT) from the ELUCIDATE trial (see Table 16).
There is as yet no certified reference material or reference method for the ELF test. Analysis of bias
was, therefore, verified by comparing the difference between the means (x) of five replicates of three
manufacturers’ reference QC materials (Lot: Low-2418261, Mid-2418262, High-2418263), measured over
5 days, with their respective assigned values (x0). Data were analysed according to the ACB method
verification protocol.877 However, as Spreadsheet C882 enables inclusion of only two replicates per day,
statistical analysis was performed as above using the Analyse-it software in accordance with the methods
specified in CLSI guideline EP15-A2.878 Tests for equality and equivalence were both performed. Equality
tests assess whether or not the methods are producing identical results (average bias = 0), whereas
equivalence tests assess whether or not the bias is within an allowable goal specified by the manufacturer.
A false-rejection rate of 5% was used.
Results
Assessment of imprecision
The results shown in Tables 94 and 95 confirm that the manufacturer’s claims for ELF test imprecision are
verifiable for both repeatability and intermediate imprecision when using control materials, but not for
repeatability in two of three pooled serum samples.
The Levey–Jennings plots in Figure 59 demonstrate a low level of ELF test imprecision over time against
an ELF value range spanning the clinical decision thresholds used within the ELUCIDATE trial (≥ 8.4 for
randomisation and ≥ 9.5 for management of cirrhosis). The full range of ELF values observed in the
ELUCIDATE trial was 6.41–17.84 (mean 9.304, median 9.11).
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Tables 96 and 97 show the repeatability and intermediate imprecision of the ELF component analytes HA,
PIIINP and TIMP-1 for control materials and pooled serum samples, respectively. The imprecision of the
component analytes was worse than that of the ELF value, with all three components exceeding the NACB
≤ 5% CV criteria for at least one concentration of control materials and at least two concentrations of
pooled serum samples. Furthermore, TIMP-1 exceeded the manufacturer’s intermediate imprecision claims
in two of three control materials and three of three pooled serum samples, whereas PIINP exceeded both
claims at the mid level and HA exceeded the repeatability claim at the high level in pooled serum samples.
Assessment of bias
The results of the assessment of bias are shown in Table 98 and Figure 60. These suggest that, although
the ELF value bias was not equal to zero (p < 0.001), it was within the acceptable bias goals assigned
by the manufacturer (p < 0.001). Similarly, the measured bias of two out of three HA, two out of three
PIIINP and three out of three TIMP-1 reference QC materials was not equal to zero (p < 0.001), but all
were within the acceptable bias goal (p < 0.001). However, it is interesting to note that, although it was
within the manufacturer’s acceptable range, the percentage bias of TIMP-1 ranged from –21.19% to
–20.26%, exceeding the FDA performance goal for a bias of < 20%.
Determination of analytical performance goals
The APGs based on components of biological variation of the ELF value were determined to be as follows:
l APG for CVA = 0.5 × 4.85 = 2.4%
l APG for BA = 0.25 × (4.85 + 10) = 3.7%,
[CVI =√(0.47/9.3 × 100)2 – 1.42) = 4.85% (where σ total measurement variability is 0.47, CVA is < 1.4%
and mean ELF value is 9.3); CVG = 0.93/9.3 × 100 = 10% (where σ between-individual variability is 0.93
and mean ELF value is 9.3].
TABLE 94 Verification of ELF repeatability and intermediate imprecision for control materials
Reference
materials
Mean (ng/ml)
for HA, TIMP-1
and PIIINP
Repeatability
(CV%)
Intermediate
imprecision
(CV%)
Claimed
repeatability
(CV%)
Claimed
intermediate
imprecision
(CV%)
Verification claim
(5% significance
level)
ELF (Low) 7.2 0.7 0.9 0.6 1.1 Within claims
ELF (Mid) 9.1 0.3 0.7 0.3 1.0 Within claims
ELF (High) 11.1 0.3 0.7 0.3 0.7 Within claims
TABLE 95 Verification of ELF repeatability and intermediate imprecision for pooled serum
Reference
materials
Mean (ng/ml)
for HA, TIMP-1
and PIIINP
Repeatability
(CV%)
Intermediate
imprecision
(CV%)
Claimed
repeatability
(CV%)
Claimed
intermediate
imprecision
(CV%)
Verification claim
(5% significance
level)
ELF (Low) 7.6 0.5 1.2 0.7 1.1 Within claims
ELF (Mid) 9.2 0.6 1.4 0.3 1.0 Exceeds
repeatability claim
ELF (High) 11.1 0.5 0.9 0.3 0.7 Exceeds
repeatability claim
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FIGURE 59 Levey–Jennings charts of ELF values across 5 days. (a) Low QC; (b) mid QC; (c) high QC; (d) low serum
pool; (e) mid serum pool; and (f) high serum pool. Dots represent within-run means; the solid line represents the
between-run mean; and the dotted lines represent ±1 SD. (continued )
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FIGURE 59 Levey–Jennings charts of ELF values across 5 days. (a) Low QC; (b) mid QC; (c) high QC; (d) low serum
pool; (e) mid serum pool; and (f) high serum pool. Dots represent within-run means; the solid line represents the
between-run mean; and the dotted lines represent ±1 SD.
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TABLE 96 Verification of HA, PIIINP and TIMP-1 repeatability and intermediate imprecision for control materials
Variable Lot
Mean
concentration
(ng/ml) for
HA, TIMP-1
and PIIINP
Repeatability
(CV%)
Intermediate
imprecision
(CV%)
Claimed
repeatability
(CV%)
Claimed
intermediate
imprecision
(CV%)
Verification claim
(5% significance
level)
HA
Low 2418261 19.7 3.3 4.5 4.5 7.5 Within claims
Mid 2418262 48.7 2.4 5.7 3.6 7.7 Within claims
High 2418263 201.7 2.6 4.8 3.9 6.6 Within claims
TIMP-1
Low 2418261 89.3 2.8 9.4 2.5 5.1 Exceeds
intermediate claim
Mid 2418262 272.3 1.8 7.3 1.9 6.0 Within claims
High 2418263 500.0 1.8 8.9 1.8 5.2 Exceeds
intermediate claim
PIIINP
Low 2418261 2.3 3.8 4.7 5.0 6.6 Within claims
Mid 2418262 5.7 1.1 4.5 3.3 6.8 Within claims
High 2418263 12.5 2.3 6.0 2.2 4.4 Within claims
TABLE 97 Verification of HA, PIIINP and TIMP-1 repeatability and intermediate imprecision for pooled serum
Marker Lot
Mean
concentration
(ng/ml) for
HA, TIMP-1
and PIIINP
Repeatability
(CV%)
Intermediate
imprecision
(CV%)
Claimed
repeatability
(CV%)
Claimed
intermediate
imprecision
(CV%)
Verification claim
(5% significance
level)
HA
Low 2418261 11.4 3.1 4.3 5.2 5.9 Within claims
Mid 2418262 41.4 3.3 5.5 3.6 7.7 Within claims
High 2418263 174.3 5.2 7.4 3.9 6.6 Exceeds
repeatability claim
TIMP-1
Low 2418261 141.3 4.6 7.4 1.8 3.3 Exceeds both
claims
Mid 2418262 245.8 2.1 9.6 1.9 6.0 Exceeds
intermediate claim
High 2418263 342.1 5.3 9.7 1.6 3.1 Exceeds both
claims
PIIINP
Low 2418261 5.4 2.9 6.9 3.3 6.8 Within claims
Mid 2418262 7.8 4.7 7.8 1.9 2.9 Exceeds both
claims
High 2418263 17.9 2.8 5.2 2.2 4.4 Within claims
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TABLE 98 Verification of ELF value and component analyte bias using the manufacturer’s reference QC material
Reference
material Lot
Target (ng/ml) for
HA, TIMP-1 and PIIINP Low High
Mean (ng/ml) for HA,
TIMP-1 and PIIINP
Bias (ng/ml) for HA,
TIMP-1 and PIIINP
Bias
(%)
Equality test
(5% significance level)
Equivalence test
(5% significance level)
HA
Low 2418261 20.1 15.07 25.13 19.71 –0.39 –1.94 Not equal to zero Within goal
Mid 2418262 50.8 38.1 63.5 48.72 –2.08 –4.10 Not equal to zero Within goal
High 2418263 200 150 250 201.67 1.67 0.84 Equal to zero Within goal
PIIINP
Low 2418261 2.45 1.837 3.063 2.30 –0.15 –6.06 Not equal to zero Within goal
Mid 2418262 5.96 4.47 7.45 5.68 –0.28 –4.68 Not equal to zero Within goal
High 2418263 12.4 9.3 15.5 12.48 0.08 0.68 Equal to zero Within goal
TIMP-1
Low 2418261 95.6 71.7 119.5 75.60 –20.00 –20.92 Not equal to zero Within goal
Mid 2418262 296 222 370 236.02 –59.98 –20.26 Not equal to zero Within goal
High 2418263 531 398 564 418.48 –112.52 –21.19 Not equal to zero Within goal
ELF
Low 2418261 7.3 6.73 7.75 7.21 –0.09 –1.26 Not equal to zero Within goal
Mid 2418262 9.2 8.63 9.65 9.10 –0.10 –1.11 Not equal to zero Within goal
High 2418263 11.2 10.6 11.6 11.13 –0.07 –0.61 Not equal to zero Within goal
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FIGURE 60 Difference plot showing the bias of three manufacturers’ reference QC materials for (a) ELF; (b) HA;
(c) PIIINP; and (d) TIMP-1. (continued )
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Discussion
This study has verified the manufacturer’s intermediate imprecision and bias performance claims for the
ELF test, in an accredited NHS laboratory. The results suggest that the ELF test is a precise and true assay
with intermediate imprecision of < 1.4% and bias of < –1.26%. As the only assay factor that varied was
time, the intermediate imprecision presented here is likely to underestimate the total intra-laboratory
intermediate imprecision (M-Factor = 4).
In contrast, the manufacturer’s repeatability claims for the ELF test were not verified in two of three pooled
serum samples. This may reflect specific characteristics of the pooled clinical samples as the manufacturer’s
claimed repeatability at these concentrations is highly precise and the observed repeatability of < 1% is well
below the specified requirements of the FDA and NACB of ≤ 15% and ≤ 5% CV, respectively. The ELF test
imprecision was also within the APG for imprecision of 2.4% based on components of biological variation.
The imprecision of the individual components was less good and failed to meet all of the manufacturer’s
claims and NACB criteria. However, all measurements had coefficients of variation of < 10% of the mean
value and met the FDA criteria, so analytical performance is within ranges generally considered to be
acceptable for clinical application.
This study has also verified the ELF test’s claims for bias using reference QC materials. The observed ELF
test percentage bias was low across all three QC samples, with < –1.26% difference from the assigned
value, well below the FDA goal for bias of < 20% and the APG for bias of 3.7% based on components
of biological variation.
However, the comparable performance of the component analytes was less reassuring. TIMP-1 had the
highest percentage bias of up to –21.19%, which, although within the manufacturer’s acceptable range,
exceeded the FDA performance goal of < 20%.
It is interesting to note the comparative precision and bias of the ELF test for HA, PIIINP and TIMP-1.
As might be expected, the logarithmic transformation of the biomarker concentrations within the ELF
test also transforms the variance, greatly reducing the percentage CVs. Although this appears to be the
main reason for the perceived improvements in precision, benefit may also be derived from the ‘averaging’
effect of the triple biomarker panel and the preferential weighting for HA, the most precise component.
It is not immediately clear from the instructions for use whether clinical laboratories should undertake QC
only for the ELF values or for the ELF values and each of the component analytes. Results of the verification
reported here suggest that one or more individual component analytes might fail QC, even though the ELF
values remained within acceptable limits. This might lead to rejection of an unnecessarily high number of
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FIGURE 60 Difference plot showing the bias of three manufacturers’ reference QC materials for (a) ELF; (b) HA;
(c) PIIINP; and (d) TIMP-1.
VERIFICATION OF THE ANALYTICAL PERFORMANCE OF THE ADVIA CENTAUR ENHANCED LIVER FIBROSIS TEST
NIHR Journals Library www.journalslibrary.nihr.ac.uk
308
tests. In view of the increasing number of complex decision algorithms that are being applied in laboratory
medicine, this is an important issue that requires further research and guidance.
A limitation of this study was the use of pooled patient samples. Although this is not uncommon in
precision studies, as the volume of available sample material is limited, the pooling of patient samples may
dilute out any interfering substances and could also introduce interactions that would not naturally occur
within an individual sample. The lack of available certified reference materials or reference methods was
also a limitation of this study. Bias was, therefore, assessed using manufacturer’s reference QC materials in
the intra-laboratory study, as recommended by Khatami et al.877
A further potential limitation was that components of biological variation (e.g. CVI and CVG) were derived
from the same study and not from a prospectively designed and powered biological variation study.290,883
However, the data presented should provide a realistic estimation of the total measurement variability and
are more likely to over- than underestimate variability.
Multisite evaluation of the Enhanced Liver Fibrosis test
When introducing new assays such as the ELF test to multiple sites within a health-care system, it is essential
to demonstrate that good between-laboratory agreement can be achieved across multiple laboratories. Such
inter-laboratory method performance studies can helpfully contribute to the validation of analytical methods
as they incorporate assessment of the additional variance encountered when comparing results between
laboratories.884 Once a test has been accepted into clinical practice, continued performance surveillance is
usually the responsibility of external quality assessment providers.885
Inter-laboratory and external quality assessment studies usually involve distributing aliquoted samples of
the same material (usually pooled human serum, plasma or urine) to laboratories participating in the
study. Participants run the required test or tests in each of the specimens and return the results to the
co-ordinating centre. Analysis of the submitted results enables calculation of between-laboratory
agreement (and sometimes within-laboratory agreement). For heterogeneous analytes such as the ELF
test components, the target values are usually consensus means.
Study aim
With the aim of assessing the feasibility of introducing the ELF test into NHS diagnostic laboratories,
an inter-laboratory study was carried out to determine between-laboratory agreement (reproducibility) of
all components of the ELF test.
Study design
Eight NHS diagnostic laboratories were invited to participate in the inter-laboratory study, for which
availability of a Siemens ADVIA Centaur system was required. Specimens were sent to each participating
laboratory together with 10 serum samples.
Test materials and distribution
Suitable anonymised left-over clinical samples from patients with liver disease were identified by staff in
the Blood Sciences Laboratory at Leeds Teaching Hospitals. Ten 5.0-ml pools were prepared by combining
two to three of the clinical samples and 0.5 ml of each pool was transferred to each of 10 prelabelled
tubes (specimens E001–E010). Sets of 10 specimens were packaged according to UK NEQAS (Edinburgh)
procedures and sent, together with a personalised results sheet (see Appendix 2), to each of the
participating laboratories. Specimens were sent at ambient temperature to mimic routine clinical practice.
Participants were requested to assay the specimens following the procedure recommended by Siemens
for the ELF test and to return their results sheets and assay printouts by e-mail or fax to the UK NEQAS
(Edinburgh) unit. They were asked to submit results for each individual component of the test as well as
the final ELF value.
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Laboratory procedures
The ELF test was set up on the individual analysers at the different sites with assistance from staff from
Siemens, as is usual in clinical laboratories. Siemens also kindly supplied all reagents and controls required.
The specimens were analysed in singlicate twice, in two separate runs. The manufacturer’s instructions
were followed in all cases and three kit controls were included in each run.
Results
Results obtained from the individual sites are shown in full in Appendix 2 and summarised in Table 99.
Between-run agreement for all analytes and all specimens was generally very good, with CVs for each pair
of runs < 10% for all sites, except for site 6, where a hardware issue was identified with the analyser,
which resulted in imprecise results for HA (see Appendix 2). Between-method agreement for the final ELF
value was excellent, with between-method CVs for the 10 specimens as measured at eight sites ranging
from 0.4% to 1.2% (see Table 99).
Discussion
The multisite study described here considered primarily the verification of analytical imprecision. The
results confirm that the ELF test is reproducible. The between-laboratory imprecision of < 1.2% observed
across eight centres is well within the APG for imprecision of 2.4% based on components of biological
variation and is also well within the specified requirements of the FDA and NACB of ≤ 15% and ≤ 5% CV,
respectively. However, prior to its implementation into routine clinical practice, further work would be
desirable to confirm the analytical specificity (including interference and cross-reactivity), analytical sensitivity,
limits of detection/quantitation and measuring range of the test. Further characterisation of pre-analytical
and biological factors, including within-individual variation, time from sample collection to analysis or
stabilisation, type of collection tube, storage temperature, duration of storage, aliquot volume, number of
freeze–thaw cycles and specific systematic factors (e.g. medications, fasting, alcohol and smoking), should
also be conducted prior to implementation. These further studies are planned as part of an ongoing NIHR
Career Development Fellowship (Dr Del Galdo), which will include assessment of the clinical utility of HA,
PIIINP and TIMP-1 in patients with systemic sclerosis.
TABLE 99 Between-laboratory agreement of the ELF value as determined for specimens E001–E010 in eight
accredited NHS clinical laboratories
Site
ELF value
E001 E002 E003 E004 E005 E006 E007 E008 E009 E010
QC identifier
Low Mid High
1 10.3 9.5 9.8 9.3 9.5 9.7 9.5 10.8 10.3 10.0 7.6 9.1 11.0
2 10.4 9.5 9.8 9.4 9.6 9.8 9.6 10.8 10.3 10.2 7.6 9.2 11.1
3 10.4 9.6 9.9 9.4 9.6 9.9 9.6 10.8 10.4 10.3 7.7 9.2 11.1
4 10.4 9.5 9.8 9.3 9.5 9.8 9.5 10.7 10.3 10.2 7.6 9.2 11.0
5 10.4 9.5 9.8 9.4 9.5 9.8 9.5 10.8 10.3 10.2 7.6 9.1 11.0
6 10.6 9.5 10.0 9.4 9.6 10.0 9.6 11.1 10.3 10.4 7.7 9.3 11.1
7 10.4 9.5 9.8 9.4 9.6 9.8 9.5 10.8 10.3 10.2 7.6 9.1 11.0
8 10.3 9.5 9.8 9.3 9.5 9.8 9.5 10.8 10.3 10.2 7.6 9.1 11.0
Mean 10.4 9.5 9.8 9.4 9.6 9.8 9.5 10.8 10.3 10.2 7.6 9.2 11.0
SD 0.10 0.04 0.08 0.05 0.05 0.09 0.05 0.13 0.04 0.12 0.05 0.08 0.05
CV% 0.9 0.4 0.8 0.6 0.6 0.9 0.6 1.2 0.4 1.2 0.7 0.8 0.5
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Study conclusions
The work presented here demonstrates that the ELF test performs as specified by the manufacturer and
suggests that its transfer to routine use in NHS laboratories is feasible.
Provided the manufacturer’s instructions are followed and suitable QC procedures are implemented, the
analytical performance of the ELF test should be appropriate for clinical use.
Further high-quality studies of pre-analytical and biological requirements should be conducted to
determine the total ELF test measurement uncertainty.
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Chapter 18 Design and set-up of the
ELUCIDATE trial
Study design
The ELUCIDATE trial was a multicentre individually RCT that aimed to determine whether or not the use of the
ELF test in addition to standard clinical monitoring significantly alters the diagnostic timing and subsequent
management of cirrhosis of the liver, compared with standard clinical monitoring alone, in order to reduce the
incidence and consequences of serious complications and improve outcomes for patients and service provision.
In the trial the ELF test was used to test for liver cirrhosis in patients with CLD and pre-cirrhotic moderate to
severe fibrosis (as classified by clinical, laboratory or histological evidence) as a result of viral liver disease,
non-alcoholic fatty liver disease, alcoholic liver disease, primary biliary cirrhosis, primary sclerosing cholangitis,
autoimmune hepatitis, haemochromatosis or combinations of these diseases.
Enhanced Liver Fibrosis test values have been evaluated in previous studies to relate biopsy evidence to ELF
results (Table 100).
It can be seen that ELF values of < 8.4 are not associated with fibrosis on biopsy and they carry only a very
small risk of serious liver complications (see Figure 64). Scores of ≥ 9.5, however, are associated with
cirrhosis on biopsy and a higher risk of serious complications (see Figure 64).
This trial aimed to answer the following questions:
l Does the use of serum markers of liver fibrosis permit earlier detection of liver cirrhosis in patients with
CLD to allow earlier interventions?
l Does the use of serum markers of liver fibrosis affect the process of care, through (1) increased use of
beta-blockers/band ligation of varices to prevent haemorrhage; (2) increased use of endoscopy and
ultrasound/AFP assays to detect HCC at a surgically curable stage; and (3) effective early treatment to
normalise liver function tests (LFTs) in patients with hepatitis B and hepatitis C?
l Does the use of serum markers of liver fibrosis result in patient benefit through improved survival and
reduced liver-related morbidity and mortality?
l Does the use of serum markers of liver fibrosis improve the cost-effectiveness of the management of
end-stage liver disease?
We also carried out a qualitative exit study to investigate patient understandings of clinical biomarkers;
patient experiences and the acceptability and perceived utility of testing; and motivations for testing.
The design of the trial is summarised in Figure 61.
TABLE 100 Enhanced Liver Fibrosis test values and fibrosis staging
Fibrosis stage (Ishak886) ELF range
Normal/mild (F0–F2) < 8.37
Moderate (F3) 8.37–8.73
Moderate/severe (F4) 8.74–9.12
Severe (F5) 9.13–9.49
Cirrhosis (F6) ≥ 9.5
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Patients suspected of having CLD
Eligibility and consent
Registration
ELF screening test
Randomisation
Repeat ELF test (fasted sample)
Standard care arm Standard care plus ELF arm
ELF value < threshold;
patient INELIGIBLE for
randomisation
ELF value ≥ threshold:
patient ELIGIBLE for
randomisation
(providing patient shows no
clinical signs of cirrhosis)
Diagnosis of cirrhosis
on clinical/biochemical criteria
ELF test
Diagnosis of cirrhosis
ELF value ≥ threshold
Liver-related outcomes
Variceal bleeding, ascites, encephalopathy, HCC, transplantation, death
Overall mortality
Primary end point
Time to first liver-related event
Incidence of morbidity or mortality
Secondary end point
Time to diagnosis of cirrhosis
Instigation of variceal prophylaxis, HCC screening and antibiotic prophylaxis
Initial follow-up visit 3 months post cirrhosis diagnosis, then follow-up visits every 
6 months
Standard outpatient assessment
every 6 months
Standard outpatient assessment
plus ELF test at outpatient
assessment
every 6 months
Resume routine
care
FIGURE 61 The ELUCIDATE trial flow chart showing recruitment, randomisation and follow-up procedures.
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The ELUCIDATE final trial protocol is provided as supplementary material (see Report Supplementary
Material 1).
Ethics approval and research governance
Ethics approval for the trial was given by Leeds Central Research Ethics Committee, later known as Yorkshire
and Humber – Bradford Leeds Committee (main REC) on 2 February 2010 (reference number 10/H1313/2).
Participating sites were required to have obtained local management approvals and undertaken a site
initiation meeting with the central co-ordinating clinical trials unit (CTRU, University of Leeds) prior to the
start of recruitment into the trial. The trial was registered with the International Standard Randomised
Controlled Trial (ISRCTN) register (ISRCTN74815110).
A summary of the changes made to the original protocol is given in Appendix 3.
Participants
The trial recruited patients with CLD from liver clinics in secondary care through the NIHR CRN
Comprehensive Clinical Research Networks.
Inclusion criteria for registration
Patients were considered eligible for registration if they met all of the following criteria:
l aged ≥ 18 years and < 75 years
l had CLD due to any aetiology, including viral hepatitis C or B, non-alcoholic liver disease, alcoholic liver
disease, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, haemochromatosis
or combinations of these diseases, with no diagnosis of cirrhosis
l had a life expectancy of > 6 months
l were likely to comply with the follow-up schedule
l were able to provide written informed consent.
Exclusion criteria for registration
Patients with any of the following criteria were not eligible for registration into the trial:
l imaging, histological or laboratory (other than ELF) diagnosis of cirrhosis/portal hypertension as
evidenced by any one of the following –
¢ imaging evidence of portal hypertension (splenomegally, varices or ascites)
¢ liver biopsy diagnostic of cirrhosis (Ishak fibrosis stage F6 or equivalent)
¢ thrombocytopenia (platelet count of < 100 × 109/l)
¢ hypoalbuminaemia (albumin level less than the lower limit of normal)
l acute liver injury or acute liver failure (hepatic dysfunction of < 6 months in duration)
l an ongoing or previous episode of hepatic decompensation (acute or chronic liver failure) including
encephalopathy, variceal bleeding, ascites, jaundice or liver synthetic dysfunction
l an established diagnosis of HCC or elevated AFP without investigation to exclude HCC
l being treated with heparin (ELF test cannot be performed)
l previously screened and found ineligible for the ELUCIDATE trial.
Screening and consent procedure
Nurses reviewed their caseload for potentially eligible participants. Subjects fulfilling the eligibility criteria
were invited to participate in the study. Whenever possible, eligible patients were sent a patient
information summary to consider prior to their next clinic appointment.
At their next clinic visit, patients were provided with the full patient information leaflet and further verbal
details of the trial. Assenting patients were formally assessed for eligibility and invited to provide informed,
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written consent for registration, subsequent randomisation (if eligible at that time) and long-term follow-up
via routine NHS data sources. Patients were permitted to have more time to consider trial participation and,
if they subsequently assented, eligibility assessments and consent were undertaken at a later clinic visit.
All participants were informed that they were free to withdraw at any time without reason and without it
affecting the quality of their care.
Registration and baseline Enhanced Liver Fibrosis test
Consenting patients were registered into the ELUCIDATE trial via a 24-hour telephone registration system
and provided a fasted serum sample for an ELF test (patients should have refrained from eating a large
meal in the 2 hours prior to providing the sample). The ELF test was sent off to a central laboratory
(iQur Ltd) for analysis.
Eligibility for randomisation
Only patients with an ELF value of above a predefined threshold (denoting at least moderate fibrosis),
and who had no clinical, histological or laboratory diagnosis of cirrhosis were eligible for randomisation.
As knowledge of ELF values may cause patients or clinicians to modify their behaviour, which might
influence disease progression and result in confounding, to ensure equipoise, results were fed back to the
investigator simply as (1) below the threshold and not eligible for randomisation or (2) equal to or above
the threshold and eligible for randomisation.
In March 2011, after 43 patients had been randomised, the ELF test threshold for randomisation was
amended from 11.0 to 8.4 to incorporate patients with an identified risk of progression to cirrhosis and
severe complications (see Figure 64).
Randomisation
Patients with a registration ELF value equal to or above the threshold (originally 11.0, amended to 8.4 after
March 2011) were invited back to clinic for a randomisation visit. The randomisation visit should have
occurred as soon as possible following receipt of the registration test results and preferably within 6 weeks
of the registration visit, but up to 12 weeks was permissible. If > 12 weeks had passed since registration, a
repeat ELF test was taken to ensure that the patient remained eligible for the trial and had not progressed
to cirrhosis. At the randomisation visit, patients were assessed to ensure that their liver disease had not
progressed to clinically evident cirrhosis in the interval from their registration visit and were asked whether
or not they were still happy to continue participating in the trial and were willing to be randomised.
Assenting patients judged to still be pre-cirrhotic were individually randomised at the end of their
baseline assessments.
Randomisation was undertaken using an automated 24-hour telephone randomisation system, which was
administered remotely. The randomisation service was provided by the CTRU at the University of Leeds,
a UK Clinical Research Collaboration-registered trials unit. A computer-generated minimisation program
incorporating a random element was used to ensure that treatment groups were well balanced for the
following characteristics:
l centre
l age (≥ 18 to < 40, ≥ 40 to < 65, ≥ 65 to < 75 years)
l sex (male, female)
l baseline ELF value [11–11.49, 11.5–11.99, 12–12.49 and 12.5+ or ≥ 8.4 to < 9.5, ≥ 9.5 to < 11.5,
≥ 11.5 to < 12.5 and ≥ 12.5 from protocol version 5.0 onwards (March 2011)]
l history of high alcohol consumption (at any time), defined as > 6 units (60 g of alcohol) per day for
≥ 12 months for males and > 4 units per day for ≥ 12 months for females (yes, no)
l current alcohol consumption per day [males: 0 units (teetotal), < 3 units (light), 3–6 units (moderate),
> 6 units (high); females: 0 (teetotal), < 2 units (light), 2–4 units (moderate), > 4 units (high)]
l type of CLD (alcoholic liver disease, viral, unknown/other, non-alcoholic fatty liver disease).
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Patients were randomised to one of two treatment groups on a 1 : 1 ratio: standard clinical monitoring
plus ELF test monitoring (intervention arm) or standard clinical monitoring alone (non-intervention arm).
For patients randomised to the intervention arm, if their ELF value at registration was above the threshold
for cirrhosis diagnosis, the randomisation system also notified the caller of that so that management of
cirrhosis could begin.
Quality assurance of the Enhanced Liver Fibrosis test
All sites were issued with a sample processing SOP. Samples were used to determine eligibility for
randomisation only if they had been kept at room temperature for no longer than 2 days between being
taken and arriving at iQur Ltd. If shipping delays were anticipated (e.g. at a weekend), samples were
stored in the fridge and shipped when delivery within 2 days was possible. If a sample had been kept at
room temperature for > 2 days from the time that it was taken, then a repeat sample was requested.
Patients were requested to refrain from eating a large meal in the 2 hours prior to providing the blood
sample for each ELF test. For the ELF sample collected at the randomisation visit, patients were requested
to have fasted (gone without food for > 4 hours), to allow for glucose ± homeostatic model assessment –
insulin resistance testing.
Treatment group allocation
Screening for cirrhosis with standard clinical monitoring
Patients allocated to the standard clinical monitoring arm were seen in clinic every 6 months and monitored
as per standard practice. If a patient was deemed to be cirrhotic on clinical criteria [by examination, on the
basis of laboratory tests (other than ELF) or through imaging], cirrhosis management commenced.
Screening for cirrhosis with standard clinical monitoring plus Enhanced Liver Fibrosis test
Patients allocated to the intervention arm were seen in clinic every 6 months and monitored as per standard
practice. In addition, they also had their ELF value measured every 6 months by the central laboratory. If a
patient was deemed to be cirrhotic on clinical criteria [by examination, on the basis of laboratory tests (other
than ELF) or through imaging], cirrhosis management commenced. If a patient had an ELF value that was
above a predefined threshold, the patient was deemed to be cirrhotic. The investigator was informed that
the patient was above the threshold and the patient was recalled into clinic as soon as possible for cirrhosis
management to commence.
The ELF threshold for cirrhosis was originally ≥ 12.5 but this was changed to ≥ 9.5 in protocol version 5.0
onwards (March 2011).
Data collection and management
Trial data were recorded by research staff on CRFs and submitted to the CTRU. Sites were provided with
guidance on the schedule of CRFs, data to be collected and completion of CRFs. Data were entered into
the trial database by CTRU staff using Infermed’s (London, UK) MACRO® Electronic Data Capture platform.
A number of manual and in-built database cross-checks were routinely performed to check for missing and
inconsistent data items, which were reported back to sites for resolving at the earliest opportunity.
Baseline registration assessment
Baseline assessments consisting of a physical examination, medical history and demographic details were
conducted in the month prior to registration or at the registration visit. At the randomisation visit, a blood
sample was taken for the ELF test and the patients completed the EuroQol-5 Dimensions (EQ-5D) and
Short Form questionnaire-12 items (SF-12) version 2 health questionnaires.
Baseline randomisation assessment
At this visit, patients had another ELF sample taken and completed the EQ-5D/SF12v2 and Health Usage
Questionnaire. Patients were not told their randomisation allocation until after they had completed the
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questionnaires. In addition, patients had the following assessments performed: LFTs, full blood count,
international normalised ratio and glucose level.
Follow-up
From the date of randomisation, patients underwent follow-up assessments every 6 months until
30 months post randomisation, unless they were diagnosed as cirrhotic. At each follow-up visit all patients
underwent a physical examination (weight, vital signs), medical history (including details of concomitant
disease and medication) and blood tests (simple LFTs, platelets, albumin and clotting) and were required
to complete the EQ-5D/SF-12v2 and Health Usage Questionnaire. In addition, patients randomised to the
follow-up arm with ELF testing also underwent blood sample collection at each follow-up visit, with the
samples sent to the central iQur Ltd laboratory for ELF testing. Patients were requested to refrain from
eating a large meal in the 2 hours prior to providing the sample. In both treatment arms, when patients
were diagnosed as cirrhotic (either by ELF testing or clinical means) within 30 months post randomisation,
they were required to attend an initial post-cirrhotic follow-up assessment at 3 months post diagnosis and
then every 6 months until 30 months post randomisation.
Follow-up and management of patients diagnosed with cirrhosis
The trial protocol included recommendations for the management of varices, ascites and HCC after a
diagnosis of cirrhosis, based on appraisal of national and international guidelines, but sites were permitted to
follow their own established protocols provided that these were documented and adhered to for all study
participants and that they included as a minimum ultrasound scanning, oesophagogastroduodenoscopy
(OGD) and measurement of AFP levels.
All patients with a diagnosis of cirrhosis were required to have an OGD as screening for varices within
3 months of their cirrhosis diagnosis, unless they had had an OGD in the previous 18 months, in which
case the next OGD should have occurred within 18 months of the previous OGD, unless clinically indicated
sooner. If the previous OGD did not identify oesophageal varices, subsequent OGDs were repeated every
18 months. If small oesophageal varices were identified on OGD, OGDs were repeated every 6 months to
look for variceal progression. For large oesophageal varices that were being treated, the timing of
subsequent OGDs was dictated by local guidance.
Moderate or large oesophageal varices should have been banded as primary prophylaxis, with banding
repeated weekly until the varices were obliterated. Alternatively, patients could be treated with
non-cardioselective beta-blockers as primary prophylaxis. As secondary prophylaxis, bleeding oesophageal
varices should have been banded weekly until obliterated and, in addition, patients should have been
considered for treatment with beta-blockers, unless contraindicated.
For prophylaxis of spontaneous bacterial peritonitis, all patients with ascites were treated with 400 mg of
norfloxacin (Noroxin®, Merck Sharp & Dohme Corp., a subsidary of Merck & Co, Inc.) once daily or with an
alternative antibiotic as per local protocol.
All patients diagnosed with cirrhosis were required to have their AFP measured and an ultrasound scan
performed for HCC screening within 3 months of a diagnosis of cirrhosis, unless they had had an
ultrasound scan or AFP test within the previous 6 months, in which case the next ultrasound scan or AFP
test should have been performed within 6 months of the previous scan, unless clinically indicated sooner.
The AFP test was repeated every 6 months. If the previous ultrasound scan did not identify any lesions and
the patient’s AFP level remained stable, a subsequent ultrasound scan was repeated every 6 months. Any
space-occupying lesions, equivocal ultrasound scans or rising AFP levels in the absence of a lesion on
ultrasound were followed by triple-phase CT and/or MRI scans.
Suspected HCC was managed according to local, national and international guidelines and the
management pathway was documented on the patient’s CRF.
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Patients were considered for liver transplantation if they had a solitary lesion measuring < 5 cm in diameter
or three lesions measuring < 3 cm in diameter, no evidence of extrahepatic manifestations and no evidence
of vascular invasion. If a patient underwent liver transplantation, further 6-monthly follow-up ceased.
All other patients were considered for therapeutic interventions as per local protocols.
End points
Primary end point (according to protocol version 7.0, 30 January 2013)
The primary end point was time from randomisation to occurrence of the first severe complication. Severe
complications were defined as:
l variceal haemorrhage confirmed by one of the following –
¢ visualisation through endoscopy
¢ imaging
¢ post mortem
l spontaneous bacterial peritonitis –
¢ ascites confirmed by –
¢ imaging and/or
¢ aspiration and
¢ infection confirmed by –
¢ microscopy and/or
¢ culture
l HCC beyond the Milan criteria57,887 (note that, for the purposes of the trial, cases of HCC falling within
the Milan criteria were not regarded as end points as they are regarded as treatable)
l encephalopathy – grade 3 or 4 defined using the West Haven criteria888 (Table 101)
l liver-related mortality – any of the following:
¢ any mention of liver disease in part 1 of the death certificate
¢ death from HCC
¢ death from liver failure
¢ death from bleeding from portal hypertension
¢ death from hepatorenal syndrome
¢ death from sepsis occurring as a result of CLD
¢ death from spontaneous bacterial peritonitis
¢ death from encephalopathy.
Secondary end points (according to protocol version 7.0, 30 January 2013)
l Time from diagnosis of cirrhosis (by ELF testing or clinical means) to incidence of first
severe complication.
l Time from randomisation to diagnosis of cirrhosis by ELF testing or clinical means (to allow instigation
of prophylaxis and screening).
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l Process outcomes, namely:
¢ treatment of varices with beta-blockers/band ligation
¢ use of endoscopy and ultrasound/AFP tests
¢ treatment to normalise LFTs in patients with hepatitis B and hepatitis C.
l Detection and timing of complications following cirrhosis, including:
¢ detection of small varices
¢ detection of large varices
¢ incidence of treatable HCC.
l All causes of mortality.
l Specific liver-related morbidity.
l Economic evaluation of the ELF test in the early detection of cirrhosis and as such in the initiation of
measures to reduce the incidence of severe complications following cirrhosis.
l Quality of life.
l Proportion of non-randomised patients (ELF value of < 8.4) who go on to develop cirrhosis (diagnosed
by clinical means) within the follow-up period.
The process outcomes were added as secondary end points by way of a protocol amendment in January 2013,
as part of the NIHR-approved trial extensions. The overall aim, and primary outcome, of the study was to
reduce the incidence of severe complications and improve survival in this patient population through the use
of ELF tests. For this to happen the use of such tests would have to affect clinical practice, that is, the process
of care would have to change. This is a necessary step in order to expect an improvement in these primary
outcomes and was by no means guaranteed.
Health-related quality of life
Health-related quality of life was assessed at registration, randomisation and 6-monthly intervals post
randomisation for 30 months (five follow-up visits), using the SF-12v2.
TABLE 101 Westhaven criteria for semiquantitative grading of mental state
Grade Criteria
1 Trivial lack of awareness
Euphoria or anxiety
Shortened attention span
Impaired performance of addition
2 Lethargy or apathy
Minimal disorientation for time or place
Subtle personality change
Inappropriate behaviour
Impaired performance of subtraction
3 Somnolence to semistupor, but responsive to verbal stimuli
Confusion
Gross disorientation
4 Coma (unresponsive to verbal or noxious stimuli)
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Long-term follow-up
All patients who were registered into the trial (whether randomised or not) were flagged with the Health
and Social Care Information Centre collection of for (now known as NHS Digital http://digital.nhs.uk/;
accessed 22 May 2018) longer-term morbidity and mortality data.
Statistical analysis
The analysis and reporting of the trial was undertaken in accordance with CONSORT guidelines.235 The
original sample size calculation is given in detail in Appendix 4. This sample size calculation was not
straightforward without the availability of the simulation approach, derived later on as part of the
methodology workstream and described in Chapter 19. All statistical analysis was undertaken using SAS®
software version 9.4 (SAS Institute Inc., Cary, NC, USA; SAS and all other SAS Institute Inc. product
or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other
countries. ® indicates USA registration), following a predefined analysis plan agreed with the Trial Steering
Committee. The primary comparative analyses between the randomised groups were conducted on an
intention-to-treat basis without imputation of missing data.
Health economic methods
The main trial was supplemented with an economic evaluation consisting of two components:
1. a within-trial economic evaluation to compare the observed costs and outcomes of the cohort of
patients randomised to ELF guided detection and management with those of a cohort of patients
randomised to standard care, from the perspective of the NHS and Personal Social Services
2. a long-term economic evaluation using the clinical trial outcome and resource utilisation data to update
the parameters of the pre-existing lifetime horizon cost-effectiveness model and subsequent calculation
of the expected ICER for ELF guided detection and management, using a lifetime horizon.
At the outset of the trial, the primary outcome measure for the within-trial economic evaluation was
QALYs. Quality of life weights were calculated using the EQ-5D algorithm. Life-years lived were obtained
from the mortality data collected at the end of the clinical trial. Costs and outcomes will be discounted
at 3.5% per annum. All costs will be indexed to the trial start year (2009) using the NHS Pay and Prices
Index.889 The primary result of the economic evaluation will be the ICER of ELF guided detection and
management compared with standard care. This will be calculated as the difference in the mean cost of
the interventions divided by the difference in the mean outcomes.
Parameter uncertainty will be examined using a non-parametric bootstrap simulation.38
The results of the probabilistic sensitivity analysis will be presented as the expected ICER, a scatterplot on
the cost-effectiveness plane and a cost-effectiveness acceptability curve. The expected net benefit of
ELF-guided detection and management will be calculated for a range of values of lambda, including
£5000, £15,000, £20,000 and £30,000.
Secondary within-trial economic evaluation
The secondary within-trial economic evaluation will substitute SF-12v2 quality of life weights for the EQ-5D
quality of life weights used in the primary analysis. In all other regards, the secondary within-trial economic
evaluation will be identical to the primary within-trial economic evaluation.
Long-term economic evaluation
The clinical trial outcome and resource utilisation data will be used. Parameter uncertainty will be examined
using Monte Carlo simulation. The results of the probabilistic sensitivity analysis will be presented as the
expected ICER, a scatterplot on the cost-effectiveness plane and a cost-effectiveness acceptability curve. The
expected net benefit of ELF-guided detection and management will be calculated for a range of values of
lambda, including £5000, £15,000, £20,000 and £30,000.
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Delayed set-up time and initially slow recruitment resulted in two successful applications for 1-year,
no-cost extensions. The analysis plan required evaluation of changes in the process of care of patients as
a consequence of the use of ELF monitoring. Final evaluation of the impact on QALYs will follow the
collection of long-term outcomes, including survival, from cancer registry and NHS information sources.
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Chapter 19 Value of modelling development,
modification and extension of the ELUCIDATE trial
Background
The ELUCIDATE trial was planned to run for 5 years, allowing sufficient time to randomise 1000 patients
and follow them using the active monitoring intervention with ELF-based testing for 30 months. The trial
began late because of delays in set-up and, by November 2012, 25 months after the first participant
was recruited, only 530 patients had been randomised. At that time the Programme Grants for Applied
Research Board conducted a site visit and raised doubts concerning the project team’s ability to complete
adequate recruitment in the remaining period of grant funding and accepted the investigators’ request
and recommendation for a 1-year extension and an additional new focus on process of care outcomes.
The board recommended early closure of the trial.
The Trial Management Group (TMG) had identified the shortfall in recruitment and had worked with the
20 established sites to promote the trial, but also opened 17 additional sites bringing the total number of
sites open to 37. Between the time of the site visit and the closure of recruitment, on the recommendation
of the board, there was an upsurge in recruitment from new and established centres and a further
348 patients were randomised to the study in 4 months (39.6% of the total recruited in 14.8% of the
recruitment period), bringing the total number of patients randomised and in follow-up to 878.
Rather than restricting the trial to investigating diagnostic performance and process outcomes only,
this number of patients was sufficient to provide adequate power to enable completion of the trial in
accordance with the original protocol and assessment of the clinical and health-care outcome end points
identified in the original protocol, funded as part of the Programme Grants for Applied Research grant
application. However, this required a further 12-month study extension to permit all enrolled patients to
complete 30 months of exposure to the monitoring intervention in the trial (Figures 62 and 63). The case
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FIGURE 62 A comparison of the model prediction of the identification of patients as cirrhotic over time (green line)
with the observed patterns in the ELUCIDATE trial used to calibrate the model.
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was made for the extension to complete the trial based on the rapid final surge in recruitment and a
modelling of the likely impact of ELF testing allowing revised estimates of study power. This was approved
by NIHR.
It was recognised that delivery of the evaluation of the impact of ELF testing on the clinical and health-care
outcomes will still (as originally approved) require the collection of ‘routine data’ from death certification,
the Office for National Statistics (ONS), Hospital Episode Statistics (HES) and cancer and transplant registries
at 5 years.
We performed modelling incorporating data from previous studies of disease progression in similar cohorts
of patients with CLD investigated for CLD with ELF and this was the basis of all previous power calculations.
However, importantly, at the point at which the extensions were approved, we were able to analyse
preliminary data from the ELUCIDATE trial, allowing greater confidence in both the models themselves and
the results and conclusions that can be drawn from them.
The model represents a significant innovation, allowing us to accurately predict the development of
cirrhosis (see Figure 62).
The modelling also allowed us to demonstrate the impact on follow-up and monitoring using ELF tests that
would occur with and without the 1-year extension (see Figure 63).
The ELUCIDATE trial, like all trials, depends for its statistical power on the number of events and the effect
size. The 30-month period of active follow-up within the trial was both a period of case discovery and data
collection and, vitally, the key monitoring intervention within the trial that could produce a clinical effect.
We were testing the performance of the ELF test as a means of discovering cases of cirrhosis and thereby
influencing the behaviour of clinicians in delivering, as a consequence of the identification of cirrhosis
by ELF criteria, the appropriate investigations and treatments necessary for patients in the diagnostic
cirrhotic category.
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FIGURE 63 Estimated pattern of development of cirrhosis without a trial extension, showing follow-up times
assuming that the intervention finished at the end of October 2014.
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The shortening of the period of ‘active follow-up’ would, therefore, have had an effect on case discovery
and would also have influenced the effect size by reducing the period of the intervention (i.e. ELF
monitoring and treatment of cirrhosis once detected). We expected a reduction in effect size as well as
reductions in case discovery if we were unable to complete the period of active follow-up/intervention.
We know from the existing literature that, when patients are diagnosed with cirrhosis, appropriate
monitoring and treatment for major events such as bleeding or liver cancer result in a reduction of such
events by 50% in RCTs. However, in the ELUCIDATE trial we always carefully considered whether or not
clinical behaviours would change sufficiently and would result in the full effect in cirrhotic patients. Allowing
for this in power calculations for the long-term clinical end points, we always mitigated the effect size from
the 50% ceiling that is apparent in the literature to 40%, to allow for the possibility that clinicians would not
implement the consequences of the diagnosis comprehensively and in a timely fashion in the real world.
In estimating the impact of the extension to 30 months in all patients to complete active follow-up/
intervention (see Figures 62 and 63), we took account of a reduction in case discovery and a reduction
in effect size. Using our established ability to model the trial, we calculated the loss of power as a
consequence of loss of case discovery and very conservative estimates of reduction in effect size.
With the extension to enable the completion of the 30-month monitoring/intervention in all randomised
patients, and retaining our previous (mitigated) effect size of 40%, the power of the study was 79.5%.
Without the extension, if we made a conservative assumption of a reduced effect size to 35%, power
dropped to 63%. A more likely reduction in effect size to 30% resulted in power of only 49%.
Such detailed modelling in the trial when preliminary data became available provided justification for the
extension of the trial to complete the monitoring intervention for all enrolled patients based on the impact
on the power calculations. The additional data generated will allow more robust economic analysis of
the relationships between changes in the process of care (within the 30-month follow-up data) and the
longer-term clinical and health-care outcomes (ONS and HES data).
At the end of the 30-month monitoring period we were able to conduct analyses and we report on
the impact of ELF testing on the diagnosis of cirrhosis and on the process of care (AFP measurement,
ultrasound scans, prescription of treatments, etc.). We will conduct (and have funded) the 5-year follow-up
analysis using ONS and HES data as planned and approved.
Modelling methodology
The following gives details and assumptions for the simulation model on which the sample size estimate,
and ultimately the extension request, was based.
The model relies on the data in Figure 64, from previously published data35 which show the likely
occurrence of severe complications for different starting ELF ranges. It is then possible to fit a (parametric)
model for each of the ELF ranges and to use this model to predict the subsequence occurrence of severe
complication events. We decided to incorporate into our model a delay before events start to occur,
followed by a negative exponential event-occurrence pattern, adopting a conservative approach.
Therefore, if Si(t) (i = 1,6) are the times to incidence of severe complications for each of a range of six
presentation ELF values (namely < 8.39, 8.4–9.49, 9.5–10.49, 10.5–11.49, 11.5–12.49, ≥ 12.5), then:
Si(t)=
1, t ≤ di
e−αi(t−d i), t > d i
,

(34)
where αi (i = 1,6) are the exponential parameters and di(i = 1,6) are the delays before severe complications
start to occur in each of the six groups.
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For the purposes of the model patients were divided into those who present with an ELF value of > 9.5
and those who present with an ELF value of < 9.5. In the ELF arm patients with an ELF value of > 9.5 are
classified as cirrhotic based on this ELF result. We can establish the proportions of patients who present
with an ELF value of > 9.5, and with an ELF value in the ranges 9.5–10.49, 10.5–11.49, 11.5–12.49 and
> 12.5, from the ELF arm and apply these proportions in the simulation to both arms, as, although we do
not know these figures in the control arm, they would be expected to be the same.
In addition, it was necessary to consider the rate of development of cirrhosis in both arms for patients with a
starting ELF value of < 9.5. These rates will be different as, in the ELF arm, this rate is based on the measured
ELF value, whereas in the control arm it is based on clinical grounds only. As treatment is initiated only once
cirrhosis has been diagnosed, any treatment effect was applied to patients diagnosed as cirrhotic.
We analysed the cumulative incidence curves for development of cirrhosis in the trial and assumed for
simplicity that, for patients who were not already defined as cirrhotic by their starting ELF value, there was
a uniform rate of development of cirrhosis, say λ, which fitted reasonably well with the observed data, as
shown in Figure 62. This would imply that the development of cirrhosis for the population not already
defined as cirrhotic by their starting ELF value follows an exponential distribution, specifically:
Pc(t) = 1− e−λt , (35)
where Pc(t) is the probability of the patient becoming cirrhotic by time t and with different rates of
development of cirrhosis in the ELF and control arms, as the ELF arm rate is dependent on the ELF level
crossing the 9.5 threshold, whereas the rate is defined by clinical judgement in the control arm.
Refinements were considered, but the simulation results do not appear to be particularly sensitive to the
assumption of a uniform rate of development of cirrhosis. Note that Figure 62 shows the time to
development of cirrhosis for both arms combined (either defined by ELF value in the ELF arm or defined by
clinical judgement in the control arm). These results, broken down by treatment arm, with associated model
fits, were presented, in confidence, to the Data Monitoring and Ethics Committee (DMEC). Figure 63
provides a likely projection of Figure 62 without the trial extension, depicting graphically the cohort of
patients who would not receive the full trial intervention (active monitoring for 30 months) in the event that
the extension had not been granted.
Further refinements of the simulation model were possible looking at different models both for the
development of cirrhosis and for subsequent occurrence of severe complications. For instance, in the latter
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FIGURE 64 Expected incidence of severe complications as related to presentation ELF value.
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case, we may consider models in which the incidence of severe complications plateaus after a particular
period of time, for example (using previous terminology):
Si(t) =
1, t≤d i
pi + (1− pi)e
− αi(t−d i), t > d i
,

(36)
where pi is the proportion of patients in the ith group who never experience a severe complication.
To complete the model, we applied an assumed treatment effect, which applies a proportional hazards
improvement in time to the development of severe complications for patients diagnosed as cirrhotic
(in either arm). This simply changed the negative exponential parameter for the time to occurrence of severe
complications in each of the different ELF ranges (9.5–10.49, 10.5–11.49, 11.5–12.49 and > 12.5). Again,
using previous nomenclature, these times to occurrence of severe complications are, therefore, assumed to be:
Si(t) =
1,t≤d i
e− θαi(t−d i),t > d i
,

(37)
where θ is the assumed HR. We assumed an effect size of 40%, equivalent to a HR of 0.6, for the trial
design/sample size calculations for the primary outcome. We can readily estimate possible different effect
sizes using this model.
Putting together all of these assumptions it is possible to simulate the trial. In the ELF arm patients are
assumed to present with proportions in the different ELF ranges; in addition, patients with an ELF value of
< 9.5 are assumed to have a rate of subsequent development of cirrhosis, with such patients developing
cirrhosis at different ELF values, to match what we have seen in the trial to date. They then have a probability
of developing a severe complication based on the negative exponential distributions described. The situation
is similar in the control arm except that treatment is initiated somewhat later after the clinically based
diagnosis of cirrhosis. For each simulated trial the times to severe events are generated given the actual
recruitment times and a specified duration of follow-up (e.g. 5 years) and are then compared between the
two arms using the log-rank test. Figure 65 provides a typical example and Figure 66 provides the theoretical,
expected curves that result from these model assumptions (in this case with an effect size of 40%).
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FIGURE 65 Simulation of the development of severe liver complications in the trial until December 2019 by
randomised arm.
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The trial power was calculated for different type 1 error rates by simply counting the proportion of simulations
in which the resulting p-value was less than the assumed type 1 error.
Note that it was practicable to apply such a model only when the trial was under way for a reasonable
period of time, as we needed estimates of the rates of development of cirrhosis in the ELF and control
arms, as well as the ELF ranges for the proportions of patients who do develop cirrhosis, at the point
at which they develop cirrhosis. Using this type of simulation modelling approach, it would have been
possible to apply this model prior to the start of the trial, but these rates would have had to be estimated
based on few data. This should, for future trials, form part of the trial design sample size assumptions. It
would perhaps have been possible to estimate these parameters from pilot data on sequential ELF values
for a cohort of patients. For future designs, it would be helpful to collect such pilot data, which would be
likely to be of fundamental importance to the trial design.
None of these estimated rates involved looking at unblinded primary event data.
Conclusions
These arguments and the modelling specifically allowed us to demonstrate our ability to complete the
ELUCIDATE trial robustly and with good power for the principal clinical and health-care outcomes.
Our approach has the potential to be generalisable to a variety of other monitoring trials and provides a
basic framework for trial design in this area, which to date has been lacking. For instance, the model can
be applied to situations in which patients are all initially below the threshold for intervention and who pass
this threshold only as the study proceeds. We hope to be able to provide appropriate software so that
these methods can be made widely available. This is in line with our remit in this programme grant to use
the ELUCIDATE trial as an exemplar to aid in the design, analysis and interpretation of future monitoring
trials. Note that the simulation approach described herein incorporates this variability in sequential
ELF values as they change over time, through the models and parameters that relate to the rate of
development of cirrhosis, as this is highly correlated with changing ELF values.
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FIGURE 66 Simulated trial outcomes for each trial arm with follow-up continuing until December 2019.
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Chapter 20 Recruitment to and delivery of the
ELUCIDATE trial
Trial organisation
Registration and randomisation
Eligible and consenting patients were registered and randomised into the study using an automated
24-hour telephone registration and randomisation system. Registered patients who met the ELF threshold
criteria for randomisation were preferably randomised within 6 weeks of the registration visit.
Clinical queries
The Co-chief Investigators based at University College London Hospital (UCLH)/Royal Free Hospital, London
(Professor William Rosenberg and Dr Sudeep Tanwar) were the contacts for clinical queries and the review
of any related and unexpected serious adverse events (RUSAEs).
Project and trial management
The CTRU, Leeds Institute of Clinical Trials Research at the University of Leeds, was responsible for the
overall project and data management of the study. The TMG, comprising the Chief Investigators, health
economists, scientific advisors, trial co-ordinators and statistician, was responsible for the ongoing
management and promotion of the study and for the interpretation of the results.
Trial Steering Committee
The Trial Steering Committee provided overall supervision of the trial, in particular relating to trial progress,
adherence to the study protocol, patient safety and consideration of new information. The committee included
an independent chairperson (Professor James Neuberger), an independent clinician (Dr Jonathan Fallowfield),
an independent scientific adviser (Dr Christine Patch), a statistician (Dr Andrew Roddam), a health economist
(Dr Simon Dixon), the Chief Investigator (Professor William Rosenberg) and members of the TMG. The PPI
representatives were Tilly Hale and Joan Bedlington.
Leeds National Institute for Health Research Biomarker Research Tissue Bank
Patients who were recruited to the trial were asked on the patient information sheet if they would be
happy to provide an additional blood sample for the Leeds NIHR Biomarker Bank at their randomisation
visit. For all patients who consented, a serum sample was obtained, processed and stored on site within
a –70 to –80°C freezer. On a site reaching 50 patients or at the end of the trial, these samples were
collected for storage at the Leeds NIHR Biomarker Bank, for use in future research projects.
Enhanced Liver Fibrosis testing and the provision of Enhanced Liver Fibrosis and
Enhanced Liver Fibrosis/National Institute for Health Research Biomarker Bank kits
Both the ELF/NIHR Biomarker Research Tissue Bank kits used at randomisation and the ELF kits to be used
for the tests performed at patient registration, follow-up (patients in the ELF arm) and once patients had
been diagnosed as cirrhotic (patients in the control arm) were prepared and dispatched by the Clinical
and Biomedical Proteomics Group at St James’s University Hospital, Leeds. The serum samples sent for ELF
testing were processed at the iQur laboratory based at Royal Free Hospital, London. Results from these
tests were disseminated to the CTRU. The CTRU then notified sites of a patient’s eligibility and current
cirrhotic status (the latter pertaining only to those patients in the ELF screening arm).
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Accrual
Thirty-seven centres across the UK were opened to recruitment between 23 September 2010 and
31 October 2012 (Table 102). In total, 1303 participants were registered into the trial, of whom 878 were
subsequently randomised (Figure 67), 440 patients to the standard clinical monitoring arm and 438 to the
standard clinical monitoring plus ELF test arm. Monthly and cumulative registrations and randomisations
across the centres are shown in Tables 102 and 103. In each case it can be seen that the additional
centres added late in the trial process added very substantial numbers of patients, frequently surpassing
the achievements of centres open throughout the trial. Of the 425 registered patients who did not
proceed to randomisation, the main reason was because their baseline ELF value was lower than the
threshold required for randomisation (Table 104).
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TABLE 102 Number of registrations per site per month
Site Date opened 2011
Year (n)
Accrual per centre
2012 2013
January February March April May June July August September October November December January February March
H1 23 September 2010 126 8 5 4 5 1 1 3 2 1 2 0 1 4 4 0 167
H2 18 May 2011 104 14 13 10 6 13 5 8 6 7 5 10 2 8 12 0 223
H3 15 June 2011 39 1 1 9 3 5 0 2 0 0 0 0 0 0 0 0 60
H4 24 June 2011 5 0 0 6 5 4 0 1 4 4 2 6 0 1 1 0 39
H5 13 July 2011 14 23 12 12 3 9 0 0 0 2 0 0 4 2 0 0 81
H6 26 July 2011 4 6 18 5 5 8 1 10 0 0 2 4 0 0 3 0 66
H7 26 July 2011 1 3 1 6 3 0 0 1 6 2 7 5 0 2 2 0 39
H8 4 August 2011 2 2 3 5 3 3 0 0 3 4 1 4 1 0 0 2 33
H9 14 September 2011 1 0 0 0 0 1 1 0 1 2 1 2 1 1 8 0 19
H10 6 September 2011 3 2 5 2 1 2 2 0 2 1 5 2 0 3 3 0 33
H11 17 October 2011 1 8 4 5 9 6 4 9 2 2 2 3 2 6 5 0 68
H12 5 January 2012 0 0 0 0 4 1 2 0 0 0 0 0 0 10 0 17
H13 5 January 2012 0 0 0 3 1 0 2 1 2 2 0 0 1 0 0 12
H14 5 January 2012 0 0 2 2 2 1 1 0 1 0 1 1 0 0 0 11
H15 6 March 2012 0 0 0 0 0 0 0 0 1 0 0 4 0 5
H16 6 March 2012 0 0 0 0 2 6 1 1 0 0 0 0 0 10
H17 27 March 2012 0 0 1 7 5 0 3 3 2 2 2 0 25
H18 3 April 2012 1 3 2 3 0 0 3 3 1 3 6 0 25
H19 19 April 2012 2 13 2 4 0 2 7 4 1 6 7 0 48
H20 20 April 2012 1 5 3 7 3 4 6 8 0 0 11 0 48
H21 26 April 2012 6 3 1 4 2 3 2 3 1 0 0 25
H22 24 May 2012 0 1 2 0 1 1 4 1 2 7 0 19
H23 14 May 2012 0 0 1 0 0 2 7 7 13 7 0 37
H24 28 May 2012 0 0 0 0 1 0 0 0 0 0 0 1
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TABLE 102 Number of registrations per site per month (continued )
Site Date opened 2011
Year (n)
Accrual per centre
2012 2013
January February March April May June July August September October November December January February March
H25 7 June 2012 5 2 1 3 2 0 1 1 0 15
H26 3 July 2012 1 0 0 0 0 0 0 0 0 1
H27 30 July 2012 1 2 2 6 0 10 5 0 26
H28 21 June 2012 2 0 3 1 1 0 3 0 10
H29 25 July 2012 0 2 1 1 1 4 1 0 10
H30 25 July 2012 0 1 0 1 0 0 0 0 2
H31 30 July 2012 0 0 0 0 0 3 4 0 7
H32 1 August 2012 0 0 0 0 2 0 7 0 9
H33 21 August 2012 0 0 7 5 7 12 19 0 50
H34 26 September 2012 0 0 0 0 0 0 2 2
H35 10 October 2012 7 12 4 12 12 0 47
H36 18 October 2012 0 2 2 1 3 2 10
H37 31 October 2012 0 3 0 0 3
Monthly accrual 67 62 66 52 86 28 72 50 45 78 99 44 101 147 6
Cumulative accrual 300 367 429 495 547 633 661 733 783 828 906 1005 1049 1150 1297 1303 1303
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TABLE 103 Number of randomisations per site per month
Site 2011
Year (n)
Accrual
per
centre
2012 2013
January February March April May June July August September October November December January February March April
H1 62 3 3 2 5 2 6 0 1 5 0 0 0 1 1 2 1 94
H2 44 5 7 15 4 11 11 1 3 8 2 6 2 5 6 3 3 136
H3 19 8 2 1 7 4 5 1 0 0 0 0 0 0 0 0 0 47
H4 4 0 0 0 2 6 5 0 2 2 5 3 2 1 1 1 0 34
H5 0 0 4 7 4 5 0 0 0 0 0 0 0 0 0 0 0 20
H6 1 2 10 12 3 5 3 2 6 0 2 1 0 2 0 1 0 50
H7 0 0 1 3 1 1 2 1 3 2 1 7 1 1 1 1 0 26
H8 1 1 4 0 3 4 0 0 2 3 3 2 2 2 0 1 1 29
H9 1 0 0 0 0 0 1 0 1 0 2 0 1 2 2 4 1 15
H10 1 1 4 2 1 2 1 1 0 2 0 4 1 0 3 0 2 25
H11 0 2 3 3 2 6 1 3 6 0 1 3 2 1 6 1 1 41
H12 0 0 0 0 1 3 1 2 0 0 0 0 0 0 5 4 16
H13 0 0 0 0 0 3 1 1 1 1 2 0 0 0 0 0 9
H14 0 0 1 1 1 1 2 0 1 0 0 1 0 1 0 0 9
H15 0 0 0 0 0 0 0 0 0 0 0 1 1 3 5
H16 0 0 0 0 0 0 2 4 0 0 0 0 0 0 6
H17 0 0 0 1 7 3 1 3 0 4 0 2 0 21
H18 0 1 2 1 2 0 0 3 1 1 1 2 3 17
H19 0 2 8 8 2 0 1 7 3 3 2 5 2 43
H20 0 0 1 1 1 6 0 1 0 5 0 1 5 21
H21 0 2 5 1 4 2 2 0 3 1 0 0 20
H22 0 0 0 2 0 1 0 1 0 0 3 7 14
H23 0 0 0 1 0 1 2 4 6 8 6 3 31
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TABLE 104 Reasons why registered patients were not randomised
Reason Total (N= 425), n (%)
Patient’s baseline ELF value was lower than the threshold for eligibility 317 (74.6)
Patient can no longer attend appointments 14 (3.3)
Patient developed cirrhosis between registration and randomisation 2 (0.5)
Other 58 (13.6)
Missing 34 (8.0)
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Chapter 21 Preliminary analysis of the
ELUCIDATE trial
In this chapter, we present the analysis of the ELUCIDATE trial to date agreed by the DMEC. This includespatient characteristics, ELF values, compliance, time to cirrhosis-associated ELF values and changes in the
process of care.
Baseline characteristics
The computerised minimisation in the ELUCIDATE trial worked as expected and the treatment arms were
balanced with regard to all baseline characteristics (Tables 105 and 106).
TABLE 105 Patient characteristics at randomisation
Characteristic
Trial arm, n (%)
Total (N= 878), n (%)ELF (N= 438)a,b Standard care (N= 440)
Age (years) (categorised)
18–39 47 (10.7) 51 (11.6) 98 (11.2)
40–64 306 (69.9) 304 (69.1) 610 (69.5)
65–75 85 (19.4) 85 (19.3) 170 (19.4)
Age (years)
Mean (SD) 54.0 (11.64) 53.8 (11.19) 53.9 (11.41)
Median (range) 55.0 (23.0–74.0) 54.0 (22.0–74.0) 55.0 (22.0–74.0)
Missing 0 0 0
Sex
Male 246 (56.2) 246 (55.9) 492 (56.0)
Female 192 (43.8) 194 (44.1) 386 (44.0)
ELF value at registration (categorised)
8.4–9.49 240 (54.8) 242 (55.0) 482 (54.9)
9.5–11.49 174 (39.7) 172 (39.1) 346 (39.4)
11.5–12.49 14 (3.2) 15 (3.4) 29 (3.3)
≥ 12.5 10 (2.3) 11 (2.5) 21 (2.4)
Registration ELF value
Mean (SD) 9.6 (1.07) 9.7 (1.03) 9.6 (1.05)
Median (range) 9.4 (8.4–17.4) 9.4 (8.4–14.2) 9.4 (8.4–17.4)
Missing 0 0 0
History of alcohol consumption
Yes 101 (23.1) 107 (24.3) 208 (23.7)
No 337 (76.9) 333 (75.7) 670 (76.3)
continued
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As expected, the distribution of patients with and without viral disease varied across the sites (Table 107).
Sites in areas where the patient population consists of a high proportion of patients with viral liver disease
specialised in treating this group of patients, notably Royal Free Hospital, UCLH, Kings College Hospital,
Royal Blackburn Hospital, Victoria Hospital Blackpool and Torbay General Hospital.
Protocol violators
Protocol violators in the ELUCIDATE trial include patients who scored < 8.4 in any post-randomisation ELF
test and patients who were randomised later than 12 weeks after registration.
Enhanced Liver Fibrosis test value of < 8.4 at follow-up
In total, 55 (25.5%) out of 216 patients with at least one reported ELF test after randomisation in the ELF
arm and one (7.1%) out of 14 in the control arm had an ELF value of < 8.4 (Table 108). The proportion
of patients who had an ELF value lower than this threshold value was largest (28.6%, 28/98) among
patients with viral liver disease as the primary diagnosis (Table 109). Moreover, within this group of
TABLE 105 Patient characteristics at randomisation (continued )
Characteristic
Trial arm, n (%)
Total (N= 878), n (%)ELF (N= 438)a,b Standard care (N= 440)
Current alcohol consumption
Teetotal 230 (52.5) 231 (52.5) 461 (52.5)
Light 153 (34.9) 151 (34.3) 304 (34.6)
Moderate 41 (9.4) 41 (9.3) 82 (9.3)
Heavy 14 (3.2) 17 (3.9) 31 (3.5)
Primary diagnosis
Alcoholic liver disease 35 (8.0) 33 (7.5) 68 (7.7)
Viral liver disease 176 (40.2) 177 (40.2) 353 (40.2)
Other/unknown 114 (26.0) 117 (26.6) 231 (26.3)
Non-alcoholic fatty liver disease 113 (25.8) 113 (25.7) 226 (25.7)
Time from registration to randomisation (days)
Mean (SD) 43.5 (32.42) 42.2 (34.03) 42.9 (33.23)
Median (range) 35.0 (7.0–349.0) 35.0 (6.0–328.0) 35.0 (6.0–349.0)
Missing 0 0 0
a Three patients randomised before 22 March 2011 were done so using the old baseline ELF value categories.
b 13 participants were already registered with ELF results that meant they were ineligible, before the protocol amendment.
After the approval of v5.0 of the protocol, these participants were re-approached and randomised into the ELUCIDATE trial.
TABLE 106 Number of patients diagnosed with viral liver disease at randomisation (overall)
Diagnosed with viral liver
disease at randomisation
Trial arm, n (%)
Total (N= 878), n (%)ELF (N= 438) Standard care (N= 440)
Yes 176 (40.2) 177 (40.2) 353 (40.2)
No 262 (59.8) 263 (59.8) 525 (59.8)
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TABLE 107 Number of patients diagnosed with viral liver disease at randomisation by site
Site
Liver disease, n (%)
Total, n (%)Viral No viral
Royal Free Hospital 81 (59.1) 56 (40.9) 137 (100.0)
UCLH 85 (89.5) 10 (10.5) 95 (100.0)
Royal Liverpool University Hospital 5 (10.2) 44 (89.8) 49 (100.0)
Royal Devon and Exeter Hospital 14 (29.8) 33 (70.2) 47 (100.0)
Royal Blackburn Hospital 43 (100.0) 0 (0.0) 43 (100.0)
St James’s University Hospital 11 (26.8) 30 (73.2) 41 (100.0)
Bradford Royal Infirmary 2 (4.9) 39 (95.1) 41 (100.0)
Singleton Hospital 22 (57.9) 16 (42.1) 38 (100.0)
Royal Bournemouth Hospital 6 (18.2) 27 (81.8) 33 (100.0)
Queen Alexandra Hospital 4 (13.3) 26 (86.7) 30 (100.0)
Basingstoke and North Hampshire Hospital 0 (0.0) 29 (100.0) 29 (100.0)
Southampton General Hospital 2 (7.7) 24 (92.3) 26 (100.0)
Royal London Hospital 11 (42.3) 15 (57.7) 26 (100.0)
James Cook University Hospital 0 (0.0) 21 (100.0) 21 (100.0)
Nottingham Queen’s Medical Centre 7 (33.3) 14 (66.7) 21 (100.0)
University Hospital Lewisham 7 (33.3) 14 (66.7) 21 (100.0)
King’s College Hospital 20 (100.0) 0 (0.0) 20 (100.0)
Torbay District General Hospital 10 (58.8) 7 (41.2) 17 (100.0)
Derriford Hospital 0 (0.0) 16 (100.0) 16 (100.0)
Royal Hallamshire Hospital 4 (26.7) 11 (73.3) 15 (100.0)
Princess Alexandra Hospital 0 (0.0) 15 (100.0) 15 (100.0)
Royal Albert Edward Infirmary 0 (0.0) 14 (100.0) 14 (100.0)
Chelsea and Westminster Hospital 2 (15.4) 11 (84.6) 13 (100.0)
Totals for other sitesa that randomised
< 10 patients per site
17 (24.3) 53 (75.7) 70 (100.0)
a Hull Royal Infirmary, Freeman Hospital, Royal Sussex County Hospital, University Hospital Durham, Kingston Hospital,
Victoria Hospital Blackpool, Royal Preston Hospital, Rotherham District General Hospital, Bronglais General Hospital,
Royal Hampshire County Hospital, University Hospital Bristol, Queen Elizabeth Hospital (Birmingham), Royal Lancaster
Infirmary and Warrington Hospital.
TABLE 108 Patients with ELF values of < 8.4 at follow-up
ELF value of < 8.4 at follow-up
Trial arm, n (%)
Total (N= 230),
n (%)ELF (N= 216)
Standard care
(N= 14)
Yes 55 (25.5) 1 (7.1) 56 (24.3)
No 160 (74.1) 13 (92.9) 173 (75.2)
Missing 1 (0.5) 0 (0.0) 1 (0.4)
Note
The denominator was all patients with at least one reported ELF test after randomisation.
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patients, the proportion of patients with an ELF value of < 8.4 was largest in those patients treated for
hepatitis B or hepatitis C: 40.0% (8/20) and 42.3% (11/26), respectively, compared with 17.3% (9/52) in
patients who had not received any treatment since randomisation (Table 110). Response to treatment
might, therefore, play a role in the decrease in ELF values. This is also possibly the case for patients with
non-alcoholic fatty liver disease. Here, weight loss might be the reason for a decrease in ELF values;
however, we have not collected data on weight loss to explore this hypothesis.
More than 12 weeks between registration and randomisation
In total, 44 (10.0%) out of 438 patients in the ELF arm and 26 (5.9%) out of 440 patients in the control
arm were not randomised within 12 weeks of registration (Table 111). For some of these patients, the ELF
test was repeated before randomisation. Only 15 (3.4%) out of 438 patients in the ELF arm and 8 (1.8%)
out of 440 patients in the standard arm were not randomised within 12 weeks of the (repeated)
registration ELF test.
TABLE 109 Protocol violators (ELF value of < 8.4 at follow-up) by primary diagnosis
ELF value
of < 8.4 at
follow-up
Primary diagnosis, n (%)
Total
(N= 230), n (%)
Alcoholic
liver disease
(N= 16)
Viral liver
disease
(N= 98)
Other/unknown
(N= 62)
Non-alcoholic
fatty liver disease
(N= 54)
Yes 1 (6.3) 28 (28.6) 13 (21.0) 14 (25.9) 56 (24.3)
No 15 (93.8) 70 (71.4) 48 (77.4) 40 (74.1) 173 (75.2)
Missing 0 (0.0) 0 (0.0) 1 (1.6) 0 (0.0) 1 (0.4)
TABLE 110 Protocol violators (ELF value of < 8.4 at follow-up) with a primary diagnosis of viral liver disease by
hepatitis treatment status since randomisation
ELF value of < 8.4
at follow-up
Treatment, n (%)
Total
(N= 98), n (%)
Hepatitis B
(N= 20)
Hepatitis C
(N= 26)
No hepatitis
(N= 52)
Yes 8 (40.0) 11 (42.3) 9 (17.3) 28 (28.6)
No 12 (60.0) 15 (57.7) 43 (82.7) 70 (71.4)
TABLE 111 Patients who were randomised > 12 weeks after trial registration and those who were randomised
within 12 weeks of an additional pre-ELF test randomisation
Randomisation point
Trial arm, n (%)
Total (N= 878), n (%)ELF (N= 438) Standard care (N= 440)
Randomisation within 12 weeks of registration
Yes 394 (90.0) 414 (94.1) 808 (92.0)
No 44 (10.0) 26 (5.9) 70 (8.0)
Randomisation within 12 weeks of registration ELF test
Yes 421 (96.1) 432 (98.2) 853 (97.2)
No 15 (3.4) 8 (1.8) 23 (2.6)
Missing 2 (0.5) 0 (0.0) 2 (0.2)
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Visit compliance
Pre- and post-cirrhotic follow-up visit compliance in the ELUCIDATE trial was generally poor in both the ELF
arm and the standard care arm.
Compliance with pre-cirrhotic follow-up visits
According to the protocol, patients in both the ELF arm and the standard care arm should have been
seen every 6 months. If compliance is defined as being compliant with all visits, allowing visits to take
place between 5 and 7 months after the previous visit, 67 (29.8%) out of 225 patients with expected
pre-cirrhotic follow-up visits in the ELF arm and 81 (19.7%) out of 411 patients with expected pre-cirrhotic
follow-up visits in the standard care arm were compliant (Table 112). The denominator in the ELF arm
is substantially smaller than that in the standard care arm because many patients in the ELF arm were
diagnosed with cirrhosis at randomisation and, thus, did not have any pre-cirrhotic follow-up visits.
Timing of pre-cirrhotic follow-up visits
A total of 597 pre-cirrhotic follow-up visits took place in the ELF arm, with on average 7.4 (SD 3.42)
months between visits. In the standard care arm, there were 1424 reported pre-cirrhotic follow-up visits,
with on average 7.0 (SD 2.89) months between visits (Table 113 and Figure 68).
Compliance with post-cirrhotic follow-up visits
According to the study protocol, all patients diagnosed as cirrhotic either by ELF testing or clinical means
should attend an initial post-cirrhotic follow-up visit, at 3 months after the diagnosis of cirrhosis. All
subsequent follow-up visits for the purposes of data collection should take place every 6 months. If
compliance is defined as being compliant with all visits, 43 (16.2%) out of 266 patients with expected
post-cirrhotic follow-up visits in the ELF arm and 4 (21.1%) out of 19 patients with expected post-cirrhotic
follow-up visits in the standard care arm were compliant (Table 114). The denominator in the standard
care arm is substantially smaller than that in the ELF arm because only a small number of patients in the
standard care arm were diagnosed with cirrhosis.
TABLE 112 Overall pre-cirrhotic follow-up compliance for patients who were expected to have at least one visit
post randomisation
Compliance status
Trial arm, n (%)
Total (N= 636), n (%)ELF (N= 225) Standard care (N= 411)
Compliant 67 (29.8) 81 (19.7) 148 (23.3)
Non-compliant 158 (70.2) 330 (80.3) 488 (76.7)
Note
Patients were defined as compliant if they had been compliant for all visits so far.
TABLE 113 Time between pre-cirrhotic follow-up visits (for visits that were expected to take place 6 months after
the previous visit)
Time between follow-up visits (months)
Trial arm
Total (n= 2021)ELF (n= 597) Standard care (n= 1424)
Mean (SD) 7.4 (3.42) 7.0 (2.89) 7.1 (3.06)
Median (range) 6.2 (1.8–33.2) 6.2 (1.0–31.0) 6.2 (1.0–33.2)
Missing 0 0 0
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Timing of post-cirrhotic follow-up visits
Looking only at post-cirrhotic visits that were expected to take place 6 months after the previous visit, the
time between visits was on average 6.5 (SD 2.80) months in the ELF arm (n = 695). In the standard care
arm the time between visits was on average 7.2 (SD 4.71) months (n = 35) (Table 115 and Figure 69).
Enhanced Liver Fibrosis test compliance
Patients in the ELF arm should have had an ELF test at every pre-cirrhosis follow-up visit. Patients in the
standard care arm should have had one ELF test after diagnosis of cirrhosis.
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FIGURE 68 Time between pre-cirrhotic follow-up visits (for visits that were expected to take place 6 months after
the previous visit).
TABLE 114 Overall post-cirrhotic follow-up compliance for patients who were expected to have at least one visit
post diagnosis of cirrhosis
Compliance status
Trial arm, n (%)
Total (N= 285), n (%)ELF (N= 266) Standard care (N= 19)
Compliant 43 (16.2) 4 (21.1) 47 (16.5)
Non-compliant 223 (83.8) 15 (78.9) 238 (83.5)
Note
Patients were defined as compliant if they had been compliant for all visits so far.
TABLE 115 Time between post-cirrhotic follow-up visits (for visits that were expected to take place 6 months after
the previous visit)
Time between follow-up visits (months)
Trial arm
Total (n= 729)ELF (n= 694) Standard care (n= 35)
Mean (SD) 6.5 (2.80) 7.2 (4.71) 6.5 (2.92)
Median (range) 6.1 (0.7–23.4) 5.9 (2.3–25.2) 6.1 (0.7–25.2)
IQR 5.2, 7.2 4.4, 7.4 5.2, 7.2
Missing 0 0 0
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Enhanced Liver Fibrosis test compliance in the Enhanced Liver Fibrosis arm
Compliance to ELF tests in the ELF arm was 72%, with compliance being defined as having an ELF test at
every recorded pre-cirrhosis follow-up visit (Table 116). Note that the denominator includes only ELF arm
patients who were expected to have at least one pre-cirrhotic follow-up visit and, for instance, does not
include those patients who were diagnosed with cirrhosis at randomisation.
Most ELF tests were not carried out because of administrative errors (n = 31) or lack of staff (n = 27) and
most cases of non-compliance occurred at a small number of sites.
Enhanced Liver Fibrosis test compliance in the standard care arm
According to the protocol, patients in the standard care arm should have one ELF test after the confirmed
clinical diagnosis of cirrhosis. In total, 12 out of 20 patients (60%) in the standard care arm who were
expected to be tested were compliant with the ELF test; for one patient there was not enough information
available to assess compliance (Table 117).
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FIGURE 69 Time between post-cirrhotic follow-up visits (for visits that were expected to take place 6 months after
the previous visit).
TABLE 117 Standard care arm: ELF test compliance
Compliance status Total (N= 20), n (%)
Compliant 12 (60.0)
Non-compliant 7 (35.0)
Insufficient information 1 (5.0)
TABLE 116 Enhanced Liver Fibrosis arm: overall ELF test compliance
Compliance status Total (N= 225), n (%)
Compliant 162 (72.0)
Non-compliant 63 (28.0)
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Compliance with cirrhosis management
Compliance with the timing of AFP tests, scans (ultrasound, CT or MRI) and endoscopies (OGD) was
assessed for patients who were diagnosed with cirrhosis.
Alpha-fetoprotein tests
Test compliance
According to the protocol, the timing of the initial AFP test following a diagnosis of cirrhosis depended on
whether or not an AFP test was carried out in the 6 months prior to the diagnosis. If a patient had had an
AFP test within 6 months of being diagnosed as cirrhotic, the next AFP measurement should be performed
within 6 months of the previous test unless clinically indicated sooner. If the patient had not had an AFP
test within 6 months of being diagnosed as cirrhotic, the next AFP measurement should be performed
within 3 months of the diagnosis of cirrhosis. After the initial AFP test, the test should be repeated every
6 months. AFP test compliance was low in both the ELF arm and the standard care arm, at 12.6% and
11.8%, respectively (Table 118). Compliance was defined as being compliant with all visits so far and
1-month tolerance was applied.
Test timings
For all AFP measurements that were due to take place 6 months after the previous measurement, the
median time between measurements was 6.0 (range 1.8–26.8) months in the ELF arm and 6.2 (range
3.0–25.3) months in the standard care arm (Table 119 and Figure 70).
Scans (ultrasound, computed tomography and magnetic resonance imaging)
If a cirrhotic patient had received a scan within 6 months of being diagnosed as cirrhotic, the next scan
should have been performed within 6 months of the previous scan, unless clinically indicated sooner.
If the patient had not had a scan within 6 months of being diagnosed as cirrhotic, he or she should have
received a scan as screening for HCC within 3 months of the diagnosis of cirrhosis. Subsequent scans were
to be repeated every 6 months from the timing of the previous scan.
Scan compliance
Compliance with scans was low in both the ELF arm and the standard care arm, at 29.5% and 14.3%,
respectively (Table 120).
TABLE 118 Overall AFP test compliance for patients who were expected to have at least one test
Compliance status
Trial arm, n (%)
Total (N= 248), n (%)ELF (N= 231) Standard care (N= 17)
Compliant 29 (12.6) 2 (11.8) 31 (12.5)
Non-compliant 202 (87.4) 15 (88.2) 217 (87.5)
TABLE 119 Overall timings for all AFP measurements due to take place 6 months after the previous measurement
Time (months)
Trial arm
Total (n= 487)ELF (n= 465) Standard care (n= 22)
Mean (SD) 6.7 (3.56) 7.9 (5.06) 6.8 (3.64)
Median (range) 6.0 (1.8–26.8) 6.2 (3.0–25.3) 6.0 (1.8–26.8)
IQR 4.4, 7.4 5.1, 8.5 4.4, 7.6
Missing 0 0 0
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Scan timings
For all scans that were due to take place 6 months after the previous scan, the median time between
measurements was 6.8 (range 0.0–30.0) months in the ELF arm and 7.5 (range 1.3–11.7) months in the
standard care arm (Table 121 and Figure 71).
Endoscopies
Oesophagogastroduodenoscopy compliance
According to the protocol, all patients with a diagnosis of cirrhosis were to have an OGD as screening for
varices within 3 months of diagnosis, unless they had had an OGD in the 18 months prior to the diagnosis
of cirrhosis.
Compliance with the timing of endoscopies was fair in both the ELF arm and the standard care arm,
at 54.9% and 50.0%, respectively (Table 122).
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FIGURE 70 Overall AFP test timings (for all AFP measurements due to take place 6 months after the previous one).
TABLE 120 Overall scan compliance for patients who were expected to have at least one scan
Compliance status ELF (N= 207), n (%) Standard care (N= 14), n (%) Total (N= 221), n (%)
Compliant 61 (29.5) 2 (14.3) 63 (28.5)
Non-compliant 146 (70.5) 12 (85.7) 158 (71.5)
TABLE 121 Overall scan timings for all scans due to take place 6 months of the previous scan
Time (months)
Trial arm
Total (n= 267)ELF (n= 249) Standard care (n= 18)
Mean (SD) 7.9 (3.90) 7.4 (2.65) 7.8 (3.83)
Median (range) 6.8 (0.0–30.0) 7.5 (1.3–11.7) 6.8 (0.0–30.0)
IQR 5.7, 9.2 6.0, 9.1 5.7, 9.2
Missing 0 0 0
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Withdrawals
In total, 32 patients in the ELF arm and 24 patients in the standard care arm withdrew from different
aspects of the trial. Twenty-one patients in the ELF arm withdrew consent for further ELF testing. Of
these 21 patients, 10 did not want to attend or were unable to attend for testing (with two specifically
mentioning distance), five moved location, two did not want the ELF test [in one case because of difficulties
with bleeding the patient and one case in which the patient mentioned that the ELF test indicated cirrhosis
but a FibroScan (EchoSens, Paris, France) indicated that they were not cirrhotic and so they did not want
more ELF tests] and four gave no reason for withdrawing consent. It can be seen that only two patients
specifically mentioned issues with the ELF test itself. An additional 51 patients (28 in the ELF arm and 23 in
the standard care arm) were no longer willing to be followed up as per the protocol schedule; 14 of these
patients (ELF arm, n = 9; standard care arm, n = 5) were willing for further data to be collected at their
standard visits, if available, and 27 patients (ELF arm, n = 16; standard care arm, n = 11) were willing to
have their long-term data collected via a patient registry.
Disease progression to cirrhosis
In total, 281 (64.2%) out of 438 patients in the ELF arm and 20 (4.5%) out of 440 patients in the standard care
arm were diagnosed with cirrhosis (Table 123). A total of 197 (70.1%) ELF arm patients were diagnosed at
randomisation but none of the patients in the standard care arm was diagnosed at randomisation (Table 124).
Overall, almost all ELF arm patients were diagnosed with an ELF test (99.6%), whereas the most frequent
method of diagnosis in the standard care arm was a FibroScan (45.0%) (Table 125). Tables 126–128 provide
the method of diagnosis of cirrhosis for patients who were not diagnosed at randomisation, the first method of
diagnosis of cirrhosis for patients overall and the first method of diagnosis of cirrhosis for patients who were not
diagnosed at randomisation, respectively.
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FIGURE 71 Overall scan timings (for all scans due to take place 6 months after the previous one).
TABLE 122 Overall compliance for patients who were expected to have at least one endoscopy
Compliance status
Trial arm, n (%)
Total (N= 165), n (%)ELF (N= 153) Standard care (N= 12)
Compliant 84 (54.9) 6 (50.0) 90 (54.5)
Non-compliant 69 (45.1) 6 (50.0) 75 (45.5)
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TABLE 123 Diagnosis of cirrhosis overall by arm
Diagnosis of cirrhosis
during the trial
Trial arm, n (%)
Total (N= 878), n (%)ELF (N= 438) Standard care (N= 440)
Yes 281 (64.2) 20 (4.5) 301 (34.3)
No 157 (35.8) 420 (95.5) 577 (65.7)
TABLE 124 Timing of diagnosis by arm
Diagnosis of cirrhosis
after randomisation
Trial arm, n (%)
Total (N= 301), n (%)ELF (N= 281) Standard care (N= 20)
Yes 84 (29.9) 20 (100.0) 104 (34.6)
No 197 (70.1) 0 (0.0) 197 (65.4)
TABLE 125 Method of diagnosis of cirrhosis overall by arm
Method of diagnosis
Trial arm, n (%)
Total (N= 301), n (%)ELF (N= 281) Standard care (N= 20)
Liver biopsy 1 (0.4) 2 (10.0) 3 (1.0)
Ultrasound scan 2 (0.7) 7 (35.0) 9 (3.0)
Liver CT scan 0 (0.0) 3 (15.0) 3 (1.0)
MRI scan 1 (0.4) 0 (0.0) 1 (0.3)
Gastroscopy 1 (0.4) 7 (35.0) 8 (2.7)
FibroScan 2 (0.7) 9 (45.0) 11 (3.7)
Clinical judgement 2 (0.7) 6 (30.0) 8 (2.7)
ELF test 280 (99.6) 0 (0.0) 280 (93.0)
Note
Methods of diagnosis are not mutually exclusive.
TABLE 126 Method of diagnosis of cirrhosis for patients who were not diagnosed at randomisation
Method of diagnosis
Trial arm, n (%)
Total (N= 104), n (%)ELF (N= 84) Standard care (N= 20)
Liver biopsy 1 (1.2) 2 (10.0) 3 (2.9)
Ultrasound 1 (1.2) 7 (35.0) 8 (7.7)
Liver CT scan 0 (0.0) 3 (15.0) 3 (2.9)
Gastroscopy 0 (0.0) 7 (35.0) 7 (6.7)
FibroScan 1 (1.2) 9 (45.0) 10 (9.6)
Clinical judgement 2 (2.4) 6 (30.0) 8 (7.7)
ELF test 83 (98.8) 0 (0.0) 83 (79.8)
Note
Methods of diagnosis are not mutually exclusive.
DOI: 10.3310/pgfar06030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 3
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Selby et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
347
Process of care outcomes
In this section the frequency of biopsy, AFP testing, imaging and endoscopy visits is summarised by
treatment arm for both non-cirrhotic and cirrhotic patients. The difference in the proportion of patients
undergoing/receiving each process end point between the treatment groups is compared using logistic
regression, adjusting for the stratification factors. When the process outcome relates to the numbers of
tests being performed (e.g. ultrasound, AFP), the two arms are compared using the Mann–Whitney
non-parametric test.
Frequency of biopsies
In total, 12.1% of patients in the ELF arm had at least one biopsy post randomisation compared with
9.1% of patients in the standard care arm (Table 129). The odds ratio is 1.405, with higher odds for
patients in the ELF arm to have a biopsy than patients in the standard care arm, but the 95% CI around
this odds ratio (0.884 to 2.233) includes the critical value of 1 (equal odds) and the difference between the
ELF arm and the standard care arm is, therefore, not statistically significant.
TABLE 127 First method of diagnosis of cirrhosis overall
Method of diagnosis
Trial arm, n (%)
Total (N= 301), n (%)ELF (N= 281) Standard care (N= 20)
Liver biopsy 1 (0.4) 2 (10.0) 3 (1.0)
Ultrasound scan 0 (0.0) 6 (30.0) 6 (2.0)
Liver CT scan 0 (0.0) 2 (10.0) 2 (0.7)
Gastroscopy 0 (0.0) 3 (15.0) 3 (1.0)
FibroScan 1 (0.4) 6 (30.0) 7 (2.3)
Clinical judgement 1 (0.4) 1 (5.0) 2 (0.7)
ELF test 278 (98.9) 0 (0.0) 278 (92.4)
TABLE 128 First method of diagnosis of cirrhosis for patients who were not diagnosed at randomisation
Method of diagnosis
Trial arm, n (%)
Total (N= 104), n (%)ELF (N= 84) Standard care (N= 20)
Liver biopsy 1 (1.2) 2 (10.0) 3 (2.9)
Ultrasound scan 0 (0.0) 6 (30.0) 6 (5.8)
Liver CT scan 0 (0.0) 2 (10.0) 2 (1.9)
Gastroscopy 0 (0.0) 3 (15.0) 3 (2.9)
FibroScan 1 (1.2) 6 (30.0) 7 (6.7)
Clinical judgement 1 (1.2) 1 (5.0) 2 (1.9)
ELF test 81 (96.4) 0 (0.0) 81 (77.9)
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Frequency of alpha-fetoprotein tests
Table 130 shows the frequency of AFP measurements post randomisation by arm. AFP measurements
were more frequent in patients in the ELF arm, which can also be seen in the histogram in Figure 72,
where the mass of the distribution of the number of AFP tests per randomised patient in the ELF arm is
located to the right of the distribution in the standard care arm. The median number of AFP measurements
was 2 (range 0–7) in the ELF arm compared with 1 (range 0–5) in the standard care arm; the difference
between the two distributions was statistically significant, with a p-value of < 0.001 (Table 131). AFP
measurements are a process of care in cirrhotic patients and this difference suggests that patients in the
ELF arm not only were more likely to be diagnosed with cirrhosis (see Disease progression to cirrhosis) but
also were more likely to receive the processes of care to monitor cirrhotic patients for major complications.
The timing of post-diagnosis AFP testing followed the same pattern in the ELF arm as in the standard care
arm (Figure 73). Moreover, before the diagnosis of cirrhosis, the average number of AFP tests per year was
very similar in both arms, at 0.68 in the ELF arm and 0.56 in the standard care arm (Table 132). After the
diagnosis of cirrhosis, this number was 0.90 in the ELF arm and 0.95 in the standard care arm (see Table 132).
This is further evidence for the causal link between the diagnosis of cirrhosis and the higher frequency of AFP
testing, independent of treatment allocation. Although we have seen in Disease progression to cirrhosis that
participants in the ELF arm are more likely to be diagnosed with cirrhosis, we can see here that this diagnosis
will also lead to a higher frequency of AFP testing in the ELF arm.
TABLE 130 Number of AFP tests per randomised patient by arm
Number of AFP tests
Trial arm, n (%)
Total (N= 878), n (%)ELF (N= 438) Standard care (N= 440)
0 89 (20.3) 130 (29.5) 219 (24.9)
1 66 (15.1) 92 (20.9) 158 (18.0)
2 68 (15.5) 80 (18.2) 148 (16.9)
3 89 (20.3) 67 (15.2) 156 (17.8)
4 67 (15.3) 50 (11.4) 117 (13.3)
5 37 (8.4) 21 (4.8) 58 (6.6)
6 16 (3.7) 0 (0.0) 16 (1.8)
7 6 (1.4) 0 (0.0) 6 (0.7)
TABLE 129 Number of randomised patients having at least one biopsy (pre or post diagnosis of cirrhosis)
Has the patient had at least
one biopsy during the trial?
Trial arm, n (%)
Total (N= 878) Odds ratioa 95% CIELF (N= 438)
Standard care
(N= 440)
Yes 53 (12.1) 40 (9.1) 93 (10.6) 1.405 0.884 to 2.233
No 385 (87.9) 400 (90.9) 785 (89.4)
a Odds ratio is adjusted for stratification factors.
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FIGURE 72 Number of AFP measurements per randomised patient by arm.
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FIGURE 73 Number of AFP measurements post diagnosis per 6-month period.
TABLE 131 Number of AFP tests per randomised patient by arm
Number of AFP tests
Trial arm
Total (N= 878)
p-value, Wilcoxon test
(two-sided)ELF (N= 438) Standard care (N= 440)
Mean (SD) 2.4 (1.82) 1.7 (1.53) 2.1 (1.72)
Median (range) 2.0 (0.0–7.0) 1.0 (0.0–5.0) 2.0 (0.0–7.0) < 0.001
Missing 0 0 0
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Frequency of ultrasound scans
Table 133 shows the frequency of ultrasound scans post randomisation by arm. Ultrasound scans were
performed more frequently in patients in the ELF arm, which can also be seen in the histogram in Figure 74,
where the mass of the distribution of the number of scans per randomised patient in the ELF arm is located
to the right of the distribution in the standard care arm. The median number of ultrasound scans was 1
(range 0–6) in the ELF arm compared with 0 (range 0–5) in the standard care arm; the difference between
the two distributions was statistically significant, with a p-value of < 0.001 (Table 134).
TABLE 132 Frequency of AFP testing before and after the diagnosis of cirrhosis
Trial arm
Total number of AFP tests Total years of follow-up
Average number of AFP
tests per year of follow-up
Any
time
Before
diagnosis
After
diagnosis
Any
time
Before
diagnosis
After
diagnosis
Any
time
Before
diagnosis
After
diagnosis
ELF 1060 383 677 1322.19 567.28 754.91 0.80 0.68 0.90
Standard care 758 721 37 1326.63 1287.56 39.07 0.57 0.56 0.95
TABLE 133 Number of ultrasound scans per randomised patient by arm
Number of ultrasound scans
Trial arm, n (%)
Total (N= 878), n (%)ELF (N= 438) Standard care (N= 440)
0 151 (34.5) 233 (53.0) 384 (43.7)
1 98 (22.4) 111 (25.2) 209 (23.8)
2 77 (17.6) 55 (12.5) 132 (15.0)
3 53 (12.1) 30 (6.8) 83 (9.5)
4 40 (9.1) 8 (1.8) 48 (5.5)
5 16 (3.7) 3 (0.7) 19 (2.2)
6 3 (0.7) 0 (0.0) 3 (0.3)
0 2 64 8
0
10
40
30
20
50
Number of scans
P
e
rc
e
n
ta
g
e
ELF
Standard care
Trial arm
FIGURE 74 Number of ultrasound scans per randomised patient by arm.
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Ultrasound scans are a process of care in cirrhotic patients and this difference demonstrates that patients in
the ELF arm not only were more likely to be diagnosed with cirrhosis (see Disease progression to cirrhosis)
but also were more likely to receive the processes of care of cirrhotic patients. This is a really important
finding as only regular and frequent ultrasound scans can detect HCC early.
The timing of post-diagnosis ultrasound scans followed the same pattern in the ELF arm as in the standard
care arm (Figure 75). Moreover, before the diagnosis of cirrhosis, the average number of ultrasound scans
per year was very similar in both arms, at 0.29 in the ELF arm and 0.26 in the standard care arm (Table 135).
After the diagnosis of cirrhosis, this number was 0.66 in the ELF arm and 0.74 in the standard care arm.
This is further evidence for the causal link between the diagnosis of cirrhosis and the higher frequency of
TABLE 134 Number of ultrasound scans per randomised patient by arm
Number of ultrasound scans
Trial arm
Total (n= 878)
p-value, Wilcoxon
test (two-sided)ELF (n= 438) Standard care (n= 440)
Mean (SD) 1.5 (1.52) 0.8 (1.08) 1.2 (1.36)
Median (range) 1.0 (0.0–6.0) 0.0 (0.0–5.0) 1.0 (0.0–6.0) < 0.001
Missing 0 0 0
(Number of patients diagnosed with cirrhosis:
281 in the ELF arm; 20 in the standard arm)
1 – 6 7 – 12 13 – 18 19 – 24 25 – 30 31 – 36
94.7 93.5 93.8 94.6 98.0 92.9
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FIGURE 75 Number of ultrasound scans post diagnosis per 6-month period.
TABLE 135 Frequency of ultrasound scans before and after the diagnosis of cirrhosisa
Arm
Total number of ultrasound
scans Total years of follow-up
Average number of ultrasound
scans per year of follow-up
Any
time
Before
diagnosis
After
diagnosis
Any
time
Before
diagnosis
After
diagnosis
Any
time
Before
diagnosis
After
diagnosis
ELF 664 163 501 1322.19 567.28 754.91 0.50 0.29 0.66
Standard care 358 329 29 1326.63 1287.56 39.07 0.27 0.26 0.74
a For five scans (four in the ELF arm and one in the standard care arm) the scan dates were missing. These scans are
excluded from this table.
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ultrasound scans, independent of treatment allocation. Although we have seen in Disease progression to
cirrhosis that participants in the ELF arm are more likely to be diagnosed with cirrhosis, we can see here that
this diagnosis will also lead to a higher frequency of ultrasound scans in both trial arms. Table 135 shows an
excess of 306 scans in the ELF arm compared with the standard care arm.
Frequency of oesophagogastroduodenoscopy
In total, 34.9% of patients in the ELF arm had a least one endoscopy (OGD) post randomisation compared
with 2.7% of patients in the standard care arm. The (adjusted) odds ratio is 83.9, with higher odds for
patients in the ELF arm to have an endoscopy than patients in the standard care arm. The 95% CI around
this odds ratio is 36.9 to 192.4; therefore, the difference between the ELF arm and the standard care arm
is clearly significant (Table 136). This is likely to be because a larger proportion of patients are diagnosed
with cirrhosis in the ELF arm than in the standard care arm and these patients have endoscopies as part of
their cirrhosis management, as expected.
When looking only at the subset of patients who were diagnosed with cirrhosis, 54.4% of patients in the
EFL arm had at least one OGD post diagnosis compared with 60% of patients in the standard care arm.
The (adjusted) odds ratio (1.3) is still in favour of the ELF arm but the 95% CI (0.4 to 4.9) shows that
this difference in odds is no longer significant (Table 137). This means that the odds of having an OGD
post diagnosis of cirrhosis are equivalent, suggesting that patients received the same processes of care
with regard to OGD in both arms. However, as a result, overall in the trial to date there were a total of
165 additional OGDs performed in the ELF arm, with only 14 OGDs performed in the standard care arm
and 179 performed in the ELF arm (Table 138). This is probably the single largest difference in process of
care tests between the arms.
TABLE 136 Number of randomised patients having at least one OGD since randomisation
Has the patient had
at least one OGD?
ELF (N= 438),
n (%)
Standard care
(N= 440), n (%)
Total (N= 878),
n (%) Odds ratioa 95% CI
Yes 153 (34.9) 12 (2.7) 165 (18.8) 83.894 36.573 to 192.443
No 285 (65.1) 428 (97.3) 713 (81.2)
a Odds ratio is adjusted for stratification factors.
TABLE 137 Number of patients having at least one OGD post diagnosis of cirrhosis
Has the patient had at
least one OGD since
diagnosis of cirrhosis?
ELF (N= 281),
n (%)
Standard care
(N= 20), n (%)
Total (N= 301),
n (%) Odds ratioa 95% CI
Yes 153 (54.4) 12 (60.0) 165 (54.8) 1.304 0.350 to 4.861
No 128 (45.6) 8 (40.0) 136 (45.2)
a Odds ratio is adjusted for stratification factors.
TABLE 138 Number of OGDs performed by arm
Trial arm Total (N= 193), n (%)
ELF 179 (92.7)
Standard care 14 (7.3)
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Frequency of beta-blocker/band ligation treatment
In total, nine (2.1%) patients in the ELF arm and seven (1.6%) in the standard care arm were diagnosed
with varices (Table 139) and five (1.1%) patients in the ELF arm and three (0.7%) in the standard care arm
were treated with beta-blockers or band ligation (Table 140). The adjusted odds ratio for treatment with
beta-blockers or band ligation is 1.3 (95% CI 0.1 to13.8), showing that there is no significant difference in
the likelihood of being treated between the ELF arm and the standard care arm.
Frequency of treatment to normalise liver function tests
In total, 57 (13%) patients in the ELF arm and 48 (10.9%) in the standard care arm received treatment to
normalise LFTs (Table 141). The adjusted odds ratio is 1.5 (95% CI 0.9 to 2.7), suggesting that there is no
statistically significant difference in the odds of receiving treatment to normalise LFTs between the two
arms. However, again, the numbers are small and a few more ELF arm patients are receiving treatment to
normalise LFTs, which is in the right direction, even though this difference is not significant.
TABLE 139 Number of patients who developed varices by arm
Has the patient
developed varices?
Trial arm, n (%)
Total (N= 878), n (%)ELF (N= 438) Standard care (N= 440)
Yes 9 (2.1) 7 (1.6) 16 (1.8)
No 429 (97.9) 433 (98.4) 862 (98.2)
TABLE 140 Number of patients treated with beta-blockers or band ligation
Has the patient been treated
with beta-blockers or band
ligation?
Trial arm, n (%)
Total
(N= 878), n (%)
Odds
ratioa 95% CIELF (N= 438)
Standard care
(N= 440)
Yes 5 (1.1) 3 (0.7) 8 (0.9) 1.343 0.131 to 13.754
No 433 (98.9) 437 (99.3) 870 (99.1)
a Odds ratio adjusted for stratification factors.
TABLE 141 Number of randomised patients receiving treatment to normalise LFTs
Has the patient received
treatment to normalise LFTs?
Trial arm, n (%)
Total
(N= 878), n (%)
Odds
ratioa 95% CIELF (N= 438)
Standard care
(N= 440)
Yes 57 (13.0) 48 (10.9) 105 (12.0) 1.510 0.850 to 2.681
No 381 (87.0) 392 (89.1) 773 (88.0)
a Odds ratio is adjusted for stratification factors.
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Related unexpected serious adverse events
There were no RUSAEs reported in the ELUCIDATE trial.
Health economic consequences
The follow-up period for the ELUCIDATE trial has been extended to 5 years beyond the end of the NIHR
programme grant, meaning that we are unable, at this stage, to access data on resources used and quality
of life by arm. This prevented QALYs being estimated and the assessment of the cost-effectiveness of the
ELF test in the early detection of cirrhosis.
Considering that one of the aims of the trial was to assess how the use of the ELF test affects the process
of care, the aim of the health economic analysis at this stage was restricted to a descriptive analysis of
the costs associated with the process of care outcomes. These are, namely, increased use of endoscopy,
biopsy, ultrasound and AFP tests to detect HCC at a surgically curable stage and increased use of
beta-blockers/band ligation of varices to prevent haemorrhage/HCC.
Descriptive analysis
Costs associated with process of care outcomes
For costing of the process of care outcomes we assigned a unit cost to the mean values for tests reported by
several hospitals (as reported in the statistical analysis and Table 142) for the various procedures. Unit costs
and their sources are presented in Table 142. Costs for endoscopy (OGD) and ultrasound scans were obtained
from NHS Reference Costs 2013–2014.890 When costs were not available from national databases they were
obtained from the literature. This was the case for the AFP test and liver biopsy, whose costs were obtained
from a study on antiviral therapy for mild chronic hepatitis C.891 Finally, drug costs were obtained from the
British National Formulary.892 Costs were adjusted using 2015 prices and were discounted at 3.5%. Costs in
each arm of the trial for liver biopsies, ultrasound scans, AFP testing, OGD and treatment with beta-blockers
are given in Tables 143–147, respectively.
TABLE 142 Unit costs and their sources
Activity
Unit
cost (£)
2015
prices (£) Comments Source
Liver biopsy 249.00 334.14 Average across three hospitals Wright et al.891
AFP test 6.03 8.09 Average across three hospitals Wright et al.891
Ultrasound scan 47.00 48.83 – NHS Reference Costs 2013–2014890 –
diagnostic imaging
Endoscopy (OGD) 406.00 421.80 – NHS Reference Costs 2013–2014890 –
day case
Beta-blockers
Propranolol
(Inderal,
AstraZeneca)
1.45 – 40mg, 28-tablet pack;
dose: 40 mg twice daily
BNF892
Carvedilol
(Coreg,
GlaxoSmithKline)
1.26 – 12.5 mg, 28-tablet pack;
dose: 12.5 mg once daily
BNF892
Nadolol
(Corgard, Pfizer)
5.00 – 80mg, 28-tablet pack;
dose: 40 mg once daily
BNF892
BNF, British National Formulary.
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TABLE 143 Liver biopsy
Variable
Trial arm
Total (n= 878)ELF (n= 438) Standard care (n= 440)
Mean (SD) number of liver biopsies per patient 0.1 (0.3) 0.1 (0.3) 0.1 (0.3)
Average cost (£) 14,635 14,702 29,337
Discounted cost (£) 13,200 13,260 26,460
TABLE 144 Ultrasound scans
Variable
Trial arm
Total (n= 878)ELF (n= 438) Standard care (n= 440)
Mean (SD) number of ultrasound scans per patient 1.5 (1.52) 0.8 (1.08) 1.2 (1.36)
Average cost (£) 32,081 17,188 51,447
Discounted cost (£) 28,935 15,502 46,402
TABLE 145 Alpha-fetoprotein test
Variable
Trial arm
Total (n= 878)ELF (n= 438) Standard care (n= 440)
Mean (SD) number of AFP tests per patient 2.4 (1.82) 1.7 (1.53) 2.1 (1.72)
Average cost (£) 8504 6051 14,916
Discounted cost (£) 7670 5458 13,454
TABLE 146 Endoscopy OGD
Variable
Trial arm
Total (n= 878)ELF (n= 438) Standard care (n= 440)
Mean (SD) number of OGDs per patient 0.4 (0.6) 0.03 (0.2) 0.2 (0.5)
Average cost (£) 73,899 5567 74,068
Discounted cost (£) 66,653 5022 66,805
TABLE 147 Treatment with beta-blockers
Treatment
Trial arm, 1-year cost (£)
ELF (n= 5) Standard care arm (n= 3)
Propranolol 170 102
Carvedilol 74 44
Nadolol 147 88
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The statistical results showed that the average number of liver biopsies performed was very similar in the
two arms of the trial, at 0.1 (SD 0.3). The discounted cost of liver biopsies was just over £13,000 in
both arms.
The statistical results showed that diagnosis of cirrhosis (defined in the ELUCIDATE trial as an ELF value of
≥ 9.5) leads to a higher frequency of ultrasound scans, AFP tests and endoscopies (OGD) in both trial arms,
as expected, given that these constitute processes of care in cirrhotic patients. However, ultrasound scans,
AFP tests and endoscopies (OGD) are more frequent in patients in the ELF arm because they are more
likely to be diagnosed with cirrhosis. This translates into a higher average cost of ultrasound scans in the
ELF arm, specifically £28,935 compared with £15,503 in the standard care arm.
The same applies to AFP tests. AFP testing is a process of care in cirrhotic patients and, hence, these tests
were administered more frequently in the ELF arm than on the standard care arm. On average, £7670
was spent on AFP tests in the ELF arm, whereas the average cost of AFP tests in the standard care arm
was £5458.
The statistical results showed that there was a significant difference between the groups in the mean
number of OGDs performed, at 0.4 (SD 0.6) in the ELF arm and 0.03 (SD 0.2) in the standard arm.
This translates into a remarkable difference in cost, with £66,653 spent on endoscopies in the ELF arm
compared with £5022 in the standard care arm.
It was not possible to distinguish between the use of beta-blockers or band ligation (it was recorded only if
patients had been treated with either) and so we assumed that the first choice of treatment was drug
therapy. This is supported by the UK guidelines on the management of variceal haemorrhage in cirrhotic
patients,893 which advise towards pharmacological treatment with propranolol as first-line therapy (40 mg
twice daily). Carvedilol (12.5 mg once daily) or nadolol (40 mg once daily) are suggested as alternatives to
propranolol. Once initiated, the treatment continues indefinitely. In the ELF arm, five patients were treated
for varices whereas in the standard care arm three patients were treated. We assumed that treatment
started in the last year of follow-up and we calculated the cost for 1 year. The least expensive treatment is
carvedilol, which cost £74 in the ELF arm and £44 in the standard care arm. The most expensive treatment
is propranolol, with a cost of £170 in the ELF arm and £102 in the standard care arm.
Severe complications and deaths
The primary outcome of the trial is the incidence of severe complications; this will be analysed using
registry (ONS/HES) data in the long-term follow-up analysis in 2021. In this report, the number of severe
complications and the number of deaths are, therefore, not presented by arm.
In total, 16 (1.8%) of the randomised patients had at least one severe complication. When looking at the
first identified severe complication in these 16 patients, HCC was the most common complication, with
10 cases (62.5%). Two patients had variceal haemorrhage and two had encephalopathy. Two patients
with HCC and one patient with encephalopathy subsequently died of liver-related causes.
A total of 17 (1.9%) of 878 randomised patients died during follow-up. Five of these deaths (29.4%) were
liver related (variceal haemorrhage, n = 1; HCC, n = 2; liver failure, n = 1; sepsis, n = 1); for one patient this
information was missing.
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Discussion
Although there was relatively low compliance to trial procedures, this was not unexpected in this group of
patients. It should also be noted that fairly strict definitions of compliance were reported, with a tight
window, usually of 1 month, in which to have the test performed; the ‘window’ graphs show that the
majority of tests were still carried out, if often considerably later than would be ideal. Furthermore, in
terms of looking at a series of tests, if one test at one particular time point was missed, that test would
have been likely to have been carried out at the next visit, reducing the impact of the missed test.
The analysis of the process of care outcomes showed substantial differences in the care delivered between
the ELF arm and the standard care arm, despite the apparent lack of compliance. Furthermore, when
considering tests performed after the diagnosis of cirrhosis, which is defined by an ELF threshold value in
the ELF arm and, therefore, includes vastly more patients in the ELF arm, differences in tests performed,
such as AFP tests, ultrasound scans and OGDs, were very large (18 times as many AFP tests, 17 times as
many ultrasound scans and 13 times as many OGDs were performed in the ELF arm) and so it seems clear
that a very different treatment package was delivered in the two trial arms despite the low compliance
under the definition used.
In terms of the design and outcome of the trial, the main effect of low compliance will be its potential impact
on the effect size for the primary end point of occurrence of severe complications. For the intervention to be
successful, it has to be successfully delivered, otherwise it cannot be expected to result in a difference in
outcome. It is difficult to judge whether or not the magnitude of the low compliance would be sufficient to
cause a substantial reduction in the effect size. However, the previous comments about the stringency of
compliance reporting, combined with the large differences found in the use of tests such as AFP tests,
ultrasound scans and OGDs, are crucial, and any reduction in effect size as a result of low compliance,
as defined, would be expected to be relatively minor. We will be able to analyse effect size in relation to
adherence to protocol guidelines in the final analysis, at which time it should be possible to quantify any such
effect. This analysis will be included in the statistical analysis plan for analysis of the long-term follow-up for
the primary end point.
The unsurprisingly higher cost associated with the ELF arm (£116,629 vs. £39,345) is the result of the
additional care provided, mainly in the form of additional diagnostic investigations, as a consequence of
more patients having an ELF value of ≥ 9.5 on ELF testing and, hence, being diagnosed with cirrhosis. This
additional care is directed at preventing complications (in the case of beta-blocker therapy) or detecting
complications early and at a curable stage. This should translate to improved survival rates and improved
quality of life at the end of the extended follow-up period. The cost-effectiveness of the ELF test in the
early detection of cirrhosis will ultimately depend on the impact that the additional process of care in the
ELF arm has on survival rates, quality of care and health-care resource use.
The descriptive analysis has a number of limitations and assumptions. Information was not available on
when the diagnostic investigations occurred during the 30-month follow-up and so we assumed that,
for example, all ultrasound scans were carried out in the last year of follow-up and we discounted costs
in the third year. With regard to the treatment of varices, patients can be treated surgically or with
pharmacological treatment; we assumed that patients were all treated with beta-blockers, based on UK
guidelines that advise the use of pharmacological treatment in first line. Finally, information on when
treatment was initiated was not available; hence, we assumed that treatment starts in the last year of
follow-up and we discounted costs in the third year. In addition, we did not know which particular drug
was used; thus, we included the cost of both the most and the least costly treatment courses.
These data will allow us to complete the planned evaluation of the cost per QALY generated by the ELF
monitoring strategy when the outcome data become available. In the meantime we will explore further
modelling approaches to relate the cost of the strategy against potential improvements in outcomes that
may be estimated from the changes in process of care.
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Chapter 22 Workstream 3: next steps and
preliminary conclusions
Summary and discussion of the results of the ELUCIDATE trial to date
At the time of compiling this report the data gathered during the conduct of the ELUCIDATE trial have
been divided by randomisation arm only for the analysis of indicators of cirrhosis and changes in the
process of care.
A number of observations can be made concerning two broad categories of data: those relating to the
clinical aspects of the study and those relating to the conduct of the study.
Clinical aspects
Baseline demographics
Randomisation was effective in that there were no significant differences in the baseline characteristics
between the two arms. The median age of participants was 55 years and there was a slight over-
representation of men at 56%.
Enhanced Liver Fibrosis testing at registration
The median ELF value at registration was 9.4. Nearly 55% of those registered had an ELF value in the
range 8.4–9.49, indicating that they were pre-cirrhotic and at low risk of liver-related complications of
CLD (see Figure 64). Only 5.7% (n = 50) of participants had an ELF value that exceeded 11.49 and were,
thus, at higher risk of liver-related complications within the next 5 years. This distribution of liver fibrosis
among the participants means that only a relatively small proportion are likely to develop liver-related
outcomes during the course of the trial. Longer-term follow-up will be required to capture these events
and to determine if earlier detection of cirrhosis and management alters the course of disease and the
incidence of morbidity and mortality.
The change to a randomisation threshold of 8.4 in March 2011 did not introduce bias but did reduce the
risk of serious liver-related complications in the trial overall (see Figure 64).
Alcohol consumption
The levels of alcohol consumption in the cohort were relatively low compared with what was anticipated
for patients with CLD. Only 9.3% reported moderately heavy levels of current consumption and only 3.5%
reported current heavy alcohol consumption. Again, this lower than anticipated alcohol consumption is
likely to reduce the incidence of liver-related events in the cohort during the trial and during subsequent
follow-up. Patients may have under-reported alcohol use in both arms of the trial.
Aetiology of chronic liver disease
The distribution of aetiologies of CLD among the cohort differs from that seen in the majority of liver
clinics, with alcoholic liver disease under-represented at 7.7% and viral hepatitis over-represented at
40.2%. Non-alcoholic fatty liver disease accounted for 25% of the cohort; this is similar to the rate of
non-alcoholic fatty liver disease seen in most liver clinics. The course of the ELUCIDATE trial paralleled
the introduction of highly effective therapies for HCV infection and more widespread treatment of HBV
infection. As a consequence it is likely that patients recruited with these conditions will have been treated
during the course of the trial and are likely to experience improvement in their liver fibrosis. Although this
is likely to reduce the anticipated incidence of liver-related events, it will have created the opportunity to
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analyse the ability of ELF and other biochemical tests to monitor improvements in fibrosis consequent on
control or eradication of hepatitis virus infection.
It is unfortunate that so few patients were recruited with alcoholic liver disease as their primary aetiology
as these patients are at highest risk of liver-related events and are likely to be the group in which early
detection of cirrhosis might be most beneficial. However, patients with alcoholic liver disease are often
difficult to recruit and retain in clinical trials.
The significant representation of non-alcoholic fatty liver disease may be valuable. Fatty liver disease is
increasingly recognised as an important cause of CLD and one in which the currently available therapeutic
interventions (diet and exercise) have limited effect. However, new specific and general antifibrotic
therapies are undergoing trials in non-alcoholic fatty liver disease and so it will be valuable to know what
strategies are most effective in detecting cirrhosis in this condition.
The proportion of patients with viral hepatitis among those recruited varied considerably between sites,
from 0% to 100%. This is likely to reflect the specialist interest of the local principal investigator, the
representation of these patients in the local clinic population and the willingness of the investigators and
patients to enrol these patients in the study.
Progression to cirrhosis
Inevitably, the proportion of patients progressing to ‘cirrhosis’, as defined by ELF testing, was greater in the
ELF arm than in the standard care arm (64.2% vs. 4.5%). However, the definition of cirrhosis for each arm
differed at this stage of the analysis, being defined by an ELF value of > 9.5 in the ELF arm and according
to clinical criteria in the standard care arm. Patients with an ELF value of > 9.5 have a significant risk of
serious complications (see Figure 64) and the investigators and steering group judged that was a sufficient
justification for the initiation of measures to reduce the risk of serious complications.
In the ELF arm, 70% of the patients registered were diagnosed as cirrhotic at randomisation at the time of
their first ELF test. None of the patients in the standard care arm was diagnosed as cirrhotic when they
attended their randomisation visit. This difference supports the hypothesis that ELF will detect cirrhosis in
patients who would not be recognised as cirrhotic using clinical criteria. However, this may merely reflect
a difference in case definition or, at best, ‘lead time’ bias. Longer-term follow-up will determine what
proportion of patients in each arm progressed to clinically relevant outcomes associated with cirrhosis.
Only nine patients in the ELF arm (0.4%) were diagnosed as cirrhotic using criteria other than ELF testing.
The most common methods for diagnosing cirrhosis in the standard care arm were elastography (3.7%),
ultrasound (3%), gastroscopy (2.7%) and clinical judgement (2.7%).
Following randomisation, 84 patients in the ELF arm and 20 patients in the standard care arm were
subsequently diagnosed as cirrhotic during the course of the trial. Three patients in the ELF arm were
diagnosed using clinical measures (one each of biopsy, elastography and clinical judgement). Ultrasound
and elastography were the most common means of diagnosing cirrhosis in the standard care arm, with six
patients diagnosed by each method.
Study conduct
Recruitment
Recruitment to the ELUCIDATE trial was slower than anticipated and the start-up time was longer than
anticipated in many centres. However, 46 NHS trusts are participating in the ELUCIDATE trial, with a wide
geographical distribution across the country. Many hospitals had little previous experience of recruitment into
liver RCTs. The extension of the trial to additional centres ultimately allowed the recruitment of almost 90% of
the target recruitment number but the delays have limited our ability to thus far analyse long-term outcomes.
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Compliance
Pre-cirrhotic patients
Compliance with follow-up visit attendance was generally poor in both arms. This reflects clinical experience
in liver clinics, where ‘did not attend’ rates vary between 5% and 25%. The ELUCIDATE protocol required
6-monthly attendance at clinics for pre-cirrhotic patients. It was apparent during the feasibility planning for
the study that many clinics booked less frequent appointments for patients with CLD. It was decided that,
rather than change the protocol, this variance in clinic practice would be captured in the conduct of the
study. Thus, the low rates of compliance with the protocol were anticipated. Only 23.3% of patients
complied with all planned visits and the rate of compliance was higher in the ELF arm at 29.8% than in
the standard care arm at 19.7%.
Post-cirrhotic patients
Compliance with the protocol was even worse for patients following the diagnosis of cirrhosis. Again, this
is likely to be because of local clinical practice deviating from national and international guidelines, as well
as the ELUCIDATE protocol. Compliance with clinic visits was worse in the ELF arm at 16.2% than in the
standard care arm at 21.1%. This may reflect greater concern for patients diagnosed as cirrhotic in the
standard care arm, although the number of patients compliant with the protocol in the standard care arm
was very small (n = 4).
Reasons for non-compliance
The most frequently reported reasons for non-compliance with clinic visits were administrative errors or
lack of staff. Interestingly, the majority of these deviations occurred at UCLH and the Royal Free Hospital,
where large numbers of patients were recruited, and at King’s College Hospital.
The ELUCIDATE trial provided no separate funding for research nurses to conduct the study. It was
anticipated that NIHR-supported staff would recruit and consent patients to the study and this was certainly
the case at the majority of sites. However, the relatively light research tasks involved in the conduct of the
ELUCIDATE trial became ‘onerous’ at those centres recruiting large numbers of patients, when processing large
numbers of blood samples and CRFs became time-consuming. These observations have implications for future
NIHR studies that seek to rely on Portfolio adoption and access to NIHR faculty to conduct ‘non-onerous’ tasks
critical to the completion of a study. Direct costing of the research component of observational studies should
be considered but this will have significant impact on the cost of studies such as the ELUCIDATE trial.
Smaller centres with fewer competing studies performed particularly well and this must be recognised as a
success of the NIHR goal to have more NHS trusts engaged in clinical research that is relevant to the NHS.
Compliance with cirrhosis management
Compliance with AFP testing was low in both arms, at 12.6% and 11.8% in the ELF and standard care
arms, respectively.
Process of care outcomes
Frequency of biopsies
There was no significant difference in the number or proportion of patients undergoing liver biopsy
between the different arms of the study. This suggests that clinicians did not regard an ELF-based
diagnosis of cirrhosis as an indication for a liver biopsy.
Alpha-fetoprotein testing
A diagnosis of cirrhosis should be followed by monitoring for the development of HCC. Guidelines
recommend the use of AFP measurement and ultrasound scanning every 6 months and this practice was
incorporated into the ELUCIDATE trial protocol. Measurement of AFP was more frequent in the ELF arm
than in the standard care arm, confirming that the investigators adhered to the protocol and conducted
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appropriate tests following the diagnosis of cirrhosis by ELF testing. Once cirrhosis was diagnosed the
adherence to protocol was the same in both arms.
This suggests that if ELF testing correctly defines cirrhosis then clinicians will test for AFP as a screening test
for HCC. This suggests that cancers may be diagnosed more frequently and earlier through the use of
biochemical testing for cirrhosis and raises the possibility that more HCCs could be cured and that the
outcomes in HCC could be improved. It remains to be determined whether or not this strategy will
improve survival from HCC.
Ultrasound scans
More ultrasound scans were performed in the ELF arm than in the standard care arm confirming that the
investigators adhered to the protocol and conducted appropriate tests following the diagnosis of cirrhosis
by ELF testing. Once cirrhosis was diagnosed the adherence to protocol was the same in both arms.
This suggests that if ELF testing correctly defines cirrhosis then clinicians will screen for HCC appropriately.
This suggests that cancers may be diagnosed more frequently and earlier through the use of biochemical
testing for cirrhosis and raises the possibility that more HCCs could be cured and that the outcomes in HCC
could be improved. It remains to be determined whether or not this strategy will improve survival from HCC.
Oesophagogastroduodenoscopy
The overall frequency of OGD was 34.9% in the ELF arm and 2.7% in the standard care arm. Following
the diagnosis of cirrhosis the frequency of OGD was similar in both arms, with 54.4% of ELF arm
cirrhotic patients and 60% of standard care arm cirrhotic patients undergoing endoscopy. This is a critical
investigation for diagnosing treatable varices and so is an important step in reducing the incidence of
life-threatening complications of cirrhosis. As more patients underwent OGD for a cirrhotic indication in
the ELF arm (and RCT evidence has shown that treatment of varices reduces morbidity and mortality in
CLD), the greater use of OGD in the ELF arm may translate into an overall benefit in terms of a reduction
in morbidity and mortality in the ELF arm over time.
Diagnosis of varices
The number of patients deemed to have developed varices was greater in the ELF arm than in the standard
care arm (n = 9 or 2.1% vs. n = 7 or 1.6%), but this difference was not statistically significant.
Of the patients diagnosed as cirrhotic who had an OGD to detect varices, 9 out of 153 (5.9%) in the ELF
arm and 7 out of 12 (58.3%) in the standard care arm were found to have varices. At this stage of the
analysis it is not possible to determine the diagnostic accuracy of either strategy but the number of cases
detected was similar in each arm, suggesting that either strategy is equally effective at detecting varices.
Six of the 20 cases of cirrhosis in the standard care arm were detected using FibroScan. As an alternative
method of non-invasive testing for fibrosis with similar effectiveness to ELF testing, the use of FibroScan in
the standard care arm will have enriched for cirrhosis in this arm, reducing the measured effectiveness of
the intervention (ELF testing). Access to FibroScan is limited in the UK and so once unblinding has occurred
it will be possible to discern the impact of FibroScan on the detection of cirrhosis and treatment in the
standard care arm.
Beta-blocker prescription or band ligation
The number of patients diagnosed and treated for portal hypertension and oesophageal varices was
greater in the ELF arm (9 diagnosed, 5 treated) than in the control arm (7 diagnosed, 3 treated). Of the
cases of diagnosed varices, five out of nine in the ELF arm and three out of seven in the standard care
arm began treatment. The difference in use of beta-blockers and that of band ligation were not statistically
significantly different. This suggests that the instigation of life-saving treatment was no greater in the ELF
arm and suggests that the study is unlikely to provide evidence of benefit from the early diagnosis of
cirrhosis. However, the numbers reaching this end point to date are small and, at this stage, the impact of
the use of FibroScan in the standard care arm cannot be determined.
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Treatment
A similar number of patients in each arm underwent treatment to normalise their liver function during the
course of the ELUCIDATE trial, with 13% of ELF arm patients and 10.9% of standard care arm patients
receiving treatment. This suggests that eradication or control of viral hepatitis is unlikely to account for the
lower than anticipated incidence of complications of cirrhosis during the trial study period.
The trial outcomes
The ELUCIDATE trial was designed to test the hypothesis that earlier diagnosis of cirrhosis in patients with
CLD through the use of serum testing would permit earlier and more widespread targeted screening for
oesophageal varices and HCC linked to treatment and that this would result in reductions in morbidity
and mortality.
More patients in the ELF arm than in the standard care arm were diagnosed with cirrhosis and then
underwent screening for oesophageal varices and HCC. The excess of cases of cirrhosis in the ELF arm was
anticipated as the criterion for diagnosing cirrhosis in the ELF arm was a universally applied biochemical
threshold of an ELF value of > 9.5 whereas diagnosis of cirrhosis in the standard care arm relied on
clinical recognition. Whether or not this early diagnosis proves to be of long-term clinical benefit remains to
be determined. It is inevitable that earlier diagnosis will incur greater costs attributable to investigation and
preventative treatment of complications. However, these costs may be exceeded by the costs of managing
decompensated liver disease presenting de novo in patients who have been diagnosed with cirrhosis later.
The rate of screening among cirrhotic cases detected in each arm was similar, suggesting that the
investigators adhered to the trial protocol and complied with guidelines for the management of cirrhosis
equally for cirrhotic patients in each arm in accordance with the hypothesis underpinning the trial.
The number of cases of oesophageal varices diagnosed and treated was similar in each arm and, thus,
the proportion of cirrhotic patients in each arm with varices and started on treatment was far higher in the
standard care arm. This suggests that standard care may be more efficient and equally as effective as the
use of ELF testing to detect and treat varices, although at present we do not know if cases of varices were
missed in the standard care arm.
Six of the 20 cases of cirrhosis in the standard care arm were diagnosed following the use of FibroScan,
a non-invasive test for cirrhosis that performs as effectively as ELF testing. Because the randomisation
blinding has not been broken, we do not know at this stage what proportion of patients with varices in
the standard care arm was diagnosed using FibroScan, but it is clear that one-third of the cirrhotic cases in
the standard care arm were detected using this non-invasive test.
FibroScan is a technology that emerged into use in the NHS during the course of the ELUCIDATE trial. It
was not CE marked when the trial was initiated and access to the technology remains limited within NHS
trusts. The authors of the trial did not include FibroScan as part of the intervention arm of the trial because
of the lack of regulatory approval at the start of the trial, limited access to the technology and the lack of
consensus on thresholds for the diagnosis of cirrhosis. However, during the course of the study FibroScan
has entered more widespread, but not universal, use. Although the use of an alternative novel non-invasive
test for fibrosis may be regarded as ‘contaminating’ the control arm of the trial, the Chief Investigators took
a pragmatic decision to not exclude the use of FibroScan but to record its use by investigators in both arms
of the trial. It may be that the use of FibroScan in the standard care arm will have eliminated the intended
difference between the arms and, hence, the power of the study to detect any benefit of the early
detection of cirrhosis. Once the trial is unblinded it may be possible to determine the proportion of cases of
cirrhosis diagnosed and managed in the standard care arm using the non-invasive test FibroScan as an
alternative to ELF testing.
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Another explanation for the high pick-up rate for varices among the cirrhotic patients in the standard care
arm is a ‘Hawthorne effect’. It is likely that investigators were more vigilant about the onset of cirrhosis in
patients in the standard care arm than for patients outside the trial. If one of the benefits of conducting
the ELUCIDATE trial in a large number of NHS trusts is diffusion of best practice, then this should be seen
as a benefit of conducting research in clinical services. This possibility could be explored through qualitative
research conducted with the principal investigators.
If the use of ELF testing to detect cirrhosis is beneficial then those patients most likely to benefit will be
those who are asymptomatic and have few clinical signs of cirrhosis. These patients are unlikely to be
diagnosed in the standard care arm and are likely to be over-represented among the patients presenting
for the first time with life-threatening variceal haemorrhage and inoperable HCC. It remains to be seen
if complications will be detected and managed more effectively in this group of patients in the ELF arm
compared with the standard care arm but this should be discernible with longer follow-up of the two arms
once randomisation is unblinded.
The trial process
The trial process was ultimately successful in approaching the final target, but with important delays.
The randomisation process was effective in that there were no significant differences between the patients
recruited to the two arms of the trial. However, the recruitment process was slower than anticipated
because of a number of problems with the regulatory processes, enforced changes to the protocol and
problems at the participating sites. Much has been learned through the conduct of the study and some of
the issues over regulatory processes have been addressed by the NIHR and will be addressed by the Health
Research Authority. It is apparent that some of the smaller centres made proportionally greater contributions
to recruitment than some of the larger centres. It was clear that site-specific visits by the Co-principal
Investigator made a significant difference to recruitment.
The spectrum of aetiologies of CLDs among the participants was similar to that seen in the outpatient
departments of specialist centres, but differs from the case mix presenting to accident and emergency
departments and admitted to hospital wards. Thus, compared with hospital inpatients, the cohort under-
represented alcoholic liver disease and over-represented viral hepatitis and non-alcoholic fatty liver disease.
However, as the purpose of the study was to investigate the impact of detecting cirrhotic cases among
hospital clinic attenders, this is a representative sample.
The spectrum of liver fibrosis among trial participants reflected the trial design and focused on pre-cirrhotic
patients. Although this targeted the cohort of patients most likely to benefit from the early diagnosis of
cirrhosis, a longer period of follow-up than allowed for in the period of the programme grant will be required
to accumulate sufficient events for adequate statistical power. Thus, a later follow-up will be required. As this
will not incorporate continued monitoring for progression of fibrosis, this will diminish any potential benefit
from the intervention, limiting the main benefit to those patients reaching cirrhosis during the on-trial
monitoring period of 30 months.
The patients most likely to benefit from monitoring for cirrhosis are those with progressive liver disease
who develop cirrhosis during the study period. The modest levels of drinking (again possibly because of a
Hawthorne effect) and the introduction of effective therapies for HCV and HBV infection during the
conduct of the study are likely to reduce the proportion of patients with progressive fibrosis.
Compliance with trial visits was moderate and provides a good reflection of clinical practice. These data
will permit more accurate estimates of feasibility and power when designing future monitoring and
interventional studies in CLD.
Longer-term follow-up and analysis of the process of care, clinical events and outcomes by randomisation
arm, as well as investigation of the impact of non-invasive screening for cirrhosis in the standard care arm
WORKSTREAM 3: NEXT STEPS AND PRELIMINARY CONCLUSIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
364
will have to await unblinding of the trial and the passage of time. However, frameworks for the analysis of
the data can now be developed to permit a full evaluation of the trial in due course.
Long-term follow-up studies
When the DMEC determines that the study can be fully unblinded we will conduct an analysis of
outcomes in each arm as planned. Specifically, we will determine the numbers and proportions of patients
in each arm who:
l were diagnosed with cirrhosis
l underwent OGD
l had their AFP level measured
l underwent ultrasonography
l were diagnosed with HCC
l the size and number of HCCs at the time of diagnosis
l underwent treatment for HCC
l were diagnosed with oesophageal varices
l started therapy for oesophageal varices, including
¢ band ligation
¢ beta-blockers
l presented with haematemesis as a result of portal hypertension
l presented with ascites
l presented with spontaneous bacterial peritonitis
l presented with encephalopathy
l presented with any other complication of cirrhosis
l underwent liver transplantation
l died from any cause
l died from a liver-related cause.
In the ELF arm, cases diagnosed with cirrhosis will be analysed to determine the true- and false-positive
rates for ELF testing by assigning a diagnosis of cirrhosis using clinical parameters, including:
l non-invasive blood tests for cirrhosis, including platelet count, aspartate aminotransferase (AST)/ALT
ratio, AST-to-platelet ratio index and fibrosis-4
l fibroelastography, including FibroScan and acoustic radiation force impulse
l imaging, including ultrasonography, CT and MRI
l the clinical judgement of the clinician when recorded.
In cases diagnosed as having cirrhosis in the standard care arm, we will attempt to determine the impact of
the use of FibroScan by comparing the number of patients diagnosed with cirrhosis and rate of diagnosis at
those centres using FibroScan with the number and rate at those centres that had no access to FibroScan.
The accuracy of ELF testing and standard care in diagnosing clinically important cirrhosis will be determined
by comparing the numbers and proportions of cases developing clinical signs of decompensated cirrhosis,
HCC, transplantation or death in each arm at the time of censoring. These rates will be compared among
those cases undergoing treatment for portal hypertension as well as among all cases per arm.
We will evaluate the impact of treatment for underlying CLDs by analysing the frequency of treatments of
disease by aetiology in each arm. Specifically, we will investigate changes in ELF values in response to therapy in
the ELF arm.
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We will investigate the correlation between ELF value at randomisation and the incidence of complications
of cirrhosis in all participants.
Feasibility of the long-term data collection: sustaining data collection from the end of
the active period of follow-up to the long-term outcomes
There are few prospective inception cohort studies of patients with CLD investigated for long-term
complications of CLD. In previous studies we have successfully monitored cohorts of patients with liver
disease using ONS and HES data. In a former study we followed those patients initially recruited for the
original ELF study of biomarkers of liver fibrosis, from which the ELF test was derived, using routine data
sources, including death certification and detailed interrogation of clinical case notes.35 For those patients
lost to follow-up by the hospital services, we contacted their general practitioner. Using these methods we
were able to obtain data on > 95% of the patients recruited into the study. Although examining the case
notes of the participants was feasible, it proved to be labour intensive, necessitating one or two
investigators spending 1–2 days extracting data at each participating site.
In a separate study of middle-aged women participating in screening for ovarian cancer [UK Collaborative
Trial of Ovarian Cancer Screening (UKCTOCS)] who had provided prior consent for follow-up using routine
data sources, we investigated the incidence of hospital admissions and deaths from liver-related conditions
using routine data sources and patients’ NHS numbers.894 In this study of 110,000 women we established
a set of International Statistical Classification of Diseases and Related Health Problems, Tenth Revision
(ICD-10)895 codes that could be used to define the incidence of liver-related outcomes and showed that
NHS numbers could be used to access these data through routinely gathered, centrally stored HES data.
The cohort of patients with CLD recruited for the ELUCIDATE trial represent the range of CLDs commonly
encountered in NHS clinical practice and were recruited at a similar stage of disease severity. From the
outset we proposed to follow the cohort to assess their long-term morbidity and mortality to obtain a
clearer picture of the course and consequences of CLD in the NHS.
It became apparent when the threshold for entry into the ELUCIDATE trial was reduced from an ELF
value of 11.0 to an ELF value of 8.4 in March 2011 that a minority of patients recruited would develop
liver-related morbidity or mortality during the course of the funded period of the study. Recognising this,
the Trial Steering Group agreed to plan for a separately funded follow-up of the ELUCIDATE cohort at 5
and 10 years. We consulted with the NHS Information Centre (now known as the Health and Social Care
Information Centre) to discuss data collection on the trial cohort at two time points, including exploration
of process, costs and anticipated outputs. We were informed that this was a provided service and accessed
by many health and research teams and that we should ensure that consent for such a follow-up was
obtained from the patients at the time of recruitment to the trial and that 6 months prior to the censoring
date a request should be submitted to the Health and Social Care Information Centre for mortality and
morbidity data on the cohort of recruited patients.
The proposed methodology is to use routine data sources including death certification, cancer registries
and HES data to gather clinical outcome data on the whole cohort. The NHS numbers of all participants
who have provided informed consent for long-term follow-up will be provided to NHS Digital (formerly
the Health and Social Care Information Centre) to obtain details of their clinical encounters with NHS
secondary care providers. In addition to HES data, cancer registries and death certification registries will be
searched for morbidity and mortality using participants’ NHS numbers.
Management
The long-term follow-up for clinical outcomes will be conducted at 5 years after the completion of the
ELUCIDATE trial. A working group led by the Chief Investigator, Professor William Rosenberg, and
comprising Professor Peter Selby, Professor Walter Gregory and Dr Julie Parkes will meet on an annual
basis to ensure a sustained effort to deliver the additional data. The full protocol will be developed and
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renewed annually and will take into account the relevant processes for application to the Health and Social
Care Information Centre at the time of censoring.
Planned analyses
Using NHS numbers, patients’ records will be surveyed for clinical outcomes associated with CLD, including
the following ICD-10 codes: K70, K73, K74, K76, I850, I859, Z944 and C220. Codes K70, K73, K74 and
K76 relate to CLD or cirrhosis. I850, I859, Z944 and C220 code for events associated with decompensation
of CLD.
Cancer registries will be interrogated for incidence of HCC and cholangiocarcinoma. The UK Liver
Transplant register will be interrogated for liver transplantations, indications for transplantation and the
outcomes of transplantation.
Anticipated outcomes from the long-term follow-up
The long-term follow-up of the ELUCIDATE cohort is of considerable importance to the full evaluation of
the trial’s impact and will permit us to:
l Determine the relationship between change in ELF value and incidence of liver-related events. These
analyses will provide the definitive assessment of the clinical effectiveness of ELF testing and will provide
the data on which the full health economic analysis of the cost-effectiveness of the use of biochemical
strategies for the early diagnosis and management of cirrhosis will be carried out.
l Determine the prognostic performance of the ELF test in predicting liver disease morbidity and liver and
all-cause mortality.
l Determine the incidence of clinical events in patients diagnosed as having cirrhosis based on the
ELF test.
l Compare the incidence of liver-related events between patients diagnosed with cirrhosis based on ELF
testing and patients diagnosed with cirrhosis based on standard clinical criteria.
Limitations
The ELUCIDATE trial is subject to several limitations. The slow start and slow initial recruitment (despite the
‘late surge’ in recruitment) mean that prolonged follow-up is now needed for us to be able to report the
primary health-related end points. Our focus was always on an ‘end-to-end’ trial (from diagnostic test to
patient outcomes and service outcomes), so this is disappointing. However, the lessons learned and the
‘process of care’ analysis will be very valuable as an exemplar trial. We run the risk that new technologies will
supervene during the follow-up period. Compliance with the trial process was satisfactory but compliance
with the interventions required by the test outcomes was lower than expected, which may also reduce the
impact on the primary outcomes.
The ELUCIDATE trial is certainly of value as an example of an exemplar trial in an important area of health
care. It should help those who are strategically planning the evaluation of new biomarkers to judge the
feasibility of timely delivery of end-to-end trials and judge the pace of alternative strategies, which we
discuss in Chapter 24.
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Chapter 23 Patient and public perspectives
The multiple possible roles for biomarkers in patient management are likely to influence patient experiencein many different ways. Monitoring of disease progression in CLD has the potential to cause anxiety, but
also to stimulate possible lifestyle change by bringing home the reality of liver damage much earlier. Little
research has been carried out into the psychosocial aspects of biomarkers, and the possible benefits and
harms of their use need to be examined explicitly in future studies.
This chapter is in two parts. The first part presents the results of the research exit interviews with patient
participants in the RCT reported in the ELUCIDATE trial workstream (workstream 3). The second part
pulls together this information with the contributions made by PPI representatives consulted about the
methodology work conducted in the methodology workstream (workstream 1) and reported in Chapter 9.
Part 1: patients’ experiences in the ELUCIDATE trial – a qualitative study
about patient experiences of taking part in a trial to test biological fluid
biomarkers for liver disease
This qualitative substudy of the ELUCIDATE trial aimed to explore the experiences and perspectives of
patients who were enrolled in the ELUCIDATE trial, in order to provide additional insight about using the
ELF test as part of patient care.
The starting point for the work is that patients may have very different experiences of having their disease
monitored by the ELF test or similar tests. For some it may be reassuring to know that they are being tested
regularly and may allow them to feel in control through knowing what is going on with their health.322
Others may believe that their symptoms are not indicative of cancer or may be anxious about their condition
potentially getting worse, even though this might never happen. If patients are anxious they might
consequently utilise a number of coping strategies to cope with the associated distress.322,896 Anxious
patients might be hypervigilant with regard to potential symptoms, engage in information seeking and/or
develop avoidant attitudes and behaviours.896,897
Some patients might not adhere to monitoring because they fear its iatrogenic effects whereas older patients
might believe that they are less likely to develop neoplasm because of their more advanced age or overall
perceived lower susceptibility to cancer.897–899 Systemic factors also importantly determine surveillance
experiences. Health information given to patients, the role of health-care professionals and previous
experiences with cancer importantly determine the acceptance and understanding of monitoring practices.898,900
Patients’ understanding of clinical biomarkers and experiences of testing, their acceptability to the patients,
their perceived utility and patient experiences and motivations for testing are, therefore, important factors
of translation of biomarkers into clinical practice. By exploring patients’ experiences of being monitored by
ELF test, this study will assess how acceptable the testing is to patients and so enable better support to be
provided to liver patients undergoing monitoring in the future.
Method
We planned to approach 13 patients to take part in an in-depth semistructured interview that was guided
by a semistructured topic guide.
Sites
It was planned to recruit participants from three sites, chosen to represent different sizes of institution and
different types of catchment area: Leeds Teaching Hospitals NHS Trust, Bradford Teaching Hospitals NHS
Foundation Trust and University College Hospitals NHS Trust. However, because of delays in obtaining
permissions, it was possible to conduct the research at only two sites, Leeds and Bradford.
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Sample
Patients were sampled purposively with the aim of recruiting eight participants from the standard care arm
and eight participants from the intervention arm of the ELUCIDATE trial; other factors such as age and sex
were considered. Participants had to be able to comply with the requirements of the study protocol and be
able to provide written, informed consent. Patients were excluded if they were unable to comply with the
requirements of the protocol or could not provide informed consent.
Recruitment
Eligible patients were first approached by a research nurse who was part of the hepatology team. The
research nurse provided each patient with a patient information pack containing an information sheet, an
opt-out form, a demographic form and a Freepost envelope. The research nurse asked for verbal consent
to pass the patient’s contact details to the researchers from the University of Leeds who would conduct
the interviews. All patients were given 7 days from the day that they were given the patient information
pack to consider taking part. If after considering the information they did not want to participate, they
could choose to opt out by completing the opt-out form and returning it in the Freepost envelope; after
this no further contact with the patient was made. The use of an opt-out approach for recruitment was
chosen as this is something that most patients find acceptable (particularly in this population of trial
participants) and can minimise response bias.901
Interviews
After 7 days the researchers from the University of Leeds contacted patients to confirm that they were still
interested and to schedule an interview. Patients could either agree to the interview or request more time
to consider the information and contact could be made at a later date. The interviews were 30–45 minutes
in length and were carried out over the telephone or face-to-face in a location that was convenient for
the patient. Several studies have provided evidence that there are minimal differences in the results of
semistructured interviews that are conducted over the telephone or face-to-face.902,903 Interviews were
audio recorded with the consent of patients.
The interviews were guided by a semistructured topic guide that included questions about the patients’
understanding and experience of taking part in the ELUCIDATE trial and of the ELF test. Participants were
also asked whether or not they would recommend this type of study to patients in the future.
Analysis
The interviews were professionally transcribed verbatim and managed using NVivo Version 10 (QSR
International, Warrington, UK). The data were analysed inductively, with no prior hypotheses, using
thematic analysis. Analysis was undertaken by two researchers who independently coded for emerging
themes and then compared themes and codes. The analysis was further refined by using a constant
comparison and contrastive approach and looking for negative cases in order to examine for similarities
and differences within and between patients in different centres and within and between trial arms.
Results
Thirteen patients were contacted by the research nurses at the two sites. Of these, one patient opted out
of the study, one was too ill to take part and two could not be contacted at their existing address. Nine
interviews were completed, three with participants from the standard care arm and six with participants
from the intervention arm.
Participant characteristics
All of the patients were of a similar ethnic origin. The mean age of participants was 63.4 years, with a
range of 56–75 years. Six of the participants were female and three were male. Participants had the
following conditions:
l haemochromatosis (n = 1)
l fatty liver (n = 1)
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l non-alcoholic fatty liver disease (n = 1)
l methotrexate-related liver fibrosis (n = 1)
l hepatitis C (n = 2)
l autoimmune hepatitis (n = 1)
l primary biliary cirrhosis (n = 1)
l not stated (n = 1).
Participants demonstrated a range of educational abilities:
l secondary school (n = 3)
l college/diploma (n = 3)
l university (n = 3).
Four participants were retired, three were in a professional role, one was unable to work because of ill
health and one chose not to state their employment status (Table 148).
Key themes
The themes that were found tended to be related to the questions in the topic guide:
l participants’ experience and understanding of the ELUCIDATE trial
l participants’ experience and understanding of the ELF test
l support and information offered to participants.
Generally, the participants interviewed had a good experience and found the ELF test acceptable
compared with current available alternatives. An alternative view was presented by a patient who had
been told that she was at risk of becoming cirrhotic. The use of language when communicating risk of
cirrhosis to patients requires attention.
Participants’ experience and understanding of the ELUCIDATE trial
Participants’ understanding of the ELUCIDATE trial was generally clear. They appreciated the fact that the
ELF test would indicate changes from fibrosis to cirrhosis:
my understanding is that, as biopsies are quite invasive, I found it quite invasive, and the trials are
looking at different markers in the blood to see whether they could find the beginning of the cirrhosis
so that you know, . . . people could start the treatment maybe sooner.
ELU03
However, some people struggled to remember what the trial entailed:
Yeah it was a bit long ago I can’t really remember.
ELU06
This probably reflected the length of time between taking part in the study and the qualitative exit
interview. Most participants who took part in the trial appeared to do so for altruistic reasons, and partly
to benefit themselves through being monitored and assessed more regularly:
as far as I’m concerned if you can help people by being a guinea pig it’s a common sense, and it
might help me as well as other people you know.
ELU02
it gave me a little bit of confidence that I was involved, and people were looking out for what was
going on with my liver so I was quite happy to do that.
ELU03
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TABLE 148 ELUCIDATE trial patient characteristics
Patient number Site Sex Liver condition Trial arm Result Education Occupation Ethnic origin Religion
ELU01 1 M Fatty liver Standard care No cirrhosis University degree Professional White British Christian
ELU02 1 M Haemochromatosis Standard care No cirrhosis University degree Retired White British Christian
ELU03 1 F Methotrexate
related
Standard care No cirrhosis College/diploma Retired White British Christian
ELU04 1 M Not stated ELF No cirrhosis Secondary school Not stated White British Christian
ELU05 1 F Non-alcoholic fatty
liver disease
ELF No cirrhosis University degree Professional White British None
ELU06 2 F Hepatitis C ELF No cirrhosis Secondary school Professional White British Prefer not
to disclose
ELU07 2 F Autoimmune
hepatitis
ELF ELF test indicated cirrhosis;
followed cirrhosis pathway
College/diploma Retired White Christian
ELU08 2 F Hepatitis C
genotype 1
ELF ELF test indicated cirrhosis,
which was later found not
to be the case
College/diploma Retired White British Buddhist
ELU09 2 F Primary billiary
cirrhosis
ELF No cirrhosis Secondary school Unable to work
because of ill health
White British None
F, female; M, male.
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a closer eye would be kept on that when I had the specialist scans looking at the physical nature of
the liver.
ELU05
One participant did refer to the fact that her treatment was expensive and so she wanted to give
something back for that reason:
I just felt I had a very expensive treatment and it was the least I could do.
ELU06
The ELUCIDATE trial compared participants in two trial arms, one in which they were monitored with the
ELF test and one in which they received routine expert care. Some participants were clear about the fact
that there were two arms in the trial:
My understanding was some people had the ELF test and some people did not I think they were
looking to compare the two, and the outcomes.
ELU01
However, others were less clear:
No, I was just told they were doing this trial, you know, obviously to see, to try and get some way of
finding out if people were going to develop any other problems later on.
ELU07
Participants struggled to recall the difference between the arms because of length of time between the
interviews and taking part in the trial. This was also because most perceived no negative impact and they
were used to having blood tests as part of routine care. However, participants’ expectations of the study
were quite high as the opportunity to have a less invasive test was appealing:
so obviously so yeah anything rather than going through a biopsy from my point of view, just having
blood samples taken would be a lot better, so I said fine I’d go for that.
ELU01
I found the biopsy quite distressing, and apparently I’ve got really tough muscles! And it took a lot of
getting into my muscle, it was awful, so I was quite happy with the bloods and weights and things.
ELU03
After considering the information most participants thought that taking part would be less of a problem
than routine care:
I didn’t think there would be any detrimental effects, not any.
ELU06
Participants weighed up the potential risks and benefits and judged the ELUCIDATE trial to be of low risk
and low effort, as demonstrated by the following quotation:
I think it was a positive thing really it certainly didn’t make me worry about it but it certainly gave me
a bit more depth of understanding of what was going on I think really.
ELU01
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The participants interviewed in this study were satisfied with the fact that they would be monitored
more regularly:
No, in fact, I mean to some degree it helped me because it had to be done every 3 months, and X used
to make sure I got an appointment. Some of my appointments, I would have waited for far longer.
ELU07
The main negative issues were reported in terms of having difficulty parking at the research unit and the
cost of travelling in their own vehicles:
The only negative experience is travelling from X to [name of hospital site] and back you know and
parking there.
ELU02
Participants’ experience and understanding of the Enhanced Liver Fibrosis test
Participants were not told the results of the ELF test unless there was a change in their condition:
No I did ask and he said normally, unless there was a major problem, where you needed treatment
then they wouldn’t get back to you on your blood results.
ELU03
In most cases, this meant that no additional information was provided to participants. This was an acceptable
situation for seven participants who were interviewed. With any diagnostic and monitoring test some patients
will show a false-positive or a false-negative result. We interviewed a further participant, who said that:
I was told that I was cirrhotic . . . But I wasn’t. And that worried me considerably, being left, you
know, just being told I was . . . cirrhotic, and just being told that, with no follow-up, if you see what
I mean. So I had to do my own follow-up with my own doctor.
ELU08
The professional team was able to use other information to confirm that this participant was not cirrhotic.
However, it had caused the participant to be concerned. They were reassured when other tests indicated
that they were not cirrhotic:
The nurse told me, ‘Oh well, you know, it’s unlikely because, you know, your blood tests are fine’, but
when you’re told something like that, it’s very shocking.
ELU08
This participant would have liked to have spoken to a doctor or been offered a further scan. Some
discussion of why the professionals were certain that she did not have cirrhosis could have helped:
So, I’m not really sure, I think I would have liked to have talked to a doctor and then they would have
said, ‘Look, this really is rubbish’, you know, ‘You’re absolutely fine’.
ELU08
In this case, the participant sought additional support from a patient forum. Being familiar with the
internet and potential support options seemed to be of benefit for this participant, but such options might
not readily be accessed by those with a lower level of health literacy:
Well yes, I mean, I was on a forum as well and we shared a lot of information on the forum about
treatments that we were having at various hospitals through the country, so it was quite interesting, really.
ELU08
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Seven of the nine participants interviewed did not have changes in their test results so were unable to
comment on the question concerned with changes made in relation to test results. One of the two
participants who had received above-threshold ELF test results reported that they were now following the
cirrhosis pathway, but the other said:
Well, I’m not sure, [I’d make a change] especially as the test got me wrong.
ELU08
Again, attention should be paid to the way in which information about monitoring tests is communicated
to patients; this includes the description of the test and what happens when a result is not correct. The
issue of a test result indicating a diagnosis was also raised by this participant, who said:
Yeah I’d been seeing Dr X and he explained . . . [they could] possibly look at some alternatives to give
me a good diagnosis, one of the things would have been a liver biopsy, which . . . I didn’t particularly
fancy, and then he explained that they were then looking at this trial, and would be looking at
alternative ways of helping make diagnoses and things and asked me if I’d be interested.
ELU05
Support and information received as part of the ELUCIDATE trial
Overall, participants had positive experiences whilst being enrolled on the ELUCIDATE trial and felt that the
study was explained well:
No no not at all it was explained very well in the first place . . . it was very much, full detail was given
and you know explanation all the way through as to what was happening and the whys and the
wherefores so yeah it was good, yeah.
ELU01
Participants reported having a high level of trust in the professional team caring for them and carrying out
the research. They appreciated that most of the study tasks and paperwork were completed alongside
routine care:
That was usually what happened, yes, occasionally it didn’t work but usually it did, and we, we linked
the two together so, I went for the appointment and did the study at the same time.
ELU01
Completing questionnaires and associated forms was found to be acceptable:
Well, it was mainly just filling out a form, so yes, it was absolutely fine.
ELU08
However, one participant had noted that the order of the questions had been changed and commented:
I personally found it quite tedious, filling them in every time but I know you needed the information.
ELU05
Participants did not remember being signposted to sources of information about research per se. Overall,
those who took part in the study felt that it was important ‘that someone is the guinea pig’ and felt that
they ‘wanted to give something back’ and did not expect any further reward, for example:
They did also offer to pay my expenses which I said no, I wasn’t bothered about that.
ELU03
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Participants talked about the fact that the research nurses went above and beyond to help and support
them. Most participants who took part in these interviews would recommend taking part in this type of
research study. They wanted to be able to give something back as part of a reciprocal process. In general,
they fitted the profile of those who usually agree to take part in research studies, including having a high
level of trust in the professional team and wanting to give something back.
Participants’ perspectives of taking part in the ELUCIDATE trial: discussion points
Participants may have had very different experiences in the ELUCIDATE trial depending on a number of
factors. The specific arm of the trial that participants were allocated to and whether or not they were told
that they were at elevated risk of cirrhosis would have influenced their experience. Additional influencing
factors may have been dependent on their personal circumstances, such as the condition they had,
whether or not their employer would accommodate regular hospital appointments and the costs of taking
part, including the costs of absence from work, travel to hospital sites and parking. Withdrawals from the
trial may indicate that ongoing monitoring is not acceptable or convenient for some patients.
The trial information provided to participants as part of the ELUCIDATE trial was perceived to be sufficient,
with few gaps noted, although some direction to professional support or peer support should be considered
in future trials. The issue of information needing to be tailored to individuals makes this difficult to get
right in every case. The research nurses at both of these sites (Leeds and Bradford) provided support to
participants that was found to be personal and effective.
The process of having a blood test in addition to existing tests and in place of more invasive tests was
found to be acceptable to participants. This was reflected in the experiences of patients who were not
indicated to be at increased risk of cirrhosis according to the ELF test. One patient we spoke to had a
different experience, having been told that she was cirrhotic based on a test result, which was resolved in
the context of other information. Participants who were interviewed had a high level of trust in professionals
and were comfortable in NHS environments. There were no reports here of participants who had problems
with medical tests or who had had previous negative experiences, although the sample was limited.
There was only one example of a participant with what was perceived as an inaccurate result, so it would
be good to know how well this reflected other ‘false-positive’ experiences in the trial. This participant
experienced a level of shock and worry that should be considered further in terms of how this information
is presented to patients and the type of support that could be offered (this is supported by PPI work).
When implementing this test in clinical practice, some attention needs to be paid to how the risk of cirrhosis
is communicated to patients. A monitoring test is not necessarily the basis of a diagnosis; however, the
language used for diagnostic and monitoring tests is often used interchangeably and can be confusing to
both professionals and patients.
Limitations
The sample here was small and it is possible that other sites may have had different experiences. Most
participants reported positive experiences and there may have been some bias in the selection and availability
of participants for interview: none of those interviewed had undergone additional invasive tests in light of
their ELF test result (e.g. endoscopy) and nor were those who dropped out of the study represented. This
means that the generally benign nature of participants’ experiences may not fully reflect any potential for
harm, as relevant accounts may have been missed. Additional information could have been collected if there
had been time to develop the insight from this qualitative study into a questionnaire for a larger sample of
study participants, to confirm these experiences.
Conclusion
As the alternative to a blood test is a more invasive biopsy, the ELF test proves to be an acceptable method
of assessment. However, caution needs to be applied and some scrutiny given over how test results are
communicated to patients, as part of a considered implementation strategy for any biomarker proven to
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be effective in a trial. Patients have the highest expectations that ethical methods are applied at all stages.
Lessons from PSA testing demonstrate a need to fully understand all of the factors that affect test
interpretation prior to implementation in clinical practice.
Part 2: drawing threads together
Part 1 in this chapter reports on a piece of qualitative research that specifically addressed participation in
the ELUCIDATE trial. As will be recalled, more general issues about biomarker evaluation research were
discussed with patient and public representatives in a consultation exercise, reported in Chapter 9.
Although fully recognising that these are two different types of activity, each generating very salient points
of their own, a number of common themes can also be identified.
The patient interviews clearly indicate that adding ELF testing to an ongoing monitoring regime, as was
performed in the intervention arm of the ELUCIDATE trial, was acceptable to participants and fitted well
with routine care in this group of at-risk patients. Reassurance of continuing low scores (below the cut-off
point) could be obtained by these means.
Individuals who were test/diagnosis positive were obviously in a different position. The term used in the trial
protocol for participants testing positive in the intervention arm (and, hence, used by staff when communicating
with participants) was ‘diagnosis’. A test score above the specified cut-off point triggered the initiation of a
cirrhosis management protocol, which included further tests. The interviewee who had experienced this care
pathway was told by staff that the subsequent tests had not supported this ‘diagnosis’, that is, that the ELF
result had been a false-positive result, with upsetting as well as confusing consequences.
No quantitative argument is being made here. Clearly, interview numbers were small and many factors
will have influenced who was available and willing to be interviewed. However, almost two-thirds of trial
participants in the intervention arm were found to be test positive at some stage, and the interviewee’s
experience does chime with concerns about false alarms expressed by members during the PPI consultation
in workstream 1.
Clinicians’ desire not to miss preventable disease is very powerful, but the possibility of causing harm is real
and must be considered. National screening programmes, for example, have been criticised for ignoring
negative effects and a more balanced presentation of the pros and cons is now advocated.
The pathway from the introduction of a new monitoring strategy through to patient benefit is clearly
complicated, but the health economic approach (see Chapter 8) lays out the fundamental trade-off very
clearly: does the gain in ‘utility’ (quality of life multiplied by cost) achieved by successfully treating more
cases outweigh the loss in utility incurred by unnecessarily treating more non-cases? Patients and family
members can readily recognise the trade-off being made here and can relate it to their own circumstances
and experience. Members of the PPI consultation group could also see that the numbers (e.g. test scores) on
which decisions were based reflected professionals’ judgements and preferences as well as scientific ‘facts’.
Thinking first about judgements and preferences, members of the PPI consultation group could readily
appreciate that a traditional clinical approach tends to focus on the benefits of successfully treating those
patients who can benefit, and has relatively little to say about ‘the price’ – in every sense of the word –
being paid for that. PPI members appreciated the application of a ‘precautionary principle’ to detecting the
recurrence or progression of disease – assuming of course that early information is preventative – but they
also emphasised the possibilities for harm. It could be additionally pointed out here (echoing a point
previously made in Chapter 5) that the case for paying more attention to negative consequences when
designing monitoring strategies is even stronger than for screening because monitoring offers multiple
opportunities for harm.
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The established health economic argument (see Chapter 8) here is that an inefficient use of resources will
displace more efficient use of those same resources. This argument is more customarily thought of in terms
of more and less effective treatments, but it also applies to more and less efficient use of follow-on testing
resources. An additional point can also be made: if the eligibility criteria for enhanced monitoring are
made too broad, then people at high risk of developing (or already having) the condition of interest will be
on the same waiting lists for follow-on tests as people at much lower risk. PPI representatives familiar with
an overburdened NHS, its resource constraints and waiting lists had no difficulty appreciating this point
and wanted a more transparent and considered approach to be adopted. Simply widening the definition
of who is eligible for enhanced care could be seen as seldom the best approach, even if the enhanced
regime was acceptable and relatively benign from an individual patient’s perspective.
As for ‘scientific facts’, the existence of sizeable evidence gaps in the biomarker pipeline came as quite a
surprise to members of the PPI consultation group. They were aware that very substantial sums continue to
be spent worldwide on biomarker research and assumed that all components of the ACCE pipeline would
already be of the highest methodological quality. When they realised that the quality of evidence sufficient to
justify the use of a given test strategy in the NHS was not in fact uniformly high, they were rather shocked.
A number of other points with implications for patients are worth spelling out here, even though they
were not discussed in detail with patients themselves. In the intervention arm of the trial, test-positive
patients were managed as though they had been diagnosed with cirrhosis. The first management change
was to implement more intensive monitoring, some of which entailed quite unpleasant procedures, for
example endoscopy. One of the interviewed patients commented (see Part 1: patients’ experiences in the
ELUCIDATE trial – a qualitative study about patient experiences of taking part in a trial to test biological
fluid biomarkers for liver disease, Results) that being monitored with a blood test like ELF was an attractive
alternative to having a biopsy, but the alternatives are actually more complicated than that, as the trial
results (see Chapter 22) show. Many more endoscopies were conducted in the intervention arm, but there
was no reduction in the biopsy rate. Inevitably, such management is also more costly.
Patient benefit cannot, of course, result from extra monitoring per se, but only from a timely response to
information generated by the more frequent/intensive testing schedule. Process outcomes provide an early
signal that changes to management are being triggered by test results, but it is important to maintain a
distinction between process outcomes that reflect extra monitoring and process outcomes that reflect the
initiation of treatment.
The clinical effectiveness of treatment at the particular stage of disease identified by the initial test (and
any confirmatory tests) must next be evaluated, and here a robust randomised design is essential. Correctly
identified early cases (as well, of course, as early identified false-positive results) may not be better off if
early treatment does not lead to better outcomes than late treatment – and all will have spent more time
under investigation with associated anxiety.
Here we come back to the crucial question asked earlier: does the gain in utility (quality of life times
cost) achieved by successfully treating more cases outweigh the loss in utility incurred by unnecessarily
treating more non-cases? A single RCT can answer this question in relation to a particular combination
of measure, cut-off point, monitoring schedule, management protocols and patient population, but
experience suggests that the choice of many of these study attributes is not evidence based. A research
pipeline that operates in this way is inevitably inefficient, as it places no burden on investigators to justify
many of their choices, still less to make some effort to optimise the combination selected. The implications
for trial participants as well as for patients more generally are substantial.
Given the sums of money spent on biomarker research to date, and the lack of demonstrable patient
benefit, some kind of change is clearly desirable. Patients and the public purse need all ACCE ingredients
to be of the highest quality, not just those currently favoured by the research pipeline as it currently
operates. This chapter concludes with an overview of the case for doing things better.
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Guidelines to improve research quality
Guidelines for researchers about how best to conduct and report different kinds of biomarker studies have
been available for some time. The REMARK guidelines,367 for example, offer reporting recommendations
for tumour marker prognostic studies, and the STARD guideleines368 do a similar job for diagnostic
accuracy studies. More recently, the MONITOR904 group have proposed a four-phase model for biomarker
monitoring trials,904 and a position statement drawing together all of the main good practice guidelines
has been issued by the European Group on Tumor Markers (EGTM).342,904
In a welcome convergence, the four stages identified in the EGTM position statement, aimed at an
oncology readership, are similar to the stages identified by the MONITOR group for triallists and by the test
evaluation working group of the EFLM.338 The first three stages all bear a close resemblance to the ACCE
framework that was drawn on for the work reported in Chapter 9, but the last stage in the EGTM
statement refers to regulatory approval, the last stage in the trial design proposal refers to audit and
economic impact (including quality of life, assessed using established methods) and the last stage in the
EFLM document refers to ‘the impact of testing on the patient, the organisation and society’. In 2015,
IFCC took the emphasis on patients one step further in a report entitled ‘Current evidence and future
perspectives on the effective practice of patient-centred laboratory medicine’.905 The report argued that
laboratory medicine specialists needed to work with multidisciplinary groups seeking to ‘optimise clinical
outcomes and patient experiences in an efficient and cost-effective way’.
Gaps in the evidence
From a standard methodological perspective, the research pipeline on non-invasive liver markers can be
seen to have gaps in it, but in more heavily researched areas, the same is also true.345 Some gaps remain in
territory that is well charted in other respects. In respect of a basic analytical validity question, for example,
a study showing that a prompt repeat of PSA testing could reduce the number of unnecessary biopsies in
men being screened for prostate cancer was published only in 2016.906 Further down the pipeline, Bessen
et al.907 modelled the cost utility of different mammographic follow-up schedules and showed that they
could be tailored according to risk of recurrence. Assumptions about the effects on patients of receiving
reassuring test results may also not stand up to scrutiny. Rolfe and Burton908 found little evidence of
psychological benefit for patients in relation to diagnostic tests that had essentially been ordered for
reassurance purposes, although there may of course be benefits for the patients’ doctors.909
There are also areas of relatively uncharted research territory. Further targeted methodological work could
help to fill important evidence gaps, for example on the interdependency of patient mix, cut-off points and
schedules in maximising overall patient benefit. The implications for both modelling and care of variation
between patients in, for example, progression rates have been little studied in a monitoring context
(compared with the screening context), and nor have the implications for research and service provision of
omitting diagnostic testing from a monitoring care pathway. Traditionally, diagnosis is seen as informing
treatment options, depending on the cause identified, and monitoring is seen as informing the timing of
treatment, but these boundaries are blurring and no longer cover all possibilities. One important piece of
work arising out of the present study will be the drawing together of the models described in Chapter 1,
and another will be the further study of patient preferences for monitoring schedules with different
properties and different implications for preventative behaviour and lifestyle change.
The work we presented to our PPI consultation group raises an important issue about the role of PPI in
future ‘methodological’ studies. At the outset of this programme of work we were hesitant about trying to
communicate ‘methodological’ knowledge to lay members and some colleagues took the view that it
could not meaningfully be done. However, our meeting showed that the public have a more sophisticated
palate, and a greater interest in this topic, than researchers have traditionally given them credit for.
Participants demonstrated a genuine interest in these issues and asked pertinent questions, but we had
scheduled to meet with the group only once. With hindsight, a series of four to five meetings with the
group to facilitate a more wide-reaching discussion about the implications of the work and possible ways
forward would have been more useful, both to them and to us.
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Choosing wisely
In 2012 the American Board of Internal Medicine Foundation launched a campaign called Choosing
Wisely. This campaign aims to reduce the number of unnecessary tests and procedures by promoting
effective conversations between patients and their doctors.910 In 2015, the Academy of Medical Royal
Colleges publicised their initiative to bring the campaign to the UK.911 The emphasis in both campaigns is
on avoiding unnecessary treatments, but unnecessary tests and assessments are also addressed. In the UK
campaign, doctors are encouraged to provide patients with resources to understand potential benefits and
harms. They are encouraged to ask questions about the need for the test or procedure and about the
alternative options. High-quality research evidence is clearly needed if clinicians are to be able to answer
questions of this kind.
Personalised medicine, innovation and the funding of research
At the end of Chapter 9, the point was made that the acknowledged role for patient choice in treatment
decisions also needs to be thought through in relation to testing decisions. For example, the choice of
cut-off point for ELF testing – the case management threshold – was lowered in the ELUCIDATE trial from
12.5 to 9.5, primarily on the basis of judgements about which risk categories were likely to carry weight
with clinicians. By increasing the numbers of test positives in this way, fewer people with incipient cirrhosis
will have been missed, but inevitably this will have been accompanied by an increase in the number of
people switched to an intensive monitoring regime unnecessarily. It seems likely that many patients would
arrive at a different trade-off here, not least because of the need to take probabilities of benefits and
harms into account as well as their potential magnitude.
Bossuyt and Parvin912 draw a similar conclusion in their paper about the evaluation of biomarkers used to
guide treatment decisions – a not dissimilar function in principle from the monitoring markers under
scrutiny in this report. After describing studies in which cancer patients were asked about the size of
treatment benefit they would need to expect for adjuvant chemotherapy to be worthwhile, these authors
concluded that, ‘for some the required gain may be fairly large, while for others extending survival is
extremely important, and their threshold for accepting treatment is close to zero’. Bossuyt and Parvin912
went on to say, ‘This is definitely an area for personalized medicine: not in the abundant use of next-
generation sequencing, but in the recognition that personal values and trade-offs differ.’ Although direct
research evidence is not available, the patient perspectives described in this report make it likely that very
similar conclusions could be drawn about the use of monitoring tests for disease progression.
As Bossuyt and Parvin912 note, in respect of test evaluation metrics, ‘The classical clinical performance
measures, such as clinical sensitivity and specificity, can only be used in rare circumstances’. It can be
argued, however, that research funding is much more likely to be available for studies of the sensitivity and
specificity of innovative new markers than it is to fill gaps in our understanding of the real-world performance
of existing ones, and funding for trials – even quite speculative ones – is much more widely available than
funding for well-designed, descriptive longitudinal studies, or studies of patient perspectives on the quality
and role of tests used in their care. Although the need to fill gaps in the evidence base for using biomarkers
in patient care is scientifically and professionally convincing, as long as the current incentive structure for
researchers remains, little is likely to change and the potential for patient benefit is unlikely to be realised.
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Chapter 24 Programme conclusions and the
framework for biomarker evaluation
General conclusions
In Chapters 9, 15 and 23 we have summarised and discussed the principal conclusions from each of the
workstreams in methodology (workstream 1), clinical translation (workstream 2) and the ELUCIDATE trial
(workstream 3).
Taken together they represent a substantial overview of the state of the art and the challenges in the
introduction of known biomarkers into clinical practice and health-care systems. We have shared the results
and the experience of this investigation with patients at the application, study design, study delivery, analysis
and evaluation stages. In each workstream we have confirmed the importance of a rigorous and systematic
approach to biomarker evaluation and made recommendations to help future work in this area. The
incomplete and inadequate nature of some of the methodological approaches taken in this field was clearly
identified in workstream 1; similar limitations of approaches in the laboratory and in sample preparation and
study design in many cases were described in workstream 2. The challenges, both conceptual, logistic and
organisational, of delivering ‘end-to-end’ clinical trials such as the ELUCIDATE trial to determine the place of
new biomarkers in clinical practice were shown in workstream 3.
The investigators conclude that there are a number of important, generic and recurring themes in what we
have learned in these studies:
l Multidisciplinary research teams are essential to establish individual and portfolios of biomarker
evaluation projects. All of the parts of the pipeline must be critically evaluated to a high standard using
standardised approaches if the field is to move forward adequately.
l The organisational and logistic challenges have to be addressed by well-trained teams with adequate
resources to operate to the standards that are required.
l Innovation in study design and research methodology is essential. ‘End-to-end’ RCTs will remain the gold
standard for evaluating the place of a new biomarker or panel of biomarkers in clinical practice. Such
study designs must be carefully and comprehensively grounded in appropriate prior knowledge of the
performance of the test and the evaluation of the test in appropriate large current clinical populations.
Statistical methods for the design of trials and the calculation of power have been developed in the
course of this programme. To be useful at the beginning of a RCT, researchers require access to
high-quality population-based cohorts of well-characterised patients with the disease under study,
whose data reflect the current biological basis of disease (such as causative factors) and the current
treatment environment.
l New study designs and logistic solutions have to be deployed to streamline the biomarker pipeline.
The methodology workstream (workstream 1) highlights these issues for monitoring studies.
l For clinical translation (workstream 2), studies of analytical and clinical validity are crucial parts of the
evaluation of tests but are beset by the challenge of having large numbers of good-quality samples
with excellent annotated clinical data that are representative of the key clinical populations, are current
and have adequate follow-up to answer long-term questions. Samples have to be carefully curated but
managed, used, sustained and understood by specialised multidisciplinary research and innovation
teams. Workstream 2 demonstrates this very clearly. Broadly, it took us 5 years to design and deliver
the samples and clinical data sets for renal disease; it took us 5 months to review all of the literature on
available biomarkers in RCC, find and validate the assays and report the findings in this report. Future
strategies will require access to pre-existing sets of data and samples. We will curate these and sustain
and use them as a resource for academic and commercial collaborators. This will be facilitated by the
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NIHR DEC. This should mean more ‘5-month’ study turnaround times. Even this would be at risk if our
specialised multidisciplinary team, with nationwide clinical contacts, lost its energy or focus. Establishing
and sustaining this approach in other topics will be challenging. Nevertheless, we have shown that with
the appropriate infrastructure and planning, the analytical and clinical validity of tests may be evaluated
promptly for the purposes for which they are intended – allowing robust initial evaluation of tests,
which can then be evaluated for their impact on health-care outcomes using RCTs or other strategies.
l The ELUCIDATE trial illustrates what can be achieved through the commitment and engagement of
investigators in the NHS. It was slow in terms of set-up and initial recruitment. More centres were
opened and existing centres often responded and recruitment flourished to bring in a large proportion
of patients in the final months, even under threat of closure. To some extent the lessons are, therefore,
conventional – work harder and faster, open more centres, drive the process by motivating the centres –
and large RCTs get delivered.
l We think, however, that the learning points from the ELUCIDATE trial are less conventional and the
response needs to be more radical. The ‘end-to-end’ nature of this RCT, from the initial use of a
biomarker to the consequent change in clinical behaviour to yield the desired changes in the process
of care, through to long-term impacts on survival and other major clinical events, although desirable,
is rarely going to be deliverable without radical changes in how we all work. The ELUCIDATE trial
suffered from ‘conventional’ RCT challenges of scale, recruitment and set-up and the responses are
listed above. It also suffered from changes that occurred in the disease population (more alcohol-
related liver disease), changes in the diagnostic options (the availability of FibroScan in more centres)
and changes in the therapeutic options (the availability of antiviral drugs for hepatitis). These changes
happened between the studies of cohorts and during the conduct of the trial. They will continue
during the planned long-term follow-up using NHS informatics in ONS and HES data. Therefore, the
value of the trial to the NHS is restricted by its scale, duration and, of course, cost.
l Our solution for the ELUCIDATE trial was rapid recruitment in the later phases; innovative modelling to
support design and power calculations; analysis of process of care end points that reflect the impact
of biomarker monitoring on clinical behaviour and practice; and longer-term follow-up using health
informatics. This approach needs to be prospectively developed for future trials. Modern health
informatics can provide large, current, relevant clinical data sets to complete the study design and early
economic modelling quickly in the appropriate clinical populations. This means that trials may then be
conducted in reasonably stable epidemiological, diagnostic and therapeutic environments. These will
have to come from patient electronic records using carefully developed technical, confidentiality and
governance routes, which are in the process of being put in place. The RCTs may then focus on
changing clinical behaviour and the process of care. Long-term follow-up will come from health
informatics (as in the ELUCIDATE trial) but will use Electronic Patient Record-based sources rather than
the derived databases of ONS/HES origins.
l Patient engagement has been constructive in the course of this programme and should remain a central
feature of this field, as with all fields of biomedical and health research. We drew extensively on patient
input not only in evaluating the methodological findings of workstream 1 but also in the design, delivery
and evaluation of the preliminary results of workstream 3. Patients were involved in the clinical
translation workstream in study design and advised at all stages of the delivery of the cohorts and have
commented on the analysis and reporting of the three workstreams.
There is increasing concern about the volume of biomedical research undertaken that is irreproducible,
with systematic reviews estimating that between 50% and 89% of preclinical research contains one or
more errors, flaws, inadequacies or omissions that prevent the replication of results.732 With growing
financial pressures on researchers in the UK and elsewhere, research funders and publishers have a
responsibility to ensure that the time and public money spent on research are spent wisely. This programme
has highlighted the need for appropriate validation and verification of biomarker assays and diagnostic tests
prior to conducting research studies (see also Chapter 13). The level of validation/verification should be
appropriate to the stage of test development and its intended clinical use. If a test is used to inform clinical
decision-making within a trial, or provides an end point or outcome measure within an interventional trial, it
is essential that it is validated fully in a clinical laboratory as early as possible during its development. When a
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test or assay is to be used purely in an observational ‘research use only’ context, then less rigorous assay
validation, as described in Chapter 13, may be sufficient. However, appropriate assay validation should be an
essential requirement for funding and publication of biomarker studies.
This programme has identified new methodological approaches and new biomarkers that justify evaluation
of clinical utility in kidney disease and shown that the deployment of the ELF test will alter clinical practice
in ways that are likely to be associated with improved outcomes. It is disappointing that we do not have
the final evidence of the impact of the ELF test on the important outcomes of liver disease, including
cancer, haemorrhage and survival.
The experience of this programme has contributed to two broad aspects of a framework for the introduction
of biomarkers into health-care systems:
1. a framework for introducing biomarkers into clinical practice through the NIHR DEC
2. a framework for the design and conduct of clinical trials for biomarker evaluation based on innovative study
design and modern health informatics, and early engagement with health economics, discussed above.
The samples and clinical data accumulated in this programme will be an important asset for future studies,
both for the programme investigators and collaborating centres who have delivered the samples and the
data and guided the research and for new collaborations in academia and industry through the NIHR DEC
and other routes.
The National Institute for Health Research Diagnostic Evidence
Co-operative at Leeds
The IVD industry is the second largest UK medical technology sector by employment and the fifth largest
by turnover, so is of fundamental importance to the UK economy and a huge area for growth, with a
17% increase between 2010 and 2011. The Leeds NIHR DEC was designed based substantially on the
experience in this programme and takes four complementary strategic approaches to enhancing the
evidence base for IVDs (Figure 76). We will:
1. Deploy and refine methods in IVD study design, health economics and health informatics to improve and
speed up the way that IVDs can be evaluated for NHS use, drawing on our experience in this programme.
2. Sustain and strengthen our working networks of co-operating NHS sites to deliver studies effectively
with their patients and samples. Drawing on the experience in workstream 2, we can sustain the
capability and capacity to more rapidly evaluate new biomarkers in renal and liver diseases. This
approach has been extended to musculoskeletal diseases and oncology/haematology.
3. Invite, select and prioritise specific IVD candidates in our clinical areas, from our own work partners and
interested parties, and help them develop and deliver appropriate studies and evidence.
4. Create a strong stakeholder engagement group to work with our teams, patients and academic and
commercial partners, to shape our strategies, research programmes and projects and identify new
opportunities together.
Investigators in this applied programme are playing a major role in the national NIHR DEC developments.
Jon Deeks leads on a joint methodology group for the four DECs (Imperial, Oxford, Newcastle and Leeds).
Peter Selby, Mike Messenger and Steph Roberts organise and lead the Leeds DEC and other programme
investigators (William Rosenberg, Cathie Sturgeon, Andrew Lewington, Naveen Vasudev, Claire Hulme,
Carys Lippiatt, Chris McCabe, Roz Banks, Doug Altman and Walter Gregory) have leading roles.
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In vitro diagnostics evaluation methodology research
Our NIHR DEC at Leeds is promoting a coherent philosophy based on continuous decision modelling through
all phases of development. A central model for each project will draw on real-time NHS data mining to define
the clinical pathway and key clinical decision points and their relationship with clinical outcomes and costs.
Based on recent successful examples using these methods, time to adoption can be accelerated and research
design efficiency can be promoted. Finding solutions to the challenges of evaluating diagnostics will be an
important part of the DEC mission. Such challenges include the rapidly evolving nature of multiple competing
technologies and real-world characterisation of diagnostic test properties and their impact on clinical and
economic outcomes and optimisation of case definition thresholds. Members of and collaborators with the
NIHR DEC at Leeds have been at the centre of recent methodology innovations aimed at addressing some of
these challenges. The expertise is divided into three themes:
1. Study design and conduct. The gold standard for demonstrating clinical utility is the RCT. In response to
the need for faster time to market, coupled with the complexities of evaluating diagnostic tests, new
trial methods are required. Drawing on experience from our NIHR biomarkers programme and the
ELUCIDATE trial, including recruiting almost 900 patients, we have developed concepts for RCTs to
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FIGURE 76 The Leeds NIHR DEC diagnostic evaluation pipeline and development areas.
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evaluate changes in care processes and modelling strategies to test long-term patient and NHS-centred
outcomes. The DEC strategy will build on this to streamline randomised designs, making more use of
early field trials, surrogates, modelling, routine linked data and integrated economic data collection.
2. Health economics. The gold standard for demonstrating cost-effectiveness is a model-based economic
evaluation. Modelling will commence at the very start of IVD development under guidance from the DEC
during selection and prioritisation. By introducing a model early, it is possible to characterise the potential
impact of an IVD on the clinical pathway, clinical decision points and expected clinical end economic
outcomes. The optimal case definition threshold for tests can be proposed for cost-effectiveness in
addition to clinical validity alone. Models will be maintained as IVD development progresses, populated
by meta-analysis of evidence generated both within and external to the DEC. Probabilistic modelling will
be used to characterise areas of uncertainty in the evolving evidence for value between each phase of
development, thus enabling iterative research design efficiency. Expected cost-effectiveness can be
established as well as commercial headroom for the manufacturer. The trade-off between investment in
a large RCT and alternative cheaper or quicker study designs can be described through the modelling
process, including the use of Bayesian decision modelling and value of information analysis.
3. Health informatics. Central to improving the efficiency of IVD development will be early testing in real
NHS settings. For this to be achievable, outcomes monitoring through pre-established clinical data
collection is necessary. To demonstrate the potential impact of a new IVD, the standard care pathway
with real-world outcomes needs first to be defined. A framework has been developed by Leeds
researchers that allows the pathway (including event probabilities and patient characteristics) to be
defined directly from observed clinical events held within clinical databases (the Leeds Patient Pathway
Manager) using data-mining techniques. This allows a central decision model to be populated at the
patient level with observed outcomes. Linkage with NHS finance and resource usage databases such as
HES, Patient Level Information and Costing Systems and primary care databases allows a full economic
model to be constructed. Applied examples and a set of modelling tools have been developed in Leeds in
which standard care and IVD-specific clinical data feeds directly into a decision-analytic model to produce
estimates of longer-term health impact and cost-effectiveness.
Qualify analytical validity
Independent verification of the technical performance of an IVD can be conducted by the DEC IVD
Validation Group, including assessments of analytical sensitivity, specificity, precision, parallelism, recovery,
selectivity, LoQ and vulnerability to interferences.
Qualify clinical validity
The IVD clinical performance (e.g. sensitivity, specificity, predictive values) will be reviewed and can be
verified by the IVD Validation Group using samples from our established networks of co-operating NHS
sites and biobanks, established as part of the NIHR Biomedical Research Unit, ELUCIDATE trial and NIHR
biomarker applied programme. The DEC will identify funding (commercial consortia and/or public) to
replenish biospecimen resources and support multicentre biobanking programmes alongside registries,
providing low-cost high-value prospective samples and data for rapid IVD evidence generation in priority
clinical areas.
Evaluation of clinical utility and cost-effectiveness
Decisions about the research design priorities will be decided by the DEC Methodology Group, following
an update of the pathway model developed in Figure 76, stage 1, to include data gathered in Figure 76,
stages 2 and 3; pathway outcomes from linked NHS data sets; and re-estimation of uncertainties and value
of information. When further evidence is required the Methodology Group will make recommendations
about research designs. When necessary, the DEC will then utilise the expertise of the Leeds CTRU on
running trials of IVDs, incorporating the enhanced methodologies developed in DEC research programmes.
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The interactions between workstreams
We have given clear examples in which the interaction between workstreams has been synergistic. The
methodology work provided a literature-based and evidence-based framework for the development of
workstream 2 and workstream 3. For instance, the simulation modelling made possible a radical redesign of
the ELUCIDATE trial and provided a robust approach to power calculations that underpinned the completion
of the trial and its extensions. The methodology workstream also emphasised the critical importance of the
determination of analytical and clinical validity of tests in a meaningful way that can underpin evaluations of
clinical utility and cost-effectiveness. This resulted in the re-evaluation of the ELF test as a laboratory test,
reported in Chapter 17, and the rigorous reappraisals of the assays used throughout workstream 2, including
those prioritised as a consequence of the literature reviews. The experience of developing the RCT informed
the development of the cohorts for the workstream 2 renal cancer and RT work. Our ability to work with
centres, promote trial set-up, open new centres and motivate our collaborators allowed delivery of the
recruitment to target. However, it is important that we acknowledge again that the delay in delivering the
ELUCIDATE trial meant that large bodies of information broken down by trial arm were not available for our
methodology research.
Incorporating large clinical cohorts and RCTs into an applied programme is the attraction of the synergies
of the kind described in the previous paragraph. However, delays in setting up and recruiting into those
cohorts do have the potential to undermine the delivery of the programme as a whole and limit the
synergy between the workstreams. There is no absolute ideal model, but we would urge caution in the
integration of large RCTs into integrated programmes of work when other workstreams are dependent on
the timely completion of those trials.
Future methodology research
To validate a method one must provide objective evidence that it fulfils the evidence requirements for a
specific intended use and is ‘fit for purpose’.869 However, defining the requirements remains a challenge,
even after several decades of intensive efforts by members of the laboratory medicine community.873 In
1999 a landmark conference in Stockholm agreed a hierarchical structure for setting APGs.874 A more
recent 2014 conference in Milan revised and refined this, suggesting three approaches based on:875
1. the effect of analytical performance on clinical outcome (either directly or indirectly)
2. components of biological variation of the measurand or
3. ‘state of the art’.
However, although the Milan consensus provides a useful framework, it did not consider the interconnectivity
of the approaches and the possibility that there may be a unified strategy for combining them. Furthermore,
very few examples have been reported of APGs based on the effect on clinical outcomes, probably because
of the complexity and cost of these approaches.913 Whether or not it is pragmatic and appropriate to
recommend that manufacturers, clinical scientists and researchers invest significant time and resources in
striving to set APGs against the highest model, clinical outcomes, when a simpler solution may be ‘fit for
purpose’, is, therefore, debatable.
The current statement also does not consider the role of cost-effectiveness, a major component of UK
health-care decision-making. On an almost monthly basis, the NICE Diagnostic Assessment Programme
produces health technology assessments and economic models that should, in principle, be adaptable to
evaluating the impact of APGs on clinical outcomes and cost-effectiveness. Health economists and decision
modelers have a wealth of methodological expertise that may be highly useful in developing APGs. Similarly,
a better understanding of analytical and pre-analytical factors may prove useful in health technology
assessments. Further methodological work in this area should be pursued.
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Considering the demonstrable impact of pre-analytical and analytical factors on biomarker measurements,
better utilisation of metrological concepts (e.g. measurement uncertainty) by medical statisticians may improve
diagnostic test study and trial design, particularly in terms of power calculations, optimal cut-off thresholds
and monitoring intervals. Furthermore, the specific impact of random (imprecision) and systematic (bias and
specificity) factors on trial design should be considered. A recent simulation study of glycated haemoglobin
measurement convincingly demonstrated that, when using a fixed guideline-based cut-off point, varying
the bias and imprecision had very different effects on diagnostic accuracy, with bias having the most
severe consequences.864
Limitations
A programme with a responsibility for developing a framework built on excellent research innovative
methodology, excellent clinical biochemistry and appraisal of the analytical and clinical validity of tests and
also delivering a substantial RCT of a monitoring regimen was likely to be challenging. Our literature
reviews demonstrate the scale of the challenge. There were likely to be disappointments and limitations.
We feel that it is appropriate to highlight five of these:
1. The delays in set-up and recruitment into the study cohorts in workstream 2 and the ELUCIDATE trial
had a negative impact on our ability to generate large and complete data sets with adequate long-term
follow-up to answer questions conclusively. Further follow-up is required and will be carried out.
2. The low to moderate compliance rate in the ELUCIDATE trial may reduce the effect size of any benefit
of ELF, and may possibly render the trial underpowered, although a different package of investigations
was clearly delivered between the arms following the diagnosis of cirrhosis.
3. The absence of long-term follow-up data precludes conclusions being made about the true value of the
ELF test to alter the serious consequences of liver disease.
4. The absence of long-term follow-up data at this stage means that there are limited opportunities for
more methodological research.
5. The discovery pipeline in renal and liver disease has not yet provided exciting new molecular biomarkers
to evaluate in our cohorts.
Final comments
In this programme, we have summarised what is known about monitoring tests using prominent examples
and rigorous methodological appraisal and systematic overview; developed new approaches to evaluating
the analytical and clinical validity of new biomarkers, particularly exploring the requirements for underpinning
infrastructures; considered the products of modern proteomics; and delivered an exemplar RCT that has
demonstrated changes in the process of care for a vitally important and growing area of morbidity and
mortality in the UK. Incomplete follow-up as a consequence of delays in set-up and recruitment have limited
our conclusions; these can be remedied by health informatic strategies, which we have outlined and planned
and will robustly deliver.
The work of this programme was pivotal in our proposal for a NIHR DEC and the methodological, clinical
biochemistry and clinical trials conclusions from the programme will continue to underpin the delivery
of diagnostic evidence and the development of novel methods for delivering it in a more timely and
cost-effective way for many years to come.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Appendices to Chapter 11
 
     
                                                    
The following Site Specific Procedures are for collection, processing, and distribution of samples for 
the Renal Cell Carcinoma (RCC) NIHR Biomarker Research Tissue Bank (bioRTB). The objective 
being to validate biomarkers for prognosis and longitudinal monitoring in patients with renal cell 
carcinoma 
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TABLE 149 Between-laboratory results for HA, sites 1–4
Sample ID
Site, HA (µg/l)
1 2 3 4
Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV
E001 87 83 85 2.9 3.3 83 91 87 5.4 6.2 88 102 95 9.9 10.4 88 86 87 1.5 1.7
E002 54 51 52 1.8 3.5 51 52 52 0.6 1.2 51 59 55 6.2 11.3 53 51 52 1.5 2.8
E003 76 76 76 0.5 0.6 76 80 78 3.2 4.1 78 89 83 7.6 9.1 70 83 76 8.9 11.7
E004 35 36 36 0.3 1.0 39 39 39 0.3 0.8 38 44 41 4.3 10.6 37 36 36 0.7 1.8
E005 51 51 51 0.3 0.6 51 55 53 2.4 4.5 55 57 56 1.8 3.2 50 51 50 0.6 1.1
E006 68 65 66 2.1 3.2 69 73 71 2.4 3.3 80 86 83 4.4 5.4 70 72 71 1.2 1.6
E007 41 43 42 1.3 3.1 42 44 43 1.9 4.5 44 47 46 2.6 5.7 41 43 42 1.4 3.5
E008 97 100 98 2.7 2.8 97 102 100 4.0 4.0 109 100 104 5.7 5.5 98 99 99 0.7 0.7
E009 65 62 64 2.3 3.6 65 63 64 1.5 2.4 71 65 68 3.7 5.5 66 65 65 1.1 1.7
E010 85 95 90 6.8 7.5 94 102 98 5.4 5.5 120 103 111 11.6 10.4 101 101 101 0.0 0.0
QC 1 20 20 20 0.1 0.5 22 20 21 1.4 6.6 25 23 24 1.6 6.9 21 20 21 0.8 3.9
QC 2 46 43 45 2.2 5.0 48 47 48 1.2 2.6 51 52 51 0.5 0.9 49 46 48 2.5 5.3
QC 3 175 161 168 10.0 6.0 180 173 176 5.1 2.9 191 195 193 3.2 1.6 169 160 164 6.4 3.9
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TABLE 150 Between-laboratory results for HA, sites 5–8
Sample ID
Site, HA (µg/l)
5 6 7 8
Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV
E001 84 82 83 1.7 2.1 121 99 110 15.4 14.1 84 83 83 0.4 0.5 83 85 84 1.4 1.6
E002 52 49 51 2.0 3.9 39 63 51 16.8 33.0 51 51 51 0.1 0.2 51 53 52 1.3 2.5
E003 73 69 71 2.9 4.1 105 83 94 15.4 16.3 74 71 72 1.7 2.4 73 75 74 1.4 1.8
E004 35 37 36 1.1 3.2 50 27 39 15.9 41.4 35 36 35 0.6 1.6 36 36 36 0.2 0.6
E005 47 52 49 3.7 7.4 64 42 53 15.9 30.0 49 50 50 0.1 0.1 50 52 51 1.6 3.2
E006 71 66 68 4.0 5.8 93 71 82 15.5 18.8 68 69 68 1.1 1.6 73 73 73 0.4 0.5
E007 41 42 42 0.7 1.6 60 32 46 20.0 43.4 42 44 43 1.6 3.7 43 43 43 0.2 0.4
E008 100 101 100 0.8 0.8 153 146 150 5.0 3.3 101 104 102 2.0 2.0 105 103 104 1.6 1.6
E009 60 69 64 5.9 9.2 45 95 70 35.3 50.7 68 61 65 5.1 7.9 65 66 66 0.8 1.2
E010 102 105 104 2.6 2.5 145 114 129 22.2 17.2 101 101 101 0.1 0.1 95 109 102 9.6 9.4
QC 1 21 21 21 0.3 1.3 24 25 25 0.8 3.5 20 20 20 0.2 0.8 23 22 22 0.6 2.9
QC 2 45 43 44 1.8 4.1 62 52 57 6.8 12.0 45 44 45 0.4 0.9 44 44 44 0.0 0.1
QC 3 156 167 162 8.0 5.0 141 212 177 50.7 28.7 173 167 170 4.2 2.4 167 167 167 0.6 0.4
A
P
P
E
N
D
IX
2
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
5
1
6
TABLE 151 Between-laboratory results for PIIINP, sites 1–4
Sample ID
Site, PIIINP (µg/l)
1 2 3 4
Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV
E001 15.8 16.2 16.0 0.2 1.5 17.1 17.0 17.0 0.1 0.6 16.6 15.9 16.2 0.5 3.2 15.3 16.1 15.7 0.5 3.4
E002 9.4 9.5 9.4 0.0 0.2 10.0 9.9 10.0 0.1 0.6 9.8 9.9 9.9 0.1 1.3 8.9 9.1 9.0 0.2 1.9
E003 8.5 8.7 8.6 0.1 1.7 9.1 9.0 9.0 0.1 1.4 8.8 8.8 8.8 0.0 0.2 8.3 8.8 8.6 0.4 4.2
E004 12.6 12.8 12.7 0.2 1.3 13.3 13.4 13.3 0.0 0.1 12.9 13.0 12.9 0.1 0.5 12.6 12.5 12.5 0.0 0.3
E005 9.8 10.0 9.9 0.1 0.9 10.8 10.7 10.8 0.1 0.7 10.5 10.7 10.6 0.1 1.1 10.1 10.3 10.2 0.1 1.4
E006 10.2 10.3 10.2 0.1 0.8 10.7 10.9 10.8 0.2 1.6 10.7 10.7 10.7 0.0 0.1 10.3 10.2 10.3 0.1 0.8
E007 10.6 10.4 10.5 0.1 1.3 11.2 11.5 11.3 0.2 1.9 10.9 10.8 10.8 0.0 0.2 10.3 10.3 10.3 0.0 0.3
E008 22.5 22.0 22.2 0.4 1.6 23.1 23.3 23.2 0.2 0.8 23.6 22.0 22.8 1.1 4.8 21.5 21.5 21.5 0.0 0.1
E009 21.8 20.2 21.0 1.1 5.1 21.5 21.7 21.6 0.2 0.8 21.7 21.7 21.7 0.0 0.1 20.5 19.4 19.9 0.7 3.7
E010 10.2 9.9 10.0 0.2 1.9 10.4 10.5 10.4 0.0 0.4 10.1 10.6 10.4 0.3 2.9 10.2 9.9 10.0 0.2 2.1
QC 1 3.5 3.3 3.4 0.1 4.0 3.6 3.6 3.6 0.0 0.5 3.4 3.5 3.4 0.1 1.9 3.2 3.4 3.3 0.1 2.6
QC 2 6.5 6.2 6.3 0.2 3.3 6.5 6.6 6.5 0.1 1.0 6.2 6.2 6.2 0.0 0.1 6.3 6.0 6.1 0.2 2.8
QC 3 12.3 11.7 12.0 0.4 3.5 12.4 12.4 12.4 0.0 0.1 12.0 12.4 12.2 0.3 2.3 12.0 11.8 11.9 0.1 1.2
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TABLE 152 Between-laboratory results for PIIINP, sites 5–8
Sample ID
Site, PIIINP (µg/l)
5 6 7 8
Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV
E001 16.3 16.7 16.5 0.2 1.5 16.7 16.7 16.7 0.0 0.0 16.7 16.0 16.3 0.4 2.7 16.6 16.3 16.5 0.2 1.2
E002 9.7 10.2 9.9 0.3 3.4 9.7 9.8 9.7 0.0 0.1 9.8 10.0 9.9 0.1 1.4 9.9 9.6 9.8 0.2 2.4
E003 9.3 8.7 9.0 0.4 4.5 9.1 8.9 9.0 0.1 1.1 9.3 9.0 9.1 0.2 1.7 8.9 9.0 8.9 0.0 0.4
E004 12.8 13.8 13.3 0.7 5.1 13.2 13.4 13.3 0.2 1.3 13.1 13.3 13.2 0.1 0.9 13.8 13.5 13.6 0.2 1.6
E005 9.8 11.2 10.5 0.9 9.0 10.9 10.9 10.9 0.0 0.5 10.7 10.9 10.8 0.2 1.5 10.7 10.6 10.6 0.1 0.8
E006 10.4 11.2 10.8 0.6 5.3 10.8 10.8 10.8 0.0 0.3 11.1 10.8 10.9 0.2 2.3 10.9 10.9 10.9 0.0 0.1
E007 11.1 11.3 11.2 0.1 1.1 11.1 11.3 11.2 0.2 1.5 11.2 11.3 11.3 0.1 1.1 11.1 11.2 11.2 0.1 0.8
E008 23.6 22.6 23.1 0.7 2.9 22.9 23.4 23.2 0.4 1.6 22.7 22.3 22.5 0.3 1.5 22.8 23.2 23.0 0.3 1.4
E009 21.1 21.7 21.4 0.4 1.9 21.2 21.6 21.4 0.3 1.3 21.2 22.3 21.7 0.8 3.7 21.4 21.5 21.5 0.1 0.4
E010 10.9 10.5 10.7 0.2 2.3 10.6 10.6 10.6 0.0 0.1 10.3 10.5 10.4 0.1 1.3 10.8 11.2 11.0 0.2 2.2
QC 1 3.3 3.3 3.3 0.0 0.2 3.2 3.3 3.3 0.1 1.7 3.4 3.5 3.4 0.0 1.2 3.2 3.3 3.3 0.1 3.2
QC 2 6.2 6.4 6.3 0.1 2.3 6.5 6.4 6.4 0.1 1.8 6.2 6.3 6.3 0.1 1.1 6.2 6.0 6.1 0.1 2.2
QC 3 11.9 12.9 12.4 0.7 5.9 12.3 12.1 12.2 0.1 1.0 12.3 12.5 12.4 0.1 1.0 12.2 12.2 12.2 0.0 0.1
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TABLE 153 Between-laboratory ELF scores for TIMP-1, sites 1–4
Sample ID
Site, TIMP-1 (µg/l)
1 2 3 4
Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV
E001 270 261 265 6.2 2.3 286 280 283 4.1 1.5 266 264 265 1.4 0.5 282 274 278 5.7 2.0
E002 235 243 239 5.7 2.4 247 246 247 0.6 0.2 234 242 238 5.8 2.4 242 246 244 2.8 1.2
E003 253 251 252 1.8 0.7 271 268 270 2.5 0.9 254 262 258 5.2 2.0 262 270 266 5.8 2.2
E004 193 197 195 2.9 1.5 210 202 206 5.5 2.7 193 200 196 5.2 2.6 201 200 200 0.7 0.4
E005 240 231 235 5.9 2.5 252 250 251 1.5 0.6 236 245 240 5.9 2.4 246 242 244 3.0 1.2
E006 214 213 213 1.3 0.6 228 227 227 0.6 0.3 213 227 220 10.0 4.5 225 222 224 2.2 1.0
E007 294 299 297 3.4 1.1 310 314 312 2.8 0.9 290 298 294 5.3 1.8 307 298 302 6.1 2.0
E008 298 287 293 7.4 2.5 299 306 302 4.7 1.6 292 297 294 4.0 1.3 298 298 298 0.0 0.0
E009 244 236 240 5.5 2.3 256 253 255 2.1 0.8 243 252 247 6.0 2.4 252 254 253 1.6 0.6
E010 272 257 264 10.3 3.9 278 274 276 2.6 0.9 266 277 272 7.6 2.8 285 278 281 4.8 1.7
QC 1 99 99 99 0.1 0.1 100 98 99 1.4 1.4 96 95 95 1.3 1.3 98 99 99 0.3 0.3
QC 2 270 277 273 4.6 1.7 287 270 278 12.2 4.4 280 269 274 8.4 3.1 277 285 281 5.2 1.8
QC 3 559 538 549 15.2 2.8 577 577 577 0.2 0.0 560 561 560 0.8 0.1 572 603 588 21.5 3.7
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TABLE 154 Between-laboratory ELF scores for TIMP-1, sites 5–8
Sample ID
Site, TIMP-1 (µg/l)
5 6 7 8
Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV
E001 272 278 275 4.5 1.6 279 280 280 1.0 0.4 267 262 265 3.3 1.2 274 278 276 2.8 1.0
E002 239 238 239 0.9 0.4 246 247 246 0.1 0.1 235 230 232 3.2 1.4 234 240 237 4.0 1.7
E003 260 267 263 5.0 1.9 266 270 268 3.1 1.2 255 250 253 3.5 1.4 257 261 259 2.6 1.0
E004 194 202 198 5.2 2.6 206 199 202 4.7 2.3 190 187 189 2.1 1.1 196 200 198 2.5 1.3
E005 241 245 243 2.9 1.2 252 256 254 2.5 1.0 230 239 234 6.5 2.8 245 239 242 4.4 1.8
E006 221 223 222 1.8 0.8 224 233 228 6.0 2.6 217 216 216 1.3 0.6 219 223 221 3.3 1.5
E007 294 291 293 2.3 0.8 301 310 305 6.3 2.1 289 285 287 3.3 1.1 301 309 305 5.6 1.8
E008 293 295 294 1.0 0.3 300 302 301 1.2 0.4 287 291 289 2.8 1.0 281 293 287 8.4 2.9
E009 250 248 249 1.6 0.6 255 253 254 1.6 0.6 246 240 243 4.0 1.7 256 249 253 4.9 2.0
E010 272 271 272 1.2 0.4 279 281 280 1.0 0.4 263 263 263 0.1 0.1 275 263 269 8.4 3.1
QC 1 94 101 98 5.1 5.2 97 100 99 2.2 2.2 96 96 96 0.1 0.1 100 101 100 0.3 0.3
QC 2 272 274 273 1.3 0.5 278 275 276 2.4 0.9 269 267 268 1.4 0.5 272 286 279 9.6 3.4
QC 3 565 579 572 10.3 1.8 582 584 583 1.2 0.2 573 560 567 9.0 1.6 583 579 581 2.4 0.4
A
P
P
E
N
D
IX
2
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
5
2
0
TABLE 155 Between-laboratory ELF values, sites 1–4
Sample ID
Site, ELF value
1 2 3 4
Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV
E001 10.4 10.3 10.3 0.03 0.3 10.4 10.5 10.4 0.04 0.4 10.4 10.5 10.4 0.1 0.6 10.4 10.4 10.4 0 0
E002 9.5 9.5 9.5 0.01 0.1 9.5 9.5 9.5 0.00 0.0 9.5 9.6 9.6 0.1 1.2 9.5 9.5 9.5 0 0
E003 9.8 9.8 9.8 0.01 0.1 9.8 9.9 9.8 0.02 0.2 9.8 9.9 9.9 0.1 0.9 9.7 9.9 9.8 0.1 1.4
E004 9.3 9.3 9.3 0.02 0.2 9.4 9.4 9.4 0.01 0.1 9.4 9.5 9.4 0.1 1.1 9.3 9.3 9.3 0.0 0.2
E005 9.5 9.5 9.5 0.01 0.1 9.6 9.6 9.6 0.03 0.3 9.6 9.7 9.6 0.0 0.4 9.5 9.5 9.5 0.0 0.1
E006 9.7 9.7 9.7 0.03 0.3 9.8 9.9 9.8 0.04 0.4 9.9 10.0 9.9 0.1 0.6 9.8 9.8 9.8 0.0 0.1
E007 9.5 9.5 9.5 0.02 0.2 9.5 9.6 9.6 0.06 0.6 9.5 9.6 9.6 0.0 0.5 9.4 9.5 9.5 0.0 0.3
E008 10.8 10.8 10.8 0.00 0.0 10.8 10.8 10.8 0.05 0.5 10.9 10.8 10.8 0.1 0.7 10.7 10.7 10.7 0.0 0.1
E009 10.3 10.2 10.3 0.08 0.8 10.3 10.3 10.3 0.02 0.2 10.4 10.3 10.4 0.0 0.4 10.3 10.2 10.3 0.0 0.4
E010 10.0 10.1 10.0 0.04 0.4 10.1 10.2 10.2 0.05 0.5 10.3 10.2 10.3 0.1 0.6 10.2 10.1 10.2 0.0 0.3
QC 1 7.6 7.5 7.6 0.03 0.4 7.7 7.6 7.6 0.05 0.6 7.7 7.7 7.7 0.0 0.6 7.6 7.6 7.6 0.0 0.2
QC 2 9.2 9.1 9.1 0.06 0.6 9.2 9.2 9.2 0.03 0.3 9.2 9.2 9.2 0.0 0.0 9.2 9.1 9.2 0.1 0.6
QC 3 11.1 10.9 11.0 0.08 0.8 11.1 11.1 11.1 0.03 0.2 11.1 11.2 11.1 0.0 0.3 11.0 11.0 11.0 0.0 0.3
D
O
I:
1
0
.3
3
1
0
/p
g
fa
r0
6
0
3
0
P
R
O
G
R
A
M
M
E
G
R
A
N
TS
FO
R
A
P
P
LIE
D
R
E
S
E
A
R
C
H
2
0
1
8
V
O
L.
6
N
O
.
3
©
Q
u
een
’s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
8
.
Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
Selb
y
e
t
a
l.
u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cialC
are.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
llrep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
al
jo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercialrep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,
Evalu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,
So
u
th
am
p
to
n
SO
1
6
7
N
S,
U
K
.
5
2
1
TABLE 156 Between-laboratory ELF values, sites 5–8
Sample ID
Site, ELF value
5 6 7 8
Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV Run 1 Run 2 Mean SD %CV
E001 10.4 10.4 10.4 0.0 0.0 10.7 10.5 10.6 0.1 1.1 10.4 10.4 10.4 0.0 0.1 10.4 10.3 10.3 0.03 0.3
E002 9.5 9.5 9.5 0.0 0.1 9.3 9.7 9.5 0.3 3.0 9.5 9.5 9.5 0.0 0.1 9.5 9.5 9.5 0.01 0.1
E003 9.8 9.7 9.8 0.1 0.6 10.1 9.9 10.0 0.1 1.4 9.8 9.8 9.8 0.0 0.2 9.8 9.7 9.8 0.04 0.4
E004 9.3 9.4 9.4 0.1 0.8 9.6 9.1 9.4 0.4 3.9 9.4 9.4 9.4 0.0 0.0 9.3 9.3 9.3 0.02 0.2
E005 9.4 9.6 9.5 0.1 1.4 9.8 9.4 9.6 0.3 2.7 9.6 9.6 9.6 0.0 0.1 9.5 9.5 9.5 0.02 0.2
E006 9.8 9.8 9.8 0.0 0.1 10.1 9.8 10.0 0.2 1.5 9.8 9.9 9.8 0.0 0.1 9.8 9.8 9.8 0.01 0.1
E007 9.5 9.5 9.5 0.0 0.1 9.8 9.3 9.6 0.4 3.8 9.5 9.6 9.5 0.0 0.2 9.5 9.5 9.5 0.04 0.4
E008 10.8 10.8 10.8 0.0 0.1 11.2 11.1 11.1 0.0 0.1 10.8 10.8 10.8 0.0 0.1 10.8 10.8 10.8 0.01 0.1
E009 10.2 10.4 10.3 0.1 0.9 10.0 10.6 10.3 0.5 4.4 10.3 10.3 10.3 0.0 0.0 10.3 10.3 10.3 0.05 0.4
E010 10.2 10.2 10.2 0.0 0.1 10.5 10.3 10.4 0.1 1.4 10.2 10.3 10.2 0.1 0.8 10.2 10.2 10.2 0.01 0.1
QC 1 7.5 7.6 7.6 0.0 0.5 7.7 7.7 7.7 0.1 0.7 7.6 7.6 7.6 0.0 0.0 7.6 7.6 7.6 0.00 0.0
QC 2 9.1 9.1 9.1 0.0 0.2 9.4 9.2 9.3 0.1 1.3 9.1 9.1 9.1 0.0 0.0 9.1 9.1 9.1 0.00 0.0
QC 3 10.9 11.1 11.0 0.1 0.8 10.9 11.2 11.1 0.2 2.2 11.0 11.0 11.0 0.0 0.0 11.0 11.0 11.0 0.02 0.2
A
P
P
E
N
D
IX
2
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
5
2
2
Appendix 3 Summary of changes to the original
ELUCIDATE trial protocol
Protocol
version Date approved Summary of amendment
Version 1.0 2 February 2010 Not applicable
Version 2.0 25 March 2010 l Onset of grade 3 or 4 encephalopathy added as an end point
so patients can be censored at this time point
l Mortality from HCC expanded to include further liver-related
mortalities
l Unresectable HCC moved from secondary to primary end point
Version 3.0 30 April 2010 l Timing of optional biobank sample changed from registration
to randomisation
Recruitment halted between 24 December 2010 and 29 March 2011 whilst protocol amendment approved. Forty-three
patients registered up until 24 December 2010
Version 4.0 Not approved because of concerns
regarding information provision for
re-approached patients who had
previously failed the eligibility criteria
l ELF thresholds updated to 8.4 (previously 11.0) for eligibility
and 9.5 (previously 12.5) for a diagnosis of cirrhosis
Version 5.0 14 March 2011 l ELF thresholds updated to 8.4 (previously 11.0) for eligibility
and 9.5 (previously 12.5) for a diagnosis of cirrhosis
l Additional co-primary end point added – time from
randomisation to first severe complication
l Original primary end point amended to time from diagnosis of
cirrhosis (by ELF testing or clinical means) to incidence of first
severe complication
l Follow-up period extended to 5 years beyond the end of the
NIHR programme grant
l Introduction of patient guidelines for quality of life questionnaire
completion
l Amendment to sample size and power calculations (sample
size remained unchanged)
l Minimisation categories for baseline ELF testing amended to
≥ 8.4 to < 9.5, ≥ 9.5 to < 11.5 ≥ 11.5 to < 12.5 and ≥ 12.5;
(previously 11–11.49, 11.5–11.99, 12–12.49, 12.5+)
l Analysis details amended to reflect above changes
Version 6.0 30 May 2012 l Eligibility criteria reworded for clarity (patient population
unchanged)
l Time from diagnosis of cirrhosis to first severe complication
changed from a co-primary end point to a secondary end point
l Definition of HCC as a severe complication amended to HCC
beyond the Milan criteria (previously beyond the extended
Milan criteria)
l Definition of liver-related mortality (severe complication)
amended to also include death from spontaneous bacterial
peritonitis and death from encephalopathy
l Secondary end point changed to specific liver-related morbidity
(previously mortality – typographical error)
l Clarified that recruitment will be 24 months, with an
additional 30 months of follow-up and an additional
39 months of long-term follow-up for the primary end point
(taking it to 5 years after the end of the programme grant)
l Sample size and statistical analysis sections amended to take
account of extended recruitment and follow-up duration and
the new single primary end point
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Protocol
version Date approved Summary of amendment
Version 7.0 04 March 2013 l Recruitment closure ahead of the preplanned 1000 patients
l Addition of a new secondary end point (process outcomes),
namely treatment with beta-blockers/band ligation of varices,
use of endoscopy and ultrasound/alphafetoprotein tests and
treatment to normalise LFTs in patients with hepatitis B and
hepatitis C infection
l Clarification that, if an ELF sample has been at room
temperature for > 2 days before receipt at the central
laboratory, a repeat sample will be required
l Change to the acceptable time window between registration
and randomisation
l Clarification that, if > 12 weeks have passed between the
registration ELF sample and randomisation, a repeat blood
sample should be taken for ELF testing, to ensure that the
patient remains eligible for randomisation
l Clarification that variation of ± 1 month around the visit due
date is permitted
l Timing of follow-up visits following a diagnosis of cirrhosis
amended to 3 months post cirrhosis diagnosis and 6-monthly
thereafter (previously 3-monthly from diagnosis of cirrhosis)
l Post-cirrhosis monitoring assessments (OGD, ultrasound, AFP
testing) previously described as mandatory at 3 months post
diagnosis of cirrhosis are now mandatory at this time point
only if they have not been performed within a specified time
window prior to diagnosis of cirrhosis
l Clarification that screening/non-registration logs after the
closure of the trial will no longer be required
l Confirmation that some surplus samples from the central
laboratory will be sent for quality assurance testing
l Clarification that baseline samples are acceptable within
1 month prior to registration (previously 14 days)
l Clarification that variation of follow-up visits within 1 month
before or after the scheduled visit date is permitted
l Definition of the end of the trial amended to the date that the
last patient’s last data item is collected (previously the last
follow-up visit)
l Sample size section updated to include the power based on an
assumption that approximately 700 patients will have been
randomised when the trial closes
l Interim analysis section amended to include the new process
outcomes end point and the follow-up until July 2014
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Appendix 4 Original sample size calculation for
the ELUCIDATE trial
Note that when these figures were derived, prior to the start of the trial, the ELF threshold for definingcirrhosis was set at 11 and, therefore, many fewer patients would have been defined as cirrhotic by
ELF testing. The threshold was changed to 9.5 after the recruitment of three patients in March 2011,
when it was realised that the threshold of 11 was too stringent.
The ELUCIDATE trial is testing the hypothesis that, if we monitor patients with CLD using the ELF value,
we will detect liver cirrhosis earlier and, as a result, there will be fewer severe complications as well as
improvements in other important patient outcomes. We are, therefore, aiming to show that the incidence
of severe complications following cirrhosis is less in the ELF arm. This is the primary end point on which the
trial is powered.
The trial will recruit over 18 months, with an additional 30 months of follow-up. Previous studies have led
us to anticipate that, in the standard care arm, at 36 months, we will observe severe complications of the
order of 2% for variceal bleeds, 1% for major bleeds and 0.7% for inoperable HCCs, giving a 3.7%
incidence of potentially preventable undesirable clinical end points.914
Previous data have illustrated that approximately 20% of patients will have varices suitable for therapy.49
Such therapy has a large effect on the progression of these varices (for instance, a reduction from 37%
progressing to 11% progressing); on the risk of bleeding from these varices (reduced from 30% to 14%
in patients with medium to large varices); and on mortality at 36 months (reduced from 7% to 2% over
24 months).49 Based on these data, we hypothesise that we could reduce the incidence of the undesirable
clinical end points of cirrhosis by a half, or even two-thirds, in the ELF arm.
We anticipate that we will observe approximately twice as many patients developing cirrhosis in the ELF
arm (approx. 20% of patients) than in the standard arm (approx. 10% of patients) over the 18 months of
recruitment and 30 months of follow-up. Using this accrual and follow-up rate, along with the expected
incidence rate, we can calculate the expected number of events in each arm using the method described
by Collett915 for sample size estimates based on exponential survival distributions (more details of which
can be seen in the statistical analysis plan). This gives expected numbers with severe complications of 19
and 6 in the control and experimental arms, respectively, assuming a two-thirds reduction in severe
complications; or 12 and 6, respectively, assuming a reduction in severe complications of half.
With 1000 patients randomised, we would have > 99% power to detect this difference in numbers of
patients encountering severe complications, subsequent to being detected with cirrhosis, with a 5% type 1
error, 18 months of recruitment and 30 months of follow-up. Sample size calculations are provided in the
following paragraphs.
If it is assumed for simplicity that cirrhosis will be detected at uniform intervals throughout the 4 years of
the trial, then we can estimate a pair of actuarial incidence curves (assuming exponentiality in generating
these incidence curves) that give us the 19 and 6 events that we originally estimated, with 18 months of
recruitment and 30 months of follow-up. These hypothetical curves are presented below.
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The exponential parameters give medians of 2.85 years in the control arm and 27 years in the ELF arm
(consistent with such a big, two-thirds reduction in severe complications). Carrying out sample size
calculations with these figures gives a total sample size, say ns (within cirrhosis patients), of 150 (> 99%
power).916 For this calculation we are assuming that cirrhosis patients are identified over an 18-month
period, with a further 30 months of follow-up, and that twice as many are identified in the ELF arm (20%
of the total in the ELF arm vs. 10% of the total in the control arm). The power calculation for severe
complications allows for this. If the total sample size of cirrhotic patients is nt, then ns = 20%(1/2nt) + 10%
(1/2nt) = 15%(nt). So, nt = 100/15 and ns = 150. We, therefore, multiply 150 by 100/15 to obtain the total
sample size of monitored patients, which is equal to 1000 (> 99% power).
Note that we have been plotting the likely incidence of severe complications following detection of
cirrhosis, so that, even though the curve of the cumulative numbers detected with cirrhosis may have a
shape that is concave then linear, with a slow start because of the initial 18-month accrual, the incidence
of severe complications following cirrhosis might reasonably be expected to follow the exponential pattern
assumed, where the likelihood of a severe complication that follows the detection of cirrhosis is unrelated
to the time followed up after detection of cirrhosis.
There is a possibility that the trial itself will affect the control arm (contamination) positively. We have,
therefore, gone on to look at this contamination issue. Suppose that the control arm receives more
successful interventions, etc. and the difference in severe complications is reduced by only a half (instead
of two-thirds). We therefore assume that there are in fact only 12 events in the control arm instead of 19,
as in the following graph.
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The exponential parameters in this case give medians of 5.5 years in the control arm and 27 years in the
ELF arm. Carrying out sample size calculations with these figures gives a total sample size (within cirrhosis
patients) of 143 (80% power) or 191 (90% power). We again multiply these values by 100/15 to obtain
the total sample size of monitored patients of 953 (80% power) or 1273 (90% power).
This scenario might not be appropriate if we had a sizeable number of patients with severe complications
before their cirrhosis is detected. However, if this happened, we would treat any patients having severe
complications without prior detection of cirrhosis as having a zero time to incidence of severe complications
following cirrhosis on the incidence curve. If this was similar in both arms the curves would simply start at
the same probability (> 0) on the y-axis, and subsequent divergence of the curves would be more acute
than previously to cause the overall twofold difference we are looking for.
The trial as its current size is, thus, well powered (at least 80% even under the assumption that we see
only a 50% reduction in the incidence of severe complications) to show that this ELF monitoring policy will
be of real clinical benefit.
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